<SEC-DOCUMENT>0001193125-19-289953.txt : 20191112
<SEC-HEADER>0001193125-19-289953.hdr.sgml : 20191112
<ACCEPTANCE-DATETIME>20191112161443
ACCESSION NUMBER:		0001193125-19-289953
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		26
FILED AS OF DATE:		20191112
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			89bio, Inc.
		CENTRAL INDEX KEY:			0001785173
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831114349
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-234174
		FILM NUMBER:		191209572

	BUSINESS ADDRESS:	
		STREET 1:		535 MISSION STREET
		STREET 2:		14TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
		BUSINESS PHONE:		4155004614

	MAIL ADDRESS:	
		STREET 1:		535 MISSION STREET
		STREET 2:		14TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94105
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d743471d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4)<BR>Registration Nos. 333-234174 and 333-234617 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>PROSPECTUS </U></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>5,304,687 Shares </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g36i06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This is 89bio,
Inc.&#146;s initial public offering. We are selling 5,304,687&nbsp;shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no public market
existed for the shares. Our common stock has been approved for listing on The Nasdaq Global Market under the symbol &#147;ETNB.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
are an &#147;emerging growth company&#148; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to do so in future filings.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Investing in the common stock involves risks that are described in the &#147;<A HREF="#toc743471_2">Risk&nbsp;Factors</A>&#148;
section beginning on page 10 of this prospectus. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,874,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,941,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,933,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#147;Underwriting&#148; for additional information regarding compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also exercise their option to purchase up to an additional 795,703&nbsp;shares from
us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing
stockholders affiliated with our directors have agreed to purchase an aggregate of approximately $51&nbsp;million of shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other
purchasers in this offering. The underwriters will receive the same underwriting discount and commissions on these shares of common stock as they will on any other shares of common stock sold to the public in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares will be ready
for delivery on or about November&nbsp;13, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="bottom"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>RBC&nbsp;Capital&nbsp;Markets</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus is November&nbsp;11, 2019. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_4">Industry and Market Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_9">Selected Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_10">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_18">Material U.S. Federal Income Tax Considerations to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_22">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc743471_23">Index to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or in any
free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We
and the underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its
date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering, or
possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves
about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information
that you should consider before deciding to invest in our common stock. You should read the entire prospectus carefully, including &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and our consolidated financial statements and notes to those consolidated financial statements included elsewhere in this prospectus, before making an investment decision. Some of the statements in this summary constitute
forward-looking statements, see &#147;Special Note Regarding Forward-Looking Statements.&#148; In this prospectus, unless the context requires otherwise, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;89bio&#148; or the
&#147;company&#148; refer to (i) 89Bio Ltd. for the periods prior to the Reorganization (as defined below) and (ii) 89bio, Inc. for the periods after completion of the Reorganization, in each case together with its consolidated subsidiaries.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment
of liver and cardio-metabolic diseases. Our lead product candidate, <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (&#147;FGF21&#148;), is currently being developed
for the treatment of nonalcoholic steatohepatitis (&#147;NASH&#148;). NASH is a severe form of nonalcoholic fatty liver disease (&#147;NAFLD&#148;), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver
failure, hepatocellular carcinoma (&#147;HCC&#148;) and death. There are currently no approved products for the treatment of NASH. FGF21 is a clinically-validated mechanism that has been shown in humans to reduce liver fat (steatosis) and address
cardio-metabolic dysregulation. We believe BIO89-100 may be a differentiated FGF21 therapy based on its robust and durable biological effects and a favorable tolerability profile, as well its potential for a longer dosing interval. Combining these
characteristics with the ability to address the key liver pathologies in NASH, as well as the underlying metabolic dysregulation in NASH patients, BIO89-100 has the potential to become a mainstay of NASH therapy. We successfully completed a Phase
1a, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> single ascending dose (&#147;SAD&#148;) clinical trial with 58 healthy volunteers. The magnitude and significance of
<FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> biological effects after a single dose on lipid parameters were robust and durable. In July 2019, we initiated our proof of concept (&#147;POC&#148;) Phase 1b/2a clinical trial in patients
with NASH or patients with NAFLD and a high risk of NASH and we expect to report topline data in the second half of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prevalence
of NAFLD, which affects approximately 25% of the global population, and NASH, which develops in approximately 20% to 25% of NAFLD patients, is growing and is driven primarily by the worldwide obesity epidemic. The critical pathophysiologic
mechanisms underlying the development and progression of NASH include reduced ability to handle lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. Patients with NASH frequently have other
significant metabolic <FONT STYLE="white-space:nowrap">co-morbidities</FONT> such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and these further contribute
to the risk of cardiovascular disease. The number of NASH cases in the United States is projected to expand from 16.5&nbsp;million in 2015 to 27&nbsp;million in 2030, with similar prevalence growth expected in Europe. Diet and exercise are currently
the standard of care for NAFLD and NASH, but adherence to this treatment regimen is poor and there remains a high unmet need in the treatment of NASH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also intend to develop <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of severe hypertriglyceridemia
(&#147;SHTG&#148;), a condition identified by severely elevated levels of triglycerides (&#147;TG&#148;) (greater than or equal to 500&nbsp;mg/dL), which is associated with an increased risk of NASH, cardiovascular events and acute pancreatitis.
SHTG accounts for up to 10% of all acute pancreatitis episodes. It is estimated that there are 2.5 million to 4&nbsp;million patients in the United States with TG <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;500&nbsp;mg/dL and up to 50% of
SHTG patients treated with certain </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved drugs are refractory to current standard of care. We expect to initiate our Phase&nbsp;2 trial in SHTG patients in the first half of 2020 in order to evaluate the ability of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> to reduce fasting plasma triglyceride levels compared to baseline levels and to report topline data in the first half of 2021. At this stage, we have not sought a Special Protocol Assessment or other
agreement with the FDA on the required clinical trials needed to support an application for approval of BIO89-100 in SHTG. However, based on FDA guidance for the development of SHTG treatments, as well as the regulatory path followed by other
companies that have successfully developed SHTG therapies, we believe that a combination of smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for BIO89-100. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has the potential to address multiple drivers underlying metabolic dysregulation,
which would make it an ideal candidate for selected liver and cardio-metabolic diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Lead Product Candidate,
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> is a specifically engineered
FGF21 analog that we believe has the potential to address the critical pathophysiologic mechanisms underlying NASH. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 has been clinically shown to
reduce liver fat (steatosis). It is also thought to exert effects on liver fibrosis by improving metabolic regulation, which reduces ongoing liver injury thus giving the liver time to heal. FGF21 also generates an
<FONT STYLE="white-space:nowrap">on-target</FONT> effect to increase adiponectin, a hormone released from adipose tissue that, among other functions, can suppress development and progression of hepatic fibrosis. However, FGF21 in its native form
suffers from a short half-life and a tendency to aggregate in solution, both of which impact its suitability as a viable drug. To address these challenges, we have specifically engineered <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to maintain
the clinical benefits of FGF21, while extending half-life in vivo, protecting against proteolysis, reducing renal clearance, minimizing susceptibility to aggregate in solution and optimizing potency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BIO89-100 has been evaluated in seven animal studies of NASH, diabetes and obesity, including studies in mice and non-human primates. Each
study was customized to assess endpoints relevant to liver and metabolic diseases and conducted according to standard practices at experienced contract research organizations (&#147;CROs&#148;). In these preclinical studies, consistent beneficial
effects across a range of endpoints were observed, including improvements in hepatic steatosis, injury and fibrosis in a diet-induced NASH study of 50 mice (see &#147;Business&#151;BIO89-100&#151;Results of DIN Mouse Studies&#148; Figure 11 which
illustrates that statistically significant mean changes with respect to hepatic steatosis and fibrosis were each observed and Figure 12 which illustrates that statistically significant mean changes with respect to injury were observed) and improved
glycemic control and lipid handling in a study of 24 spontaneously diabetic obese cynomolgus monkeys with elevated triglycerides (see &#147;Business&#151;BIO89-100&#151;Results of Spontaneously Diabetic Obese Cynomolgus Monkey Studies&#148; Figures
20 and 21, respectively which illustrate that statistically significant mean changes with respect to glycemic control and lipid handling were each observed). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2019, we announced positive topline data from our Phase 1a,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> SAD clinical trial of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in 58 healthy volunteers. In this SAD study,
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated a favorable tolerability profile in the 43 volunteers who received <FONT STYLE="white-space:nowrap">BIO89-100</FONT> with a half-life of 55 to 100 hours. At single doses of 9.1&nbsp;mg
and higher, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated significant improvements in key lipid parameters measured at Day 8 and Day 15 after dosing on Day 1. The mean changes versus baseline include reductions in triglycerides (up
to 51%) and <FONT STYLE="white-space:nowrap">LDL-C</FONT> (up to 37%) and increase in <FONT STYLE="white-space:nowrap">HDL-C</FONT> (up to 36%) despite the baseline values being in the normal range. As compared to placebo treatment, these mean
changes were all statistically significant (p&nbsp;&lt;&nbsp;0.001). <FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated rapid (beginning from Day 2), sustained and durable improvements in lipid parameters for two weeks or more after
single dose administration. Based on these findings and results from our animal studies, we believe such a lengthy duration of effect may confer longer dosing intervals to BIO89-100. We are currently enrolling our POC Phase 1b/2a trial with 83 total
patients randomized to receive once weekly or </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
once every two weeks subcutaneous dosing of either BIO89-100 or placebo, in each case, for up to 12 weeks. This trial is designed to assess the safety, tolerability and pharmacokinetic
(&#147;PK&#148;) properties of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> as well as changes in liver steatosis and key biomarker assessments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also intend to develop <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of SHTG. In diabetic obese cynomolgus monkeys
with elevated triglycerides, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> showed significant effects on triglycerides at doses as low as 0.1 mg/kg/week, with a 78% reduction from baseline observed at the highest dose level of 1.0 mg/kg/week. In
our Phase 1a SAD study, BIO89-100 showed a significant reduction in triglycerides of up to 51% after a single dose in healthy volunteers. While currently approved SHTG therapies decrease TG levels, they generally do not have broader metabolic
benefits. To the extent that we are able to show in subsequent human clinical trials that BIO89-100 significantly decreases both TG and LDL-C levels and improves other metabolic parameters, we believe that BIO89-100 could be a differentiated therapy
in this indication. We expect to initiate our Phase&nbsp;2 trial in SHTG patients in the first half of 2020 in order to evaluate the ability of BIO89-100 to reduce fasting plasma triglyceride levels compared to baseline levels and to report topline
data in the first half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BIO89-100 Patent Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We retain exclusive worldwide rights to <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> BIO89-100 is protected by a family of issued
patents with claims directed to composition of matter and methods of use. The first of our patents for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> are projected to expire in the United States in 2028, with the final composition-of-matter
patent projected to expire in the United States in 2038, in each case, without patent term extensions. Because BIO89-100 is a biologic drug, marketing approval is also expected to provide 12 years of market exclusivity in the United States from the
approval date of a biologics license application (&#147;BLA&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Team </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management team has extensive drug development, manufacturing and commercialization experience, having brought many successful drugs to
market, including biologic agents. We are also supported by a group of directors and leading investors whose collective experience will assist us in realizing our corporate strategy. Our existing investors include OrbiMed, Longitude Capital, RA
Capital and Pontifax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Strategy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for the
treatment of liver and cardio-metabolic diseases. The key components of our strategy are to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advance <FONT STYLE="white-space:nowrap">BIO89-100</FONT> through clinical development for the treatment
of NASH. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand the breadth of indications for BIO89-100 with an initial focus on SHTG. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Scale-up</FONT> and optimize the manufacturing of
<FONT STYLE="white-space:nowrap">BIO89-100.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Establish a commercial infrastructure in key geographies. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Construct a diversified multi-asset pipeline of novel therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with our Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
business is subject to a number of risks that you should be aware of before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular, you
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
should evaluate the specific factors set forth under &#147;Risk Factors&#148; in deciding whether to invest in our common stock. Among these important risks are the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for
commercial sale. We have incurred net losses since our inception, we expect to incur significant and increasing operating losses and we may never be profitable. Our stock is a highly speculative investment. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require substantial additional capital to finance our operations,
which may not be available to us on acceptable terms, or at all. As a result, we may not complete the development and commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or develop new product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our financial condition raises substantial doubt as to our ability to continue as a going concern.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business depends on the success of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> our only product
candidate under clinical development, which is in the early stages of clinical development and has not completed a pivotal trial. If we are unable to obtain regulatory approval for and successfully commercialize
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> or other future product candidates, or we experience significant delays in doing so, our business will be materially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain
outcomes, and the results of prior preclinical or clinical trials are not necessarily predictive of our future results. Our clinical trials may fail to adequately demonstrate the safety and efficacy of
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are initially developing <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of NASH, an
indication for which there are no approved products. This makes it difficult to predict the timing and costs of the clinical development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in NASH. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates may cause undesirable side
effects or have other properties that could delay or prevent their regulatory approval or limit the commercial profile of an approved label. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others discovering, developing or commercializing competing
products before or more successfully than us. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third
parties developing FGF product candidates, which could adversely affect our stock price, our ability to attract additional capital and our development program. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have relied on, and expect to continue to rely on, third-party manufacturers to produce <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. Any failure by a third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our
ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing,
and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our success depends upon our ability to obtain and maintain intellectual property protection for our products and
technologies. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on a license from Teva Pharmaceutical Industries Ltd. (&#147;Teva&#148;) and a sublicense from ratiopharm
GmbH (&#147;ratiopharm&#148;), a Teva affiliate, to patents and <FONT STYLE="white-space:nowrap">know-how</FONT> related to glycoPEGylation technology that are used in the development, manufacture and commercialization of <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> Any termination or loss of significant rights, including the right to glycoPEGylation technology, or breach, under these agreements or any future license agreement related to our product candidates, would
materially and adversely affect our ability to continue the development and commercialization of the related product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were
incorporated in January 2018 in Israel under the name 89Bio Ltd. 89bio, Inc., the registrant whose name appears on the cover page of this prospectus, was incorporated in June 2019 for the purpose of an internal reorganization transaction.
In&nbsp;September 2019, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. Following this exchange (the &#147;Reorganization&#148;), 89Bio Ltd. became a wholly owned subsidiary of
89bio, Inc. and 89bio, Inc. owns the business described and for which historical financial information is included elsewhere in this prospectus. Shares of the common stock of 89bio, Inc. are being offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 535 Mission Street, 14th Floor, San Francisco, California 94105 and our telephone number is
(415) <FONT STYLE="white-space:nowrap">500-4614.</FONT> Our website is<I> www.89bio.com</I>. The information on, or that can be accessed through, our website is not part of this prospectus and is not incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;),
as modified by the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth
companies, including relief from the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, less extensive disclosure obligations regarding executive compensation in our registration statements, periodic
reports and proxy statements, exemptions from the requirements to hold a nonbinding advisory vote on executive compensation, and exemptions from stockholder approval of any golden parachute payments not previously approved. We may also elect to take
advantage of other reduced reporting requirements in future filings. As a result, our stockholders may not have access to certain information that they may deem important and the information that we provide to our stockholders may be different than,
and not comparable to, information presented by other public reporting companies. We could remain an emerging growth company until the earlier of (1)&nbsp;the last day of the year following the fifth anniversary of the completion of this offering,
(2)&nbsp;the last day of the year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (3)&nbsp;the last day of the year in which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year or (4)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities
during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act also provides that an emerging growth company may take advantage of the
extended transition period provided in the Securities Act for complying with new or revised accounting standards. An emerging growth company may therefore delay the adoption of certain accounting standards until those standards would otherwise apply
to private companies. We have elected to avail ourselves of this exemption and, as a result, will not be subject to the same implementation timing for new or revised accounting standards as are required of other public companies that are not
emerging growth companies, which may make comparison of our consolidated financial information to those of other public companies more difficult. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>5,304,687 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of common stock </P></TD>
<TD>The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 795,703 additional shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>12,993,279&nbsp;shares (or 13,788,982&nbsp;shares if the underwriters exercise in full their option to purchase additional shares of our common stock). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We expect that our net proceeds from this offering will be approximately $76.5&nbsp;million (or approximately $88.4&nbsp;million if the underwriters exercise in full their option to purchase 795,703 additional shares), after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the development of BIO89-100 for the treatment
of NASH and SHTG, for the manufacture of BIO89-100 and scale up, to evaluate potential new indications for BIO89-100 and for working capital and other general corporate purposes. See &#147;Use of Proceeds&#148; for additional information.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should carefully read and consider the information set forth in the &#147;Risk Factors&#148; section of this prospectus together with all of the other information set forth in this prospectus, before deciding whether to invest in shares of
our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market trading symbol </P></TD>
<TD>&#147;ETNB&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding following this offering (i) is based on
611,226&nbsp;shares of our common stock and 42,826,389 shares of our convertible preferred stock outstanding as of June 30, 2019, (ii) includes 1,173,611 shares of our convertible preferred stock issued in July 2019, (iii) gives effect to the
Reorganization and the automatic conversion immediately prior to the completion of this offering of all outstanding shares of our convertible preferred stock into 7,077,366&nbsp;shares of our common stock, and (iv) excludes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">721,079&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of June 30,
2019 under our 2019 Equity Incentive Plan (as amended and restated, the &#147;2019 Plan&#148;) at a weighted-average exercise price of $1.93 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">583,080&nbsp;options to purchase shares of our common stock granted subsequent to June 30, 2019 at a
weighted-average exercise price of $4.26 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">343,083&nbsp;shares of our common stock reserved for future issuance under our 2019 Plan as of June&nbsp;30, 2019
and 396,727 and 1,383,302 additional shares of common stock reserved for future </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
issuance on July 28, 2019 and October 24, 2019, respectively, as well as any automatic increase in the number of shares of common stock reserved for future issuance thereunder; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">225,188&nbsp;shares of our common stock to be reserved for future issuance under our 2019 Employee Stock Purchase
Plan, which became effective in connection with this offering, as well as any automatic increase in the number of shares of common stock reserved for future issuance thereunder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted, we have presented the information in this prospectus based on the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of the Reorganization; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion of all shares of our convertible preferred stock outstanding into 7,077,366 shares of our common
stock, which conversion will occur immediately prior to the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">one-for-6.217</FONT> reverse stock split for our common stock and a
proportional adjustment to the conversion ratio of our convertible preferred stock effected on October&nbsp;25, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock in this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding stock options after June 30, 2019; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our second amended and restated certificate of incorporation (the &#147;Amended
Certificate&#148;) with the Secretary of State of the State of Delaware, and the adoption of our second amended and restated bylaws (the &#147;Amended Bylaws&#148;), each of which will occur immediately prior to the completion of this offering. See
&#147;Description of Capital Stock&#151;Anti-Takeover Effects of Our Amended Certificate, Amended Bylaws and Delaware Law.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing stockholders affiliated with our directors have agreed to purchase an aggregate of approximately $51&nbsp;million of shares of
our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. The underwriters will receive the same underwriting discount and commissions on these shares of common
stock as they will on any other shares of common stock sold to the public in this offering. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following summary consolidated statement of operations data for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31,
2018 are derived from our audited consolidated financial statements included elsewhere in this prospectus. The following summary consolidated statement of operations data for the period from January 18, 2018 (inception) to June 30, 2018 and the six
months ended June 30, 2019 and summary consolidated balance sheet data as of June 30, 2019 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our unaudited interim condensed
consolidated financial statements were prepared on the same basis as our audited consolidated financial statements and, in our opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair
statement of our unaudited interim condensed consolidated financial statements. Our historical results presented below are not necessarily indicative of the results to be expected for any future period, and our interim results are not necessarily
indicative of the results to be expected for the full year or any future period. You should read this information in conjunction with the information in &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from&nbsp;January&nbsp;18,<BR>2018 (inception)&nbsp;to</B><br><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from&nbsp;January&nbsp;18,<BR>2018 (inception)&nbsp;to<BR>June&nbsp;30, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated&nbsp;Statement&nbsp;of&nbsp;Operations&nbsp;Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 31.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute pro forma net loss per share, basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,127,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See Notes 2 and 11 to our audited consolidated financial statements and Notes 2 and 10 to our unaudited interim
condensed consolidated financial statements included elsewhere in this prospectus for an explanation of the calculations of our net loss per share, basic and diluted, and the weighted-average number of shares used in the computation of per-share
amounts. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;June 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro&nbsp;Forma</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As&nbsp;
Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated&nbsp;Balance&nbsp;Sheet&nbsp;Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The pro forma column reflects (i) the issuance in July 2019 of 1,173,611 shares of our convertible preferred
stock and (ii) the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 7,077,366 shares of our common stock immediately prior to the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted column reflects $76.5&nbsp;million in estimated net proceeds from the issuance and
sale of shares of our common stock in this offering, at the initial public offering price of $16.00&nbsp;per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below
before deciding whether to purchase shares of our common stock. You should also refer to the other information contained in this prospectus, including our audited consolidated financial statements and related notes included elsewhere in this
prospectus and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our business, financial condition, results of operations and prospects could be materially and adversely affected by any of these
risks or uncertainties. In any such case, the trading price of our common stock could decline, and you could lose all or part of your investment. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Industry </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are
a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred net losses since our inception, we expect to incur significant and increasing operating losses and we may
never be profitable. Our stock is a highly speculative investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company with a
limited operating history that may make it difficult to evaluate the success of our business to date and to assess our future viability. We commenced operations in 2018, and to date, our operations have been limited to&nbsp;organizing and staffing
our company, business planning, raising capital, acquiring our initial product candidate, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and licensing certain related technology, conducting research and development activities, including
preclinical studies and early clinical trials, and providing general and administrative support for these operations. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital
expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect and/or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial
sale, we have not generated any revenue from product sales to date and we continue to incur significant research and development and other expenses related to our ongoing operations. We have limited experience as a company conducting clinical trials
and no experience as a company commercializing any products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not profitable and have incurred net losses since our inception. As
of June 30, 2019, we had an accumulated deficit of $35.6&nbsp;million. Consequently, predictions about our future success or viability may not be as accurate as they would be if we had a longer operating history or a history of successfully
developing and commercializing pharmaceutical products. We have spent, and expect to continue to spend, significant resources to fund research and development of, and seek regulatory approvals for, <FONT STYLE="white-space:nowrap">BIO89-100</FONT>
and any future product candidates. We expect to incur substantial and increasing operating losses over the next several years as our research, development, preclinical testing and clinical trial activities increase. As a result, our accumulated
deficit will also increase significantly. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate
of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our shareholders&#146; (deficit) equity and working capital. The net losses we
incur may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT>
comparison of our results of operations may not be a good indication of our future performance. Even if we eventually generate product revenue, we may never be profitable and, if we do achieve profitability, we may not be able to sustain or increase
profitability on a quarterly or annual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no source of product revenue and may never become profitable. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> is in the early stages of development. To date, we have not generated any revenue from the
licensing or commercialization of <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> We will not be able to generate product revenue unless and until <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate, alone or with
future partners, successfully completes clinical trials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receives regulatory approval and is successfully commercialized. As <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is in the early stages of development, we do not expect to receive revenue
from it for a number of years, if ever. Although we may seek to obtain revenue from collaboration or licensing agreements with third parties, we currently have no such agreements that could provide us with material, ongoing future revenue and we may
never enter into any such agreements. Our ability to generate future product revenue from <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates also depends on a number of additional factors, including our or our future
partners&#146; ability to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully complete research and clinical development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and
any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally
compliant manufacturing of bulk drug substances and drug products to maintain that supply; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch and commercialize future product candidates for which we obtain marketing approval, if any, and, if
launched independently, successfully establish a sales force, marketing and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrate the necessary safety data post-approval to ensure continued regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain coverage and adequate product reimbursement from third-party payors, including government payors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve market acceptance for our or our future partners&#146; products, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish, maintain, protect and enforce our intellectual property rights; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire and retain qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, because of the numerous risks and uncertainties associated with pharmaceutical product development, including that our product
candidates may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or if or when we will achieve or maintain profitability. In addition, our
expenses could increase beyond expectations if we decide, or are required by the U.S. Food and Drug Administration (the &#147;FDA&#148;) or comparable foreign regulatory authorities, to perform studies or trials in addition to those that we
currently anticipate. Even if we complete the development and regulatory processes described above, we anticipate incurring significant costs associated with launching and commercializing these products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we generate revenue from the sale of any of our product candidates that may be approved, we may not become profitable and may need to
obtain additional funding to continue operations. If we fail to become profitable or do not sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we will require substantial additional capital to finance our operations, which may not be available to us on
acceptable terms, or at all. As a result, we may not complete the development and commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or develop new product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a clinical-stage biopharmaceutical company, our operations have consumed significant amounts of cash since our inception. We expect our
research and development expenses to increase substantially in connection with our ongoing activities, particularly as we conduct our Phase 1b/2a clinical trial of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and seek regulatory approvals for <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds from this offering, together with our existing cash and
cash equivalents and the funds available from the first tranche of the potential term loan discussed under the section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity and
Capital Resources&#148;, will fund our projected operating requirements into the second half of 2021. Our forecast of the period of time through which our financial resources will adequately support our operations is a forward-looking statement and
involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#147;Risk Factors&#148; section. We have based this estimate on assumptions that may prove to be
wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both short and long-term, will depend on many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing, costs and results of preclinical and clinical studies for <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign
regulatory authorities, including the potential for such authorities to require that we perform more studies than those that we currently expect or change their requirements on studies that had previously been agreed to; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio,
including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing of any patents or other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market acceptance of any approved product candidates, including product pricing and product coverage and adequate
reimbursement by third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of acquiring, licensing or investing in additional businesses, products, product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of selecting, auditing and potentially validating a manufacturing site for commercial-scale
manufacturing of <FONT STYLE="white-space:nowrap">BIO89-100;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates for which we may receive regulatory approval and that we determine to commercialize ourselves or in collaboration with our future partners. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will require additional capital to discover, develop, obtain regulatory approval for and commercialize
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates. We do not have any committed external source of funds. We expect to finance future cash needs through public or private equity or debt offerings or product
collaborations. Additional capital may not be available in sufficient amounts or on reasonable terms, if at all. If we do not raise additional capital, we may not be able to expand our operations or otherwise capitalize on our business
opportunities, our business and financial condition will be negatively impacted and we may need to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significantly delay, scale back or discontinue research and discovery efforts and the development or
commercialization of any product candidates or cease operations altogether; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek strategic alliances for research and development programs when we otherwise would not, or at an earlier
stage than we would otherwise desire or on terms less favorable than might otherwise be available; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relinquish, or license on unfavorable terms, our rights to technologies or any product candidates that we
otherwise would seek to develop or commercialize ourselves. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> receives approval and is
commercialized, we will be required to make milestone and royalty payments to Teva, from whom we acquired certain patents and intellectual property relating to <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> and from whom we licensed patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> related to glycoPEGylation technology that is used in the manufacture of <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> For additional information regarding this license agreement, please see
&#147;Business&#151;Agreements with Teva.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to stockholders purchasing shares in this offering,
restrict our operations or require us to relinquish rights to our technologies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stockholders purchasing shares in this offering
could suffer dilution or be negatively affected by fixed payment obligations we may incur if we raise additional funds through the issuance of additional equity securities or debt, such as the potential term loan discussed under the section entitled
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity and Capital Resources&#148;. Furthermore, these securities may have rights senior to those of our common stock and could contain
covenants or protective rights that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. If we need to secure additional financing, such additional fundraising efforts may divert our management and research efforts from our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent we obtain additional funding through product collaborations, these arrangements would generally require us to relinquish
rights to some of our technologies, product candidates or products, and we may not be able to enter into such agreements, on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail
or terminate some or all of our development programs or product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial condition raises substantial doubt as to our ability to
continue as a going concern. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements have been prepared assuming that we will continue to operate
as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Based on our current forecast, and without accounting for the proceeds from this offering or any other offering,
we do not have sufficient resources for at least the next year following the date that the consolidated financial statements appearing elsewhere in this prospectus were issued. To date, we have not generated revenues from our activities and have
incurred substantial operating losses. We expect that we will continue to generate substantial operating losses for the foreseeable future until we complete development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or our other product
candidates and seek regulatory approvals to market such product candidates. We will continue to fund our operations primarily through utilization of our current financial resources and additional raises of capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These conditions raise substantial doubt about our ability to continue as a going concern. Additionally, our independent registered public
accounting firm has included in its audit opinion for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018 an explanatory paragraph that there is substantial doubt as to our ability to continue as a going concern. We plan to
address these conditions by raising funds from our current investors as well as potential outside investors. However, there is no assurance that such funding will be available to us, will be obtained on terms favorable to us or will provide us with
sufficient funds to meet our objectives. The reaction of investors to the inclusion of a going concern statement by our auditors and our potential inability to continue as a going concern may materially adversely affect our share price and our
ability to raise new capital or enter into partnerships. If we become unable to continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than
the values reflected in our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business depends on the success of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> our only
product candidate under clinical development, which is in the early stages of clinical development and has not completed a pivotal trial. If we are unable to obtain regulatory approval for and successfully commercialize <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> or other future product candidates, or we experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, the primary focus of our product development has been <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of patients
with NASH. Currently, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is our only product candidate under clinical development. This may make an investment in our company riskier than similar companies that have multiple product candidates in
active development and that therefore may be able to better sustain a failure of a lead candidate. Successful continued development and ultimate regulatory approval of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of NASH or
other indications, including SHTG, is critical to the future success of our business. We have invested, and will continue to invest, a significant portion of our time and financial resources in the clinical development of <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> If we cannot successfully develop, obtain regulatory approval for and commercialize <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> we may not be able to continue our operations. The future regulatory
and commercial success of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is subject to a number of risks, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not have sufficient financial and other resources to complete the necessary clinical trials for <FONT
STYLE="white-space:nowrap">BIO89-100,</FONT> including, but not limited to, the clinical trials needed to obtain drug approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the mechanism of action of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is complex, and we do not know the
degree to which it will translate into a therapeutic benefit, if any, in NASH or any other indication, and we do not know the degree to which the complex mechanism of action may contribute to long-term safety issues or adverse events, if any, when <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> is taken for prolonged periods such as in the treatment of NASH or any other indication; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to obtain adequate evidence from clinical trials of efficacy and safety for <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of NASH or other indications; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in our clinical trials for <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> we may need to adjust our clinical
trial procedures and may need additional clinical trial sites, which could delay our clinical trial progress; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our clinical trials may not meet the level of statistical or clinical significance required by the
FDA or comparable foreign regulatory authorities for marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients in our clinical trials may suffer serious adverse effects for reasons that may or may not be related to <FONT
STYLE="white-space:nowrap">BIO89-100,</FONT> which could delay or prevent further clinical development; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the standards implemented by clinical or regulatory agencies may change at any time and we cannot be certain what
efficacy endpoints the FDA or foreign clinical or regulatory agencies may require in pivotal clinical trials with respect to NASH or any other indication for the approval of <FONT STYLE="white-space:nowrap">BIO89-100;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of later stage clinical trials may not be as favorable as the results we have observed to date in our
preclinical studies and Phase 1a clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we obtain accelerated approval of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any other product
candidate based on a surrogate endpoint, we may be required to conduct a post-approval clinical outcomes trial to confirm the clinical benefit of the product candidate; if any such post-approval trial is not successful we may not be able to continue
marketing the product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot be certain of the number and type of clinical trials and
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies that the FDA or other regulatory agencies will require in order to approve <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of NASH or any other indication, including
SHTG; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if approved for NASH or SHTG, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> will likely compete with products
that may reach approval for the treatment of NASH prior to <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> products that are currently approved for the treatment of SHTG and the <FONT STYLE="white-space:nowrap">off-label</FONT> use of currently
marketed products for NASH and SHTG; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to obtain, maintain or enforce our patents and other intellectual property rights.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development in the pharmaceutical industry, only a small percentage results in the
submission of a new drug application or a new BLA to the FDA and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> any such approval may
be subject to limitations on the indicated uses or patient populations for which we may market the products. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we may be unable to
successfully develop or commercialize <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> If we or any of our future development collaborators are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize <FONT
STYLE="white-space:nowrap">BIO89-100,</FONT> we may not be able to generate sufficient revenue to continue our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical drug development
involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and the results of prior preclinical or clinical trials are not necessarily predictive of our future results. Our clinical trials may fail to adequately
demonstrate the safety and efficacy of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates will be subject to rigorous and extensive clinical trials and extensive regulatory approval processes implemented by the FDA and comparable foreign regulatory authorities
before obtaining marketing approval from these regulatory authorities. The drug development and approval process is lengthy and expensive, and approval is never certain. Investigational new drugs, such as
<FONT STYLE="white-space:nowrap">BIO89-100,</FONT> may not prove to be safe and effective in clinical trials. We have no direct experience as a company in conducting later stage clinical trials required to obtain regulatory approval. We may be
unable to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers of participants or begin or successfully complete clinical trials in a timely fashion, if at all. In addition, the design of a clinical
trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. Because we have limited experience as a company designing
clinical trials, we may be unable to design and execute a clinical trial to support regulatory approval. Even if our current clinical trial is successful, it will be insufficient to demonstrate that <FONT STYLE="white-space:nowrap">BIO89-100</FONT>
is safe or effective for registration purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is a high failure rate for drugs and biologic products proceeding through clinical
trials. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate may not be predictive of the
results of later-stage clinical studies or trials and the results of studies or trials in one set of patients or line of treatment may not be predictive of those obtained in another. In fact, many companies in the pharmaceutical and biotechnology
industries have suffered significant setbacks in late stage clinical trials even after achieving promising results in preclinical studies and earlier stage clinical trials. In addition, data obtained from preclinical and clinical activities is
subject to varying interpretations, which may delay, limit or prevent regulatory approval. It is impossible to predict when or if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate will prove effective or safe in
humans or will receive regulatory approval. Owing in part to the complexity of biological pathways, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate may not demonstrate in patients the biochemical and pharmacological
properties we anticipate based on laboratory studies or earlier stage clinical trials, and they may interact with human biological systems or other drugs in unforeseen, ineffective or harmful ways. The number of patients exposed to product
candidates and the average exposure time in the clinical development programs may be inadequate to detect rare adverse events or findings that may only be detected once a product candidate is administered to more patients and for greater periods of
time. To date, our Phase 1a clinical trial has involved a small patient population of healthy volunteers and, because of the small sample size in such trial, the results of this clinical trial may be subject to substantial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
variability and may not be indicative of either future interim results or final results in patients with liver or cardio-metabolic diseases. If we are unable to successfully demonstrate the
safety and efficacy of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or other future product candidates and receive the necessary regulatory approvals, our business will be materially harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays in clinical testing, our commercial prospects will be adversely affected, our costs may increase and our business may be harmed.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Conducting clinical studies for any product candidates for approval in the United States requires filing an investigational new
drug (&#147;IND&#148;) application and reaching agreement with the FDA on clinical protocols, finding appropriate clinical sites and clinical investigators, securing approvals for such studies from the institutional review board at each such site,
manufacturing clinical quantities of product candidates and supplying drug product to clinical sites. Currently, we have an active IND with the FDA in the United States for <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Because our IND is with
the gastrointestinal division of the FDA, we may be required to file an additional IND with another division for any future indications, including SHTG. If any such future IND is not approved by the FDA, our clinical development timeline may be
negatively impacted and any future clinical programs may be delayed or terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that we will be able to
successfully accomplish required regulatory activities or all of the other activities necessary to initiate and complete clinical trials. As a result, our preclinical studies and clinical trials may be extended, delayed or terminated, and we may be
unable to obtain regulatory approvals or successfully commercialize our products. We do not know whether any other clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Our product
development costs will increase if we experience delays in clinical testing. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates and may harm our business, results of operations and prospects. Events that may result in a delay or unsuccessful completion of clinical development include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ongoing discussions with the FDA or comparable foreign authorities regarding the scope or design of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deviations from the trial protocol by clinical trial sites and investigators, or failures to conduct the trial in
accordance with regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to repeat clinical trials as a result of inconclusive or negative results or poorly executed testing or
changes in required endpoints by the FDA or comparable foreign authorities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable FDA inspection and review of a clinical trial site or records of any clinical or preclinical
investigation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the placement of a clinical hold on a clinical trial by the FDA or comparable foreign authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining, or the inability to obtain, required approvals from institutional review boards or other
governing entities at clinical sites selected for participation in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third parties, such as CROs, to satisfy their contractual duties to us or meet expected deadlines;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the testing, validation, manufacturing and delivery of the product candidates to the clinical sites;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficient supply or deficient quality of product candidate materials or other materials necessary to conduct
our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for clinical trials in selected patient populations, delays in identification and auditing of central or other
laboratories and the transfer and validation of assays or tests to be used to identify selected patients; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in enrolling participants into our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in patients completing a trial or returning for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays caused by patients dropping out of a trial due to side effects, disease progression or otherwise;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected drug-related adverse effects experienced by participants in our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implementation of new, or changes to, guidance or interpretations from the FDA or comparable foreign authorities
with respect to approval pathways for any product candidates we are pursuing, such as the draft guidance documents from the FDA and the European Medicines Agency for the development of NASH that were issued in 2018 and 2019; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the
ineligibility of a site to participate in our clinical trials; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in government regulations or administrative actions or lack of adequate funding to continue the clinical
trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our or our future collaborators&#146; inability to timely complete clinical development could result in
additional costs to us as well as impair our ability to generate product revenue, continue development, commercialize <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates, reach sales milestone payments and receive
royalties on product sales. In addition, if we make changes to a product candidate, we may need to conduct additional nonclinical studies or clinical trials to bridge or demonstrate the comparability of our modified product candidate to earlier
versions, which could delay our clinical development plan or marketing approval for our current product candidate and any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely
affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials largely depends on patient enrollment. We may encounter delays in enrolling,
or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Furthermore, as a result of the
inherent difficulties in diagnosing NASH, which can currently only be definitively diagnosed through a liver biopsy, and the significant competition for recruiting NASH patients in clinical trials, we or our future collaborators may be unable to
enroll the patients we need to complete clinical trials on a timely basis, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many factors affect patient enrollment, including:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population, which may be limited due to diagnostic requirements;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and location of clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition with other companies for clinical sites or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability and amount of any patient stipend; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility and exclusion criteria for the trial, including any potential requirement for a biopsy;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant adverse events or other side effects observed, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that enrolled participants will drop out before completion; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages of
the drug being studied in relation to other available therapies (oral versus injectables, like <FONT STYLE="white-space:nowrap">BIO89-100),</FONT> including any new drugs that may be approved for the indications we are investigating.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our competitors, some of whom have significantly greater resources than we do, are conducting clinical
trials for the same indications and seek to enroll patients in their studies that may otherwise be eligible for our clinical studies or trials, which could lead to slow recruitment and delays in our clinical programs. Further, since the number of
qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which could further reduce the number of patients who are available for our clinical
trials in these sites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays
or may require us to abandon one or more clinical trials altogether. If we are unable to enroll a sufficient number of patients that will complete clinical testing, we will be unable to seek or gain marketing approval for <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates and our business will be harmed. Even if we are able to enroll a sufficient number of patients in our clinical studies or trials, delays in patient enrollment may result
in increased costs or may affect the timing or outcome of our clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any
future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are initially developing <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of NASH, an indication
for which there are no approved products. This makes it difficult to predict the timing and costs of the clinical development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of NASH. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current research and development efforts are focused on developing <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of
NASH, an indication for which there are no approved products. The regulatory approval process for novel product candidates such as <FONT STYLE="white-space:nowrap">BIO89-100</FONT> can be more expensive and take longer than for other, better known
or extensively studied product candidates. As other companies are in later stages of clinical trials for their potential NASH therapies, we expect that the path for regulatory approval for NASH therapies may continue to evolve in the near term as
these other companies refine their regulatory approval strategies and interact with regulatory authorities. Such evolution may impact our future clinical trial designs, including trial size and endpoints, in ways that we cannot predict today. Our
anticipated development costs would likely increase if development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate is delayed because we are required by the FDA to perform studies or trials in addition to, or
different from, those that we currently anticipate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of any increase in our anticipated development
costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates may cause
undesirable side effects or have other properties that could delay or prevent their regulatory approval or limit the commercial profile of an approved label. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Undesirable side effects caused by <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates could cause us or
regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Additional clinical studies
may be required to evaluate the safety profile of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. While no serious adverse events were reported in our Phase 1a clinical trial of
<FONT STYLE="white-space:nowrap">BIO89-100,</FONT> the following treatment-related adverse events were reported in at least two subjects in the treatment cohort: injection site reactions and headaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Future results of our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In
such an event, we could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product
candidates for any or all targeted indications. Drug-related side effects could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences could
materially and adversely affect our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It may be difficult to discern
whether certain events or symptoms observed during our clinical trials or by patients using our approved products are related to <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates or approved products or some other
factor. As a result, we and our development programs may be negatively affected even if such events or symptoms are ultimately determined to be unlikely related to <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates or
approved products. We cannot assure you that additional or more severe adverse side effects related to <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates will not be observed in our clinical trials or in the
commercial setting. Further, we expect that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> will require multiple administrations vis subcutaneous injection in the course of a clinical trial, and this chronic administration increases the risk that
our clinical drug development programs may not uncover all possible adverse events that may eventually be experienced by patients treated with <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> such as rare adverse events or chance findings that may
only be detected once product candidates are administered to ore patients or for greater periods of time. If observed, such adverse side effects could delay or preclude regulatory approval of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any
future product candidates, limit commercial use or result in the withdrawal of previously granted marketing approvals. If we or others identify undesirable or unacceptable side effects caused by <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or
any future product candidates or products: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to modify, suspend or terminate our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to modify or include additional dosage and administration instructions, warnings and
precautions, contraindications, boxed warnings, limitations, restrictions or other statements in the product label for our approved products, or issue field alerts to physicians and pharmacies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to conduct costly additional clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to limitations on how we may promote our approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our approved products may decrease significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require us to take our approved products off the market; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to regulatory investigations, government enforcement actions, litigation or product liability
claims; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our products may become less competitive or our reputation may suffer. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any of these results could decrease or prevent any sales of our approved product or
substantially increase the costs and expenses of commercializing and marketing our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition, which may result in
others discovering, developing or commercializing competing products before or more successfully than us. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical
industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe the key competitive factors that will affect the development and commercial success of
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience of dosing, price, the level of generic competition and reimbursement. Our competitors include
multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and pharmaceutical companies are pursuing the development or marketing of pharmaceuticals that
target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Given the high incidence of NASH and
SHTG, it is likely that the number of companies seeking to develop products and therapies for the treatment of liver and cardio-metabolic diseases, such as NASH and SHTG, will increase. For additional information regarding our competition, please
see &#147;Business&#151;Competition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are no currently approved therapies for the treatment of NASH. Although there are no
approved therapies that specifically target the signaling pathways that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is designed to affect, there are numerous currently approved therapies for treating diseases other than NASH and some of these
currently approved therapies may exert effects that could be similar to <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Many of these approved drugs are well-established therapies or products and are widely accepted by physicians, patients and
third-party payors. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We
expect that if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates are approved, they will be priced at a significant premium over competitive generic products, including branded generic products. This may make it
difficult for us to differentiate our products from currently approved therapies, which may adversely impact our business strategy. In addition, many companies are developing new therapeutics, and we cannot predict what the standard of care will be
as <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates progress through clinical development. In addition, to the extent <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates are approved
for cardio-metabolic indications, such as SHTG, the commercial success of our products will also depend on our ability to demonstrate benefits over the then-prevailing standard of care, including diet, exercise and lifestyle modifications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates are approved for the treatment of SHTG, we will
compete with currently approved therapies and therapies further along in development. Our competitors both in the United States and abroad include large, well-established pharmaceutical and generic companies with significantly greater name
recognition. Our competitors may be able to charge lower prices than we can, which may adversely affect our market acceptance. Many of these competitors have greater resources than we do, including financial, product development, marketing,
personnel and other resources. Clinical trials for the treatment of SHTG may be relatively costly and time consuming. The requirements for approval by the FDA and comparable foreign regulatory authorities may change over time and this may require
changes to ongoing or future clinical trial designs that could impact timelines and cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our competitors market products that are
more effective, safer or cheaper than our products or that reach the market sooner than our products, we may not achieve commercial success. In addition, the biopharmaceutical industry is characterized by rapid technological change. Because our
research approach integrates many technologies, it may be difficult for us to stay abreast of the rapid changes in other technologies. If we fail to stay at the forefront of technological change, we may be unable to compete effectively.
Technological advances or products developed by our competitors may render our technologies, products or product candidates obsolete, less competitive or not economical. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many of our competitors have substantially greater financial, technical, human and other
resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly longer operating histories and greater experience than we have in
undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Many of our competitors have established distribution channels for the commercialization of
their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result, our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other
intellectual property rights that limit our ability to develop or commercialize our product candidate or any future product candidates. Our competitors may also develop and succeed in obtaining approval for drugs that are more effective, more
convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively
against these companies, then we may not be able to commercialize our product candidate or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors
also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and enrolling patients for clinical trials, as well as in acquiring technologies complementary to, or
necessary for, our programs. Our inability to compete effectively in any of these aspects of our business could harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing FGF product candidates,
which could adversely affect our stock price, our ability to attract additional capital and our development program. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Lack of
efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing FGF product candidates like ours. For example, Bristol-Myers Squibb Company and Akero Therapeutics, Inc. are also developing
FGF21 product candidates for the treatment of NASH. We have no control over their clinical trials or development program, and lack of efficacy, adverse events or undesirable side effects experienced by subjects in their clinical trials could
adversely affect our stock price, our ability to attract additional capital and our development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or even the viability of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> as a product candidate,
including by creating a negative perception of FGF therapeutics by healthcare providers or patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline and preliminary data from our
clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which are based on a preliminary analysis of
then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and
conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or
different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially
different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. In addition, we
may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment
continues and more patient data become available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, adverse changes between interim data and final data could significantly harm
our business and prospects. Additional disclosure of interim data by us or by our competitors in the future could also result in volatility in the price of our common stock after this offering. Further, others, including regulatory agencies, may not
accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of
the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions,
conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates may be harmed, which could harm our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter difficulties in managing our growth, which could adversely affect our operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are in the early stages of building the full management team and employee base that we anticipate we will need to complete the development <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and other future product candidates. As of June&nbsp;30, 2019, we had 14 employees, some of whom are based in the United States and some of whom are based in Israel. As we advance our preclinical and
clinical development programs for product candidates, seek regulatory approval in the United States and elsewhere and increase the number of ongoing product development programs, we anticipate that we will need to increase our product development,
scientific and administrative headcount. We will also need to establish commercial capabilities in order to commercialize any product candidates that may be approved. Such an evolution may impact our strategic focus and our deployment and allocation
of resources. Our management, personnel and systems may experience difficulty in adjusting to our growth and strategic focus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability
to manage our operations and growth effectively depends upon the continual improvement of our procedures, reporting systems and operational, financial and management controls. We may not be able to implement administrative and operational
improvements in an efficient or timely manner and may discover deficiencies in existing systems and controls. If we do not meet these challenges, we may be unable to execute our business strategies and may be forced to expend more resources than
anticipated addressing these issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may acquire additional technology and complementary businesses in the future. Acquisitions
involve many risks, any of which could materially harm our business, including the diversion of management&#146;s attention from core business concerns, failure to effectively exploit acquired technologies, failure to successfully integrate the
acquired business or realize expected synergies or the loss of key employees from either our business or the acquired businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, in order to continue to meet our obligations as a public company and to support our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management, personnel and systems may not be
adequate to support this future growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we are unable to successfully manage our growth and the increased complexity of our
operations, our business, financial position, results of operations and prospects may be materially and adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We must attract and
retain highly skilled employees in order to succeed. If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business
will suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to attract or retain qualified personnel and consultants due to the intense competition for such
individuals among in the biotechnology and pharmaceutical industries. If we are not able to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development and
commercial objectives, our ability to raise additional capital and our ability to implement our business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our industry has
experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the development, regulatory, commercialization and business development expertise of the members of our executive team, as well as other key
employees and consultants. If we lose one or more of our executive officers or other key employees or consultants, our ability to implement our business strategy successfully could be seriously harmed. Any of our executive officers or other key
employees or consultants may terminate their employment at any time and replacing such individuals may be difficult and time-consuming because of the limited number of individuals in our industry with the necessary breadth of skills and experience.
Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate such individuals. Additionally, we do not currently maintain &#147;key person&#148; life insurance on
the lives of our executives or any of our employees. This lack of insurance means that we may not receive adequate compensation for the loss of the services of these individuals. If we are unable to continue to attract and retain high-quality
personnel, the rate and success with which we can discover and develop product candidates and our business will be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have relied on, and
expect to continue to rely on, third-party manufacturers to produce <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. Any failure by a third-party manufacturer to produce acceptable product candidates for us
pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacturing of biologic drugs such as <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is complex and the process of identifying the
qualifying suppliers takes a significant investment of time and money. We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the
capabilities to do so. As a result, we currently rely, and expect to rely for the foreseeable future, on third-party manufacturers to supply us with <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently have a sole source relationship with Northway Biotechpharma (&#147;BTPH&#148;) pursuant to which they supply us with <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> If there should be any disruption in our supply arrangement with BTPH, including any adverse events affecting BTPH, it could have a negative effect on the clinical development of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and other operations while we work to identify and qualify an alternate supply source. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do
not have a long-term supply agreement with any third-party manufacturer. Reliance on third-party manufacturers entails risks to which we would not be subject if we manufacture product candidates or products ourselves. For example, if we do not
maintain our key manufacturing relationships, we may fail to find replacement manufacturers or develop our own manufacturing capabilities in a timely manner or at all, which could delay or impair our ability to obtain regulatory approval for our
products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers, we may not be able to enter into agreements with them on terms and conditions favorable to us, and there could be a substantial
delay before new facilities could be qualified and registered with the FDA and other comparable foreign regulatory authorities. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails
additional risks, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible failure of the third party to manufacture product candidates according to our schedule, or at all,
including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party because of factors beyond our control
(including a failure to manufacture product candidates in accordance with our product specifications); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or
active drug or placebo not being properly identified; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial
interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance, quality assurance and safety and pharmacovigilance
reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain raw materials necessary for the manufacture of <FONT STYLE="white-space:nowrap">BIO89-100</FONT>
under our current manufacturing process, such as reagents that are needed for the glycoPEGylation, are available only from a single supplier. In April 2018, we entered into a Reagent Supply and Technology Transfer Agreement with Teva under which
Teva agreed to supply us several reagents required for the glycoPEGylation process until December&nbsp;31, 2022 and transfer the <FONT STYLE="white-space:nowrap">know-how</FONT> required for our production of these reagents. We expect the
manufacture of these reagents will be transferred to a new supplier prior to expiration of the agreement with Teva. Any complications arising under our agreement with Teva, with the subsequent transfer of
<FONT STYLE="white-space:nowrap">know-how</FONT> to us, or any difficulties securing a new supplier could considerably delay the manufacture of <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Any significant delay in the acquisition or decrease
in the availability of these raw materials from Teva or any new supplier could considerably delay the manufacture of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> which could adversely impact the timing of any planned trials or the regulatory
approvals of <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and other comparable foreign regulatory authorities require
manufacturers to register manufacturing facilities. The FDA and other comparable foreign regulatory authorities also inspect these facilities to confirm compliance with current good manufacturing practices (&#147;cGMP&#148;). Contract manufacturers
may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. We may have little to no
control regarding the occurrence of third-party manufacturer incidents. Any failure to comply with cGMP requirements or other FDA or comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability
to develop <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates and market our products following approval. Our sole source supplier, BTPH, has not yet manufactured a commercial product, and as a result, has not been
subject to inspection by the FDA and other comparable foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates are approved by the FDA or other comparable foreign regulatory authorities for commercial sale, we may need to manufacture such product candidate in larger
quantities. We intend to use third-party manufacturers for commercial quantities of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to the extent we advance this product candidate and other product candidates. Our manufacturers may not be able to
successfully increase the manufacturing capacity for any of our product candidates in a timely or efficient manner, or at all. If we are unable to successfully increase the manufacturing capacity for a product candidate, the regulatory approval or
commercial launch of that product candidate may be delayed or there may be a shortage in the supply of the product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the operations of our third-party manufacturers may be subject to earthquakes,
power shortages, telecommunications failures, failures or breaches of information technology systems, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, and other natural or <FONT
STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions. Damage or extended periods of interruption to our facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could
cause us to cease or delay development of some or all of our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <FONT
STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future
dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop our product candidates and commercialize any products that receive regulatory approval on a timely basis.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the
original manufacturer, we may have difficulty transferring such skills or technology to another third party and a feasible alternative many not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license
from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures
that comply with quality standards and with all applicable regulations and guidelines. For example, in the event that we need to switch our third-party manufacturer of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> from BTPH, which is our sole
manufacturing source for BIO89-100, we anticipate that the complexity of the glycoPEGylation manufacturing process may materially impact the amount of time it may take to secure a replacement manufacturer. The delays associated with the verification
of a new manufacturer, if we are able to identify an alternative source, could negatively affect our ability to develop product candidates in a timely manner or within budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of biologic products is complex and we are subject to many manufacturing risks, any of which could substantially increase our costs and
limit supply of our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To date, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has been manufactured by a single
third-party manufacturer, BTPH, solely for preclinical studies and clinical trials. This manufacturer may not be able to scale production to the larger quantities required for large clinical trials and to commercialize
<FONT STYLE="white-space:nowrap">BIO89-100.</FONT> The process of manufacturing <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is complex, highly regulated and subject to several risks, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the process of manufacturing biologics is susceptible to product loss due to contamination, equipment failure,
improper installation or operation of equipment, vendor or operator error and improper storage conditions. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply
disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, the manufacturing facilities may need to be closed for an extended period of time to
investigate and eliminate the contamination; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing facilities in which our products are made could be adversely affected by equipment failures,
labor and raw material shortages, financial difficulties of our contract manufacturers, natural disasters, power failures, local political unrest and numerous other factors; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any adverse developments affecting manufacturing operations for our products may result in shipment delays,
inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of our products. We may also have to record inventory write-offs and incur other charges and expenses for products that fail to meet
specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The manufacture of biologic products, and in particular, the glycoPEGylation process, is
complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in
scaling up and validating initial production and ensuring the avoidance of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator
error and shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. We cannot assure you that any stability or other issues relating to the manufacture of
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> will not occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have limited process development capabilities and have
access only to external manufacturing capabilities. We do not have and we do not currently plan to acquire or develop the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in human clinical trials or
commercialization. Any delay or interruption in the supply of clinical trial materials, including as a result of breach by us or BTPH of our agreement with BTPH, or our inability to agree to the terms of supply or related services in any statement
of work, could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate
clinical trials completely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We plan to develop a new drug product formulation for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and we may be
unsuccessful. Any changes in methods of product candidate manufacturing or formulation may result in the need to perform new clinical trials, which would require additional costs and cause delay. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to develop a new drug product formulation of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for late stage clinical trials and
commercialization. Our current drug product is stored as a frozen liquid and is therefore not well-suited to larger clinical trials or commercialization. We have engaged a formulation development company to explore both a new refrigerated liquid
formulation and a <FONT STYLE="white-space:nowrap">freeze-dried,</FONT> or lyophilized formulation. We also plan to begin development of a <FONT STYLE="white-space:nowrap">pen-type</FONT> autoinjector for the new drug product formulation. There is
no assurance that we will be successful in developing a new drug product formulation or an autoinjector on a timely basis or at all, which could impede our development and commercialization strategy for
<FONT STYLE="white-space:nowrap">BIO89-100.</FONT> The FDA or other comparable foreign regulatory authorities could require nonclinical studies or clinical trials to support introduction of any new formulation and autoinjector, which could delay
completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase our clinical trial costs, delay approval of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and jeopardize
our ability to commence product sales and generate revenue from <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third
parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently rely on, and expect to continue to rely on, third parties, such as CROs, clinical data management organizations,
medical institutions, consultants and clinical investigators, to conduct our clinical trials and certain aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us at any time. If we need to
enter into alternative arrangements, it would delay our product development activities and such alternative arrangements may not be available on terms acceptable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for research and development activities will reduce our control over these activities, but will not
relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to
comply with standards, commonly referred to as current Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity
and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties
do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining,
marketing approvals for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the
part of our distributors could delay clinical development, marketing approval and/or commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates, producing additional losses and depriving us of potential
revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, while we have received the majority of the knowledge with regard to our current product candidate from Teva, we may
still depend on Teva to provide information and documentation regarding certain aspects of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. If Teva delays providing or fails to provide such information or
documentation, we may also be delayed in our efforts to successfully commercialize <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. We also depend on Teva to support our efforts to transfer the manufacturing
process to a contract manufacturer. If Teva is unable to or otherwise fails to support such transfer, we may incur significant delay and increased costs in commercializing <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture
some or all of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to depend on collaborators, partners, licensees, clinical investigators, CROs,
manufacturers and other third parties to support our discovery efforts, to formulate product candidates, to conduct clinical trials for some or all of our product candidates, to manufacture clinical and commercial scale quantities of our drug
substance and drug product and to market, sell and distribute any products we successfully develop. Any problems we experience with any of these third parties could delay the development, commercialization and manufacturing of our product
candidates, which could harm our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that we will be able to successfully negotiate agreements
for, or maintain relationships with, collaborators, partners, licensees, clinical investigators, CROs, manufacturers and other third parties on favorable terms, if at all. If we are unable to obtain or maintain these agreements, we may not be able
to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize BIO89-100 and any future product candidates, which will in turn adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to expend substantial management time and effort to enter into relationships with third parties and, if we successfully enter into
such relationships, to manage these relationships. In addition, substantial amounts will be paid to third parties in these relationships. However, we cannot control the amount or timing of resources our future contract partners will devote to our
research and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill their obligations to us under these arrangements in a timely fashion, if at all. In addition, while we
manage the relationships with third parties, we cannot control all of the operations of and any outsourcing used by such third parties. We rely on third parties&#146; knowledge regarding specific local laws and regulatory requirements in foreign
jurisdictions, where applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to develop and commercialize additional product candidates, we may be unable to grow our business.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although the development and commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is currently our primary
focus, as part of our longer-term growth strategy, we plan to evaluate the development and commercialization of other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapies related to NASH and other liver and cardio-metabolic diseases. The success of this strategy depends primarily upon our ability to identify and validate new therapeutic candidates, and
to identify, develop and commercialize new drugs and biologics. Our research efforts may initially show promise in discovering potential new drugs and biologics, yet fail to yield product candidates for clinical development for a number of reasons,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need to rely on third parties to generate molecules for some of our product candidate programs;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may encounter product manufacturing difficulties that limit yield or produce undesirable characteristics that
increase the cost of manufacturing our product candidates, cause delays or make our product candidates unmarketable; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates may cause adverse effects in patients or subjects, even after successful initial toxicology
studies, which may make the product candidates unmarketable; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates may not demonstrate a meaningful benefit to patients or subjects; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our future collaboration partners may change their development profiles or plans for potential product candidates
or abandon a therapeutic area or the development of a partnered product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced
to abandon our development efforts for one or more programs, which could have a material adverse effect on our business, operating results and prospects and could potentially cause us to cease operations. Future research programs to identify new
product candidates may require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Product candidates may require additional, time-consuming development efforts prior to commercial sale, including preclinical studies,
clinical trials and approval by the FDA and/or comparable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product
candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, be successfully
commercialized, be widely accepted in the marketplace, or be more effective than other commercially available alternatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may use our limited
financial and human resources to pursue a particular research program or product candidate that is ultimately unsuccessful or less successful than other programs or product candidates that we may have forgone or delayed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because we have limited personnel and financial resources, we may forego or delay the development of certain programs or product candidates
that later prove to have greater commercial potential than the programs or product candidates that we do pursue. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
Our spending on current and future research and development programs for product candidates may not yield any commercially viable products. Similarly, our decisions to delay or terminate drug development programs may also be incorrect and could
cause us to miss valuable opportunities. If we fail to accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration,
licensing or other arrangements or we may allocate our limited internal resources to that product candidate when it would have been more advantageous to enter into such an arrangement. Any such failure could have a material adverse effect on our
business, financial condition, results of operations or prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As we evolve from a company that is primarily involved in clinical development to a company that is
also involved in commercialization, we may encounter difficulties in expanding our operations successfully. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As we advance our
product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing, and marketing and sales capabilities and may need to further contract with third parties to provide these capabilities, such as
collaborators, distributors, marketers and additional suppliers. We currently have no experience as a company in or infrastructure for sales, marketing and distribution, and our operations are currently limited to clinical development activities and
as our operations expand, we likely will need to manage additional relationships with such third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate is approved, we intend either to establish a sales and organization with technical expertise and supporting distribution capabilities to commercialize <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate or to outsource such functions to one or more third parties. Either of these options would be expensive and time-consuming. Some or all of these costs may be incurred in
advance of any approval of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate. In addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we
intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely affect the commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and other future product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Maintaining third-party relationships for these purposes will impose significant added responsibilities on members of our
management and other personnel. We must be able to effectively manage our development efforts, recruit and train sales and marketing personnel, effectively manage our participation in the clinical trials in which our product candidates are involved
and improve our managerial, development, operational and finance systems, all of which may impose a strain on our administrative and operational infrastructure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing or distribution services, any product revenues that we receive,
or the profitability of these product revenues to us, are likely to be lower than if we were to market and sell any products that we develop without the involvement of these third parties. In addition, we may not be successful in entering into
arrangements with third parties to sell and market our products or in doing so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to
sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to establish commercial collaborations for our product candidates, and, if we are not able to establish them on commercially reasonable
terms, we may have to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our drug development programs and the potential
commercialization of our product candidates will require substantial additional cash to fund expenses. We may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a
collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors.
Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of
manufacturing and delivering such product candidate to patients, the potential of competing products and the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without
regard to the merits of the challenge and industry and market conditions generally. The collaborators may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a
collaboration could be more attractive than the one with us for our product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Collaborations are complex and time-consuming to negotiate and document. In addition, there
have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to
curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any
sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may
need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product
revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates may not achieve adequate market acceptance among
physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if our product
candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. Given the number of drugs in development for the treatment of NASH, if we are
unsuccessful in achieving a differentiated profile with <FONT STYLE="white-space:nowrap">BIO89-100</FONT> based on efficacy, safety and tolerability, dosing and administration, market acceptance will be limited. Efforts to educate the medical
community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. Demonstrating the safety and efficacy of our product candidates and obtaining regulatory approvals will not
guarantee future revenue. Our commercial success also depends on coverage and adequate reimbursement of our product candidates by third-party payors, including government payors, which may be difficult or time-consuming to obtain, may be limited in
scope and may not be obtained in all jurisdictions in which we may seek to market our products. Governments and private insurers closely examine medical products to determine whether they should be covered by reimbursement and, if so, the level of
reimbursement that will apply. We cannot be certain that third-party payors will sufficiently reimburse sales of our products, or otherwise enable us to sell our products at profitable prices. Similar concerns could also limit the reimbursement
amounts that health insurers or government agencies in other countries are prepared to pay for our products. In many countries or regions where we may market our products, either directly or with collaborators, the pricing of prescription drugs is
controlled by the government or regulatory agencies. Regulatory agencies in these countries could determine that the pricing for our products should be based on prices of other commercially available drugs for the same disease, rather than allowing
us to market our products at a premium as new drugs. This may be particularly true for drugs that treat NASH or SHTG, which some healthcare providers and payors may deem to be a &#147;lifestyle&#148; disease that could be ameliorated by changes in
diet and exercise. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy, safety and dosing profile of the product candidate as demonstrated in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of the product candidate as well as competitive products;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of the product candidate as a safe and effective treatment by physicians and patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages of the product candidate over alternative treatments, including any
similar generic treatments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage and adequate reimbursement and pricing by third parties and government authorities,
including any requirements for biopsy-proven NASH prior to being approved for reimbursement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patients&#146; willingness to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage and/or adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the frequency and severity of adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of sales and marketing efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to the product candidate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a
determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of
influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#146; organizations, hospitals, other healthcare providers, government agencies or private insurers
will determine that our products are safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not
generate or derive sufficient revenue from that product candidate and may not become or remain profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we commercialize <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate, we may face challenges to achieving profitability such as our products becoming subject to unfavorable pricing regulations, third-party reimbursement practices or
healthcare reform initiatives, which could harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The regulations that govern marketing approvals, pricing and
reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some
countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical
pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay or limit
our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenue we generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our
investment in one or more product candidates, even if our product candidates obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any
products successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government health care programs and private
health insurers. Such third-party payors determine which medications they will cover and establish reimbursement levels. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of
reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure
that coverage and reimbursement will be available for any product that we or our future collaborators commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or
the price of, any product candidate for which we or our future collaborators obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we and our future collaborators may not be
able to successfully commercialize any product candidate for which marketing approval is obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining coverage and reimbursement for newly approved
drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all
cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary.
Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net
prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at
lower prices than in the United States. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our
operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To become and
remain profitable, we or any potential future collaborator must develop and eventually commercialize <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates with significant market potential at an adequate profit margin
after cost of goods sold and other expenses. Commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates may entail a substantial cost of goods sold and there can be no assurance that we will be able to
achieve a suitable gross margin with respect to sales of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform in the United States may negatively impact our ability to profitably sell our product candidates, if approved, and to recoup the
upfront investment needed to obtain regulatory approval of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third-party payors, whether domestic or
foreign, or governmental or commercial, are continually developing and advancing new methods of controlling healthcare costs. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the
healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010
(collectively, the &#147;Affordable Care Act&#148;) was enacted, which includes measures that have significantly changed the way health care is financed by both governmental and private insurers. Among the provisions of the Affordable Care Act of
particular importance include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for
drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a licensure framework for follow-on biologic products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an extension of a manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services
(&#147;CMS&#148;) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been judicial and congressional challenges to
certain aspects of the Affordable Care Act which could potentially void or significantly modify the Affordable Care Act in part or in whole. For example, since January 2017, President Trump signed two Executive Orders and other directives designed
to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. On December&nbsp;22, 2017, President Trump signed into law The Tax Cuts and Jobs Act of 2017 (the &#147;Tax Act&#148;), which includes a provision repealing
the individual mandate to maintain health insurance coverage under the Affordable Care Act effective January&nbsp;1, 2019. Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018
that delayed the implementation of certain mandated fees under the Affordable Care Act, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans and the annual
fee imposed on certain health insurance providers based on market share. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the
Affordable Care Act, and because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. While neither the Texas District Court Judge, the Trump administration nor CMS have stated that the
ruling will have an immediate effect, it is unclear how this decision, subsequent appeals, if any, and other efforts will impact the Affordable Care Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the same time, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the
relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration&#146;s budget proposals for fiscal years 2019 and 2020 contain further
drug price control measures that could be enacted during the budget process or in other future legislation. The Trump administration released a &#147;Blueprint,&#148; or plan, to lower drug prices and reduce out of pocket costs of drugs that
contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs
of drug products paid by consumers. We expect that the healthcare reform measures that have been adopted and may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive
for any approved product and could seriously harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate product revenue, attain profitability or commercialize our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at
broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate product revenue, attain
profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which we may obtain regulatory approval and may affect our overall financial condition, including our ability to recoup the upfront investment needed to obtain regulatory approval for our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement risks
associated with doing business outside of the United States. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our use of our international facilities subject us to U.S. and
foreign governmental trade, import and export, and customs regulations and laws. Compliance with these regulations and laws is costly and exposes us to penalties for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Furthermore, if we succeed
in developing any products, we intend to market them in other jurisdictions in addition to the United States. If approved, we may hire sales representatives and conduct physician and patient association outreach activities outside of the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Doing business internationally potentially involves a number of risks, including but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import
restrictions, employment laws, regulatory requirements, and other governmental approvals, permits and licenses; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rejection or qualification of foreign clinical trial data by the competent authorities of other countries;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional potentially relevant third-party patent rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a shortage of high-quality employees; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laws and business practices favoring local companies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor reimbursement regimes, government payors or patient <FONT
STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limits in our ability to penetrate international markets; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local
and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak
of disease, boycotts, curtailment of trade and other business restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the imposition of restrictions on the activities of foreign agents and representatives; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain expenses including, among others, expenses for travel, translation and insurance; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within
the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any of these factors could harm our ongoing international clinical operations and supply
chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>If we fail to comply with foreign regulatory requirements governing human clinical trials and marketing approval for drugs, we could be prevented
from selling our product candidates in foreign markets, which may adversely affect our operating results and financial condition</I></B><B>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement for marketing our product candidates
outside the United States vary greatly from country to country and may require additional testing. We expect that our future clinical development of our product candidates will involve a number of clinical trials in foreign jurisdictions. We have no
direct experience as a company in obtaining foreign regulatory approvals. The time required to obtain approvals outside the United States may differ from that required to obtain FDA approval. We may not obtain foreign regulatory approvals on a
timely basis, if at all. Approval by the FDA does not guarantee approval by comparable foreign regulatory authorities, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the
FDA. Failure to comply with these regulatory requirements or obtain required approvals could impair our ability to develop foreign markets for our product candidates and may have a material adverse effect on our results of operations and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products
that we may develop. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our product candidates in
human clinical trials and will face an even greater risk if we commercialize any resulting products. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, or others using our products. If we cannot
successfully defend ourselves against claims that our product candidates or products that we may develop caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls or a change in the indications for which products may be used; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination of clinical trial sites or entire trial programs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial subjects or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of management and scientific resources from our business operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we may develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our clinical trial liability insurance coverage may not adequately cover all liabilities that we may incur. We may not be able to maintain
insurance coverage at a reasonable cost or in an amount adequate to satisfy any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liability that may arise. Our inability to obtain product liability insurance at an acceptable cost or to otherwise protect against potential product liability claims could prevent or delay the
commercialization of any products or product candidates that we develop. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for our product candidates in development,
but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. If we are sued
for any injury caused by our products, product candidates or processes, our liability could exceed our product liability insurance coverage and our total assets. Claims against us, regardless of their merit or potential outcome, may also generate
negative publicity or hurt our ability to obtain physician endorsement of our products or expand our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, contractors, vendors,
principal investigators, consultants and future partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other misconduct by our employees, contractors, vendors, principal investigators, consultants or future
partners. Misconduct by these parties could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial
information or data timely, completely or accurately, or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and
other business arrangements. Third-party misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Although we intend to
adopt a Code of Business Conduct and Ethics, which will be effective prior to the consummation of this offering, it is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted
against us resulting from this misconduct and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. If
we or our future partners market products in a manner that violates fraud and abuse and other healthcare laws, or if we or our future partners violate government price reporting laws, we or our future partners may be subject to administrative civil
and/or criminal penalties, among other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most states also have statutes or regulations similar to these federal laws, which may
apply to items such as pharmaceutical products and services reimbursed by private insurers. We and/or our future partners may be subject to administrative, civil and criminal sanctions for violations of any of these federal and state laws.
Pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to
prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion; and submitting inflated best
price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve
substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other
healthcare laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business operations and relationships with investigators, healthcare professionals, consultants,
third-party payors, patient organizations and customers are subject to broadly applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product
candidate for which we obtain regulatory approval. Our current and future arrangements may expose us to broadly applicable fraud and abuse and other healthcare laws that may constrain the business or financial arrangements and relationships through
which we would market, sell and distribute our products. Even though we will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws pertaining to fraud and
abuse are and will be applicable to our business. Such laws include, but are not limited to, the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal false claims, false statements and civil monetary penalties laws, including the federal civil False
Claims Act (&#147;FCA&#148;), which can be enforced through civil whistleblower or qui tam actions, prohibit, among others, any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or
knowingly making, or causing to be made, a false statement to get a false claim paid. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying,
soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed
healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, on the other. Although there are several statutory exceptions
and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject
to scrutiny if they do not qualify for an exception or safe harbor. In addition, the intent standard under the federal Anti-Kickback Statute was amended by the Affordable Care Act to a stricter standard such that a person or entity no longer needs
to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the FCA. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which prohibits,
among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying,
concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare
matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patient data privacy and security regulation, including, in the United States, HIPAA, as amended by the Health
Information Technology for Clinical Health Act of 2009 (&#147;HITECH&#148;), and their respective implementing regulations, which impose specified requirements on &#147;covered entities,&#148; including healthcare providers, health plans, and
healthcare clearinghouses, as well as their respective &#147;business associates&#148; that perform services for them that involve the use, or disclosure of, individually identifiable health information relating to the privacy, security and
transmission of individually identifiable health information. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the
Affordable Care Act, that require applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions,
to track and annually report to CMS payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and investment interests held by physicians or their immediate family members in the applicable
manufacturer, and disclosure of such information will be made by CMS on a publicly available website. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analogous state, local or foreign laws, such as state anti-kickback and false claims laws, which may apply to
items or services reimbursed by any third-party payor, including commercial insurers; state and local marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements; state laws that require
biopharmaceutical companies to comply with the biopharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require licensure or registration
by sales and marketing agents of a pharmaceutical company; state laws that require disclosure of information related to drug pricing; and state and foreign laws governing the privacy and security of health information in certain circumstances, many
of which differ from each other in significant ways and may not have the same effect as HIPAA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pharmaceutical and other
healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to
pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion; and submitting inflated best price information to the
Medicaid Rebate Program to reduce liability for Medicaid rebates. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is
possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and
regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. For example, in June 2018, California enacted the California Consumer Privacy Act of 2018 (the &#147;CCPA&#148;), which takes effect
on January&nbsp;1, 2020. The CCPA gives California residents the right to access and require deletion of their personal information, the right to&nbsp;opt out of certain personal information sharing, and the right to detailed information about how
their personal information is collected,&nbsp;used and shared. The CCPA provides civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the CCPA includes
exemptions for certain clinical trials data, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. The CCPA has prompted a wave of proposals for
new&nbsp;federal and state privacy legislation that, if passed,&nbsp;could increase our potential liability, increase our compliance costs and adversely affect our business. Several foreign jurisdictions, including the European Union (EU), its
member states, the United Kingdom, Japan and Australia, among others, have adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure and transfer of the personal information of individuals
in these jurisdictions. Additionally, certain countries have passed or are considering passing laws that require local data residency and/or restrict the international transfer of data. These laws have the potential to increase costs of compliance,
risks of noncompliance and penalties for noncompliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and
Medicaid, additional oversight and reporting obligations, contractual damages, reputational harm, diminished </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found
not to be in compliance with applicable laws, that person or entity may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on our information technology systems and those of our third-party collaborators, service providers, contractors or consultants. Our internal
computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, disruptions, or incidents, which could result in a material disruption of our development programs or
loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business and have a material adverse effect on our reputation, business, financial condition or results of operations.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including
intellectual property, proprietary business information and personal information. Our internal technology systems and infrastructure, and those of our current or future third-party collaborators, service providers, contractors and consultants are
vulnerable to damage from computer viruses, unauthorized access or use resulting from malware, natural disasters, terrorism, war and telecommunication and electrical failures,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, cyber-attacks or cyber-intrusions over the Internet, hacking, phishing and other social engineering attacks, persons inside our organizations
(including employees or contractors), loss or theft, or persons with access to systems inside our organization. Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and
they are being conducted by increasingly sophisticated and organized foreign governments, groups and individuals with a wide range of motives and expertise. In addition to extracting or accessing sensitive information, such attacks could include the
deployment of harmful malware, ransomware, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering and other means to affect service reliability and threaten the security,
confidentiality, integrity and availability of information. The prevalent use of mobile devices that access sensitive information also increases the risk of data security incidents which could lead to the loss of confidential information or other
intellectual property. While to our knowledge we have not experienced any material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or the operations of third-party
collaborators, service providers, contractors and consultants, it could result in a material disruption of our development programs and significant reputational, financial, legal, regulatory, business or operational harm. The costs to us to
mitigate, investigate and respond to potential security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented
security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm
to our business and our competitive position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For example, the loss of clinical trial data from completed, ongoing or planned clinical
trials for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any real or perceived security breach affects our systems (or those
of our third-party collaborators, service providers, contractors or consultants), or results in the loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information or damage
to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product
candidates could be delayed. Such a breach may require notification to governmental agencies, the media or individuals pursuant to various foreign, domestic (federal and state) privacy and security laws, if applicable, including HIPAA, as amended by
HITECH, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. In addition, our liability insurance may not be sufficient in type or amount to cover us
against claims related to security breaches, cyberattacks and other related incidents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any failure or perceived failure by us or any
third-party collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations, or any data security </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incidents or other security breaches that result in the accidental, unlawful or unauthorized access to, use of, release of, processing of, or transfer of sensitive information, including
personally identifiable information, may result in negative publicity, harm to our reputation, governmental investigations, enforcement actions, regulatory fines, litigation or public statements against us, could cause third parties to lose trust in
us or could result in claims by third parties, including those that assert that we have breached our privacy, confidentiality, data security or similar obligations, any of which could have a material adverse effect on our reputation, business,
financial condition or results of operations. To the extent we maintain individually identifiable health information, we could be subject to fines and penalties (including civil and criminal) under HIPAA for any failure by us or our business
associates to comply with HIPAA&#146;s requirements. Moreover, data security incidents and other security breaches can be difficult to detect, and any delay in identifying them may lead to increased harm. While we have implemented data security
measures intended to protect our information, data, information technology systems, applications and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or data security incidents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal
information. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may collect, process, use or transfer personal information from individuals located in the European Economic Area
in connection with our business, including in connection with conducting clinical trials in the European Economic Area (the &#147;EEA&#148;). Additionally, if any of our product candidates are approved, we may seek to commercialize those products in
the European Economic Area. The collection and use of personal health data in the European Economic Area is governed by the provisions of the General Data Protection Regulation ((EU) 2016/679) (the &#147;GDPR&#148;), along with other European Union
and country-specific laws and regulations. The United Kingdom and Switzerland have also adopted data protection laws and regulations. These legislative acts (together with regulations and guidelines) impose requirements relating to having legal
bases for processing personal data relating to identifiable individuals and transferring such data outside of the European Economic Area, including to the United States, providing details to those individuals regarding the processing of their
personal data, keeping personal data secure, having data processing agreements with third parties who process personal data, responding to individuals&#146; requests to exercise their rights in respect of their personal data, reporting security
breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers or corporate representatives, conducting data protection impact assessments and record-keeping. The
GDPR imposes additional responsibilities and liabilities in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. Failure to comply with the
requirements of the GDPR and related national data protection laws of the member states of the European Economic Area and other states in the European Economic Area may result in substantial fines, other administrative penalties and civil claims
being brought against us, which could have a material adverse effect on our business, financial condition and results of operations. European data protection authorities may interpret the GDPR and national laws differently and may impose additional
requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and only protect us from some business risks, leaving us exposed to significant uninsured liabilities. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter. We believe that we maintain insurance customary for
businesses of our size and type, including clinical trial liability insurance. However, there are types of losses we may incur that cannot be insured against or that we believe are not economically reasonable to insure. Moreover, any loss incurred
could exceed policy limits and policy payments made to us may not be made on a timely basis. Such losses could adversely affect our business prospects, results of operations, cash flows and financial condition. We do not know if our current levels
of coverage are adequate or if we will be able to obtain insurance with adequate levels of coverage in the future, if at all. Any significant uninsured liability may require us to pay substantial amounts, which could materially and adversely affect
our financial position and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disputes under key agreements or conflicts of interest with our scientific advisors or clinical
investigators could delay or prevent development or commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any agreements we have or may
enter into with third parties, such as collaboration, license, formulation supplier, manufacturing, clinical research organization or clinical trial agreements, may give rise to disputes regarding the rights and obligations of the parties.
Disagreements could develop over contract interpretation, rights to ownership or use of intellectual property, the scope and direction of research and development, the approach for regulatory approvals or commercialization strategy. We intend to
conduct research programs in a range of therapeutic areas, but our pursuit of these opportunities could result in conflicts with the other parties to these agreements that may be developing or selling pharmaceuticals or conducting other activities
in these same therapeutic areas. Any disputes or commercial conflicts could lead to the termination of our agreements, delay progress of our product development programs, compromise our ability to renew agreements or obtain future agreements, lead
to the loss of intellectual property rights, result in increased financial obligations for us or result in costly litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We work
with outside scientific advisors and collaborators at academic and other institutions that assist us in our research and development efforts. Our scientific advisors are not our employees and may have other commitments that limit their availability
to us. If a conflict of interest between their work for us and their work for another entity arises, we may lose their services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market
opportunities for any product that we or our strategic collaborators develop are smaller than we believe they are, our revenue may be adversely affected and our business may suffer. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to initially focus our product candidate development on therapies for the treatment of liver and cardio-metabolic diseases. Our
projections of addressable patient populations that have the potential to benefit from treatment with our product candidates are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature,
surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected.
Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter
the market. If any of our estimates are inaccurate, the market opportunities for any of our product candidates could be significantly diminished and have an adverse material impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Monitoring safety of patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval
and commercialize. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For our ongoing clinical trial and planned clinical trials, we have and expect to contract with CROs and
clinical trial sites experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these CROs and clinical trial sites may have difficulty observing patients and treating toxicities, which may be more
challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or
terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could similarly have difficulty in managing adverse events.
Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new
physicians and centers administering our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our
business and financial condition. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Global credit and financial markets have experienced extreme disruptions at various points over
the last few decades, characterized by diminished liquidity and credit availability, declines in consumer confidence, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If another such disruption in credit and financial markets and deterioration of confidence
in economic conditions occurs, our business may be adversely affected. If the equity and credit markets were to deteriorate significantly in the future, it may make any necessary debt or equity financing more difficult to complete, more costly, and
more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and share price and could require us to delay or abandon
development or commercialization plans. In addition, there is a risk that one or more of our service providers, manufacturers or other partners would not survive or be able to meet their commitments to us under such circumstances, which could
directly affect our ability to attain our operating goals on schedule and on budget. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. and certain foreign export and import
controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and
other serious consequences for violations, which can harm our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and
regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls, the U.S. Foreign
Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in
which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper
payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products sell our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses,
patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for
the corrupt or other illegal activities of our employees, agents, contractors, and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above
may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in our effective income tax rate could adversely affect our results of operations. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to income taxes in the United States and various foreign jurisdictions. Various factors may have favorable or unfavorable
effects on our effective income tax rate. These factors include, but are not limited to, interpretations of existing tax laws, changes in tax laws and rates, the accounting for stock options and other stock-based compensation, changes in accounting
standards, future levels of research and development spending, changes in the mix and level of <FONT STYLE="white-space:nowrap">pre-tax</FONT> earnings in different jurisdictions, the outcome of audits or other examinations by the U.S. Internal
Revenue Service and tax regulators in other jurisdictions, the accuracy of our estimates for unrecognized tax benefits, the realization of deferred tax assets and changes to our ownership or capital structure. The impact of the above-mentioned
factors and others on our effective income tax rate may be significant and could adversely affect our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Regulatory Approvals </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">BIO89-100</FONT> has not received regulatory approval. If we are unable to obtain
regulatory approvals to market <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates, our business will be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not expect <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate to be commercially available for several
years, if at all. <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is and any future product candidate will be subject to strict regulation by regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorities in the United States and in other countries. We cannot market any product candidate until we have completed all necessary preclinical studies and clinical trials and have obtained the
necessary regulatory approvals. We do not know whether regulatory agencies will grant approval for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate. Even if we complete preclinical studies and clinical trials
successfully, we may not be able to obtain regulatory approvals or we may not receive approvals to make claims about our products that we believe to be necessary to effectively market our products. Data obtained from preclinical studies and clinical
trials is subject to varying interpretations that could delay, limit or prevent regulatory approval, and failure to comply with regulatory requirements or inadequate manufacturing processes are examples of other problems that could prevent approval.
The regulatory authorities in the United States and the EU have not approved any products for the treatment of NASH, and while there are recent guidelines issued by the FDA for the development of drugs for the treatment of NASH and a FDA surrogate
endpoint table for drug approval that includes SHTG, it is unclear whether the requirements for approval will change in the future. Any such changes may require us to conduct new trials that could delay our timeframe and increase the costs of our
programs related to <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate for the treatment of NASH or SHTG. While the FDA has approved reduction in triglycerides levels as a surrogate endpoint for the full approval of
drugs for the treatment of SHTG, it is unclear whether this endpoint will apply to any product candidates that we develop. If such endpoint is not deemed to apply to our product candidates, it would delay our development timeline and increase the
costs of our programs for the treatment of SHTG. We have not had any discussions with the FDA regarding a surrogate endpoint or accelerated approval regulations. However, we currently expect that our SHTG program would be subject to smaller clinical
trials and that we may expect a relatively quick overall development timeline for this indication. These expectations are based on a published FDA surrogate endpoint table for drug approval that includes SHTG, as well as the development path
followed by other companies that developed an SHTG therapy. However, we do not have a Special Protocol Assessment or other agreement with the FDA on the required clinical trials needed to support an application for approval of BIO89-100 in SHTG, and
the overall clinical requirements and development timeline may be greater than expected. In addition, we may encounter delays or rejections due to additional government regulation from future legislation, administrative action or changes in the
policies of the FDA or comparable foreign regulatory authorities. Even if the FDA or a comparable foreign regulatory authority approves a product, the approval will be limited to those indications covered in the approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to obtain regulatory approvals for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate, if they
exhibit harmful side effects after approval, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates, we will have
tested them in only a small number of patients during our clinical trials. If our applications for marketing are approved and more patients begin to use our product, new risks and side effects associated with our products may be discovered. As a
result, regulatory authorities may revoke their approvals. We have not had any discussions with the FDA regarding a surrogate endpoint or accelerated approval regulations. However, based on recent guidelines issued by the FDA for the development of
drugs for the treatment of NASH, if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is approved by the FDA based on a surrogate endpoint pursuant to section 506(c) of the Federal Food, Drug, and Cosmetic Act and the accelerated approval
regulations (21 C.F.R. part 314, subpart H; 21 C.F.R. part 601, subpart E), consistent with FDA guidance, we will be required to conduct additional clinical trials establishing clinical benefit on the ultimate outcome of NASH. If <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> is approved by the FDA for the treatment of SHTG based on an endpoint of the reduction of triglycerides, the FDA may still require a cardiovascular outcomes study as part of a post-marketing authorization
commitment. Such a study would be time consuming and costly and we cannot guarantee that we will see positive results, which could result in the revocation of the approval. Additionally, we may be required to conduct additional clinical trials, make
changes in labeling of our product, reformulate our product or make changes and obtain new approvals for our and our suppliers&#146; manufacturing facilities for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates. We
might have to withdraw or recall our products from the marketplace. We may also experience a significant drop in the potential sales of our product if and when regulatory approvals for such product are revoked. As a result, we may experience harm to
our reputation in the marketplace or become subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lawsuits, including class actions. Any of these results could decrease or prevent any sales of our approved product or substantially increase the costs and expenses of commercializing and
marketing our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and
inherently unpredictable. Our inability to obtain regulatory approval for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates would substantially harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Currently, we do not have any product candidates that have received regulatory approval. The time required to obtain approval from the FDA and
comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory
authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s development and may vary among jurisdictions. It is possible that
none of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates will ever obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate could fail to receive regulatory approval from the FDA or comparable foreign regulatory authorities for many reasons, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreement with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate that a product candidate is safe and effective for its proposed indication;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of clinical trials to meet the level of statistical significance required for approval;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreement with our interpretation of data from preclinical studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the insufficiency of data collected from clinical trials of a product candidate to support the submission and
filing of a BLA or other submission or to obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to obtain approval of the manufacturing processes or facilities of third-party manufacturers with whom we
contract for clinical and commercial supplies; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for
approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory authorities may require more information, including additional
preclinical or clinical data to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program for other reasons. If we were to obtain approval, regulatory authorities may
approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not
include the labeling claims necessary or desirable for the successful commercialization of that product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to obtain regulatory
approval in international jurisdictions would prevent us from marketing our product candidates outside the United States. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we
succeed in developing any products, we intend to market them in foreign jurisdictions in addition to the United States. In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with
numerous and varying regulatory requirements. We may not obtain foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. Approval by one regulatory authority
outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. If we fail to obtain approval of any of our product candidates by regulatory authorities in another country we will be
unable to commercialize our product in that country, and the commercial prospects of that product candidate and our business prospects could decline. The approval procedure varies among countries and can involve additional testing. The time required
to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many
countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory
requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. Further, clinical trials conducted in one country may not be accepted by regulatory
authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval
process in others. Also, regulatory approval for any of our product candidates may be withdrawn if we fail to comply with regulatory requirements, if problems occur after the product candidate reaches the market or for other reasons. If we fail to
comply with the regulatory requirements in international markets and fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and
our business will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate receives
regulatory approval, it may still face future development and regulatory difficulties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Even if we obtained regulatory approval
for a product candidate, it would be subject to ongoing requirements by the FDA and comparable foreign regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety
surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The FDA and comparable foreign regulatory authorities will continue to closely monitor the safety profile of any product
even after approval. If the FDA, or comparable foreign regulatory authorities, become aware of new safety information after approval of any of our product candidates, it may require labeling changes or establishment of a risk evaluation and
mitigation strategy or similar strategy, impose significant restrictions on a product&#146;s indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other
regulatory authorities for compliance with cGMP, regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the
facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we,
our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, or undesirable side effects caused by such products are identified, a regulatory agency may: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings
about such product; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandate modifications to promotional materials or require us to provide corrective information to healthcare
practitioners; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that we conduct post-marketing studies; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for
inspection costs, required due dates for specific actions and penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek an injunction or impose civil or criminal penalties or monetary fines; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend marketing of, withdraw regulatory approval of or recall such product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any ongoing clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications or supplements to applications filed by us; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain products, refuse to permit the import or export of products or require us to initiate a product
recall. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to commercialize our products
and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Advertising and promotion of any product candidate that obtains approval in the United States will be
heavily scrutinized by the FDA, the Department of Justice, the Department of Health and Human Services&#146; Office of Inspector General, state attorneys general, members of Congress and the public. Violations, including promotion of our products
for unapproved (or <FONT STYLE="white-space:nowrap">off-label)</FONT> uses, are subject to enforcement letters, inquiries and investigations, and significant civil and criminal sanctions by the government. In the United States, engaging in the
impermissible promotion of our products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses can also subject us to false claims litigation under federal and state statutes, which can lead to significant civil and criminal penalties.
Additionally, comparable foreign regulatory authorities will heavily scrutinize advertising and promotion of any product candidate that obtains approval outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may
have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Intellectual
Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success depends upon our ability to obtain and maintain intellectual property protection for our products and technologies.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success will depend in significant part on our current or future licensors&#146;, licensees&#146; or collaborators&#146;
ability to establish and maintain adequate protection of our owned and licensed intellectual property covering the product candidates we plan to develop, and the ability to develop these product candidates and commercialize the products resulting
therefrom, without infringing the intellectual property rights of others. In addition to taking other steps to protect our intellectual property, we hold issued patents, we have applied for patents, and we intend to continue to apply for, patents
with claims covering our technologies, processes and product candidates when and where we deem it appropriate to do so. We have filed numerous patent applications both in the United States and in certain foreign jurisdictions to obtain patent rights
to inventions we have discovered, with claims directed to compositions of matter, methods of use and other technologies relating to our programs. There can be no assurance that any of these patent applications will issue as patents or, for those
applications that do mature into patents, that the claims of the patents will exclude others from making, using or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
selling our product candidates or products that compete with or are similar to our product candidates. In countries where we have not sought and do not seek patent protection, third parties may
be able to manufacture and sell our product candidates without our permission, and we may not be able to stop them from doing so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With
respect to patent rights, we do not know whether any of the pending patent applications for any of our product candidates will result in the issuance of patents that effectively protect our technologies, processes and product candidates, or if any
of our issued patents or our current or future licensors&#146;, licensees&#146; or collaborators&#146; issued patents will effectively prevent others from commercializing competitive technologies, processes and products. Publications of discoveries
in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not at all, until they are issued as
a patent. Therefore, we cannot be certain that we or our current or future licensors, licensees or collaborators were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our current
or future licensors, licensees or collaborators were the first to file for patent protection of such inventions. For a description of our patent portfolio, see &#147;Business&#151;Intellectual Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any changes we make to our <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates to cause them to have what we
view as more advantageous properties may not be covered by our existing patents and patent applications, and we may be required to file new applications and/or seek other forms of protection for any such altered product candidates. The patent
landscape surrounding the technology underlying our product candidates is crowded, and there can be no assurance that we would be able to secure patent protection that would adequately cover an alternative to
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and
time-consuming, and we and our current or future licensors, licensees or collaborators may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that
we or our current or future licensors, licensees or collaborators will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection for them.
Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology that we license from or license to third parties and may
be reliant on our current or future licensors, licensees or collaborators to perform these activities, which means that these patent applications may not be prosecuted, and these patents enforced, in a manner consistent with the best interests of
our business. If our current or future licensors, licensees or collaborators fail to establish, maintain, protect or enforce such patents and other intellectual property rights, such rights may be reduced or eliminated. If our current or future
licensors, licensees or collaborators are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar to the patent rights of other biotechnology companies, the scope, validity and enforceability of our owned and licensed patent rights
generally are highly uncertain and involve complex legal and factual questions. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices
in the United States and abroad. In recent years, these areas have been the subject of much litigation in the industry. As a result, the issuance, scope, validity, enforceability and commercial value of our and our current or future licensors&#146;,
licensees&#146; or collaborators&#146; patent rights are highly uncertain. Our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; pending and future patent applications may not result in patents being issued that
protect our technology or product candidates, or products resulting therefrom, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our
current or future licensors, licensees or collaborators to narrow the scope of the claims of pending and future patent applications, which would limit the scope of patent protection that is obtained, if any. Our and our current or future
licensors&#146;, licensees&#146; or collaborators&#146; patent applications cannot be enforced against third parties practicing the technology that is currently claimed in such applications unless and until a patent issues from such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications, and then only to the extent the claims that issue are broad enough to cover the technology being practiced by those third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, given the amount of time required for the development, testing and regulatory review of new product candidates, patents
protecting such candidates might expire before or shortly after the resulting products are commercialized. As a result, our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may not provide us with sufficient rights to exclude
others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms for our issued patents, where available. This includes in the United States under the Hatch-Waxman Act, which permits a patent term
extension of up to five years beyond the original expiration date of the patent as compensation for regulatory delays. However, such a patent term extension cannot lengthen the remaining term of a patent beyond a total of 14 years from the
product&#146;s approval date. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. During the period of patent term extension, the
claims of a patent are not enforceable for their full scope, but are instead limited to the scope of the approved product. In addition, the applicable authorities, including the FDA in the United States, and any comparable foreign regulatory
authorities, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. In addition, we may not be granted an extension because
of, for example, failing to apply within applicable deadlines, failing to apply prior to the expiration of relevant patents or otherwise failing to satisfy applicable requirements. If this occurs, any period during which we have the right to
exclusively market our product will be shorter than we would otherwise expect, and our competitors may obtain approval of and launch products earlier than might otherwise be the case. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The legal protection afforded to inventors and owners of intellectual property in countries outside of the United States may not be as
protective or effective as that in the United States and we may, therefore, be unable to acquire and enforce intellectual property rights outside the United States to the same extent as in the United States. Whether filed in the United States or
abroad, our patent applications may be challenged or may fail to result in issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, our existing patents and any
future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing or commercializing competing products. Furthermore, others may independently develop or commercialize similar or alternative
technologies or drugs, or design around our patents. Our patents may be challenged, invalidated, circumvented or narrowed, or fail to provide us with any competitive advantages. In many foreign countries, patent applications and/or issued patents,
or parts thereof, must be translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect
translation, which may result in patent protection that does not adequately cover our technologies in those countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Filing,
prosecuting, enforcing and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are less extensive than those
in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and certain state laws in the United States. Consequently, we may not be able to prevent third parties
from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use technologies in jurisdictions where
we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products
may compete with <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending
intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating
to biopharmaceuticals. This could make it difficult for us to stop the infringement of our patents or the marketing of competing products in violation of our proprietary rights, generally. Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could place our patent applications at risk of not
issuing and could provoke third parties to assert claims against us or our collaborator. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The requirements for patentability differ and certain countries have heightened requirements for patentability, requiring more disclosure in
the patent application. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if patents are infringed or if we
are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. In addition, many countries limit the enforceability of patents against government
agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. Accordingly, our efforts to enforce intellectual property rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on a license from Teva and a
sublicense from ratiopharm to patents and <FONT STYLE="white-space:nowrap">know-how</FONT> related to glycoPEGylation technology that are used in the development, manufacture and commercialization of
<FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Any termination or loss of significant rights, including the right to glycoPEGylation technology, or breach, under these agreements or any future license agreement related to our product candidates,
would materially and adversely affect our ability to continue the development and commercialization of the related product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2018, we entered into an Asset Transfer and License Agreement (the &#147;FGF21 Agreement&#148;) with Teva under which we acquired
certain patents, intellectual property and other assets relating to Teva&#146;s glycoPEGylated FGF21 program, including <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Under this agreement, we were granted a perpetual, <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> (but exclusive as to BIO89-100), <FONT STYLE="white-space:nowrap">non-transferable,</FONT> worldwide license to patents and <FONT STYLE="white-space:nowrap">know-how</FONT> related to glycoPEGylation
technology used in the development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and products containing BIO89-100. The FGF21 Agreement also contains numerous covenants with which we must comply, including
the utilization of commercially reasonable efforts to develop and ultimately commercialize <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> as well as certain reporting covenants and the obligation to make royalty payments, if and when <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> is approved for commercialization. Our failure to satisfy any of these covenants could result in the termination of the FGF21 Agreement. In addition, we entered into a Sublicense Agreement with ratiopharm
(the &#147;ratiopharm Sublicense&#148;), under which we were granted a perpetual, exclusive, worldwide sublicense to patents and know-how related to glycoPEGylation technology used in the development, manufacture and commercialization of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and products containing <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Termination of the FGF21 Agreement or the ratiopharm Sublicense will impact our rights under the intellectual property licensed to
us by Teva and ratiopharm, respectively, including our license to glycoPEGylation technology, but will not affect our rights under the assets assigned to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beyond this agreement, our commercial success will also depend upon our ability, and the ability of our licensors, to develop, manufacture,
market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. A third party may hold intellectual property rights, including patent rights, that are important or necessary to
the development of our product candidates. As a result, we may enter into additional license agreements in the future. If we fail to comply with the obligations under these agreements, including payment and diligence obligations, our licensors may
have the right to terminate these agreements, in which event we may not be able to develop, manufacture, market or sell any product that is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covered by these agreements or to engage in any other activities necessary to our business that require the freedom to operate afforded by the agreements, or we may face other penalties under the
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any of the foregoing could materially and adversely affect the value of the product candidate being developed under any such
agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or amended agreements, which may not be available to us on equally favorable terms, or at all, or
cause us to lose our rights under these agreements, including our rights to intellectual property or technology important to our development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and
pharmaceutical companies, our success is heavily dependent on intellectual property rights, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves technological and legal complexity, and obtaining and
enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. The U.S. Supreme Court in recent years has issued rulings either narrowing the scope of patent protection available in certain circumstances or weakening the
rights of patent owners in certain situations or ruling that certain subject matter is not eligible for patent protection. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events
has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts, the USPTO and equivalent bodies in foreign jurisdictions, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents or to enforce existing patents and patents we may obtain in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patent reform laws, such as the Leahy-Smith America Invents Act (the &#147;Leahy-Smith Act&#148;), as well as changes in how patent laws are
interpreted, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act made a number of significant changes to U.S. patent law. These
include provisions that affect the filing and prosecution strategies associated with patent applications, including a change from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT> patent system, and a change allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to
attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, <I>inter partes </I>review and derivation proceedings. The USPTO has developed regulations and procedures to govern administration of the
Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-inventor-to-file&#148;</FONT></FONT>
provisions, became effective in 2013. The Leahy-Smith Act and its implementation may increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to obtain intellectual property
rights or technology necessary to develop and commercialize <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The patent landscape around our programs is complex, and we are aware of several third-party patents and patent applications containing
subject matter that might be relevant to <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Depending on what claims ultimately issue from these patent applications, and how courts construe the issued patent claims, as well as depending on the
ultimate formulation and method of use of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates, we may need to obtain a license to practice the technology claimed in such patents. There can be no assurance that such
licenses will be available on commercially reasonable terms, or at all. If a third party does not offer us a necessary license or offers a license only on terms that are unattractive or unacceptable to us, we might be unable to develop and
commercialize one or more of our product candidates, which would have a material adverse effect on our business, financial condition and results of operations. Moreover, even if we obtain licenses to such intellectual property, but subsequently fail
to meet our obligations under the relevant license agreements, or such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
license agreements are terminated for any other reasons, we may lose our rights to the technologies licensed under those agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The licensing or acquisition of third-party intellectual property rights is an area in which many companies operate that have interests that
are in conflict with ours, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive
advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be
unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual
property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits or other proceedings to protect or enforce our intellectual property, which could
be expensive, time-consuming and unsuccessful and have a material adverse effect on the success of our business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third parties
may infringe our patents or misappropriate or otherwise violate our intellectual property rights. In the future, we may initiate legal proceedings to enforce or defend our intellectual property rights, to protect our trade secrets or to determine
the validity or scope of intellectual property rights we own or control. Also, third parties may initiate legal proceedings against us to challenge the validity or scope of intellectual property rights we own, control or to which we have rights. For
example, generic or biosimilar drug manufacturers or other competitors or third parties may challenge the scope, validity or enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. These
proceedings can be expensive and time-consuming and many of our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. Accordingly, despite our efforts, we
may not be able to prevent third parties from infringing upon or misappropriating intellectual property rights we own, control or have rights to, particularly in countries where the laws may not protect those rights as fully as in the United States.
Litigation could result in substantial costs and diversion of management resources, which could harm our business and financial results. In addition, if we initiated legal proceedings against a third party to enforce a patent covering a product
candidate, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendants usually assert counterclaims alleging invalidity or unenforceability. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that
someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. In an infringement or declaratory judgment proceeding, a court may decide that a patent owned by or
licensed to us is invalid or unenforceable, or may refuse to stop the other party from using the subject matter alleged to be infringing on the grounds that our patents do not cover that subject matter. An adverse result in any litigation proceeding
could put one or more of our patents at risk of being invalidated, narrowed, held unenforceable or interpreted in such a manner that would not preclude third parties from entering the market with competing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third-party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO, or opposition, derivation, revocation,
reexamination, <I>inter partes </I>review or interference proceedings, or other <FONT STYLE="white-space:nowrap">pre-issuance</FONT> or post-grant proceedings or other patent office proceedings or litigation in the United States or other
jurisdictions provoked by third parties or brought by us, may be necessary to determine the inventorship, priority, patentability or validity of inventions with respect to our patents or patent applications. An unfavorable outcome could leave our
technology or product candidates without patent protection, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or could require us to obtain license rights from the
prevailing party in order to be able to manufacture or commercialize our product candidates without infringing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third-party patent rights. Our business could be harmed if the prevailing party in such a case does not offer us a license on commercially reasonable terms, or at all. Even if we obtain a
license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent
applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Even if we successfully defend such litigation or proceeding, we may incur substantial
costs and our defense may distract our management and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery
required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, many foreign jurisdictions have rules of
discovery that are different than those in the United States and that may make defending or enforcing our patents extremely difficult. There could also be public announcements of the results of hearings, motions or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights or we may initiate legal
proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, the outcome of which would be uncertain and could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our commercial success depends upon our ability to develop, manufacture, market and sell <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and
any future product candidates that we may develop and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and
pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may initiate legal proceedings against us alleging that we infringe their intellectual property rights or we
may initiate legal proceedings against third parties to challenge the validity or scope of intellectual property rights controlled by third parties, including in oppositions, interferences, revocations, reexaminations, <I>inter partes </I>review or
derivation proceedings before the USPTO or its counterparts in other jurisdictions. These proceedings can be expensive and time-consuming and many of our adversaries in these proceedings may have the ability to dedicate substantially greater
resources to prosecuting these legal actions than we can. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We could be found liable for monetary damages, including treble damages and
attorneys&#146; fees, if we are found to have willfully infringed a patent of a third party. A finding of infringement could prevent us from commercializing our <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates or
force us to cease some of our business operations, which could materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may not be aware of all third-party
intellectual property rights potentially relating to <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidates and technologies. We are not aware of any facts that would lead us to conclude that the valid and enforceable
claims of any third-party patents would reasonably be interpreted to cover our product candidates. As to pending third-party applications, we cannot predict with any certainty which claims will issue, if any, or the scope of such issued claims. Even
if we believe third-party intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A court of competent jurisdiction could hold
that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the
asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing
evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If any such third-party patents (including those that may issue from such
applications) were successfully asserted against us or other commercialization partners </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and we were unable to successfully challenge the validity or enforceability of any such asserted patents, then we and other commercialization partners may be prevented from commercializing our
product candidates, or may be required to pay significant damages, including treble damages and attorneys&#146; fees if we are found to willfully infringe the asserted patents, or obtain a license to such patents, which may not be available on
commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to
us, and it could require us to make substantial licensing and royalty payments. Any of the foregoing would have a material adverse effect on our business, financial condition and operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our therapeutic candidates or
products, we have not conducted a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">freedom-to-operate</FONT></FONT> search or analysis for any of our therapeutic candidates or products, and we may not be aware of patents or pending
or future patent applications that, if issued, would block us from commercializing our therapeutic candidates or products. Thus, we cannot guarantee that our therapeutic candidates or products, or our commercialization thereof, do not and will not
infringe any third party&#146;s intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting misappropriation of intellectual
property, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we seek to ensure that our employees
do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual
property, including trade secrets or other proprietary information, of any such employee&#146;s former employer, or that third parties have an interest in our patents as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> Litigation
may be necessary to defend against these claims. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or the services of personnel or sustain other damages.
Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable
terms, or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of
intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The
assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the
ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our inability to protect our confidential information and trade secrets would harm our business and competitive position. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for some of our technology and product candidates, we also rely substantially on trade secrets, including
unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary materials and information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and
other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, these steps may be inadequate, we may fail to enter into agreements with all such parties or any of
these parties may breach the agreements and disclose our trade secrets and there may be no adequate remedy available for such breach of an agreement. We cannot assure you that our trade secrets will not be disclosed or that we can meaningfully
protect our trade secrets. Enforcing a claim that a party illegally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be
less willing, or unwilling, to protect trade secrets. If a competitor lawfully obtained or independently developed any technology or information that we protect as trade secret, we would have no right to prevent such competitor from using that
technology or information to compete with us, which could harm our competitive position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address
all potential threats. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because
intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any
future product candidates we may develop or utilize similar technology but that are not covered by the claims of the patents that we exclusively license or may own in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future collaborators, might not have been the first to make the inventions covered by the issued
patents and pending patent applications that we exclusively license or may own in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our future collaborators, might not have been the first to file patent applications covering certain of
our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or exclusively licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications or those that we may file in the future will not result in
issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in major commercial markets in which we do not have sufficient patent rights to stop such sales; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may be asserted against our product candidates and technologies in a manner that harms our
business; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent application in order to maintain certain trade secrets or <FONT
STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such trade secrets or <FONT STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not maintained and adequately protected, we may not be able to build name recognition in our
markets of interest, and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Failure to obtain trademark registrations in the future, could
limit our ability to protect and enforce our trademarks and impede our marketing efforts in the countries in which we operate. We may not be able to protect our rights to trademarks and trade names which we may need to build name recognition with
potential partners or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
customers in our markets of interest. As a means to enforce any future trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate
trademark opposition proceedings. This can be expensive, and strain the financial resources of a company of our size, and time-consuming, and we may not be successful in enforcing our trademark rights. In addition, our registered or unregistered
trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Future trademark applications in the United States and in other foreign jurisdictions where we may file may not be allowed or may subsequently
be opposed. Even if these applications result in registration of trademarks, third parties may challenge our use or registration of these trademarks in the future. Over the long term, if we are unable to establish name recognition based on our
trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering
and Ownership of Our Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There is no existing market for our common stock and we do not know if one will develop, which may make it
difficult for you to sell shares of our common stock. Even if a market does develop, the price of shares of our common stock in the market may not exceed the offering price. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has not been a public market for our common stock or any of our equity interests. We cannot predict the extent
to which investor interest in our company will lead to the development of an active trading market on The Nasdaq Global Market or how liquid that market may become. An active public market for our common stock may not develop or be sustained after
this offering. If an active trading market does not develop or is not sustained, you may have difficulty selling any shares of our common stock that you buy. An inactive market may also impair our ability to raise additional capital or use our
shares of common stock to acquire companies, products or technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initial public offering price for our common stock was
determined by negotiations among us and the representatives of the underwriters and may not be indicative of prices that will prevail in the open market following this offering. Consequently, you may not be able to sell shares of our common stock at
prices equal to or greater than the price you pay in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock may be volatile, and you may lose all or part of
your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The market price of our common stock could fluctuate significantly, and you may not be able to resell your
shares at or above the offering price. Those fluctuations could be based on various factors in addition to those otherwise described in this prospectus, including those described in these &#147;Risk Factors.&#148; Any of these factors may result in
large and sudden changes in the volume and trading price of our common stock. In the past, following periods of volatility in the market price of a company&#146;s securities, stockholders have often instituted securities class action litigation
against that company. If we were involved in a class action suit, it could divert the attention of management, result in negative press reports and, if adversely determined, have a material adverse effect on our results of operations and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the stock market, in general, and the stocks of many small healthcare and biotechnology companies, in particular,
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock,
regardless of our actual operating performance. Further, a decline in the broader financial markets and related factors beyond our control may cause the price of our common stock to decline rapidly and unexpectedly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock, or the perception that such sales may occur, could depress the price of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, following this
offering could depress the market price of our common stock. Our principal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders, executive officers and directors and certain other equity holders have agreed with the underwriters not to offer, sell, dispose of or hedge any shares of our common stock or
securities convertible into or exchangeable for shares of our common stock, subject to specified limited exceptions and extensions described elsewhere in this prospectus, during the period ending 180 days after the date of the final prospectus,
except with the prior written consent of BofA Securities, Inc., SVB Leerink LLC and RBC Capital Markets, LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate
will authorize us to issue up to 100,000,000&nbsp;shares of common stock, of which 12,993,279&nbsp;shares will be outstanding after this offering (assuming no exercise of the underwriters&#146; option to purchase additional shares) and
1,304,159&nbsp;shares will be issuable upon the exercise of outstanding stock options. All of the shares sold in this offering will be freely tradable after the expiration date of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements,
excluding any acquired by persons who may be deemed to be our affiliates. The remaining 7,688,592 shares are currently restricted as a result of securities laws or the lock-up agreements, but will be eligible for sale after this offering as
described in the section titled &#147;Shares Eligible for Future Sale.&#148; Shares of our common stock held by our affiliates will continue to be subject to the volume and other restrictions of Rule 144 under the Securities Act. BofA Securities,
Inc., SVB Leerink LLC and RBC Capital Markets, LLC may, in their discretion and at any time without notice, release all or any portion of the shares subject to the <FONT STYLE="white-space:nowrap">lock-up.</FONT> Sales of a substantial number of
such shares upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements, the perception that such sales may occur or early release of these agreements, could cause
our market price to fall or make it more difficult for you to sell your common stock at a time and price that you deem appropriate. See &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Moreover, after this offering, holders of an aggregate of&nbsp;7,077,366 shares of our common stock will have rights, subject to certain
conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, promptly following this offering, we intend to file a registration statement registering under the Securities Act the shares of
our common stock reserved for issuance under our 2019 Plan, including shares issuable upon exercise of outstanding options. See &#147;Shares Eligible for Future Sale&#148; for a more detailed description of the shares that will be available for
future sales upon completion of this offering. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Further, as opportunities present themselves, we may enter into financing or similar arrangements in the
future, including the issuance of debt or equity securities. If we issue common stock or securities convertible into our common stock, our common stockholders would experience additional dilution and, as a result, the price of our common stock may
decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our directors, executive officers and current holders of 5% or more of our capital stock will continue to have substantial control over
our company after this offering, which could limit your ability to influence the outcome of matters subject to stockholder approval, including a change of control. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Without giving effect to any shares they may purchase in this offering, directors and executive officers will beneficially own approximately
23.6% of our outstanding common stock after this offering and other holders of 5% or more of our common stock will beneficially own approximately 58.7% of our outstanding common stock after this offering. Without giving effect to any shares they may
purchase in this offering, our current directors, officers and stockholders who own greater than 5% of our outstanding common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis), together with their affiliates, will beneficially
own, in the aggregate, approximately 60.8% of our outstanding common stock after this offering. In addition, our existing stockholders affiliated with our directors have agreed to purchase an aggregate of approximately $51 million of shares of our
common stock in this offering at the initial public offering price and on the same terms as the other purchasers in this offering. As a result, our current directors, officers and stockholders who own greater than 5% of our outstanding common stock
(on an as-converted basis), together with their affiliates, will beneficially own approximately 85.3% of our outstanding voting stock upon the closing of this offering (assuming no exercise of the underwriters&#146; option to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase additional shares and no exercise of outstanding options). As a result, after this offering, our executive officers, directors and other holders of 5% or more of our common stock, if
they act, will be able to influence or control matters requiring approval by our stockholders, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. In addition, our current directors,
executive officers and other holders of 5% or more of our common stock, acting together, would have the ability to control the management and affairs of our company. They may also have interests that differ from yours and may vote in a way with
which you disagree and that may be adverse to your interests. This concentration of ownership may have the effect of delaying, preventing or deterring a change of control of our company, could deprive our stockholders of an opportunity to receive a
premium for their shares of our common stock as part of a sale of our company and could affect the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities
or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our stock or business, the price of our common stock and trading volume could decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about
us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company or if they cease to cover our company, the trading price
for our stock would likely be negatively impacted. In the event that securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business,
demand for our common stock could decrease and the price of our common stock could decline. In addition, if our operating results fail to meet the forecast of analysts, the price of our common stock would likely decline. If one or more of these
analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause the price of our common stock and trading volume to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Participation in this offering by our existing stockholders would reduce the available public float for our shares. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing stockholders affiliated with our directors have agreed to purchase an aggregate of approximately $51&nbsp;million of shares of
our common stock in this offering at the initial public offering price. Such purchases could reduce the available public float for our shares because such stockholders may be restricted from selling the shares by restrictions under applicable
securities laws. As a result, any purchase of shares by such stockholders in this offering may reduce the liquidity of our common stock relative to what it would have been had these shares been purchased by investors that were not existing
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified material weaknesses in our internal control over financial reporting. If our remediation of the material
weaknesses is not effective, or if we experience additional material weaknesses or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or
results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective internal controls over financial reporting are necessary for us to provide reliable financial information and, together with
adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In
addition, any testing by us conducted in connection with Section&nbsp;404 (&#147;Section&nbsp;404&#148;) of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), or any subsequent testing by our independent registered
public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify
other areas for further attention or improvement. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our
annual or interim consolidated financial statements will not be prevented or detected on a timely basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with our financial statement close process for 2018, we identified material
weaknesses in the design and operating effectiveness of our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These material weaknesses related
to the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not have an internal finance department. Consequently, we lacked sufficient personnel with an appropriate
level of knowledge and requisite U.S. generally accepted accounting principles expertise to identify, evaluate and account for complex and <FONT STYLE="white-space:nowrap">non-routine</FONT> transaction and an adequate supervisory review structure
that is needed to comply with financial reporting requirements. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We did not have an adequate assessment of risks that could significantly impact internal control over financial
reporting and did not effectively design controls in response to the risks of material misstatement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are taking
steps to remediate these material weaknesses through the implementation of appropriate segregation of duties, formalization of accounting policies and controls, hiring of our Chief Financial Officer and additional qualified accounting and finance
personnel and engagement of financial consultants to enable the implementation of internal controls over financial reporting. We also plan to implement certain accounting systems to automate manual processes. However, we are still in the process of
implementing these steps and cannot assure you that we will be successful in doing so or that these measures will significantly improve or remediate the material weaknesses described above. We, and our independent registered public accounting firm,
were not required to perform an evaluation of our internal control over financial reporting as of December 31, 2018 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure you that we have identified all material
weaknesses or that there will not be additional material weaknesses or deficiencies that we will identify. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of this offering,
we will be required to comply with Section&nbsp;404, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of our internal control
over financial reporting commencing with our second annual report. To achieve compliance with Section&nbsp;404 within the prescribed period, we will need to continue to dedicate internal resources, outside consultants and continue to execute a
detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes, as appropriate, validate through testing that controls are functioning as documented and implement a
continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over
financial reporting is effective as required by Section&nbsp;404 and material weaknesses may still exist. We also cannot assure you that there will not be additional material weaknesses or significant deficiencies in our internal controls in the
future. In the event that we are not able to successfully remediate the existing material weaknesses in our internal control over financial reporting or demonstrate compliance with the Sarbanes-Oxley Act, that our internal control over financial
reporting is perceived as inadequate or that we are unable to produce timely or accurate consolidated financial statements, investors may lose confidence in our operating results, the price of our common stock could decline and we may not be able to
remain listed on The Nasdaq Global Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will
devote substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other
expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an &#147;emerging growth company.&#148; As a public company, we will be subject to the reporting requirements of the Exchange Act,
the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel will need to devote a substantial amount of time to these compliance
initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The increased costs will increase our net loss. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability
insurance and we may be forced to accept reduced policy limits or incur substantially higher costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these
requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company, as defined in the Securities Act, and we cannot be certain if the reduced disclosure requirements applicable to
emerging growth companies will make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined
in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies,
including relief from the auditor attestation requirements of Section&nbsp;404 less extensive disclosure obligations regarding executive compensation in our registration statements, periodic reports and proxy statements, exemptions from the
requirements to hold a nonbinding advisory vote on executive compensation, and exemptions from stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information
that they may deem important. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in the
Securities Act for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to
avail ourselves of this exemption and, as a result, will not be subject to the same implementation timing for new or revised accounting standards as for other public companies that are not emerging growth companies, which may make comparison of our
consolidated financial statements to those of other public companies more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our common
stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the price of our common stock may be more
volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion as to the use of proceeds from this offering and may not use the proceeds effectively. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management will retain broad discretion as to the application of the proceeds of this offering and may spend these proceeds in ways in
which you may not agree. You will not have the opportunity, as part of your investment decision, to assess whether we are using the proceeds appropriately. Our management might not apply our net proceeds in ways that ultimately increase the value of
your investment. We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering. Until the net proceeds are used, they may be placed in investments that do not produce significant
income or that may lose value. The failure of our management to apply these funds effectively could result in unfavorable returns and uncertainty about our prospects, each of which could cause the price of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of our common stock for return on your
investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to retain most, if not all, of our available funds and earnings to fund the development and growth of our
business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in our common stock as a source for any future dividend income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has significant discretion as to whether to distribute dividends and in what amounts. Even if our board of directors
decides to declare and pay dividends, the timing, amount and form of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
future dividends, if any, will depend on, among other matters, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received
by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you
purchase shares of our common stock sold in this offering, you will incur immediate and substantial dilution. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you purchase
shares of our common stock in this offering, you will incur immediate and substantial dilution in the amount of $9.04 per share because the initial public offering price of $16.00&nbsp;per share is substantially higher than the as adjusted net
tangible book value per share of our outstanding common stock. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares. In addition,
you may also experience additional dilution upon future equity issuances or the issuance of stock options to purchase our common stock granted to our employees, directors and consultants under our stock option plan after this offering. To the extent
we raise additional capital by issuing equity securities, our stockholders may experience additional dilution. In addition, as of June 30, 2019, we had outstanding stock options to purchase 721,079&nbsp;shares of our common stock, all of which have
exercise prices below the initial offering price. To the extent these outstanding options are ultimately exercised, you will experience further dilution. See &#147;Dilution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Amended Certificate, Amended Bylaws and Delaware law could prevent a third party from acquiring us (even if an acquisition would benefit our
stockholders), may limit the ability of our stockholders to replace our management and limit the price that investors might be willing to pay for shares of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate and our Amended Bylaws could have the effect of making it more difficult for a third party to acquire, or of
discouraging a third party from attempting to acquire, control of us. These provisions could delay or prevent a change in control of the company and could limit the price that investors might be willing to pay in the future for shares of our common
stock. These provisions, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a staggered board of directors divided into three classes serving staggered three-year terms, such that
not all members of the board will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue new series of preferred stock without stockholder approval and create,
subject to applicable law, a series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate the ability of our stockholders to call special meetings of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate the ability of our stockholders to fill vacancies on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for nominations for election to our board of directors or for proposing
matters that can be acted upon by stockholders at our annual stockholder meetings; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to establish the number of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our board of directors is expressly authorized to make, alter or repeal our Amended Bylaws;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that shareholders can remove directors only for cause and only upon the approval of not less than 66<SUP
STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB> of all outstanding shares of our voting stock; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of not less than 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB
STYLE="vertical-align:bottom">3</SUB> of all outstanding shares of our voting stock to amend our bylaws and specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the jurisdictions in which certain stockholder litigation may be brought. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a Delaware corporation, we will be subject to the anti-takeover provisions of
Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years
after the date of the transaction in which the person first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding disinterested shares. The application of Section&nbsp;203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Our Amended Certificate provides that the Court of Chancery of the State of Delaware and the federal district courts of the United
States will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate to be in effect upon the completion of this offering provides that the Court of Chancery of the State of
Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of a fiduciary duty; any action
asserting a claim against us arising pursuant to the Delaware General Corporation Law, our Amended Certificate or our Amended Bylaws; or any action asserting a claim against us that is governed by the Delaware internal affairs doctrine. This
provision would not apply to claims brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our Amended Certificate provides further that the federal district
courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of
such exclusive forum provision. These choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees. If a court were
to find the choice of forum provision contained in our Amended Certificate to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business.
For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the
rules and regulations thereunder, and the Court of Chancery of the State of Delaware recently determined that the exclusive forum provision of federal district courts of the United States for resolving any complaint asserting a cause of action
arising under the Securities Act is not enforceable. However, this decision may be reviewed and ultimately overturned by the Delaware Supreme Court. If the Court of Chancery&#146;s decision were to be overturned, we would enforce the federal
district court exclusive forum provision in our Amended Certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains &#147;forward-looking statements&#148; within the meaning of the federal securities laws, which statements are
subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this prospectus, including statements concerning our plans, objectives, goals,
strategies, future events, future revenues or performance, financing needs, plans or intentions relating to product candidates, estimates of market size, business trends, the anticipated timing, costs, design and conduct of our planned clinical
trials for <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> our only product candidate, the timing and likelihood of regulatory filings and approvals for <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> our ability to commercialize <FONT
STYLE="white-space:nowrap">BIO89-100,</FONT> if approved, the pricing and reimbursement of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> if approved, the potential to develop future product candidates, our ability to scale up manufacturing, the
potential benefits of strategic collaborations and our intent to enter into any strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated product development
efforts and the anticipated use of the net proceeds from this offering, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148;
&#147;objective,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;could,&#148; &#147;can,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;believe,&#148; &#147;design,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148;
&#147;plan&#148; or the negative of these terms, and similar expressions intended to identify forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These
statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this prospectus. Such risks, uncertainties and other
factors include, among others, the factors disclosed in the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in
this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We caution you that the risks, uncertainties and other factors referred to above and elsewhere in this prospectus may
not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks. In addition, we cannot
assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. Forward-looking
statements are not historical facts, and reflect our current views with respect to future events. Given the significant uncertainties, you should evaluate all forward-looking statements made in this prospectus in the context of these risks and
uncertainties and not place undue reliance on these forward-looking statements as predictions of future events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All forward-looking
statements in this prospectus apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this prospectus. We disclaim any intent to publicly update or revise any forward-looking statements
to reflect subsequent events or circumstances, except as required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_4"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research,
as well as from industry and general publications, and research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal
research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of the industry and market, which we believe to be reasonable. In addition, while we believe the industry, market and competitive
position data included in this prospectus is reliable and based on reasonable assumptions, we have not independently verified any third-party information, and all such data involve risks and uncertainties and are subject to change based on various
factors, including those discussed in &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds of approximately $76.5&nbsp;million (or approximately $88.4&nbsp;million if the
underwriters&#146; option to purchase additional shares is exercised in full) from the issuance and sale of the shares of common stock offered by us in this offering, after deducting underwriting discounts and commissions and estimated offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents,
primarily as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $20.0 to $30.0 million to complete our ongoing POC Phase 1b/2a clinical trial and initiate our
subsequent Phase 2b clinical trial of BIO89-100 in patients with NASH; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $5.0 to $10.0 million to fund our Phase&nbsp;2 trial of BIO89-100 in patients with SHTG, as well as
evaluate potential new indications for BIO89-100; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $5.0 to $10.0 million for BIO89-100 manufacturing and scale up; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and other general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our expected use of proceeds from this offering represents our current intentions based on our present plans and business condition. As of the
date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. We may also use a
portion of the proceeds to license, acquire or invest in complementary businesses, technology, products or assets, however we have no current commitments to do so. As a result, our management will have broad discretion over the use of the proceeds
from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our current business plans, we believe that the net proceeds from this offering, together with our existing
cash and cash equivalents and the funds available from the first tranche of the potential term loan discussed under the section entitled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Liquidity
and Capital Resources,&#148; will be sufficient to fund our planned operations into the second half of 2021. The expected net proceeds from this offering will not be sufficient for us to fund <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any
future product candidate through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates.
The amount and timing of our actual expenditures will depend on numerous factors, including the pace and results of our research and development efforts, the timing and success of clinical trials, the timing and costs associated with the manufacture
and supply of product candidates, the timing of regulatory submissions and any unforeseen cash needs. For additional information regarding our potential capital requirements, including factors that could cause actual costs to vary from the estimates
set forth above, see &#147;Risk Factors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we may invest the proceeds in
interest-bearing, investment-grade securities, certificates of deposit or government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock and have no present intention to pay cash dividends on our common stock for
the foreseeable future. Any determination to pay dividends to holders of our common stock will be at the discretion of our board of directors and will depend on many factors, including our financial condition, results of operations, liquidity,
earnings, projected capital and other cash requirements, legal requirements, restrictions in the agreements governing any indebtedness we may enter into, business prospects and other factors that our board of directors deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis after giving effect to the Reorganization; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to give effect to (i) the Reorganization, (ii) the issuance in July 2019 of 1,173,611 shares
of our convertible preferred stock and (iii) the automatic conversion of all outstanding shares of our convertible preferred stock into 7,077,366&nbsp;shares of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis giving effect to (i)&nbsp;the Reorganization; (ii)&nbsp;the other pro forma
items described immediately above and (iii)&nbsp;the issuance and sale of 5,304,687&nbsp;shares of our common stock in this offering at the initial public offering price of $16.00&nbsp;per share, after deducting underwriting discounts and
commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read the following table in conjunction with
&#147;Use of Proceeds,&#148; &#147;Selected Consolidated Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and related notes
included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As&nbsp;of&nbsp;June 30,
2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Actual</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share<BR>and&nbsp;per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">99,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares, $0.001 par value; 60,000,000 shares authorized as of June 30, 2019;
42,826,389 shares issued and outstanding as of June 30, 2019 actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares, $0.001 par value, no shares authorized, issued or outstanding, actual;
10,000,000&nbsp;shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 72,882,353 shares authorized, 611,226&nbsp;shares issued and
outstanding, actual; 100,000,000&nbsp;shares authorized, 7,688,592&nbsp;shares issued and outstanding, pro forma; and 100,000,000&nbsp;shares authorized, 12,993,279&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding following this offering (i) is based on
611,226&nbsp;shares of our common stock and 42,826,389 shares of our convertible preferred stock outstanding as of June 30, 2019, (ii) includes 1,173,611 shares of our convertible preferred stock issued in July 2019, (iii) gives effect to the
Reorganization and the automatic conversion immediately prior to the completion of this offering of all outstanding shares of our convertible preferred stock into 7,077,366 shares of our common stock, and (iv)&nbsp;excludes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">721,079 shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2019
under our 2019 Plan at a weighted-average exercise price of $1.93 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">583,080 options to purchase shares of our common stock granted subsequent to June 30, 2019 at a weighted-average
exercise price of $4.26 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">343,083 shares of our common stock reserved for future issuance under our 2019 Plan as of June&nbsp;30,&nbsp;2019
and 396,727 and 1,383,302 additional shares of common stock reserved for future issuance on July&nbsp;28, 2019 and October&nbsp;24, 2019, respectively, as well as any automatic increase in the number of shares of common stock reserved for future
issuance thereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">225,188 shares of our common stock to be reserved for future issuance under our 2019 Employee Stock Purchase
Plan, which became effective in connection with this offering, as well as any automatic increase in the number of shares of common stock reserved for future issuance thereunder. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you invest in the shares of our common stock in this offering, your ownership interest will be immediately diluted. Dilution represents the
difference between the amount per share paid by investors in this offering and the pro forma as adjusted net tangible book value per share of our common stock immediately after the completion of this offering. The data in this section are derived
from our consolidated balance sheet as of June 30, 2019. Our historical net tangible book value per share is equal to our total tangible assets less the amount of our total liabilities and convertible preferred stock, divided by the sum of the
number of shares of our common stock outstanding on June 30, 2019. Our historical net tangible book value (deficit) as of June&nbsp;30,&nbsp;2019 was $(35.6)&nbsp;million, or $(58.30)&nbsp;per share of common stock. Pro forma net tangible book
value, before the issuance and sale of shares in this offering, gives effect to the conversion of all outstanding shares of our convertible preferred stock as of June 30, 2019 and all shares of our convertible preferred stock issued in July 2019
into an aggregate of 7,077,366&nbsp;shares of common stock. Our pro forma net tangible book value as of June&nbsp;30, 2019 was $13.7 million, or $1.78 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After giving effect to our receipt of the estimated net proceeds from the issuance and sale of our common stock in this offering at the
initial public offering price of $16.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June 30, 2019 would have been $90.4
million, or $6.96 per share of our common stock. This represents an immediate increase in net tangible book value to our existing stockholders of $5.18&nbsp;per share and an immediate dilution to new investors in this offering of $9.04 per share.
The following table illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value (deficit) per share as of June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(58.30)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to the pro forma adjustments described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors participating in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in pro forma net tangible book value per share to new investors participating in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of our common stock in full, our pro
forma as adjusted net tangible book value after this offering would be $7.42 per share, and there would be an immediate dilution of approximately $8.58 per share to new investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents on a pro forma as adjusted basis, as described above, the differences between the existing stockholders and the
purchasers of shares in this offering with respect to the number of shares purchased from us, the total consideration paid, and the average price paid per share at the initial public offering price of $16.00 per share: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ROWSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Weighted-<BR>Average<BR>Price<BR>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,688,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,304,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.8%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,993,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters were to fully exercise their option to purchase 795,703&nbsp;additional
shares of our common stock from us, the percentage of shares of our common stock held by existing investors would be 55.8%, and the percentage of shares of our common stock held by new investors would be&nbsp;44.2%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing stockholders affiliated with our directors have agreed to purchase an aggregate of approximately $51&nbsp;million of shares of
our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. The table above does not reflect the purchase of any shares in this offering by these existing
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock to be outstanding following this offering (i) is based on 611,226&nbsp;shares of our
common stock and 42,826,389 shares of our convertible preferred stock outstanding as of June 30, 2019, (ii) includes 1,173,611 shares of our convertible preferred stock issued in July 2019, (iii) gives effect to the Reorganization and the automatic
conversion immediately prior to the completion of this offering of all outstanding shares of our convertible preferred stock into 7,077,366 shares of our common stock, and (iv)&nbsp;excludes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">721,079 shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2019
under our 2019 Plan at a weighted-average exercise price of $1.93 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">583,080 options to purchase shares of our common stock granted subsequent to June 30, 2019 at a weighted-average
exercise price of $4.26 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">343,083 shares of our common stock reserved for future issuance under our 2019 Plan as of June&nbsp;30,&nbsp;2019
and 396,727 and 1,383,302 additional shares of common stock reserved for future issuance on July 28, 2019 and October 24, 2019, respectively, as well as any automatic increase in the number of shares of common stock reserved for future issuance
thereunder; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">225,188 shares of our common stock to be reserved for future issuance under our 2019 Employee Stock Purchase
Plan, which became effective in connection with this offering, as well as any automatic increase in the number of shares of common stock reserved for future issuance thereunder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options are exercised, new options or other securities are issued under our equity incentive plans, or we issue
additional shares of common stock in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we
believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, including warrants issued pursuant to the potential term loan, the issuance of
these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following tables set forth selected historical consolidated financial data as of and for the periods indicated. The historical
consolidated statement of operations data for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018 and the consolidated balance sheet data as of December 31, 2018 are derived from our audited consolidated financial statements
included elsewhere in this prospectus. The historical consolidated statement of operations data for the period from January&nbsp;18, 2018 (inception) to June 30, 2018 and the six months ended June 30, 2019 and the consolidated balance sheet data as
of June 30, 2019 are derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. Our unaudited interim condensed consolidated financial statements were prepared on the same basis as our
audited consolidated financial statements and, in our opinion, reflect all adjustments, consisting only of normal recurring adjustments, that are necessary for the fair statement of our unaudited interim condensed consolidated financial statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our historical results presented below are not necessarily indicative of the results to be expected for any future period, and our
interim results are not necessarily indicative of the results to be expected for the full year or any future period. This information should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations&#148; and our consolidated financial statements and the related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,<BR>2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from&nbsp;January&nbsp;18,<BR>2018 (inception) to<BR>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and per&nbsp;share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement&nbsp;of&nbsp;Operations&nbsp;Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 19,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 26.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 31.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute pro forma net loss per share, basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,127,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See Notes 2 and 11 to our audited consolidated financial statements and Notes 2 and 10 to our unaudited interim
condensed consolidated financial statements included elsewhere in this prospectus for an explanation of the calculations of our historical and pro forma net loss per share, basic and diluted, and weighted-average number of shares used in the
computation of the per share amounts. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>As&nbsp;of&nbsp;June&nbsp;30,&nbsp;2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance&nbsp;Sheet&nbsp;Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated
financial statements and related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with
respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those described in or implied by these forward-looking statements. Factors
that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled &#147;Risk Factors&#148; included elsewhere in this prospectus. Unless the context requires
otherwise, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;89bio&#148; or the &#147;company&#148; refer to (i)&nbsp;89Bio Ltd. for the periods prior to the Reorganization and (ii)&nbsp;89bio, Inc. for the periods after
completion of the Reorganization, in each case together with its consolidated subsidiaries. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment
of liver and cardio-metabolic diseases. Our lead product candidate, <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> a specifically engineered glycoPEGylated analog of FGF21, is currently being developed for the treatment of NASH. NASH is a severe
form of NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, HCC and death. There are currently no approved products for the treatment of NASH. FGF21 is a clinically-validated mechanism that
has been shown in humans to reduce steatosis and address cardio-metabolic dysregulation. We believe BIO89-100 may be a differentiated FGF21 therapy based on its robust and durable biological effects and a favorable tolerability profile, as well as
its potential for a longer dosing interval. Combining these characteristics with the ability to address the key liver pathologies in NASH, as well as the underlying metabolic dysregulation in NASH patients,
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> has the potential to become a mainstay of NASH therapy. We successfully completed a Phase 1a, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> SAD
clinical trial with 58 healthy volunteers. The magnitude and significance of <FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> biological effects after a single dose on lipid parameters were robust and durable. In July 2019, we initiated our
POC Phase&nbsp;1b/2a clinical trial in patients with NASH or patients with NAFLD and a high risk of NASH and we expect to report topline data in the second half of 2020. We also intend to develop <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for
the treatment of SHTG, a condition identified by severely elevated levels of triglycerides (greater than or equal to 500&nbsp;mg/dL), which is associated with an increased risk of NASH, cardiovascular events and acute pancreatitis. We expect to
initiate our Phase&nbsp;2 trial in SHTG patients in the first half of 2020 in order to evaluate the ability of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to reduce fasting plasma triglyceride levels compared to baseline levels and to report
topline data in the first half of 2021. Based on FDA guidance for the development of SHTG treatments, as well as the regulatory path followed by other companies that have successfully developed SHTG therapies, we believe that a combination of
smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for BIO89-100. We believe <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has the potential to address multiple drivers
underlying metabolic dysregulation, which would make it an ideal candidate for selected liver and cardio-metabolic diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We commenced
operations in 2018 and have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, acquiring our initial product candidate, <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> and
licensing certain related technology, conducting research and development activities, including preclinical studies and early clinical trials, and providing general and administrative support for these operations. We have funded our operations since
our inception to June&nbsp;30, 2019 through the issuance and sale of capital stock, from which we have raised aggregate net proceeds of $42.5&nbsp;million. Additionally, in July 2019, we issued and sold capital stock from which we raised aggregate
net proceeds of $1.2&nbsp;million. As of June&nbsp;30, 2019, our cash and cash equivalents totaled $21.9&nbsp;million. Based on our current operating plan, we believe that our cash and cash equivalents and the funds available from the first tranche
of the potential term loan discussed below, together with the estimated net proceeds from this offering, will be sufficient to meet our anticipated cash requirements into the second half of&nbsp;2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not have any products approved for sale and have incurred net losses since our
inception. Our net losses for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018 were $16.2&nbsp;million. Our net loss for the six months ended June&nbsp;30, 2019 was $19.4&nbsp;million. As of June&nbsp;30, 2019, we had an
accumulated deficit of $35.6&nbsp;million. We expect to continue to incur significant expenses and increasing operating losses as we advance <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates through clinical trials,
seek regulatory approval for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates, expand our clinical, regulatory, quality, manufacturing and commercialization capabilities, protect our intellectual property, prepare
for and, if approved, proceed to commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates, expand our general and administrative support functions, including hiring additional personnel, and incur
additional costs associated with operating as a public company. Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical trials and our expenditures on other research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never generated revenue and do not expect to generate revenue from product sales unless and until we successfully complete development
and obtain regulatory approval for <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> which we expect will not be for at least several years, if ever. Accordingly, until such time as we can generate significant revenue from sales of <FONT
STYLE="white-space:nowrap">BIO89-100,</FONT> if ever, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other
similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a
negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to
develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reorganization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were incorporated in January 2018 in Israel under the name 89Bio Ltd. 89bio, Inc., the registrant whose name appears on the cover page of
this prospectus, was incorporated in June 2019 for the purpose of an internal reorganization transaction. In&nbsp;September 2019, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio,
Inc. Following the Reorganization, 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. and 89bio, Inc. owns the business described and for which historical financial information is included elsewhere in this prospectus. Shares of the common
stock of 89bio, Inc. are being offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Teva </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2018, we entered into the FGF21 Agreement with Teva, under which we acquired certain patents, intellectual property and other assets
relating to Teva&#146;s glycoPEGylated FGF21 program, including BIO89-100. Under the FGF21 Agreement, Teva also granted us a perpetual, non-exclusive (but exclusive as to BIO89-100), non-transferable, worldwide license to patents and know-how
related to glycoPEGylation technology for use in the research, development, manufacture and commercialization of BIO89-100 and products containing BIO89-100. We also entered into an Asset Transfer and License Agreement with Teva under which we
acquired from Teva certain patents, intellectual property and other assets relating to Teva&#146;s development program of small molecule inhibitors of FASN (the &#147;FASN Agreement&#148; and collectively with the FGF21 Agreement, the &#147;Teva
Agreements&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the Teva Agreements, we paid Teva a nonrefundable upfront payment of $6.0 million. See
&#147;Business&#151;Agreements with Teva.&#148; In addition, we are required to make certain payments to Teva under each of the Teva Agreements of up to $2.5 million for the achievement of certain development milestones, and additional payments of
up to $65.0 million upon achievement of certain commercial milestones, for a total under both Teva Agreements of up to $135.0 million. We are also obligated to pay Teva tiered royalties at percentages in the low-to-mid single-digits on worldwide net
sales of products containing BIO89-100 or FASN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The assets acquired from Teva did not meet the definition of a business and therefore, this
acquisition was treated as an asset acquisition for accounting purposes. In addition, we recorded the total consideration transferred to Teva in connection with this acquisition as research and development expense because the acquired technology
represented <FONT STYLE="white-space:nowrap">in-process</FONT> research and development and had no alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of
Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for the development of our lead product candidate, <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> Our research and development expenses consist primarily of external costs related to preclinical and clinical development, including costs related to acquiring patents and intellectual property, expenses
incurred under license agreements and agreements with contract research organizations and consultants, costs related to acquiring and manufacturing clinical trial materials, including under agreements with contract manufacturing organizations and
other vendors, costs related to the preparation of regulatory submissions and expenses related to laboratory supplies and services, as well as personnel costs. Personnel costs consist of salaries, employee benefits and share-based compensation for
individuals involved in research and development efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expense all research and development expenses in the periods in which they
are incurred. We accrue for costs incurred as the services are being provided by monitoring the status of specific activities and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Payments
associated with licensing agreements to acquire licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are expensed as incurred. Where contingent
milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are probable and estimable, which is generally upon achievement
of milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase substantially for the foreseeable future as we continue the
development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and continue to invest in research and development activities. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming, and
the successful development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates is highly uncertain. To the extent that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> continues to advance into larger and later
stage clinical trials, our expenses will increase substantially and may become more variable. The actual probability of success for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate may be affected by a variety of
factors, including the safety and efficacy of our product candidates, investment in our clinical programs, manufacturing capability and competition with other products. As a result, we are unable to determine the timing of initiation, duration and
completion costs of our research and development efforts or when and to what extent we will generate revenue from the commercialization and sale of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future clinical development costs may vary significantly based on factors such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per-patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of doses evaluated in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product
candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our general and administrative expenses consist primarily of personnel costs, expenses for outside professional services, including legal,
human resource, audit and accounting services, consulting costs and allocated facilities costs. Personnel and related costs consist of salaries, benefits and share-based compensation for personnel in executive, finance and other administrative
functions. Facilities costs consist of rent and maintenance of facilities. We expect our general and administrative expenses to increase for the foreseeable future as we increase the size of our administrative function to support the growth of our
business and support our continued research and development activities. We also anticipate increased expenses as a result of operating as a public company, including increased expenses related to audit, legal, regulatory and <FONT
STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other (Income) Expenses, Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other (income) expenses, net primarily consists of the revaluation of our convertible preferred share liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Period from
January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018 and the Six Months Ended June&nbsp;30, 2019 </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table
summarizes our results of operations for the periods presented (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period from<BR>January&nbsp;18,<BR>2018 (inception)<BR>to&nbsp;June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months<BR>Ended&nbsp;June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Increase/<BR>(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes the period-over-period changes in research and development expenses for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period from<BR>January&nbsp;18,<BR>2018 (inception)<BR>to&nbsp;June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Six Months<BR>Ended&nbsp;June&nbsp;30,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Increase/<BR>(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Up-front</FONT> license payment to Teva</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $0.8&nbsp;million, or 12%, from $6.7&nbsp;million during the
period from January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018 to $7.5&nbsp;million during the six months ended June&nbsp;30, 2019. The increase was primarily due to an increase of $2.4&nbsp;million in contract manufacturing costs, an increase
of $2.3&nbsp;million in clinical development costs, and an increase of $0.4&nbsp;million in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> costs, related to advancing our current clinical programs with our lead product candidate, <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> In addition, personnel-related costs, including share-based compensation, increased by $1.3&nbsp;million and other expenses increased by $0.3&nbsp;million due to increased headcount and other costs as we
ramped up our operations. These increases were partially offset by a $6.0&nbsp;million decrease due to a one time <FONT STYLE="white-space:nowrap">up-front</FONT> license payment to Teva in the period from January&nbsp;18, 2018 (inception) to
June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expenses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $1.1&nbsp;million, or 406%, from $0.3&nbsp;million during the period January&nbsp;18, 2018
(inception) to June&nbsp;30, 2018 to $1.4&nbsp;million during the six months ended June&nbsp;30, 2019. The increase was primarily due to an increase of $0.7&nbsp;million in personnel-related costs, including share-based compensation, driven by an
increase in headcount and an increase of $0.4&nbsp;million in professional and accounting consulting service fees, incurred in connection with our preparation to become a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other (Income) Expenses, Net </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other
(income) expenses, net increased by $10.1&nbsp;million, from $0.4&nbsp;million during the period from January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018 to $10.6&nbsp;million during the six months ended June&nbsp;30, 2019. The increase was
primarily due to the revaluation of our convertible preferred share liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the period presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period
from<BR>January&nbsp;18,&nbsp;2018<BR>(inception) to<BR>December&nbsp;31,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $13.7&nbsp;million for the period presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period
from<BR>January&nbsp;18,&nbsp;2018<BR>(inception) to<BR>December&nbsp;31,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Up-front</FONT> license payment to Teva</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-clinical</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expenses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $1.5&nbsp;million for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018.
General and administrative expenses consisted primarily of $0.9&nbsp;million in payroll and related expenses and $0.5&nbsp;million in legal fees and professional consulting service fees, each related to the establishment of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other (Income) Expenses, Net </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other
(income) expenses, net was $1.0&nbsp;million for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018, which was primarily due to the revaluation of our convertible preferred share liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of
September 30, 2019, we estimate that our cash and cash equivalents were approximately $16.2&nbsp;million. Our independent registered public accounting firm, Brightman Almagor Zohar &amp; Co., a Firm in the Deloitte Global Network, has not reviewed,
and does not express an opinion with respect to, these estimates. Our actual cash and cash equivalents as of September 30, 2019 may differ from these estimates due to the completion of our financial closing procedures, final adjustments and other
developments that may arise between now and the time the financial results for our third fiscal quarter are finalized. Our financial statements for the quarter ended September 30, 2019 will not be available until after this offering is completed,
and consequently will not be available to you prior to investing in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since our inception to June&nbsp;30, 2019, we have funded our operations from the issuance
and sale of capital stock, from which we have raised aggregate net proceeds of $42.5&nbsp;million. As of June&nbsp;30, 2019, we had available cash and cash equivalents of $21.9&nbsp;million and an accumulated deficit of $35.6&nbsp;million.
Additionally, in July 2019, we received aggregate net proceeds of $1.2&nbsp;million in connection with the issuance of Series&nbsp;A convertible preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have received a <FONT STYLE="white-space:nowrap">non-binding</FONT> indicative term sheet from one or more financial institutions for a
term loan consisting of a first tranche of $10.0&nbsp;million with the potential for an additional tranche of $5.0&nbsp;million subject to satisfaction of certain terms and conditions. If we enter into the term loan, we expect that we would issue to
the financial institutions warrants to purchase shares of our common stock. We also expect that obligations under the term loan would be secured by a first priority lien on all assets with a negative pledge on our intellectual property. The term
loan and the anticipated terms thereof are subject to the lenders&#146; due diligence, internal approval processes and negotiation and execution of definitive agreements, and could ultimately never materialize. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to our lead
product candidate, <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> We plan to increase our research and development expenses substantially for the foreseeable future as we continue the clinical development of our current and future product
candidates. At this time, due to the inherently unpredictable nature of clinical development, we cannot reasonably estimate the costs we will incur and the timelines that will be required to complete development, obtain marketing approval, and
commercialize our current product candidate or any future product candidates. For the same reasons, we are also unable to predict when, if ever, we will generate revenue from product sales or our current or any future license agreements which we may
enter into or whether, or when, if ever, we may achieve profitability. Clinical and preclinical development timelines, the probability of success, and development costs can differ materially from expectations. In addition, we cannot forecast the
timing and amounts of milestone, royalty and other revenue from licensing activities, which future product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements
would affect our development plans and capital requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on our current operating plans, we expect that the net proceeds from
this offering, together with our existing cash and cash equivalents and the funds available from the first tranche of the potential term loan discussed above, will be sufficient to fund our operations into the second half of 2021. However, our
operating plans and other demands on our cash resources may change as a result of many factors, and we may seek additional funds sooner than planned. There can be no assurance that we will be successful in acquiring additional funding at levels
sufficient to fund our operations or on terms favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our future funding requirements will depend on many factors, including the
following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, timing, scope, results and costs of our clinical trials of
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> and preclinical studies or clinical trials of other potential product candidates we may choose to pursue in the future, including the ability to enroll patients in a timely manner for our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of obtaining clinical and commercial supplies and validating the commercial manufacturing
process for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any other product candidates we may identify and develop; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost, timing and outcomes of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to current or
any future collaboration or license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> other product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with attracting, hiring and retaining additional qualified personnel as our business grows;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public
company, including enhanced internal controls over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual
property rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect to continue to generate substantial operating losses for the foreseeable future as we expand
our research and development activities. We will continue to fund our operations primarily through utilization of our current financial resources and through additional raises of capital. These conditions, and our cash and cash equivalents balances,
raise substantial doubts about our ability to continue as a going concern for at least a year after the filing date of the interim condensed consolidated financial statements, included elsewhere in this prospectus. We plan to address these
conditions by raising funds from our current investors as well as outside potential investors. However, there is no assurance that such funding will be available to us or that it will be obtained on terms favorable to us or will provide us with
sufficient funds to meet our objectives. The interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount or classification of
liabilities that may be required should we be unable to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital
through partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams or research programs or to grant licenses on terms that may not be favorable to us. If we
raise additional capital through public or private equity offerings, the ownership interest of our then-existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our
stockholders&#146; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our clinical trials or preclinical studies, research and development programs or commercialization
efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to a share purchase agreement (the &#147;Series A SPA&#148;) entered into with investors in April 2018, subject to the satisfaction,
as determined in good faith by our board of directors, of certain milestones set forth in the Series A SPA, we may sell additional shares of Series A convertible preferred stock to our investors for aggregate gross proceeds of up to $16.0 million.
We do not expect to fully satisfy these milestones prior to this offering and do not anticipate selling any additional shares of Series A convertible preferred stock prior to this offering. The Series&nbsp;A SPA will terminate upon consummation of
this offering and no shares of Series A convertible preferred stock will be issued under the Series A SPA after this offering. See Note 7 to our interim condensed consolidated financial statements appearing elsewhere in this prospectus for more
information about the Series A SPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period
from<BR>January&nbsp;18,&nbsp;2018<BR>(inception) to<BR>December&nbsp;31,&nbsp;2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Period from</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>January&nbsp;18,&nbsp;2018<BR>(inception) to<BR>June&nbsp;30,&nbsp;2018</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six
Months<BR>Ended<BR>June&nbsp;30,&nbsp;2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Operating Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2019, net cash used in operating activities was $8.1&nbsp;million, which consisted of a net loss of
$19.4&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $10.6&nbsp;million and a net change of $0.7&nbsp;million in our net operating assets and liabilities. The
<FONT STYLE="white-space:nowrap">non-cash</FONT> charges are primarily comprised of the revaluation of our convertible preferred share liability of $10.5&nbsp;million and $0.1&nbsp;million in share-based compensation. The change in our operating
assets and liabilities was primarily due to a $1.3&nbsp;million increase in accrued expenses as we grew our operations, offset in part by a $0.5&nbsp;million decrease in accounts payable due to the timing of payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the period from January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018, net cash used in operating activities was $6.6&nbsp;million,
which consisted of a net loss of $7.4&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-charges</FONT> of $0.4&nbsp;million and a net change of $0.4&nbsp;million in our net operating assets and liabilities. The <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges are primarily comprised of the revaluation of our convertible preferred share liability of $0.4&nbsp;million. The change in our operating assets and liabilities was primarily due to a
$0.4&nbsp;million increase in accounts payable and accrued expenses as we grew our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the period from January&nbsp;18,
2018 (inception) to December&nbsp;31, 2018, net cash used in operating activities was $12.5&nbsp;million, which consisted of a net loss of $16.2&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of
$1.1&nbsp;million and a net change of $2.6&nbsp;million in our net operating assets and liabilities. The <FONT STYLE="white-space:nowrap">non-cash</FONT> charges are primarily comprised of the revaluation of our convertible preferred share liability
of $1.0&nbsp;million and $0.1&nbsp;million in share-based compensation. The change in our net operating assets and liabilities was primarily due to a $2.7&nbsp;million increase in accounts payable and accrued expenses as we grew our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Used in Investing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2019, the period from January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018, and the period from
January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018, net cash used in investing activities primarily consisted of purchases of fixed assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Cash Provided by Financing Activities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2019 net cash provided by financing activities was $18.8&nbsp;million, which consisted of net
proceeds of $18.8&nbsp;million from the issuance and sale of our convertible preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the period from January&nbsp;18
(inception) to June&nbsp;30, 2018 net cash provided by financing activities was $14.8&nbsp;million, which primarily consisted of net proceeds of $14.7&nbsp;million from the issuance and sale of our convertible preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018, net cash provided by financing activities was
$23.8&nbsp;million, which primarily consisted of net proceeds of $23.7&nbsp;million from the issuance and sale of our convertible preferred shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2018 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments&nbsp;Due&nbsp;by&nbsp;Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;to&nbsp;3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3&nbsp;to&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>More&nbsp;than&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contractual obligations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, under the Teva Agreements, we have milestone and royalty payment obligations if
and when we achieve certain milestones and commercialize products developed under the agreements. Because these obligations are uncertain, and their timing and amount are not known, they are not included in the table above. See
&#147;Business&#151;Agreements with Teva.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts in the table above do not include: (a)&nbsp;a non-cancellable purchase
commitment entered into in July 2019 related to the supply of reagents in the amount of &#128;1.2&nbsp;million, or $1.4&nbsp;million (using the exchange rate as of June&nbsp;30, 2019), pursuant to a purchase order issued to Teva; or
(b)&nbsp;non-cancellable purchases commitments entered into in June, July and August 2019 amounting in total to &#128;4.1&nbsp;million, or $4.7&nbsp;million (using the exchange rate as of June&nbsp;30, 2019), that we will be responsible to pay in
connection with multiple statements of work with a contract manufacturer related to scale-up activities of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and the production of material for preclinical and clinical studies, and for the technology
transfer related to the manufacturing of certain enzymes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also enter into agreements in the normal course of business with contract
research organizations for clinical trials, preclinical studies, manufacturing and other services and products, which are generally cancelable upon written notice. These obligations and commitments are also not included in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and regulations
of the SEC, and do not have any holdings in variable interest entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are
exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash and cash equivalents of $11.2&nbsp;million and $21.9&nbsp;million as of December&nbsp;31, 2018 and June&nbsp;30,
2019, respectively, which consist of bank deposits. Historical fluctuations in interest rates have not had a significant impact on our financial condition or results of operations, and a hypothetical future 10% relative increase or decrease in
interest rates would not have a material impact on the value of our cash and cash equivalents or on our future financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Risk </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United States and Israel. We make payments to vendors for research and development services with payments denominated in foreign
currencies, including the Israeli New Shekel and Euro. We are subject to foreign currency transaction gains or losses on our payments denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material
and we have not had a formal hedging program with respect to foreign currency. A 10% increase or decrease in currency exchange rates would not have a material effect on our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Polices and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our
historical experience and on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future
performance, as these policies relate to the more significant areas involving management&#146;s judgments and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and
Development Expenditures </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We record accrued expenses for estimated preclinical and clinical trial and research expenses related to
the services performed but not yet invoiced pursuant to contracts with research institutions, contract research organizations and clinical manufacturing organizations that conduct and manage preclinical studies, and clinical trials, and research
services on our behalf. Payments for these services are based on the terms of individual agreements and payment timing may differ significantly from the period in which the services were performed. Our estimates are based on factors such as the work
completed, including the level of patient enrollment. We monitor patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. Our
estimates of accrued expenses are based on the facts and circumstances known at the time. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. As
actual costs become known, we adjust our accrued expenses. To date, we have not experienced significant changes in our estimates of preclinical studies and clinical trial accruals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Share Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The freestanding instruments related to the commitments by the Series A convertible preferred shareholders to purchase and by us to sell our
Series A convertible preferred shares in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per share, are considered a liability (or an asset) measured
at fair value as the shares underlying the rights contain liquidation preferences upon certain &#147;deemed liquidation events&#148; that are not solely within the Company&#146;s control and which are considered in-substance contingent redemption
features. The instruments are subject to revaluation at each balance sheet date until settlement, with revaluations recognized as a component of other (income) expenses, net in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
recognize compensation expense related to share-based awards granted to employees, directors, and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers, including stock options, based on the estimated fair value of the awards on the
date of grant. We estimate the grant date fair value, and the resulting share-based compensation, using the Black-Scholes option-pricing model. The grant date fair value of the share-based awards, which have graded vesting, is recognized using the
straight-line method over the requisite service period of each award, which is generally the vesting period of the respective awards. We recognize forfeitures as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We use the Black-Scholes option-pricing model to estimate the fair value of stock option awards that requires the use of subjective
assumptions to determine the fair value of share-based awards. These assumptions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected volatility</I>&#151;Since we are privately held and do not have any trading history for our shares of
common stock, the expected volatility is based on the historical volatilities of the shares of common stock of similar publicly traded companies in the biotechnology sector. The historical volatility data was computed using the daily closing prices
for the selected companies&#146; shares during the equivalent period of the calculated expected term of the share-based awards. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-free interest rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon bonds
in effect at the time of grant for periods corresponding with the expected term of the option. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected</I> <I>term</I>&#151;The expected term of options granted to employees and directors is determined
using the &#147;simplified&#148; method. Under this approach, the expected term is presumed to be the mid-point between the weighted-average vesting term and the contractual term of the option. The simplified method makes the assumption that the
employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options would expire. The expected option term for options granted to non-employees is based on the contractual term.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected dividend</I>&#151;We have never paid dividends on our shares of common stock and have no plans to pay
dividends on our shares of common stock. Therefore, we used an expected dividend of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will continue to use
judgment in evaluating the expected volatility and expected term utilized for our share-based compensation calculations on a prospective basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Given the absence of a public trading market for our shares of common stock, our board of directors exercised their judgment and considered a
number of objective and subjective factors to determine the best estimate of the fair value of our shares of common stock, including timely valuations of our shares of common stock prepared by an unrelated third-party valuation firm, important
developments in our operations, sales of convertible preferred shares, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of
comparable public companies, and the lack of liquidity of our shares of common stock, among other factors. After the closing of this offering, our board of directors will determine the fair value of each share of common stock based on the closing
price of our shares of common stock as reported on the date of grant. Our board of directors intended all options granted to be exercisable at a price per share not less than the estimated per share fair value of shares of common stock underlying
those options on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2019 and during the period from January&nbsp;18, 2018
(inception) to December&nbsp;31, 2018, share-based compensation was $111,000 and $108,000, respectively. As of June&nbsp;30, 2019, there was $682,000 of unrecognized share-based compensation related to stock options granted, which is expected to be
recognized over a weighted average period of 3.0&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on the initial offering price of $16.00&nbsp;per share, the aggregate
intrinsic value of outstanding stock options as of June&nbsp;30, 2019 was $10.1&nbsp;million, of which $0.9&nbsp;million related to vested options and $9.2&nbsp;million related to unvested options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See
Note 2 to our consolidated financial statements included elsewhere in this prospectus for more information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their
potential impact on our financial condition of results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Accounting Election </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting
new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have elected to use this extended transition period to enable us to comply with new or revised accounting standards that have different
effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a
result, our consolidated financial statements and our interim condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> a
specifically engineered glycoPEGylated analog of FGF21, is currently being developed for the treatment of NASH. NASH is a severe form of NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure,
HCC and death. There are currently no approved products for the treatment of NASH. FGF21 is a clinically-validated mechanism that has been shown in humans to reduce steatosis and address cardio-metabolic dysregulation. We believe BIO89-100 may be a
differentiated FGF21 therapy based on its robust and durable biological effects and a favorable tolerability profile, as well its potential for a longer dosing interval. Combining these characteristics with the ability to address the key liver
pathologies in NASH, as well as the underlying metabolic dysregulation in NASH patients, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has the potential to become a mainstay of NASH therapy. We successfully completed a Phase 1a, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> SAD clinical trial with 58 healthy volunteers. The magnitude and significance of <FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> biological effects
after a single dose on lipid parameters were robust and durable. In July 2019, we initiated our POC Phase 1b/2a clinical trial in patients with NASH or patients with NAFLD and a high risk of NASH and we expect to report topline data in the second
half of 2020. We also intend to develop <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of SHTG, a condition identified by severely elevated levels of triglycerides (greater than or equal to 500&nbsp;mg/dL), which is associated
with an increased risk of NASH, cardiovascular events and acute pancreatitis. We expect to initiate our Phase&nbsp;2 trial in SHTG patients in the first half of 2020 in order to evaluate the ability of
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> to reduce fasting plasma triglyceride levels compared to baseline levels and to report topline data in the first half of 2021. Based on FDA guidance for the development of SHTG treatments, as well as
the regulatory path followed by other companies that have successfully developed SHTG therapies, we believe that a combination of smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to
market for BIO89-100. We believe <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has the potential to address multiple drivers underlying metabolic dysregulation, which would make it an ideal candidate for selected liver and cardio-metabolic
diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prevalence of NAFLD, which affects approximately 25% of the global population, and NASH, which develops in approximately
20% to 25% of NAFLD patients, is growing and is driven primarily by the worldwide obesity epidemic. NAFLD and NASH patients have an excessive accumulation of fat in the liver resulting primarily from a caloric intake above and beyond energy needs.
In NAFLD patients, this abnormal liver fat contributes to the progression to NASH, a liver necro-inflammatory state, that can lead to scarring, also known as fibrosis, and, for some, can progress to cirrhosis and liver failure. The critical
pathophysiologic mechanisms underlying the development and progression of NASH include reduced ability to handle lipids, increased insulin resistance, injury to hepatocytes and liver fibrosis in response to hepatocyte injury. Patients with NASH
frequently have other significant metabolic <FONT STYLE="white-space:nowrap">co-morbidities</FONT> such as obesity, hyperglycemia, dyslipidemia and systemic hypertension (a constellation of which is commonly referred to as metabolic syndrome) and
these further contribute to the risk of cardiovascular disease. The number of NASH cases in the United States is projected to expand from 16.5&nbsp;million in 2015 to 27&nbsp;million in 2030, with similar prevalence growth expected in Europe. Diet
and exercise are currently the standard of care for NAFLD and NASH, but adherence to this treatment regimen is poor and there remains a high unmet need in the treatment of NASH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> is a specifically engineered FGF21 analog that we believe has the potential to address the
critical pathophysiologic mechanisms underlying NASH. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 has been clinically shown to reduce steatosis in the liver. It is also thought to exert
effects on liver fibrosis by improving metabolic regulation, which reduces ongoing liver injury thus giving the liver time to heal. FGF21 also generates an <FONT STYLE="white-space:nowrap">on-target</FONT> effect to increase adiponectin, a hormone
released from adipose tissue that, among other functions, can suppress development and progression of hepatic fibrosis. However, FGF21 in its native form suffers from a short half-life and a tendency to aggregate in solution, both of which impact
its suitability as a viable drug. To address these challenges, we have specifically engineered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> to maintain the clinical benefits of FGF21, while extending half-life in vivo, protecting against proteolysis, reducing renal clearance,
minimizing susceptibility to aggregate in solution and optimizing potency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BIO89-100 has been evaluated in seven animal studies of NASH,
diabetes and obesity, including studies in mice and non-human primates. Each study was customized to assess endpoints relevant to liver and metabolic diseases and conducted according to standard practices at experienced CROs. In these preclinical
studies, consistent beneficial effects across a range of endpoints were observed, including improvements in hepatic steatosis, injury and fibrosis in a diet-induced NASH study of 50 mice (see &#147;BIO89-100&#151;Results of DIN Mouse Studies&#148;
Figure 11 which illustrates that statistically significant mean changes with respect to hepatic steatosis and fibrosis were each observed and Figure 12 which illustrates that statistically significant mean changes with respect to injury were
observed) and improved glycemic resistance and lipid handling in a study of 24 spontaneously diabetic obese cynomolgus monkeys with elevated triglycerides (see &#147;BIO89-100&#151;Results of Spontaneously Diabetic Obese Cynomolgus Monkey
Studies&#148; Figures 20 and 21, respectively, which illustrate that statistically significant mean changes with respect to glycemic control and lipid handling were each observed). We believe this demonstrates
<FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> potential to simultaneously address the multiple drivers of NASH pathogenesis. The histological endpoints assessed in these preclinical studies, NAFLD activity score (&#147;NAS&#148;) and
fibrosis score, mirror the endpoints we expect to assess in our clinical development. In addition, treatment with <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in animal models demonstrated consistent reductions in body weight. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2019, we announced positive topline data from our Phase 1a,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> SAD clinical trial of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in 58 healthy volunteers. In this SAD study,
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated a favorable tolerability profile in the 43 volunteers who received <FONT STYLE="white-space:nowrap">BIO89-100</FONT> with a half-life of 55 to 100&nbsp;hours. At single doses of
9.1&nbsp;mg and higher, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated significant improvements in key lipid parameters measured at Day&nbsp;8 and Day&nbsp;15 after dosing on Day&nbsp;1. The mean changes versus baseline include
reductions in triglycerides (up to 51%) and <FONT STYLE="white-space:nowrap">LDL-C</FONT> (up to 37%) and increase in <FONT STYLE="white-space:nowrap">HDL-C</FONT> (up to 36%) despite the baseline values being in the normal range. As compared to
placebo treatment, these mean changes were all statistically significant (p &lt; 0.001). <FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated rapid (beginning from Day 2), sustained and durable improvements in lipid parameters for two
weeks or more after single dose administration. Based on these findings and results from our animal studies, we believe such a lengthy duration of effect may confer longer dosing intervals to <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> We are
currently enrolling our POC Phase 1b/2a trial with 83 total patients randomized to receive once weekly or once every two weeks subcutaneous dosing of either <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or placebo, in each case, for up to 12
weeks. This trial is designed to assess the safety, tolerability and PK properties of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> as well as changes in liver steatosis and key biomarker assessments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also intend to develop <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of SHTG, a condition identified by severely
elevated levels of triglycerides (greater than or equal to 500&nbsp;mg/dL) and which is associated with an increased risk of NASH, cardiovascular events and acute pancreatitis. SHTG accounts for up to 10% of all acute pancreatitis episodes. It is
estimated that there are 2.5&nbsp;million to 4&nbsp;million patients in the United States with TG <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 500 mg/dL and up to 50% of SHTG patients treated with certain approved drugs are refractory to current
standard of care. In a study of 24 diabetic obese cynomolgus monkeys with elevated triglycerides, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> showed significant effects on triglycerides at doses as low as 0.1 mg/kg/week, with a 78% reduction
from baseline (range of 52% reduction to 94% reduction) observed at the highest dose level of 1.0 mg/kg/week on Day 56. In our Phase 1a SAD study, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> showed a significant reduction in triglycerides of
up to 51% after a single dose in healthy volunteers. While currently approved SHTG therapies decrease TG levels, they generally do not have broader metabolic benefits. To the extent that we are able to show in subsequent human clinical trials that
BIO89-100 significantly decreases both TG and LDL-C levels and improve other metabolic parameters, we believe that BIO89-100 could be a differentiated therapy in this indication. We expect to initiate our Phase&nbsp;2 trial in SHTG patients in the
first half of 2020 in order to evaluate the ability of BIO89-100 to reduce fasting plasma triglyceride levels compared to baseline levels and to report topline data in the first half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We retain exclusive worldwide rights to <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> <FONT STYLE="white-space:nowrap">BIO89-100</FONT>
is protected by a family of issued patents with claims directed to composition of matter and methods of use. The first of our patents for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are projected to expire in the United States in 2028, with the final composition-of-matter patent projected to expire in the United States in 2038, in each case, without patent term extensions.
Because <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is a biologic drug, marketing approval is also expected to provide 12 years of market exclusivity in the United States from the approval date of a BLA. We license the patents and know-how
related to the glycoPEGylation technology for use in the research, development, manufacture and commercialization of BIO89-100 from Teva and ratiopharm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our management team has extensive drug development, manufacturing and commercialization experience, having brought many successful drugs to
market, including biologic agents. We are also supported by a group of directors and leading investors whose collective experience will assist us in realizing our corporate strategy. Our existing investors include OrbiMed, Longitude Capital, RA
Capital and Pontifax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
goal is to become a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The key components of our strategy are to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Rapidly advance <FONT STYLE="white-space:nowrap">BIO89-100</FONT> through clinical development for the
treatment of NASH.</B> We believe BIO89-100 may be a differentiated FGF21 therapy based on its robust and durable biological effects and a favorable tolerability profile, as its potential for a longer dosing interval, and is well positioned to
address the complex pathophysiology of NASH. We are currently enrolling patients in our POC Phase 1b/2a clinical trial to evaluate the safety and efficacy of <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> We believe that our trial design and the
use of well-established surrogate clinical endpoints can contribute meaningfully to the rapid advancement of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> through its clinical development. With potential for
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> to be established as a mainstay monotherapy for NASH, we continue to explore opportunities to combine <FONT STYLE="white-space:nowrap">BIO89-100</FONT> with products targeting other pathways within
NASH for possible development as a combination therapy. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand the breadth of indications for BIO89-100 with an initial focus on SHTG.</B> While we are focused on
becoming a leader in the treatment of NASH, the mechanism of action of our FGF21 analog supports evaluation across a spectrum of liver and cardio-metabolic diseases. We believe <FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> mechanism and
potentially robust and durable biological effects and favorable tolerability profile, as well as its potential for a longer dosing interval make it an ideal candidate for selected liver and cardio-metabolic diseases. We intend to develop <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of SHTG. Based on FDA guidance for the development of SHTG treatments, as well as the regulatory path followed by other companies that have successfully developed SHTG therapies, we
believe that a combination of smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for BIO89-100. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">Scale-up</FONT> and optimize the manufacturing of <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> </B>We currently use an external contract manufacturing organization (&#147;CMO&#148;) to manufacture <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for our ongoing and planned clinical trials. While
these trials are ongoing, we plan to work with our CMO to optimize and <FONT STYLE="white-space:nowrap">scale-up</FONT> the manufacturing process for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to support the increased production that will be
needed for later-stage clinical trials and commercialization, if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is approved. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Establish a commercial infrastructure in key geographies.</B> We have worldwide rights to <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and intend to develop the sales infrastructure required for commercialization in the United States. We also plan to evaluate options, including strategic collaborations, for commercializing <FONT
STYLE="white-space:nowrap">BIO89-100,</FONT> if approved, in other key markets, such as Europe and China. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Construct a diversified multi-asset pipeline of novel therapies.</B> We intend to employ a value-driven
strategy to identify, acquire, develop and commercialize product candidates for liver and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
cardio-metabolic diseases. We intend to focus on product candidates that we believe have attractive profiles in early clinical testing, address a clear unmet medical need and can advance quickly
and efficiently into late-stage development. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Focus on Liver and Cardio-Metabolic Disease </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are focused on developing and commercializing therapeutic interventions that have a clinically meaningful impact on patients with liver and
cardio-metabolic diseases. These diseases, including NASH and SHTG, represent leading global causes of morbidity and mortality. Despite a wave of public health campaigns to promote better diet and exercise habits and a range of treatment options
available for many of these diseases, there is a significant unmet medical need for more effective therapies to improve patient outcomes and reduce the burden on global healthcare systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently developing our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, for the treatment
of NASH. We believe BIO89-100 is an ideal candidate for the treatment of NASH based on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its ability to address the key liver pathologies in NASH; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its ability to address the underlying metabolic dysregulation in NASH patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its balance of its robust and durable biological effects and favorable tolerability profile; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">its potential for a longer dosing interval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Given the potential of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to meaningfully reduce triglycerides, we also intend to develop <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of SHTG. There is regulatory precedence for the approval of a therapy for the treatment of patients with SHTG in the United States and the reduction in triglycerides from baseline is
recognized by the FDA as the primary endpoint for full approval. Based on FDA guidance for the development of SHTG treatments, as well as the regulatory path followed by other companies that have successfully developed SHTG therapies, we believe
that a combination of smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for BIO89-100. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASH Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NAFLD is emerging as the
most common chronic liver disorder, driven primarily by the global obesity epidemic. NAFLD affects approximately 25% of the population globally and is often referred to as the hepatic manifestation of metabolic syndrome. Patients with NAFLD have an
excessive accumulation of fat in the liver resulting from a caloric intake above and beyond energy needs. This abnormal fat in the liver contributes to the progression of NAFLD to NASH, a necro-inflammatory state in the liver that ultimately leads
to scarring, also known as fibrosis; and for certain patients, progression to cirrhosis and liver failure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients with NASH exhibit
suboptimal lipid handling, increased insulin resistance, caloric overload and inadequate fat burning, all of which contribute to the increased risk of cardiovascular disease. Due to an increase in obesity and Type 2 diabetes, which predispose
individuals to more significant liver disease, the number of NASH cases in the United States is projected to expand from 16.5&nbsp;million in 2015 to 27&nbsp;million in 2030. Currently, there are no approved products for the treatment of NASH and
diet and exercise is established as the standard of care. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disease Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NAFLD is a condition of excess fat accumulation, or steatosis, of more than 5% in liver cells, also known as hepatocytes. NASH, a severe form
of NAFLD, is characterized histologically by the additional presence of inflammation and hepatocellular injury such as visible ballooning and has a significantly worse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prognosis, with the potential to progress to liver fibrosis, cirrhosis or HCC. Steatohepatitis is a key catalyst in fibrosis development, and there is a substantial collinearity between the
presence of NASH and fibrosis severity. While NAFLD has historically been viewed as benign in terms of liver-related outcomes, recent studies have challenged this notion since patients with NAFLD may develop NASH and fibrosis over time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Figure 1 below shows the increase in prevalence liver-related mortality rates by fibrosis stage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 1: Prevalence and Liver-Related Mortality Rate by Fibrosis Stage </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g45e83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is estimated that 20% to 25% of NAFLD patients progress to NASH. Of those with NASH, cirrhosis develops
in approximately 20% and 45% of patients and in some cases, cirrhosis progresses to decompensated cirrhosis, which results in permanent liver damage that can lead to liver failure. In addition, it is estimated that 8% of patients with advanced
fibrosis will develop HCC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is a high unmet need in the treatment of NASH, and there are currently no approved therapies. In the
United States, the number of NASH cases is projected to expand from 16.5&nbsp;million in 2015 (5.1% of the population) to 27&nbsp;million in 2030. The expected lifetime economic burden of all patients with NASH in the United States in 2017 is
estimated at $223&nbsp;billion. NASH is currently the second leading cause of liver transplants behind hepatitis C, and is expected to become the leading cause of liver transplants by 2020. Additionally, multiple epidemiological studies have linked
NAFLD to increased cardiovascular disease, concluding that the majority of deaths among NAFLD patients are attributable to cardiovascular disease. As a result, we believe it is important that new therapeutics options for NASH also address the
underlying cardiovascular and metabolic dysregulations in these patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Etiology </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Understanding of the pathophysiologic mechanisms that lead to NASH has evolved in recent years. Excessive caloric overload, metabolic
dysregulation, cardio-metabolic <FONT STYLE="white-space:nowrap">co-morbidities</FONT> and genetic risk factors increase the likelihood of developing NASH, with a multitude of potential mechanistic contributors to pathophysiology. In NASH, the
liver&#146;s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed. This occurs when there is an excess of free fatty acids deposited in the liver or their disposal from the liver is impaired. The
accumulation of surplus free fatty acids leads to the formation of toxic lipid species. These toxic lipids then induce endoplasmic reticulum stress, oxidative stress and an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inflammatory response, which can result in hepatocellular injury and death. This may lead to fibrosis and genomic instability, which may worsen over time to cirrhosis and HCC, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As shown in Figure 2 below, the critical pathophysiologic mechanisms underlying development and progression of NASH include (1)&nbsp;reduced
ability to handle lipids, (2)&nbsp;increased insulin resistance, (3)&nbsp;injury to hepatocytes and (4)&nbsp;development and progression of liver fibrosis in response to hepatocyte injury. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 2: Mechanisms Underlying Development and Progression of NASH </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g40l24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reduced Ability to Handle Lipids </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Excess consumption of calories, poor diet and a sedentary lifestyle, each often associated with obesity, can burden the body with a surplus of
carbohydrates and lipids. This burden can be progressively more difficult for the liver to handle thereby resulting in steatosis in the liver. The problem is compounded further as insulin resistance develops. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Free fatty acids (&#147;FFA&#148;) accumulate in the liver primarily from three sources, namely, through (1)&nbsp;the transfer from peripheral
adipose tissues where triglycerides are mobilized, <FONT STYLE="white-space:nowrap">(2)&nbsp;de-novo</FONT> lipogenesis (&#147;DNL&#148;), and (3)&nbsp;direct dietary intake. The FFA that lead to NASH are believed to arise primarily from the
peripheral tissue pool and secondarily through DNL. The increase in the influx of FFA to the liver from the peripheral tissues is driven by excessive caloric intake greater than the body&#146;s demand and increased insulin resistance resulting in
deposition of fat to the liver for processing. DNL is a distinct process in the liver by which hepatocytes convert excess carbohydrates, especially fructose, to fatty acids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The three main fates of fatty acids in the liver are (1)&nbsp;mitochondrial beta-oxidation (to release ATP, or energy), (2) <FONT
STYLE="white-space:nowrap">re-esterification</FONT> to form triglyceride, which can then be exported into the blood as very low density lipoproteins, or (3)&nbsp;stored in lipid droplets, resulting in liver steatosis and ultimately NASH.
Adiponectin, a hormone derived from adipose tissue, appears to have a pivotal role in improving fatty acid oxidation and decreasing fatty acid synthesis, components of lipid handling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An increase in cholesterol accumulation in the liver can also contribute to NASH, though its role is not as clearly defined as in the case of
triglycerides. The dysregulation of the cholesterol pathway can result in an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase in the cholesterol levels in the liver. The increased cholesterol can accumulate in the liver cell membranes and activate Kupffer cells (activated stellate macrophages), thereby
triggering inflammatory pathways and resulting in the progression of NASH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Increased Insulin Resistance </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Insulin resistance, which typically develops in obese individuals, is considered to be a fundamental underlying mechanism in the majority of
NASH patients. Fatty acids are primarily delivered to the liver from blood following lipolysis of triglycerides in adipose tissue, a process that is regulated by the actions of insulin on adipocytes. Insulin resistance in adipose tissue manifests as
dysregulated lipolysis resulting in excessive delivery of FFA to the liver. The liver tries to cope with the large influx of FFA; however, the <FONT STYLE="white-space:nowrap">build-up</FONT> of metabolic intermediates interferes with signaling,
resulting in hepatic insulin resistance and the inability of the liver to process this excess FFA influx. The state of hepatic insulin resistance further exacerbates the problem by triggering DNL and the
<FONT STYLE="white-space:nowrap">build-up</FONT> of excess fat in the liver. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Injury to Hepatocytes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">When the disposal of fatty acids through beta-oxidation or the formation of triglycerides is chronically overwhelmed, fatty acids can form
lipotoxic species that lead to stress on the endoplasmic reticulum, oxidative stress and inflammation, all of which are pivotal processes in the development of NASH. Liver inflammation may be an important link between the initial metabolic stress
and subsequent hepatocyte death and stimulation of fibrogenesis in NASH by promotion of the expression of <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines and of apoptosis (cell death). These processes are core to the
steatohepatitis that gives NASH its name. For example, hepatocyte apoptosis results in the ballooning of cells, a classic pathological feature of NASH. While hepatocytes are the primary and major target of toxic lipids, other cells such as Kupffer
cells and hepatic stellate cells are also affected by lipotoxicity and contribute to the development of NASH pathology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additional
factors, including dysregulation of cytokines and adipokines, energy depletion, anti-oxidant deficiencies, products of the gut microbiome and iron load may modulate hepatocyte vulnerability to the development of lipotoxic stress, injury and
inflammation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development and Progression of Liver Fibrosis in Response to Hepatocyte Injury </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Signaling from stressed or injured hepatocytes and Kupffer cells leads to activation of quiescent hepatic stellate cells. Upon activation,
hepatic stellate cells release collagen and other factors. When the production of collagen and matrix proteins is faster than their degradation, accumulation of these proteins in the extracellular matrix can lead to progressive fibrosis. As the
lipotoxicity and inflammation continue to damage the liver, the hepatic stellate cells continue to be activated resulting in greater collagen deposition that ultimately leads to fibrosis and cirrhosis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Co-morbidities</FONT> Associated with NASH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Patients with NASH frequently have other significant <FONT STYLE="white-space:nowrap">co-morbidities&#151;hypertriglyceridemia,</FONT>
obesity, hyperlipidemia/dyslipidemia, hyperglycemia (including Type 2 diabetes) and systemic hypertension, a constellation of which is commonly referred to as metabolic syndrome&#151;which also increase the risk of developing cardiovascular disease.
Figure 3 below shows certain <FONT STYLE="white-space:nowrap">co-morbidities</FONT> associated with NASH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 3: NASH Co-morbidities
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt" BGCOLOR="#44b7ff">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF"><B><FONT STYLE="white-space:nowrap">Selected&nbsp;Co-morbidities</FONT></B></FONT></P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt" BGCOLOR="#44b7ff">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF"><B>Prevalence&nbsp;in&nbsp;NASH</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF"><B>Population</B></FONT></P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hypertriglyceridemia</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83%</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Obesity</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82%</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hyperlipidemia&nbsp;/&nbsp;Dyslipidemia</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72%</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Metabolic syndrome</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71%</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Type 2 diabetes</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44%</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The association between NASH and features of metabolic syndrome appears to be bidirectional. Metabolic
syndrome increases the risk of NASH and NASH may also exacerbate several features and <FONT STYLE="white-space:nowrap">co-morbidities</FONT> of metabolic syndrome. Type 2 diabetes, hypertriglyceridemia, obesity and other features of metabolic
syndrome have all been shown to be associated with an increased risk for NASH and advanced liver fibrosis. In addition, it is estimated that approximately 30% of obese patients and approximately 30% of patients with Type 2 diabetes have NASH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, NASH was found to independently increase the risk of <FONT STYLE="white-space:nowrap">non-liver-related</FONT> adverse outcomes,
including cardiovascular risk and malignancy. Multiple epidemiological studies have linked NASH to increased cardiovascular morbidity, concluding that the majority of deaths among NASH patients are attributable to cardiovascular disease
(cardiovascular death is four times higher than death related to liver disease). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In considering therapeutic options to treat NASH, we
believe it is important to address the underlying metabolic <FONT STYLE="white-space:nowrap">co-morbidities</FONT> in addition to the liver pathology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diagnosis </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Most people with NASH are
asymptomatic and their disease is often discovered incidentally following a liver imaging procedure, such as an ultrasound, prescribed for other reasons or as part of an investigation for elevated liver enzymes. Once suspected clinically, a liver
biopsy is required to definitively diagnose NASH, which necessitates the joint presence of steatosis, ballooning and lobular inflammation. Once pathologically confirmed, the severity of NAFLD and NASH is determined using the histologically validated
NAS, which grades disease activity on a scale of 0 to 8. The NAS is the sum of the individual scores for steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) but does not include a score for fibrosis. Fibrosis
staging <FONT STYLE="white-space:nowrap">(F0-F4)</FONT> relies on the Kleiner classification (F0 = no fibrosis; F1 = perisinusoidal or periportal fibrosis (not both); F2 = both perisinusoidal and periportal fibrosis; F3 = bridging fibrosis; F4 =
cirrhosis). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Histological diagnosis remains the gold standard for assessment of NASH and fibrosis. However, given that liver biopsy is
associated with risks of pain, bleeding and other morbidity, as well as significant cost, the procedure is not practical for general patient screening. Several <FONT STYLE="white-space:nowrap">non-invasive</FONT> tools such as clinical risk scores
and imaging techniques are increasingly used to assess NASH patients. Clinical risk scores such as the NAFLD fibrosis score, <FONT STYLE="white-space:nowrap">Fibrosis-4</FONT> index, the Enhanced Liver Fibrosis score and vibration-controlled
transient elastography (&#147;VCTE&#148;), have been validated and are increasingly used. These tools have an excellent negative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
predictive value and an acceptable positive predictive value for detection of advanced (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> F3) fibrosis, and are increasingly used in clinical
settings. Additionally, evidence is emerging that shows a correlation between reduction in steatosis as measured by magnetic resonance imaging proton density fat fraction <FONT STYLE="white-space:nowrap">(&#147;MRI-PDFF&#148;)</FONT> and improvement
histological changes in the liver. Extensive efforts are also under way to develop <FONT STYLE="white-space:nowrap">non-invasive</FONT> means to identify patients with NAS <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>4 or fibrosis <FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> F2 patients without a need for a liver biopsy. In a recent draft guidance, the FDA encouraged sponsors to identify biochemical or noninvasive imaging biomarkers that, once characterized and agreed by the FDA,
could replace liver biopsies for patient selection and efficacy assessment in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We expect that the validation and
subsequent adoption of these new tools will result in an increase in the diagnosis and treatment rates for NASH in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prevalence </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prevalence of NASH has increased significantly in recent decades, paralleling similar trends in the prevalence of obesity, insulin
resistance and Type 2 diabetes. Alarmingly, the prevalence of these conditions is expected to increase further in view of the unhealthy nutrition habits, such as consumption of a diet high in fructose, sucrose and saturated fats, and sedentary
behavior that characterize modern lifestyle. In the United States, the number of NASH cases is projected to expand from 16.5&nbsp;million in 2015 (5.1% of the population) to 27&nbsp;million in 2030. Approximately 20% of the 16.5&nbsp;million NASH
cases in 2015 had F3/F4 fibrosis, a number that is expected to increase to 7.9&nbsp;million by 2030, which will be approximately 30% of the total NASH population. Similar growth trends for NASH cases are expected in Europe (12.6&nbsp;million in 2016
to 18.3&nbsp;million in 2030 within France, Germany, Italy, Spain and the United Kingdom) as well as China (32.6&nbsp;million in 2016 to 48.3&nbsp;million in 2030). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Since no approved drugs exist currently, NASH is emerging as a major economic issue. Lifetime costs of all NASH patients in the United States
in 2017 was estimated at $223&nbsp;billion, and the cost of the advanced NASH population was estimated at $95&nbsp;billion with estimated increase in NASH cases (as mentioned above) further expected to drive costs upwards. Progression of patients
along the NASH continuum further adds to costs as mean health care costs (per month) were 32% and 247% higher for patients with compensated cirrhosis ($1,870) and <FONT STYLE="white-space:nowrap">end-stage</FONT> liver disease ($4,931),
respectively, compared to those without cirrhosis ($1,420) and these results were independent of age. The economic burden of NASH is expected to continue to increase, as NASH is anticipated to become the leading cause of liver transplants by 2020 in
conjunction with the significant increase in liver transplant costs ($577,000 in 2013 to $812,500 in 2017). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of NASH Treatment Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are currently no approved therapies for the treatment of NASH. We believe four key attributes are essential for successful NASH
therapies: (1)&nbsp;robust efficacy with respect to liver pathologies; (2)&nbsp;ability to address underlying <FONT STYLE="white-space:nowrap">co-morbidities</FONT> associated with the disease; (3)&nbsp;limited tolerability issues at effective
doses; and (4)&nbsp;patient convenience. Figure 4 below summarizes the primary interventional and therapeutic approaches to NASH that are in existence or under development and their key advantages and limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 4: Primary Interventional and Therapeutic Approaches to NASH </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD></TR>
<TR BGCOLOR="#44b7ff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:11.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT
 COLOR="#ffffff">Approach</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:11.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Advantages</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:11.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Limitations</FONT></B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Diet and exercise</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Reduction in continuing injury to the liver allowing liver to regenerate</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Inexpensive and widely available</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Poor adherence</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Farnesoid X receptor (FXR) agonism</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Statistically significant but modest reduction in liver fibrosis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Liver fat reduction with some agents</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Increase in <FONT STYLE="white-space:nowrap">LDL-C</FONT> and pruritus with some
agents</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Limited impact on NASH resolution by histology</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Peroxisome proliferator-activated receptor (PPAR) agonism</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Improvement in glycemic control with some agents</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Anti-inflammatory</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Reduction in triglycerides and liver fat with some agents</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Weight gain with certain agents</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Safety issues with certain agents (cancer, heart failure, edema) and renal adverse
events</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;No effect on liver fat with certain agents</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Thyroid receptor-&szlig; <FONT STYLE="white-space:nowrap">(THR-&szlig;)</FONT> agonism</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Reduction in <FONT STYLE="white-space:nowrap">LDL-C</FONT> and triglycerides</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Reduction in liver fat</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Potential for drug-drug interactions</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Potential risk of hypothyroidism</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Questionable effect on fibrosis</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Acetyl-CoA</FONT> (ACC) inhibition</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Reduction in DNL from inhibition</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Increase in triglycerides, risk of thrombocytopenia</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Fibroblast growth factors (FGFs)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Reduction in liver fat and fibrosis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Improvements in lipid parameters with certain agents</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;FGF19 is associated with increases in <FONT STYLE="white-space:nowrap">LDL-C;</FONT>
impact on HDL and glucose unclear</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Daily injections with some agents likely to be
poorly received by patients</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Native FGF21 is rapidly broken down by the body and is
difficult to formulate in solution</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">GLP1</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Reduction in body weight</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Well-established glycemic control agent</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;No impact on lipid parameters</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Injectable formulation in testing for NASH has burdensome dosing regime</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;&#8202;Questionable impact on fibrosis and liver fat reduction</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the market for NASH treatments will evolve to be similar to the multi-billion dollar markets
for diabetes and dyslipidemia treatments and has the potential to support multiple successful commercial products across different therapeutic classes as well as within the same class. Further, we believe potent injectable therapies have the
potential to be a preferred treatment option for some patient populations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Solution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Summary </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing
BIO89-100, a specifically engineered glycoPEGylated analog of FGF21, for the treatment of NASH and other liver and cardio-metabolic indications. FGF21 is an endogenous metabolic hormone that is naturally found as a monomeric, non-glycosylated
protein and is known to play a key role in regulating energy expenditure, and glucose and lipid metabolism. FGF21 has been clinically shown to reduce steatosis in the liver. It is also thought to exert effects on liver fibrosis by improving
metabolic regulation, which reduces ongoing liver injury thus giving the liver time to heal. FGF21 also generates an <FONT STYLE="white-space:nowrap">on-target</FONT> effect to increase adiponectin, a hormone released from adipose tissue that, among
other functions, can suppress development and progression of hepatic fibrosis. Given the relevant and broad-based effects of FGF21, we believe it is a compelling pharmaceutical target for treating NASH, which may offer benefits and/or address the
limitations relative to the therapeutic approaches described in Figure 4 above. We believe FGF21 analogs such as ours have the potential to be the mainstay of therapies for NASH because they can address liver pathologies and the underlying metabolic
dysregulation which result in NASH progression. However, FGF21 in its native form is not suitable as a pharmacological product given it is rapidly broken down by the body and it is unstable in soluble formulation. BIO89-100 is specifically
engineered to overcome these challenges while maintaining the efficacious properties of the endogenous molecule. We believe BIO89-100 may be a differentiated FGF21 therapy based on its robust and durable biological effects and a favorable
tolerability profile, as well its potential for a longer dosing interval. We are currently evaluating BIO89-100 in a POC Phase 1b/2a clinical trial in patients with NASH or patients with NAFLD and high risk of NASH. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FGF21 Overview </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fibroblast growth factors (&#147;FGFs&#148;), including FGF21 and FGF19, are a large family of cell-signaling proteins involved in the
regulation of many processes within the body. FGF21 is an endogenous metabolic hormone that regulates energy homeostasis, glucose-lipid-protein metabolism and insulin sensitivity, and modulates the pathways that mitigate against intracellular
stress. FGF21 is secreted primarily by the liver but is also secreted by the white adipose tissue (&#147;WAT&#148;), skeletal muscle and the pancreas. FGF21 exerts its biological benefits through the activation of three fibroblast growth factor
receptors (&#147;FGFRs&#148;), FGFR1c, FGFR2c and FGFR3c, and requires <FONT STYLE="white-space:nowrap">co-activation</FONT> of the transmembrane protein cofactor beta Klotho (&#147;&szlig;-Klotho&#148;). FGF21 is not believed to activate FGFR4,
which has been associated with adverse effects. FGF21 can act directly or indirectly on target organs by mediating downstream regulators, such as adiponectin, and upstream regulators that induce FGF21, such as nutritional stress or transcription
factors. Figure 5 below shows effects of FGF21 on the body. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 5: Biological Effects of FGF21 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g74s65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reducing Liver Steatosis by Improving Lipid Handling and Insulin Sensitivity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FGF21 has been clinically shown to reduce liver steatosis. FGF21 reduces liver steatosis by (1)&nbsp;increasing fatty acid oxidation in the
liver, (2)&nbsp;reducing the deposition of free fatty acids from peripheral tissue to the liver and (3)&nbsp;reducing DNL in the liver. FGF21 exerts its systemic effects by reducing the serum levels of lipids (e.g., triglycerides, LDL cholesterol)
and increasing insulin sensitivity. Increasing insulin sensitivity reduces lipolysis and can also reduce serum levels of lipids. In particular, FGF21 has been demonstrated to reduce liver fat in patients with NASH and has also shown beneficial
effects in obese diabetic patients on both serum levels of lipids and insulin resistance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Improving Liver Inflammation and Fibrosis </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FGF21 is believed to reduce liver fibrosis, the pathological change mostly clearly linked to liver-related morbidity in NASH patients via two
potential pathways. One pathway is through the metabolic benefits of FGF21 described above. Long-term improvements in metabolic regulation reduce the ongoing liver injury that drives fibrosis and thus allows the liver time to heal. The other pathway
is a direct anti-fibrotic effect mediated via adiponectin, an adipokine that is upregulated by FGF21. Increased adiponectin downregulates the hepatic stellate cells that are activated upon hepatic injury and responsible for collagen deposition and
subsequent fibrosis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FGF21 Signaling </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As noted above, FGF21 exerts its biological benefits through the <FONT STYLE="white-space:nowrap">co-activation</FONT> of FGFRs and
&szlig;-Klotho. FGFRs are expressed widely throughout the body whereas &szlig;-Klotho is primarily expressed in metabolic tissues such as adipose tissue, liver, and pancreas, thereby providing organ specificity to FGF21. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As illustrated in Figure 6 below, the binding of FGF21 is a <FONT STYLE="white-space:nowrap">two-step</FONT> process. The <FONT
STYLE="white-space:nowrap">C-terminus</FONT> of FGF21 initially binds to&nbsp;&szlig;-Klotho enabling the <FONT STYLE="white-space:nowrap">N-terminus</FONT> to form an expanded complex with one of the FGFRs. Once the
<FONT STYLE="white-space:nowrap">co-receptor</FONT> complex has formed with&nbsp;&szlig;<I>-</I>Klotho and one of the FGFRs, a series of intracellular signaling cascades is initiated. These signaling cascades enable FGF21 to exert its biological
functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6: FGF21&#146;s <FONT STYLE="white-space:nowrap">two-step</FONT> receptor binding with</B><B><I>
</I></B><B>&szlig;</B><B><I></I></B><B>-</B><B><I></I></B><B>Klotho and FGFRs </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g46x01.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">FGF21 activates three specific FGFRs (FGFR1c, FGFR2c and FGFR3c), which based on
nonclinical studies and clinical trials, appear to be responsible for mediating the desired therapeutic actions of FGF21 in NASH. FGF19 activates these receptors and acts upon another FGFR known as FGFR4. Activation of FGFR4 results in an increase
in LDL cholesterol and has been implicated in the etiology or progression of HCC. The activation and downstream signaling pathways of FGF21 are shown in Figure 7 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 7: FGF21 Receptor Activation </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g67c45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overcoming the Challenges of Developing FGF21 as a Pharmaceutical Product </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">While the observed pharmacological effects of recombinant human FGF21 in preclinical disease models clearly highlight its therapeutic
potential, FGF21 in its native form is not suitable for commercialization for two key reasons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Native FGF21 is rapidly broken down in the bloodstream and cleared through the kidneys.</B><B></B>&nbsp;The
native form of FGF21 is a 19.4 kDa protein with a half-life estimated to be less than two hours. Reducing renal clearance and protecting both ends of the protein from proteolysis remains key to extending half-life and thereby extending the duration
of its effect. If the <FONT STYLE="white-space:nowrap">N-terminus</FONT> is not intact, signaling activity of FGF21 is significantly reduced. However, if the <FONT STYLE="white-space:nowrap">C-terminus</FONT> is not intact, FGF21&#146;s ability to
bind with &szlig;-Klotho is impaired, thereby rendering it inactive. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Native FGF21 is unstable and has a tendency to aggregate in solution.</B> Hence, it is operationally
challenging to develop a stable liquid formulation at high concentration with low viscosity, which is required to achieve good bioavailability via subcutaneous injection. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Validation of FGF21 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe FGF21 has the potential to be the mainstay monotherapy for NASH because it addresses multiple facets of the disease. Specifically,
it has the potential to reduce steatosis, improve fibrosis and importantly, impact the metabolic dysregulation which continues to promote disease progression. The potential for FGF21 analogs in the treatment for NASH has been demonstrated by
clinical trial data with pegbelfermin, a pegylated form of FGF21. In a third-party Phase&nbsp;1b study, pegbelfermin was observed to result in reductions in triglycerides, LDL-C and HDL. In addition, a third-party Phase 2a study conducted in
patients with biopsy-proven NASH, pegbelfermin showed a significant reduction in absolute hepatic fat fraction measured by <FONT STYLE="white-space:nowrap">MRI-PDFF,</FONT> a significant increase in adiponectin concentration, a decrease in mean
liver stiffness and a significant decrease in concentration of <FONT STYLE="white-space:nowrap">PRO-C3,</FONT> a biomarker of fibrosis. Clinical outcomes were better when dosed as a daily injection versus a weekly injection. The compound was deemed
generally well tolerated, although a higher frequency of gastrointestinal adverse events was reported in treated patients versus placebo. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A second compound, selectively activating the FGFR1c and its <FONT STYLE="white-space:nowrap">co-receptor</FONT> &szlig;-Klotho, reported
reductions in liver fat content and improvements in metabolic parameters in a study in NAFLD patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">BIO89-100</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing <FONT
STYLE="white-space:nowrap">BIO89-100,</FONT> a specifically engineered glycoPEGylated analog of FGF21, for the treatment of NASH with fibrosis and other cardio-metabolic indications. <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has successfully
completed a Phase 1a study, and we are currently evaluating <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in a POC Phase 1b/2a clinical trial in patients with NASH or NAFLD with a high risk of NASH.
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> has been specifically engineered to: (1)&nbsp;protect against proteolysis and reduce renal clearance, (2)&nbsp;have an extended half-life, (3)&nbsp;minimize susceptibility to aggregate in solution
and (4)&nbsp;optimize its potency, enabling the potential use of lower dosage/doses. Additionally, we believe that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> may enhance binding affinity for &szlig;-Klotho, by altering the conformation of the
<FONT STYLE="white-space:nowrap">C-terminus</FONT> which could have a positive impact on efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Primary Structure and Protein Engineering of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> has been optimally constructed with
two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the <FONT STYLE="white-space:nowrap">C-terminus</FONT> end of the hormone. The mutations were incorporated into the FGF21 sequence after
existing proline to create a consensus sequence for glycosylation. Subsequently, the glycosyl linker and a single 20 kDa glycoPEG moiety were enzymatically introduced at the <FONT STYLE="white-space:nowrap">O-linked</FONT> glycosylation consensus
site (position 173) via the proprietary glycoPEGylation technology. Our glycoPEG moiety is an activated form of the PEG molecule with the use of Sialic Acid, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">CMP-SA-PEG.</FONT></FONT>
The proximity of the mutations ensures consistent and efficient attachment of the glycoPEG moiety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> has two modified natural amino acid residues: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S173T: Serine modified to Threonine at position 173; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">R176A: Arginine modified to Alanine at position 176. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, a Methionine residue was introduced at the
<FONT STYLE="white-space:nowrap">N-terminus</FONT> which acts as the translation initiation signal. A single 20 kDa linear glycoPEG moiety is attached to the Threonine in position 173 via the proprietary glycoPEGylation technology. Figure 8 below
shows the structure of <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 8: Structure of
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g17u63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The increase in the size of the molecule from 19.4 kDa to 40 kDa together with the site-specific mutations
adjacent to the primary cleavage site of FGF21 (by the FAP enzyme between positions 171 and 172 on the native amino acid chain, which would be represented by positions 172 and 173 in our molecule starting with Methionine in position 1) are designed
to prolong the half-life of the molecule. Additionally, we believe that the use of glycoPEGylation technology produces a comparatively stronger and more flexible structure, which aids in the development of a stable formulation. PEGylation technology
has been used successfully in many pharmaceutical products including products that have been marketed for more than 10 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">BIO89-100</FONT> uses a proprietary glycoPEGylation technology that has been previously validated by a third party, as this technology is incorporated in another pharmaceutical product (Lonquex<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> by Teva) that has received regulatory approval and is currently commercialized in the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Development and Selection of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The discovery program that led to the selection of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> was directed towards achieving an optimal
PK and efficacy profile. It has been shown that the in vivo half-life of FGF21 can be extended by covalently linking a single glycoPEG moiety to the molecule. We performed extensive screening of FGF21 analogs with mutations at different positions
including close to the <FONT STYLE="white-space:nowrap">N-terminus,</FONT> as well as different glycoPEGylations to select an optimized molecule based on its potency, PK and <FONT STYLE="white-space:nowrap">in-vivo</FONT> efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stage I&#151;Optimizing Selection of Mutation Sites&#151;In Vitro Potency Testing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mutations were inserted at different sites for both <FONT STYLE="white-space:nowrap">non-PEGylated</FONT> FGF21 analogs and corresponding
glycoPEGylated analogs and screened in a cell-based potency assay to select analogs that did not lose potency relative to the native hormone. Amongst the multiple glycoPEGylated analogs tested, only mutations at sites towards either <FONT
STYLE="white-space:nowrap">N-terminus</FONT> or <FONT STYLE="white-space:nowrap">C-terminus</FONT> showed potency comparable to that of native FGF21 hormone and were selected for further development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stage II&#151;Optimizing for glycoPEG (20 kDa vs 30 kDa)&#151;In Vitro Potency Testing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Analogs selected in Stage I were prepared with either a 20 kDa or a 30 kDa glycoPEG moiety and tested for potency in mouse adipocytes <FONT
STYLE="white-space:nowrap">(3T3-L1)</FONT> and human embryonic kidney <FONT STYLE="white-space:nowrap">(HEK-293)</FONT> cell lines. Minimal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
differences in potencies were observed between the 20 kDa and 30 kDa glycoPEGylated analogs. However, only the glycoPEGylated analogs that had mutations and a glycoPEG attachment at the <FONT
STYLE="white-space:nowrap">C-terminus,</FONT> as distinct from those with mutations at the <FONT STYLE="white-space:nowrap">N-terminus,</FONT> maintained their potency in both mouse and human cell lines. These analogs were selected for future
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stage III&#151;Optimizing for PK Properties and Efficacy&#151;In Vivo Testing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Selected analogs from Stage II with either a 20 kDa or a 30 kDa glycoPEG moiety, were chosen for in vivo testing in a diabetic mouse model. In
addition to PK, changes from baseline in glucose, triglycerides and insulin were measured. The data showed that the circulating half-life of the glycoPEGylated analogs for both glycoPEG sizes was extended (range 15 to 30 hours) as compared to native
FGF21 (2 hours). As expected, all analogs were observed to cause a reduction in blood glucose levels. However, the 20 kDa glycoPEGylated analogs were observed to outperform the 30 kDa analogs by improving triglycerides at lower doses and across
broader dose ranges. <FONT STYLE="white-space:nowrap">BIO89-100</FONT> resulted in the greatest reduction of insulin and was selected as the candidate for clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In summary, the mutations made to the native FGF21 molecule and the addition of the 20 kDA glycoPEG moiety via the use of the glycoPEGylation
technology were observed to significantly improve the PK properties of the molecule while retaining the therapeutic benefits. We believe that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is a well-balanced molecule with a unique profile, which
has the potential to have therapeutic benefits in NASH and cardio-metabolic diseases. Figure 9 below sets forth what we believe are the key features and potential benefits of <FONT STYLE="white-space:nowrap">BIO89-100:</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 9: Summary of BIO89-100 Attributes and Benefits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="29%"></TD></TR>
<TR BGCOLOR="#44b7ff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT
 COLOR="#ffffff">Features</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Description</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:12.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Potential Benefit</FONT></B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Use of PEG (via glycoPEGylation)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Increases protein size and hydrodynamic volume that reduces renal filtration</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Prevents degradation by endocytosis and proteolytic enzymes</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Prolongs half-life</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Protects antigenic sites present on the protein surface (i.e. antigenic epitopes)</P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Reduces immunogenicity</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Steric repulsion between the PEGylated surfaces increases water solubility and reduces
aggregates</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Results in more stable formulation</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Site-Specific
Mutations</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Mutation at position 173 is immediately adjacent to the primary cleavage (FAP enzyme) site of
FGF21</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Prolongs half-life</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">GlycoPEGylation Technology</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Allows site specific linkage (glycoPEG moiety to position 173)</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Proximity of the glycoPEG
moiety to the <FONT STYLE="white-space:nowrap">C-terminus</FONT> induces conformational changes to the molecule</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Retains potency against receptor to improve efficacy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Provides a strong and flexible glycosyl bond that helps the glycoPEG moiety remain intact,
further reducing degradation</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.50em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#9726;&#8194;&#8201;Further enhances half-life</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Therapeutic Potential of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> Supported by Preclinical Animal Models of
NASH, Diabetes and Obesity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> was evaluated in multiple distinct animal models of
NASH, diabetes and obesity, including non-human primate studies. In each of these studies, consistent and significant beneficial effects were observed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
across a range of endpoints, specifically, robust improvements in lipid handling, glycemic control and insulin resistance as well as significant improvements in hepatic steatosis, injury and
fibrosis. We believe these results demonstrate the potential of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to simultaneously address the multiple drivers of NASH pathogenesis. The histological endpoints, NAS and fibrosis score, mirror the
endpoints we expect to assess in our clinical development. In addition, treatment with <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in animal models was observed to result in consistent reductions in body weight. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> has been evaluated in three animal models of direct relevance to NASH. These included:
(1)&nbsp;Stelic Animal Model (&#147;STAM&#148;), (2) Diet-induced NASH (&#147;DIN&#148;) model and (3)&nbsp;spontaneous diabetic obese cynomolgus monkey model. Additional studies done in diabetes mouse model and diet induced obesity mouse model
showed benefits in key markers of relevance in NASH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A wide range of doses were tested in these studies as well as weekly and once every
two week dosing regimen was tested in a cynomolgus monkey study. The key outcomes of these studies are summarized in Figure 10 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 10: Summary of NASH Pharmacology Studies </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD style="width:11pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:11pt"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD style="width:10pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:10pt"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD style="width:13pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:13pt"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD style="width:7pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:7pt"></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#44b7ff">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#44b7ff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Preclinical&nbsp;pharmacology&nbsp;study</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff"><FONT STYLE="white-space:nowrap">with&nbsp;BIO89-100</FONT></FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Improved</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Insulin</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">&nbsp;&nbsp;&nbsp;&nbsp;Sensitivity&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">&nbsp;&nbsp;&nbsp;&nbsp;Improved&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Lipid</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Handling</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Reduced</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">&nbsp;&nbsp;&nbsp;&nbsp;Hepatocyte&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Injury</FONT></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ffffff"><B><FONT COLOR="#ffffff">&nbsp;&nbsp;&nbsp;&nbsp;Reduced&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ffffff"><B><FONT COLOR="#ffffff">Fibrosis</FONT></B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">STAM mouse model</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#042;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">DIN mouse model I (10 weeks)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">DIN mouse model II (19 weeks)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Diabetic obese cynomolgus monkey study 1 (8&nbsp;weeks; weekly dosing)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;Not&nbsp;evaluated&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="5" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Diabetic obese cynomolgus monkey study 2 (4&nbsp;weeks; QW or Q2W dosing)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&#10003;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="4" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">Not&nbsp;evaluated</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Legend: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#10003;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statistically significant benefit observed </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Improvement observed, but did not achieve statistical significance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of DIN Mouse Studies </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Two
pharmacology studies were conducted in a DIN mouse model. In the first study of 40 mice (10 per treatment group), the animals received <FONT STYLE="white-space:nowrap">BIO89-100</FONT> via a subcutaneous injection at 0.5 and 2 mg/kg every 3 days for
10 weeks, and a detailed assessment of liver parameters was performed to evaluate the effectiveness of the dosing regimen. Both doses of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> were observed to reduce the total NAS significantly based on
histological evaluation and improved measures with respect to both lipid handling and insulin sensitivity. In addition, expression of hepatic genes involved in inflammation and fibrosis were significantly reduced following administration of <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> In the second DIN mouse study of 50 mice (10 per treatment group), lower dose levels of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> were tested (0.02, 0.1 and 0.5 mg/kg every 3 days) but the
treatment duration was longer at 19 weeks. In this study too, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> was observed to result in significant reductions in the liver damage induced by the diet in a dose-dependent manner. Specifically,
treatment with <FONT STYLE="white-space:nowrap">BIO89-100</FONT> was observed to result in a significant mean reduction of the histological markers of NASH (Figure 11), as well as a reduction in the marker of hepatic injury (alanine amino
transaminase (&#147;ALT&#148;)) (Figure 12), in liver lipids (Figure 13), and in inflammatory and fibrotic markers (Figure 14), each in a dose dependent manner compared to vehicle treatment. In addition to the beneficial effects on the liver,
treatment with <FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated significant improvements in glycemic control and weight loss. As NAS and measures of fibrosis are histological endpoints for the assessment of NASH in clinical studies, we
believe that the observations in the STAM and DIN mouse models suggest that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is a compelling candidate for the treatment of NASH. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 11: Improvement in Histology with BIO89-100 in a DIN Mouse Model </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g31c65.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 12: Changes in ALT with
BIO89-100 in a DIN Mouse Model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g32d67.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 13: Reduction in Liver Lipids with BIO89-100 in a DIN Mouse Model </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g11f23.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 14: Changes in Inflammatory
and Fibrotic Markers with BIO89-100 in a DIN Mouse Model </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g41g83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Spontaneously Diabetic Obese Cynomolgus Monkey Studies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> efficacy was evaluated in 24 spontaneously diabetic obese cynomolgus monkeys (six per
treatment group) after multiple subcutaneous doses. In the first study, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> was administered at doses of 0.1, 0.3 and 1 mg/kg once per week for 8 weeks followed by a
<FONT STYLE="white-space:nowrap">6-week</FONT> washout phase. Administration of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> showed significant effects on triglycerides at all doses tested, with a highly robust 78% reduction observed at the
highest dose level of 1 mg/kg/week (Figure 15). Statistically significant mean reductions were observed in total cholesterol (Figure 16), glucose (Figure 17), insulin, glycated hemoglobin (HbA1c) and ALT (Figure 18), along with improvement in oral
glucose test results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 15: Changes in Triglycerides with BIO89-100 in Diabetic Monkey Study 1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g04x51.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 16: Changes in Total
Cholesterol with BIO89-100 in Diabetic Monkey Study 1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g05y72.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 17: Changes in Blood Glucose with BIO89-100 in Diabetic Monkey Study 1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g06p27.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 18: Changes in ALT with
BIO89-100 in Diabetic Monkey Study 1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g07o50.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In a second multiple-dose study in 24 spontaneously diabetic obese cynomolgus monkeys (six
per treatment group), BIO89-100 was administered for 4 weeks at 1 mg/kg once weekly or 1 or 2 mg/kg given once every 2 weeks. A rapid and dramatic reduction in triglycerides (Figure 21), up to 76%, was observed with BIO89-100. Statistically
significant mean reductions were also observed in body weight (Figure 19), HbA1c (Figure 20), glucose, and insulin, along with increased adiponectin levels (Figure 22) and improvement in oral glucose test results in all BIO89-100-treated groups
(both once weekly and every 2 weeks) in comparison to the vehicle group. The robust effect on body weight and HbA1c over the 4-week treatment period were particularly unexpected. The PD effects were relatively similar across all three dosing groups
suggesting that once every two weeks could be a viable clinical dosing strategy. BIO89-100 was also assessed in a study of sweetness preference in six obese cynomolgus monkeys. Using a two-bottle sweetness preference test, monkeys given BIO89-100 at
1&nbsp;mg/kg by subcutaneous injection every week for three weeks demonstrated a substantial reduction in sweetness preference and improvements in certain lipid parameters compared to monkeys given vehicle treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 19: Changes in Body Weight with BIO89-100 in Diabetic Monkey Study 2 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g62l42.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 20: Changes in HbA1c with
BIO89-100 in Diabetic Monkey Study 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g07v49.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 21: Changes in Triglycerides with BIO89-100 in Diabetic Monkey Study 2 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g10p10.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 22: Changes in Adiponectin
with BIO89-100 in Diabetic Monkey Study 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g11t11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe the PD effects observed in the animal studies suggest that
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> is a potent molecule that may address the key pathways in NASH by (1)&nbsp;improving lipid handling and resultant steatosis, (2)&nbsp;improving insulin resistance, (3)&nbsp;reducing hepatocyte injury
and inflammation and (4)&nbsp;improving fibrosis. Additionally, the data from the cynomolgus monkey studies suggest that the molecule may be amenable to an extended dosing interval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">BIO89-100</FONT> Clinical Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are developing BIO89-100 for the indication of NASH with fibrosis. In our randomized, double-blind, placebo-controlled, Phase 1a, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> SAD clinical trial of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> of 58 healthy volunteers, 43 healthy volunteers received
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> with a half-life of 55 to 100 hours and 15 received placebo treatment. In this SAD study, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> was well tolerated, with all treatment related adverse
events reported as mild; there were no serious adverse events reported. At single doses of 9.1 mg and higher, we observed significant improvements in key lipid parameters measured at Day 8 and Day 15 after dosing on Day 1. The mean changes versus
baseline include reductions in triglycerides (up to 51%) and <FONT STYLE="white-space:nowrap">LDL-C</FONT> (up to 37%) and increase in <FONT STYLE="white-space:nowrap">HDL-C</FONT> (up to 36%) despite the baseline values being in the normal range.
As compared to placebo treatment, these mean changes were all statistically significant (p &lt; 0.001). <FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated rapid (starting from Day 2), sustained and durable improvements on lipid
parameters for two weeks or more after single dose administration. We believe this duration of effect further supports the possibility of an extended dosing interval, as observed in our preclinical studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1a Clinical Trial of Single Dose of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in Healthy Volunteers </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We conducted a Phase 1a clinical trial to evaluate the safety, tolerability and PK of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in
healthy volunteers. We enrolled a total of 58 healthy volunteers into one of seven cohorts and randomized to receive a single dose of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or a placebo. Forty-three healthy subjects received <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> at the following doses: 0.45 mg, 1.2 mg, 3 mg, 9.1 mg, 18.2 mg, 39 mg and 78 mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">BIO89-100</FONT> Exhibited Generally Linear, Dose-proportional PK </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The PK profile of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> was generally dose-proportional or slightly more than dose-proportional with T1/2 range from approximately 55 to 100 hours. As shown in Figure 23 below, the observed median time of maximum serum
concentration ranged from 36 to 60 hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 23: Single-dose PK of BIO89-100 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g41c25.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Phase 1a clinical trial enrolled healthy volunteers with a mean (SD) age and BMI of 39.3
(9.7) years and 26.7 (3.1) kg/m2 respectively, with laboratory parameters in the normal range at baseline (mean values: TG 94.0 mg/dL; LDL 124.1 mg/dL; HDL 47.7 mg/dL). Even in this healthy study population, after a single dose administration of
BIO89-100 at doses 9.1 mg and higher, robust and durable PD effects were observed across key lipid parameters, including triglycerides (Figures 24 and 25), LDL (Figure 26) and HDL (Figure&nbsp;27), over two weeks. The changes in lipids parameters
started from Day 2 with maximal effects typically observed at Day 8 or Day 15. The effect on lipid parameters was generally dose-dependent, with single doses of BIO89-100 at 9.1 mg and higher, demonstrating significant improvements versus baseline
in key lipid parameters measured at Day 8 and Day 15 following dosing. The BIO89-100 effects appeared to plateau at 39 mg with minimal additional effect observed in 78 mg. BIO89-100 also led to increases in mean adiponectin levels (up to 146%
relative to baseline) when measured at Day 8 and Day 29. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 24: Changes in Triglycerides after Single Dose of BIO89-100 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g16b74.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 25: Changes in Triglycerides after Single Dose of BIO89-100 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g17p84.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 26: Changes in LDL
Cholesterol after Single Dose of BIO89-100 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g13p07.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 27: Changes in HDL Cholesterol after Single Dose of BIO89-100 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g75o60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> was well tolerated across the dose range in our Phase 1a
clinical trial. There were no deaths, serious adverse events or discontinuations due to adverse events. The most commonly observed treatment-related adverse events, occurring in at least two subjects in the pooled
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> group, were injection site reactions and headache, all of which were reported as mild. Injection site reactions were more frequent in the 39 mg cohort, likely due to a larger injection volume
administered at one time in that cohort. No clinically meaningful trends were observed in gastrointestinal events, laboratories or vital signs including blood pressure or heart rate changes. No tremors were reported. Five of 43 <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> treated subjects tested positive for anti-drug antibodies (&#147;ADA&#148;); however, all titers were low (<FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT> 16) and did not appear to affect the PK or safety
profile. Treatment-related treatment emergent adverse events (&#147;TEAE&#148;) reported in two subjects or more in pooled <FONT STYLE="white-space:nowrap">BIO89-100</FONT> treatment group are shown in Figure 28 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 28: Treatment-Related TEAE Reported in </B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B> 2 Subjects in Pooled BIO89-100
Treatment Group </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="14" BGCOLOR="#44b7ff"></TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF"><B>&nbsp;&nbsp;Placebo&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD VALIGN="middle" COLSPAN="13" NOWRAP ALIGN="center" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF"><B>BIO89-100</B></FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" BGCOLOR="#44b7ff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:15.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF"><B>Pooled</B></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-TOP:1px solid #ffffff; BORDER-RIGHT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff; BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff; BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff; BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff; BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff; BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff; BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff; BORDER-TOP:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=15)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">&nbsp;&nbsp;0.45&nbsp;mg&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">&nbsp;&nbsp;1.2&nbsp;mg&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">&nbsp;&nbsp;3&nbsp;mg&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">&nbsp;&nbsp;9.1&nbsp;mg&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">&nbsp;&nbsp;18.2&nbsp;mg&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">&nbsp;&nbsp;39&nbsp;mg&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">&nbsp;&nbsp;78&nbsp;mg&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;BIO89-100&nbsp;&nbsp;</FONT></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" BGCOLOR="#44b7ff"></TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD>
<TD HEIGHT="2" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff; padding-left:8pt" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">n (%)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=6)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=6)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=6)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=7)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=6)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=6)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=6)</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#44b7ff" STYLE=" BORDER-LEFT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#44b7ff">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:13.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#FFFFFF">(N=43)</FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff; padding-left:8pt" BGCOLOR="#9bbfc4"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#FFFFFF">Any Treatment</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#FFFFFF">Related TEAE</FONT></P></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">3&nbsp;(20.0)</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">0</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">0</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">0</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">1</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">3</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">6</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">3</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#9bbfc4" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff" BGCOLOR="#9bbfc4"><FONT COLOR="#FFFFFF">13&nbsp;(30.2)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#2b4772">Injection site induration</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">1 (6.7)</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">1</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">5</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">1</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">7
(16.3)</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#2b4772">Injection site erythema</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">1 (6.7)</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">3</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">2</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">5
(11.6)</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#2b4772">Injection site pain</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">2</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff; BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #ffffff">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">2
(4.7)</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #ffffff">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" STYLE="BORDER-RIGHT:1px solid #ffffff; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#2b4772">Headache</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">1
(6.7)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center" STYLE="BORDER-RIGHT:1px solid #ffffff"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">0</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:14.0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#2b4772">2
(4.7)</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#2b4772">Note: All adverse events reported in table were Grade 1.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These data supported the advancement of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> into a study in patients with NASH or
patients with NAFLD and a high risk of NASH to evaluate <FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> potential as a treatment of NASH. Based on PK/PD modeling and drug exposure analysis, we have identified
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> doses in the range of 9 mg to 36 mg weekly (&#147;QW&#148;) or every other week (&#147;Q2W&#148;) as the target dose range for evaluation in future clinical trials in patients with NASH or patients
with NAFLD and a high risk of NASH. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe that the totality of the data from our Phase 1a study, the preclinical data with <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and the clinical data from third parties collectively support the hypothesis that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has the potential to address the complex nature of NASH, especially given
the frequency of metabolic <FONT STYLE="white-space:nowrap">co-morbidities</FONT> in NASH patients. The magnitude and significance of <FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> biological effects after a single dose on lipid parameters
in healthy volunteers were observed to be robust and durable, and the magnitude of these reductions appear to be comparable or better than data reported to date in Phase 1 clinical trials of other FGF analogs, although no <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> studies have been conducted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1b/2a POC Clinical Trial
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently enrolling patients in our Phase 1b/2a POC clinical trial. Our clinical trial is a multicenter, randomized,
double-blind, placebo-controlled, multiple ascending dose-ranging trial in patients with NASH or patients with NAFLD and a high risk of NASH, with 83 total patients randomized to receive QW or Q2W subcutaneous dosing of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> or placebo for up to 12 weeks. In October 2019, we completed enrollment of the first cohort in this trial. This clinical trial is designed to assess the safety, tolerability and PK properties of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> as well as change in liver fat measured by <FONT STYLE="white-space:nowrap">MRI-PDFF</FONT> and key biomarker assessments. These data are aimed at providing <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in NASH and help inform dose selection for larger, longer-term paired-biopsy trials. At our meeting with the FDA in June 2019, the FDA
concurred with our overall trial design, including study population, dose selection and study treatment duration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our POC study is
enrolling patients with NASH or patients with NAFLD and a high risk of NASH, defined as patients with steatosis greater than 10% who have central obesity and Type 2 diabetes or central obesity and evidence of liver injury. NAFLD patients, especially
the subset of NAFLD patients we will enroll, have similar disease characteristics as patients with biopsy-proven NASH, and we expect that the data from these NAFLD patients will be informative regarding the potential of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> as treatment for NASH. The trial will include a set number of patients with biopsy confirmed NASH with fibrosis <FONT STYLE="white-space:nowrap">(F1-F3)</FONT> to help inform the design of subsequent
clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The key objectives of the trial are to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the safety and tolerability of multiple ascending doses of
<FONT STYLE="white-space:nowrap">BIO89-100;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assess change from baseline in liver fat (measured via <FONT STYLE="white-space:nowrap">MRI-PDFF);</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assess changes from baseline in lipids, glycemic control parameters, fibrosis and inflammation markers;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">characterize the PK properties of <FONT STYLE="white-space:nowrap">BIO89-100;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the immunogenicity of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> as measured by presence of ADA.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The design of the trial is presented in Figure 29 below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 29: POC Clinical Trial Design </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g89o26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our planned active treatment groups are: 3 mg, 9 mg 18 mg and 27 mg QW, and 18 mg and 36 mg Q2W. As this is
a multiple ascending dose study, we expect to have two dose escalation decision points during the study. The first decision point will be to move from the 3 mg QW dose cohort to both the 9 mg QW and 18 mg Q2W dose cohorts. The second decision point
will be to move from those two dose cohorts to the final three dose cohorts. We expect dose escalation decisions after Day 36 assessment in the relevant cohorts. We have designed the trial to detect differences on
<FONT STYLE="white-space:nowrap">MRI-PDFF</FONT> between <FONT STYLE="white-space:nowrap">BIO89-100</FONT> at different dose levels and the pooled placebo group. We expect to report topline data in the second half of 2020. In addition, we anticipate
initiating a Phase&nbsp;2b trial in the first half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">BIO89-100</FONT> Differentiation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe <FONT STYLE="white-space:nowrap">BIO89-100</FONT> could have a differentiated profile relative to other therapies targeting FGF21
and FGFR1c that are in development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A PEGylated form of FGF21 is currently in two third-party Phase 2b studies in NASH. The compound has
a reported half-life of 19 to 24 hours and includes mutations with <FONT STYLE="white-space:nowrap">non-native</FONT> amino acid substitutions. In this third party&#146;s Phase 2a study, the molecule showed a significant reduction in absolute liver
fat measured by <FONT STYLE="white-space:nowrap">MRI-PDFF</FONT> and a significant decrease in concentration of <FONT STYLE="white-space:nowrap">PRO-C3</FONT> (a biomarker of fibrosis), but no significant changes on lipid markers. Study outcomes
were better when dosed as a daily injection versus a weekly injection. The compound was deemed generally well tolerated, although a higher frequency of gastrointestinal adverse events was reported in treated patients. Sixty-three percent to 92% of
treated patients in the Phase 2a study tested positive for anti-drug and anti-FGF21 antibodies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A second compound, a long-acting <FONT
STYLE="white-space:nowrap">Fc-FGF21</FONT> fusion protein with extended half-life of approximately three to four days, has completed third-party Phase 1 studies in which patients with Type 2 diabetes demonstrated decreases in triglycerides and
increases in <FONT STYLE="white-space:nowrap">HDL-C,</FONT> with improvements in insulin sensitivity, but modest to no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes in LDL in doses approximating those advancing to further development. The highest doses tested in the single and multiple-ascending dose study were not well-tolerated with adverse events
of significance being gastrointestinal disorders and tremors. The compound is currently in a Phase 2a study in NASH with weekly dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A
third compound, an agonistic antibody selectively activating FGFR1c and its <FONT STYLE="white-space:nowrap">co-receptor</FONT> &szlig;-Klotho, has completed a third-party Phase 1 study as a once-monthly injectable insulin sensitizer for the
treatment of NASH. Reductions in liver fat content and improvements in metabolic parameters were reported in a clinical trial evaluating a high single dose in obese, insulin-resistant, <FONT STYLE="white-space:nowrap">non-diabetic</FONT> subjects
with NAFLD. The most common adverse events reported were injection site reaction and increased appetite. Subjects gained an average of 1.6 kg body weight 36 days after dosing compared to baseline. The compound agonizes only the FGFR1c receptor and
is not believed to have any activity on the FGFR2c and FGFR3c receptors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe BIO89-100 may be a differentiated FGF21 therapy based
on its robust and durable biological effects and a favorable tolerability profile. In addition, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> has the potential for a once every <FONT STYLE="white-space:nowrap">two-weeks</FONT> dosing interval
that could provide significant value to asymptomatic patients who will be taking the product chronically. In market research that we conducted amongst obese diabetic subjects (n=150), respondents were asked for their preference when selecting an
injectable product with different dosing regimens for the treatment of a chronic liver condition. In this study, 63% of respondents expressed a preference or strong preference for a product injected once every two weeks versus a product injected
every week, and 68% of respondents expressed similar preferences for a product injected once every two weeks versus a product injected daily. Further, we believe that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> may have a differentiated
tolerability profile and that tolerability issues may influence physician and patient preference in NASH, a chronic and generally asymptomatic disease. We believe the risk of CNS effects, significant gastrointestinal tolerability issues and weight
gain could significantly impact adoption by physicians and patients. Finally, based on the <FONT STYLE="white-space:nowrap">non-human</FONT> primate study results and the human SAD study results across different lipid markers (triglyceride reduction
up to 51% and LDL reduction up to 37%), we believe <FONT STYLE="white-space:nowrap">BIO89-100</FONT> may offer robust and durable biological effects. We believe that activation of the FGFR1c, 2c and 3c receptors may confer benefits versus activation
of a single receptor (FGFR1c) given the expression of the receptors in the key organs of interest (FGFR1c in adipose tissue and FGFR2c and FGFR3c in the liver) and provide a more balanced approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Severe Hypertriglyceridemia </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
also intend to develop <FONT STYLE="white-space:nowrap">BIO89-100</FONT> for the treatment of SHTG. Hypertriglyceridemia (&#147;HTG&#148;) is characterized by elevated fasting plasma triglyceride levels higher than 200 mg/dL and SHTG is typically
defined as triglyceride levels of greater than or equal to 500 mg/dL. SHTG is associated with an increased risk of NAFLD, NASH and cardiovascular diseases, as well as acute pancreatitis, accounting for up to 10% of all acute pancreatitis episodes. A
recent third-party study utilizing an <FONT STYLE="white-space:nowrap">omega-3</FONT> fatty acid <FONT STYLE="white-space:nowrap">(&#147;omega-3</FONT> FA&#148;) demonstrated the linkage between a reduction in triglycerides and favorable
cardiovascular clinical outcomes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">It is estimated that there are 2.5 million to 4&nbsp;million patients in the United States with
triglyceride levels of greater than or equal to 500 mg/dL. Of these patients, it is estimated that 42% have dyslipidemia and 27% have diabetes. This patient population is expected to increase due to the triple epidemic of obesity, metabolic syndrome
and Type 2 diabetes. In addition, the addressable market has the potential to expand as a result of increasing awareness of the importance of treating elevated TG levels, similar to the focus today of physicians on managing LDL levels, as well as
due to third party commercial efforts expected to promote TG reduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The treatment regimen for SHTG includes dietary restrictions and
lipid-lowering drug treatment such as fibrates, <FONT STYLE="white-space:nowrap">omega-3</FONT> fish oils and niacin. Some statins are indicated in HTG but do not have an indication for use in SHTG. In third-party studies, up to 50% of treated SHTG
patients were unable to reduce their triglyceride levels to &lt; 500 mg/dL despite using approved drugs and are considered refractory patients. These refractory patients have substantial unmet medical need and represent a significant market
opportunity as there are no approved therapies for the treatment of refractory SHTG. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Despite multiple agents approved for the treatment of SHTG, these agents have limitations
that may not make them ideal for all patients. For example, fibrates have demonstrated reductions in triglycerides of up to approximately 55% at 12 weeks of treatment. However, they have also shown increases in LDL-C (up to 45%), a detrimental
effect in this patient population, risk of drug-drug interactions and increases in transaminases, as well as tolerability issues including myopathy. Omega 3 fish oils have shown more modest benefits in reduction of triglycerides from baseline of
approximately 25% to 45%. However, fish oils with a higher percentage reduction in triglycerides have also showed major increases in LDL-C (up to 45%). Fish oils also have a significant pill burden given the high daily doses required. In addition,
these agents fail to meaningfully address the related co-morbidities of SHTG, including glycemic control, which, when left untreated, may further exacerbate the condition. Yet, despite these limitations, the existing drugs have achieved commercial
success with two third parties each generating peak sales of approximately $1 billion or greater. While we believe BIO89-100 has the potential to address the co-morbidities of SHTG, there is no guarantee that it would earn comparable peak sales if
it is approved by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Given the continuing unmet need in SHTG and limitations of current treatments, there are several agents in
development for the treatment of SHTG, including a fish oil product, a fibrate, and novel drugs primarily targeting rare, genetically defined subsets of SHTG, including ANGPTL3 and ApoC III inhibitors. Dyslipidemia apart from SHTG also continues to
be a very active area for pharmaceutical development. We believe <FONT STYLE="white-space:nowrap">BIO89-100</FONT> may be a differentiated SHTG therapy due to its pleiotropic metabolic benefits and its potential to target a broader patient
population versus those therapies primarily targeting rare, genetically defined subsets of SHTG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> has demonstrated significant reduction in triglyceride levels in both its <FONT
STYLE="white-space:nowrap">non-human</FONT> primate studies and our Phase 1a clinical study. In diabetic obese cynomolgus monkeys with elevated triglyceride levels, <FONT STYLE="white-space:nowrap">BIO89-100</FONT> showed significant effects on
triglycerides with a maximal reduction of 78% and 76% at doses of 1 mg/kg (see Figures 15 and 21). In monkeys treated with baseline levels of triglycerides &gt; 500mg/dL (n=4), the three monkeys treated with BIO89-100 1 mg/kg weekly had TG
reductions &gt; 90% at study end. In our Phase 1a clinical study, in patients with baseline triglyceride values in the normal range (mean baseline 94 mg/dL), <FONT STYLE="white-space:nowrap">BIO89-100</FONT> demonstrated reductions of triglycerides
from baseline up to 51% at Day 8 after a single dose in healthy volunteers. While currently approved SHTG therapies decrease TG levels, they generally do not have broader metabolic benefits. In our Phase 1a study, BIO89-100 demonstrated a reduction
in LDL of up to 37% (see Figure 26) and to the extent that we are able to show in subsequent human clinical trials that BIO89-100 significantly decreases both TG and LDL-C levels and improves other metabolic parameters, such as glycemic control, we
believe that <FONT STYLE="white-space:nowrap">BIO89-100</FONT> could be a differentiated therapy in this indication. Based on a mechanism of action that is distinct from the currently approved therapies, we believe that BIO89-100 has the potential
to be used as a monotherapy agent or in combination with other agents. Another FGF21 analog developed by a third party has also demonstrated a statistically significant reduction in triglycerides in obese, Type 2 diabetes patients. We intend to
initiate a Phase&nbsp;2 trial in SHTG patients in the first half of 2020 in order to evaluate the ability of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to reduce triglyceride levels compared to baseline levels and to report topline data in
the first half of 2021. We expect this Phase 2 trial to enroll 80 to 100 patients with triglyceride levels greater than or equal to 500 mg/dL, who will be randomized to receive multiple doses of BIO89-100 or placebo for six to eight weeks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There is regulatory precedence in the United States for the approval of therapies to treat SHTG based on such therapies demonstrating a
reduction in triglycerides from baseline at 12 weeks. The FDA surrogate endpoint table for drug approval lists a reduction in triglycerides from baseline as the endpoint for full approval of a therapy in SHTG. A clinical outcome study was not
required for certain third-party approvals in SHTG or as a post-marketing commitment. The SHTG Phase 3 trial for some of these products consisted of a single study of a 12-week duration with 75 to 100 patients per treatment group. Based on current
plans, we anticipate initiating Phase 3 trials in SHTG patients by the end of 2021, which we expect will follow existing SHTG regulatory precedence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Based on FDA guidance for the development of SHTG treatments, as well as the regulatory path followed by other companies that have
successfully developed SHTG therapies, we believe that a combination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
smaller clinical trials and shorter development timelines could mean that SHTG potentially represents a quicker path to market for BIO89-100. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Teva </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agreements Relating to FGF21
Program </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2018, we entered into the FGF21 Agreement with Teva, under which we acquired certain patents,
intellectual property and other assets relating to Teva&#146;s glycoPEGylated FGF21 program. Under this agreement, Teva also granted a perpetual, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> (but exclusive as to <FONT
STYLE="white-space:nowrap">BIO89-100),</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> worldwide license to patents and <FONT STYLE="white-space:nowrap">know-how</FONT> related to glycoPEGylation technology for use in the research,
development, manufacture and commercialization of the compound <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and products containing <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> In addition, we entered into the ratiopharm Sublicense, under
which we were granted a perpetual, exclusive, worldwide sublicense to patents and know-how related to glycoPEGylation technology used in the development, manufacture and commercialization of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and
products containing <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the FGF21 Agreement, we are obligated to use commercially
reasonable efforts to develop and commercialize <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in each of the United States and five major European countries. We have the right to sublicense all rights licensed to us by Teva under the FGF21
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the FGF21 Agreement and the FASN Agreement (as described below), we paid Teva a nonrefundable upfront payment of
$6.0&nbsp;million. In addition, under the FGF21 Agreement, we are required to make certain payments to Teva totaling $2.5&nbsp;million for the achievement of certain clinical development milestones, and additional payments totaling up to
$65.0&nbsp;million upon achievement of certain commercial milestones. We are also obligated to pay Teva tiered royalties at percentages in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digits
on worldwide net sales of products containing <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> Our royalty obligations will terminate, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, at the later of: (1)&nbsp;the date of expiration of the last to expire valid claim in the assigned patents that covers
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> in such country, (2)&nbsp;the expiration of data or regulatory exclusivity for <FONT STYLE="white-space:nowrap">BIO89-100</FONT> in such country and (3) 10 years from the first commercial sale of <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> in such country. We are not required to make any payments to ratiopharm pursuant to the ratiopharm Sublicense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The term of the FGF21 Agreement will continue, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, until the royalty term with respect to <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> in such country expires. The ratiopharm Sublicense will continue until terminated in accordance with its terms. We may terminate the FGF21 Agreement and the ratiopharm Sublicense for any reason. Either
party may terminate the FGF21 Agreement for cause for the other party&#146;s uncured material breach. ratiopharm may terminate the ratiopharm Sublicense for certain material breaches by us. Either party may terminate the FGF21 Agreement or the
ratiopharm Sublicense in the event of bankruptcy of the other party. Teva may terminate the FGF21 Agreement if we challenge the validity of any patent licensed to us under the FGF21 Agreement. Termination of the FGF21 Agreement or the ratiopharm
Sublicense will impact our rights under the intellectual property licensed to us by Teva and ratiopharm, respectively, but will not affect our rights under the assets assigned to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2018, we also entered into a Reagent Supply and Technology Transfer Agreement, under which Teva will supply us with certain
reagents required for the glycoPEGylation process that are necessary for our development and commercialization of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> and transfer to us certain <FONT STYLE="white-space:nowrap">know-how</FONT> required
for the production of such reagents. The term of this agreement was recently extended by mutual agreement until December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FASN
Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On April&nbsp;16, 2018, we entered into the FASN Agreement with Teva under which we acquired from Teva patents,
intellectual property and other assets relating to Teva&#146;s development program of small molecule inhibitors of FASN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the FASN Agreement, we are obligated to use commercially reasonable efforts to develop
and commercialize FASN in the United States and five major European countries. We have the right to sublicense all rights licensed to us by Teva under the FASN Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the FASN Agreement and the FGF21 Agreement (as described above), we paid Teva a nonrefundable upfront payment of $6.0 million. In
addition, under the FASN Agreement, we are required to make certain payments to Teva totaling $2.5 million for the achievement of certain clinical development milestones, and additional payments totaling up to $65.0 million upon achievement of
certain commercial milestones. We are also obligated to pay Teva tiered royalties at percentages in the low-to-mid single-digits on worldwide net sales of products arising from the FASN program. Our royalty obligations will terminate, on a
product-by-product and country-by-country basis, at the later of: (1) the date of expiration of the last to expire valid claim in the assigned patents that covers FASN in such country, (2) the expiration of data or regulatory exclusivity for such
product arising from the FASN program in such country and (3) 10 years from the first commercial sale of a product arising from the FASN program in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The term of the FASN Agreement will continue, on a product-by-product and country-by-country basis, until the royalty term with respect to the
product arising from the FASN program in such country expires. We may terminate the FASN Agreement for any reason. Either party may terminate the agreement for cause for the other party&#146;s uncured material breach, or in the event of bankruptcy
of the other party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring
and post-approval reporting of biologics, such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory
agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The process
required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s current
Good Laboratory Practice regulation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated
annually or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent Institutional Review Board (&#147;IRB&#148;) or ethics committee at each clinical site
before the trial is commenced; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, purity and potency of
the proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance
with current Good Clinical Practices (&#147;cGCP&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for
use in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and Clinical Development </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization
from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro
studies assessing the toxicology, PK, pharmacology and PD characteristics of the product; chemistry, manufacturing and controls information; and any available human data or literature to support the use of the investigational product. An IND must
become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, raises safety concerns or
questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND
therefore may or may not result in FDA authorization to begin a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the
investigational product to human subjects under the supervision of qualified investigators in accordance with cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical
study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND
must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan
for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various
grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized
by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical
trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to
public registries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may
overlap. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 1</I></B>&#151;The investigational product is initially introduced into healthy human subjects or
patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and,
if possible, to gain early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 2</I></B>&#151;The investigational product is administered to a limited patient population with a
specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to
beginning larger and more expensive Phase 3 clinical trials. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 3</I></B>&#151;The investigational product is administered to an expanded patient population to
further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the
overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so called Phase 4 studies may be made a condition to approval of the BLA.
Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in
commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity,
strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate
does not undergo unacceptable deterioration over its shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and Review </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and
clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. The submission
of a BLA requires payment of a substantial application user fee to FDA, unless a waiver or exemption applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Once a BLA has been
submitted, the FDA&#146;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In
both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent
and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application
review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are
in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance
with cGCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding
the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will
describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first
conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require
additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk
Evaluation and Mitigation Strategy (&#147;REMS&#148;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have
continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk
minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT
STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 postmarket studies and surveillance to further assess
and monitor the product&#146;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Programs for Serious Conditions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs and biologics to address unmet
medical needs in the treatment of serious or life- threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval. These programs can significantly reduce
the time it takes for the FDA to review a BLA, but they do not guarantee that a product will receive FDA approval. Even if a product qualifies initially, the FDA may later decide that the product no longer meets the conditions for qualification or
decide that the time period for FDA review will not be shortened. In May 2018, the Right to Try Act also established a program to increase access to unapproved, investigational treatments for patients diagnosed with life-threatening diseases or
conditions who have exhausted approved treatment options and who are unable to participate in a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A new drug or biologic is
eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation provides increased
opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the agency may review portions of the marketing
application before the sponsor submits the complete application, as well as Priority Review, discussed below. In addition, a new drug or biologic may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or
life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program beginning as early as Phase 1, and FDA
organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible
for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and accelerated approval. A product is eligible for Priority Review if it has the potential to provide a significant improvement
in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, FDA will review an application in six months compared to ten months for a standard review. Products are eligible for
accelerated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier
than an effect on irreversible morbidity or mortality which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatment. Accelerated approval is usually contingent on a sponsor&#146;s agreement to conduct additional post-approval studies to verify and describe the product&#146;s clinical benefit. In addition, unless
otherwise informed by the FDA, the FDA currently requires, as a condition for accelerated approval, that all advertising and promotional materials that are intended for dissemination or publication be submitted to FDA for review before the initial
dissemination or publication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA,
including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the
approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in
an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for
compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may
require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use.
Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of existing product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal of the FDA to permit the import or export of products; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to
safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that
are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across medical specialties. Physicians may believe that such <FONT
STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict
manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and
Reference Product Exclusivity </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Affordable Care Act, signed into
law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#147;BPCIA&#148;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product. To date, a number of biosimilars have been licensed under the BPCIA, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents
outlining an approach to review and approval of biosimilars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful
differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is
biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual,
the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities
associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still
being worked out by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years
following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed.
During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that
applicant&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as
interchangeable products. At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to
reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the
ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws and Compliance
Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United States, our current and future operations are subject to regulation by various federal, state and
local authorities in addition to the FDA, including but not limited to, the CMS, other divisions of the U.S. Department of Health and Human Services (&#147;HHS&#148;) (such as the Office of Inspector General, Office for Civil Rights and the Health
Resources and Service Administration), the U.S. Department of Justice (&#147;DOJ&#148;), and state and local governments. For example, our clinical research, sales, marketing and scientific/educational grant programs may have to comply with the
anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of HIPAA, and similar state laws, each as amended, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from
knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or
order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been
interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some
common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do
not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the
legality of the arrangement will be evaluated on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all
cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. The statutory exceptions and regulatory safe harbors are also subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act, to a stricter standard such that a
person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act also codified case law that a claim including items or services
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal FCA (discussed below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The federal false claims and civil monetary penalty laws, including the FCA, which imposes significant penalties and can be enforced by
private citizens through civil qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to, or approval by, the federal government, including
federal healthcare programs, such as Medicare and Medicaid; knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government; or knowingly making a false statement
to improperly avoid, decrease or conceal an obligation to pay money to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. Although we would not submit claims directly to
payors, manufacturers can be held liable under these laws if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product <FONT
STYLE="white-space:nowrap">off-label.</FONT> In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other
information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have been prosecuted under the FCA in
connection with their alleged <FONT STYLE="white-space:nowrap">off-label</FONT> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and
allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to
execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party
payors, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent
statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, the Affordable Care Act amended the intent standard for certain healthcare fraud statutes under HIPAA such that a
person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Also, many states have similar, and typically more prohibitive, fraud and abuse statutes or
regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to data privacy, data security and data breach notification laws, regulations, standards, and codes of conduct
by both the U.S. federal government and the states. These laws, regulations, standards, and codes of conduct may govern the collection, use, disclosure and protection of health-related and other personal information. HIPAA, as amended by the HITECH,
imposes requirements relating to the privacy, security and transmission of individually identifiable health information. HIPAA requires covered entities to limit the use and disclosure of protected health information to specifically authorized
situations, and requires covered entities to implement security measures to protect health information that they maintain in electronic form. The federal government may impose civil, criminal, and administrative fines and penalties and/or additional
reporting or oversight obligations for a violation of HIPAA&#146;s requirements. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates that receive or obtain protected health
information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave
state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition to HIPAA and HITECH, many
state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by federal law, and may have a
more prohibitive effect than federal law, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may develop products that, once approved, may be
administered by a physician. Under currently applicable U.S. law, certain products not usually self-administered (including injectable drugs) may be eligible for coverage under Medicare through Medicare Part B. Medicare Part B is the part of
Medicare that covers outpatient services and supplies, including certain pharmaceutical products, that are medically necessary to treat a beneficiary&#146;s health condition. As a condition of receiving Medicare Part B reimbursement for a
manufacturer&#146;s eligible drugs, the manufacturer is required to participate in other government healthcare programs, including the Medicaid Drug Rebate Program and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires
pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of HHS as a condition for states to receive federal matching funds for the manufacturer&#146;s outpatient drugs furnished to Medicaid
patients. Under the 340B Drug Pricing Program, the manufacturer must extend discounts to entities that participate in the program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and
timely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act (the &#147;Sunshine Act&#148;) within the Affordable Care Act, and its
implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report
annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching
hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. This information is made publicly available on a CMS website, and failure to report accurately could result in
penalties. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not <FONT STYLE="white-space:nowrap">pre-empted,</FONT> and may have a more
prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to distribute products commercially, we
must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose
requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves
through the distribution chain. Several state and local laws have been enacted requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on
sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and
biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. In addition, all of our activities are potentially subject to federal and state consumer protection and unfair competition laws.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ensuring business arrangements with third parties comply with applicable healthcare laws and regulations is a costly endeavor. If our
operations are found to be in violation of any of the federal and state healthcare laws described above or any other current or future governmental regulations that apply to us, we may be subject to significant penalties, including without
limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#147;qui tam&#148; actions brought by
individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting
obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage, Pricing and
Reimbursement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we
may obtain regulatory approval. In the United States and in foreign markets, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and
establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, private health insurers and other organizations. Adequate coverage and
reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and commercial payors are critical to new product acceptance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for
these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which therapeutics they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination
that use of a therapeutic is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We cannot be sure that reimbursement will be available for any product that we commercialize
and, if coverage and reimbursement are available, what the level of reimbursement will be. Coverage may also be more limited than the purposes for which the product is approved by the FDA or comparable foreign regulatory authorities. Reimbursement
may impact the demand for, or the price of, any product for which we obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly
challenging the price, examining the medical necessity, and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Obtaining reimbursement for our products may be
particularly difficult because of the higher prices often associated with branded drugs and drugs administered under the supervision of a physician. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical
necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. Obtaining coverage and reimbursement approval of a
product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis, with no assurance that coverage and adequate reimbursement will be obtained. A payor&#146;s decision to provide coverage for a product does not imply
that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize any product candidate that we successfully develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries.
In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some
jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of
clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward
pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <FONT STYLE="white-space:nowrap">low-priced</FONT>
markets exert a commercial pressure on pricing within a country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The marketability of any product candidates for which we receive
regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care, the increasing influence of health maintenance organizations, and
additional legislative changes in the United States has increased, and we expect will continue to increase, the pressure on healthcare pricing. The downward pressure on the rise in healthcare costs in general, particularly prescription medicines,
medical devices and surgical procedures and other treatments, has become very intense. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more
products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the United
States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates,
restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in
promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers.
The Affordable Care Act and its implementing regulations, among other things, revised the methodology for calculating rebates for covered outpatient drugs and certain biologics owed by manufacturers to the state and federal government under the
Medicaid Drug Rebate Program, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid
managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and expanded programs designed to test innovative payment models, service delivery models, or value-based arrangements, and fund
comparative effectiveness research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been
legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent or loosen certain requirements mandated by the
Affordable Care Act. On December&nbsp;22, 2017, President Trump signed into law the Tax Cuts and Jobs Act of 2017, or Tax Act which included a provision that repealed the tax penalty for an individual&#146;s failure to maintain Affordable Care <FONT
STYLE="white-space:nowrap">Act-mandated</FONT> health insurance, effective January&nbsp;1, 2019. Further, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation
of certain Affordable Care <FONT STYLE="white-space:nowrap">Act-mandated</FONT> fees, including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee
imposed on certain health insurance providers based on market share, and the medical device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Moreover, the Bipartisan Budget Act of 2018, or the BBA, among other
things, amended the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole.&#148; Additionally, in December 2018, CMS published a final rule permitting
further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation
regarding the method CMS uses to determine this risk adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2018, a United States District Court judge in Texas
ruled that the Affordable Care Act is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. The decision has been appealed to the United States Court of
Appeals for the Fifth Circuit. On March&nbsp;25, 2019, the DOJ submitted a filing to the Fifth Circuit stating that the district court&#146;s judgment should be affirmed and, on May&nbsp;1, 2019, filed a brief in the Fifth Circuit arguing that the
Affordable Care Act should be struck down in its entirety. While this U.S. District Court judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how
this decision, subsequent appeals and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We
anticipate that the Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our
business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from
being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory
approval and may affect our overall financial condition and ability to develop product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, further legislation or
regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama
signed into law the Budget </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on
Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to
Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April&nbsp;1, 2013 and will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief
Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the
government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additionally, there has been increasing legislative and
enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal legislation designed to, among other things, bring more
transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level,
the Trump administration&#146;s budget proposals for fiscal years 2019 and 2020 contain further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit
Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT>
patients. Further, the Trump administration released a &#147;Blueprint,&#148; or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the
negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. While some proposed measures will require
authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to
control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. For example, after some pharmacy benefit managers and insurers adopted policies stating that the amount of a copay coupon would not be applied to the enrollee&#146;s deductible or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> maximum (referred to as &#147;accumulator adjustment programs&#148;), some states passed legislation banning these policies. Based on a rule that will take
effect in the 2020 plan year, CMS will allow accumulator adjustment programs only when used for a branded drug that has a generic equivalent. The implementation of cost containment measures or other healthcare reforms may prevent us from being able
to generate revenue, attain profitability, or commercialize our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Regulation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the foregoing, local, state and federal laws, including in the United States and Israel, regarding such matters as safe working
conditions, manufacturing practices, environmental protection, fire hazard control and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our
business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose
individuals to hazardous or biohazardous substances, we could be liable for damages, environmental remediation, and/or governmental fines. We believe that we are in material compliance with applicable environmental laws and occupational health and
safety laws that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. We may incur significant costs to comply with such laws
and regulations now or in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is intensely competitive and subject to rapid innovation and significant technological advancements. We believe
the key competitive factors that will affect the development and commercial success of <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and any future product candidates are efficacy, safety and tolerability profile, reliability, convenience of
dosing, price, the level of generic competition and reimbursement. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies, universities and other research institutions. A number of biotechnology and
pharmaceutical companies are pursuing the development or marketing of pharmaceuticals that target the same diseases that we are targeting. Smaller or earlier-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large, established companies. Given the high incidence of NASH, it is likely that the number of companies seeking to develop products and therapies for the treatment of liver and cardio-metabolic diseases, such as
NASH, will increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is approved for the treatment of NASH, future competition could
also arise from products currently in development, including: cenicriviroc, an immunomodulator that blocks CCR2 and CCR5 from Allergan plc; <FONT STYLE="white-space:nowrap">GS-0976,</FONT> an ACC inhibitor, and
<FONT STYLE="white-space:nowrap">GS-9674,</FONT> an FXR agonist, from Gilead Sciences, Inc.; <FONT STYLE="white-space:nowrap">PF-05221304,</FONT> an ACC inhibitor, and PF-06835919, a KHK inhibitor, from Pfizer Inc.; Ocaliva, an FXR agonist from
Intercept Pharmaceuticals, Inc.; <FONT STYLE="white-space:nowrap">MGL-3196,</FONT> a beta-thyroid hormone receptor agonist from Madrigal Pharmaceuticals, Inc.; VK2809, a beta-thyroid hormone receptor agonist from Viking Therapeutics, Inc.; <FONT
STYLE="white-space:nowrap">NGM-282,</FONT> an FGF19 analog from NGM Biopharmaceuticals, Inc.; <FONT STYLE="white-space:nowrap">MK-3655,</FONT> an FGFR1c/KLB agonist antibody from Merck&nbsp;&amp; Co., Inc.; pegbelfermin, a PEGylated FGF21 analog
from Bristol-Myers Squibb Company; <FONT STYLE="white-space:nowrap">AKR-001,</FONT> a FGF21 fusion protein from Akero Therapeutics, Inc.; elobixibat, an IBAT-inhibitor from Albireo Pharma, Inc.; a <FONT STYLE="white-space:nowrap">Galectin-3</FONT>
inhibitor from Galectin Therapeutics Inc.; a synthetic conjugate of cholic acid and arachidic acid from Galmed Pharmaceuticals Ltd.; an FXR agonist from Metacrine, Inc.; FXR agonists from Novartis AG; a mitochondrial pyruvate complex modulator from
Cirius Therapeutics, Inc.; seladelpar, a PPAR delta agonist from CymaBay Therapeutics, Inc.; semaglutide, a <FONT STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist from Novo Nordisk A/S; tirzepatide, a dual
<FONT STYLE="white-space:nowrap">IP/GLP-1</FONT> receptor agonist from Eli Lilly and Company; and elafibranor, a PPAR alpha/delta agonist from Genfit S.A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">BIO89-100</FONT> is approved for the treatment of SHTG, we would face competition from currently approved
and marketed products, including statins, fibrates, Vascepa, Epanova and Lovaza, as well as generic products. Further competition could arise from products currently in development, including:
<FONT STYLE="white-space:nowrap">AKCEA-APOCIII-LRx,</FONT> an ApoC III inhibitor from Akcea Therapeutics, Inc.; evinacumab, an Anti-ANGPTL3 from Regeneron Pharmaceuticals, Inc.; pemafibrate, a PPAR alpha agonist from Kowa Research Institute, Inc.;
gemcabene; CaPre, an <FONT STYLE="white-space:nowrap">omega-3</FONT> fatty acid from Acasti Pharma Inc.; and <FONT STYLE="white-space:nowrap">ARO-APOC3,</FONT> an ApoC III inhibitor from Arrowhead Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Many of our competitors have substantially greater financial, technical, human and other resources than we do and may be better equipped to
develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly longer operating histories and greater experience than we have in undertaking nonclinical studies and human clinical trials
of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Many of our competitors have established distribution channels for the commercialization of their products, whereas we have no such channel or
capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. As a result, our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent
protection or other intellectual property rights that limit our ability to develop or commercialize our product candidate or any future product candidates. Our competitors may also develop and succeed in obtaining approval for drugs that are more
effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete
effectively against these companies, then we may not be able to commercialize our product candidate or any future product candidates or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific,
management and commercial personnel, establishing clinical trial sites and enrolling patients for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not own
or operate manufacturing facilities for the production of <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely, and expect to continue to
rely, on third parties for the manufacturing of our product candidates for preclinical and clinical testing, as well as for commercial manufacturing if <FONT STYLE="white-space:nowrap">BIO89-100</FONT> or any future product candidate receives
marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BIO89-100</FONT> drug substance is manufactured by fermentation of a recombinant
strain of the bacterium E. coli. Product accumulates as insoluble particles (inclusion bodies) within the cells and is recovered by cell disruption, followed by solubilization of the inclusion bodies, protein refolding and purification with two
chromatographic separation columns. Purified material is glycoPEGylated in a <FONT STYLE="white-space:nowrap">2-step</FONT> enzymatic reaction where a 20kDa linear glycoPEG moiety is attached to the protein through GalNAc&nbsp;and Sialic Acid
linkers. GlycoPEGylated protein is purified with two chromatographic columns to yield product with target quality attributes. Purified glycoPEGylated protein is concentrated and then formulated to a target concentration with formulation buffer as
drug product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BTPH is our sole source supplier for BIO89-100. While any reduction or halt in supply of drug product from BTPH could limit
our ability to develop BIO89-100 until a replacement contract manufacturer is found and qualified, we have recently produced several batches to support toxicology and clinical studies. We currently have material available to support our ongoing
Phase POC 1b/2a trial of BIO89-100 for the treatment of NASH and for the initiation of our SHTG trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are working with BTPH on
process optimization to support large-scale production for future trials and commercialization. In parallel, we have entered into a contract with a formulation development company to explore the potential for a new refrigerated liquid formulation
and/or a <FONT STYLE="white-space:nowrap">freeze-dried,</FONT> or lyophilized product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>BTPH Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May 7, 2018, we entered into a master services agreement with BTPH, under which BTPH agreed to provide us certain services, including the
manufacturing, packaging, labeling and storing of BIO89-100, under statements of work for such services to be agreed by the parties from time to time. The master services agreement will continue for the duration of time that BTPH is providing
services to us, unless earlier terminated by either party upon its terms. We may terminate the agreement at any time after a specified notice period and subject to the payment of certain agreed upon fees where such termination results in
cancellation of manufacturing scheduled within a certain period. In addition, either party may terminate the agreement for cause for the other party&#146;s uncured material breach, in the event of bankruptcy of the other party, in the event of the
commission of fraud by the other party or in the event of a force majeure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and Marketing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial
sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may elect to establish our own sales force to market and sell a product for which we obtain regulatory approval if we expect that the
geographic market for a product we develop on our own is limited or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that the prescriptions for the product will be written principally by a relatively small number of physicians. If we decide to market and sell any products ourselves, we do not expect to
establish direct sales capability until shortly before the products are approved for commercial sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We plan to seek third-party support
from established pharmaceutical and biotechnology companies for those products that would benefit from the promotional support of a large sales and marketing force. In these cases, we might seek to promote our products in collaboration with
marketing partners or rely on relationships with one or more companies with large established sales forces and distribution systems. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual
Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our success depends in part upon our ability to protect our core technology and intellectual property. To protect our
intellectual property rights, we rely on patents, trademarks, copyrights and trade secret laws, confidentiality procedures, and employee disclosure and invention assignment agreements. Our intellectual property is critical to our business and we
strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, novel biological discoveries, new targets and applications, and other
inventions that are important to our business. For our product candidates, we generally intend to pursue patent protection covering compositions of matter, methods of making and methods of use. As we continue the development of our product
candidates, we plan to identify additional means of obtaining patent protection that would potentially enhance commercial success, including pursuit of claims directed to new therapeutic indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FGF21 Patents </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our FGF21 patent
portfolio includes two families: the first is entitled &#147;Remodeling and GlycoPEGylation of Fibroblast Growth Factor (FGF)&#148; and the second is entitled &#147;Mutant <FONT STYLE="white-space:nowrap">FGF-21</FONT> Peptide Conjugate and Uses
Thereof.&#148; The first family provides granted patent protection in 39 countries around the globe, including the United States (USPN 9,200,049; expiry June&nbsp;25, 2028), Canada, Europe (broadly), and Japan (latter three expire October&nbsp;31,
2025) for FGF21 conjugates comprising a variety of modifying groups that can be attached at several different amino acid positions. GlycoPEGylated FGF21 is specifically claimed. The granted claims broadly protect our lead drug candidate <FONT
STYLE="white-space:nowrap">BIO89-100</FONT> and pharmaceutical compositions thereof, as well as methods for making and using <FONT STYLE="white-space:nowrap">BIO89-100</FONT> to treat FGF21 deficiency in a patient in need thereof. One U.S.
application is pending in this family. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The second family is specifically directed to <FONT STYLE="white-space:nowrap">BIO89-100.</FONT>
The progenitor PCT Application for this family was filed on September&nbsp;4, 2018 (PCT/US18/49379; projected expiry September&nbsp;4, 2038). A U.S. Prioritized Examination Continuation Patent Application (Application Serial No.&nbsp;16/225,640) was
filed in parallel with PCT/US18/49379 on September&nbsp;4, 2018 and from which U.S. Patent Number 10,407,479 issued on September 10, 2019. The issued claims are directed to <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and a defined genus
specifically encompassing <FONT STYLE="white-space:nowrap">BIO89-100</FONT> and compositions thereof (including site-specific mutations at positions 173 and 176), as well as methods for making and using
<FONT STYLE="white-space:nowrap">BIO89-100</FONT> for a variety of therapeutic indications. Such indications include methods for treating NASH or metabolic syndrome. Subjects wherein there is a need to reduce blood glucose or to reduce HbA1C include
those afflicted with diabetes Type 2, NASH and metabolic syndrome. The claims encompass different therapeutic regimens for administering <FONT STYLE="white-space:nowrap">BIO89-100</FONT> (e.g., once a week or once every two weeks), which regimens
are based on <FONT STYLE="white-space:nowrap">BIO89-100&#146;s</FONT> surprisingly long half-life in vivo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">National phase entry of this
PCT Application in March of 2020 provides the opportunity to pursue global protection of specific mutant FGF21 peptide conjugates, and particularly <FONT STYLE="white-space:nowrap">BIO89-100.</FONT> National phase entry is envisioned in at least
Europe, China, Japan, Canada, Israel and Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FASN Patents </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our FASN patent portfolio currently consists of three patent families, including patents and/or patent applications in the United States, the
European Patent Convention, Canada, Mexico, Israel and Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The first patent family, directed to <FONT STYLE="white-space:nowrap">TEV-48317,</FONT>
which we acquired from Teva under the FASN Agreement, and other <FONT STYLE="white-space:nowrap">1,4-substituted</FONT> piperidine-based FASN inhibitors, is currently protected by two granted U.S. patents that cover these compounds, pharmaceutical
compositions comprising these compounds, and methods of treating FASN-mediated disorders using these compounds. The <FONT STYLE="white-space:nowrap">non-extended</FONT> term for these patents would expire on June&nbsp;17, 2036. A pending U.S.
application is directed to additional methods of treatment using these compounds. The second patent family is directed to other <FONT STYLE="white-space:nowrap">1,4-substituted</FONT> piperidine-based FASN inhibitors, pharmaceutical compositions,
and methods of treating FASN-mediated disorders. The third patent family is directed to spiropiperidine FASN inhibitors, pharmaceutical compositions containing these compounds, and methods of treating FASN-mediated disorders using these compounds.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30,
2019, we had 13 full-time employees and 14 total employees. 11 employees are engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our
relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We lease office space, which consists of approximately 1,600 square feet located at 6 Hamada Street, Herzliya, 4673340, Israel. The lease
expires on April&nbsp;30, 2020. We also lease access to shared office space at 535 Mission Street, San Francisco, California 94105 on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">month-to-month</FONT></FONT> basis. We believe
that our current spaces are adequate for our needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently not
a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and
settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table sets forth certain information regarding our executive officers and directors as of November&nbsp;11, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive&nbsp;Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rohan Palekar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Waisbourd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer and Chief Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ryan Martins</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hank Mansbach, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quoc <FONT STYLE="white-space:nowrap">Le-Nguyen</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technical Operations Officer and Head of Quality</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Grunberg, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hayden, M.B. Ch.B.,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomer Kariv<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anat Naschitz<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Member&nbsp;of&nbsp;the&nbsp;Audit&nbsp;Committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Member of the Compensation Committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Member of the Nominating and Corporate Governance Committee </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a biographical summary of the experience of our executive officers and directors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Rohan
Palekar</I></B> has served as our Chief Executive Officer and a member of our board of directors since June 2018. Prior to joining our company, Mr.&nbsp;Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a
specialty pharmaceutical company, from December 2015 to July 2017, where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr.&nbsp;Palekar also served as Executive Vice President and Chief Operating Officer of
Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr.&nbsp;Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to
2011, where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr.&nbsp;Palekar spent over 16 years at Johnson&nbsp;&amp; Johnson, a
diversified healthcare company, in various senior commercial and strategic management roles. Mr.&nbsp;Palekar earned his M.B.A. from the Tuck School of Business at Dartmouth College, his B.Com. in Accounting from the University of Mumbai and his
L.L.B. in Law from the University of Mumbai. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Palekar is qualified to serve on our board of directors because of his
broad and long experience in the biopharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Ram Waisbourd</I></B><B> </B>has served as our Chief Operating Officer
and Chief Business Officer since May 2018. Prior to joining our company, Mr.&nbsp;Waisbourd served as Vice President of Strategy and Transformation, Global Research and Development, at Teva Pharmaceutical Industries Ltd., a pharmaceutical company,
from November 2016 to April 2018, where he was responsible for Teva research and development strategy, novel pipeline funding transactions and digital initiatives. Mr.&nbsp;Waisbourd also served as Vice President of Transformational Initiatives and
Operations, Global Research and Development at Teva from September 2015 to October 2016 and Senior Director, Chief of the Research and Development Office from August 2012 to August 2015. Previously, </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&nbsp;Waisbourd served as Vice President of Business Development of XTL Biopharmaceuticals Ltd., a biotechnology company, and as Vice President of Biomedical Investments, an investment fund.
Mr.&nbsp;Waisbourd earned his M.B.A from <FONT STYLE="white-space:nowrap">Tel-Aviv</FONT> University and his B.Sc. in Economics from The Wharton School at the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Ryan Martins</I></B> has served as our Chief Financial Officer since July 2019 and previously served as our consultant since April 2019.
Prior to joining our company, Mr.&nbsp;Martins was Chief Financial Officer at Revolution Medicines, Inc., from March 2018 to October 2018, where he was responsible for all aspects of the finance function including financial accounting, capital
planning, audit, tax and investor relations. Before Revolution Medicines, Mr.&nbsp;Martins was Vice President and Head of Corporate Strategy and Investor Relations at Ultragenyx Pharmaceutical, Inc., from September 2015 to March 2018, where he was
responsible for strategic planning, capital raising, investor relations and assisting business development. Prior to Ultragenyx, Mr.&nbsp;Martins spent nearly 10 years as a biotechnology analyst at Jefferies, Lazard, and Barclays/Lehman Brothers
after holding operating roles at Chiron Corporation from 2001 to 2006. Mr.&nbsp;Martins earned his B.Sc. in Life Sciences from St. Xavier&#146;s College, a M.S. degree in Biology from Virginia Tech and an M.B.A. from the Haas School of Business at
U.C. Berkeley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Hank Mansbach, M.D.</I></B> has served as our Chief Medical Officer since December 2018. Prior to joining our
company, Dr.&nbsp;Mansbach was at Ultragenyx Pharmaceutical Inc., a biotechnology company where he served Head of Global Clinical Development for Metabolic and Neurologic Diseases from June 2018 to December 2018, Vice President of Global Clinical
Development and Ultra Programs from March 2017 to June 2018 and Vice President of Medical Affairs from May 2015 to March 2017. During his time at Ultragenyx, Dr.&nbsp;Mansbach was responsible for leading clinical development programs for metabolic
disorders and building and leading the Medical Affairs team. Before Ultragenyx, Dr.&nbsp;Mansbach served as Vice President of Medical Affairs at Medivation, Inc., a biopharmaceutical company, from August 2009 to April 2015, where he played a key
role in the development and commercialization of enzalutamide for the treatment of advanced prostate cancer. Earlier in his career, Dr.&nbsp;Mansbach served as Senior Vice President of Global Drug Development at Valeant Pharmaceuticals and Chief
Medical Officer at Cortex Pharmaceuticals, Inc., a pharmaceutical company. Dr.&nbsp;Mansbach began his industry career at Glaxo Wellcome after clinical practice and research in neurology. He earned his M.D. from Duke University and a B.A. in
Philosophy from Yale University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Quoc <FONT STYLE="white-space:nowrap">Le-Nguyen</FONT></I></B> has served as our Chief Technical
Operations Officer and Head of Quality since March 2019. Prior to joining our company, <FONT STYLE="white-space:nowrap">Mr.&nbsp;Le-Nguyen</FONT> was Senior Vice President, Global Head of Technical Operations&nbsp;&amp; Quality for Aduro BioTech,
Inc., a biotechnology company, from September 2015 to July 2018, where he was responsible for clinical supply including analytical and process development, manufacturing, supply chain and quality for cell therapy, small molecule and antibody
platforms. Prior to Aduro, <FONT STYLE="white-space:nowrap">Mr.&nbsp;Le-Nguyen</FONT> was the Vice President of Manufacturing Operations for Bayer AG from September 2007 to September 2013, where he was responsible for the Betaferon/Betaseron
franchise. Prior to Bayer, Mr. Le-Nguyen worked in biologics manufacturing for Novartis International AG, Chiron Corporation and BioMarin Pharmaceutical Inc. <FONT STYLE="white-space:nowrap">Mr.&nbsp;Le-Nguyen</FONT> earned his B.S. in Biochemistry
from the University of California, Davis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Derek DiRocco, Ph.D. </I></B>has served as a member of our board of directors since April 2018. Dr.&nbsp;DiRocco has been a principal at
RA Capital Management, LLC, an investment advisory firm that invests in healthcare and life science companies, since December 2017 and was previously an analyst from June 2015 to December 2017 and an associate from July 2013 to June 2015.
Dr.&nbsp;DiRocco earned his Ph.D. in Pharmacology from the University of Washington and his B.A. in Biology from College of the Holy Cross. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;DiRocco is qualified to serve on our board of directors because of his experience as an investor in biotechnology
companies and role in early stage companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Gregory Grunberg, M.D.</I></B> has served as a member of our board of directors since
April 2018. Dr.&nbsp;Grunberg has been a Managing Director at Longitude Capital Management Co., LLC, a venture capital firm, since February 2012. Prior to joining Longitude, Dr. Grunberg was a Principal at Rho Ventures, a venture capital firm, where
he worked from May 2007 to January 2012. Dr. Grunberg maintains a limited clinical practice in internal medicine and affiliations with University of California, San Francisco and Kaiser Permanente. Dr.&nbsp;Grunberg has served on the boards of Kala
Pharmaceuticals Inc., a pharmaceutical company, since April 2016, and WelbeHealth LLC, a private healthcare services company, since April 2018. He has served as a board observer at Sydnexis, Inc., an private biotechnology company, since September
2017. He previously served on the board of California Cryobank (acquired by GI Partners) from August 2014 to August 2018 and led Longitude&#146;s investment in Practice Fusion (acquired by Allscripts Healthcare Solutions, Inc.). While at Rho
Ventures he served on the board of AqueSys Inc. (acquired by Allergan plc) from June 2010 to December 2011 and was a board observer at both SARCode Bioscience Inc. (acquired by Shire plc) from June 2011 to February 2012 and PHT Corporation (acquired
by eResearchTechnology, Inc.) from November 2010 to November 2012. Dr. Grunberg earned his M.D. and M.B.A. from Duke University and his A.B. in Economics and English from Amherst College. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Grunberg is qualified to serve on our board of directors because of his extensive experience investing in and guiding
early phase companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Michael Hayden, M.B. Ch.B., Ph.D. </I></B>has served as a member of our board of directors since April 2018.
Dr.&nbsp;Hayden is currently a Killam Professor at the University of British Columbia and the director of the Translational Laboratory in Genetic Medicine at the National University of Singapore and A*STAR. Dr.&nbsp;Hayden was the President of
Global Research and Development and Chief Scientific Officer at Teva Pharmaceutical Industries Ltd., a pharmaceutical company, from May 2012 to December 2017, and served as an advisor to Teva from December 2017 to August 2018. During this time
approximately 35 new products were approved in major markets with many for diseases of the CNS such as migraine. He led the development of the first deuterated drug to be approved by the FDA and the second drug ever to be approved for Huntington
disease. He is also the Founder and a Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia. Dr.&nbsp;Hayden has served on the boards of Aurinia Pharmaceuticals Inc., a biopharmaceutical
company, since February 2018, Ionis Pharmaceuticals, Inc., a biopharmaceutical company, since September 2018, and Xenon Pharmaceuticals, Inc., a pharmaceutical company, since November 1996. Dr.&nbsp;Hayden received his M.B. Ch.B. in Medicine, Ph.D.
in Genetics and Diploma in Child Health from the University of Cape Town. He received his American Board Certification in both internal medicine and clinical genetics from Harvard Medical School and an FRCPC in internal medicine from the University
of British Columbia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Hayden is qualified to serve on our board of directors because of his extensive experience as a
senior executive and member of the board of other life science companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Tomer Kariv</I></B> has served as a member of our board
of directors since May 2018. Mr. Kariv has served as co-founder and managing partner of the Pontifax Group, a venture capital firm, since December 2004. He serves on the boards of Eloxx Pharmaceuticals, Inc., a pharmaceutical company, since December
2017, and Logicbio Therapeutics, Inc., a pharmaceutical company, since June 2017. He previously served on the board of VBI Vaccines Inc., a pharmaceutical company, from January 2018 to June 2019, Medical Compression Systems Ltd, a pharmaceutical
company, from August 2012 to April 2015, Macrocure Ltd, a pharmaceutical company, from March 2008 to January 2017, Arno Therapeutics Inc., a pharmaceutical company, from September 2010 to August 2017, and Check-Cap Ltd, a medical diagnostics
company, from March 2008 to June 2018. Mr. Kariv earned his B.A. in Economics from Harvard University and a J.D. from Harvard Law School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Kariv is qualified to serve on our board of directors of his extensive experience in investing in, guiding and leading <FONT
STYLE="white-space:nowrap">start-up</FONT> companies and experience as a director in similar stage companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B><I>Anat Naschitz
</I></B>has served as a member of our board of directors since January 2018, and played a key role in creating 89Bio, Ltd. as a spinout from a pharmaceutical company. Ms. Naschitz has served as Managing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Director at OrbiMed, a global healthcare investment firm, since January 2010. Ms. Naschitz has over 20 years of healthcare experience. Previously, Ms. Naschitz created, invested in and advised
healthcare companies across stages and substance. She was an Associate Partner with McKinsey in London from 1995 to 2002, where she managed strategy, company formation through spinouts and mergers and acquisitions projects for senior management of
the world&#146;s leading pharmaceutical and biotechnology companies. Subsequently Ms. Naschitz was a Principal at Apax Partners, where she invested in healthcare companies. She currently serves on the boards of biotech and digital health companies
and served on the board of Medigus Ltd., a medical device company, from March 2013 to June 2017. Ms.&nbsp;Naschitz earned her M.B.A. at INSEAD and her L.L.B. at Tel Aviv University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We believe Ms.&nbsp;Naschitz is qualified to serve on our board of directors because of her long industry experience and experience as an
investor in biotechnology companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Family Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Composition of our Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of six members, each of whom are members pursuant to the board composition provisions of our current
certificate of incorporation and agreements with our stockholders. Our current certificate of incorporation and agreements among our stockholders provide for two directors to be appointed by entities affiliated with OrbiMed, one director to be
appointed by Longitude, one director to be appointed by RA Capital and two directors (only one of which has been appointed to date) to be appointed by the holders of at least 50% of our Series A convertible preferred shares, including either OrbiMed
IL or OrbiMed US (the &#147;Requisite Preferred&#148;), and one director who shall be the presiding Chief Executive Officer of our company, currently Mr. Palekar. Ms. Naschitz is the designee of OrbiMed IL, Mr. Kariv is the designee of OrbiMed US,
Dr. DiRocco is the designee of RA Capital, Dr. Grunberg is the designee of Longitude and Dr.&nbsp;Hayden is an industry director who has been appointed by the Requisite Preferred. These board composition provisions will terminate upon the completion
of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors, although no changes to our board composition are expected at that time. Our board of directors may
therefore consider a broad range of factors relating to the qualifications and background of nominees, including the identification of persons who will further the interests of our stockholders through their established record of professional
accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, and professional and personal experiences and expertise relevant to our
growth strategy. We have no formal policy regarding board diversity. Our Amended Certificate and Amended Bylaws, both to become effective upon the completion of this offering, provide that the number of directors shall be fixed from time to time by
a resolution of the majority of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has determined that all members of our board of directors, except Mr.&nbsp;Palekar, are independent directors for
purposes of applicable Nasdaq listing rules. In making such independence determination, our board of directors considered the relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with us and all other facts and
circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director. In considering the
independence of the directors listed above, our board of directors considered the association of our directors with the holders of more than 5% of our common stock and other affiliations, including family and other relationships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we expect that the composition and functioning of our board of directors and each of our committees will
comply with all applicable requirements of the Nasdaq listing rules and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the rules and regulations of the SEC. Mr.&nbsp;Palekar is not an independent director under these rules because he is currently employed as the chief executive officer of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Term of Office, Removal and Vacancies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our
Amended Certificate and Amended Bylaws provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the
votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of
a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Election of Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate provides that our board of directors will be divided into three staggered classes of directors and each will be
assigned to one of the three classes. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will
expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2020 for Class&nbsp;I directors, 2021 for Class&nbsp;II directors and 2022 for Class&nbsp;III directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;I directors will be Mr.&nbsp;Palekar and Dr.&nbsp;Grunberg; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;II directors will be Dr.&nbsp;Hayden and Mr.&nbsp;Kariv; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;III directors will be Dr.&nbsp;DiRocco and Ms.&nbsp;Naschitz. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a
change of our management or a change in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure and the Role of our Board in Risk Oversight </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Leadership Structure </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
board of directors has designated Ms.&nbsp;Naschitz and Dr.&nbsp;Grunberg to serve as co-lead independent directors as our board of directors currently does not have a chairman. Separating the role of lead independent director from the chief
executive officer position allows our chief executive officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business, while allowing the co-lead independent directors to lead our board of
directors in its fundamental role of providing advice to and oversight of management. Our board of directors is actively seeking to identify additional candidates for our board of directors, including a candidate to serve as chairman of our board of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although our Amended Bylaws do not require that we separate the chief executive officer and board leadership positions, our
board of directors believes that having separate positions is the appropriate leadership structure for us at this time. Our board of directors recognizes that, depending on the circumstances, other leadership models, such as combining the role of
executive chairman of the board with the role of chief executive officer, might be appropriate. Accordingly, our board of directors may periodically review its leadership structure. Our board of directors believes its administration of its risk
oversight function has not affected its leadership structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our independent directors will meet alone in executive session regularly
throughout each year. The purpose of these executive sessions is to promote open and candid discussion among independent directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Role of our
Board in Risk Oversight </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We face a number of risks, including those described under the section titled &#147;Risk Factors&#148;
included elsewhere in this prospectus. Our board of directors believes that risk management is an important part of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
establishing, updating and executing on the company&#146;s business strategy. Our board of directors, as a whole and at the committee level, has oversight responsibility relating to risks that
could affect the corporate strategy, business objectives, compliance, operations and the financial condition and performance of the company. Our board of directors focuses its oversight on the most significant risks facing the company and on its
processes to identify, prioritize, assess, manage and mitigate those risks. Our board of directors and its committees receive regular reports from members of the company&#146;s senior management on areas of material risk to the company, including
strategic, operational, financial, legal and regulatory risks. While our board of directors has an oversight role, management is principally tasked with direct responsibility for management and assessment of risks and the implementation of processes
and controls to mitigate their effects on the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of our Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee, each
of which will operate pursuant to a charter that will be effective upon the completion of this offering. The composition and functioning of all of our committees will comply with all applicable requirements of the Sarbanes-Oxley Act of 2002, The
Nasdaq Global Market and SEC rules and regulations. A current copy of the charters of the committees of our board of directors will be posted on our website, which is located at <I>www.89bio.com</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;DiRocco
and Dr.&nbsp;Hayden serve on the audit committee, which is chaired by Mr.&nbsp;Kariv. Our board of directors has determined that each member of the audit committee is &#147;independent&#148; for audit committee purposes as that term is defined in
the rules of the SEC and the applicable Nasdaq listing rules, and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board of directors has designated Mr.&nbsp;Kariv as an &#147;audit committee financial
expert,&#148; as defined under the applicable rules of the SEC as a result of his more than 25 years of experience in identifying and managing investments in, and evaluating financial statements of, both private and public companies, including 15
years serving as founder and chief executive officer of a healthcare-focused venture capital firm, as well as his service on other public company audit committees. In order to be considered independent for purposes of Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee:
(1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. In determining that
Mr.&nbsp;Kariv is independent, our board of directors considered his role as managing partner of the Pontifax Group, which currently holds slightly greater than 10% of our outstanding voting stock, and the fact that
<FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act provides that an audit committee member may still be considered independent if he or she does not fall within the <FONT STYLE="white-space:nowrap">less-than-10%</FONT>
stock ownership safe harbor provision of this rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of the audit committee are to oversee the accounting and
financial reporting processes and the internal and external audit processes. The audit committee also assists our board of directors in fulfilling its oversight responsibilities by reviewing the financial information provided to stockholders and
others and the system of internal controls established by management and our board of directors. The audit committee oversees the independent auditors, including their independence and objectivity. However, committee members will not act as
professional accountants or auditors, and their functions are not intended to duplicate or substitute for the activities of management and the independent auditors. The audit committee is empowered to retain independent legal counsel and other
advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities, and to approve the fees and other retention terms of the advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Grunberg and Dr.&nbsp;Hayden serve on the compensation committee, which is chaired by Ms.&nbsp;Naschitz. Our board of directors has
determined that each member of the compensation committee is &#147;independent&#148; as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
defined in the applicable Nasdaq listing rules, including the additional independence requirements set forth in Nasdaq Rule 5605(d)(2). In order to be considered independent for purposes of
Nasdaq Rule 5605(d)(2), a member of a compensation committee of a listed company may not, other than in his or her capacity as a member of the compensation committee, our board of directors or any other board committee, accept, directly or
indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The primary
responsibilities of the compensation committee are to periodically review and approve the compensation and other benefits for our employees, officers and independent directors. This includes reviewing and approving corporate goals and objectives
relevant to the compensation of our executive officers in light of those goals and objectives, and setting compensation for these officers based on those evaluations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Naschitz and Dr.&nbsp;DiRocco serve on the nominating and corporate governance committee, which is chaired by Dr.&nbsp;Grunberg. Our
board of directors has determined that each member of the nominating and corporate governance committee is &#147;independent&#148; as defined in the applicable Nasdaq listing rules. The primary responsibilities of the nominating and corporate
governance committee are to develop and recommend to our board of directors criteria for identifying and evaluating qualified candidates for directorships and recommend candidates for election or reelection to our board of directors at each annual
stockholders&#146; meeting. The nominating and corporate governance committee also is responsible for making recommendations to our board of directors concerning the structure, composition and function of our board of directors and its committees.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Governance Matters </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee
Interlocks and Insider Participation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee has at any time during the prior three
years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of our board of directors or compensation committee of any entity that has one or more executive
officers serving on our board of directors or compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Code of Business Conduct and Ethics </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a written code of business conduct and ethics, effective upon the completion of this offering, that applies
to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code will be posted on the
investor relations section of our website, which is located at <I>www.89bio.com</I>. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the
nature of such amendment or waiver on our website or in a current report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the total cash and equity compensation paid to our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on our board of directors during 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option&nbsp;Awards<BR>($)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total&nbsp;($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hayden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,700</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Grunberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomer Kariv</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anat Naschitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Amounts shown in this column represent the aggregate grant date fair value (calculated in accordance with FASB
Accounting Standards Codification Topic 718) of stock options granted during the year. A description of the methodologies and assumptions we use to value equity awards and the manner in which we recognize the related expense are described in Note 8
to our consolidated financial statements included elsewhere in this prospectus, Share-Based Compensation. These amounts may not correspond to the actual value eventually realized by the director because the value depends on the market value of our
common stock at the time the award is exercised. As of December&nbsp;31, 2018, Dr.&nbsp;Hayden held 88,467 outstanding stock options. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Hayden is party to a letter agreement with the Company pursuant to which the Company pays him a monthly
fee of $3,334 for service on the Board. Includes $10,000 paid in 2019 for services rendered in 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other than as set
forth in the Director Compensation Table above, we did not compensate our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for 2018. We have also reimbursed directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including travel, food and lodging, incurred in attending meetings of our board of directors and/or its committees. We did not compensate Mr.&nbsp;Palekar for his service on our board
of directors during 2018 and we do not expect to compensate our employee directors for their service on our board of directors in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation policy, effective upon the completion of this offering. Under the policy, each director who is not an employee will be paid cash compensation as set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual retainer for board of directors membership</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional annual retainer for service as a committee chair*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional annual retainer for service as chairman of the board of directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Applies with respect to each of the audit, compensation, and nominating and corporate governance committees
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will pay all such amounts in quarterly installments. In addition, the compensation committee of our board of
directors may in its discretion grant equity awards to any or all <FONT STYLE="white-space:nowrap">non-employee</FONT> directors under the 2019 Plan. Such awards may include: (i)&nbsp;an initial, <FONT STYLE="white-space:nowrap">one-time</FONT>
equity award granted to a new <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon his or her election to our board of directors; (ii)&nbsp;equity awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors on an
annual basis for their service on our board of directors; and/or (iii)&nbsp;equity awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors on an annual basis for their service in a leadership role or on a committee of our
board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will reimburse all necessary and reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in connection with their service on our board of directors, subject to
any applicable Company policies that may be in effect from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-employee</FONT> director
may decline all or any portion of his or her compensation by giving notice to us prior to, as the case may be, the date cash is to be paid or equity awards are to be granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors periodically reviews our director compensation program and may revise the compensation arrangements for our directors
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our officers and directors. The indemnification agreements and our Amended Bylaws, to be
effective upon the completion of this offering, require us to indemnify these individuals to the fullest extent permitted by Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our named executive officers (&#147;NEOs&#148;) for 2018, which consist of our principal executive officer and the next most
highly-compensated executive whose total compensation did not exceed $100,000 in 2018, are: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rohan Palekar, our Chief Executive Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Ram Waisbourd, our Chief Operating Officer and Chief Business Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2018 Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
following table summarizes the compensation awarded to, earned by or paid to our NEOs for 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal
Position<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Bonus<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>All&nbsp;Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rohan Palekar,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">194,792</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">97,396</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">414,908</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,065</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">708,161</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Waisbourd,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Operating Officer and</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Business Officer<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">115,522</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36,288</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">130,383</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">35,809</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">318,002</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Messrs. Palekar and Waisbourd commenced employment as of July&nbsp;16, 2018 and May&nbsp;1, 2018, respectively.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Following the end of the fiscal year, we awarded Messrs. Palekar and Waisbourd bonuses in respect of our
performance in fiscal year 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Amounts shown in this column represent the aggregate grant date fair value (calculated in accordance with FASB
Accounting Standards Codification Topic 718) of stock options granted during the year. A description of the methodologies and assumptions we use to value equity awards and the manner in which we recognize the related expense are described in Note 9
to our consolidated financial statements included elsewhere in this prospectus, Share-Based Compensation. These amounts may not correspond to the actual value eventually realized by each NEO because the value depends on the market value of our
common stock at the time the award is exercised. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 401(k) employer matching contribution. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We paid the amounts reported for Mr.&nbsp;Waisbourd in New Israeli Shekels. We have translated amounts paid in
New Israeli Shekels into U.S. dollars based on the foreign exchange rate as of December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Includes a $9,623 contribution by us to Mr.&nbsp;Waisbourd&#146;s severance fund, a $6,444 contribution by us
for Israeli social insurance and $11,185 in aggregate contributions to pension and Israeli educational funds and a car allowance of $8,557. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2018 Fiscal-Year End </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding outstanding equity awards at the end of 2018 for each of our NEOs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option&nbsp;Awards<SUP
STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options<BR>(#) <BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options<BR>(#) <BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Exercise&nbsp;Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rohan Palekar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/09/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Waisbourd</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/09/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Each option award expires on the tenth anniversary of the date of grant. Twenty-five percent of each outstanding
stock option award vests on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the employee&#146;s start date (July 16, 2018, in the case of Mr.&nbsp;Palekar and May&nbsp;1, 2018, in the case of Mr.&nbsp;Waisbourd) and the remainder
vests in equal quarterly installments thereafter, subject to continued service through each such vesting date. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2018, we were party to an offer letter agreement with Mr.&nbsp;Palekar, effective as of July&nbsp;16, 2018, pursuant to which
he serves as our Chief Executive Officer. The agreement provides for a base salary, eligibility </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to receive an annual performance bonus and eligibility to participate in employee benefit or group insurance plans maintained from time to time by the Company. The agreement also provided for the
grant of a stock option award as described in the 2018 Summary Compensation Table. The agreement provides for employment on an <FONT STYLE="white-space:nowrap">at-will</FONT> basis and thus either party may terminate at any time for any or no
reason, subject to the severance provisions described below in the section titled &#147;Post-Employment Compensation and Change in Control Payments and Benefits.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2018, we were party to an employment agreement with Ram Waisbourd, effective as of May&nbsp;1, 2018, pursuant to which he serves as our
Chief Operating Officer and Chief Business Officer. The employment agreement provides for employment on an <FONT STYLE="white-space:nowrap">at-will</FONT> basis and thus either party may terminate the agreement by providing 90 days prior written
notice; provided, however, that we may terminate earlier and without prior notice, or with shorter notice, provided that we make payment in lieu of such notice and further provided that we may terminate the agreement immediately upon written notice
in the event of &#147;cause&#148; (as defined therein). The agreement provides for a base salary, global overtime remuneration (collectively, the &#147;Salary&#148;), eligibility to receive an annual performance bonus, vacation, sick leave, car
allowance and convalescence pay. Pursuant to the agreement, we have effected a manager&#146;s insurance policy for Mr.&nbsp;Waisbourd pursuant to which we make contributions on his behalf as well as the required statutory deductions from Salary and
any other amounts payable under the agreement on his behalf to the relevant authorities in accordance with Israeli law. We contribute an amount equal to 8.5% of his Salary toward the policy for the severance pay component and 6.5% of his Salary
toward the policy for pension and disability insurance. We also make the required statutory deductions on behalf of Mr.&nbsp;Waisbourd equal to 6% of his Salary and contribute an amount equal to 7.5% of his Salary to an education fund. The agreement
also provided for the grant of a stock option award as described in the 2018 Summary Compensation Table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For 2018,
Mr.&nbsp;Palekar&#146;s annualized base salary was $425,000 and Mr.&nbsp;Waisbourd&#146;s annualized Salary was $173,283. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incentive Compensation
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For fiscal year 2018, Mr.&nbsp;Palekar and Mr.&nbsp;Waisbourd had target bonus opportunities equal to 45% of base salary and 20% of
Salary, respectively, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for the length of time employed during the year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Following the
end of the fiscal year, our board of directors evaluated the performance of Messrs. Palekar and Waisbourd and based on Company performance in 2018, determined to award bonuses equal to $97,396 and $36,288, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Employment Compensation and Change in Control Payments and Benefits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Severance </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Mr.&nbsp;Palekar
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreement with Mr.&nbsp;Palekar, upon a termination without cause (as defined in the
agreement) not in connection with a change in control (as defined in the agreement), Mr.&nbsp;Palekar will receive, subject to execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release of claims in favor of the Company (the
&#147;release condition&#148;), severance equal to six months of the base salary as then in effect, a <FONT STYLE="white-space:nowrap">pro-rata</FONT> amount of the target bonus opportunity based on the number of months employed during the year of
termination and payment or reimbursement of COBRA premiums for up to six months, or, if sooner, until eligible for similar coverage through another employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If Mr.&nbsp;Palekar is terminated without cause or for good reason (as defined in the agreement) within 90 days prior to, or 12 months
following, the consummation of a change in control, then, subject to the release condition, the benefits described above will be provided for 12 months and all outstanding equity awards will vest in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Mr.&nbsp;Waisbourd </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of his employment agreement, as well as in accordance with Israeli law, upon a termination of Mr.&nbsp;Waisbourd&#146;s
employment, Mr.&nbsp;Waisbourd is entitled to the payments we have made on his behalf to the Manager&#146;s Insurance Policy. If Mr.&nbsp;Waisbourd is terminated without cause within 12 months following a change of control transaction, all
outstanding equity awards will vest in full. Further, upon the completion of 12 months of employment with the Company or any successor following a change of control transaction, all unvested options granted pursuant to his employment agreement will
vest in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit Plans </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended
and Restated 2019 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2018, our board of directors adopted and our shareholders approved the 89Bio Ltd. 2018
Equity Incentive Plan (the &#147;2018 Plan&#148;). In connection with the Reorganization, in September 2019, our board of directors adopted and our stockholders approved the 2019 Plan, the successor to the 2018 Plan. From and after the effective
date of the 2019 Plan, no additional stock awards can be made under the 2018 Plan. In addition, all stock awards granted under the 2018 Plan prior to the effective time of the 2019 Plan that were outstanding as of the effectiveness of the 2019 Plan
were canceled and replaced with equivalent awards under the 2019 Plan. In October 2019, our board of directors adopted and our stockholders approved an amendment and restatement of the 2019 Plan to, among other things, increase the aggregate maximum
number of shares of our common stock that may be issued pursuant to stock awards under the 2019 Plan (the &#147;Share Reserve&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Purpose.</I> The 2019 Plan is intended to help us secure and retain the services of eligible award recipients, provide incentives for such
persons to exert maximum efforts for our success and the success of our affiliates and provide a means by which the eligible recipients may benefit from increases in the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Eligibility. </I>Awards may be granted to our and our affiliates&#146; employees, including officers, non-employee directors and
consultants. Only our employees and those of our affiliates are eligible to receive incentive stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The
2019 Plan provides for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Code, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards
and performance cash awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares.</I> Subject to adjustment for certain dilutive or related events, the Share Reserve is
2,844,193 shares of common stock. On January 1, 2020, and each January 1 thereafter until January 1, 2029, the Share Reserve will automatically increase by 4% of the number of shares of our capital stock issued and outstanding on the immediately
preceding December 31, or a lesser number of shares determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Share Reserve will not be reduced if an
award or any portion thereof (i) expires, is cancelled or forfeited or otherwise terminates without all of the shares covered by such award having been issued or (ii) is settled in cash. If any shares of common stock issued under an award are
forfeited back to or repurchased by us, such shares will revert to and again be made available for issuance under the 2019 Plan. Any shares retained or not issued by us in satisfaction of tax withholding obligations or as consideration for the
exercise or purchase price of an award will also again become available for issuance under the 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The aggregate maximum number of
shares of common stock that may be issued on the exercise of incentive stock options is 2,844,193. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Shares issued under the 2019 Plan may
consist of our authorized but unissued or reacquired common stock, including shares repurchased by us on the open market or otherwise or shares classified as treasury shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I> Our board of directors has the authority to administer the 2019 Plan, including the powers to: (i)&nbsp;determine
who will be granted awards and what type of award, when and how each award will be granted, the provisions of each award (which need not be identical), the number of shares or cash value subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an award and the fair market value applicable to an award; (ii)&nbsp;construe and interpret the 2019 Plan and awards granted thereunder and establish, amend and revoke rules and regulations for
administration of the 2019 Plan and awards, including the ability to correct any defect, omission or inconsistency in the 2019 Plan or any award document; (iii)&nbsp;settle all controversies regarding the 2019 Plan and awards granted thereunder;
(iv)&nbsp;accelerate or extend, in whole or in part, the time during which an award may be exercised or vested or at which cash or shares may be issued; (v)&nbsp;suspend or terminate the 2019 Plan; (vi)&nbsp;amend the 2019 Plan; (vii)&nbsp;submit
any amendment to the 2019 Plan for stockholder approval; (viii)&nbsp;approve forms of award documents for use under the 2019 Plan and to amend the terms of any one or more outstanding awards; (ix)&nbsp;generally exercise such powers and perform such
acts as our board of directors may deem necessary or expedient to promote our best interests and that are not in conflict with the provisions of the 2019 Plan or any award documents; and (x)&nbsp;adopt procedures and sub-plans as are necessary or
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the 2019 Plan, our board of directors may delegate all or some of the administration of the
2019 Plan to a committee of one or more directors and may delegate to one or more officers the authority to designate employees who are not officers to be recipients of options and stock appreciation rights (and, to the extent permitted by
applicable law, other stock awards) and, to the extent permitted by applicable law, to determine the terms of such awards and the number of shares of common stock to be subject to such stock awards granted to such employees. Unless otherwise
provided by our board of directors, delegation of authority by our board of directors to a committee or an officer will not limit the authority of our board of directors. All determinations, interpretations and constructions made by our board of
directors (or another authorized committee or officer exercising powers delegated by our board of directors) in good faith will be final, binding and conclusive on all persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Stock Options.</I> A stock option may be granted as an incentive stock option or a nonqualified stock option. The option exercise price may
not be less than the fair market value of the stock subject to the option on the date the option is granted (or, with respect to incentive stock options, less than 110% of the fair market value if the recipient owns stock possessing more than 10% of
the total combined voting power of all classes of our stock or the stock of any affiliate (a &#147;Ten Percent Stockholder&#148;) unless the option was granted pursuant to an assumption or substitution for another option in a manner satisfying the
provisions of Section&nbsp;409A and, if applicable, Section&nbsp;424(a) of the Code, including, for avoidance of doubt, the options granted in substitution for awards outstanding under the 2018 Plan). Options will not be exercisable after the
expiration of ten years from the date of grant (or five years, in the case of an incentive stock option issued to a Ten Percent Stockholder). Each award agreement will set forth the number of shares subject to each option. The purchase price of any
shares acquired pursuant to an option may be payable in cash, check, bank draft, money order, net exercise or as otherwise determined by our board of directors and set forth in the award agreement, including through an irrevocable commitment by a
broker to pay over such amount from a sale of the shares issuable under the option and the delivery of previously owned shares. The vesting schedule applicable to any option, including any performance conditions, will be as set forth in the award
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. A stock appreciation right (&#147;SAR&#148;) is a right that entitles the participant to
receive, in cash or shares of stock or a combination thereof, as determined by our board of directors, value equal to or otherwise based on the excess of (i)&nbsp;the fair market value of a specified number of shares at the time of exercise over
(ii)&nbsp;the exercise price of the right, as established by our board of directors on the date of grant. Upon exercising a SAR, the participant is entitled to receive the amount by which the fair market value of the stock at the time of exercise
exceeds the exercise price of the SAR. The exercise price of each SAR may not be less than the fair market value of the stock subject to the award on the date the SAR is granted, unless the SAR was granted pursuant to an assumption of or
substitution for another option in a manner satisfying the provisions of Section&nbsp;409A of the Code. SARs will not be exercisable after the expiration of ten years from the date of grant. Each award agreement will set forth the number of shares
subject to the SAR. The vesting schedule applicable to any SAR, including any performance conditions, will be as set forth in the award agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Provisions Applicable to Both Options and SARs. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Our board of directors may, in its sole discretion, impose limitations on the transferability of options and SARs.
Unless our board of directors provides otherwise, an option or SAR will not be transferable except by will or the laws of descent and distribution and will be exercisable during the lifetime of a participant only by such participant. Our board of
directors may permit transfer of an option or SAR in a manner not prohibited by applicable law. Subject to approval by our board of directors, an option or SAR may be transferred pursuant to the terms of a domestic relations order or similar
instrument or pursuant to a beneficiary designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Termination of Service</I>. Except as otherwise provided in an applicable award
document or other agreement between us or any affiliate and a participant, upon a termination for any reason other than for cause or due to death or disability, a participant may exercise his or her option or SAR (to the extent such award was
exercisable as of the date of termination) for a period of three months following the termination date or, if earlier, until the expiration of the term of such award. Upon a termination due to a participant&#146;s disability, unless otherwise
provided in an applicable award or other agreement, the participant may exercise his or her option or SAR (to the extent that such award was exercisable as of the date of termination) for a period of twelve months following the termination date or,
if earlier, until the expiration of the term of such award. Upon a termination due to a participant&#146;s death, unless otherwise provided in an applicable award or other agreement, the participant&#146;s estate may exercise the option or SAR (to
the extent such award was exercisable as of the termination date) for a period of eighteen&nbsp;months following the termination date or, if earlier, until the expiration of the term of such award. Unless provided otherwise in an award or other
agreement, an option or SAR will terminate on the date that a participant is terminated for cause and the participant will not be permitted to exercise such award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Awards Other Than Options and SARs. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and Restricted Stock Units.</I> Restricted shares are awards of shares, the grant, issuance, retention, vesting and/or
transferability of which is subject during specified periods of time to such conditions (including continued employment) and terms as our board of directors deems appropriate. Restricted stock units (&#147;RSUs&#148;) are an award denominated in
units under which the issuance of shares (or cash payment in lieu thereof) is subject to such conditions (including continued employment) and terms as our board of directors deems appropriate. Each award document evidencing a grant of restricted
stock or RSUs will set forth the terms and conditions of each award, including vesting and forfeiture provisions, transferability and, if applicable, right to receive dividends or dividend equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards. </I>A performance award is a stock or cash award that is payable contingent upon the attainment during a performance
period of certain performance goals. A performance award may, but need not, require the completion of a specified period of service. The length of any performance period, the applicable performance goals and the measurement of whether and to what
degree such performance goals have been attained will be as determined by the compensation committee, our board of directors or an authorized officer. We retain the discretion to reduce or eliminate the compensation or economic benefit upon the
attainment of any performance goals and to define the manner of calculating the performance criteria it selects to use for a performance period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments.</I> In the event of any change in our capitalization, our board of directors will appropriately and proportionately
adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the 2019 Plan; (ii)&nbsp;the class(es) and maximum number of securities that may be issued pursuant to the exercise of incentive stock options; and (iii)&nbsp;the class(es)
and number of securities or other property and value (including price per share of stock) subject to outstanding stock awards. Our board of directors will make such adjustments, and its determination will be final, binding and conclusive. Unless
provided otherwise in an award or other agreement, in the event of our dissolution or liquidation, all outstanding stock awards (other than stock awards consisting of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vested and outstanding shares of our common stock not subject to a forfeiture condition or the our right of repurchase) will terminate immediately prior to the completion of such dissolution or
liquidation, and the shares of common stock subject to the our repurchase rights or subject to forfeiture may be repurchased or reacquired by us notwithstanding the fact that the holder of such stock award is providing continuous service; provided,
however, that our board of directors may, in its sole discretion, provide that some or all stock awards will become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent not already expired or terminated)
before the dissolution or liquidation is completed but contingent upon its completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Change in Control</I>. Unless provided
otherwise in an award agreement or other agreement between us or an affiliate and the participant, in the event of Change in Control (as defined in the 2019 Plan), our board of directors will take one or more of the following actions with respect to
each outstanding award, contingent upon the closing or completion of the Change in Control: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) &nbsp;&nbsp;&nbsp;&nbsp;arrange for the
surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) to assume or continue the award or to substitute a similar stock award for the award (including, but not limited to, an award to acquire
the same consideration per share paid to the stockholders of the company pursuant to the Change in Control); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii)
&nbsp;&nbsp;&nbsp;&nbsp;arrange for the assignment of any reacquisition or repurchase rights held by us in respect of common stock issued pursuant to the award to the surviving corporation or acquiring corporation (or the surviving or acquiring
corporation&#146;s parent company); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) &nbsp;&nbsp;&nbsp;&nbsp;accelerate the vesting, in whole or in part, of the award (and, if
applicable, the time at which the award may be exercised) to a date prior to the effective time of such Change in Control as determined by our board of directors, with such award terminating if not exercised (if applicable) at or prior to the
effective time of the Change in Control, and with such exercise reversed if the Change in Control does not become effective; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv)
&nbsp;&nbsp;&nbsp;&nbsp;arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us with respect to the award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) &nbsp;&nbsp;&nbsp;&nbsp;cancel or arrange for the cancellation of the award, to the extent not vested or not exercised prior to the
effective time of the Change in Control, in exchange for such cash consideration, if any, as our board of directors, in its reasonable determination, may consider appropriate as an approximation of the value of the canceled award; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) &nbsp;&nbsp;&nbsp;&nbsp;cancel or arrange for the cancellation of the award, to the extent not vested or not exercised prior to the
effective time of the Change in Control, in exchange for a payment equal to the excess, if any, of (A)&nbsp;the value in the Change in Control of the property the participant would have received upon the exercise of the award immediately prior to
the effective time of the Change in Control, over (B)&nbsp;any exercise price payable by such holder in connection with such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors need not take the same action or actions with respect to all awards or portions thereof or with respect to all
participants and may take different actions with respect to the vested and unvested portions of an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the absence of any
affirmative determination by our board of directors at the time of a Change in Control, each outstanding award will be assumed or an equivalent award will be substituted by such successor corporation or a parent or subsidiary of such successor
corporation, referred to as a Successor Corporation, unless the Successor Corporation does not agree to assume the award or to substitute an equivalent award, in which case the vesting of such award will accelerate in its entirety (along with, if
applicable, the time at which the award may be exercised) to a date prior to the effective time of such Change in Control as our board of directors will determine (or, if our board of directors does not determine such a date, to the date that is
five days prior to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective date of the Change in Control), with such award terminating if not exercised (if applicable) at or prior to the effective time of the Change in Control, and with such exercise reversed
if the Change in Control does not become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Acceleration of Awards upon a Change in Control</I>. An award may be subject to
additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the award agreement for such award or as may be provided in any other written agreement between us or an affiliate and the participant, but
in the absence of such provision, no such acceleration will occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Termination and Amendment</I>. Our board of directors or the
compensation committee may suspend or terminate the 2019 Plan at any time. No incentive stock options may be granted under the 2019 Plan after the tenth anniversary of the date our board of directors adopted the 2019 Plan. No awards may be granted
under the 2019 Plan while the 2019 Plan is suspended or after it is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2019, our board of directors adopted and our stockholders approved our 2019 Employee Stock Purchase Plan in order to enable
eligible employees to purchase shares of our common stock at a discount following the date of this offering. Purchases will be accomplished through participation in discrete offering periods. Our 2019 Employee Stock Purchase Plan, excluding any <FONT
STYLE="white-space:nowrap">sub-plans</FONT> thereunder, is intended to qualify as an employee stock purchase plan under Section&nbsp;423 of the Code. We have initially reserved a number of shares of our common stock for issuance under our 2019
Employee Stock Purchase Plan equal to 225,188&nbsp;shares. The number of shares of common stock reserved for issuance under our 2019 Employee Stock Purchase Plan will increase automatically on January&nbsp;1 of each year, for ten years, by 1% of the
total number of shares of our common stock outstanding on December&nbsp;31 of the preceding calendar year. However, our board of directors may reduce the amount of the increase in any particular year at their discretion, including a reduction to
zero. The maximum number of shares that may be issued to any employee in a given offering period will be 1,666&nbsp;shares of common stock; provided, however, that the administrator of the 2019 Employee Stock Purchase Plan may change this limitation
at any time on a prospective basis to apply to future offering periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our compensation committee administers our 2019 Employee Stock
Purchase Plan. All of our employees who work 20 or more hours per week or for five more months per year that are employed at the beginning of an enrollment period are generally eligible to participate in our 2019 Employee Stock Purchase Plan.
Employees who are 5% stockholders, or would become 5% stockholders as a result of their participation in our 2019 Employee Stock Purchase Plan, cannot participate in our 2019 Employee Stock Purchase Plan. Under our 2019 Employee Stock Purchase Plan,
eligible employees are able to acquire shares of our common stock by accumulating funds through payroll deductions. Our eligible employees are able to select a rate of payroll deduction between 1% and 15% of their eligible compensation. We also have
the right to amend or terminate our 2019 Employee Stock Purchase Plan at any time. Our 2019 Employee Stock Purchase Plan will continue until terminated in accordance with the provisions therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For each offering period, new participants will be required to enroll in a timely manner. Once an employee is enrolled, participation will be
automatic in subsequent purchase periods. No offering period can run for more than 27 months. An employee&#146;s participation automatically ends upon termination of employment for any reason, unless provided otherwise by the compensation committee
in the event of a termination occurring within 30 days prior to the end of an offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition to the share limit for each
offering period, no participant will have the right to purchase shares of our common stock in an amount, when aggregated with purchase rights under all our employee stock purchase plans that are also in effect in the same calendar year, that has a
fair market value of more than $25,000, determined as of the first day of the applicable purchase period, for each calendar year in which that right is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding. The purchase price for shares of our common stock purchased under our 2019 Employee Stock Purchase Plan will be not less than 85% of the lesser of the fair market value of our common
stock on (i)&nbsp;the first trading day of the applicable offering period and (ii)&nbsp;the last trading day of each purchase period in the applicable offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we experience any change in our capitalization without receipt of consideration by the Company, the type and number of securities covered
by each outstanding purchase right and the number of authorized shares under the 2019 Employee Stock Purchase Plan will be appropriately and proportionately adjusted by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we experience a proposed liquidation or dissolution, any offering period will terminate immediately prior to the consummation of such
transaction and all outstanding purchase rights will automatically terminate and the amounts of all payroll deductions will be refunded without interest to the participants. In the event of a proposed sale of all or substantially all of our assets,
or our merger or consolidation or similar combination of the Company with or into another entity, then in the sole discretion of our board of directors, (1)&nbsp;each purchase right will be assumed or an equivalent right substituted by the successor
corporation or parent or subsidiary of such successor entity, (2)&nbsp;on a date established by our board of directors on or before the date of consummation of such merger, consolidation, combination or sale, such date will be treated as a purchase
date, and all outstanding purchase rights will be exercised on such date, (3)&nbsp;all outstanding purchase rights will terminate and the accumulated payroll deductions will be refunded without interest to the participants, or (4)&nbsp;outstanding
purchase rights will continue unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The compensation committee may adopt rules or procedures relating to the operation and
administration of our 2019 Employee Stock Purchase Plan to accommodate specific requirements of local laws and jurisdictions and, if necessary, can establish <FONT STYLE="white-space:nowrap">sub-plans</FONT> for particular foreign jurisdictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors or compensation committee may terminate or suspend our 2019 Employee Stock Purchase Plan at any time and may
revise or amend the plan in any respect, subject to required stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company offers eligible employees, including its NEO based in the United States, the opportunity to participate in its <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) plan. Employees can contribute <FONT STYLE="white-space:nowrap">1%-100%</FONT> of their eligible earnings up to the Internal Revenue Service&#146;s annual limits on a <FONT
STYLE="white-space:nowrap">before-tax</FONT> basis. For every dollar an employee contributes up to 6% of their compensation, the Company may contribute 25 cents per dollar, provided that there are no matching contributions in excess of 1.5% of
eligible IRS compensation. The Company match provided to our Chief Executive Officer in 2018 is reflected in the &#147;All Other Compensation&#148; column of the 2018 Summary Compensation Table above. The Company funds are 100% vested after the
completion of one year of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Retirement Benefits </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We do not maintain any defined benefit pension plans or any nonqualified deferred compensation plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of each transaction or series of similar transactions since January&nbsp;18, 2018, our inception, or any currently
proposed transaction, to which we were or are a party in which: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount involved exceeded or exceeds $120,000 or one percent of our total assets at December&nbsp;31, 2018;
and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors or executive officers or any beneficial owners of 5% of any class of our voting capital
stock or and affiliate or immediate family member thereof, had or will have a direct or indirect material interest, other than compensation and other arrangements that are described under the section titled &#147;Executive Compensation&#148; or that
were approved by our compensation committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC
and generally includes voting or investment power with respect to such securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of Securities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April
2018, with subsequent closings in December 2018 and June and July 2019, we issued an aggregate of 44,000,000 shares of our Series&nbsp;A convertible preferred shares at a purchase price of $1.00 per share pursuant to a share purchase agreement
entered into with investors, for an aggregate purchase price of approximately $44.0&nbsp;million. Each share of our Series&nbsp;A convertible preferred shares will automatically convert into 0.161 shares of our common stock immediately prior to the
completion of this offering. Additionally, in April 2018, we issued 610,865 shares of our ordinary shares to OrbiMed Israel Partners II, L.P. and OrbiMed Private Investments VI, L.P., for total proceeds of $10,994. All purchasers of our convertible
preferred shares are entitled to specified registration rights. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for more information regarding these registration rights. The following table summarizes purchases of our
Series&nbsp;A convertible preferred shares by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares&nbsp;of<BR>Series&nbsp;A<BR>Convertible<BR>Preferred<BR>Shares</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>Purchase<BR>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,888,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,888,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Pontifax<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with RA
Capital<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,327,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,327,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Longitude Venture Partners III,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,916,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,916,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genworks 2 Consulting Inc.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">366,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">OrbiMed Israel Partners II, L.P. (&#147;OrbiMed Israel&#148;) together with its affiliate fund OrbiMed Private
Investments VI, L.P. is a holder of 5% or more of our capital stock. Anat Naschitz is a managing director at OrbiMed Israel and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Pontifax (Israel) V L.P., together with its affiliate funds Pontifax (Cayman) V L.P. and Pontifax (China) V
L.P., is a holder of 5% or more of our capital stock. Tomer Kariv is <FONT STYLE="white-space:nowrap">co-founder</FONT> and managing partner of the Pontifax Group and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">RA Capital Healthcare Fund, L.P. together with its affiliate funds Blackwell Partners LLC - Series A and RA
Capital Nexus Fund, L.P. is a holder of 5% or more of our capital stock. Derek DiRocco is a principal at RA Capital Management, LLC and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Longitude Venture Partners III, L.P. is a holder of 5% or more of our capital stock. Gregory Grunberg, M.D. is a
Managing Director at Longitude Capital Management Co., LLC and a member of our board of directors. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Michael Hayden, a member of our board of directors, is affiliated with Genworks 2 Consulting Inc.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors&#146; Rights Agreement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a party to an investors&#146; rights agreement, effective as of&nbsp;September 17, 2019 (the &#147;IRA&#148;), with the holders of our
Series A convertible preferred shares, including our 5% stockholders and entities affiliated with our directors. The IRA provides these holders the right, following the completion of this offering, to demand that we file a registration statement or
request that their shares be covered by a registration statement that we are otherwise filing. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. The IRA also
provides such holders a right of first offer to purchase future securities sold by us, which such right shall terminate immediately prior to the consummation of this offering and do not apply to the shares of common stock issued pursuant to this
registration statement. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are party to
a voting agreement, effective as of&nbsp;September 17, 2019 (the &#147;Voting Agreement&#148;), with the holders of our Series A convertible preferred shares, including our 5% stockholders and entities affiliated with our directors. Each of our 5%
stockholders have appointed representatives to our board of directors. The voting agreement will terminate upon the completion of this offering, and members previously elected to our board of directors pursuant to this agreement will continue to
serve as directors until they resign, are removed or their successors are duly elected by the holders of our common stock. The composition of our board of directors after this offering is described in more detail under
&#147;Management&#151;Composition of Our Board of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT>
Agreement </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a party to a right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreement, effective as
of&nbsp;September 17, 2019 (the &#147;ROFR Agreement&#148;), with the holders of our Series A convertible preferred shares, including our 5% stockholders and entities affiliated with our directors. The ROFR Agreement will terminate upon completion
of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our named executive officers. For more information regarding the agreements with our named
executive officers, see &#147;Executive Compensation&#151;Employment Agreements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">See &#147;Director Compensation&#148; for information regarding compensation of our directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
connection with this offering, we entered into agreements to indemnify our directors and executive officers. These agreements will, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees),
judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s
status as a member of our board of directors to the maximum extent allowed under Delaware law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Grants to Executive Officers and
Directors </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted stock options to our executive officers and certain of our directors as more fully described in the
sections entitled &#147;Executive Compensation&#148; and &#147;Management&#151;Director Compensation.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indications of Interest to Participate in this Offering </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing stockholders affiliated with our directors have agreed to purchase an aggregate of approximately $51&nbsp;million of shares of
our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding beneficial ownership of our equity interests as of October&nbsp;28, 2019 by: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each stockholder or group of stockholders known by us to be the beneficial owner of more than 5% of our
outstanding equity interests (our &#147;5% and Greater Stockholders&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our NEOs; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC, and thus represents voting or investment power with respect to our
securities as of October&nbsp;28, 2019. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire
within 60 days after October&nbsp;28 knowledge and subject to applicable community property rules, the persons and entities named in the table have sole voting and sole investment power with respect to all equity interests beneficially owned. Unless
otherwise indicated, the address of each individual listed in this table is 535 Mission Street, 14th Floor, San Francisco, CA 94105. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
percentage ownership information shown in the column titled &#147;Shares Beneficially Owned Prior to the Offering&#148; in the table below is based on 7,688,592&nbsp;shares of our common stock outstanding as of October&nbsp;28, 2019, which includes
7,077,366 shares of our common stock resulting from the conversion of all outstanding shares of our convertible preferred stock into our common stock immediately prior to the completion of this offering, as if this conversion had occurred as of
October&nbsp;28, 2019. The percentage ownership information shown in the column titled &#147;Shares Beneficially Owned After the Offering&#148; in the table below is based on 12,993,279&nbsp;shares of our common stock outstanding after this
offering, assuming 5,304,687&nbsp;shares of common stock being sold in this offering. Shares of our common stock that a person has the right to acquire within 60 days after September&nbsp;30, 2019 are deemed outstanding for purposes of computing the
percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as
a group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing stockholders affiliated with our directors have agreed to purchase an aggregate
of approximately $51&nbsp;million of shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering. The following table does not reflect the purchase of any
shares in this offering by these existing stockholders. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares<BR>Beneficially<BR>Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage of
Shares<BR>Beneficially Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Before&nbsp;the<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>After&nbsp;the<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% and Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,166,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Longitude Venture Partners III,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,916,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entitles affiliated with RA
Capital<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,661,214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Pontifax<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rohan Palekar<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ram Waisbourd<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derek DiRocco</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Grunberg<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,916,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Hayden<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tomer Kariv<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anat Naschitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Executive Officers and Directors as a group (10 persons)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,069,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 305,613&nbsp;shares of common stock owned by OrbiMed Israel Partners II, L.P., (b)
305,613&nbsp;shares of common stock owned by OrbiMed Private Investments VI, L.P., (c) 1,277,858&nbsp;shares of common stock issuable upon the conversion of shares of convertible preferred stock owned by OrbiMed Israel Partners II, L.P., and (d)
1,277,858&nbsp;shares of common stock issuable upon the conversion of shares of convertible preferred stock owned by OrbiMed Private Investments VI, L.P. The business address of OrbiMed Israel Partners II, L.P. (&#147;OIP II&#148;) is 89 Medinat
Hayehudim St., building E, Herzliya 4614001 Israel. OrbiMed Israel GP II, L.P. (&#147;Israel GP II&#148;) is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (&#147;Advisors Israel II&#148;) is the general partner of Israel GP
II. Advisors Israel II and Israel GP II may be deemed to have shared voting and investment power over all of the shares of common and convertible preferred stock held by OIP II, and both Advisors Israel II and Israel GP II may be deemed to directly
or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares held by OIP II. Advisors Israel II exercises this investment power through an investment committee comprised of Carl L. Gordon, Jonathan T.
Silverstein, Nissim Darvish, Anat Naschitz, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,916,787&nbsp;shares of common stock issuable upon the conversion of shares of convertible
preferred stock. Longitude Capital Partners III, LLC (&#147;LCP III&#148;) is the general partner of Longitude Venture Partners III, L.P. (&#147;LVP III&#148;) and may be deemed to have shared voting, investment and dispositive power over the shares
held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by LCP III and LVP III. Gregory Grunberg
is a member of LCP III. Each of these individuals disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein. Gregory Grunberg shares in the control of the Company securities held directly or
indirectly by LVP III/LCP III due to (a)&nbsp;his beneficial ownership in the Company&#146;s shares and (b)&nbsp;his position as a director of the Company. The mailing address of Longitude Venture Partners III, L.P. is 2740 Sand Hill Road, 2nd
Floor, Menlo Park, CA 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,185,315&nbsp;shares of common stock issuable upon the conversion of shares of convertible
preferred stock owned by RA Capital Healthcare Fund, L.P., or RA Capital Fund, (b) 287,125&nbsp;shares of common stock issuable upon the conversion of shares of convertible preferred stock owned by a separately managed account (the
&#147;Account&#148;), and (c) 188,774&nbsp;shares of common stock issuable upon the conversion of shares of convertible preferred stock owned by RA Capital Nexus Fund, L.P. (the &#147;RA Capital Nexus Fund&#148;). Dr.&nbsp;Peter Kolchinsky is the
managing member of RA Capital Management, LLC (&#147;RA Capital&#148;), the general partner and investment advisor of RA Capital Fund and the investment advisor of the Account and RA Capital Nexus Fund. Dr.&nbsp;Kolchinsky and RA Capital may be
deemed to beneficially own the shares held by RA Capital Fund, the Account and RA Capital Nexus Fund. Dr.&nbsp;Kolchinsky and RA Capital disclaim beneficial ownership of all applicable shares except to the extent of their actual pecuniary interest
therein. The mailing address for the entities listed above is 200 Berkeley Street, 18th Floor, Boston, MA 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 534,342&nbsp;shares of common stock issuable upon the conversion of shares of convertible
preferred stock owned by Pontifax (Israel) V, L.P., (b) 142,726&nbsp;shares of common stock issuable upon the conversion of shares of convertible preferred stock owned by Pontifax (Cayman) V, L.P., and (c) 207,603&nbsp;shares of common stock
issuable upon the conversion of shares of convertible preferred </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
stock owned by Pontifax (China) V, L.P. (together, the &#147;Pontifax Entities&#148;) Pontifax 5 G.P. L.P., or Pontifax 5 G.P., is the general partner of each of the Pontifax Entities, and
Pontifax Management 4 G.P. (2015)&nbsp;Ltd., or Pontifax Management, is the general partner of Pontifax 5 G.P. Mr.&nbsp;Tomer Kariv, a member of our board of directors, and Mr.&nbsp;Ran Nussbaum, are the Managing Partners of Pontifax Management and,
as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. In that context, Mr.&nbsp;Kariv disclaims beneficial ownership of such shares, except to the extent of his pecuniary
interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section&nbsp;16 of the Securities Exchange Act of 1934, as amended, or otherwise.
The address of each of the Pontifax Entities is c/o The Pontifax Group, 14 Shenkar Street, Herzelia, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 101,634&nbsp;shares of common stock underlying options that are exercisable as of October&nbsp;28,
2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 45,865&nbsp;shares of common stock underlying options that are exercisable as of October&nbsp;28,
2019 or will become exercisable within 60 days after such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;58,978&nbsp;shares of common stock issuable upon the conversion of shares of convertible
preferred stock owned by Genworks 2 Consulting Inc., over which Dr. Hayden&#146;s wife has sole voting and investment power, and (b)&nbsp;36,692&nbsp;shares of common stock underlying options that are exercisable as of October&nbsp;28, 2019 or will
become exercisable within 60 days after such date. The address of Genworks 2 Consulting Inc. is 4484 West 7th Avenue, Vancouver, BC, Canada V6R1W9. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of
the material terms of our capital stock, as well as other material terms of our Amended Certificate and Amended Bylaws, as each will be in effect prior to the closing of this offering, and certain provisions of Delaware law. This summary does not
purport to be complete and is qualified in its entirety by the provisions of our Amended Certificate and Amended Bylaws, copies of which will be filed with the SEC as exhibits to the registration statement, of which this prospectus forms a part.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our authorized capital stock will consist of&nbsp;100,000,000&nbsp;shares of common stock, $0.001
par value per share, and&nbsp;10,000,000&nbsp;shares of preferred stock, $0.001 par value per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;28, 2019,
611,226&nbsp;shares of our common stock and 44,000,000 shares of convertible preferred stock were outstanding and held by 10 stockholders of record. This amount does not take into account the conversion of all outstanding shares of our convertible
preferred stock into common stock upon the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate will authorize the issuance of up to&nbsp;100,000,000&nbsp;shares of our common stock. All outstanding shares of our
common stock are validly issued, fully paid and nonassessable, and the shares of our common stock to be issued in connection with this offering will be validly issued, fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of our common stock will be entitled to one vote per share on all matters submitted to a vote of stockholders, and our Amended
Certificate will not provide for cumulative voting in the election of directors. The holders of our common stock will receive ratably any dividends declared by our board of directors out of funds legally available therefor. In the event of our
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the holders of our common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;28,
2019, there were 44,000,000 shares of our preferred stock outstanding, which will convert into 7,077,366&nbsp;shares of our common stock upon the closing of this offering such that we will have no shares of preferred stock outstanding. Under the
terms of our Amended Certificate, upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to&nbsp;10,000,000&nbsp;shares of preferred stock in one or more
series, to establish from time to time the number of shares to be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations
or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting
power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying,
deferring or preventing a change in our control and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no current plans to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, the holders of&nbsp;7,077,366 shares of our common stock, including those issuable upon the conversion
of convertible preferred stock will be entitled to rights with respect to the registration of these securities under the Securities Act. These rights are provided under the terms of the IRA. The IRA includes demand registration rights, short-form
registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be
borne by the holders of the shares being registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Beginning 180 days after the effective date of this registration statement, the holders of&nbsp;7,077,366 shares of our common stock,
including those issuable upon the conversion of convertible preferred stock upon completion of this offering, are entitled to demand registration rights. Under the terms of the IRA, we will be required, upon the written request of at least 50% of
the holders of the registrable securities, including either OrbiMed Israel Partners II, L.P. or OrbiMed Private Investments VI, LP, provided that the anticipated aggregate offering price is at least $10&nbsp;million, to file a registration statement
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> and use commercially reasonable efforts to effect the registration of these shares for public resale. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-1</FONT> is
further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the IRA, if we register any of our common stock either for our own account or for the account of other security holders, the
holders of Registrable Shares party to the IRA are entitled to include their shares in the registration, subject to certain marketing and other limitations. We may terminate or withdraw any registration initiated before the effective date of such
registration in our sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the IRA, if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written
request of at least 10% of the holders of registrable securities to sell registrable securities at an aggregate price of at least $5&nbsp;million, we will be required to use commercially reasonable efforts to effect a registration of such shares.
The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Our Amended Certificate, Amended Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate and our Amended Bylaws, both to become effective upon the completion of this offering, include a number of provisions
that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors
rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Issuance of undesignated preferred stock:</I></B><B> </B>Under our Amended Certificate, our board of
directors has the authority, without further action by the stockholders, to issue up to&nbsp;10,000,000&nbsp;shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of
directors. The existence of authorized but unissued shares of preferred stock enables our board of directors to make it more difficult to attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Classified board</I></B><B>:</B><B><I> </I></B>Our Amended Certificate establishes a classified board of
directors consisting of three classes of directors, with staggered three-year terms. Only one class of directors will be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. This provision may have the effect of delaying a
change in control of our board of directors. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Election and removal of directors and board vacancies</I></B><B>:</B><B><I> </I></B>Our Amended Bylaws
provide that directors will be elected by a plurality vote. Our Amended Certificate and Amended Bylaws also provide that our board of directors has the right to increase or decrease the size of the board and to fill vacancies on the board. Directors
may be removed only for cause by the affirmative vote of the holders of at least 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the votes that all our stockholders would be entitled to cast in an
annual election of directors. Only our board of directors is authorized to fill vacant directorships. In addition the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of the directors
then in office. These provisions prevent stockholders from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Requirements for advance notification of stockholder nominations and proposals</I></B><B>:</B><I> </I>Our
Amended Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors that specify certain requirements as to the timing, form and content of a stockholder&#146;s notice.
Business that may be conducted at an annual meeting of stockholders will be limited to those matters properly brought before the meeting. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of
stockholders or to nominate directors at annual meetings of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>No written consent of stockholders</I></B><B>:</B><B><I> </I></B>Our Amended Certificate provides that all
stockholder actions be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take
stockholder actions and would prevent the amendment of our Amended Bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>No stockholder ability to call special meetings</I></B><B>:</B><B><I> </I></B>Our Amended Certificate and
Amended Bylaws provide that only a majority of the members of our board of directors then in office may be able to call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted
upon at a special meeting of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Amendments to certificate of incorporation and bylaws:</I></B><B> </B>Any amendment to our Amended
Certificate will be required to be approved by a majority of our board of directors as well as, if required by law or the Amended Certificate, a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding
shares of each class entitled to vote thereon as a class, except that the amendment of provisions to board classification, stockholder action, certificate amendments, and liability of directors must be approved by not less than 66<SUP
STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the outstanding shares entitled to vote on the amendment, voting together as a single class. Any amendment to our Amended Bylaws must be approved by either a
majority of our board of directors or not less than 66<SUP STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the outstanding shares entitled to vote on the amendment, voting together as a single class.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These provisions are designed to enhance the likelihood of continued stability in the composition of our board of
directors and its policies, to discourage certain types of transactions that may involve an actual or threatened acquisition of us and to reduce our vulnerability to an unsolicited acquisition proposal. We also designed these provisions to
discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they may also reduce fluctuations in the market price
of our shares that could result from actual or rumored takeover attempts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will be subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In
general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an
interested stockholder, unless the business combination is approved in a prescribed manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate requires that the Court of Chancery of the State of Delaware be the exclusive forum for the following types of actions
or proceedings under Delaware statutory or common law: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a breach of fiduciary duty owed by any director, officer or other employee to us or our
stockholders; (3)&nbsp;any action asserting a claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law, our Amended Certificate or Amended Bylaws; or (4)&nbsp;any action asserting a claim
against us or any director or officer or other employee that is governed by the internal affairs doctrine. This provision would not apply to claims brought to enforce a duty or liability created by the Exchange Act or any other claim for which the
federal courts have exclusive jurisdiction. Our Amended Certificate provides further that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the
Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. Although we believe these provisions benefit us by providing increased consistency in the
application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">American
Stock Transfer and Trust Company, LLC serves as the transfer agent and registrar for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on The Nasdaq Global Market under the symbol &#147;ETNB.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for shares of our common stock. Future sales of our common stock, including shares
issued upon the vesting of restricted stock units or the exercise of options or warrants, in the public market after this offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to fall or
impair our ability to raise equity capital in the future. As described below, only a limited number of shares of our common stock will be available for sale in the public market for a period of several months after the completion of this offering
due to the contractual and legal restrictions on resale described below. Future sales of our common stock in the public market either before (to the extent permitted) or after restrictions lapse, or the perception that those sales may occur, could
adversely affect the prevailing market price of our common stock at such time and our ability to raise equity capital at a time and price we deem appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale of Restricted Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately
following the completion of this offering, we will have an aggregate of 12,993,279&nbsp;shares of common stock outstanding. Of the outstanding shares of our common stock, the 5,304,687&nbsp;shares sold in this offering (or 6,100,390&nbsp;shares if
the underwriters exercise in full their option to purchase additional shares) will be freely tradable without restriction or further registration under the Securities Act, except that any shares held by our affiliates, as that term is defined in
Rule 144 of the Securities Act, may generally be sold only in compliance with the limitations described below. All remaining shares of our common stock held by existing stockholders immediately prior to the closing of this offering will be
&#147;restricted securities&#148; as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the
Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, which rules are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We and all of our directors and officers, as well as the other holders of substantially all shares of our common stock outstanding immediately
prior to the completion of this offering, have agreed with the underwriters that, for a period of 180 days following the date of this prospectus, subject to certain exceptions, we and they will not, directly or indirectly, offer, sell, contract to
sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any of shares of our common stock, or any options or warrants to purchase any shares of our common stock, or any securities convertible into, or exchangeable for
or that represent the right to receive shares of our common stock. BofA Securities, Inc., SVB Leerink LLC and RBC Capital Markets, LLC may, in their discretion, release all or any portion of the shares from these restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, as
currently in effect, once we have been subject to the public company reporting requirements of the Exchange Act for at least 90 days, a person (or persons whose shares are required to be aggregated) who is not deemed to have been one of our
&#147;affiliates&#148; for purposes of Rule 144 at any time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule 144 for at least 6 months, including the holding period of any
prior owner other than one of our &#147;affiliates,&#148; is entitled to sell those shares in the public market (subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable) without complying with the
manner of sale, volume limitations or notice provisions of Rule 144, but subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year,
including the holding period of any prior owner other than affiliates, then such person is entitled to sell such shares in the public market without complying with any of the requirements of Rule 144 (subject to the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement referred to above, if applicable). In general, under Rule 144, as currently in effect, once we have been subject to the public company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting requirements of the Exchange Act for at least 90 days, our affiliates, as defined in Rule 144, who have beneficially owned the shares proposed to be sold for at least 6 months are
entitled to sell in the public market, upon expiration of any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and within any three-month period, a number of those shares of our common stock that does not exceed the greater of:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one percent of the number of shares of our common stock then outstanding, which will equal approximately
129,933&nbsp;shares of our common stock immediately after this offering (calculated on the basis of the assumptions described above and assuming no exercise of the underwriter&#146;s option to purchase additional shares of our common stock); or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the 4 calendar weeks
preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Such sales under Rule 144 by our
&#147;affiliates&#148; or persons selling shares on behalf of our &#147;affiliates&#148; are also subject to certain manner of sale provisions, notice requirements and to the availability of current public information about us. Notwithstanding the
availability of Rule 144, the holders of substantially all of our restricted securities have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements as referenced above and their restricted securities will become eligible for sale
(subject to the above limitations under Rule 144) upon the expiration of the restrictions set forth in those agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon expiration
of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period described above, 7,688,592 shares of our common stock will be eligible for sale under Rule 144 (including shares issued pursuant to Rule
701 described below). We cannot estimate the timing or the number of shares that our existing stockholders and other equity holders may elect to sell under Rule 144 or pursuant to Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration
statements. See &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common
stock from us in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule 701 under the Securities Act before the effective date of the registration statement of which this prospectus is a part
(to the extent such common stock is not subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement) is entitled to rely on Rule 701 to resell such shares beginning 90 days after we become subject to the public company reporting
requirements of the Exchange Act in reliance on Rule 144, but without compliance with the holding period requirements contained in Rule 144. Accordingly, subject to any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, beginning
90 days after we become subject to the public company reporting requirements of the Exchange Act, under Rule 701, persons who are not our affiliates, as defined in Rule 144, may resell those shares without complying with the minimum holding period
or public information requirements of Rule 144, and persons who are our affiliates may resell those shares without compliance with Rule 144&#146;s minimum holding period requirements (subject to the terms of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements referred to above, if applicable). In addition, after the effective date of this offering, we plan to register on a Form <FONT STYLE="white-space:nowrap">S-8</FONT> registration statement
all shares of our common stock that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period described above,
7,688,592&nbsp;shares of our common stock will be eligible for sale under Rule 144 (including shares issued pursuant to Rule 701). We cannot estimate the timing or the number of shares that our existing stockholders and other equity holders may
elect to sell under Rule 144 or pursuant to registration statements. For a description of certain registration rights granted, see &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering. The discussion does not purport to be a complete analysis of
all potential tax consequences. The consequences of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws, are not discussed. This discussion is
based on the U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the
&#147;IRS&#148;), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that purchase our common stock pursuant to this offering and hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code
(generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including without limitation
the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk-reduction strategy or as part of a
conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, investment funds, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements classified as partnerships for U.S. federal income tax purposes
(and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons required to accelerate the recognition of any item of gross income with respect to our common stock as a
result of such income being recognized on an applicable financial statement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or have owned, actually or constructively, more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise
as compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>This discussion is for informational purposes only and is not tax advice. Investors
should consult their tax advisors with respect to the application of the U.S. federal income tax laws to their particular situations as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the
U.S. federal estate or gift tax laws or under the laws of any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxing jurisdiction or under any applicable income tax treaty. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common
stock that is not a &#147;U.S. person.&#148; A &#147;U.S. person&#148; is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that: (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code); or (ii)&nbsp;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we make distributions
of cash or other property on our common stock, those distributions will generally constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal
income tax principles. If the amount of such distributions exceed our current and accumulated earnings and profits, such excess will generally constitute a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of capital and will first be applied
against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#147;Sale or
Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes the applicable withholding agent with documentation required to claim benefits under such tax treaty (generally, a valid IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or a suitable successor or substitute form)). This certification must be provided before the payment of
dividends and must be updated periodically. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts
withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding U.S. federal withholding tax on distributions, including their eligibility
for benefits under any applicable income tax treaties and the availability of a refund on any excess U.S. federal tax withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If
dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (or, if required by
an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder will generally be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8ECI</FONT> (or a suitable successor or substitute form) certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business
within the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends will be subject to U.S. federal income tax
on a net income basis at the regular graduated rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate
specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties
that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The foregoing discussion is subject to the discussion below under &#147;Additional Withholding Tax
on Payments Made to Foreign Accounts&#148; and &#147;Information Reporting and Backup Withholding.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and the Foreign Account Tax Compliance Act (&#147;FATCA&#148;), a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business within the United States (or, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest (&#147;USRPI&#148;) by reason of our status as a U.S.
real property holding corporation (&#147;USRPHC&#148;) for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gain described in the
first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may
be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by
an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With
respect to the third bullet point above, we believe we currently are not, and we do not anticipate becoming, a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair
market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, we cannot assure you that we will not become a USRPHC in the future. Even if we are or were to become a USRPHC, gain arising
from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded&#148; on an &#147;established
securities market&#148; (as such terms are defined by applicable Treasury Regulations), and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the
<FONT STYLE="white-space:nowrap">5-year</FONT> period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. If we are determined to be a USRPHC and the
foregoing exception does not apply, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons and, in
addition, a purchaser of our common stock may be required to withhold tax with respect to that obligation. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rules
described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding potentially
applicable income tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Payments of dividends on our common stock generally will not be subject to backup withholding provided the applicable withholding agent does
not have actual knowledge or reason to know the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a U.S. person and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
status by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> <FONT
STYLE="white-space:nowrap">W-8EXP,</FONT> or other applicable IRS form, or otherwise establishes an exemption. Information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of an applicable treaty or agreement to the tax authorities
of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Information reporting and,
depending on the circumstances, backup withholding generally will apply to the proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers, unless the applicable
withholding agent receives the certification described above and does not have actual knowledge or reason to know that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a U.S. person, or the holder otherwise establishes an exemption.
Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the
United States generally will not be subject to backup withholding or information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax.
Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely
furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as FATCA) on certain types of
payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on, and subject to
the discussion of certain proposed U.S. Treasury regulations below, the gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a
<FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless: (i)&nbsp;the foreign financial institution undertakes certain diligence, reporting and withholding obligations; (ii)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial U.S. owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial U.S. owner; or
(iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the
diligence, reporting and withholding requirements in (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified U.S.
persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to noncompliant foreign financial institutions and certain
other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The U.S. Treasury recently released proposed regulations which, if finalized in their present form, would eliminate the federal withholding
tax of 30% applicable to the gross proceeds of a sale or other disposition of our common stock. In its preamble to such proposed regulations, the U.S. Treasury stated that taxpayers may generally rely on the proposed regulations until final
regulations are issued. There can be no assurance that final regulations would provide an exemption from the FATCA withholding tax for gross proceeds. The FATCA withholding tax generally applies to all withholdable payments without regard to whether
the beneficial owner of the payment would otherwise be entitled to an exemption from imposition of withholding tax pursuant to an applicable tax treaty with the United States or U.S. domestic law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment
in our common stock. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc., SVB Leerink LLC and RBC Capital Markets, LLC are acting as representatives of each of the underwriters named below.
Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number
of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriter</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,148,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,724,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RBC Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,304,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our existing stockholders affiliated
with our directors have agreed to purchase an aggregate of approximately $51&nbsp;million of shares of our common stock in this offering at the initial public offering price per share and on the same terms as the other purchasers in this offering.
The underwriters will receive the same underwriting discount and commissions on these shares of common stock as they will on any other shares of common stock sold to the public in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of
$0.672 per share. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, underwriting discount and proceeds
before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">84,874,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,606,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,941,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,832,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,933,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,773,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at $2.4 million and are
payable by us. We have also agreed to reimburse the underwriters for certain of their expenses incurred in connection with, among others, the review and clearance by the Financial Industry Regulatory Authority, Inc. in an amount of up to $40,000.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to 795,703 additional
shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares
proportionate to that underwriter&#146;s initial amount reflected in the above table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or
securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of BofA Securities, Inc., SVB Leerink LLC and RBC Capital
Markets, LLC. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file or make a confidential submission of a registration statement related to the
common stock, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement that transfers or is designed to, intended to, or which could reasonably
be expected to lead to or result in the transfer, in whole or in part, the economic consequence of ownership of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities convertible
into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of
disposition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Nasdaq Global Market Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock has been approved for listing on The Nasdaq Global Market under the symbol &#147;ETNB.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Before this offering, there has been no public market for our common stock. The initial public offering price was determined through
negotiations between us and the representatives. In addition to prevailing market conditions, the factors considered in determining the initial public offering price were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues, </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the
offering the shares will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions
and Penalty Bids </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from
bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter
repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on The Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the European Economic Area </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each a
&#147;Member State&#148;), no shares have been offered or will be offered pursuant to the to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in
that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation), except that offers of shares may be made to the public in that
Member State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require us or any representative to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each person in a Member State who initially acquires any shares or to whom any offer is made
will be deemed to have represented, acknowledged and agreed to and with us and the representatives that it is a qualified investor within the meaning of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each
such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their
offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant Member State to qualified investors, in circumstances in which the prior consent of the representatives has
been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the representatives and their affiliates will rely upon the truth and accuracy
of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to
the public&#148; in relation to any shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the
United Kingdom </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer
subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article
49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom,
any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss
Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss
Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other
offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, our company or the shares have been or will be
filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to
acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
(&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in
connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or
subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations Act&#148;), and does not
purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities
and Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to any Japanese Person, except
in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148;
shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors
in Singapore </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the
shares were not offered or sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus or any
other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any
person in Singapore other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to
Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions
specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each
term as defined in Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the
shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a <FONT
STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are
not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common stock offered by this prospectus will be passed upon for us by Gibson, Dunn&nbsp;&amp; Crutcher LLP.
Certain legal matters in connection with this offering will be passed upon for the underwriters by Cooley LLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements included in this prospectus have been audited by Brightman Almagor Zohar&nbsp;&amp; Co., a Firm in the
Deloitte Global Network, an independent registered public accounting firm, as stated in their report appearing herein which report expresses an unqualified opinion on the consolidated financial statements and includes an explanatory paragraph
referring to going concern. Such consolidated financial statements have been so included in reliance upon the report of such Firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc743471_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect
to the shares of our common stock offered hereby. This prospectus, which constitutes a part of the registration statement,<I></I>&nbsp;does not contain all of the information set forth in the registration statement, some items of which are contained
in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement and its exhibits. Statements contained in
this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that
has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The exhibits to the registration statement should be reviewed for the complete contents of
these contracts and documents. A copy of the registration statement and its exhibits may be obtained from the SEC upon the payment of fees prescribed by it. The SEC maintains a website at <I>www.sec.gov </I>that contains reports, proxy and
information statements and other information regarding companies that file electronically with it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of this offering, we have
become subject to the information and periodic and current reporting requirements of the Exchange Act, and in accordance therewith, will file periodic and current reports, proxy statements and other information with the SEC. The registration
statement, such periodic and current reports and other information can be obtained electronically by means of the SEC&#146;s website at <I>www.sec.gov. </I>We maintain a website at <I>www.89bio.com</I>, at which, following the completion of this
offering, you may access these material free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessible through our website is not a part of this prospectus,
and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc743471_23"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Page</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>89bio, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Audited Balance Sheet as of
June&nbsp;28, 2019 (Inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_2">Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_3">Notes to Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>89Bio Ltd. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Audited
Consolidated Financial Statements as of December&nbsp;31, 2018 and for the Period from January&nbsp;18, 2018 (Inception) to December&nbsp;31, 2018 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_4">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-6</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_5">Consolidated Balance Sheet</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-8</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_6">Consolidated Statement of Operations and Comprehensive Loss</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">F-9</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_7">Consolidated Statement of Shareholders&#146; Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-10</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_8">Consolidated Statement of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-11</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_9">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>89Bio Ltd. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unaudited
Interim Condensed Consolidated Financial Statements as of June&nbsp;30, 2019 and for the Period from January 18, 2018 (Inception) to June&nbsp;30, 2018 and for the Six Months Ended June&nbsp;30, 2019 </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_10">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-28</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_11">Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-29</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_12">Condensed Consolidated Statements of Convertible Preferred Shares and Shareholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-30</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_13">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-31</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin743471_14">Notes to Unaudited Interim Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">F-32</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors of 89bio, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the
Financial Statements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheet of 89bio, Inc. (the &#147;Company&#148;) as of June&nbsp;28, 2019
(inception), and the related notes (collectively referred to as the &#147;financial statement&#148;). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company as of June&nbsp;28, 2019,
in conformity with accounting principles generally accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This financial statement is the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statement is free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement
of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our
audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement. We believe that our audit provides a reasonable basis for our
opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Brightman Almagor Zohar&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certified Public Accountants </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Firm in the Deloitte Global
Network </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel Aviv, Israel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 19, 2019, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except for the retroactive effect of the 1-for-6.217 reverse stock split and the Reorganization, as described in Note 2 and Note 4, respectively, as to which
the date is October 28, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_2"></A>89bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheet </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>June&nbsp;28,<BR>2019&nbsp;(inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 1,000 shares authorized, none issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of this balance sheet. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_3"></A>89bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Balance Sheet </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization
and Background </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">89bio, Inc. (the &#147;Corporation&#148;) was formed as a Delaware corporation on June&nbsp;28, 2019. The Corporation
was formed for the purpose of completing an initial public offering and related transactions in order to carry on the business of 89Bio Ltd. As the manager of 89Bio Ltd., the Corporation will operate and control all of the businesses and affairs of
89Bio Ltd., and its subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
balance sheet is presented in accordance with generally accepted accounting principles in the United States of America (&#147;GAAP&#148;). Statements of operations, stockholders&#146; equity and cash flows have not been presented because there have
been no activities in this entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October 24, 2019, the Corporation&#146;s board of directors approved an amendment to the Corporation&#146;s amended and restated
certificate of incorporation to effect a 1-for-6.217 reverse split (&#147;Reverse Split&#148;) of shares of the Corporation&#146;s common stock and a proportional adjustment to the conversion ratio of its convertible preferred stock, which was
effected on October 25, 2019. The par value and authorized shares of common stock and the par value, authorized and outstanding shares of convertible preferred stock were not adjusted as a result of the Reverse Split. All of the share and per share
information included in the accompanying financial statement has been adjusted to reflect the Reverse Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Underwriting Commissions and Offering
Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Underwriting commissions and offering costs to be incurred in connection with the Corporation&#146;s common share offerings
will be reflected as a reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital. Underwriting commissions and offering costs are not recorded in the Corporation&#146;s balance sheet because such costs are not the
Corporation&#146;s liability until the Corporation completes a successful initial public offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organizational Costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Organizational costs are not recorded in the Corporation&#146;s balance sheet because such costs are not the Corporation&#146;s liability
until the Corporation completes a successful initial public offering. Thereafter, costs incurred to organize the Corporation will be expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Stockholders&#146; Equity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Corporation is authorized to issue 1,000 shares of common stock, par value $0.001 per share, none of which have been issued or are outstanding as of June&nbsp;28, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2019,
the Corporation increased its authorized shares from 1,000 to 72,882,353 shares of common stock, 611,226 of which have been issued and are outstanding as of September 19, 2019. Additionally, the Corporation authorized 60,000,000&nbsp;shares of
preferred stock, 44,000,000 of which have been issued and are outstanding as of September&nbsp;19, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Balance Sheet </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2019, an internal reorganization transaction was completed pursuant to which
89Bio, Ltd. became a wholly owned subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October 24, 2019, the Corporation&#146;s board of directors approved the Reverse Split,
which was effected on October 25, 2019 (see Note 2). Additionally, the Corporation increased its authorized shares from 72,882,353 to 100,000,000 shares of common stock, which is to become effective immediately prior to the completion of the
Corporation&#146;s initial public offering. As of October 28, 2019, 611,226 shares of common stock have been issued and are outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subsequent events through September 19, 2019, the date on which the balance sheet was available to be issued, and October 28, 2019, the date
the balance sheet was reissued, were evaluated by the Corporation to determine the need, if any, for recognition or disclosure in this balance sheet. The Corporation concluded that no other subsequent events have occurred that would require
recognition or disclosure to the balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_4"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">89Bio Ltd.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheet of 89Bio Ltd. and subsidiaries (the &#147;Company&#148;) as of December&nbsp;31,
2018 and the related consolidated statements of operations and comprehensive loss, change in convertible preferred shares and shareholders&#146; deficit and cash flows for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018,
and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2018, and the
results of its operations and its cash flow for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going Concern </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company&#146;s lack of revenues and substantial operating losses raise
substantial doubt about its ability to continue as a going concern. Management&#146;s plans concerning these matters are also described in Note 1 to the financial statements. The financial statements do not include any adjustments that might result
from the outcome of these uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the
Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our audit included performing procedures to assess the risks of material misstatement
of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our
audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our
opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Brightman Almagor Zohar&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certified Public Accountants </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Firm in the Deloitte Global
Network </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel Aviv, Israel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;15, 2019, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except for the retroactive effect of the 1-for-6.217 reverse stock split and the Reorganization as described in Note&nbsp;2 and Note 13, respectively, as to
which the date is October 28, 2019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_5"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheet </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares, NIS 0.01 nominal value; 60,000,000 shares authorized as of
December&nbsp;31, 2018; 24,000,000 shares issued and outstanding as of December&nbsp;31, 2018; aggregate liquidation preference of $24,000 as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, NIS 0.01 nominal value, 10,415,900 shares authorized at December&nbsp;31, 2018;
611,226 shares issued and outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred shares and shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_6"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statement of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Period&nbsp;from<BR>January&nbsp;18,<BR>2018&nbsp;(inception)<BR>to&nbsp;December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute pro forma net loss per share, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,127,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_7"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statement of Convertible Preferred Shares and Shareholders&#146; Deficit (in thousands, except share amounts) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Convertible&nbsp;Preferred<BR>Shares</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Ordinary&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Additional<BR><FONT
STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Accumulated<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>Shareholders&#146;<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amounts</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amounts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance&nbsp;as&nbsp;of&nbsp;January&nbsp;18,&nbsp;2018&nbsp;(inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred shares, net of issuance costs of $235 and the recognition of the
convertible preferred share liability of $692</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,973</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible note into preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,073</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_8"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statement of Cash Flows (in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,<BR>2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash&nbsp;flows&nbsp;from&nbsp;operating&nbsp;activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,469</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred shares and convertible preferred share liability,
net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Components of cash and cash equivalents, and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash and cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of non-cash investing and financing information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible note into preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_9"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of Business </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">89Bio
Ltd. (&#147;89Bio&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company&#146;s
lead product candidate, <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> a specifically engineered glycoPEGylated analog of fibroblast growth factor 21, is currently being developed for the treatment of nonalcoholic steatohepatitis. 89Bio Ltd. was
incorporated in Israel in January 2018. The Company has two wholly owned subsidiaries: 89bio Management, Inc., located in San Francisco, California and UAB 89bio Lithuania, located in Vilnius, Lithuania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">89bio, Inc., a Delaware corporation, does not currently have any operations and was incorporated in June 2019 for the purpose of an internal
reorganization transaction. In September 2019, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. Following this exchange, 89Bio Ltd. became a wholly-owned subsidiary of 89bio,
Inc. and 89bio, Inc. indirectly owns the business described herein. Upon the completion of a qualified public offering on specified terms, the Company&#146;s outstanding convertible preferred shares will automatically convert into shares of common
stock (see Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the
realization of assets and liquidation of liabilities in the normal course of business. To date, the Company has not generated revenues from its activities and has incurred substantial operating losses. Management expects the Company to continue to
generate substantial operating losses for the foreseeable future until it completes development of its products and seeks regulatory approvals to market such products. Management will continue to fund its operations primarily through utilization of
its current financial resources and through additional raises of capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Such conditions raise substantial doubts about the
Company&#146;s ability to continue as a going concern for at least a year after the issuance date of the accompanying consolidated financial statements. Management plans to address these conditions by raising funds from its current investors as well
as outside potential investors. However, there is no assurance that such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.
The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount or classification of liabilities that may be required should the Company be
unable to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation: </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements have been prepared in conformity with accounting principles generally accepted in United Sates of America (&#147;U.S. GAAP&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September
2019, the Company completed an internal reorganization transaction pursuant to which 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. (see Note 1). On October 24, 2019, 89bio, Inc.&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors approved an amendment to the amended and restated certificate of incorporation of 89bio, Inc. to effect a 1-for-6.217 reverse split (&#147;Reverse Split&#148;) of shares of the
common stock of 89bio, Inc. and a proportional adjustment to the conversion ratio of the convertible preferred stock, which was effected on October&nbsp;25, 2019. The par value and authorized shares of common stock and the par value, authorized and
outstanding shares of convertible preferred stock were not adjusted as a result of the Reverse Split. All of the share and per share information for 89Bio Ltd. included in the accompanying financial statements has been adjusted to reflect the
Reverse Split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany
balances and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates
and assumptions made in the accompanying consolidated financial statements include but are not limited to the fair value of stock options, the convertible preferred share liability and certain accruals. The Company evaluates its estimates and
assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consolidated Financial Statements in U.S. Dollars </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s functional currency is the U.S. dollar (&#147;dollar&#148; or &#147;$&#148;) since the dollar is the currency of the
primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances
denominated in foreign currencies have been <FONT STYLE="white-space:nowrap">re-measured</FONT> to dollars. All transaction gains and losses from <FONT STYLE="white-space:nowrap">re-measurement</FONT> of monetary balance sheet items denominated in <FONT
STYLE="white-space:nowrap">non-dollar</FONT> currencies are reflected in the consolidated statement of operations and comprehensive loss as other (income) expenses, net. Net foreign currency transaction losses were not material for the period from
January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents and Restricted Cash </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be
cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and are stated at fair value. Restricted cash consists of a money market account that serves as collateral for a credit card agreement at one of the
Company&#146;s financial institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the consolidated balance sheet. The carrying values of
Company&#146;s financial assets and liabilities, including cash and cash equivalents, restricted cash, other current assets, accounts payable, and accrued expenses approximate to their fair value due to the short-term maturity of these instruments.
Fair value is defined as the price that would be received to sell an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value in the
consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation
of these assets or liabilities as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;1</B>&#151;Observable inputs such as unadjusted, quoted prices in
active markets for identical assets or liabilities at the measurement date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;2</B>&#151;Inputs (other than
quoted prices included in Level&nbsp;1) are either directly or indirectly observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for
identical or similar assets of liabilities in markets that are not active; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level</B><B></B><B>&nbsp;3</B>&#151;Unobservable inputs
that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred
Share Liability </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The freestanding instruments related to the commitment by the Series A convertible preferred shareholders to
purchase and by the Company to sell its Series A convertible preferred shares in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per share, are
considered a liability (or an asset), measured at fair value as the shares underlying the rights contain liquidation preferences upon certain &#147;deemed liquidation events&#148; that are not solely within the Company&#146;s control and which are
considered <FONT STYLE="white-space:nowrap">in-substance</FONT> contingent redemption features (refer to Note 7 for further discussion on the redemption rights of the convertible preferred shares). The instruments are subject to revaluation at each
balance sheet date until settlement, with revaluations recognized as a component of other (income) expenses, net in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents.
Bank deposits are held by accredited financial institutions and these deposits may at times be in excess of insured limits. The Company limits its credit risk associated with cash and cash equivalents by placing them with financial institutions that
it believes are of high quality. The Company has not experienced any losses on its deposits of cash or cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment,
Net </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis
over the estimated useful lives of the related assets, generally ranging from three to seven years. Leasehold improvements are amortized on a straight-line basis over the shorter of the assets&#146; estimated useful life or the remaining term of the
lease. Maintenance and repair costs are expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates its long-lived assets, including property and equipment, for impairment whenever events or changes in
business circumstances indicate that the carrying amount of the assets or group of assets may not be fully recoverable. If indicators of impairment exist and the undiscounted future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets through an impairment charge, to their
estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. There were no such indicators for the period presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Post-Employment Benefit </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under Israeli employment laws, employees of the Company are included under Section&nbsp;14 of the Severance Compensation Act, 1963
(&#147;Section&nbsp;14&#148;) for a portion of their salaries. According to Section&nbsp;14, these employees are entitled to monthly payments made by the Company on their behalf with insurance companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Payments in accordance with Section&nbsp;14 release the Company from any future severance payments with respect of those employees. The
obligation to make the monthly deposits is expensed as incurred. In addition, the aforementioned deposits are not recorded as an asset in the consolidated balance sheet, and there is no liability recorded as the Company does not have a future
obligation to make any additional payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company leases its office facility under a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease agreement and recognizes
related rent expense on a straight-line basis over the term of the lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for the development of the Company&#146;s lead product candidate, <FONT
STYLE="white-space:nowrap">BIO89-100.</FONT> Research and development expenses consist primarily of external costs related to acquiring and licensing patents and intellectual properties, preclinical and clinical development and related supplies, and
personnel costs. Personnel costs consist of salaries, employee benefits and share-based compensation for individuals involved in research and development efforts. The Company estimates preclinical and clinical study and research expenses based on
the services performed, pursuant to contracts with research institutions that conduct and manage preclinical and clinical studies and research services on its behalf. The Company records the costs of research and development activities based upon
the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the consolidated balance sheet. These costs are a component of the Company&#146;s research and development expenses. The Company
accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates
in determining the accrued liabilities balance. As actual costs become known, the Company adjusts its accrued expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and
timing of actual services performed may vary from the Company&#146;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#146;s accruals could materially affect
the Company&#146;s results of operations. Payments associated with licensing agreements to acquire licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial
use are expensed as incurred. Contingent milestone payments, if any, are expensed when the milestone results are probable and estimable, which is generally upon achievement of the milestone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company measures its share-based payment awards made to employees, directors, and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers based on estimated fair values and recognizes compensation over the requisite service period.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of share-based payment awards on the date of grant using
a Black-Scholes option pricing model. The value of the portion of the share-based payment award that is ultimately expected to vest is recognized as an expense over the requisite service period in the consolidated statement of operations and
comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes compensation for the value of share-based payment awards, which have graded vesting, using the
straight-line method over the requisite service period of each award. The Company accounts for forfeitures as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Black-Scholes option pricing model requires a number of assumptions, of which the most significant are share price, expected volatility, expected option term (the time from the grant date until the options are exercised or expire), risk-free rate,
and expected divided rate. Expected volatility is estimated based on volatility of similar public companies in the biotechnology sector. The Company has historically not paid dividends and has no foreseeable plans to pay dividends, therefore the
Company uses an expected dividend yield of 0%. The risk-free interest rate is based on the yield from U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds with an equivalent expected term. The expected option term is calculated
for options granted to employees and directors using the &#147;simplified&#148; method. Under this approach, the expected term is presumed to be the midpoint between the weighted average vesting term and the contractual term of the option. The
simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options expire. The expected option term for options granted to <FONT
STYLE="white-space:nowrap">non-employees</FONT> is based on the contractual term. Changes in the determination of each of the inputs can affect the fair value of the share options granted and the results of operations of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Income taxes are
accounted for under the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of
existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary
differences are expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income or loss in the period that includes the enactment date. A valuation allowance is established when necessary
to reduce deferred tax assets to the amount expected to be realized. Interest and penalties related to unrecognized tax benefits are included within the provision of income tax. To date, there have been no unrecognized tax benefits balances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basic and Diluted Net Loss per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic loss per share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding during the period.
Diluted loss per share is computed by dividing the net loss by the weighted average number of ordinary shares outstanding together with the number of additional ordinary shares that would have been outstanding if all potentially dilutive ordinary
shares had been issued. Since the Company was in a loss position for the period presented, basic net loss per share is the same as diluted net loss per share since the effects of potentially dilutive securities are antidilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately prior to the completion of the Company&#146;s anticipated initial public offering (the &#147;IPO&#148;), all outstanding shares of
convertible preferred shares will convert into ordinary shares. The unaudited pro forma net loss per share for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018 was computed using the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
weighted-average number of shares of ordinary shares outstanding, including the pro forma effect of the conversion of all outstanding shares of convertible preferred shares into shares of
ordinary shares as if such conversion had occurred at the beginning of the period, or their issuance dates if later. Pro forma net loss per share does not include the shares expected to be sold in the IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
has no components of comprehensive loss other than net loss. Thus, comprehensive loss is the same as net loss for the period presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment
Reporting </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has one operating segment. The Company&#146;s chief operating decision maker, its Chief Executive Officer,
manages the Company&#146;s operations on a consolidated basis for the purposes of allocating resources and evaluating financial performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent
Accounting Pronouncements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (the &#147;FASB&#148;) issued Accounting
Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-09&#151;</FONT><I>Revenue from contracts with customers</I>, to achieve a consistent application of revenue recognition, resulting in a single revenue model to be applied by
reporting companies under U.S. GAAP. Under the new model, recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in
exchange for those goods or services. In addition, the standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard is effective for
public entities for fiscal years beginning after December&nbsp;15, 2017 and is effective for nonpublic entities for fiscal years beginning after December&nbsp;15, 2018. The standard is required to be applied retrospectively to each prior reporting
period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. The Company adopted this standard on January&nbsp;1, 2019, and as the Company has not incurred revenues to date,
the adoption of the standard will not have a significant impact on its consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB
issued ASU <FONT STYLE="white-space:nowrap">2016-02&#151;</FONT><I>Leases</I>, requiring the recognition of lease assets and liabilities on the balance sheet. The standard: (a)&nbsp;clarifies the definition of a lease; (b)&nbsp;requires a dual
approach to lease classification similar to current lease classifications; and (c)&nbsp;causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for leases with a lease-term of more than twelve months. The standard is effective for public entities for fiscal years beginning after
December&nbsp;15, 2018 and for nonpublic entities for fiscal years beginning after December&nbsp;15, 2019. The Company is currently evaluating the impact of this standard and expects the adoption will result in an insignificant increase in the
assets and liabilities on its consolidated balance sheet for operating leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-07</FONT> <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>, which is intended to reduce the cost and complexity and to improve financial
reporting for nonemployee share based payment. The standard expands the scope of Topic 718, (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently,
the accounting for share-based payments to nonemployees and employees will be substantially aligned. The standard is effective for public entities for fiscal years beginning after December&nbsp;15, 2019 and nonpublic entities for fiscal years
beginning after December&nbsp;15, 2020. Early adoption is permitted but no earlier than a company&#146;s adoption date of Topic 606. The Company early adopted this standard on January&nbsp;1, 2019, and the impact of its adoption on the
Company&#146;s consolidated financial statements is not material. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s financial liabilities measured at fair value on a recurring basis by level within the fair value
hierarchy are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The changes in the fair value of the Company&#146;s Level&nbsp;3 financial liabilities, which are measured on
a recurring basis are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of convertible preferred share liability upon issuance of convertible preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of convertible preferred share liability recorded in other (income) expense,
net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial settlement of convertible preferred share liability upon second closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s convertible preferred share liability is based on significant inputs not
observed in the market, and thus represent a Level&nbsp;3 measurement. Refer to Note 7 for further discussion on the convertible preferred share liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Consolidated Balance Sheet Components </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property
and Equipment, Net </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer software and electronic equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Depreciation expense for property and equipment was $6,000 for the period from January&nbsp;18, 2018
(inception) to December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Commitments and Contingencies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lease </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2018, the Company
entered into an operating lease agreement for its facility in Israel. The lease term was for 12 months and was amended in April 2019 to extend the lease term to April 2020. Under the lease agreement, monthly lease payments are approximately $4,000.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under the Company&#146;s <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating lease
obligations as of December&nbsp;31, 2018, are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum annual payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Rent expense was $39,000 during the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018.
The Company has a security deposit balance of $23,000, which is included in other current assets in the consolidated balance sheet as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Transfer and License Agreement with Teva Pharmaceutical Industries Ltd </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2018, the Company concurrently entered into two Asset Transfer and License Agreements (the &#147;Teva Agreements&#148;) with Teva
Pharmaceutical Industries Ltd (&#147;Teva&#148;) under which it acquired certain patents and intellectual property relating to two programs: (1)&nbsp;Teva&#146;s glycoPEGylated FGF21 program, including the compound
<FONT STYLE="white-space:nowrap">TEV-47948</FONT> <FONT STYLE="white-space:nowrap">(BIO89-100),</FONT> a glycoPEGylated long-acting FGF21 and (2)&nbsp;Teva&#146;s development program of small molecule inhibitors of Fatty Acid Synthase. Pursuant to
the Teva Agreements, the Company paid Teva an initial nonrefundable upfront payment of $6.0&nbsp;million and the Company could be obligated to pay Teva up to $67.5&nbsp;million under each program, for a total of $135.0&nbsp;million, upon the
achievement of certain clinical development and commercial milestones. In addition, the Company is obligated to pay Teva tiered royalties at percentages in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digits on worldwide net sales on all products containing the Teva compounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Teva Agreements can be terminated (i)&nbsp;by the Company without cause, after the first anniversary of the effective date, upon 120
days&#146; written notice to Teva, (ii)&nbsp;by either party, if the other party materially breaches any of its obligations under the Agreements and fails to cure such breach within 60 days after receiving notice thereof, or (iii)&nbsp;by either
party, if a bankruptcy petition is filed against the other party and is not dismissed within 60 days. In addition, Teva can also terminate the agreement related to the Company&#146;s glycoPEGylated FGF21 program in the event the Company, or any of
its affiliates or sublicensees, challenges any of the Teva patents licensed to the Company, and the challenge is not withdrawn within 30 days of written notice from Teva. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company accounted for the acquisition of technology as an asset acquisition because it
did not meet the definition of a business. The Company recorded the total consideration transferred to Teva as research and development expense in the consolidated statement of operations and comprehensive loss because the acquired technology
represented <FONT STYLE="white-space:nowrap">in-process</FONT> research and development and had no alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Convertible Note
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2018, the Company entered into a Convertible Loan Agreement (the &#147;Convertible Note&#148;) with a principal amount of
$100,000 and a fixed interest rate of 8% per annum. The Convertible Note was automatically convertible into the Company&#146;s next equity financing, or upon an earlier event of default. In April 2018, the entire amount outstanding converted into
100,000 shares of Series A convertible preferred shares upon the closing of the Series A financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Convertible Preferred Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2018, the Company entered into the Series A Share Purchase Agreement (the &#147;SPA&#148;), pursuant to which the investors committed
to invest an aggregate amount of up to $60.0&nbsp;million for the issuance of Series A convertible preferred shares at a price of $1.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initial closing occurred on April&nbsp;16, 2018, and the Company issued 14,900,000 Series A convertible preferred shares at a price per
share of $1.00 for net cash proceeds of $14.7&nbsp;million. The investors also committed to purchase 15,000,000 and 30,000,000 shares of Series A convertible preferred shares at a price of $1.00 per share in second and third closings, respectively,
contingent upon the achievement by the Company of certain development milestones and approval by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
investors&#146; commitment to purchase and the Company&#146;s commitment to sell Series A convertible preferred shares represent a freestanding instrument accounted for at fair value and <FONT STYLE="white-space:nowrap">re-measured</FONT> at each
reporting date. The Company estimates the fair value of this commitment using the Black Scholes option pricing model. On the date of the initial closing, the Company recorded the commitments associated with the second and third closings of the
Series A convertible preferred shares at a net value of $638,000. For the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018, the Company recorded an expense of $979,000 for the revaluation of the convertible preferred share
liability, within other (income) expense, net in the consolidated statement of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2018, the
Series A convertible preferred shareholders partially accelerated the second closing and the Company issued 9,000,000 Series A convertible preferred shares at a price of $1.00 per share and received net proceeds of $9.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, 36,000,000 Series A convertible preferred shares were subject to issuance upon completion of remaining
milestones or as the preferred shareholders elected to waive such milestones. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, the Company and the Series A convertible
preferred shares investors agreed to issue the remaining 6,000,000 Series A convertible preferred shares at a price of $1.00 per share related to the second closing, and to partially accelerate 14,000,000 Series A convertible preferred shares at a
price of $1.00 per share related to the third closing. The shares were issued and the aggregate net proceeds of $20.0&nbsp;million were received in June and July 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Convertible preferred shares consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Convertible&nbsp;Preferred&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Shares<BR>Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,073,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,073,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of the Company&#146;s convertible preferred shares have various rights, preferences, and
privileges as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of each share of Series A convertible preferred share shall be entitled to receive, when and if declared by the board of
directors, a noncumulative dividend at the rate of $0.08 per share per annum on each outstanding convertible preferred share. Such dividends are payable in preference to the payment of any dividends on ordinary shares declared by the board of
directors. No dividends have been declared to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Automatic Conversion Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each share of Series A convertible preferred share is convertible, at the option of the holder at any time, into the number of ordinary shares
as is determined by dividing the original issue price for such series of preferred share by the conversion price for such series of preferred share that is in effect at the time of conversion. The initial conversion price for the series of preferred
share is the original issue price for such series of preferred share multiplied by 6.217. The original issue price was $1.00 per share for the Series A convertible preferred shares. The applicable conversion price of each is subject to adjustment
upon any future stock splits or combinations, recapitalizations, or upon the issuance of any new securities as a price per share lower than the applicable conversion price of the Series A convertible preferred shares in effect immediately prior to
such issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each share of Series A convertible preferred share will automatically be converted into ordinary shares upon the earlier
of: (i)&nbsp;the closing of an underwritten public offering of ordinary shares of the Company at a price per share not less than $5.00 with aggregate gross proceeds to the Company of at least $50.0&nbsp;million (a &#147;qualified public
offering&#148;); or (ii)&nbsp;the written consent of the holders of at least 50% of the Series A convertible preferred shares, including OrbiMed Israel Partners II, L.P., or OrbiMed Private Investments VI, L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mandatory Conversion </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the
event a holder of Series A convertible preferred shares does not fund its full pro rata portion of the applicable milestone closing, then unless otherwise waived in writing by the requisite preferred, such holder&#146;s Series A convertible
preferred shares and/or ordinary shares issued upon conversion of Series A convertible preferred shares will be converted to ordinary shares, at a conversion ratio of 10 Series A convertible preferred shares to 1 ordinary share. Such holder will
lose any rights as a holder of Series A convertible preferred shares, including the right to invest in any subsequent equity or debt financing, the right to received Series A convertible preferred share preference, and the right, if any, to
designate a board seat. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each holder of the Series A convertible preferred share is entitled to one vote for each ordinary share into which such Series A convertible
preferred share could be converted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or deemed liquidation event (a
consolidation, merger or reorganization or a sale of all or substantially all of the Company&#146;s assets, or substantially all of the Company&#146;s issued and outstanding share capital of the Company), the holders of the series A convertible
preferred shares will be entitled to receive on a pro rata basis, prior and in preference to the holders of ordinary shares, an amount equal to the original issuance price (as adjusted for any share split, share combination, share dividend,
recapitalization or like events), less the amount of any distributions received in any prior liquidation event, and all declared by unpaid dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s
articles of association do not provide redemption rights to the holders of the Series A convertible preferred shares. In the event of a liquidation event, all the funds and assets of the Company available for distribution among all the shareholders
shall be distributed in the following order of preference: (a) the holders of the Series A convertible preferred shares shall be entitled to receive an amount per share equal to $1.00 per each Series A convertible preferred share (less the amount of
distributions actually received in any prior liquidation event, plus all declared but unpaid dividends) and (b) the remaining assets of the Company available for distribution to shareholders shall be distributed among the holders of ordinary shares
and to the holders of the Series A convertible preferred shares on an as-converted and pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although the convertible preferred
shares are not redeemable, in the event of certain &#147;deemed liquidation events&#148; that are not solely within the Company&#146;s control (including merger, acquisition, or sale of all or substantially all of the Company&#146;s assets), the
holders of the convertible preferred shares would be entitled to preference amounts paid before distribution to other shareholders (as explained in the previous paragraph) and hence effectively redeeming the preference amount. The convertible
preferred shares are classified outside of shareholders&#146; deficit as a result of these in-substance contingent redemption rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As
of December 31, 2018, the Company did not adjust the carrying values of the convertible preferred shares to the deemed liquidation values of such shares since a liquidation event was not probable of occurring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Ordinary Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the
Company&#146;s amended articles of association filed on May&nbsp;30, 2018, the Company is authorized to issue a total of 10,415,900 ordinary shares, of which 611,226 ordinary shares were issued and outstanding as of December&nbsp;31, 2018. The
proceeds from the issuance of the Company&#146;s ordinary shares were received in April 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The holders of ordinary shares are entitled
to one vote per ordinary share on all matters to be voted on by the shareholders of the Company and are entitled to dividends, if and when declared by the board of directors, subject to the prior rights of the preferred shareholders. No dividends
have been declared as of December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Total ordinary shares reserved for issuance are summarized as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred shares outstanding, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares available for future option grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ordinary shares reserved for issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,924,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Share-Based Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In November 2018, the board of directors of the Company (the &#147;Board&#148;) authorized the 2018 Equity Incentive Share Option Plan (the
&#147;2018 Plan&#148;). The 2018 Plan provides for the grant of 1,064,162&nbsp;share-based awards, including incentive stock options to employees, directors, and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers of the Company.
The aggregate number of ordinary shares reserved and available for grant under the 2018 Plan was 472,714 as of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board determines the period over which options become exercisable and options generally vest over a four-year period, with 25% of options
vesting on the first anniversary of employment, and thereafter, the remaining options vesting quarterly, over the following <FONT STYLE="white-space:nowrap">36-month</FONT> period. The options will expire within ten years from the date of grant. The
exercise price of awards granted will not be less than the estimated fair value of the shares on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recorded
share-based compensation for the period indicated as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,<BR>2018&nbsp;(inception)<BR>to&nbsp;December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of option awards granted was estimated at the date of grant using a Black-Scholes
option-pricing model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,&nbsp;2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity under the 2018 Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(In<BR>Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of January&nbsp;18, 2018 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Options granted for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018 were subject
to cliff vesting as of December&nbsp;31, 2018, and accordingly, there were no vested options during the period. The weighted-average grant date fair value of options granted for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31,
2018 was $1.31&nbsp;per share. As of December&nbsp;31, 2018, there was $668,000 of unrecognized share-based compensation cost related to stock options granted under the 2018 Plan, which is expected to be recognized over a weighted-average period of
3.5 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Included in the option activity table were 13,001 stock options granted to
<FONT STYLE="white-space:nowrap">non-employee</FONT> service providers during the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018. These options were granted in exchange for consulting services to be rendered and vest over
the term specified in the grant. The Company recorded <FONT STYLE="white-space:nowrap">non-employee</FONT> share-based compensation of $2,000 during the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Income Taxes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Rates Applicable to the
Income of the Company and its Subsidiaries </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is taxed according to Israeli tax laws. The tax rates applicable to the
income of the Company and its subsidiaries are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="28%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,&nbsp;2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">89Bio Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">89bio Management, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UAB 89bio Lithuania</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expense for income taxes is comprised of (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,&nbsp;2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Income Taxes </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for
financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#146;s deferred tax assets are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company has provided a valuation allowance of $3.5&nbsp;million in respect
of deferred tax assets resulting from tax loss carryforwards and other temporary differences. Realization of deferred tax assets is dependent upon future earnings, if any, the time and amount of which are uncertain. As the Company is still in its
development stage and has not yet generated revenues, it is more likely than not that sufficient taxable income will not be available for the tax losses to be utilized in the future. Therefore, a valuation allowance was recorded to reduce the
deferred tax assets to their recoverable amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Available Carryforward Tax Losses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company has an accumulated tax loss carryforward of approximately $6.7&nbsp;million. Carryforward tax losses
in Israel have no expiration date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Loss from Continuing Operations, Before Taxes on Income </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recorded loss from continuing operations, before taxes on income for the period indicated as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18, 2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lithuania</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Israel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The reconciliation of income tax expense based on the statutory tax rate to the effective tax rate is as
follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18, 2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense computed at statutory rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Net Loss and Unaudited Pro Forma Net Loss Per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive ordinary share equivalents have been excluded from the calculation of diluted net loss per
share for the period presented due to their anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,
2018<BR>(inception)&nbsp;to<BR>December&nbsp;31,<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,451,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pro forma basic and diluted net loss per share has been computed to give effect to the assumed conversion of all outstanding convertible
preferred shares into ordinary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of the unaudited pro forma net loss per share
for the period presented (in thousands except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Period&nbsp;from<BR>January&nbsp;18,&nbsp;2018<BR>(inception)<BR>to&nbsp;December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect assumed conversion of convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,683,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute pro forma loss per share, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,127,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company incurred $147,000 in professional services expense related to certain members of the board of directors for the period from
January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018. The related party liability balance was $23,000 as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.
Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January and July 2019, the board of directors granted 143,121 and 511,024 stock options, respectively, to its
employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers. 25% of the options will vest on the first anniversary of employment or the first anniversary of the day of grant, and the remaining options will thereafter vest
quarterly over the following <FONT STYLE="white-space:nowrap">36-month</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, the Company agreed to issue
20,000,000 Series A convertible preferred shares at $1.00 per share. The shares were issued and the aggregate net proceeds of $20.0 million were received in June and July 2019 (see Note&nbsp;7). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, the Company formed 89bio, Inc. for the purpose of an internal reorganization transaction. In September 2019, all of the equity
holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. Following this exchange, 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. (as mentioned in Note 1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October 24, 2019, 89bio, Inc.&#146;s board of directors approved the Reverse Split, which was effected on October 25, 2019 (see Note 2).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with ASC 855 &#147;<I>Subsequent Events</I>&#148; the Company evaluated subsequent events through August&nbsp;15, 2019, the
date these consolidated financial statements were available to be issued and October 28, 2019, the date these consolidated financial statements were reissued. The Company concluded that no other subsequent events have occurred that would require
recognition or disclosure in the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_10"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;31,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma<BR>June&nbsp;30,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 11,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 11,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; (deficit) equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares, NIS 0.01 nominal value; 60,000,000 shares authorized as of
December&nbsp;31, 2018 and June&nbsp;30, 2019 (unaudited); 24,000,000 and 42,826,389 shares issued and outstanding as of December&nbsp;31, 2018 and June&nbsp;30, 2019 (unaudited), actual; aggregate liquidation preference of $24,000 and $42,826 as of
December&nbsp;31, 2018 and June&nbsp;30, 2019 (unaudited), actual; no shares issued and outstanding as of June&nbsp;30, 2019 pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, NIS 0.01 nominal value, 10,415,900 shares authorized at December&nbsp;31, 2018
and June&nbsp;30, 2019 (unaudited); 611,226&nbsp;shares issued and outstanding as of December&nbsp;31, 2018 and June&nbsp;30, 2019 (unaudited), actual; 7,499,818 issued and outstanding as of June&nbsp;30, 2019 pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred shares and shareholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 11,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_11"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period&nbsp;from<BR>January&nbsp;18,<BR>2018&nbsp;(inception)<BR>to&nbsp;June&nbsp;
30,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six
Months<BR>Ended&nbsp;June&nbsp;30,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_12"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Convertible Preferred Shares and Shareholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Convertible&nbsp;Preferred<BR>Shares</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Ordinary Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Additional<BR><FONT
STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Accumulated<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>Shareholders&#146;<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amounts</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amounts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;18, 2018 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred shares, net of issuance costs of $228 and the recognition of the
convertible preferred share liability of $638</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,034</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible note into preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,134</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Convertible
Preferred<BR>Shares</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Ordinary Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Additional<BR><FONT
STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Accumulated<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>Shareholders&#146;<BR>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amounts</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amounts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,073</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,057</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred shares, net of issuance costs of $0 and the partial settlement
of the convertible preferred share liability of $6,269</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,826,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,095</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,826,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,168</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,358</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_13"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period
from<BR>January&nbsp;18,<BR>2018<BR>(inception)&nbsp;to<BR>June&nbsp;30,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months<BR>Ended<BR>June&nbsp;30,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred shares and convertible preferred share liability,
net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible note</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Components of cash and cash equivalents, and restricted cash:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash and cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosures of noncash investing and financing information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible note into preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin743471_14"></A>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Description of Business </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">89Bio
Ltd. (&#147;89Bio&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The Company&#146;s
lead product candidate, <FONT STYLE="white-space:nowrap">BIO89-100,</FONT> a specifically engineered glycoPEGylated analog of fibroblast growth factor 21, is currently being developed for the treatment of nonalcoholic steatohepatitis. 89Bio Ltd. was
incorporated in Israel in January 2018. The Company has two wholly owned subsidiaries: 89bio Management, Inc., located in San Francisco, California and UAB 89bio Lithuania, located in Vilnius, Lithuania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying
condensed consolidated financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. To date, the Company has
not generated revenues from its activities and has incurred substantial operating losses. Management expects the Company to continue to generate substantial operating losses for the foreseeable future until it completes development of its products
and seeks regulatory approvals to market such products. Management will continue to fund its operations primarily through utilization of its current financial resources and through additional raises of capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Such conditions raise substantial doubts about the Company&#146;s ability to continue as a going concern for at least a year after the filing
date of the accompanying condensed consolidated financial statements. Management plans to address these conditions by raising funds from its current investors as well as outside potential investors. However, there is no assurance that such funding
will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The accompanying condensed consolidated financial statements do not include any
adjustments relating to the recoverability and classification of assets, carrying amounts or the amount or classification of liabilities that may be required should the Company be unable to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September
2019, the Company completed an internal reorganization transaction pursuant to which 89Bio Ltd. became a wholly owned subsidiary of 89bio, Inc. (see Note 12). On October 24, 2019, 89bio, Inc.&#146;s board of directors approved an amendment to the
amended and restated certificate of incorporation of 89bio, Inc. to effect a 1-for-6.217 reverse split (&#147;Reverse Split&#148;) of shares of the common stock of 89bio, Inc. and a proportional adjustment to the conversion ratio of the convertible
preferred stock, which was effected on October&nbsp;25, 2019. The par value and authorized shares of common stock and the par value, authorized and outstanding shares of convertible preferred stock were not adjusted as a result of the Reverse Split.
All of the share and per share information for 89Bio Ltd. included in the accompanying unaudited interim condensed consolidated financial statements has been adjusted to reflect the Reverse Split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Condensed Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited financial statements as
of December&nbsp;31, 2018 and for the period from January&nbsp;18, 2018 (inception) to December&nbsp;31, 2018 and, in the opinion of management, reflect all adjustments, which include only </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
normal recurring adjustments, necessary to present fairly the Company&#146;s financial position as of June&nbsp;30, 2019, and its results of operations and comprehensive loss, cash flows and
shareholders&#146; deficit for the period from January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018 and the six months ended June&nbsp;30, 2019. The financial data and the other financial information contained in these notes to the condensed
consolidated financial statements related to the period from January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018 and the six months ended June&nbsp;30, 2019 are unaudited. The results of operations for the six months ended June&nbsp;30, 2019 are
not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2019 or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the
Company&#146;s audited consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Financial Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company completed an internal reorganization transaction in September 2019, pursuant to which 89Bio Ltd. became a wholly owned subsidiary
of 89bio, Inc., a newly formed Delaware corporation. As part of the transaction, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheet information as of June&nbsp;30, 2019 has been prepared to give effect to the exchange of all outstanding
convertible preferred shares of 89Bio Ltd. into shares of common stock of 89bio, Inc. as if the exchange had occurred on June&nbsp;30, 2019. The shares of common stock issuable and the proceeds expected to be received in the Company&#146;s
anticipated IPO are excluded from such pro forma financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma net loss per share, basic and diluted for
the six months ended June&nbsp;30, 2019 was computed using the weighted-average number of shares of ordinary shares outstanding, including to give effect to the exchange of all outstanding shares of convertible preferred shares of 89Bio Ltd. into
equivalent shares of common stock of 89bio, Inc. as if such exchange had occurred at the beginning of the period, or their issuance dates if later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation
of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of
the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are
not limited to the fair value of stock options, the convertible preferred share liability and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those
estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities are recorded at fair value on a recurring basis in the balance sheets. The carrying values of
Company&#146;s financial assets and liabilities, including cash and cash equivalents, restricted cash, other current assets, accounts payable, and accrued expenses approximate to their fair value due to the short-term maturity of these instruments.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. Assets and liabilities recorded at fair value are
categorized based upon the level of judgment associated with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity with the inputs to the valuation of these assets or liabilities as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level 1</B>&#151;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the
measurement date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level 2</B>&#151;Inputs (other than quoted prices included in Level&nbsp;1) are either directly or indirectly
observable inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets and quoted prices for identical or similar assets of liabilities in markets that are not active; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Level 3</B>&#151;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the
assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Share Liability </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The freestanding instruments related to the commitment by the Series A convertible preferred shareholders to purchase and by the Company to
sell its Series A convertible preferred shares in subsequent closings, contingent upon the achievement of certain developmental milestones and approval by the board of directors, at a fixed price per share, are considered a liability (or an asset),
measured at fair value as the shares underlying the rights contain liquidation preferences upon certain &#147;deemed liquidation events&#148; that are not solely within the Company&#146;s control and which are considered <FONT
STYLE="white-space:nowrap">in-substance</FONT> contingent redemption features (refer to Note 7 for further discussion on the redemption rights of the convertible preferred shares). The instruments are subject to revaluation at each balance sheet
date until settlement, with revaluations recognized as a component of other (income) expenses, net in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company has deferred offering costs consisting of legal, accounting and other fees and costs directly attributable to the Company&#146;s anticipated IPO. The deferred offering costs will be offset against the proceeds received upon the completion of
the anticipated IPO. In the event the anticipated IPO is terminated, all of the deferred offering costs will be expensed. As of December&nbsp;31, 2018, the Company did not record any deferred offering costs. As of June&nbsp;30, 2019, the Company had
$204,000 of deferred offering costs on the consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (the &#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;)
2014-09&#151;<I>Revenue from contracts</I><I> </I><I>with customers</I>, to achieve a consistent application of revenue recognition, resulting in a single revenue model to be applied by reporting companies under U.S. GAAP. Under the new model,
recognition of revenue occurs when a customer obtains control of the promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the
standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard is effective for public entities for fiscal years beginning after December
15, 2017 and is effective for nonpublic entities for fiscal years beginning after December 15, 2018. The standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of
initially applying it recognized at the date of initial application. The Company adopted this standard on January 1, 2019, and as the Company has not incurred revenues to date, the adoption of the standard did not have a significant impact on its
consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU 2016-02&#151;<I>Leases</I>, requiring the recognition
of lease assets and liabilities on the balance sheet. The standard: (a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c) causes lessees to recognize leases on
the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease-term of more than twelve months. The standard is effective for public entities for fiscal years beginning after December 15, 2018 and for
nonpublic entities for fiscal years beginning after December 15, 2019. The Company is currently evaluating the impact of this standard and expects the adoption will result in an insignificant increase in the assets and liabilities on its
consolidated balance sheet for operating leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued ASU No. 2018-07 <I>Compensation&#151;Stock</I><I>
</I><I>Compensation (Topic 718): Improvements</I><I> </I><I>to Nonemployee Share-Based</I><I> </I><I>Payment Accounting</I>, which is intended to reduce the cost and complexity and to improve financial reporting for nonemployee share based payment.
The standard expands the scope of Topic 718, (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to
nonemployees and employees will be substantially aligned. The standard is effective for public entities for fiscal years beginning after December 15, 2019 and nonpublic entities for fiscal years beginning after December&nbsp;15, 2020. Early adoption
is permitted but no earlier than a company&#146;s adoption date of Topic 606. The Company early adopted this standard on January 1, 2019, and the impact of its adoption on the Company&#146;s consolidated financial statements is not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair
value of the Company&#146;s financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;1</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;2</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Level&nbsp;3</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="16"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred share liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The changes in the fair value of the Company&#146;s Level&nbsp;3 financial liabilities, which
are measured on a recurring basis are as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>June&nbsp;30,<BR>2019</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognition of convertible preferred share liability upon issuance of convertible preferred
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revaluation of convertible preferred share liability recorded in other (income) expense,
net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial settlement of convertible preferred share liability upon second closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,860</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Partial settlement of convertible preferred share liability upon third closing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of the Company&#146;s convertible preferred share liability is based on significant inputs not
observed in the market, and thus represent a Level&nbsp;3 measurement. Refer to Note 7 for further discussion on the convertible preferred share liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Consolidated Balance Sheet Components </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued
Expenses </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>June&nbsp;30,<BR>2019</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee and related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Commitments and Contingencies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Asset Transfer and License Agreement with Teva Pharmaceutical Industries Ltd </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2018, the Company concurrently entered into two Asset Transfer and License Agreements (the &#147;Teva Agreements&#148;) with Teva
Pharmaceutical Industries Ltd (&#147;Teva&#148;) under which it acquired certain patents and intellectual property relating to two programs: (1)&nbsp;Teva&#146;s glycoPEGylated FGF21 program, including the compound
<FONT STYLE="white-space:nowrap">TEV-47948</FONT> <FONT STYLE="white-space:nowrap">(BIO89-100),</FONT> a glycoPEGylated long-acting FGF21 and (2)&nbsp;Teva&#146;s development program of small molecule inhibitors of Fatty Acid Synthase. Pursuant to
the Teva Agreements, the Company paid Teva an initial nonrefundable upfront payment of $6.0&nbsp;million and the Company could be obligated to pay Teva up to $67.5&nbsp;million under each program, for a total of $135.0&nbsp;million, upon the
achievement of certain clinical development and commercial milestones. In addition, the Company is obligated to pay Teva tiered royalties at percentages in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digits on worldwide net sales on all products containing the Teva compounds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Teva Agreements can be terminated (i)&nbsp;by the Company without cause, after the first anniversary of the effective date, upon 120
days&#146; written notice to Teva, (ii)&nbsp;by either party, if the other party materially breaches any of its obligations under the Agreements and fails to cure such breach within 60 days after receiving
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notice thereof, or (iii)&nbsp;by either party, if a bankruptcy petition is filed against the other party and is not dismissed within 60 days. In addition, Teva can also terminate the agreement
related to the Company&#146;s glycoPEGylated FGF21 program in the event the Company, or any of its affiliates or sublicensees, challenges any of the Teva patents licensed to the Company, and the challenge is not withdrawn within 30 days of written
notice from Teva. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company accounted for the acquisition of technology as an asset acquisition because it did not meet the definition
of a business. The Company recorded the total consideration transferred to Teva as research and development expense in the condensed consolidated statements of operations and comprehensive loss because the acquired technology represented <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development and had no alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Convertible Note </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In March 2018, the Company entered into a Convertible Loan Agreement (the &#147;Convertible Note&#148;) with a principal amount of $100,000
and a fixed interest rate of 8% per annum. The Convertible Note was automatically convertible into the Company&#146;s next equity financing, or upon an earlier event of default. In April 2018, the entire amount outstanding converted into 100,000
shares of Series A convertible preferred shares upon the closing of the Series A financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Convertible Preferred Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In April 2018, the Company entered into the Series A Share Purchase Agreement (the &#147;SPA&#148;), pursuant to which the investors committed
to invest an aggregate amount of up to $60.0&nbsp;million for the issuance of Series A convertible preferred shares at a price of $1.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The initial closing occurred on April&nbsp;16, 2018, and the Company issued 14,900,000 Series A convertible preferred shares at a price per
share of $1.00 for net cash proceeds of $14.7&nbsp;million. The investors also committed to purchase 15,000,000 and 30,000,000 shares of Series A convertible preferred shares at a price of $1.00 per share in second and third closings, respectively,
contingent upon the achievement by the Company of certain development milestones and approval by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
investors&#146; commitment to purchase and the Company&#146;s commitment to sell Series A convertible preferred shares represent a freestanding instrument accounted for at fair value and <FONT STYLE="white-space:nowrap">re-measured</FONT> at each
reporting date. The Company estimates the fair value of this commitment using the Black Scholes option pricing model. On the date of the initial closing, the Company recorded the commitments associated with the second and third closings of the
Series A convertible preferred shares at a net value of $638,000. For the period from January 18, 2018 (inception) to June&nbsp;30, 2018 and for the six months ended June&nbsp;30, 2019, the Company recorded an expense of $357,000 and
$10.5&nbsp;million, respectively, for the revaluation of the convertible preferred share liability, within other (income) expense, net in the condensed consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In December 2018, the Series A convertible preferred shareholders partially accelerated the second closing and the Company issued 9,000,000
Series A convertible preferred shares at a price of $1.00 per share and received net proceeds of $9.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2019, the
Company and the Series A convertible preferred shares investors agreed to issue the remaining 6,000,000 Series A convertible preferred shares at a price of $1.00 per share related to the second closing, and to partially accelerate 14,000,000 Series
A convertible preferred shares at a price of $1.00 per share related to the third closing. The shares were issued and the aggregate net proceeds of $20.0 million were received in June and July 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Immediately subsequent to the issuance of shares as agreed by the Company and the investors
in June 2019, 16,000,000 Series A convertible preferred shares were subject to issuance upon completion of remaining milestones or as the preferred shareholders elect to waive such milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Shares </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Convertible preferred shares consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Convertible Preferred Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares<BR>Authorized</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares<BR>Issued
and<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Carrying<BR>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Liquidation<BR>Preference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,073,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,073,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>June&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Convertible Preferred Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares<BR>Authorized</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares<BR>Issued
and<BR>Outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Carrying<BR>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Liquidation<BR>Preference</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,826,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,168,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,826,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,826,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,168,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,826,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s articles of association do not provide redemption rights to the holders of the Series A
convertible preferred shares. In the event of a liquidation event, all the funds and assets of the Company available for distribution among all the shareholders shall be distributed in the following order of preference: (a)&nbsp;the holders of the
Series A convertible preferred shares shall be entitled to receive an amount per share equal to $1.00 per each Series A convertible preferred share (less the amount of distributions actually received in any prior liquidation event, plus all declared
but unpaid dividends) and (b) the remaining assets of the Company available for distribution to shareholders shall be distributed among the holders of ordinary shares and to the holders of the Series A convertible preferred shares on an as-converted
and pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although the convertible preferred shares are not redeemable, in the event of certain &#147;deemed liquidation
events&#148; that are not solely within the Company&#146;s control (including merger, acquisition, or sale of all or substantially all of the Company&#146;s assets), the holders of the convertible preferred shares would be entitled to preference
amounts paid before distribution to other shareholders and hence effectively redeeming the preference amount. The convertible preferred shares are classified outside of shareholders&#146; deficit as a result of these
<FONT STYLE="white-space:nowrap">in-substance</FONT> contingent redemption rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December 31, 2018, and June&nbsp;30, 2019, the
Company did not adjust the carrying values of the convertible preferred shares to the deemed liquidation values of such shares since a liquidation event was not probable of occurring. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Ordinary Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Total ordinary shares reserved for issuance are summarized as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>June&nbsp;30,<BR>2019</B></P></TD>

<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A convertible preferred shares outstanding, as converted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,888,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares available for future option grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">472,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">343,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total ordinary shares reserved for issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,924,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,952,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Share-Based Compensation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2019, there were 343,083 ordinary shares reserved and available for grant under the 2018 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recorded share-based compensation for the periods indicated as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period&nbsp;from<BR>January&nbsp;18,<BR>2018&nbsp;(inception)<BR>to&nbsp;June&nbsp;
30,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;months<BR>ended<BR>June&nbsp;30,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair value of option awards granted for the periods indicated was estimated at the date of grant using a
Black-Scholes option-pricing model with the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period&nbsp;from<BR>January&nbsp;18,&nbsp;2018<BR>(inception)&nbsp;to<BR>June&nbsp;
30,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;months<BR>ended<BR>June&nbsp;30,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">2.54-2.60</FONT></TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity under the 2018 Plan for the six months
ended June&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number<BR>of<BR>Options</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Aggregate<BR>Intrinsic<BR>Value</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">591,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance outstanding as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Net Loss and Unaudited Pro Forma Net Loss Per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive ordinary share equivalents have been excluded from the calculation of diluted net loss per
share for the periods presented due to their anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Period
from<BR>January&nbsp;18,&nbsp;2018<BR>(inception)&nbsp;to<BR>June&nbsp;30,<BR>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months<BR>Ended<BR>June&nbsp;30,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,412,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,888,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">721,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,412,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,609,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pro forma basic and diluted net loss per share has been computed to give effect to the completion of an internal reorganization transaction
and assumes the exchange of all outstanding shares of convertible preferred shares of 89Bio Ltd. into shares of common stock of 89bio, Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Six&nbsp;Months<BR>Ended<BR>June&nbsp;30,<BR>2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect assumed conversion of convertible preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,972,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute pro forma loss per share, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583,692</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>89Bio Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Related Party Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company incurred $128,000 and $80,000 in professional services expense related to certain members of the board of directors for the period
from January&nbsp;18, 2018 (inception) to June&nbsp;30, 2018 and for the six months ended June&nbsp;30, 2019, respectively. The related party liability balance was $23,000 and $4,000 as of December&nbsp;31, 2018 and June&nbsp;30, 2019, respectively.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent Events </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July
2019, the board of directors granted 511,024 stock options, to its employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers. 25% of the options will vest on the first anniversary of employment or the first anniversary of
the day of grant, and the remaining options will thereafter vest quarterly over the following <FONT STYLE="white-space:nowrap">36-month</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company issued 1,173,611 Series A convertible preferred shares at $1.00 per share and aggregate net proceeds of
$1.2&nbsp;million were also received in July 2019, related to the shares the Company agreed to issue to investors in June 2019 (see Note&nbsp;7). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2019, the Company completed an internal reorganization transaction pursuant to which 89Bio Ltd. became a wholly owned subsidiary
of 89bio, Inc., a newly formed Delaware corporation. As part of the transaction, all of the equity holders of 89Bio Ltd. exchanged 100% of the equity of 89Bio Ltd. for 100% of the equity of 89bio, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October 24, 2019, 89bio, Inc.&#146;s board of directors approved the Reverse Split, which was effected on October 25, 2019 (see Note 2).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In accordance with ASC 855 &#147;<I>Subsequent Events</I>&#148; the Company evaluated subsequent events through September 19, 2019, the
date the unaudited interim condensed consolidated financial statements were available to be filed and October 28, 2019, the date the unaudited interim condensed consolidated financial statements were reissued. The Company concluded that no other
subsequent events have occurred that would require recognition or disclosure in the accompanying financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Through and including
December&nbsp;6, 2019, (the 25th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in
addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </P>
<P STYLE="margin-top:46pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>5,304,687&nbsp;Shares </B></P> <P STYLE="font-size:46pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g743471g36i06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:46pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:46pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:46pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">P R O S P E C T U S </P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:46pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>BofA Securities
</B></P> <P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SVB Leerink </B></P>
<P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>RBC Capital Markets </B></P>
<P STYLE="margin-top:23pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co. </B></P>
<P STYLE="margin-top:46pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;11, 2019 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g743471g04x51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g04x51.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!) )= P$1  (1 0,1 ?_$ !X
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M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*4YO\
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MI<5W56'L$L1SZ>796#?1)4-[?1++OVV/>0L4O78@&RR,NN17?)2/I ,5]_<
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ML8WOV[SWHE&ZQ38'H7-K5"W6E6<),A!6.OFM'QIX^U*;<2EUO?M,%"OH=$/
M*0P=&G,$ 'C#&#OL-^=RL7)PLBW%RZ;,?(I;A;3:I1T/OW!]P00RL-JZD,I*
MD$^1S<',Z;E786?C78F7CN4NHO0I8C>XV#[JRD,CJ2EB%71F1@3OSI1 !D.&
ML4I[<R:^ R0Q\+[@5]B.-D_4OWQ3)&FW1P"4MJ%8*W[U*4NI:2M*]Z_U_=__
M ,FK-IB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E*<W_ +S/(?\
MQ[3?]'N>9?;^]8W\D_\ ?W2I/IW?QU_NDEUY1+9C&FAQH9<C(EC 1X SYIQQ
MK[0H808K2WRBRRGUML###,-K>??>6AIEI"W'%I0G>]3KK>UTJJ1[++'6NNNM
M2[V.Y"HB(H+,[,0JJH)8D  DR+NE2/;:ZUUUJSV6.P1$1 6=W=B%554%F9B
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M*!@C2Z\C\W"\Y1Q2=GXG_E?+3?"\0:SUQ1X!^&/33G]8_.!N#CQ-\#_Z-4<
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MR;KG5G(>*<NX/5$TSE-/C:G"K+?DY-8^R3INR3A>_:/L=NLLH^;8;=9I)?\
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M::^KZW27W%^FM;TG7-S\V[J.7=F7\?,N8:1!QKJK4!*J*D'9*::E2JI1]%$
M[G9/9Z1TK%Z+T[%Z;B!C3C(0;+&YW9%UC-;D9>19[V9.5>]F1D6'Z=MCMH @
M"09ISI1B(Q$8B>;WE-)*YEYC>#W5];]W&VJTVC@UH>U]C2HZ_1)8%6$=<_1Z
M/]$F:F\TVK2M.*$6C7LK4VK7NO"E0ZAT3QMTD]W_ #"O6\4?5D]"S<;,O8#Y
MD=(/503[@-OVW/#^*;?S?UOP7U7>D_/C=%RC_P#=NMX65B4J3\N75OS6=>QX
MZ]^,](<\+/<1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$Y_P";0P/YY/(*?6EQZ49L
M5/@&B7]M+4U'+YW4I]QIA264.-I=(DVAW$^VI+@T5&)7ZN#[<7V<SJ5EW2NE
M]-6FBBC&\^]VI0H^7?9;96MV4>1%EE5:FNIM JKN!Z2 /-]/Z!3B=?ZUUY\O
M-S,OJ*8N-57EV);3TS$I0.^+TU0BMCT9-S+?D)R(LMKJ=MLI8] 9QIZ2,1&(
MC$1B)YV_E.:E*SWC6]9*VCUMO-[? 7VJ+TE2E;L]>V3)U$=*D_:;V3=PZJE+
MB=Z]AU#6][UKUWKVWY/,VG#\7=(^*.L+-N;I6=WT/@.KUOTO-+;[<5Q,NYCO
MY#ZYXO\ *%AW9GA'JYQAO,PJ4ZK@Z!Y'.Z1:G4\)5UW#-E8E*C1'<ZWWG=5(
MML5?J74;U!.>^@[I5X"VPSOM)5[V*L<4),1SGM)^RKVQ#&5>TG[._7UU]6>4
MZAA7=-S\WIV2..1@9>3A7K[:NQ;GHM&CW&GK8=YZG S*>HX&%U#'/+'S\3&S
M*&_A4Y5*7U']J.IDHS4FW&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E*<W_O,\A_\>TW
M_1[GF7V_O6-_)/\ W]TJ3Z=W\=?[I)=>42V,1&(C$1B)3GD%%+E^+]$:9804
M3&UY^RAC.(TX@@ZH/L6H%C:-ZWI?OBX9EO2=ZWK>U:UO6]?5E^,YKOJ96*D.
M &!T5Y>GD#\B-[!E&2@LHM1E# H258 JP7U<2#V(.M$'L=RB_P G[*H_HW0_
M/MON$$<,N?0^&Z6XO;BE5_G=NDX_G;^E*WM>VY#EK]&E&/;]%>X.;_2GV5;]
MG^45!;XELZNBA:O$G3NE>)%T- W]6P*;^HC0[;KZL,^IM;'*LSQOY.W-?AJO
MI+L6M\-]1ZKX<;9V?)Z3GW4=..SWU9THX%J[T>-@[:U.U\\+/<QB(Q$>OZ/^
M/U:_X_[_ *O_ ':WO_W8B5!TCR"X5QY"E=4[%S/GKFDZV@2WW:NP4B1M7]AL
M.+D)!B1.?<]=>Z'#%??=WO6FVU;SM]+\-^(>MG_T/T3JO4Q\WPL#*R*EU[FR
MZNIJJU'S9W51\R)Q>J>(_#_1!OJ_6^E=-/R3-S\;'M;ZA7398MMC'Y*B,Q^0
M,I7^FS0[#]CD'+/(KNRE?99.Y]Q>T0=4?=5_82QT+K:>9<]*;5]E2B ;26PA
MM6E[7O\ LYWOW!=1QN_6^L>&/#NN[5]3Z[B9&8JCW+=,Z+^=NIH?D$LQ$8GM
MK7><']WG3LGMT7I'B;Q"3V6SIO0\NC#8GVX]2ZP.E=-=>X/*O+<:[]Y$U]A\
M])V]"1=<\4.34NHGU20DQG.P>0K8MC;EXZ6C17FS]<FI74XP9.PI45348'J3
M8=<220NT#J::CB=K\S_DXQL(G*\9=:S\\9*J5Z)X99L4XQJ))K/6<_I%K$6C
MO;8:6T548C;:U-?\[_E$R<P#%\']'P<%L9F#=:\2JN4N0+% 6P='P>K5J#6W
M:JL7*2K,<M-+6\P^-_* E?\ FWX=07K^G_IMVNV>Q]__ )@4OWOI_P"IGU_Y
M?T9J>7^39/\ I7CC(_[OZ#A[_9^<L[7\[?\ ':\S\H[_ /1?!./_ /']=S-#
M_P#9N#O^S^SNW#_E "_JWT/P^@=;_3MOCO9[2M&O^53G<:BA>]?>II.M_=K'
MG_DW3VZ9XWR#\M];Z%A@_B!X?S2/V$QY'Y1G]^I^"L<'^#T3KF60/N)Z_A@G
M\5 D'JU _*$A3M_+*\K/'VU,N60-N+K]C\5K$)"5P7Z-PI[@-?)J_?X*>0"Z
M_)+]XFSREOD=O,?$M2H[1.X]C;R.K?DTOJPZD\&^)<)J*62[*Q?&&*^1F.;'
M(MR4R_#>1C^8J\5'PE6%5HE32Q46-JX_2ORD479=K^,/#F8M]RO3BY/A')2C
M$05J&JQWQ/$>/D>6S;)^*MS+-CDMJAC6LX^"_* B_P#G)X=3WI^G_H3VNI^W
MO]X%T]WZ_=_6^GW[S4\S\FS_ /1/'&-_WAT'-U]?_5F!O_R_\-KR_P HZ?\
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M3M2EW)=L27CCPNE]!G2T0T:*=8;+8(F)+#04&%1X8*0/%)ZM7CRKPYB9O2_
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MI[%KMQ^EYG4#6Y*JI.6^$"&W6++.-3^<O_*OUSIJ64]9\"MTWJ:,BIB97B3
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MK54@)5E# G9# -O8W)#FG.G&(G//0>!<@MW:N)=PGZ/&&=6YQ+6&+J-T:>D
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M@5:;&M,P*.G2X6: 7KW(S#++>];]4MM-IUOT0GTRV1<3W??8?256_5'U@_\
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M?[A+G_,9CEC?97_UBO\ RL<;_M:_Z$_XT?1_R*_:OQO]PES_ )C,<L;[*_\
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M>+D]= CV+9&.6.4L0/-6FH1N*D*<T!8I60BB$2C4'HF3M^$I%;V$VD4UUM8
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MU=L\X\T0B(?FBCHZNV0T )]X, *4M_-K]OT^/[!F_2+Z:VK:U'T2#IT4:WQ
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M.P^FW"Q0#5 B*G\G"G^C79BG@2]HC3Y:$KND5"W7<L^4A8V8KQLDL@&G$P0
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M!V[YQ3/3<XH$&/+'0E]RJR$:V#I,BDB2,D://3O1&@0AWB6*KSZ[NE(9.BV
MRU>!;;6EB/7QL^CLD'V<'?8A0+%6K9/=[:];!V#Y2(S(5?:^^@"._$@#OLDH
MQLT!OBC_ #'?2,^;-=4J(%)X[W(26.(F7I&(<YW.K-B*[!B<U-.LBVD";>+
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M*4TPR&0^,VVEEUQ"L>=<4-?FV>6Q+,G-N#$G9)7>B20"21LD;]X\NOD&X)R
MT&XKR  ( !UL  D=OD3-:QQCCPH8L<-R?FH\>#.(LX0+%$J[08=E:'9$;L(H
MK<4E@><;%''&1+-(0>@=AEE)&FVD)3+XB\DDWW$E>!/F/LILGB3R[KLD\?;9
M/:8\JK6O+KT&Y@<%URUKEK7TM=M^^NVY/BHZ/.>CB30 S"(@Q<C$OE"L$/1<
M@X =%.'QSKJ%K",7%R<E&K*&4T^H"0.#4O8Y9#;E0)&P"0&&F .MC8;1^L;
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M.&TZ@>,";8"ZY00MMB@J5(#L 5)8E3H]U)=R0>Q+,?UCL:ZSK=:'1!&U4Z(
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M6V;RZ^3;#-P7; ^X8ZV=_/?O,O?+N9[G9NT;YW1=V:S &15CL6ZC7]SM@BY
M<<0^-FY?Y?\ ,)4 X0444P,\A\<D<8=EYM;;+:4X\ZWBJ>;9P0AE7FW%2"2"
MJ[T""200 023\YGRZ^1;RTY,"&;BO)@= @G6R"  0>QT/JGP!Y+RJ,777(WF
M?/H]RH$'%U-P&F5P1=7*E"$ER9-=4/&MJA")$M""CGHW8SA9"4O$*<<3I6LF
M^\\P;K2+  X-CGF - /W]0 [#>]#L(%58XZK0<=E=(OI).R5[=MGN=>Y[F2X
MV%AY)YLF1B8R0(:!DHMH@T 4IYN,F-"ZEXYMU]IQ: 970(6I(1*M#G:#%T4V
M[\.U[$ S+V#,!L'0)'==\3V^:[.C[C9U)$ ]R 3HCN/D?<?@=#?UZD2$Y-RR
M/;K3('-.?A-4LLV0IS0E-K@S=3/D3&9"0-K2&8U"8(L\\8<XTF+T*\48PR2^
MM;S2%IF;[CSW=:?, #[L<\P 0 _?U  D '8 ) ]Y$5UCCJM!Q)*Z51Q).R5[
M=B2 3KW/>;X"I5F-KL+4A8..U6JX/ #0D,0,@X*.;JSP)-<4PV;\1OXB$+C(
MXV,+6I90AP(IK3R2V&WDQ-CEVL+'FW(LP.B>8(;VU]($@CV()'L9D*H4* .*
MZ 'N!QUQ]_JT-?41N8*N>T%<M$3ZZ/3U3L 9-2$#-*K,*J6A#[*<7)V(Z(D=
MA;,C3)^2D#Y":)#>9>E3C2RSEOODO.+SYMO%E\RSBX4,O-N+!  H8;T0H "@
M[X@ #6A'!-AN"[4L5/$;4MW8@ZV"Q)+:]_G,LJF4\]^0*.J=:,)ED'M2I!4%
M%D/R;<J%#1DHW(.O"K<-1)1M=K\>>@E3B3 H*&$(TXQ&!-L8%E@UIW''7'3,
M./$L1KOVT78C7L68CW.W%3O:J=[WV'?8 ._KV%4'?R4#Y"5?4/'#DU.G;U9!
MJT!,2W0_:8L9$_%P)VB8Q3UL>7%.I8AP]2C9&[S;&9*6L.YJRS@4P['3T[)Q
MXH HEUF7?8M:%RJU=UXEAZO1ZOI'CKRTXJG%%*@JH.R:UHK5G;B"7^D6"GMM
MCKV&_IMLMMF!TS$ :^]J\>^86^X5BZRD",U)U:=!LX@X,?!CBEV.*F8ZQ1DX
M00J(=F090>:B(LTTV EH5^R-1L?%VQ<_# B1S.$RKJZWK5NSJ4))8D(RE&4>
MKB5*LP 96X\B4XL29EJ:W97([JP8=A]($,#O6P=@;*D<M -L#4L@FETXR838
M2ZG62I]!3!R)PF!BWYA)PL+,UL4Q,DZ*HU)0U=L5@@6"-/:>9A9V9BVUI!DS
M6'ZA98%XAW"Z(XAFXZ+*Y&MZT717(_A*K>X!$^"D\BJEM[WH;WHKO>M[XLR_
M@Q'L3(R-Q;C@8D2 )R;F8H,!+*GH(,:B59@2%G%ZC]*FHD=J*2S'2RM1,5I4
MB&ADS>HR/UM[?P0WNYG(R"6)ON)9>+$VOME[^ECR[KZF['MZC]9D?*JT!Y=>
ME.U'!=*>W<=NQ[#N._8?5/YL?'N=V*$F83=8AX/4Y77JF9+5N'AHB>:K9+!P
M94,!+-1JR00WP)67 T@;;:Q1Y:04"L4DC9"29%J,K<V;BP<*[,R\QHAB-]R"
MJGO[E1O8&IEJT8$: VO$E0 >/<:!UV&B1V]MG6CWEB @AQ@0<;'"L!1\>*."
M"$*TAD80,1I# PH[+>DH:8'9;0TTTA.D-MH2E.M:UK65$DDDG9)))/N2>Y)_
M&3    [ =@/N$RLQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
)$1B(Q$8B?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g743471g05y72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g05y72.jpg
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M 0$! 0$! 0$!_\  $0@!( )= P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M\*?5*NQ5JX=WZ<V#YUT/B(7Q[\,[7RVJTNPVPLXKH7DQ:)]2B34EX/)&[6>
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M!2=WWRNY\?7T8L.JS$%BD\2D6D+S#MMHY^ LLRQ6GELUSXXHS!J@$M8)3X6
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M[V*UK:51>24WW6V5D6GDO&GW%8KOD"Q (,J/4'10[TH0V-[2@2PL=,Z(B,.
MT=O[Q'+6CH'6I8HSS%[%99_"[39Z/8>93P_F;7_&6_5U=?ZC6J1UFE=DYM/E
M@;G7 W8^><SZ!"F5"Z.5M2T&JG$DCG*]:&8TR:#LC+ZZ3@TJ,A$L6T-@MEUO
MRI:REZ+=-6S46VUGG6&^BY!YIL!D.K/:;":69361E+CNNG5+%MKV' M2MQQ?
M0^B2"K#N&GKEG&G1C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B0V9SVD$+N.Z3-K >5>Q-6+TD=:7XB'"\.I'R TJ:KS,A7I] LF1
M#C)DN-M.T.OP8ZE?J/1F8LL%9J#L*RXL*;]TNH*JVO[0#$ _43]<Q**6#E1S
M"E0WQ"L02OZ"0"1\I2(+PJ\3*P"Z'6:]X]\L#@.K"U K^*'U6!'AV$#N8Z1;
M NMH1KW %&)/.$X(85N ,@$U?$846/-2E_6PV?FNU3MDW,U+<JR7)*MK7+YL
M1V+-LD=B2.TI&+CJ'5::P+!IP%^D-[X_)=]P!H ]P)S"?#+Q7!6L+>1'"N?0
M+?7)%6F K"P'UHH*GTL+#K=;)PI"G5*9*P  Z &=*I_XQ(C842(4DS68[2$0
MV=F,C5MD6E&#AEY=F%C%W!'Q4L2VO0$D@#9DC%QPP84UAAQT>/<<!Q4@_ A=
M#?KH 'T$M4-R+EX#F3'&!-"JL;DT>O2*DWSM8:'+J"JQ+;>9E@7P<UJ1!DB9
M+4A]J1"DM.L/-NN(<0I*MZRIKKFM\\V.;N0?S>1#\QZ-R'<,-#1]98*ZQ7Y0
M117QX\-#CQ/J->FC*$B^,OA;PRGN4:)R'E-#J?5>@\]'O!6@3+6[QT$.?BF^
M:CW%^A\H7F5XV):,5V$IYR%7FQ\TDPU @1R#Z=@Y>?D/YAONL>FNUN7(_DZV
M4K:?@%#*W%SZMO1V2)2*,6I> KK1;'0:U])P04'UG1&P/0:WZ"4^&NGU,#RJ
M.G.1A;'XZ]9L_1+K)ZD1J+,X=(L5EZ"!KT4+-N0C3BXI1VU#:F%:'RR%??02
M:KL"6V]OX8B;Z;VKZMAJMS+DTK77Y(<@\5J9BPK/J A=MZ8:Y$?'4K#8&036
M&IL-C%RNQMG"\2P^/(*-$CN )M0KQ>\=5"?D_OBO-_@'UL-\7^!:J@K077*M
MEM'OD+H3J/J FO\ QQ.C.HFH^MZ*:T0TO4K7M<T_:\K?+VBWEYWG\N;<O.X\
M?,Y;WRX^[O?T>WI+_(IUQ\JOCY?E:XC7E[WPUZ<=]]?7W]9%7?"GQ0>I(KGB
M^#<]U4PEB+6T7!:$;9FQ+.?A(&'CR3[+S=A65.BVF!)J:\5<?+"8T0407('Q
M(T9K/V_,\PV>T6\V54)Y=BBGDJ\?HZ5B64:]UB6&B29C[+C< GDIQ!+ :_K,
M-,=^NR  3ON  >TKJS\[^I_*MI.GV>G<,;M4,'SCQ4*562&&Q]1PESA_*WE/
M(I )EAL:AN?#'Z-TN%[K[<>B&W(%2(:F&_5M2SJ7 .CY' M;F!PQ.VK]RZ[E
MZ]M\7.]'>B#N8M7A\N+)3R"IC\2!V#>]77KT^&T'J-;&I>]'\:N"\UW3%T3E
M%-J[_/9UQ*4^6+%(:G!BW08L:#=RR)ZU+FS"UIA0X<0V4(/RY\^-$C,O2%-Q
MVDHU[,K(M\SS+G<6A X)[,*MFL:] $))4#0!)[=Y:E%2<>%:KP+%=#N"_P!,
M[]=M\2>YF!%^(/B^%/\ 0+2(X3S4;8.IA;/7+\4AUF#'D6(%=M+U<Q;^FT):
MAP[>IQ3UH:&MPM6"5Z)9;<N2A#J<CFY;+4C9%I2ED:M2QTK5_P V?F4]$WOB
M.RZ$Q&-CAG84UAK RN>(]X-](?H;^MK7(]SLS ^1=(XY#YGRL9;;D#XT(YIU
M[AQ/D!UWW5N*&O56M(H72*@)&27V-$VK6*=(<^E"([B9+E</E5L.QE1_?(^6
M+9>;;C76UYMIR%O4;]ZMT)L=B >/ ZL#'MS5?KT8N2KA6&85BNVHUGMV=6 1
M0#Z\AM->O%CZ>LZ=JXQX9"[C3Z%;Z'R2)>NL1.\!*36BD&$FP72!T4?-MGD)
M$#1%JW+FQ+(.DSBUX6WK3*VIKGMG&U3M-O2E^<R/8EEYKI..UC@GC6:R$QB3
MZ J0!6/EV](:K&#*C+7SL\T(IUR8."UV@>YY#9<_M]9!.8C/J=G9^V&;'R>-
MX]]%[ESH:S!L$JK_  (]9:W$"0%\]C22\-A3S"" P1M=,CFYD9PK&#[V!:G)
M'_VMF=IZG1CJEQR:L>T[4/R5'+'S?=)UV+?E.(/$M[VM]YA6,*RTM7Y+W(--
MQXEE '#N/@0/=WK>O=WKM+, >$/B35H1(;7O'_FPF"7AA1Q./#!(0B<.K5M$
MWNMCI&]N*4X.KMM AS8"#M7N@62.C-C&8L9'L-U-GYCD%LFUBI8@EO0NC5N?
MTNC,K'U8$[V3,QB8R@A::QO6]+Z\6#+^ZP!'U:&I?5;H=.IY.XF:Q7!8,IT"
MPIMEUG#X^F)%FLJ XNOI-%EZWOWF>D*%$C=/;]&_=($9O[3>LUVL=PBNS,*U
MX5@G81.1;BOU#DS'7UDRY452Q50"YY.1_6;0&S\] #] E(6+AGB]UJ7?><V.
MFU.XDH5VB].Z("D2R;Y1BXWJFRZDR6/2FI[<[2+/SEF94) 1V7L01H*EU:6+
M<K+Z1SFPM^72*[5=ZP:S54P  *5V!]*-:]RTAPVN0M]\'F-RIJJ+.:,JL>7-
MP2=\G4KLG>_>3::WHI[NN/:=<R8\2/+@% Y(=D<O[8"LE:=Z6'I\YF(<9D5R
ML6R51UW4,TXUIV!H';V)M=9-#G8LV$0U)BL/H2MSUBKF8;&Y1=0R/Y3.-KIG
M3S/+;Z^2:8J=@C1(D$XV2HK)KM5E\P+V.U5N/,?5IO=Y#T/:9/EG(?%\)L'7
M^24'G0=SQMMMG!A1=9#QA\GF%TN%4@OVMOV#;;,B*=M-/M8^:2(2]/R3@@[%
M(*E2FIC;ZXNORVY-=9:WM2(S%R2+:T<\/D51T( '964C0UJ3750O%:T0>0S
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M7*GD)\V6[(G$2$R0M3LF=/DR9;ZO5TX\K2$:3@[O8W)SR/8;^H#L  -  ?
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M_LHBZ476^*NEV6V6+X&\*(KV.ZKOQ".(9B0NJNO4U#0.M5TU5]O<K1=*,O\
M\$;JG_Y@7F;_ "/%/]%S,/Q[A?\ NMX>_;US_P#W<K_E/TW_ -R/"G[?$O\
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M509F8@NC+;V;;<5J#! Q 7U)=_H\=:[S07*,^C2^@H!XL"G=>QY/HL0#O>@
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M*;<G+R;3VJQL6A'NOL/T:T.@6T#3_BOQFWU5BW=Q[@B%*\DN[NC3/0DQ).B
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MEOIXQ878EG?9%N)<+,:T'XBRIIV^F>).N=&5J^G=3RJ,=]^9ALPOP+03LB[
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M22X %)^-F2;33#S;2)LKH=/QKJ!EV9'E+;F9CY3546/;33NFBA42QZJ&?DM
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MG+R_-NIJ0MI*ZF1= ,W*PL[;MYXF>TG7E_\ )9/_ %=[_9JQ$Q%4_O6K?_8
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M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2CZI^R
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M7F8-)K:S0M8Y 9$)9$=@%-0\=YHS5;1UFZ.U]-9DW&W."PH=A[T1H]-J/MH
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M3K2VG)6FI*W8S&.8]=F0[U':,M?I6*AR%2!P$4L%TP/8$CZB1W,T*ZU*KC3
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MC=F]"A\88Y0L$O:RIN5M*O6"+@![W)F\M*]O8OE;<DJ0X5=:EJW&SEQ+5A'
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M51'QY$R7:&F[,NT27-$*K%JJ2A(K">@PUP(A^?'"[S."XJ>X.K5JH="J6GS
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MQZ2>*P04 X=(E'H;J62Z%&*Z)??9@-/YFU"<O+4 VMHJ@;Z(+%5 &0PZ58,
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MS;Z_L'W1\HB/[A^*W]/' ?/[/NCFWU_8/NCY1$?W#\5OZ>. ^?V?=)YGY?\
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M\&Y @A#R';X<NX^&CWE="_,NW$#E'$/\@8@ZLIP;72#DV] A+BSD2QU?GO1
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MV=AXBBGNS6JM+=ES5_%FV1<IAU-4CFVP.ZH0HK4J#8N25!8N#I?9SR.B3Y@
M XDM4;6#%0@(&^_([TIJWVX__,[#?]7N>_:HK%Y?WBQTKH*:;#K .XUSD3G6
MTL5TPS<C]3AZY_V.R2ZI<@AH*/'A[E5+=0:;3K4,D^\)C3+JVA2(#[;6LO7
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MYM*8?CNN,N(^;6VU[3^WFN6*N&4Z92K*1Z@C1!'Z#WF1 ((/<'L1\C,95ZF
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A"/J/R^L>A'8]IG,QDQB(Q$YD?J=?Y_\ 7O$3ZQ$8B?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g743471g06p27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g06p27.jpg
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MF7VORX!N3D\O+9FKWOUX,[%?ELZDEQZ$UPJ1=<R-*!KF 'U\N050?GH337Q
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MB]I]K<[7\RRQ]:YN[Z^7)B=?FW(HO%%7>^*JN_GH ;DH^!2_U%[^9]K(24?
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M+R_%/AC-Z#AA7S<7KO0NI8Q=N-=&+F>V=#ZI?<_<58]3V=#NR+CI:J:6=_=
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MTE"$ZTE*=:UK6M:SRS,6)9B69B69F))8D[))/<DGN2>Y,]2JA0%4!54 !5
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MP M:=WM3?NY+5N!E'D*:]A>_>X*/(0M2FU#?G-*78U* D+?40-ZWYBD_FX$
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MJ66.A068>*$..B\JF->/9]&K,HXLJ-41R!".>YT5930]^$B*P8ID7EO-9M6
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MZ?WA<<L;^*O_ +Q7_I8U;^77_9-_G1\%[[^$OC_Y#KI_>%QRQOXJ_P#O%?\
MI8U;^77_ &3?YT?!>^_A+X_^0ZZ?WA<<L;^*O_O%?^EC5OY=?]DW^='P7OOX
M2^/_ )#KI_>%QRQOXJ_^\5_Z6-6_EU_V3?YT?!>^_A+X_P#D.NG]X7'+&_BK
M_P"\5_Z6-6_EU_V3?YT?!>^_A+X_^0ZZ?WA<<L;^*O\ [Q7_ *6-6_EU_P!D
MW^='P7OOX2^/_D.NG]X7'+&_BK_[Q7_I8U;^77_9-_G1\%[[^$OC_P"0ZZ?W
MA<<L;^*O_O%?^EC5OY=?]DW^='P7OOX2^/\ Y#KI_>%QRQOXJ_\ O%?^EC5O
MY=?]DW^='P7OOX2^/_D.NG]X7'+&_BK_ .\5_P"EC5OY=?\ 9-_G1\%[[^$O
MC_Y#KI_>%QRQOXJ_^\5_Z6-6_EU_V3?YT?!>^_A+X_\ D.NG]X7'+&_BK_[Q
M7_I8U;^77_9-_G1\%[[^$OC_ .0ZZ?WA<<L;^*O_ +Q7_I8U;^77_9-_G1\%
M[[^$OC_Y#KI_>%QRQOXJ_P#O%?\ I8U;^77_ &3?YT?!>^_A+X_^0ZZ?WA<<
ML;^*O_O%?^EC5OY=?]DW^='P7OOX2^/_ )#KI_>%QRQOXJ_^\5_Z6-6_EU_V
M3?YT?!>^_A+X_P#D.NG]X7'+&_BK_P"\5_Z6-6_EU_V3?YT?!>^_A+X_^0ZZ
M?WA<<L;^*O\ [Q7_ *6-6_EU_P!DW^=,Q 1?7AI85ZTWCF\Q!(]?WV.@.5V>
MM2Q'M#/)&]UFI'L=K##]$M3#[_K0)WO S;PK>Q77T&#Q8T%3PKM5NVBUR.H[
M]]J*$)[; ]X:/?OK1R!9OWF0CX@5LI_K-C:_J/\ WED95)QB(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B?-^?EORUY[\M^6O/R\]_>UY_/Y>?Z_E\V(FM
M%O=[,N?Y-;1(F8'D0R.ACV#E==M(Q]"DWFN>W@NJD66WKJ,0<TJ2L =;C0BI
M1+5?B#Y%M7PLZ3;%-UP\D]2-W3LA:[ ZG,%V!3>K8CD8>4V.;\GV>MASM6A%
M+@4UN_[V[A7GU?HB>!5Z=XSZ+?FX-N+?5X9MZ9XPZGT>W'\1XB-XF\/T]8JZ
M5T1>MYN.XQ>FW]5RKZ<0OU+-QL5A[9CXC743T>&5WJBJI<V^O!6T6SM],M*Q
MW[8Y%;]]BS&HPYI=9'AY69! IPIQ)\?6P&9 M(D>(VPHZ2>0[(E2Z&<_V?*'
M45R%O&=D<3D>7[U;!'!H6NRU4QE=G2A [<44*6<@NU7^UA?!XZST)O!5_1;>
MDOX3Z.ME?15S![/F4/EX[KU:W.PL#(R>N78]6-D]5R7QJ#?DWM8,?%1DQ:;]
MF2)46*/(@XT68F&1G'(Z+-DE0XAQ2=>;0Q$H@"44 TYOYE$ICS-MZ^?T%_1G
M6M-BUNU2+98%)2MG\M7;X*UG"S@#\6X-KY&?.,&O#NS,:KJ&5=A83VJN5EX^
M*,Z['I)]^VK#;)Q!D.H[BHY- ;T\Q?64/1JK8BNU7.[RN[Y7XN,JM>@$5DWH
M/0)VD3-UL@HEFN,U"P<]*[J;\15P]5JKUB3K%=@6&I1WH#1HJRECLQ?)Q<>Y
MNJ9.59[7377CTTBALS,MQ;<J]5OR;:JK;/9VKH7R**'HIJ46',#+RT*_HGB#
MK'2Z? 70>@88\.]2S,OK'4^I-U:CPUX:Z=X@P>@]+NOZ3T+ S^H=-Q/PS7F]
M6O/5NK]7P^K=3ZC8^(OAI\>Y:5LLS-B\[4^82I>[;MB>0W[=(^-_*/4"][O\
MF$E+M&H_UV/CVZLD#6Y%5HU ?$]UM,;I4GN;T#J.2HWT-;NQ^'G5\^/'E^/K
MAO\ %Y[[<.6N>^W'>^TKMY>6_'EOC^+];7QXZ[\M;XZ[[UKO,/X?-SZJ+([F
M/EEN,^7O0-4C?0]6G5VW0]6N3U6]S_RXUJY;WZ'JZAE6C_+:ZWJ%6;M3BO:W
M+)X^8./#?EU>9Y7#R_,X#GQ\OW/7ZW#W>7+4C3RX'?+7-^'/ESX<CQY<_>^[
MEWXZWWEY9KRZ5+W9B2>Y'?%0<39IZQ#0!958A*E9+M4I>5M#"=+K@"I_GDO!
M6T"*(FO<D3KL9),Z3"[/46EX1+S2KL?7G5\F55Y .SK6X"?C'C:K(6X[X\@?
M>UZ'O*[M^4^@S-QVH5G4EOQ1R0JP&];T1VW\)*>>U)VB4>J4Y^QV*X$UR#CX
MHRUVZ7/G;+8S16$)-FYJ4DRC#"3I(KUBW4K(6T-ZNA!4M",,-(A:_F6._%4#
M,2$10J*#Z*H    [>G?U/>21>"*G)GX@ LYVS'XDD_$_U#T':3'(24UAZ>WV
M.(Z['67G*K-; E^'[L@<=0S2(^.YDSTD2Y<372I&7,T-%*<L4E''7#W=N>LW
MDN"A9H6KH@EDV0\[;I\AJ"EO%#[3038 3;Y1KR/,"C9'$$5_57ZS*6Y:4#7L
M%HM#5\F'D6@)L"OS ]/ GL/>(+_68]E(7CMMY7PL[Z,GD+ W5!;RQ< >@=C"
M=(Z,3%E6N3@F.NW?Y)R1CD*01%:"(JZHA$.F*]&%W$-!+KS*:ZN)6Y'+\KSM
MTFO@:J#JL$(&\BOF!R .^?+EOWN1/+WMS./YGE_2\N8LM&WUR*^:_ G7;ZNM
M:[:UKMJ;$YK2^:5!_*&V>)+H,+#3WB$H<5'UR>ACK#+P71G:;9)R7C*6L SE
M:;13I+@,%"4(0$M <ZMHZWV^YRMA;6$57XLDVT;QXIBULRXUA+*0H:KS$56L
MV+>%@R6:PD;'9$K"]PS#AJ#DU[@&]  PY$6<6)"Z-?)32H0;T>[,Q.QI?>OO
M@6K3KA/%=7K<ZJ[:Y+SC5QW:/??E-NTZIT-\H=V+XCK4A\=W+>][E_?]:-^(
M>\>]:T_[>:^3P]HO\OCY?G6^7PUQX<VX\==N/'6M=M:U+J>7DU<]\_*KY\O7
MEP'+>^^][WOXRVLIEL_(>T'=;LL3:3:#*>**IP1_08B%)%O]2\5IUD$ A:3W
MUY_I98-;BZK:6(CHUZ,H8@-!X9*AU>E 5J@3UP$!$L<]S?7:04H4\Q<1V%;-
M]&^&%):S& J!=G7=58L)MR%YN7L5-E5MG-8VL&*'(4<P-.F03I4O^DTH5M6.
M4TE)"J%1FT&:N?J50")PRB4DNSA2,;92JC6R+#'3#X!4L!./PP3LL%*$Q3 L
M83(BGJ(8-?CAAP'B6W7 V&1U-MIY%H466!""@=PI7?$KR/$CD2=$:ULDZ]3N
M=!-\%Y AN*[!UL'0V#K0WOUT /E,A:ENMU>R.,)GEO(@9A;**JD-5H6ZF/(V
MVFMID-Z 5/*7K6H=)V]![D-CZ)WZ/MYA/KKOCKDOU]\/4?6UWX_E:[ZWKO,M
M]4^OH?JZY>GPWVW\M]M^L_+E2NVLD1IL,5W>8KU<Z/?'.>52:K/BK$1TV).8
M\/QU8C[':7;_ %SHG.4PA[G2ZZW+]^^6W.)*1(N=I'BPZ0!7JQ&];Z [!]G5
MFJK\UU;$/E,#DARB>6U=O("I^./Y=H'EILV%G/.^E[$&XA;&\M67('F B@J"
MW-73B?,7=W-">;\0@"C]9,X\Z4A/2#KM'4>R%\XA1K!>$1^VJW&&$ABBJD"7
MF1=&O[D#HL,IN)9>=EE1C\K$IF/<?A6I:+6:D\>RH5FQ1:W&O?O$ DZ WKL"
M1R^KL \=\M'6C!RX1B@Y/KW1L#O^<@=O76QO6MC>Y^>M E.JO'\ JMR'\5$!
M>F)A9UGMUG!Z9/4T2KPG9[D@:'LV^:0TES.P73K$ .# 3971CA:ISKG" KK7
M5UD]VO,V7I6K2!DO6<-JRNE1#2K\VH393S6%JUTL2R^2"]ENZWY@-PTD-GT*
MM[0'#;+L+&7B+6[-P4UE[5TK>8>%::=2IX\OU SDSH34SQ@F]Q9YK[IQ*OVR
M3-><(D+!)T*3AP[L&-#;$+B86!&E)".>4BRR:D,SDC%;/DQJ]'RL2%'LF3XL
M_ [F$,?S=WL@'8*+0QK);8+,5!UP'U0VAR(8G2E6ULDW>7JI6)[EBA < =P!
MLCZQ[$C9UL ;(98EPU79M=^OK%D1<7*.TUU\F9D[,=TM<:=+2?68PWC<;6X2
MYU^-H4"+4^<JME:==XO.VJ%M  4)9[N9'3\C% )GD>1[/7P*>9] %""K844D
M7LS5L;&+V\&U>J,A+)7M0QD:?.\YPW+AJW98V:)-BFH*&54'%.:GRBP8!68@
MD";P9H3;GY6=$UX@A[UT4>LR'59*&L-R<)ML_P#)'Q*@)YE3(OL?/8J'@J-"
M5_ISM6Z2!:: 5-3I4MP&.I-XBJ_69]NP2T=-VUQ,9UZO9O+KYBD,M>D7GBGS
M7-%K,UC-5SJ*6!5"Y)LK9G7B"J#?/?S@]G$V$,WO'C>/+46H $5;.+AJR6W2
M$<*K%CM^V_?"W[*1Q_GCEP#F0;'JL@,R3-B=FG)QU0Z5#C'2J;,Z1:!3I,)H
M:2?C[44;:HQ9>XZRG'3@IY;W.R. OMX%2O(ZX\>/?N0O#W- [ * (=;4!2!-
MRGEY2<M\N/?ERW]A//WMD:)#>\-Z))W+8RF61B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1/S&B/'MT9-VD";3PFK
MQ_!F/&/.^#!KHL'UT^6OP%X8O;O.ZM:YWF9_,8:(9J=ALSD0":N*Z-)R<&F5
M][6">.&[M?6;IU7E@)D.<@X*Y_E-0%K-?EBUT6T7,Q=4Y$;J ;CK8W.>,RSE
MMJ5%/M38O,6[<,'-:N:S6!Q+ ;U82N]Z(!EZ@^/#PW&6"1K!=BN5<F8Z?Y]
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MD9O>FE;V9I0J9)BW6*KJJE7%K+NQ%V*1MSIF&M?;Z_=WD6OJ1F1B=KP!TC$
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M9A,8*2"7(1\9(/3\C*@%O"S,@7-ECDMGU#*XVBQ:^PI%*JS\CI5"J6;B =$
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M[,1.?Q)?[4G^5O\ LQ$?$E_M2?Y6_P"S$1\27^U)_E;_ +,1'Q)?[4G^5O\
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MOIM(+%>&5U#&Q[?=^/E6NKA3\"1H_":VU#QX42X=\[5P 'EW;DV'B8L 5-3
M_/I"7CI5,ZT(M&@P(A1LV"G6S65@NRD>*W+",FFB;TP-K;O6R?"N5C=)Z9U=
ML[IAIZFUJU5>UI6]9J+ \FL"UM]4\@CL:VTK=S/1Y?@C-Q.A]&ZZ_4^C>1UE
MKUII;.KJLJ-)8>_9;PILWP(<5.QJ<JC=V[;:5:W(ND0=(1<19Z\Z.^^"RS=Z
MG-UHG9*1F7VBDQ4LW&F&QNE$(3M\=QIMYQH@=LAMUI>T>?OQSCNJ/91;L!MX
M]]=Z@;(T7K+*K=O0]P"#K1$\IF8CX;BMKL6\LG,-BY-656-EE"L]+,H;:[*$
MAN)4^C":W#^*(UD6&(-I<E+EJ3"T:?@JA&2D[)#=R<!N<S=:0-L31#K,?0(7
MGTR;)DJCI!T]-@K#K+HH^RW7-KV $L!:%'O6HUC*JG%W4M5AWKWK6N4 ;7CP
M<$$ZG)]I("[0D^ZC*@+'SR'+H-#>JQ6Q)UWY+KXSA#^*KXDK3A]0FH&,E[%!
M-5:7.BQW'B8 ZX<5KDB%.5OY1#3<18A4=CCFG''$;:"+CY=[<3(;BPXVQC@:
M!U8K,B-YBACV8)DLI5^!5D)QSV'<@J.0Y$H&7O\ $90S*%8@=P7I4@KR#!OI
MAZ_5(;L= -WR7BO^%&41U[GUB]PO]:DY>OPH7PZR6J5)*)Y2]57VQ:E*3RHR
M/7!WV9+L0QL<]),DP*_@:)8383\R7I_(6@7*34X5V.TK4 7AQ]($VW.I0A!"
MD/[W$[XY.5HU_1MJQ"R@:9B?HBO9"VAQL);??W>VQHF=VSQ*5.FT^C76;KEP
M#C+U7?E"&$7&#@S45Z!E5U*0\O%FF,/-34+ S\S;9(,916D5RBV\UAQ_8(J#
M*:\*RRRVM7K)J?@2&)4[%A5@P&N+,BU@G7OV(#K?:;9"HB.58"Q>0! !'==@
M@D:958N1Z\4<ZV-2#/\ C,IK/OQ"*!U(R*&3$#"R\=4C) "1G++4Z_>*M"L&
M":=CVB+!7+77EBZ?.04/*'_##0A]I9((N7IUH*_2T@^\>)<!@J.];MKUTCHP
M/;6AL$]P(>V)W^CM.M#LA.V9%=5[?E*ZZWKN=$#MO!R_B_=:?NP %(FHJ6B.
M*6/I,"!<(.4@?0G*:;VV.GP)YZ2>BE%B'$\QARZO"1;#%LEH&0F["Z")%0\N
M_ WK@;\HFQ65LE*7-;*WNV#&*%=;[@7,'8G@K!5V690T6S-&P!&#+2U@#@K[
MR&\,&WKL?*!0#WF4EM  \=D:#U*(Z%*6>)BXV4$)IQ"XRPK-T+Z(4^Q8[77C
M(#VQR']JD!4U9$\K2DMMNUVRU:5'4ZQ+H]/4MI:H(Q((L 9=;[J41@W?7;W^
M'\]''XLV*[186 !'#LV_@P9EX_?[O+^:RGXRUM?1K_9K^C*9;/N(C$'MW_5(
MD=<! (^1D78FQ[:C8\Z1=1N$-:4XT",Z4XTTI]#;7K.(:VAE+CB$J<VG2EIU
MY[UU:>DVWWX^.N5T_EDY%..I&;2X5K[%J5F%;,_!2P+E58A0= G0/G,OQ+C8
MF'FYMG3NMFO!P\K-L4])RZV=,2BR]ZZVN2NOS76LI6K.H9RH+ '8QM9Z''V:
M#C)X6%LK3$DVXZVUN&*)VCT27A5Z]81#S#J5+84MM;:]^VTI"MZ0K>T)V.I=
M OZ=F9.#;F=.9\=E5F]LJJ!YUI8/<M*.I"N P9>S!@"0-G0Z%XTP^O=(P>KX
M_2^N5TYU=EB5GI>3>4\N^V@_2XR6TN&:HNC(YY5LC$*25%)7/N-ZK?9$U42(
MCG*$)+<:A),TFJ2KQ#1?6K$76FG#K@Q<668!X8]<8S$QJN>SJ)21):CI"6@Q
MC7)B*Y:XE1H+%_I=9)'&Q2I&.O+W$\L^8" Q+"Y=+[RJVN+>F.0_F+I=5MY&
MP];*Z^>2 ')8%&!*CB:R>6U8KO:QBL^(KH=EH7YIZ0Z.!#5B+XLJUU%V,FWK
M%:Y+IU&YQ=9)ZFS.K*P+!CM;Z.Q7Z?%2-?M)%DL< =$O2D?LU!0,GPZ4M\C=
MI>QLD)9R4(@HMNK7S%X$MOR>=C!T"(P;B=:.$R+'K\W2 *M)9-,6<VUUN>!Y
M #]\XH"K<F4KL>LB2O%=TQ43+R>JM#C"LQH=UBY)-,N$ZV]1YF#ZG+5LAJ'K
MMA/E9"#L;O/!QP.F'*JXT>R;)&V;G=?'$BU3=XPJ057FQ/(U$<T7Z17I#CDR
M!0R>:=T@/O0"6OL\8^U6:)XJ.P<'B[>X1:5]U6V58U]K-KH';UKH<MCY'L$@
M6/SZ0JL&RN/G[Y T^Y_*=FQ04E7MS R'?1@P2H,<>R%()=2.N29D6(5AMEY\
M=^4<]D76L* #:';WEK:Q.!1PW$_C$-M!H;T1R.QL =YL&X_1\5[-8J/S#*5V
M/@"!R/PWOCV/K*.;\2W1RF(YH4&A!G63FL%V:(+DXZ>3&PM6GJIUJS-T2;;;
MLK;I]N 5S0<,ZSC$Q4>AF1F3DU#_ ,GDBRNS[)5L[-A"VOCL R\F=;*$\U?<
M.D/G=DTQVH'F>]M:/:;#H )MJUN!(8J%9+6\MM-];Z/ZVP-$GA[O?9JYWJ9!
MJ=+DJX.#'S-]GZ=!1[UD"+D(VO[LWLE/DS$<#(PI1KHP;1 (@+,K&;*FB !U
MEM-N+\]2NM2]@<DK4EC$(0"W#L I(8#OHDZ.E!.ILO80J%1HV,BCD-A>7?9
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M%UPY<?CSUH>GKK<3D +RX/\ O?FZ)0'RP-D[Y\?LUO?YIV'>+<2L=!Z#7K1
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M*!.[(@X>.3SMQZP.-[!007&^GTR#WLA(PX6WHBU"L'$$@0S5AD<!M,POQRH
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M=, 1L=P='Y?"8=[F'-"895=(YY1GZ^L"'BEP3U2@'89<772S#Z_&JC%QZ@E
M09TC(&PX>V-CQA9YA 3;#Q3ZUR\ZT-R%M@8%FY<VY<F #'>][8 !CZD  ]@(
MX(1QX+QT!KB-:7NHUK6E)) ^'PG8CFO.FWJZ2W0:4@BH!ZCZF0BJP27JN!I*
MT:!KKJ0-+A ](<<3H:-4,SI*UI]CR5O6Z#=;NP>;9IV)<<V]\_-N_O'[]RY:
MZ](>";50%]U?=&O1>W8?=,M6ZI5J;&ZAJA6X"J0Z7G"4Q5;AXZ#C=$.I0EU_
M0,6,*+IYU+3:7'=->VM+:-*5O2$^4'=[#RL=G;TY.Q8Z^6V),DJJ@TJJH]=*
M !_4-?*>9-"HRCH&353*GN2J;#PU6D-UV'V=6ABFUM$CU\O8?KPS!#2UMOM1
MS@S;K:E(<2I*MZW+S;=./,LU807'-M.1W!<;]XCX$[C@FU/!=J-*>(VH^2]N
MP^Z<(+G5"JS\>_5Z=6ZRJ*9F&(]FNPX,$&*W8%0ZYK: (ID0+;LCNOPNB"%C
MJ?4B.'0EQ*-*2HUUK@A['?D5)YL6)X<N/=MGMS;0WKWC,+6BZXHJZWKB H][
M6^PT._$?U3Z+SGGH;ISHE#I@KLK*F3DHZ/5X1AR2FY(&4BY&8/6T"E1DH?&3
MDW'&R!&W"R@9B4$?><'D"VWANN.MVV'BH5=NWNJ"I"COV4%5( [ JI^ F#6@
M#:1!O;'2CN=$;/;N=$C?KW/SF2BJ12X*&&KL)4*O#5\.0'EQ(**@(F.AA942
M09EQ9,:,$$9"8D!I4<>3'-:822S(,,FMNI):0ZG#66,Q=K'9B.)9F8L5(XE2
M2=ZX]M;UKMZ2D*H'$*H .P  !L'8.O38/?[^\KGHWAYY7TZ& KUAK4>-#!,-
M1ZX^(BX(48N$9CS8IF$<;(B#$A"B1\B>+$2,+J+L-;:-.^3$U#*/.V3=3E74
ML75R6)WMF<Z;8;EV8;)(!8-R1]#FK:&H/378.+*-:UH ?5T1KT.M ]B-%?Q2
M.\GDGS:B3,27$E5:#;8+C$1/O <8"'(ABCMSC0"HV08827'DQ.[-87X@D5UM
MZ+*FY4D);+T@6MZI;K5;D';>]Z+$@D\=\@3HAN"!@>Q"J#V DRBD:*CTUZ#8
M]=:/PUR.OELZ]9A*/QCGU"I\C1HV!CY"OS<J3-SP4M$0&P9F4*T$VLDJ"BXB
M+K S;;$9&L,!1<%'Q[* !W4"Z)]5]V=F1;;8+"Q#JH52K-M5&^P8L7/=F)+,
M3W(WK0$5K15*@ @G9! T3V^  7X#6@!V^<D#W-N=$$Q!I%!I3YE?EI6?@2WJ
MM!NDPD[.S>[+-S40^L!3L;+3-CWN?E9();)DA-[W*EO/';V_D/.N 8"VS3*J
ML/,;3*J\%5N_=53W5![!?=';M)<$['@NP2P]T=B3R)';L2WO$^I/<]YY@^4\
MNCASPX_FU!!$E-R"I,4.G5X8>1W+-#L2FSV&8Y#1>Y)@01F0V0ES9C0H[9'J
M(8;TG)OO8@FZTE=<2;')&B2-$GMHDD:]"3KU@(@V B@'>]*!O?8[[?'X_.=T
M%SNKURSR]LB@$#2<K P%6:::9#&CX6MUQ^6.CX2""#%&:CP5RD[+RINOT5XP
MTQ/JO;%"CA@SW.Z*C'85G??<LSOQ#,Y)))TJJ/D!\R20102P'<@+\-!1O0&A
MV&R3]Y^0 %@95)1B(Q+4]/S_ /81Y>?S;^?6).<D?IM?Q_T;Q$@C?)>5-2\W
M8&N9\^;GK*T>Q8YMNF5Q$O8&)1YHB39FY),;HV5:D2&67SVSGGT%O--.D:<6
MVE6K?/NXJOG6\4(*+YC\4(&@5&]*0"0-:T#VD/*KV6\M-ML,>"[;EW.SK9V>
MYWZ_&>I/,^;IFINR)Y_2$V*S EQEDGTU2!U-6"-D&F&#X^;E= >_2H)K PS)
M8A[Y#!+0[#;S:T--Z3CSKN*IYMG!""B\VXJ02057>E())! !!)U'EU[+<$Y,
M"&/$;8'U!.MD'X@SI Y7R^*=@'XOF]"C7ZHZ<_5W@*?7@W:V]*/;)DWH!P>.
M;7#NR)"E/G.1VQEEO*VZ1MQ>]JS)OO;ERNM;GKGNQSST-#EL^]H=AO>AV@5U
MCCJM!QWQTJCCOUX]NV_CKUDJ.A8:3=T_)1,9(/IC9.'2\< *6[J(FMA[F8K3
MC[3B]1LMN.C]R8.M^['[ #V4T[L5CV(!F7LK,!M6[$CWEWQ;M\5V>)]1LZ]9
M(@'U /8CN >QUL?<=#8]#H;])'(_EO,H[Y.*C^=40#=.>/?J.PJC7Q=U5^5(
MT9*/5S;$>C<&[)%Z]Z/<C/=5F$?HY&W'?SV3-]S<MW6GGH/NQSS &@&V?>T.
MPWO0["1%=8XZ1!QV5TJ^[OUX]NV_CKUF>!JE;C:]"5,2$CM5NMC5X6"AWQT&
M!1C53< ?K.QFS-$;T_!$Q<:7%E*4HH,T$0UEY)3#;R8FQR[6%CS<N68'1;S-
MA]ZUV8,0P]""0>QF0JA0NAQ7CH>H''7'U_)(!!^! /K/(W0*(F:C+$FE5)-@
MAGY@J(G4UN&U,Q1-A+DI"?(C9/07OH+\Y(3$L=,.BOM.29DI(DFJ?>-)6[GS
M;>)3S+.+<0R\VXD* J@C>CQ"J%V.P4 =@)%D37+@O(;TW$;'([;1UL<B23\R
M3OUF0?IU1*?(*)JU<()+]^][(?@XQY\KXF["OR7O#S@JG'OB#];KSQWJ*5[V
M[ PKA'J+BP=L8%CC0#N -: 8]M<M:[]M<VU\N3:]3NKBN]Z&^_?0WWUO^OB-
M_</D)6%'\.O*:&9;I&/K0$M(7<%Z&L)L_&09KQ]<?4:X]73-#1 +4J"8Y(G.
M3)TXU*6"SN$>I:IJ<<8%4Q=;EWVA 7*BL\E"LP ?M[XVQXD:'$+Q1->XJ]]P
M6I%Y=@2PT20NRO?W3H#8[G>]EM[8DS(2W .9S/0*UTDF#88G*N6J5CQ@@886
M/7.*.G93<\\M$5N79E'9.RR\E)+CI8 :PGNB&6469(BXMP/"Y5RU/2'/!QH[
M+$\=*O'ZW'CQ15&U)4;"E0QV-2%P^AM>X[#6]D[]-[V2>Q&R=ML@:L5^F4XF
M55.DU.M$3:RO?ES+\%%NRJS?@A-9]\5(N"J+45\FS"Z_[QM[;OP0HF*]OW!]
MT=50LL XAW"ZUQ#,!KD'UK>M<P&_G -ZC<EQ7>^*[WO>AO>BN]_/B2N_D2/2
M1P;CG(0QX803E?-Q1*[*+FZ^*-1ZPP/!33JX]QR7AF6HM+<7*..1,4M9X26"
MUKC(]2G=J#&VW,Y&02Q-]Q++Q8FUR64;TK'EW4<F['MW/S,G757Z>6FE(*^X
MONGYCMV/8=Q\A/+9>,<VL]>FJT]5(2'!L%65198FO0T-$2A%%(:!"DJ8B19C
ME$"UR6AX]B", $4QMJ*2A$:Z 6* 6(3(N1U?FS%'\U0[,P%HV19K?=U8E@3^
M-Z[!(,VJ1E*\0 R\#Q !X'6UWKLI T0/AZ:.B+/;;0TA#32$-MMH2VVVVG2$
M-H1K24(0A.M)2A*=:2E*=:TG6M:UK6M93+)SQ$8B=R/TNOX_Z=XB<L1&(FM^
M;$1B(Q$8B<D?IM?Q_P!&\B_U3^;]8B=V4Q&(C$1B)VH^C^/_ ,-8B<\1&23Z
MP_/^HQ&71&(G?KZ-?[-?T8B?<1&(C$3[KZ=?[=?TY@^A^X_JB=^41&(C+D^J
M/S_K,1DHG-'T_P 7_CK$3MQ$8B>C$UXQ$[4?1_'_ .&L1.>(C$1B(Q$[]?1K
M_9K^C,#T'W#]4R?4_>?US[F9B,1&(G)'Z;7\?]&\1.[$1B(R@^I^\_KEX]!]
MP_5&8F9V-_?_ (O_ !Q$[,1/NOIU_MU_3B8/H?N/ZIWXE$8B=R/TNOX_Z=XB
M<L1&(C$1B)Z,1&(C$M3T_/\ ]A&).<D?IM?Q_P!&\1.[$1B(Q$8B=J/H_C_\
M-8B<\1.2/TVOX_Z-XD7^J?S?K$[L2F,1._7T:_V:_HQ$^XB,2ROX_F_[QB61
4B(Q$8B=R/TNOX_Z=XB<L1&(G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g743471g07o50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g07o50.jpg
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M 0$! 0$! 0$! 0'_P  1" $A ET# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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M_3WE6>$3QCW3Q(]H\'QI-ED@(ZV>#3MIO8J'O?L(#7>.6]4Y70;&?)1#K31
M$@'(.V)^(&)0R^Q!SS&UM;T^E6\V;@UXN/F@("4SJ!19[G[-=3=8@#>Q!'4,
M1_>4_A*8V4U]F,>Q ;&M]1#X_75V5HQ(_'[Q'_209,7:!?5_9*6^9I\3WB93
MSHCP_F>)O=+;Z%#:KR;:WWL2OHIK0GPCO:>9Z@B%Q.JYZU4A[#I#7OWSUM6Z
M>I7^BO6^R8GJ_:1B>IZ1[=/LQ;U-]_\ F]AOM[;_ +LMT?[=Z?KW]/0-_7NN
MNWK!>OW-]-'6M[_?)3XTNQ]'A.D72BTBV35*"YCX /%CXF'C(,I0A4]>XN.C
MN?<Y;?<3K7K0*6Y*VBTZ%7ZUA5CW59%UGU\2(XFF#14U266(MAMY+#Q0&&^M
M9+66Z_?9I$W^QW']Z6RK7%C(C%!7AY%^P?)< (F_W+MF_P#-U/TGY0<Q\;'B
MAGKEX+>73G5[R\?Q/L5:KWB>FF=;4?V*)[K>V[%PP&QH2/K122>-0TR<L85>
MEF%/:WO;NEI6WN+<#$6O/N6FO5^.SXB_2AL>OKD%?/C5[*//L)K5R\@OBUFQ
M_P!7<BWG_P!Z+K.U0/C_ -TI\?7?[C-[^8_94;_>>>W+HLYQ>#I-</Y"!UKE
M%ELS'=8BFZ<F^H0'-('G=PL#_%'W+K<9ERU0TI75\.CKY&VF3'EJA&+8.88E
M'M?;P]==E=:Y#6,+S3<B?9VL^6IK6M1?M ]-!T96^T&LH"MAV#UGL3D7>M[#
M2$7TQ94S>J%)-@K%;'T3V<]@5]+N'.T&OO3.\^^R)=^Z=)4#FU8XMS@'K5M[
MKXC^&2#ETG^D4JH1QG">6U+JC%I>A)>C?;#B$3$7:=1952FX(:9$E0M-$F ,
MDO/ 5LXS&J6RY\BTTICXN0/36JQR,BZRDH&6STFZM7ONK%2I\ D &4SKK"E:
MU)ZK77U?.SHH]&M; Q!0N.P;75E!!]]#VV.B>E]=\8?@8Y=USD R^>WOJ G*
M[G,UN-NA->.75XWH$"5U:E5GHC$2\979*SU&)L\%7;,F,8+!=DA%J(BG][E
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M/8Z4DWGP/Q+WOIGB!XH1/05FI%>\2/@[G^EG<IL;QA"^:=*XOT^ K4V1&)D
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MQ&H/?[0;Q190%5.G4JQ8,'[:Z[WK4QFNX>I0*+"7S_M M'7TA4;5MV6[ ]@
M1UUO?L?I)2Q5^O\ ,^V>%?Q-27A^[7?=S-F^R"7OJ,!SZJ1\E<J@OM]OYT#Q
MJ+G86Q3M9]D>$YC3JW"$((,22SNOD:V.G:$L(KWHMQ\O$&3CU=5XVNIK785O
MZ%=IO*LJ-L&YW;VU\P\^8ZVUW8V0:+7V<UK%K4%U]9D%0*EA[5JH/_EFV'.K
M-(W_ .R![N475K;3(]WP)5O72:Q<8\2+LL!/37=["3R:(MP$9(R\>'.LQ,5U
MPP,-$F8XU'R#CZ'--%_=>*U!7QO0NEA'(-Z3H2595QU]9D)"DJ6-()T/(_/7
MJ1B^;V"L@.&IL5@ RL;CZ08 GYM"WQ] ??S/T7S63W1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$Q<I
M"0TXD%$U$1<PB,E )N-1* "2"8^9BWM$1DN"DMI[0DI'$:T^ >QILL1[6G1W
M6U_=9(9EWU8KL%3HD;4^"IU[@CP0?!^L@@'6P#H@C8!T1[$;]B/H?<3*9$F,
M1&(C$1B(Q$8B,1&(C$1B)BQ(2% D9:8!B(L*7GU!+G902/$&D9I<:+H*.7+'
M,M()D51X6M"!*,=>V*+K0[&VVM>ADEF(52Q*KOJ"20NSL]1[#9\G7N?)D  $
MD  MK9 &SKP-GZZ^F_:93(DQB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1(H5>Z."3.AFW*J!EU89@VS"E6*(')K@926E"ESK#IB'8
M@8E+S*F'Y!([3R7FMMK5IQ'FU_/VB2$(T*2#$D8XL60CSQF#03PB&B@S0RFD
MOC%B%,+<8)&(96AYA]E:VGFEI<;6I"M;VB5P?=Y0:ZSU::' ]CBH2LR;#RVR
M%$N/39%A:)0ZK1*6MM-)AQ]L:0TA>MN/>L6YK:-(GZ;_ 'G_ "_UD?77[A_G
M_I(RKN%43;4T!5SH2;VMO3J*4JPQ>K:MK8*Y33J:WN5]\J;W&-.2.EZ"VGV%
MM9?G[.A3FK^E;Z?J^G9Z7MZG1O3WO6N^NOOX]_?Q[R.Z=NG=>_['8=O;?W=[
M]O/M[>9,/BZ3_!!?1/?M&8Y:8M72F$R^H!4E7DSVQ&#]0BBVM2^P2EGH&-U&
M[.]LV(0N*E$,$^I]2ZN-/2VM6PR--VZMU[]6Z[UVT>NQK8W[;'8>-_4?B)&Q
MOKL;\'6QO1WHZ]_.CK\C^!F4^+I/\$%]$]^T963,+8>EO5F&.G)%AE84>AMQ
M](H[CC^TNOM#I]6A9C2%;]-Y.]^;B?)/GOY=ZUK=D4NP4:V=^_MX&_\ *0S!
M02?8?_:9KXND_P $%]$]^T963'Q=)_@@OHGOVC$1\72?X(+Z)[]HQ$?%TG^"
M"^B>_:,1'Q=)_@@OHGOVC$1\72?X(+Z)[]HQ$?%TG^""^B>_:,1'Q=)_@@OH
MGOVC$1\72?X(+Z)[]HQ$A]M[C4Z @%V]W.A4IN460W&.6VPQ=;1(N"):64V"
MN9E0DEK&0\RLA(^W%,I=:4YI.G$[WD2JVW?IUV6:UOHC/K?MOJ#K?TW[RK.B
M:[NJ;]NS!=Z]];(W)>FX2*TI6AL%2%)TI*DMNJ2I*M>:5)5HG>MIWK>MZWK?
MEO7RZS'+3SB7M\]I3X+L28R@DP-;PBMD-(,CC'X^0$4XR6M"20#Q203&-[TZ
M*8.^,^E#S+B$R01X((.@?(UX(!!_(@@@_4$$>(!!]COW'C\0=$?P((/X'Q/3
M\72?X(+Z)[]HR(CXND_P07T3W[1B(^+I/\$%]$]^T8B/BZ3_  07T3W[1B(^
M+I/\$%]$]^T8B/BZ3_!!?1/?M&(CXND_P07T3W[1B(^+I/\ !!?1/?M&(CXN
MD_P07T3W[1B(^+I/\$%]$]^T8B96%L!LB<@9]L9+:FW%[VTAQ*_-"?/7RJ>7
MKR\_O_<XB3+$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$TE>\/W21+3*S
M,?(04D ->I^^@BS-LG7F;,1+]UIG7(J(W%/5DT+GJ:S$P<S75%5\B51;)7X6
MG; POW("Q#VV/\O8?@1_'^/M*Z/\]^_[P?;_ !_/P?RV;Y=5I&F4:&K\NX$N
M38<F) YJ->>(BP"9Z<DIYV(BB"!07R(J$5)^Z(PAX$!Q\ (=U0(6U[%:K_Z2
MW^_PE=RW\:]R_)*@?Z[=\GZ#\S_02/J?R']3-1N@>&JZ6KI]EOE?O0=:U+22
M+!$$N&WH[<1,,\@D.6--N4L.TQ%'-<4H[<INUK"3;@1/61L/(1Q" 90#WU9=
M==*UO67T.C#58#*;UN/ZPH;1]W7I[],GRP(+*?*^.[6,ZV!=GL/OG1](U:*!
MPA]^W;7<>P(.F%<,>#OJK7M:0NS-5Q9D-?(F/.AXL=1-/8M]2LL,,/7PPHFO
MQ0:@)RQHGG3Z6'S/WD;$-FV&-L1#M?;IN8\A1H;H+::MB&8ZL]-U;YR69CM5
M*ZL-W4'2%/F+X_LEOG5O78< J/*=T9?EUU TS=MH*R2-L&^4)GXOPB6]HL F
M1Z0U[(O5+&F(,,<E@)V#K/4KE>S*R,Y#HK4>F(-A+8Y76!PJ_"QHV_;%C0X@
M)" 6ZG/K.]5$'YRK>">S4I6'/8L>P9.VRS'VVQ(W+#%?8_6:'R@J-ZTMC.5\
M=1HAM:T![^ #J33F'APN7/\ J.KB9THB;K(STUN(KZA_4KAJ\5'.Q$'ST-U3
M#DBJHP2/46$41^P.P;,ZE:A:B.8AB>;QW9==M'IBGJYZ]G_:8'LUI\Z]1OND
M] Q7WL(^67KQV2SMWVHWH?@"" @^O5?<;8C>](/<;"]-C3I>BV"-C!G##BF!
M4CC,ZUMQU2) 1U6DZWO6ON6T+7OSWKY$[SR4D+:I)T!VV3_Y2)GL!*$ ;/C^
MHD[S%+QB(Q$8B,1&(C$1B(Q$IKI-(ND[:*C:Z3(U$4^ KM\JY8URC)25C'1+
MNNIN^WZ"BS '#E1KM61ZV*?+"9DV#'&-R .TZ=WZ*;*UKLKM%A#M4X-94'=?
M?P2V];[^X!(U[&8K$<LK(5!"NI[ D?/U\Z'OKK[;&_Q$U3?\%UT"K$?4X/IK
M*Q*]"F0(<U)M2+L_=!72(7=6(OC1OORJF$\IC(ER!I#1M8LH"HF1*<!$J5B;
MC[&#[OTA47-C4G;,&*J5ZUGYN_I$=7'K$AK-,AV "70E#YOLCA>JV?=! 8C;
M/LCJ;-[4FL#JFU8:).E;3"0VOPNWX@&;GQNB'S%O9"MRHUR/3( GG#SA'B-D
MWZT![QMH D>'-$=>I 9K"Y^+:>3SN)V[. .1]?E(&B9M6U0U!:]IL-H@=?LH
M#'JA)ZBBPJ>K:]4_(075K/CN06%A+Z;6MC8)R#U&W &_50$=A_RQ\PTI783P
M]5BT5'EX,1<(<6NS3MLZ7-HK@1+)0==A+-TJVV*KP K@LM.!-#P]9E(B/:"C
MI-^,CT#I C6Q 1APV/+ENEEQ:MBZBNE>Y&B[)4BNQVJGYG!))4$D[.R=G-CJ
MR5Z<=3WL8*#L*K6,RJ/)]E(&@=#V&AXEV9YIFC$1B(Q$8B,1&(C$1B)(JM_\
MW;__ (7_ /T8B6=B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E9Q#
M##W4N@;>9:=VFK<ZTG;C:%^CYEWSS\O2UOR\_+Y?+)^@_,_T$CZG\A_4RPO8
M0OF8OYNU]3(DQ["%\S%_-VOJ8B/80OF8OYNU]3$1["%\S%_-VOJ8B/80OF8O
MYNU]3$1["%\S%_-VOJ8B/80OF8OYNU]3$1["%\S%_-VOJ8B/80OF8OYNU]3$
M1["%\S%_-VOJ8B/80OF8OYNU]3$1["%\S%_-VOJ8B/80OF8OYNU]3$1["%\S
M%_-VOJ8B/80OF8OYNU]3$1["%\S%_-VOJ8B/80OF8OYNU]3$1["%\S%_-VOJ
M8B/80OF8OYNU]3$1["%\S%_-VOJ8B/80OF8OYNU]3$1["%\S%_-VOJ8B/80O
MF8OYNU]3$1["%\S%_-VOJ8B/80OF8OYNU]3$1["%\S%_-VOJ8B/80OF8OYNU
M]3$32?Q'>)ZZ<5\0?A&XASOB">JD>(NUVL*Y2\?8PX4_F%#I[M/9L%X7$^[R
MW9*-B1K:Y,'ODOQP.V8-4&P2Y+ST=ZCH>)X?$S^+YOD<ODEP#QE-/V6MZBZY
MV7>N2]>*K]EZV.,9E55#M\YM*^G4^^KX+X?P.3X;XDY;/Y=>+_0N/CG"JLH-
MB\GGY*9EE."EOJ)TMM&&R(B+8^K#>5%./;O>+.>G*1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1*XA/XT>@_DMSG_6[YD_0?F?Z"1]3^0_J98^1)C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1O?E\N_D
MUKY=[W_BQ$_.SA?_ "O]8(\7!WF_%=$Z6=RSA"G/NFQN <MH_6PA;*!K?EZ"
M.O\ 12+?T)LQ"&U2U)5S31'K/=(^T='S/_ 8V%P2^'Q$^V\G^)Y3-2IFI;_\
MAB"C%*G?3)^V:^^9U?Q%_P!UXG%_#*>+,%3R/,:_O<UR-*.V._\ _K,%<7"*
M$D59GZ0ZZ]5M_HGG.3E(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B41.=\
MK\9:+33XV$F9Z7K2J''(>%4$+$RUEO\ :GZD' !2!1"/-5?,;9+M4BEAT*,&
M<*"&5(SL7)PXLZ_S_EY,C?\ E_.6;2K6)=ZS&V4,4N/0=[:.3&G^HV;%RD3(
M%P\S%%+%>($=(C)< X!UX0@@1]8^WA7WF%MN*CV@'8W-6N1^)BA=(\77B7X3
M"15R"N/(:SS5%A-FX!,?7I)*MSI*WH*0T:^20RGXDCD#KD 8S4FE)9D/J0CA
MU&;Z[E?@SE.(^&/A_P"*LF_C[..^(K,JO#JQ\EK<REL8D,,JHU+6G;HQU3=<
M:B F0*;6"'D^+^,>,Y;XFY[X6QZ.0KY#X?KQK,NW(QEKP[ER K*<6T6M8W7U
M$&[J:1:";,<W5*SC<_.1G6QB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B)J+XP[-/$4BM<'H<F3%=)\3MF^U'!2T<O2)*H4DF-+F.
MR=(&7Y*V*]2.7@6)Z!-7Z#.KW)TN-4XEZ5'2O>\#34,FWD\E ^)PU/V^Q''R
M7Y"NJ<?B-[;&3F-4+5'G[,F0X&D.NF^%\>E<N_F<RM;<#X>Q_P!)W5/_ ,O*
MRUL6KBL!AL=ER^0>@7(/F^QUY=@&JSJX7JS TIGA5-JT8-"UBIS[-:KL,$CU
M8<3!07(;_%Q,:*CSWM P( HXS"=[WM+;2=;WO?RYJ+;K<BV_(N=K+K['NML;
MRSVVV=['8_5F9BQ_>9SV3D79>1=E9%C6Y&3?;D7VOY:VZYGLML8_5G=F8_O)
MELYAF*,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(E(G^'CE!,Y.VF-K -7M
M-@U%O&6.K"1T1*HEHBZ*Z$+/MN(!=8?F'[AZN8EGI$<\:><90/."2(:WQWIV
M?X?A^<C0]_R_E[2SJM6HNGP$;6X9#Z8^,:<0VX60LLTH@A]TPZ0/+=_="I"2
M/()D) I?DH@PE][>D[7Y:CWD^TT+\081O.^WRWBLK8A)$APZE\]#ZE&Q[+CQ
M5I\.UJE;[]LX70HZ?6R$CS]V+A.M5]KS4^MRE2T$"E.[.5ISM_A*U.3ISO@[
M+=5JY\UV</;:P5,+XGQ%;]%/V8]:JN36V_A<IO"@9U&19O[&FN)^+*WXRW!^
M,,5&:W@!8G+U5J6?,^&<MD_2J=5':RSC6JHYK&4[.\"['KU]K??Z$@'A2@(<
MG&EC'QTB(.> <&\V2(:$6R@@4L4AI2VGQB6'&WF'FE*;=:6E:%;2K6]\7979
M3995:C5VU.U=E;J4>NQ&*NCJP#*RL"K*0""""-B=G797;6EM3K95:BV5V(P9
M+*W4,CHRDAE92&5@2"""#J>O*2\8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$TGX;_ ,MG?NN^),G_  FG4=4SX9^!K5]V,1#U2?:?
M[UT".5]VVI-UZO#"T-DIAQ394)Q>*D!E>SS*_3Z'DO\ N[C,'B!XR,D5\QR8
M]F6R^HCC,5QX(^SX-ARBI&Q9R+HWFL:ZSE]<3PO&<"ORY68*>?YK7AEMR:2.
M&P;![[Q.-N;,*L 5MY:Q&':KQLY;_P"$'+/R\D?[L>CYSX]C^7^8G)'W'Y_Y
M&3S(DQB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*EAV&"NN=2&)9:(
M&(HO+6"!WVT/,/L/'=.;=9>:<TIMUIUM2D.-K2I"T*VE6MIWO665F3JRL596
M[*RDAE8=2&4C1!!&P1Y!\B595?LK*&5EZLK %64]@58'8((.B#X(\&4GX9'W
M^4V.]^$J:>=VSRMH6W</**<6MR:\.UJ.+:K,.R\YO>R"N.V >4Y8:TG;CPU9
MC>?2IZO7V9O:^V^+%7F,7COC.A1VYAGPOB!4  H^)\.M&R[V4?=3G,9J>7K8
MZ5\NWDZ:QUQ#KB_A5FXC*Y#X.O8]>("9O .YV;_AG+L=<2E23MGX3)6WB+!Y
M9<6KC;K/FREWN-G#SMHQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?G/6_LG_APG
M>Q]UXZ5&=>B2.#6ABGV"]C<FNEWY[,S>EG#28\?8.9Q5U]R:BSXTT12[H-66
MY+3#CT0HY YB1>LN^#>7JP.-SU? L7DZ#D58QSL;'RJZOE*%ZLRS']3NKJW_
M  YNZ;T_7:]NZO\ [/>>IXKA^46SB[5YG&.51AMR6)B9U5.D:MGHY"S$]7U$
ML1O^$;(->P+0FU+7%'^/3P7'E-@.^)_BL#)._(U%72^P5"EG%?>]6B*NQ5?D
M5.ZWORVUH;UNM_)M&MZWFO;X9^(5!8<-R-J#W?'Q;<JL#\?4QEM37[^VIJG^
M#?BM%+CX>Y:ZL>39B85V;4!^)LQ%N37[^VOWR^ZOU'F5XTA5*Z+1+@EW7FVJ
MKVZOV#3FOO\ FC<3(%Z7K_K3YYK+L/,QM_:,7)Q]>#ZU%M6OS[JLTV1QW(8>
M_M>#F8NO?[1BWT:_/U46>^G7VB]$CC)CG]TJ=YB(Z7D*_(2E.L4/9HX&>B'$
MM2L(8;"F&C#2\8ZM#<A&O.H,"<6E!++:E:UNN1BY.(ZUY6/?C6/6EJ)D564N
MU5@VEBK8JEJW )1P"K#V)E,K"S,&Q:LW$R<.UZDO2O*HMQ['IM&ZKE2U$9JK
M "4L *.!M29+,P3S1B(Q$8B,1-8_%ET>S4;EB:YS@I W9.T62)XKQMQ2-O;C
M;O=VS$$7)T?6]*?C>7U &T=3FV];UZV'I9PZ=[=?:2K<<'B4Y.;ZN6O; X^F
MSD<\;UWQ\;J1C@_1LR]J,*LZ.GR%.M SH/AK Q\SD3?G+VXOB<>SEN4&]"S$
MPRI7$#?W;.1R7Q^.I/TMRT;V!EP<NYS6>0<XH_+:8*L2K4"KPU4A&GE^N*<!
MA060D%R!.]:69*'J:6=*'N^;Y\B04:0I;[[BU>#-R[L_+R<W((:[*NLOL(&E
M#6,6*HOLJ+OJB#PB *  !-9R.?D<IGYG(Y3!LC-R+<FXJ-*'M<N51?9*TV$K
M0?*B*J*  !%O_A!RS\O)'^['H^><>Q_+_,3PGW'Y_P"1D\R),8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$36..Z_RV)[AUJ.F;_58(N/K?-XDI$_,A
MP3>I&-(O!<@(P3+N!BF/!,3<9LE(;S_J%DZ:<]%UIY#>;T;2BN*V*L3HJ.WX
M?0;(_=L#?TF'UJ@[(;%#*!L,>OX_4Z!_?HG7UE,^*#IO,A!Z-WGG'2>?6#IW
M YDN=8K4%=:R;,]$Y;86Q8[KW+PAAY-QPZ1G:\*):*C'I0M9/1J52FTZ2A3V
ME=?\)W5LW(_#O*L<;B?B.A,=LJ]66CC.7QB]O"\M8Q'R58^2[XF;9_<XO/SS
M[A=<E\5U6*O'_$/%J,GEOAV]\A<6AE:[DN(R0E7-<36H/SVY&,B9>'7HE^3P
M, >VP=FQ?$1PXT8<H7J-/>:*8:(:2B69V_ZMY"7$:=%__$L.Z2K6G&'VFWV5
M^;;K:'$J3KD6QKT=D:MNRL5.B&7:G1ZNI*,OCPRL58:*D@@SK$RJ'176P=74
M,.P*MI@".R, ZMY\JRAE.PP!!$SG,>N4;K\;,2U$DWI0&"FR8 ]Y\ L#R-&:
M9?TMA!;32GA2&'VGAWTZ^Z2K:7$MN)6VFEM-E) L&BR]AY!\>WT^H^LO7:EH
M8H=A6*GP1Y'Y_3\#++S',D8B,1&(C$1B(Q$8B,1&(C$1B)H98KU</%W/3/,^
M&V.5IWA]@9,R Z]XBZX4L.9O9\>0L.=Y-X>)AK]ZIA]M^)Z#VH%3@=7<296.
M>O&W5$C/4CIJ<;'X*JO,Y&I,CE+46W XJT!J\96 :K.Y6L^^P19B\<X[7#K=
MEA<8I5D]E1AXOPQ35R'+T5Y7-W5I?Q?!WJ'IPT=0U/)<Y4??L"+<'B7TV0.F
M1G*N(:Z<O8ODM%IW,B+#0>?UR*J5-JL?3HFOUV%&2)'1@+$,ZK3;+2?-3CKK
MJW"2RWUNEG&/$&FOD%D//.:#)R<C,OMRLJY[\BYR]MMC=G=C]2?H -!5&E50
M%4!0 .6S,S*Y#*OS<V^S)R\FPVWWW,6LL=OJ3]   JJ %10J(%50!;4C&1LN
M*L*6CP9,-WY'!)$0<T5SY/+[L<EMUI?R;WK[I&_DWF)'>M@R,R,/9D8JP_(@
M@S"ECUL'K=ZW'LR,48?DRD$?XRA+3X0O"A>-K7<?#+P"SO.;VK94YQ[GTD8E
M>]^?K6S2J^X6R]K?RZ>:>0ZG?RZ7K>;.GG>;QO&/S'*4C]FK/RD77X%5M"D?
MN(U-SC_$_P 28GC%^(.:QQ^S3RF;6I'X%%O"D?N((_=-4.+>!>.\/M;L$GX)
M[Y)\%./Z)T@^;YQ:/>W5>$WDJ,O,_!QR;%3[!-M6JKR#$%#0M?&LO-;I4SV8
MV-#W,@6C0J!7-MD_$]O,-6OQ)CIR@KJ2FK,I]/!Y/&K4>U5]-1HO7LSV-5F8
M]ZL[,4:DL6F[ROC2[X@:M?C##KYL5U#'IY#&]+C.9PZE)UZ&312<7)3LSW-1
MGXF2C6NYK?'+L\N@+Q;$<W,%KGBYY^3X?))\AF/"ZDS*+N?AILY;SFAQU =?
M8C8K=!(/=TK8\)V>O\[,6XI(D078MIT4[Y&X,9:M;P64O*H%+MAE!C\O2H!9
MN^ 7?[2%'O9Q]N6NOF=:M]1XW^&1GJU_PQFKS=84N_'&L8O/XZ =F[\67L^V
MJ@UVNXF_.37S6K1]T;D"E"G"CF@DCF!&,-%"%BO-D"E#/MI=8('(94MI]AYI
M:7&G6EJ;<;4E:%;3O6\T#*5)5@592596!!4@Z((/D$'P0?(,Y9E9&9'5E=6*
MLK JRLITRLIT0P((((V#X,]&1*QB(Q$THH?_ "Z>*^^=2=_PGGGA@$E^$\RW
MO[H25[%9&HN6[W<AOWJ755.+:J/(HDST%K F&.NQ:'4I+(1OH<G_ +MX3&PA
M\N7S#)R69^TF!473C,<_AZ[^OGNNQWK.!81\JF=9F?\ <_PWA\</ESOB!JN8
MY#]JKBZ#97PV*WOK[58<KD[5V.]1XRPC:J9NOG/3DY [?_"#EGY>2/\ =CT?
M)'L?R_S$@^X_/_(R>9$F,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(FB=E[
M7*ZO-XB*SVN+>A*S8(>N7I;R.<C$\[>E>J4> +*JD01&G3JHZD520FH:_P!Q
MOWOJJ-6Z:ABXIL9J%LD#%V _Z?R]_/@_Y^W[I7?GP?KHC7[_ !_IOS^4VCY#
M8)>T\ZK<[-E:D336I%+4SI@8;5BB@Y>0!@;3I@)H<%O5I@QHZQ:2 ./'^4GY
M@CL";9:14_[_ -/X>TD>W^_]_P"'C\/$CE=@()/;.K&IA8E)A=2Y8267J-#T
M420X3T$=Q\@C3/K7GEC@A,*<<6I:FA!F][VAAK2;]FZJ.S:!.ALZ'M[#V$J$
M7LQZKLA=G0V??W,N=MAAGY&F6FM?>\FVT(_].M939/N=RV@/8":<\!\^*=0O
MOA8-_P 'JNF9/LWAT6OS2QOF-AG$IOO-PMJ\_27QWH$NAL 1*O0C^>WWGD:,
MC:(LG;?<_$?_ ']Q''?%]9[YA:K@_B<>[#EL;')X[E+/W<YQM!:QR-V\GQW)
MVN=VIOB?AW_N+EN0^$7^7$ZV\Y\,D^%_1.1D <AQ=?XGA.2O K0'57&\CQM2
MC53:S4&VCELJ;T41"1J5:^@7RO\ 31FDZ0-$GZZ198^J=!TVGR;9:$6XS6K6
M_KT=;AGX>5)4D:MO;7QJDW)Z9\NFVJ)/DC6VK_EV3]X('WIV# 5/Z@ "-H6@
M#V/]VS^'W7_<0Q\+-L<P3/&(C$1B(Q$8B,1&(C$1B)Y7S@A5+228*.IL9TUQ
M+Y#+2FPQ_P#GRUZ<6G:1F?/7K7U>33?G]VM.7%;LO8(Y7L$[!25[L"538&NQ
M )"^Y .A*AT-JT!U-[KV2D,#:ZA@A9:]]V4,RKL CLP'N0)H0=.63QR&F5RC
M2LQ4?!N$41'7'ID,67#6CQ/O"NK&D:5RJ6%6Q(0'#?6H= N'4XYT>5Z.E)-;
MYT4+6ER-OD.E6NGX<5;<E*[^?8!Z,.Q5LIX8$ ID9M; I;R6B&Q\)P4Q/%N6
MK7=,=>W2FCX05;\RJK*^*65;,7 M5;<?X># -7E\E6VZ[^7T0^+QSAJ\#Y;\
M]6R.F*F]%=KL!48&'JU6A8NN5JO1H<- P$("-&0\-$QS"!0(V,C@VV10@0QF
MFV!AAVFVF6D)0A&DZUK.;MMMOMLNNL>VZUVLMML8O98[DLSN[$LS,222223[
MSC[[[LJZW(R;;+\B^Q[;KKG:RVVVQBSV6.Q+.[L2S,Q)).R9!:I.Q9O0NA@C
M$[<)TJ#\D;'*;0OW8#L&0]4\ZRAA[V4MQ##OJG%^2U:\O/7RYCF*6GB(Q$@?
M./X/R/Y>=3_O.M^2??\ @/Z"0/;^)_J9,S0@Y(,J/D1!CX\X=X,T$UAHH,P0
MEM3) I0SZ'&2!WVEK:>8>0MIUM2D+2I*MZW*LR,KHS*RD,K*2K*P.P5(T00?
M((.P9='>MU>MF1T8,CHQ5T93M65@0592 0000?(FAW0?"C=^65FWV3P'7=7%
M+ON+ESXCBLQIN?\ #+:I]UE]YEC[7LJE]KE1QA>V_4S/*3J?%:,] JS5^QC;
M?:5TN+SF-FW8]/Q-C#D<;O6MG(U[JYFBH$ G[6A'VY57>Z\Y,A^ORTVTG1G9
M87Q)B<CD8M'QEB?I;$]2I+>6JW1\08U((4M]NKT>21%WNKDDRK.FUQ[Z&ZF8
MKC/0/LD#O*.>3/0N)^%2_667J,)*34E">(OH7.I,HB2":-2\36%>&J[5P$_V
M9]E)XT7<B8O9^B%Q[S02F66YS:/A!\J_[%R/.8V/ZK^BMO$8N4H3?@"W],8]
MK+^R7QU?KH..VS'(8_P!=FY)XWE_B3#Q#<WV=+^!PLU%J^FK_P!/XF0R;\H;
M,5;>A4.I<,99OVYO%J#_ /-?!:W(>7[[X)\1_.)CTM_X_5?&4+SGTO\ L^M]
M1Y_X_1SR_H_@V^Y\0%/_ ,QQ.77_ (_9[,O7\-SQ_HKX:?\ Y?Q64_\ S? Y
M]6OS^RVYW\NWM* \3?CC\2G&>.V>U5O['IXCI*[;V'!UG:I[AMRJHDU/OZB8
MJ5E&>1=3Z=?2 P9(D1S0":".-*.^JC2YJ!T8V>WM.(^'.'S\^FF_XKX>K&^:
MRXFODL>XUUCNU:'/PL+%#.H*]CE$IY=*[BO0[G@/A+X?Y/E,?'ROCG@*</YK
M<@FGF,2]JJ@+'JK;E..X["5[%#)W.:6K^^E5Y7TSNWX>>7@<:XISCG(2Y$A^
M!K8ST_)S*64SM@N4XX[8;Q:;#[,\0/NQ6JXRLY8IY0[[S"I>3,VPXMGT-YSO
M*YC<AR.7EMT LM(J2O?I58]0%6-15O1]&C'2NFH$;%:+OS.3YOD'Y7EL[.?H
M!=>RTUU;]&C%I HP\:CL 1CXV+7310" 156FQO<N;-?-5(';_P"$'+/R\D?[
ML>CY(]C^7^8D'W'Y_P"1D\R),8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$2J:__''T[\B^4_Z_TS)^@_,_T$CZG\A_4RULB3-8_%'1+--5& ZAS6/5
M(]AX)/\ VS>?1S"M-D6\44$F.OW+7'?D\Q>GT8J:K B'E:%"M+M6L+J5/0 V
MT=9\(\CB8^;D\3RM@KX3XCQOT3R5K>5PG>Q;>.Y<#]OB.02C+<CY[,09>,#U
MR7!Y3XMX_*OPL?EN+K]3F_AW(_2O&UKX;-1*VKY'B"?V.6X][\1 3TKRSB91
M^;&36<X+=:!V[D&[-63X^U4J\RU].]2OU3NGH:UVB=E68Z9 VI;@19$-+C;.
MC#$MDCZ(VT^VE7GK-/R_#\G\/\A=QW*XMV'F8UCJ4L5E#^G8R"ZAR MU#LA-
M5U9*6+IE)$V?"\YQ'Q'@5\AQ&;CY^):%#M38EC4V-6EK8^2BDM1D5I8OJT6A
M;*R=,HF:YE(G5R0D^16(MXN2J8C4A3I8QQ3I-HYRZ][+%%/D+^Z*FZL_Z-9L
MB]^;SJVHB;(]'X@:3KPV@,%M7V?8< :"6?4 ?16'S+_$?W3-E42I-3'90;1C
M[M6?;?XE3\K>_P#=)^]+FS#,T8B,1&(C$1B(Q$8B1RSVB+J<;J0DE/NK??;"
MC(P%K94K-29'GH6*B0D[TLLXE2=^@C6TMLM)=)*=8$8??;]F#@W\A=Z- 50J
M-;??:WIX^-0G_,R,BT@BNI 1LG99BM=:O8Z(VKY?E\/A<7[5EFQVLL7'Q,3'
M3U<S/R[-^CAX5 (:[(M(.E&D1 ]USUTUV6)^/#E6ZIXU/%S,M2\C5!/"-$TV
M\4&[:C1S%S?0KI3G-05NH%2G%N'0MJH5/L-TKT1?IXF.$AK+:X.^40$69@@S
M'U?3FY[COA7X?IXK#QGR>2NOJY"I\Q?U8J<TM7FWTH]5^%D9"5&SCZ$=LC'Q
MCC9=MM5[JDR5? F'@+A_&_/9W/<-_:UE4TY'P_7P.=ACCO@W@79'PES%R<3(
M&?S>519F7/ZU=V'Z6;5?7C4>GB6/^J /Q_1 @XSW!#7.L18HX('P@,%4Y^,C
M0VD,"BMU4HANMF,!C-H9;3#R\-I+32&0H/7W#6N$9.%Y)F>O)OXG+L8LZ9[6
M9N#8['9(S:JSF4]F).LC&R0"=V96@6FC?+^+^,=K,[&H^*\8LSV9G',G'\Y\
MQ+-9?Q^9><#.L)):RW'Y'#LL/_+P69M24U^^U:R$KC@)+V::93Z15=F!R86Q
MBZUY^DI^$E&A9'U2=I5K133#H;GH[4R0XC>E;\69Q&?A(+K:.^*YU7FXSIE8
M5GX!<JAK*>Q_]VSK8OLR*00-AQGQ'P_*VMBXV5Z6?6O:[B\ZJW Y2D?4V<?F
M)3E>F""!<E;T/HFNUU\R8YK9O)!9CI%0AS%Q6Y-4O.H^3==K8A5CGDJ\_+6G
MXV&:,? 1O?GKVB1T&*C6E*<?0E*E:VN-PG(Y-0R/0&-B'_\ O<VRO"Q"/^B_
M):M+3_T4^I8? "$D3GL[XIX3!O;"^UG-Y%??B^*INY3D0?8>IB8*7V8ZD@CU
M<H44KHE[% )&*]Z]-L/R1%?BJ* Y]Z2N#Z9V>]6K[RV:O7C41S"_0^Z1LZU^
ML;7M*7X_?HK;ST>AP>'_ .T9F1RMH_\  XU#B8FQ]&S\RHWL-^"*N/T0"5N&
MP9XOMGQ;R?C!XS#^'L9O;*YRT<AR/4^S)Q'&7C%K.O*G(YGLI(]3%)#)*LY8
MB]<]@)8B0(DNDUAZ[WY)Q [3RKA!%1ERG(,\\:*402W/1<J5%NSI@48Z/+!'
M21RA )C;BMZV.?D<-\0V5G%QL;X=S:Z:Z:Z2Z?HS,"#8]3(2FDXF4>Q1;;T>
MBQ%079%)7NVDXC"^)_@NB\9^?G?&_%WY5^7?E=+?T]Q?JL 5IPK,G*7DL!0H
MM:C$MHRZ+&M.-AY*N*J]BX.>AK+&LR\#(BRD<_M24$BN>FE+C>_1>'>1O271
MBF%^;9(A"&B1G=*:?:;<2I.N9RL3)PKFQ\NFRBY-$I8NB5/E74_=>MQ\R6(6
M1U(9&92#.\X_DL#E<5,WCLJG,QK-A;:6[ .IT]=BG3U75MM;:;52VIP4L16!
M R^>>>V0/EG\6/./R#J'^S\=DGW/YG^L@>P_(?TD\R),KWIR9=ZK*%A*[*V4
MU^7K[GL42_!CO-#@3D=)DDNN3TS""^J0.$XG26B77UO+;2EG:=K6B1[_ ,#_
M #!D'_,?R.Y.Q7ED"C$.BOA./L,O.!E;'V4(MUM*UBD[$?*%V^PI6VGMC%$C
M[<0K;+[S?HN*B3._$2/RU3JL^4*=.UJOS1H.M)",EH:.D2@TI<]<E(I!@SSH
M^M._NNM-+1K3GW>ONOEQ$D&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B537_ ../IWY%\I_U_IF3]!^9_H)'U/Y#^IEK9$F52=99B[&$P% *T%%"
MO."6'H6FFR!0W6E>@3$5!IU*QIF>1OTFB9-Q+T)!.:4EW4E(H7',]!5A8W%U
MIE\NGJY%BBS#X?LR/8K#=>3R3*0^-B'PU>."N5EJ05-%!%S\;D<KG<_?;QOP
MW=]GPZ;'HY3XF"+950Z$I;@\&E@:K.Y)6!2[+9;,#CF!5QE9:G%3\U>*>&GI
M?@<"N]Y\+SME[1RZQ=.Z%)]6\/\ ;Y2+>O*UP]OFH)JW\9M:0HD8RQB048$Q
M)4JU:=>MN@]/!65$PD2,,^B\A\9\5_:4,7!^-$P^ YC#Q:\/A?B;CJ;UX]45
M1UP^>P6NR&7%MN+6+G891<-[#O%&.;'3A\/X)YG^S9LCDO@:[,Y_BLFY\GF_
MA7E+L=LS((8_\7P>>E% 7.IIU7]ERQ9]L1 &OLO%2S=V*Z!3?$C0(CJ_"YP>
M3ME$EC"(L"1:(A)R&L0;>Q+9ROH,&>VQ+U<Z6$2]!S<3,"CD14DB-FTLNN18
M;F_G',\%RGPUG-QW+XYI]5%LJNK9;\3-Q7^:C.P,JLM3EXS@BRJZEV5E)0]6
M+*/I'!_$/%_%& .0X>\NU%C59&+>C8^=@9:>+\#D<5_UN+D(04>NP:) LK9T
MZN;^I]KB[M6XJSP^WM!2@ZE['*;VR='&CNN"R43)#[^Z%E(B08*C9(57W0QP
MK[.][]#SWHW4HQ4^X/N/8CW!'[B-$?N,Z!&#J&'L?\0?J#^\'P9)<K+2NK9U
M"M4VT4NHRR9)V7O9ZP(A( B"6!UI=&'2_)+V^TX.,X04TTEUEDG:/)UUY#0[
M+CJ=SQ_!9W)8/)\CCFA<?BJA=DFZPULX*NY2@=&5[%2MF*LR;VJJ6=@IY?FO
MB[B>"Y?@.$S1EOG?$>0V-@C&H6ZNME>JOU,MC8CU4M9<BAZTM*Z=W5*T9QHU
M]DZ1=KMR.B\"Y-TVZ\JZKV/H<>_&VVA2YT-,5SGW-17KIT^TRA,69%R;E>C(
MD:,A4A@S,.Y)W*STN'(/0#)%M.['X4LQL')S>9SL''S\'C,*POC92*]=^5EG
M[/AT)W5T6UW+V]GKL"8]&0ZH752/K_P/=B<9F<C\0<EQN)RO&\-QUALP\VM+
M*LG-SF&)Q^-7ZE=U:WV6M9<7>FX5XN/EVK67K4B_?#?V2=F_:^$=F&37/$AR
MF BDV^.=*<)C.G5AK2(F,[CSB3(:'<L-*N!3&U2[.VM3%%M;QM0M([!;4:=,
M>#EL"JOKR7'GUN)S;'-#A0KX=QV[\;EH"15DXZGY"#Z>30%OH)4NE>LYWBJ:
MNO,\4QOX+DKK#C6! MG'9)W99P^?6I9:,O%5OU1WZ69C!,K')4V)5M;FDG-Q
MB)&+5:X^J!,ODMD'2$@1H&#@X]"7I:=DUI4ML"/84I"=JTE*G2BGEM!QXB'3
M#GV!FG'->_C^/NY"UD1DJII3U<K+N)7'Q* =-;<X!T-_+76H:RZPK54CV,%.
MHYGF<;AL=++5MR<K)L^S\=QV, ^;R66P+)C8M9*@G0+W7.4HQJ5?(R+*Z:W<
M:,]@-OE^OT9P"FV!V/[1?*][ZZG?*Z]M8?A9\/TF4_'GJJ1;C>T-=:Z@\$?4
M.?2KK*9-XT6R7Y0[-?H(\.;U--^%BX39*4D<+B7!,6B\!<CXDYBI0Z69RJWC
MC\$.M]N,K&FE&IQNUF3EO>-S\&_#1Q#9_:#\9ICYV?07Q.#XK;6<?5FNJV?H
MS 1@C6XF&AJR?B+E&5+>1/V;CU%&/DU4T;#UN*YCRZ[<DY'2E5BK0]/Y/=:Q
M6J6%(ALD1L<-*\G]UA- NDJD'GR Q7BO7D:>-D5(*/?=(>40^KC\G(OS+K\K
M)L:[(R+6MNM?RSNY)9C[ >2   %4:50  )FS,S)Y#,OS<RY\C*RK;+[[G.VL
MML;LS'6@![]54!54!5 50!L-GGGGF L%5KEJ&0+8H8"6:97ZP91;"5$!O?)Y
M$ &)]$L E/EK:"0GV'T;UK:7-;SV8>?FX#FS#R;L=F'5Q6Y"6K^Q;6=UW(?J
MEJNA^HFMY+A^+YBI:>3P,;-1&[U&ZL&VBSQJW&O&KL:T:'6VBRNQ?HPE&UGE
MJ'KKT"/GKI>K'61'8#<76)*UV+<<(R7'N/[',>3+[*EV&=>BRVR8YZE]M"5R
M+1Y&DO)WV1\4%\7$KP^)XK SJ%L&1R5.#A&[(9VWWJK.*$Q6]R6K[,"=4M0F
MT/'87P *L_D[>2^)/B'E^)RWH.%P>5RW*+C85=2%33?<.0:[D:SL*J7]$9%'
MVI,JT"X7Y#P4+7@T1T#$1L* W\J XL(8 ;6_+RVK;(S;:-KWY?=+5K:U;^52
MM[WO><[DY>5F6F[+R+LFYO>R^U[7_+LY8@#Z >![ :G;X/'8'&4+B\;A8F!C
M+Y6C#QZL:H'ZMZ=*(I8_5B.Q]R29D74*<:<;0ZXPM;:T)?:TTIUE2D[2EUO3
MS;S.W&][TM&G6G6MJUK3C:T>:=^>>R5;R"+-C*[,),L,Q/\ KKYTW;:I9B 9
MV-MOI5P2]MCW%"0J5;+<WL@CVE)&D.[]$70S'DSJ3[_P']!('Y_4_P!3,K.4
M-MZ1>LM3D5U&VNZ3LF0$821$S_J]>3;%K@]N,C3+>D>;;9R' YP1&])"E6&]
M*:7M\7EBM"X/(4CD>.7?2FQRF1B=CLOQ^5IGQCOYC219BV'9MQV8]AS7(_#B
MV95G*\+E-PG-/HVY--8MPN2Z?=KYGCNU=6<NOD7)5J.1H7QCYM:;1L2GJ(-<
M\P>I(#H4@W]RS+&&Z539WRVE/K8.POH':0^O:M*W"2R 9EG2M^K'-'1[8N]W
M$>K4^7Q%K<CB* UM83KR&$#H 9F(I<] 3U&5CF[%8Z[/4Y](8L3XE-&17QOQ
M+C)P?).>N/<UWJ<+RA4$EN,Y)UK46D N>/S5Q\^L;Z59%2?:&]W')("5Y3SH
MJ.+9,'32JP,IUA>EH20)"@CDL*WK[SK#[:V74;\E(<0I*M:WK>LTSJR.ZNK*
MRL0RL"K*0?((.B"/J#YG45NEE:/6ZNCJK(Z,'1U(!#*RDJRD>002"/(,LG*R
M\Q$W/P=:!W)V&7C82.2\R/LZ5,'!%T^0OT&6O7DN-M^L<5\B4>EY[UI2O+T4
MJWKT8N)E9MOH8>-?E7%6?TL>I[;.J#;-T0,VE'N=?4#W(GBY#DN/XK'^U\GG
M8G'XHLKJ^T9F15C4^I:W6M/4M9%[.?8;WH$^P)&62K2M:4G>E)5K2DJ3O6]*
MUO7GK>MZ^3>MZ^76]?)O6><@@D$:(\$'P01[@B>P$$ @@@C8(\@@^Q!^H,^X
MDQB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1/(<>#%ADR,F8)'1X3*R
M##CB&1 Q!VD[4Z^240MMAAEM.MJ6ZZM"$)UO:E:UB)W,/L%,,DC/-$#$--OC
MD,.(>8?8>1IQIYEUO:FW6G6U)6VXA2D+0K2D[VG>MXB5+%FAQW6.KGR!0X0(
M=%Y:2686\V.,,.R;TU;KS[[JDMM--HUM2UK4E*=:WO>]9DKJLN>NFFM[;;'Z
M5UUJ7=W;J%5$4%F8GP  29AOOHQ:KLG)NKQ\>BHVW7W.M=552!F>RRQR%1$4
M$LS$  ;)GSSF.J>7H[D*[S1?WUZ]?&V.^L;_ ,S_ )HROU$E/WU_N$W/C*^X
M]V1KFER&_P#^&X#W]'-YL?3Y+\+B7_?]ZK,Y%#[??Q<-QY]>\:HXW>=\8^!]
MJXOX4;^]^LQ>5^(Z_P#I^Y?QG"6C^]^KY#DJS\OV3$;>5:8@8,0 P%'B,@Q\
M>,ED4($;3; PPZ/)M@409OY$H0G26V66][W\B4(WO>M;T%MMM]CW76/;;:Q>
MRVQB]CNQVS.S$LS$^22=SLL?'HQ**L;%IJQ\>BM:J:*46JJJI %2NNM %1%
M 55  'L)5W&YT*:@['[&/-,>S]"Z0XOWO6[%7_229T&TNL^S^_HN-]J4E*=Z
M*;%]<X"YZ+)J1WEI;50^_P# ?T$RCV_B?ZF5;USPU$3%O<[?P>S,<>\0; K
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M_G-+)[D1&(D#K_\ #?H7_P"ZJ?\ LSF(D\Q$8B0/G'\'Y'\O.I_WG6_)/O\
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M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*IK_\
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M8B,1&(C$1B)KM2[Y R_B!ZO6Q!;<W(B5.A#.O27/K]#0BG8*6Z$.<H:S3%:
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M-.AM;6A+[B-J3IUQMO:M:WKUCB$>?I*3K<CV/Y?YB0?I^?\ D9[NC<KYMUV
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M[!+3\4$-6.7=-L@S35:Z5,<?E)\X^$J1P8=23T>OSE:'MCKVJ^2N(D99N0W
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M%F5T(N(LT)DA4K4IW"U^DRDLH*KD')1@RD-LNS*P_9 ((8AEDT$O8P;KV<6
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M62#)N?GI%$A..6.2*.%:DY7#=D^JC+UZEGJ)'N%6BMJZP#X\MZMA<!54:3H
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MU]_\*OZN(G+XN?\ F37TJ_JXB/BY_P"9-?2K^KB(^+G_ )DU]*OZN(CXN?\
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M$:P@,P(UZB]=Z[#YQM.K-9G5?$O3>0V557L4-8S#DP8UDV[%,1[P_N4T.W-
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MSN=QK$[6@N>7@"C7$914),.19<G'5@T*68?B9$E@^*?=M\$'KU2D2+#A+BS
M!=#$I:PC$9[:ZJW5S;4;:_#+VT7!4@C88>FQ_#QX)F0WA4=V5E%;A'\@ZV%.
M_!T1\P'X[/M*]AO&94)Z3KT;&\]Z@6J5>K+,P0!6G)<>I[LC]7AWDSC\(Y)"
MCO5BVS\M5;8VLAI,3)T2Z-H=*("B1)G,W'6('+74CKWZ@OU[].Y'7MHZ=%6R
MOQ\RV5GP"Q7&,M"0 EAWUWI=]>Q4$'KO15B5;\"C[]AN/17C:A9V8YPV'SZ^
M1$+T/W7J)>M%7D8-<BS='JVQ094>8D%AP,=$DN2YC=@*,((':-;BHF!+FI:?
MKH4Y9N-9%NW;6S4[[!'5^OIAS:I5=L2.HZ:\D;9@JJY6!F*QKTCA;-:+*1ON
M5"'?L!Y/8GZZ4;++NU.3>(03H1U=J<C"%@7B5KZK68(,AIN*34D1,*1NX!*?
M.(*5!/V2;1216W=JD7K!%S:TC[C8Y9JL.1B&D/8&!J5^@)^]W+,/3.@!W"+Z
MA^G1E^IU,E5XL*J5(<KV(^G72GL/^DLW0?7L#XT-S9K/%/1&(G444D$,@M;)
M1"!VU.J9"&>,+<TG6ON!Q6$K>?<W_P!%MM"EJ_Q:P!LZ_KX'^,@G0WY/Y>3*
M@Z'W&#YU396YR58NY0<6]'#N"_#AL:ZZN2+2(TI+\L@,5#+2U>;SFW=[3O;3
M:4J<>;3O-70;'"!D!._/;?L-_3<Q67BI"Y1R!KQUU[_GJ3*(Z#'RS<4^Q7[J
MRB68CR&5%5*9:;81),LO->UD:'6,QZA+Z=%+]<IIC:'/-S:4;5E3602.R>-^
MSCZ>/$L+ 0"%?SH_=/UFGTQXI^FP$O>W9"OP&ZY'R'=(2FODU&<BPRIGDD\2
M''!*MK=ZF&;.?,0T5.2<C&)J5(2"F,D%ARIOL"1I#8#"I9:M,W<C&:P"Q20M
MZ[)Z>FI0*Q4!N]F^P!4;V/.<BQ6?87J#<$^0C9K]AW[GL2 Q(Z+['1\>9'9/
M$C?JM5-=,+$HIE4GYCN=<K]/2!8 K179#D=4ZS9 C[196IN6&F-2#O)2XRS0
M$72(<VL'6-D0>3FW8%U4Y1<2I[/1!L#JN,[6;4HPO>A2$32D:%X*,;"'"[*K
MV^4V0ZKZA"%6:Y50=NP-2VL"S;.]^EIE" J6\%NOS84+Q2]*"DHP&T5!@+W;
M>ZG1K0./0;<Y(FGW3JD-1F$&*@K-;Z]R8JNU:R5^],MV:Q7,'HHLL-$5.1"D
MV90>,N<*D@E')W4]J'U4Z@5TFS8[5UO<'=6K/1*VJ*EG!'7M'VFP$!D]K%1@
M$;9+6!/.F9:NJLM@+,P<'2G>]6IT+Q 358>)F:]7HN4HR/#]VGK($A,+LD%9
M9"T<KD:>*W!&5Z5@HYZ!KK@]B==+EREER)BUH6-& AQ^BIK#5BHXZN["W[3C
MTE4Z,@KN#DL'5F#/\HTH\#SMB3I<EEY3RJ@IZ-M@+=E8M65'4J5'5?/ECLGZ
M#0V8F+XA>BC76QTR1#I1:N97CE%1N<F'#3D>S>&NS=&A*-"FTAA^TR?PN[2A
MYCVNSC2A%TU*2P[<.*[!I+T</D.)3Z:6*;!ZU=]E8+(?3]"IK&%AZ+W[E=*0
M*^H.SVUJ5]>P.RD(16]2,0K#OZMBH"NV/7KO;;[[UKQ]-A^LW.S4:(JTK78B
M$E&9/IG+:?879F1-#5&0%\Z)6*0;(1 80)/O:89W86]AB%G1 (^O62)!1GL2
M(:3\E%:6,X=F4K3=8@4 ]FKJ>P!B2.J_)Y(#$^P WV&:UV0(54$&RM&V2-*]
MBH2  =GYO \#Z[^AA-TZW9J[U0:J@!03M9C=\;8G6"A9!VRR[_:+A>Z8 1 F
MLR8P$8+42:@/,2:#(>:7.1Q$NRR_!.0Z23LM>.CT&PENY^T%=$=%&/758>X*
MDDOZA4:90IZGYMZ%7M9;>NEZCTM[WV)N=T'7SH!>NSL'?D?+K9PM@\3H<!=9
MBI*YS;S@X20F!3K(-(5)N/T'6#^7Q]GE6@B9]F6<&C7>O5/0@^@M'2:QY[38
MS#0 3TI*X1:M7]:L%E4A"MF]N+B@V%*[/H/OSH?+Y)) JV0%<H:WTI.V!76E
M]+L=%@=#U4^FR=Z&ALP"W>+\AJA6.QU&DE@RH?,1.OUS=K6%)Q\M0Y?GO7.A
M0<R3&52;?F WC!N3%0YL82L,J-E+%#-^D7ZS:%Y:\#=J(]@*F[T&Z;4K:+:*
MF4-8H4Z-X8'V*HQ\:E'RM(S*OD5^JO;1!3I8X.E;8WZ>B#H@L/?ZV1!>** L
M4A51XJEVE<;9'J:P]*%$5T%V!WT&R7.MU1$Q"%3#<VP>I^BRZ[)#)"5-5,H@
M.$F8]J;"M %;QM@L@?M:G9!8= ,0WI)6[]6"]2-6+T;?6P;925*%\@R5/72M
MIB@\]05]1F5>RD[!VA[#6U\ C?8+AKIXRN<4*W6JD3\';M6"F@R4I-"AA1Y6
M_8(PT8QU0&M2*5GF.<]<.ZHU',H]JW38:5<4A,D/H%<U<?=;6EB-7U<@*23[
MD$>?!U^MU3OV]1A]#N5?+K1F1E?:@D@ ;\:/CSY^3]8![]0?J)X&?&5 J*B8
MTGD?:A)@J0D69>+<H$ZHB#AXU'.W'K ZW[$@@J-]7TR#\R4#,A*>B+2*P<02
M!#M6"3Q[@,?7QRH52I]5?F9O5'3WT#NIO!.]%"0 6ZOM0V!Z5P.SO]6? 'I_
M-^\?K%^FO# $D#M@*%XRF;3$4*PR=:6#"'U0XKH)GJ%1K\#/Q\CP$&3FA8^5
MDTFQ7/8$;LIEA/E+$TT9*U"&8N5>W(U8V%E[):WCS6UJ!]L''I>=AE(R2JDJ
MO5K6- 0!3I;&-;]7#(L)E!@C%=#J2YUKJP]#9T3L(HM+$D>5 ==J03N'2;0-
M=JG6KB$$;'@6B'CY^-%DD(:/1&2P[9L:X8PVMS0Q! +PY#HBU>N$4[L8A*'V
MG$)\%B>G8]9()1BI(]NRG3:_$ [&_8^X\3THW=58 @, 1OWT?(W^8\Z^DEV4
MEHQ$[D?O=?T_V[Q$Y8B,1-9\1&(C$1B)R1^^U_3_ &;Q$[?+7GO?EKSWY>>_
M+Y=^7WO/?^/R\]^7^3$;^GT$^XB1.1H5%EX^2B9:EU.4BIJ6W/S$9(UR'-CY
M:=VEE.YJ2")#=&.EMI&'3N1*;=,VEAG6WO)I'HY!;:I#+;8K*O16#L"J?L@@
M["^3\H\>?:5*(0044@GL05!!/XD$:)_>?,[DTNG)V-M-3K*=A/H)#VF!B];$
M);-A9)L@;>A?W!]N1K==/0ZUZ#B38&%*2K3\6"XP]6WS^LL\C1^=O((8:/GR
M-.XU^#L/9CMT3]E?'D?*/Q4_A^*J?S53]!,2SR7E:(XB*1S/GR(LI;ZR8U-,
MKB0"%E$0Q9*WP]1NAWE$%UVOE/J<;5MXB"AGG-J<BPE,6^T7DAC?<6&M-ZC[
M&NP&CVWX#OK\.S?M'<>E7K7IIH^XZ+H_=/MK_I7_ .5?P$D)-/J1L;$PQE6K
MA<1 M+8@XHF$C'XV%8<@SZRXS$@NBK%CFEUN5E*\ML-IE"H.2/B=ZV 80.Y0
M66!F86.&;RS!F#,>XLVQ!V?G57\_WU#>X!DE%( *J0OW00"!\I7P->/E)7Q_
M=)'L3,:3S7G1A9,@70:44>9"*K)9I-5@GRRJXH9 2J^22Z IY^$4&TV(J*=6
MH#8S:&-L>J0E&K"^X  76@!NX L< /LGN!O[VR3V]]DG<CTZ]D]$V5ZD]5V5
M_9/C[O[O:?$\SYP@!$4CG])1%MC>Q-QJ:I!) ;#TFP(T(@/0&ATC>A;+4CU"
M6]->C9K GT/*9D=$O6NWV]6WMO?;U'WOY/.][W^KK_\ D3]D:>FFM=$U[:ZC
M7][Z:_ZF_P#F;\3/;6*A$5/=B=C=$.FVRRG6RPR!BV5F2<P8)'Q;3KZAV!F?
M5QT%#PL!'I0PE;<5#@-D.$E)?*?A[&LZ!O:M!6@&]*H)8ZV2?F9F8^?=CK0T
M!*J%[$>[L68GW)T /\%55'[E&]GS)AK[VOYM?V9CEI]Q$8B,1/J?OZ_GUB)%
MCN>4"3LP=UDJ-3Y"Y1Z1D 6TZLPI=F!0%M]0: YY\)R5&2(HHG8R62T:8V0_
MMK2-NN>ED%UJH:UML%9WNL.P0[]]H#U.]#>QYE#766#FM"XUIRJEAKVTVMC6
MSKS]9T[YISE4C7YC= I.Y>I@@1=5E=U6"W(UF,BTN(C(ZOG; ]IA@8Y#KJ0!
M(YT8<-+CB1VV]+5K<^M=IU]6WK82SKZCZ<M]XN-Z8GZD[)^L>G7M3T3:@!3U
M7:@>P4Z\ ?37M.E7).4OC%BO\RYZ\-(3&K">.[2ZVXP=/H0:TF<,97&[;)F$
MM2,@VF2>2LW39YB-/:24_I>9+[]*?6MV%*@^H^PNQ\H._"_*/'MX'X"/2K]O
M331/8CHOD^?/M[^3Y]_)_&3DL $_0^C@A#=!EL'B:+&9)T*<+O:AC1_7(7Z@
ML=6]J8):]%YK>][;6G>]Y4$C>B1L$'1UL'W!_$'ZB7T#[C>O(_/\9#W.4\N*
M&D ">;4$D&5FE664#?IU=>$DK&I!#:I\\=R.4R9-*;,+;5*D(<.V@HE&W_1?
M=TJXNN!!%M@*KT4BQMA/'R@[\+X'RCQX'CQ*>E601Z::)[$=%T6_$C7D^3Y/
MGS,T32*>=$R\#(UF%E8.?E'IJ:AYB/&EXN3E"#69%PTP"304*\[[>..8WI;6
MT,DL,O,I;<:0I,"QPP8.P91I64D$ #6@1HCQX_*244@J5!4G9! ())WY!\>_
MG\_,]+%3JHHOL0M:KXP7M$&7[(Q#1S(OM58]W?#1/L[8R6O:*][GB/<;WH>L
MB?=4=[ H?V$;U4%W)V78GYALL=Z??<;W_?[-V_:['>]F.J@:"KKY3K0UM==3
M_P##H=?PT->PGJ?@((J03+$PL21*I]W>C)OQP;T@GW0N4<B?1-<943KW6N<F
MEQWDY_@2YB44-ZK<@7M[SAW ZAF"^?E#$#YNO;QO7S=%W^/5=^PU)52=E03X
M\D#?C>O/[NQU^&S^)E6PW .80=^>Z,%70M3GNMF'C&%1T*W'0(#*JLMMB)0+
M%#'>J%72JQN'8DCY$:L-Q:!JHQ!"$FL$YVR[VJ]$N>O;LQVQ9S\XVVV(\^H_
M8J%+]MN6(&L0HK#^IU';6AX&E'R>!H _W%ULGKK2]02#]O7A[Y7T6/ BYNL1
MHD<$VV$\%$1,"(/(1#(:H]F()2]$%;$9$ <>"B92&5%6.O"%'CUR;B&9.206
MJR[Z265R2?.V9R0VP>P(8'R0"RMM'(4NK=5T>BNP %0 /&@% (UK1\'V!(!&
MF4$]2-G=H2M4JTZ4P=-UN F#A6QV13)6'CI H9H29BK&(TP06,\\RV-88*$G
M1T-K2EF9AXJ4;TDZ/$?9PK8Z#2NZ@[)"L0/*LA\ _5&93^*LR^Q(F0JK';*I
M/CR0"?!##W_!@&'[P#[@2/%<GY8=J=T;S3GYFK0:Q)6715-KI&K%(C%%&C'S
MNGHU?O8T<TXTM@H_VA]HHPHAMQ+I#JUV%]XZZNM'0=4U8XZ@@ A?/R@@ :&A
MH ?25]*H]MUUGL=M\B_,=[VWCR=DG9^L][W/Z4YZMUBK5P$\5#VHV5#K\&B2
MB'W=0WD9%D/1SR12FG:W6WVE^K6CUU=@E.-N:B@DLP+K1_XCD?52[=6'S>&&
M_(/=P1^#M^T9/II^RH/T(4;'MY!U].JZ_P#*OX">VGU.%HM8A*C71MBPT  T
M $VM?K'W$H\UO%%O>BG9)YQ"WC3RUZTX6:0^2YYN.JWD66-:[6.=LYV?P_<
M/H - #Z  244(H1? 4:'^I_>3Y/[Y*]?>U_-K^S*2T^XB=J/O?T_[M8B<\1/
MJ-:]/S\M>>]>6]^7R[UK6_+6]_?WK7GOR_R>>_\ +B)A;/4:I=8SW)<JQ7K;
M#;(8,W$6>%C9Z,V6+M2ABO8)48L7V@=2E;8?]5ZUK:E;;4G>]Y=+'K/:MWK;
M1'9&*G1]QM2#H_4?6595<:=58>^F 8;'L='8\3#O\PYH3#*KI//*,17U@0T4
MN"?J4 [#+BZZ68?7XU48Y'J"4!!'2,@;#![8V/&%G&$!-L/%/K7/K7!NXML[
M;8]O4;MMP YWO>V  8[VP !WJ1Z=>NOIIUT!UZKK2[*C6M:4DZ'TV=3L1S7G
M+;]=);H%*;)J >H^ID(JL$E^K@:2M&@:ZZD#3D*'I+CB=#1JAF=)6O7H>2E:
MV]:WYQZMFK#MQW;YS^+^?F/[SLQZ=?R_JT^4:7Y5^4?@OCP/W"9:MU2K4V-U
M#5"M0%4A]/.$ZBJW#QT%&Z(=2A+K^@8L8473SB6FTN.Z:]-:6T:4K>D)\JN[
MV'M8[.WMV=BQU^&V),E551I551^"@ ?X">9-"HRCH&353*GN2J;#PU6D-UV'
MV=6ABFUM$CU\O8?KX9@AI:VWVHYP9MUM2D.)4E6];MZMNF'J6:?RX[MIR/(+
M#?S:_?N.B;!Z+M?"GJ-J#[@'7C^$X07.J%5GX]^KTZMUE44S,,1[-=AP8(,5
MNP*AU36T 13(@6W9'=?A=$$+'4^I,<.A+B4)4E1KK7!#V._;KONQ8GIVZ^6V
M?'=M#?\ >,A:T775%76]=0%'S:WX&AYZCS[^(&YSST-P]X2ATP5Z5E#9R4=&
MJ\(PY)3<D#*Q<C,'K:!2HR4/C)V;CC9 C;A90,Q*B/O+'D"VWAMM.MVV'JH4
M;=CI5*D*//A054@#P"JD>0(].L;TB#9V?E'DD$$GQY.B1OWT3^,]<52*7!0P
MU=A*A5X>OAR \N)!14!$Q\,++"2#,N+)C1@@C(3$@-*CCR8YK3"269!ADUMU
M)+2'4PUMC,7:QV8J5+,[%BI'4J23LJ5)4C>M'7M)"*H"A5"@["@  '>]@ :W
MOS^?GWE=]%\/?+.G0H->L%;CQH8(=F.7'Q,7!"CEPC$>;%,PCC9$08D$42/D
M3Q(B1A=15AK;1QWPQ-0JCSE$YJLN^EBRN2Q/;;,Q(8D,6'S#9) +!NR/H=U;
M0UCLHJL 5E&AXT NB-$:.P? !.B-,NSU(V9.Y/F]%F(HN**JT&VP9&HBO: X
MP(.0$%';G&P%1T@PP@L B*W9K"_$$BNMO1A4W*DA+9>D"UO8UNM5@PL;8/;R
MQ())4G8WHANB=@?!"J#["7-:$:*CV WKSH;UH^XUV.C[@DD>YF$H_&>?T.GR
M-&C8&.D*_-RI4W/!2L1 ;!F90K02%DE047$1=8&0VQ&QK# 47!1X#* !W4B^
MU>N(=M;D6VV+86*NJA5*LVU4;]F9F<[+,22Q/DC>M"52E$0H!M6/8A@NB?'T
M "^     /$D#O-^=ODQ!K]"I;QE?EI6?@2W:M!N$PD[.S6[+-S40^L';L;+3
M-CWN?E9(-;)DA-;W*EO/';]?E!=< P%M@#*JL [:957JJMY\JJ_*H/@+X'B6
M].OQ^K3Y267Y5\%CV)'CP2WS$CR3Y/F>8/E7+X\<\0#F]"!$E-G[DQ0Z?7AA
MY'<JT.Q*;/99CD-E[DF0Q&3]D)<V8T*.V1ZQ##6DR;[SHFZTE==2;'.NN]:\
M^-;.M>VSKW,"JL;U6@WO>D7SOWWX\[T-[]]>9VP7/*O7;/+VR*!0-)RL# 59
MMIID,>/AJW7")8Z/A(,(,49H %<I.RTJ;K]U>,-+3ZU[8H4<,&:YW1:V.U5F
M?ZDL[Z!9B2=GJJJ/P _$DD$56+ >2JK]-!5V0  / V23^)/[AJP,Q2\8B=J/
MO?T_[M8B<_+S^3?RZQ$Y(_?:_I_LWB)!&^2<J:EYNP-<RY\W/65H]BQS;=,K
MB)>P,RKS9$HS-R28W1DJU)$,LOGMGO/H,>:;=(TXM"5:R^O?U5?6MZIHHOJ/
MU7J-+U&]+H>!K6A[2GI5[+>FG9MACT7; ^X)UL[^N_>>I/,^;IFINR)Y_2$V
M*S EQEDGTU2!U-6"-D&F&#X^;E= >W2H)K PS)8A[Y#!+0[#;S:T--Z3'K6]
M57U;.J$%%[MU4@[!4;TI!.P1K1CTZ]ENB=F!#'J-L#[@G6R#]09T@<JY?%.P
M#\7S>A1K]4=.?JSP%/KP;M;?DWMD23T X/'-KAW9 A2GSG([8RRWM[=(VXO>
MU9)ON;OVNM;U-!]V.>_7[O?9^;7TWO7T@5UCKJM!UWUTJCKOWZ^/&_KKWDJ.
MA(:3=T1)1,9(/IC9.'2\< *6[J(FMA*F8K3C[3B]1LMN.C]R8.E>RG[ "V4T
M[L5CT*!F7PK,!M6\$CYEWU;Q]5V>I]QLZ]Y8@'W /@CR-^#K8_(Z&Q]="1R/
MY;S*.^'%1_.J(!NG/'OU'851KXNZJ_*D:,E'JYMB/1N#=DB]>U'N1GLJS"/W
M<C;COW67-UQ[[MM/?0?=CGOU&AWV?FT/ WO0\"5].L==5H.NRORK\I/DE?'C
M9\G7O,\#5*W&UZ$J8D)':K=;&KPL%#OCH,"C&JFX _6=C-F:(WI^")BXTN+*
M4I109H(AK+R2F&WDT+NSLY8]W+%F!T27WWWK7W@Q##V()'L9(50H70ZKUT/<
M#KKK[_LD @_0@'WGA30*(B9C;$FDU%-@AGY@F(G4UN&U,Q1-A,D9"?(C9307
MMH+\X?,2YTPZ*^TY)F2DB2:I]XXE;MO5MZE/4LZL%#+W;JP4*%!&]$*%4+L>
M J@> (Z)L-T7L-D'J-CL26T=;&R23KW))/O/6_3ZD4^0435JX027[=HHE^$C
M'GR=2;L*_):(><%4X][P?KE>>.]8I7M;L#"N$>L7%@[8@66#6G<:UK3-XT&
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L1._7WM?S:_LQ$^XB,1&(GW7W]?SZ_MQ$[\1&(G<C][K^G^W>(G+$1B)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g743471g07v49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g07v49.jpg
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M  (1 0,1 ?_$ !X  0 " @,! 0$            &!P4( @,$ 0D*_\0 5!
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M04L"@;F=\AE)(55.<$GVZ+=198FBNJ=5JNNH#J!ER7)W(6S@*N-K  DL",@
M@WWR[RPZ5U'M%K"C^?<R$<.J_?\ IGC0Y8SG6%B>NS;_ ,P!.$B9P7SZ?6&
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MW27XR0-NYQ9#;,"7I4H5JU+$^\W#@0VF?.U-*)IM':H4,_TFFS8<J[:>Q<6
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M8HU9^+9)5PZ')]N<$=OTB7*P7:C-8MC,:TL#LB[1N5_DO&5*M@8SC(,8YO\
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M]3ZKU#TU<_ZIU#J>MZ3U-$'XE75.F*^CO4#VI3KNC&RPA>_U(EFLFW?![?\
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M7V4K<2RTE:M:UM6FF]*WO2$^FAP/HVG/Q-FH!_0!21^\RI?PM@^&RK_,V?\
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MQJG7NE9DJTYI-KZ&]75F!:BT[J^![0KK[ZR,D D."  P.W,V/A^47 >SF0W
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M*%;%SG'KM)TCKNFLZ9UC0:;5TVX-F@ZEIZKD8CZME:V!T9D/-=U+;ZVPRLC
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MY4D]RJ)HI6I#[LRP<D7(:BPU+>6IV66YQ*DK1$KIE:U+?DUJ0XQ5C;JE*:4
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M?A#)?7/+SPJ\B&XE2Z07IU-O]3M%=D3.%>4P0/S3J]*O4B5N%65MT7I&XSA
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M/UAY&0<@X/()&0>1B<MHIO4+;6K@'(##P?L/D?;CSX,AG0/"SQ-ZF-Y^&O\
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MW*<,1S,W]#N_?TWTW_!17^IF6[]-^8L_Q _@S!MN_.I_='^)'T.[]_3?3?\
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MPR'/@#I<N-/D1$N*]%NI6FK8*=.C_15T9O5;>\=.JA"GNM:L;U&'9:U)!(!
M)F,:) ^XVVLG?;4"HFOMBUF+[N*PYVL<J"^ 0"<D37FQ?<N@7/\ D7:Z]PHX
M4O'1.M<FUQN!*[+9JG3@5:@ZN<Z[U[I,^P\MXC],+AT:@6HCNUQ+%:W#-GN4
MX?#B'[6PM@>0'Z5ZN]MU#:A5KJIN[Y%".[,=@1J@MU^Q*K$&PJFU$!)5.2#0
M>GJE5JU$N]M?:!M95"C<76PFNK<]B,=^YLLQ W-X,M>Q?<R>,7&H^/E2L-KN
MK4'@5.I-8@(#P>=K>/$*B;@VJ5;H]CM5#M-\H5NM=FC29EILO,KA3#AN"1EP
M)Q![>HDF+2O5KT?4NJ5YU+V.=QMPH=2FS8EB56(B$!%MKL52 0/(-IT%3)0A
M9P*411MV9)4AMP9D9T9F'N:MD9@<$\ C](L\N;HQ$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB)0=D\F.15.T'::9,'6[#7+1SJFE(4.DW(DVW8>IZ><ID)B8/!28<M)"-&D2
MG9$9]V/&996EUSXC;;"]"Z6YT6Q57:R6N";$'MIQW#@L#P2!CR?@)2U]2LRE
MCN5D0C:Q]UGU!P#Y\Y\ >9/F.K<NE SEGB])H,FM5EQ+5DL+%QKKP.ONK;:>
M2V<+-D50!+BFGF74HGR(ZMMNM+UK:7$;W6:;@RH:K [?50HVYO/U5QD^#X'P
M,GW*]I;>FU?K-N&!QGDYP..9@JWV_G=NN;]& %9D\HB(0E0R*0Y5NLFE!X=9
M('(0*S.1$A2\\+"N5:?(18<MQ:=SY3$?XB2!LC(>3Z>U*Q8P &0"-REUW%PI
M90<J&*-@D? 'PR%HK<C/L4DGG!VG:=H4D!L8) =?!^>/JMB'O>5?%(M>MUIG
M6,D/"T^"),2I4VLV)E9P"?GV077[%48_RU4BT C<ZG6K0\D(:DL+@ IIU_;%
M>W&+2)_0[]R(%!9R5 #+[64*61SG",H=,AN<L%^OE1SZ14 Q+$!0"<J>02P#
M+QE@2K8(R,#/CF6_8+O6*L0%C#I6,.DE1]B,H5)<0S&@U^IP69UDL9>6\IN,
M+KX;4T5$(%YCC4.-/-!XCKB7)[/K2M;N"RC(4JO'DLY(15'EF;#$*,DA6/P,
ML+*I )QD,?L"J,LQ/P49 )/Q(^<Q3'6N525BVX_3.?2%G T^QA4,7.N.K+UX
M6F<LF>%I;)*V0##D"R2YY2)IV#$2.G*D/MZB2-M][-PSFJP;6"M][;ACC"GC
MACN& >3D8\B<[M?'WQ.06'O7E1G)'/(&#D^!@_*>&)V[C$]N<[!Z[S":T,@K
M*$G(E^JDEL>,;+MU]PC.6R66F)!;//,A%RW]MQTEW6QJG-3%I9W(Z>\8S3<,
MG S6XR=N[ ]O)V@MCSMY\3@MJ.<6UG R<.O SMR>?&[V_IX\SW;ZURM+H9A7
M3.?)?L0619*^SNYUS3IVNQ(LV;+/!F]DO;)A8L,:1ER"D+3\%F*/FR''TM17
MUMQ[-WN/:LPK;&.QO:Q(&UN.&R0,'G)'',[W*^/OB>X;E]R\CGD<\C@\CC@S
MC$Z[R>>IQ,'I_/)JF:[*M[J8EUK<E353@N.M3;0YIDDO:*[#=8>;E&U>@V.X
MRZAZ2A3:]:Z:+AYIM'N"<UN/>?">/K'X+Y/R@6UGQ8A]I;AU/M'EO/U1\3X$
MP0[OG(2H.KV6'>@;@"[]%(\HIQ?4E*QMHO8TI81#@4).:][$G_%S*L;T,F,O
M;A$VHB5PI#WQ,;3LCIKPSJ:VW5U"ZP?%*R$.Y@>1@.N1Y&>1P9$75%5;>-K.
M:U/P9P6& ?!^J<'P1XF0)=HY6-I4WHVKW5RE'&&A%?)6@":&G0@XH9.B*Y&8
MGDA4J5#AIC$CHWYF[)?;;%Q'E3IRF(K:W=1%%QL%7;<6%68(RE6(568X! )R
M%.,>3P.9TVUA2^]2H(4L"& )(4 D9QR1GY>3Q,HSU3F$B37H4?H]#?F6T:Z9
MJD1FWUYV39A##4M]\K7F$$5.FAK+$"<\[.&HDQ6VH<MQ;ND1WMHYV;0&)JLP
MAVN=C85CC 8X]IY'!P>1\YWN5^T;TRPRHW#W#YKSR/M$ZX76>5DFJX^.Z7S\
M@Q<9\H747H5RKDIJU$X+S4><.KCC!)Q!R?#D/LL2H@S<J1'>>::>;0MQ"=C3
M<-P-5@V %\HPV \@MQ[01X)P# MK.W%B'<2%PZ^XC&0O/)&1D#YB1RM]_P"0
M6876R\>]UT1&N*Z\U4V+.6'5HC9)%IJU1N :&&%F940A/GR UZK&U#V8ZIS4
MLFQ$7'TZZSIV;Z:Y&=36Q->[>4!8+L=ZV)*@@#=6_/C )D5OJ8*0ZC?M*[B%
M+;E5Q@$@GAUX\Y.)(?V5^=NSXHZ!;P!B2]<?V/Y>@96 9;!7!0\J09 V5P;(
MDZKQ"1\FE0(\<O\ "./&'8(A"=D)\1AZ'9MP248 5]WW*5W)E1N7(&X#<"2N
M<+EO )DNXF<!@?=LX.<-@G#8^J>,#..<#R1+"RN3C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(GSTU]OIKU^
MK?KZ:^W7V;_L_B_!B)I!R?PY$CJ;4&.R3(-HN=:HG'JJ#FTQ!2D[H4KD<"^)
M#%:M90A2)8W;1\7U&[P2=LCO@6["!DPX$VMQ_>&EF?0NUQ+OV 41[+W86;;.
MYWS7N#HRE-N*:RJ$-M;)#GV[<E>E 4=W#,$J4;,IL[6_:58$-N^^."V1D8&W
MSFS07C[,KEX<MP_H$V1%A3+0:K@HM7X<V4.LU]14&+R:+%H\Z#HYHHU5ISPF
M$T-$(#$+C99$AXQ%;KL !2VI#U[#6,D(K$,0"E>_MJJX.W&\9)+9%: ;?>6L
M%)5]P<\;BH*@X9]N]B<C.=I(&!@NWD;0N"#>+$ ;3>C4F9=9T\9;^2C.%UEY
MH+%AR*=S2O+O*ZY#>VJ=+U8['!3?)T.>=<^4Q"< , 1H'#G,%2)B3:LEZK @
M!2XZA\L2++6[>\^!M4]L$+[BI9O<1@"(TX"V*7)#5BI> -B+O*C^DPWD$G&0
M!P#DF4=HXE(ZK8:X0042.A1J-T.AD7-)0[('?2L_S"]!+''AOM.PS;8NS\B"
M#"=:F[BQ#0>P3_B)J$0OA9<*+Q2KC&2;*K /@=BVULI(Y7*7,5<9*LHP.<B5
MM/<96SC"6(?CC>U;AL>#AJE!4X#!CD\8E4VKPW>O$2V0;+T[3D;H:I!B[Z"\
M_! 7W;8W'OD<--JDB*1<77*Y 3>WOF8,EJSG+(L4F26N*R-CNTZSW)K>V4*5
M<U8";K&;V?>]P?(]S'MC##8J9PM>%K"0;3;PP9_K\OA /?AP"O/M4;^5.XMC
M);+.6=)\15F'99ZBV(>.LLKH-3MC+!D'$> 0X\2T^+KQI;\-CT64V/K_ (XQ
M)(X8ZJ,R6G%=BY4T=$:9FLJM9MPMBDH*W3VL=QRFK"C)\9;5$$_BXW $\3EF
MFS[D(#=Q']P&WAM.3Q\<+0,?IQD<$1>T^!S=N1)CDNP6)F"6^EA4Y @"IT(<
M_:[R;Z_8;)/&A(]M;K30)PGV:Q/!QUB!6JTA&QH:+$O>X6BT4K-.H;/%*Y&Q
M5)8$A*UI5 6->_=BA,E61&RV:_J[8G1[LYM;DNQP"!NL-K,=H;;MS:V P9AA
M?>><RBX>$U>M=VL=L3>CHN&;*B+C# MH*31P7H%>YG7N5!2\4/)LOT'<KK5<
MK UXB$W2&K(4EO$Q[]Z15R#E<3!->R5JG;4E59"V0"U;VM<RE@G<W%G(#=S8
M!@]O>-TZVD5G9MY]Q#@<D+8M:UJ0-VW:%4$KMW$Y&_:=LFT[QE;,\SA4 W=7
M79F^IWGJ!P\'KS(-B?*Z6;O1"Y!Q8AHM*>"L+&]$L VO$G3)8F+FM"C95^Q2
M8\Y@G :O;:;5KP.S72JLV[ J6L(S' W<U*7&U0065=@(Q8=.#6$+<]Q[20-O
M-A<N  >.+&"G)(."=Q!SPC>,\C=$N5:)WQF78K><Y69588=*&C0@]/&W:6JG
MQ?H7\SF09NY3-*A)LSSY)*"JYLB/ C!0D,,$&#JQW*W%>%1;AM-A9CW^YO/<
MP",=P[1CC&268LQ=@['4O[F-9W!  .UMV^S/]$;N>?A@  5N2\($&2<.:3ZP
M9=A.%"=GL(5@"IL&4M-@O?5+_8'8M9DV.93'*Y-*=</L00UTJU\,#(HT0PBU
M2(SMAC'[1K]H(6E0<*BMN]RHM=-:Y<*+-X%"Y:MZU)+>P80K6=)D@FQO)9AC
M@LUEEA]I)7;FUL*RL0 N&^MNZ!G@O&BEJ\:(=8M)*1 )CW38]R5>G0LL$%L=
M1M 8"!CE^FFR<5N,4J3;KB[X8Z:.C:+S&:V&K<0/38M6'J!(8"E!D':<5[@S
M*Z,S%:E!R'_V:U$X&]GW/O#2#(8V,2"">7Q@,C +FPD#*Y]YL^MQ@*@7,U_P
M?JH 6L:BZF9>U4'5";EO"!R7V8NJ3XO4OY@UO3F_8D;:\7J^3VTE6F_B['/3
M[7LC82E\?J#N02BC[[W<!CR>YJ[,?H_UME^>%'S,+HT08#L?O8KR0/ 33IG]
M/^KJ?TL?D)PIOATGGS X,(N)&P!E6_BSCTH[,/OEP5"X+<;%U&FBH[YFPV5L
MD:(7*6-!F?DS5+JB*],*D155'%W"6SY];W269 K=N_ 4*%:S4(E+D[54A16"
MR[C8^X!6<KMV]72A, ,2-U7)+;@E+-8@R6;)+$!L;5P6;;DG=O)GGS7&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(E3?LC3/YMC?GG?U<1'[(TS^;8WYYW]7$1^R-,_FV-^>=_5Q$?LC3/YMC?G
MG?U<1/J>BR][UKY;&_/N_JXB=G[(<K^;8_Y]S]3$1^R'*_FV/^?<_4Q$?LAR
MOYMC_GW/U,1'[(<K^;8_Y]S]3$3DGH$I6O7Y='U_]YS]7$3E]/Y7\W1_SSGZ
MN(CZ?ROYNC_GG/U<1'T_E?S='_/.?JXB/I_*_FZ/^><_5Q$[-7R3O6M_+V/K
M_P#.<_5Q$^_3R3_-['YYS]3$1]/)/\WL?GG/U,1'T\D_S>Q^><_4Q$^ZO<G>
M]:^7L?7_ .<Y^KB)S^G$G^0,?G7/U<1'TXD_R!C\ZY^KB)SU=9.]>OP+'YUS
M]&3"9&<_Y?\ O$^_323_ "%C\ZY^C.]O[?\ +_WB<DW.3O?I\$Q^=<_1CM_;
M_E_[Q.?TQD?R)G\ZO]7';^W_ "_]XCZ8R/Y$S^=7^KCM_;_E_P"\1],9'\B9
M_.K_ %<KB/IC(_D3/YU?ZN(G)-OD*UZ_!LZ_^XO]&(G+Z6R/Y&S^<7^C$1]+
M9'\C9_.+_1B(^ELC^1L_G%_HQ$?2V1_(V?SB_P!&(G9JUO[UK?P;7U_^8O\
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MX[7WV[!K9*##X%5V.+WK]C:M)F#R[Y4"7;O''Z0[:+-I@]$8,@WGNFS"L8-
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M9%3 O.1X5A62</Q&''("E-13BS)A9>.WM+1)94DJ:A[<Z5MWHON&0+K0"5)
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MEVC:5&0%*^, $\8Q/&SR'DT<(_68_+^=L5N4RQ'E5]FE5IH))8C$U&HS+XI
MQ,!YF.86LLPVY'4AHFI4]M*92MN[[W[RP<W6EP<ANX^X$C:2&SD$J //@8\3
MG:JQM[=>T^5V+@X.1QC'!.?T\R2OU2KRFH+$JM@)+(P:L,-9?#CGFAX=V0)E
MN"H+;D=2(@UR4!!25P6--Q5R HEY36W!T-3, [@DAV!+;B0Q!+88;CSRV&89
M/.&;YF2VJ<953@8' X'!P/D,JIQ]@^0E76#QWY5:+R&OIJM09D\(T23'$N#
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&8B,1/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g743471g10p10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g10p10.jpg
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M 0$! 0'_P  1" $F ET# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MNZJFP!D U-(PYD$XPIIN*_NXJU9F3C+9TVNFL9;4O96+%K(\)V^3VJQ;E:I
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M 7G6QV.ZA"AT@"Z!;B>1V-[';R[F]N<V;48B,1&(C$1B(Q$8B8PQ_P!&R?\
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MT%?_ *]V_P#1CM(_DROJWM'[,+_XG8WI[_Q>(_V1_"SLJ_\ %_#;S$D?S?\
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M(XTSMI/HGT6]O;*;?P1T_'[Y_7\!#[Z>FU9'5;Q\?/6N/T\_1KJ'?Z!WFS^
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M[F-M\J?*WJ72>C] Z7%N?3@-RBT"^:K]YH%:(E0Z;%$T*I=[$6FGR%5Z.4B
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M;MS^C+YF=3F]/3;685:_/.I?]#>N/[05^3V:]H,BBCVEJ':KI/5[/#Q<'VE
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MRNMU+,S4,.17T%;J6#*2Q XF;6>,?E3T;KEKHHWK$BH<I? <=Y_7^GU ON$
M-6[RXZ!7*Q>;!SFHPCTYPM'^B&DS!4RT5>&J69BGNH#0)5[<RHSVG=/+PZJ$
ML-/.[E?:U+KME3"J=ZUM<J-'Q[ P1SI>-)8=G$V*,E[&06%*]5(+%.@6R757
M-:;;8\)""R]SNP ]UGT>SES>C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$37[EW^63R;_USYQ_
MN?I>='+_ -"Z5_L,G_C;Y37^5O\ ZR?W:S8'.=+HQ$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$XUK6M[WK6M;W]>]ZU]>_37IKUW_ "^FM:U]?\GU
M8B<XB,1&(C$1B(Q$8B,1&(C$1B)YID?<R'*B:D28FY49^/J7#<2U,B[?:4UJ
M1%=6AU#<ECVO>,.*;<2AU*5*0O6MIW(.B#H'1WH^A^@_1!^K]4^7/V.+D/FC
MSNT^4)'RWZ]9>@0-]9GU;D\,J-K8V'8ZX(CQ'7.O*0##0%*7<ACE<%#X6Y"4
M"'0)^.]%4[);>3U^J7X%J8@PJ$J/@A[BI8E';?XG;,?F'FQ.O-R4[[:G/PJ\
MI&R#DV,X\0K7L* RC_YOE ^<.( ]VF&I;8KP)I#WAYU#Q%O5O+V^!V$YU>U7
MGHD87% V$A;>F=&,='CV9L>Y,-1=%*L2E@X\-4N5,9(ZKD5V6TVU)<AM4-U&
MSY=5FUH$-"TI75LLH2JI:BA.E.G4-O0&N1UZ;E@PT^368SL6%AL9W "L6L<O
MRUMAR4D:WO979'?4S'C9XFW/B-GZYU6_]P=[CV_JE7H%+=NA#G@KGU:$5CE@
M@P/I8]%+KIPCN7+=FG)Y2U%EGVG3+ZVFAL8"PU[MS'*S$R$IIKH^3X]+6/X8
MM:UF>XJ;&\1E&AI0$7CY>^RVYE1CO4UECV^-;8J+S*! %K!"CBI.R226.QOW
M!=37>T_8OV[%KC;Z.PLZ,5> W],UF,\^29LO2+81\A.=^35SZ/22C=N&:YG=
MK;T.A.A7Y\J/=X@ZB'&0,2)O=<%O.;*=6X^./ \KG\0JV<5J08UF)758#6WB
MUI58&T#66M7D3YVFN>G[\(^+YE'XUBFV=S>E[.AYCPV9T*D^;2'B/03ZR9QY
MTHQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$2KS?:.8ULT: 'K7%%3Z[!F3C;TN"6;##=CZT[<YHN38
M_@-UY-DCTUAVWN51)15GU54;L>A&PWI-WH6]3P:+;*;LA:WI5FM++8*DX4')
M:MK^'@^.N,#DG'\3Q_DX\;P_#\T]=T_V#]K>JX&!U+IW1KLS'ZID48_3ZZ+\
M-\[+^4]53H5&75TOY3^$STNWKMB=$7K)PQTD]88=+^6_+O\ -Y+*I;@%V$).
M5R6_*@_&3QSZ)HPH$)P"0N6[!(C2H0Y"&F@Y&'*96W(@%!\.6WKV'-L^Z=:6
MO8Q\BG*K\6EBR<G0ADLJL1ZV*NEE5JI;6ZL""EB*P['6B">-UGHO4>@9IZ?U
M2FNG(\#'RJVHR\/J&)D8N72F1C96'U#I]^5@9V+?38KUY.'DWT-YE%G-'5:B
MY=_ED\F_]<^<?[GZ7G8R_P#0NE?[#)_XV^<2O\K?_63^[6; YSI=&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B>:;&^-ARX?Q$F+\7&?C?%0G?<3(WOVEM?$
M1'_95[F2S[?O&'?95[MU*%^SOT],Q9>2LNV7DI7DITR[&MJ?<P]0?<>\MHM\
M"^F_PZKO!MKM\*]/$HM\-P_AW5['.I]<;$V.2$KL;FEE[\.476PRB2^@DXL+
MW90S!>G+MIDO)O<SDISD$"S6J$]>8M%L;HT ;]MR>U2A%K(PA06MN6>.&'K1
M+\UE^S@RKB_RQU75EBEOE%MC9;=/MZ<M^0IRUQ+BE-O=ABUY#K753XZU(0WW
MCV=_RXMT#IE6*OLUB77\L3!O2@=%P<*GV=H]M.G^V^3TGH]Z>SUWM%TM,KJ7
M3^*8[]>S>C8M^9U#JJ](MS\E6HV5YI2B=-'V)T\7@FK'<+>8N1^6)&R X9N:
M19@CXD$4-F$S$MB*/"B14-UZ22D.D)S,PG[N$F:F!%[6%BOC)<;;$LNR<BS)
MN:M#76&<*BK6C/8P5*JZU)9R78-9I>7!?E7M5U[%Z[D],3IV%D8'2^B=%PNA
M=-HS,NO.SFQ\5\C)NR,S*IQ,&FR[)S\W,O1*L6I,7'LHQ.5YQSDW0<QQNVZO
M%QNE%['8:)\^W04VP!&JG2+)!44  H=;CS8,D\'?(14/BAT!#\14E]KXEEV0
MUMO3^VD=Y,VGP*:,C"JR/DXL6NPW9%3<++&M*L*[ IT[-HZ!T0#O6YY(UMS9
MEL*\];'%2-J..QL;] />9U^C+M?]9:P_V8<O_N+'RK!_HNK^U9?^+'"S],?W
M$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67_BQPL_3']Q/NCZ,NU_UEK#_9AR_^
MXL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]9:P_V8<O_N+'RK!_HNK^U9?^+'"S
M],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67_BQPL_3']Q/NCZ,NU_UEK#_9
MAR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]9:P_V8<O_N+'RK!_HNK^U9?^
M+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67_BQPL_3']Q/NCZ,NU_UE
MK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]9:P_V8<O_N+'RK!_HNK^
MU9?^+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67_BQPL_3']Q/NCZ,N
MU_UEK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]9:P_V8<O_N+'RK!_
MHNK^U9?^+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67_BQPL_3']Q/N
MCZ,NU_UEK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]9:P_V8<O_N+'
MRK!_HNK^U9?^+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67_BQPL_3'
M]Q/NCZ,NU_UEK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]9:P_V8<O
M_N+'RK!_HNK^U9?^+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67_BQP
ML_3']Q/NCZ,NU_UEK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]9:P_
MV8<O_N+'RK!_HNK^U9?^+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J_M67
M_BQPL_3']Q/NCZ,NU_UEK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C+M?]
M9:P_V8<O_N+'RK!_HNK^U9?^+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP?Z+J
M_M67_BQPL_3']Q/NCZ,NU_UEK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3[H^C
M+M?]9:P_V8<O_N+'RK!_HNK^U9?^+'"S],?W$^Z/HR[7_66L/]F'+_[BQ\JP
M?Z+J_M67_BQPL_3']Q/NCZ,NU_UEK#_9AR_^XL?*L'^BZO[5E_XL<+/TQ_<3
M[I[Q7.^O0R@V81\A3I@?%GPY,\0[SGG$)HI#8D-NRASDR$&;F1&YS"5QER8C
MC<EA+NW6%H=0A6L7R<-D95Z;6C%6"N,G*8HQ! 8*UA4\3WT00=:/:2$L!&[2
M1ON."C8^&]>^7EFA+(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)YY:I2(LE<%F
M/)G(CO*AQY<ER%%?E);5N.S)F,Q)[T2.Z]I"'I+4&:XPVI3J(DE2-,KAN05N
M(!;1XAF*J6UV#,%<J">Q8*Q [A3Z&RD4M=4N1995CFRL7VTU+?=726 MLJH>
M[&2ZQ$Y-74^10MC (UU0)==9++#[HW?@5N"Q-.G'>"=>&[H:+?,*<9$](1;N
M1O4F3(-*J-0*E")$=NS._&F13$M T<7&@$!VI!680X5Z]5&75D5+NT])ZBGR
M3Y0UG3*\T9'3CBEK?D^-98[IXYY6UAN"6)2*@;&?ZUTJ_P#R>-[.=0Z)G7<>
MGI_E&]B<L>T;=$HP_;O-]EFZ)[:5]?JJP1UKKF'AXN+E#I*C'P<RRALO*PLO
MJ39SU8=&+(_&6%T,9RI(WJ#5EU:X/0.OM;F6XRR=/E0;O6+G+K).5.CQXD7X
M217Y Y =F#%B"VPK0_Y'APA"H,-B_H:YB8'#/%_RA,SJ(Y9%@MMLJ/4,EJ+"
MRA5XFED%85505A/#1*^"CE?Y6+_9G+]L#E>R+]*/1LCV:]B'%'1<%^G=.P^H
M)[&=!IZMB4X]MMUWC5=3JRCFV9%UV8^<^3\NOR,T9%]FP&=>?-HQ$8B4QV55
MT=J=RC!Z:W: D:AFS4-H%T2Z5&_%KN&;?)URJB(-/"09K8TS.A#XLLW$Z&)F
M:1*DP7@DN"IY<CF=2^4G'R17C#(J7$MM459F3CY=F56"]./6N/4K!+75%:U<
MRMAR*&IDV3[OV%'04ZST*W.ZZ_2,^WVBZ?@7OU'V8Z#UOV;PN@9[)B=4ZQG7
M];S\BA\K Q\C)NHZ?=[,9M!:FK)3/HR5K%<NYI3'.>T*J4R18#ULF5\1'AD+
M-9BY4Z</%%>U(*%IQ$U.(D%;G$7I,B/#7,<CBXBV!<!+ ^'%8:V<'&.'B8^*
M;KLAJ:PKWWV66VW6?.LL=[7=_.Y9@I8K6I%::15 XOM7UU?:;VCZQUZOIG3N
MC4=2S;;\;I/2<'#Z=T_IN(-58>%CXN!CXN,!CXM=55MZT);EW+9EY)LR;[K'
MG.;4\]&(C$2GN],6>3RTXU5/G J;LK2UFFZFZ28M3]#9O-;>Z9&K#H1QHZFQ
M2><MVJ.#^;[K=A43=BH K075"5J_'X>,O/CKC9Q+ZX"SPW\(OR\O$6\"W+RZ
MWR\NY5=R\,\=[VF^.^7#FOB!>/FY&OEQX^;>M=]3S>/L>PQN916[&FS(7NX]
M1>K;5S<-N6EGGLCJ%QD<Q9-?.=:[,S*:YX[64-Q++[%C@Q=1X-@99,1YK2)R
M2IM\G#\G3S\/CP\7P4\7CP\GY3ELIY2=E?+J11R\/S!AY[.(;9;P_$;P^7+S
M;X<>S>8#0;ON75FO+HQ$8B,1-<N>4 C$[KV:_P J1?QP5GY&I-6 F[W?3-2.
M.DA03H-QZ"%K1ZQ$*Q":E%CXR@B6PPF$U6E4&S0Q7PL:PE(J]JVP''HK'AEC
MRL=EKK5UTS5)6S*H<Z538>1//Q%+;*@RA$(NM?S@=D4%W*ML!V<*25'=@@T!
MK@VNS&;&YJR^,1&(C$30SKU;\BXT+R6A<QG7BPR+INK* DI]FCA"%5KK]/M2
M[+!Y!N,(8&0BT>;# UD=N,U&-09)IVY2RYJT#4_*O1H?&WBFT5KX?/D A8.W
M-.!OVQ)4@LQ]5(4)Q5#VT[4O_'BLL>871+:*KQ?D*M#L?FJ/0@MSVS#1W YP
MHZOGM%5:(<H=9-T^M?."!.E[GS89KY&A_*<:9-WK6Y<IF;[Y$B0K6E//)6XK
MZU;S2MX^+9P(*<VXD#0*\CK0]PUZ";2;**6!#<1L$[(.N^S\9,\KF48B,1-0
M.LK)3_(/EP46CLH3W.JD<*W4(/ZZ3YDR-'64XXND1Q],%SN=;L5X5_Q;T0]U
M*1#%UFAMA98;:SS\&<'W:=#&N8^ WSU6MC2+22J_C"786\:_6I:@2UA8-Y=A
MM6S9OK \8:XDN!::]!CY %4U\G]+&L(XIKCYB"+0X$"MM;II\1<S-PL12/U#
MJRX1V\R6I5@+5^3?STFO3UJBPQHUD=($.Q%B(088+!P!FXL(*,@#&(T1JK)9
M'=6144&FG:UC2AA6H8>I.]@\BQ+$[+$DDRVE652&+$^)9W?YQ!=M'T UK6M
M #0 U+OS7EL8B57VZ>@7RNY$%A^B6%,4<P[\@<H6;:OQS?RC#2D. DUI.[!!
M^4U;U"*$0RF20T*^1GQ),5Z,B2U=CC=U8Y5+L_.NX^&O8]V#^4Z]0&[%M [W
M*[3JMSIV[>E>^9[^@X@D;]"1W V>VMS06GA.Y1^F<4(QC772M:CZJ\Q\42#=
M['B7HQ_J?=970Z\\7O[E>8K8CE%4/4@6F5W>E%;+V2G5&CZYLU3#_L$5=%VQ
M_"O!6E7/,;5L<D<:<<5,!7R+M<ZN=8]BI0[V>+XB^4:2"WQ*CNTJ.)[B[1Y6
M7<U)?CQ6I60;N1FM54*<6[SZG9R)T8Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1-9O*KO-B\?:)3;#4:()Z+:K]V7D
M_%ZY73MRDT(+HYUFVPZ@))%K-"J-XEPAPZ?/COS?AJV0?5&][MIO;B$H7MX>
M,N398KV-4E5%V0[*@L;C2A=@JEZP20.VV'>:^1<U*(40.SVUU*I;@-V-Q!+!
M6T 3L^4]O24_6?/*N"!/5(??N?6?E_2>*]"C\_OU*YP,O'D3"UHCS>!UT/<:
M^9Y[SR.:E4R9SR:LY/+6"G5C8%X?.&DVFY.Q^R%[].9FI.-8MU617XE=EIKQ
MCVM-#(XLL*BP6CB KORV".V]5KF*!9XR-6]5GANJ![AWK%H=2B;X<#LEE7CH
M@^[=CK\Y/%QL6HTOJ+"1FCG/ *)2JS<DZD2.J\UWV&BD8K2J]J1*KIGFC4ZW
M.V>.TY7Q(T.>29(CY8$O&A4C RRW'P3RXVMKDG84V^!8#YM!EMT@3YS,R\0>
M2[S^5X^M^(-<D7T;N;*Q:A';YIK/,M\T '9&C+'X?Y!<T\B*[+M7,)5JF@XB
MQ_I+M'/;[S_X^*7'M%1)0,U>ZW773@<D.?:D1B@=,V$E6UQ9#S$UE^,W7D8U
MN*P2X(&.^R6UV:*GBP;PW;BP(T5;1]^M=Y95=7>O*OD1V[LCIL$;!'-5V"/>
M-B77FO+8Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2A/(K@(CR+I0"H%+E<N
M?RJIT>@]6K%NH>ZONQ!;ES4_'LU6G,,W.LV^N2V(QB)&D2(9,!.C2DLZ9=;4
MTIQ"]G%R6Q;'<5UV!ZK*72SGQ:NU>#@^&Z,-J2 0P(WN4WTB]54LR<;$L5DX
M\@R'DI\RLOKW[@S5BU_8R^5W8&Y#M75.Q6:TG>CF.G=$O]JWRFT&NFGB_/6.
M71VK363?+9?,6(U/J$(?$YNJOT(/)H$^"T8KS\<H],ER=M.K75MM*:$1:EIJ
MK3QD6I5M\;:.MPN)=R3;RL(L!XL"-":[8%;CS66LQL-CNWA,;&*>'YE:LUZ5
M="O2 IK:G>R8Y2OL?^PGDK1[Q,=CC^4<+\4JCXY<V)1+C((]%Z%8:_4"=&#]
M5O(!BCU^FUBT4*C7/H]* SALFR/EVK8\3]W7Q[3==;SLZERQ;*QWNR<Q\JX<
M-55*SBPTUL;&=TLL2JQ@>(4IKS'SS%,/C>K'\E5CI0AY[=V52@L90BHK(C6(
M".1/+?E':;"^)_ACSWQ%UT5RC6"Q'9739M8F']$@W/*F%8741LX8-DC*ARRD
M4"GPS1-HC)E6RQI!;-6HA\,^4EK9@#XT75S,ZS-\/Q%514'"Z:UV\Y!.WNLM
M<J- (O+B@[ =R3?C8J8W/BS,;"I;8K4>4$#25HB G?F;CMCZGL -P,TILQB(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(D-Z%?:URZE6/H%PDRXE:JPY9,M(@#"!B8B.EQME*8P
MT5&ESI3KC[S324LL*2W[?O7ULQVW7F[*JWNL6I "[G2[(4?'N6( [?3^KO,'
M=:T9VV%4;.@2?V  DR #/)'BA&99H,F^"ZR[5#(@ 37>VYE CO%#H*-8AD45
M(ND<$T7=>&R=+<9'J?D1EM+U)9:0N,X_8<6\!"*R_-69?#U8=*Q4\@A8KW'O
MUOW>_6 OJ)8%PO%@IY[3N5# #F!OL?=O4D-R[+S>BR)HLU9QS]FA,@GMTL.^
MT8NC_P Z;*%IU92S6(*W2J$'K38@@,=+E,1AZI<]#C\QB(Q*DQ\4HML 94/
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M3N[T"=(*6'KYCC<#?/P-AI]=.W&/7S V'9.DH/CZ 3H=-/@SCXPJ@A&:=S;
M;3%79]*7&J]@!:1>?$97=4+*2E7$V"RQ64$:W(&4NP" NV"G;$$EK34. 95+
M<2 UFPA164]]RUKUY'BJB98@"ZS*M@4GRVU="K=S$V&NKJ]F+ +ESNCPJ<)D
MPYA*?[Z88Z.'63L$H?'#"8VV_@EGI/RG&#TUXI<;9PC"U:VK97YHK)98;&V
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MEE((V!ZZ/F! M6ZMB=$CB'))4A=(W%R#K1TP([?K&P03#G/+GCC$J% ENWB
M2DIF2Y@V?SB[0YX +!^CM;UELD9\*AP+7MQNK424DE-TA.D%Y<9UMLA7[)#$
M9_(K]$CPRHT 1:A#,?%\J'EYFW38-#\WML,I.'RFK>ML#ZZ*,-*/#VQ[=EU:
MG?Z2/56 QME\U?'VFB!E@MEF-5L"=CS"M>-'*?:!8JRU0=%U.(76N$)HMB(=
MJ\.&N/*=EC'I,Y4<@%=9'.HL(#9.4P,FPE4179=!E5T+(Y.A6X!VKD[&F '9
MN_D;4-ET* S,0&V5)4@,H]778')1V[CXCMHC<HZ3Y3<3Y-<V.?W6V*A6V17X
MME;#0A9(K,4.)_.- )MI@=&D/2R%BE5,_ #0(+<J3((1(L)Y$:09!()X58>1
M=7XM:;3D4Y$@#8X\NYT %#J6)T -GT5M9OD55OP9M-Q#<=;)!Y:T/>25( 'O
MT/>-X(OYF^.82UPZ;.Z#%^6)\T9 AKC02$D=+=.$4 @3D BS'5&*13-F^+JL
M.4*7.9;L0LP.FKB*%S'&LUP,ID-@J/$ D[(!'$<F!&]@JFG(.O*5(WR&\3E4
M!@I<;.M=CH\CI='T.VVHUOS CW'4SY]Y#<TZ9)#P*U+/ME3VUOC0AVJGZZ;<
M#ZJX>X,V9\48@1)T.KS UA!)B');+$)PL6B %N-F_?CV:[,:VH,7"\5]65U9
M>7-DX J2"X96VHV=*6^;WF27UV:"\MGT#(RG7$,&TP'E((T?39X_.[3# N^;
MT]V15_JS5-&<:!";38B@BQ:O3 \058M!-\18U!PL2*&OU;K5?'VRV5$1-M3
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MH[0::3?@293#^9RKF[.RN"Q8AT0\BS.Y#,%#,O.QG"%N <\@NP-0*D'H"-
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&Q$8B?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g743471g11f23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g11f23.jpg
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MZ<U.I5I5K+$K4(@2@A5& -VGJ8_*Q)/I))EVC=K-.CNQ9BUN2?'BUP/D  ^
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MK,.T15+\;2%*\.W QCG;L^>??NH"$!Z[RNFT7U/$/J'D%TPF8M]I@V,&FB=
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M)<ZNPHQ&3;W9]OA5L(&BF-P:32VZ;0J$L3.ELU6HM5: Q(O:GO6VV(%0/W5
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M)V>G0V$A=,QJR?(E"A N#90@=/F%"4J3'<>GRUO5>N]5S_XF_O.MC>RV9-B
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M3CL[;:]/8EU@5=0*T=4(JNPG:+D]X*4V[G!X5E!,PWK5[2'1'M1JT)-19E+
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MM/TSR?KI6JS2ZG3HMU>HMTUUW9W64WLM=%P"IO3=<JUSC/[M[S1_];SR@_\
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MM-=>*?\ Q1TN.4L8;BN:UM(T_P#RYGRG?_K$P/\ Y-<-_P#^;YY/_9KY&_\
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M>+OW1ZE^8_IF>D^J+^!G6OS=#_$]%/G7JL_B^\H?S.G?QCI\[-?RA?U?(W\
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M[:@1(]FM1A@>G9E9J:MP>VQ[;4Q++KBT1FFF,#0NV0+*^Z<' //@<\#W\?\
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MR:H1>CR&7$[VEQEYE:'&UIWM*T*2K6]ZWDZ?=:OC$_>$A=[E;\6_[ID@"?\
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M#J&7D'/F(.0<$$'D$$$$'D$8E&<,^I'0?N!'_P!Z]D[_ '5_A_Y"5Z?W&O\
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MO%W[H]2_,?TS/2?5%_ SK7YNA_B>BGSKU6?Q?>4/YG3OXQT^=FOY0OZOD;^
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M^]?*_P#2.B_5]3G*WW5'WYY%?HW7?K>E3 QG4$Y,C$3M8?(\?M/F_OH7?_<
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M:/66WO?J)]/HU*KBZL>BQ/WA(V^XV?%O^Z9+@G_%0S[GPOYLWD#XGX3],F/
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M5KN4-MIZ=TK6:BRS:69%[-$;:5:VLD$\\*^6\J,4;!CD^'VXH09C--S"/SL
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M:Z]-0^[3=GE^T1*UP_:#"[<C'),N7STZ>\1B(Q$8B,1&(C$1B(Q$8B<%9K,
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M"@RFI6PFDJ;L<ZW3KVK6!LEO8E3/>?(&-^#L!V[N[@][BIM0Z]IC3W-L52"
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M93GM "5(R<58)XY\[)5+]<@Y%@1C-B+'!]9$+*S2)15>IP\E%J-;V1FR)VP
M0;[VY[?VB=+K!;8SJNP$*,<<E552YV@#<Y!=L #<QQ%:E$"EMQ&[GT L2%&<
MG:@(5<G. ,\SC^&?4CH/W C_ .]>Q?[J_P /_(2&G]QK_-DKY5+HQ$\\KY:'
MZYKY2_=OG?YG.=YU9ZGGX&]%^+U?\0U<[=]2G\7_ )._%:_^*ZZ8O,]TGT.,
M1/29%_6[*I_%*I/YK0V<;]1_I_J'ZVUG^;LGYX^5/],>47ZTZK_G+Y@VSR$]
M%C$2\WP*_;% _P"#EI_HQ6:>N^]V_.7Z9N:'[X7\UOHE _+D_LA\</N-T_\
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M$TM2NCJ7!5E8%6!Y!!!GN6HHN;47LM3E6NM((4D$%V((/G!'(,MY_N3?)_\
M]7SL?_R[M/\ X9GD_P"<?0/_ #GIO_K*/^N4^M[_ ,C9_</V2N>8>+/DH-Z5
MSPB0X-UR% @7FIS9LR50+,Q&B1(I\>_)DR'G!J6V6&&6UNO.N*2AMM"EJWI.
MM[S7U?E%T)M+J57J_3F9M/<JJ-722S&M@  'R23P /$R247AT)JL #*2=I\
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M\[!_V@>1']JNA_XA1_USBC_9MY??V/\ *#_#-3_T1]!SJ_[W-S_D\3_L^/\
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M$G/>U'A08A-AV3)>5K>TM,MIWZRU[UK>])U]/Z6\P:;5!)K8 >)(( F1=4Q
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M=)ZCUCUF/*'UU_)NCOUGK?UQ_(?8=MV"/V?:]C=V>_&_LGVYVG&$SZ%O2?\
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M((D9Y$J5E32I<L5)2Y9,N7*S9A0L3ERR)&7)FR7WW#NUC%W.6.,G  X
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M+V-80SD9 "@*JHH \ JH%51XDX R22>22<(BH,+GDDDDEB2?$DL23\O P!@
M"5=D)*,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B1/\[S/V\?\0G].7;%]'SG[93O;T_,/LCYWF?M
MX_XA/Z<;%]'SG[8WMZ?F'V1\[S/V\?\ $)_3C8OH^<_;&]O3\P^R/G>9^WC_
M (A/Z<;%]'SG[8WMZ?F'V3Z3;S.]ZUM<?\0G['_MQL7T?.?MC>WI^8?9-3YV
ME_MH_P"(U_6QL7T?.?MC>WI^8?9'SM+_ &T?\1K^MC8OH^<_;&]O3\P^R/G:
M7^VC_B-?UL;%]'SG[8WMZ?F'V1\[2_VT?\1K^MC8OH^<_;&]O3\P^R/G:7^V
MC_B-?UL;%]'SG[8WMZ?F'V1\[2_VT?\ $:_K8V+Z/G/VQO;T_,/LGZFV%][U
MKUX_XC7];&Q?1\Y^V-[>GYA]DU/G26^W8_$I_3C8OH^<_;&]O3\P^R/G26^W
M8_$I_3C8OH^<_;&]O3\P^R:NK.4]&OU3'ZVO_P!'7];&Q?1\YC>WI^8?9/WY
MSE/MF/Q.OZV-B^CYS]L;V]/S#[(^<Y3[9C\3K^MC8OH^<_;&]O3\P^R/G.4^
MV8_$Z_K8V+Z/G/VQO;T_,/LCYSE/MF/Q.OZV-B^CYS]L;V]/S#[(^<Y3[9C\
M3K^MC8OH^<_;&]O3\P^R/G.4^V8_$Z_K8V+Z/G/VQO;T_,/LFHFR$]ZUOUF?
MQ.OTXV+Z/G/VQO;T_,/LG[\XR?VS/XG7Z<;%]'SG[8WMZ?F'V3Z18R6]_34S
M^M^Y:_3C8OH^<_;&]O3\P^R:GSA(_;,_BM?IQL7T?.?MC>WI^8?9'SA(_;,_
MBM?IQL7T?.?MC>WI^8?9'SA(_;,_BM?IQL7T?.?MC>WI^8?9'SA(_;,_BM?I
MQL7T?.?MC>WI^8?9'SA(_;,_BM?IQL7T?.?MC>WI^8?9'SA(_;,_BM?IQL7T
M?.?MC>WI^8?9/I-@([WZ-J9_6_<M?IQL7T?.?MC>WI^8?9/OX\0^V:_%:_3C
M8OH^<_;&]O3\P^R/CQ#[9K\5K].-B^CYS]L;V]/S#[)K?&YWV6OQ>OTYC8/?
M_P!?LC>WI^8?9'QN=]EK\7_QQL'O_-]D;V]/S#[(^-SOLM?B_P#CC8/?^;[(
MWMZ?F'V1\;G?9:_%_P#'&P>_\WV1O;T_,/LGZDU.WO6O2U^+_P".-@]_YOLC
M>WI^8?9-3XQ-^V;_ !>OTXV#W_F^R-[>GYA]D?&)OVS?XO7Z<;![_P WV1O;
MT_,/LCXQ-^V;_%Z_3C8/?^;[(WMZ?F'V1\8F_;-_B]?IQL'O_-]D;V]/S#[)
M]H+3-^GT[;_R?]#7^?\ SXV#W_\ 7[(WMZ?F'V3[^*R_LM_@?\<;![_S?9&]
MO3\P^R/BLO[+?X'_ !QL'O\ S?9&]O3\P^R/BLO[+?X'_'&P>_\ -]D;V]/S
M#[(^*R_LM_@?\<;![_S?9&]O3\P^R:FB4K>M;]*/UOM-?IQL'O\ S?9,[S[W
M^OVS]^)2?LH_ UC8/?\ F^R-Y][Y_MCXE)^RC\#6-@]_YOLC>?>^?[8^)2?L
MH_ UC8/?^;[(WGWOG^V/B4G[*/P-8V#W_F^R-Y][Y_MCXE)^RC\#6-@]_P";
M[(WGWOG^V/B4G[*/P-8V#W_F^R-Y][Y_MFJDA(WK6][1^#_G_P#;C8/?^;[)
MC>WI^:?OO\C_ /P_!_XXV#W_ )OLC>WI^8?9/I,Y_>_1O:/UOM?^.-@]_P";
M[(WM\/\ KWI]^^/?93^#C8/?^;[)G>?>^?[8]\>^RG\'&P>_\WV1O/O?/]L>
M^/?93^#C8/?^;[(WGWOG^V/?'OLI_!QL'O\ S?9&\^]\_P!L>^/?93^#E;#!
M(EBG(!CWQ[[*?P<Q,SZ3+>WOT;VG];[76)%C@9'IGW[P[]G7X.L2&\^]\_VQ
M[P[]G7X.L1O/O?/]LU=/+WK6_I?K?8Q,ER"1QQQ/WVR_\W^K$QO/O?/]L>V7
M_F_U8DU.1D^F/;+_ ,W^K$E/U+J][UKTZ_U9AC@$Q-3UU?9_[M?HRO>?>^?[
M8CUU?9_[M?HQO/O?/]L1ZZOL_P#=K]&6#D ^]$>NK[/_ ':_1F8CUU?9_P"[
M7Z,1(%S8FO&(C$1B)@9__$(RI43Q'Y,Y%DOQG%>1M?0I<=YQE:D;YGU)6T[4
MVI*MIVI*=^KO?H].M;]'IUK/J?J2JK=?U^X!O_P>WQ /_P#FZ'TS[EZ@:JWE
M7U7< W_Y>O\ $ __ .RZ9Z9US?D[2Q5[SH\4VG29!UISMU%2MMR9)6VM.S#/
MI2M"G-I4G?\ EUO6];SZ_P"5U:#R8ZZ0B CIFJ((4<>QGWIT'ZH%:#R)\J"$
M0$=%UQ!"CCV(^].\+W2Z]'I)P/!J4N0Y'ZJ"D<TIJT!8)-JE=DG&(.JS:Y"-
M0'Y,T&BJ$[A:[5'+N2 \4?RV%'A1V)9V=[]RQITJL5BX&:6%K]X@V4!3O0<X
M#;PB(0-Q-Q))"C' =K.I 7_VBE%X!"V9&UO#)&TLS9XQ7@#)Y@P?Y*]IN_0A
M5&JU6"5EV'U8_5YTFP30IC7P<)6NZQV1][%5\J1L(*:9E<_ 7@0]H=19$IQ:
MJ_&1+ I^/G]@Z73I4]CNS#L5<! P[S/ICFLLH5@!:U;=ZP#V_MNZM0NM=PJJ
M%]E926((VA;>'"DLI.Q7'"^.WD<M3\WR]Z$3H=N,#AX:CEY%!<MU28M[LJ<;
M,E+#5H4N-6>;P1E3TV<*<WDRFC]C2<#&V'(I$.@](!5^62/@9>LJEL126L L
MV/V> JA'(+VDOW1:!M3:5.0=H9L*PZARK$#;W-R[LEB64':@"\FO.6R#XC)5
M<L+@^*]\M?2ND7>D&J4P#@55RW1VY_QD$^8BKJ5TW4!CYX)".SC<%CI U#EY
MJ;QFN5!OX"VIL:BSPEM'E:U^G2JJNQ;-Q;LR1M;!WU]H=K%0I[(^QN%9^]XE
M"-LMJM:QV4I@#=SD9&UMHR 21O'?7<%X\-P[TNKS3E\^D?\ .U_[_P#Z;Q$U
ML1./+;] LEO7TMZ'S-ZWK_)_@[F9'B/A'TS!\#\!^B=>GXR8_P"U27^W2O\
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M4N7\MNJS(=/Z!51HX]4QG5+)S"ZL5!ILI3YK5=&^32[->)9.>-D6QRL5.O\
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M0+KQ-X/O6M_0V9_6_P"V+7_XWE_KF_\ *'Y%^R4>MJ/R8^5OMDX@Z[!K0<:
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M&/8I$YL',;(EZB<@Z;B3WGH[K$7WEME)(=N5'UMJ, ]C8=S.@ 1BVZM4=@5
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M098W'2R$ R$J<**0XT(GN+)?EC9\=II3T.0AO(HO.T"FT[P2F*W.\#!)7CO
M!ER1D<CTB8[6KO>R5]W ;OKW220 W/&2"!GS@CS3B9?D!R2#,K J3=J^D[<K
M9(I]9KK)L+,L!DA%MIBE/3H B$2D39(5HX!*,R"3+2VH*8DA!!,25&EQH\AI
M[B'85MM1 [MM8*H**X!8C .UEP//D8SD3!NJ!4;UR[;5&023N*\ ')&0>?-C
MG&#.5Z5UJL\JCQ)MG@V9X:[!+&2I8)7IQ856*X =$LF[%9)["4QH$ >LV.5J
M$TN4?(L*G2PP8E$#&GQT:J7N)"%,Y"@,P4NS9*JH/B3M/)PHX#,"R@YLL6O&
MX,1@DD+D*JXRS'P &1[Y\P(!QQM#[I0^AM]#FA9,N$"YD:. K)9CNAXNO:DU
MHB;&'I4:>X1<4V-&. 9DM\@38&QUBWH)6.IX?,:D9FRBROL@<%K55E1<EL.%
M*@C'B=P&%)(.5.",3"6H^\C("%E9C@+E20W.? 8SDXR"",@YFYA=[X62:)/C
MNT\F(,!AL@R8>A=&I\IH4(B$XP645).,&7$01L8Q-AB9$Z5MJ*R3EQH#CJ93
M[32AT^H7 -%PR0HS4XR2"P RO)*@L .< GP$R+JB"1;60 22'4@ '!)YX )
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M+/,H@-:8>VN0G32_5+5:X#+58REM@948@L<=T$ @MR./'D<0712074$#<06
M(7_>()SCW_"4T4\@>%AH:)T_L/-$-/U<I=H+3%VKLV<5J06";)%+"$&PB,@@
M;%PX-:L,AV6)C3&O4!EO54I0^5IJ2Z;4,<"BTX8(?8V #L5 5B1A22Z<,1[9
M?2) W4J,FVL=TO[=<E0"2P .2 %;D ^U/H,^8GD)PB9&C2F^S<M;1+U7/9M2
M;_5(LE#MO%N&JM$?BOEFWX\VP"67R(>&\VB21AL2)$-IYIEU:1TVHSCL+3[;
MD5N1W&VN00,$*Q 8^ ) /)F1=4?_ &M?]7@NN>\,KD9_K#D>D>$KNI6T-=A#
MIP"X^[ 9/6RMK7(87&<T4I5K-4PZWII?ZK;31P 1:CO:_428Z&I#?ZAU.5NC
M(=K>.U&]/#HKK_\ Q89]'A)*P<97PRP_:K%3\X,IWHO7.=<IC"7KW; @"18"
M,$371,TG 8-V*?/,!P2(]?$2)+,XRN-//"DSDCF9"H3,MIY]*$+1ZTZJ;;B1
M6C-M!9B =J@*S99O!>%;&<9QQ,/8E8&]@N2  2,L20N /$\L!QX9$X8;WKE)
M>P42HCKB#FV[H8YLL#JT$P')'XXMZJRKDR3+C1A&:\/&2 <53L4HO3@V6\]$
M:BRWO>V%KD=-<%L<UL$J.UG*L%W!Q654D %@QY'B.<C@S NK+(H8%GY"@@G&
MTOD@'(&T<'P\.>1.2<[;QAEBRR7NN\P:C4R;%&W"0Y?JHABID9\Z6+@P+*ZH
MMIL%-F$Q\\=%BE%17Y$Z%+B,MKD1GFT1["_N^PV]\$I[&_?  )*\=X $$XS@
M$$\&.UJ[WLE?=]MWU[N20-W/&2".?.")]"NS<J,QKY.@7^J+&<R*CPUY,O&H
M$0)7IA6L5VX#U3#,I]D9[E+ 6L)*9(M2G("WI+T'4GWZ%-CQS47*:P:WS:I:
MM=I+, [(<*.<AD88(S@9Q@@D+:SO(=<5D!SD  E58<^&,,.?#S>(,U==DY!M
M3:-=5YOM;M5>O32-7FL>L[2(T23/D7%M/Q3TKJK$&%,F/6%.MB&HD23(7,2R
MPZM#L+OR-OM^S]S?W0D#9X>WR0-OCD@8YF>TK_*)[7?[9?:X)W>/M< G/A@'
MF?,;LW'IOS:U#ZOS67NZ39 VG:C7JKO_ #L(1"#8F5 K7LBB_CLV,5>:&2(H
MOWI]D@ZW#<0F2M+>QHO&[--HV#+YK<; 1N!;CNC'.3@8Y\([2ON^R)WB0O>7
MO$'!"\\D'@X\\I@CY,^/ P),L+O;N63!D.M6.W^D->JT=F3JY481PA8R@<8'
M)3B)M@1&K-A5+2)BS'$.!"C'J;>@R6VYC2ZDL$];W!BRIWJW4!G*A0Q8 +N+
M+C./;#TB1-].-W:UD89NZZMD*&+8 ))QM;PSX'T&5V#Z7SJS$9@>NWRFG#(X
M5#.D@XBSA")8:%(Q(<^ 6(#8<YZ9"'3(1$?+C39++49^-.B/M.K:DLJ76U5J
M#<U;JI8J&9&"E@2"H)&"0000#G(/HDA8C'"NI( 8@,"0#@@D9R!@CGWQ(NI_
ME=X]W*JQ;C&ZUSX&'F1%E8^K/>:8&G? 5EG@XP_*A.6!UX:+-RFD;&;)ZA3?
M3(9ASX4$IIZ S;9H]36Y0TV,P.WNUV$;L;BH.WEE'CC(X)!(YD%U%++N[1 /
M'O.H.,X!(SP#YLX/(R >)6DKN?$X)I-;F]BY9#L2Y0Z"@!*Z#4HYI<TPJ(D1
M#2*>+HG*E%%3X*1T?3&W9RID349#NY#/KP&GO*[A3<5 )+"MRN%SN.=N,+@Y
M/FP<^$D;:@<&RL'(&"ZYRV-HQGQ.1@>?(QXSGS?2>=5HS\W;'?J77[!L+,LF
M@1NT@Q1GYNCHQ&80/_"Y\YB;\%@Q Y:5,*^P]QBQA9%]]]#4*2IJ*U6NNY:[
M&7<%W*C%=Q( 7(!&XEE 'B20!XB2+HIPSJIP6P6 . "2<$YP "2?  'T3@$]
MSXFOX/[/L'+G=V*/(E5Y+5_JCJCT:)))0I3X1#992BS,:8&+Q'W(&I"6I0HE
M'7O3T&2AJ7K>_O>PV]T@-[&_=) (#<=W(8'G'!!\")'M:ACV1.?#OKSC/ASS
MX'P]!]$X 3Y,^/)D -LL;MG+HPDH&JYYE9:\UH)+C#;J%W8:JX4'%B4,@'D'
M J72$"&4C1)C\>/*6EC?NS_LY-I=2K%#1:2K.IVULPS6VU\%00=K<$@D9QZ9
M@7TL 1;7@A6&74'#@E<@G(R 2,^@^@RI&>OT-P.U87S4<8#7<;]2'BQJ3!"P
M(1?FCUV9M\B7)*3(C218W7/K+)W.:4]K8^)\46VV.1)E1H&FP';MRW9U6 +E
MB5N[/9@ 'D]J@QZ3CQQF7:)C.<#<Z9/ !3=NSGS#8>?1SX3XG]LY) J$"_[Z
M)4)]**6NNTB!:0IT<=!2K3:;6.I @0R3#R)L14E=E*Q!\[T.^S%:U*E$UQ(D
M*8^QD47%S7V3BP(UA1E*L$1#86PV#C8"1_O<!<D@'!MK"A]ZE2RH&!!&YF"
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MI5 +%1HZ5IJ9.BLNX6JUCA:K&/=.%1B>\"R^ _K*"R^D D< S)=!R74#D9+
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MM>.H5Z- 4%D?$W2DT>J:&4J ;$3JU>-M;K['L[-BH+,5*ZE>!O09/KEN=W&
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M[# = B=!KOQQ?KQ1[A00_!AU=DJ0&&%(J<:&Q"C0#XD!80]AZA818#77A\[
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M$IL:PK6 ,AV#, !L'!&%Y#8QN9FRY#3%*[5#EFL0*&<^&T$ D]X\YR?$9S@
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M$\T-Z!3U<UD"[-[A-DSANQ2R'+0<V97(,,8].04/"YQZ4&4!'U^QNHLV1V*
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9!GT3< P /1Q-UF(C$1B(Q$8B,1&(C$3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g743471g11t11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g11t11.jpg
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M-391@9&QM"0T87&AI+*UP24G8G,90V-TL__$ !L! 0 # 0$! 0
M   ! @,$!08'_\0 5!$  @(! P$$!08*!@<%!@<  0(  Q$$$B$%!A,B,10R
M05%A(S-"4W&!%6)RD9.4H;/3U <6-%)SL21#@I*BP=$U1'2R\!<E)F.$HU2#
ME:6TPO'_V@ , P$  A$#$0 _ /[^,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)^7'W4CR5M?&>><RY=R[J#7'^L=WNDV
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M[+'>L]Z2ZJ*R%#!"W!.T,#,OPBX06O2H1M.^H3986; =$57&P!22X+$%@H!
MS@RPV_,WK]C&<NMUAH%@Y27IWFEQS@5\!;"=,%T;K=$[^&B54>9K;'8^7\FZ
M V[4;7>0!22B;3QLF 7H\Q,>:5KMB;5(Q]!I4W(MBW*^AOU-;;JC939IF+D-
MW-UU>'2M@,.05L' =.-/2K6%;%&K*ZJNEUPX2Q+AM!'>UUOX&8'&T89",E6G
MZUYX\]&,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1(<_P ^I,F^C^HR:R*?Z$)JQ&DB[<]'TX9'50N3@F2H.%(7O>HL(B3&
M#YDU+*$.27(4;3JU-LH1J_>6"LU!V%;.+"F?"74%58CVD D#W9,KL3>+-HWA
M2@;'(4D$J#[B0"?L$I>S>&?BM<D:;M7!>:GFTW*Y7_2"5=BR$;MO1%QG;Z64
ME7X*]7&1#AR[*/5K8LS-B19L^$_+CLO(Z%UVL3E-3:O@2OACZE7S8_V!D*?-
M02 <$B8MI=.WK4UGQ._*CUG]<_[> 6'DQY(S(/UKP/X#U&O52KLU #40H&[<
M L1R ) PI42Z5+QR^<(M!YF>C3%;:75(8,J2K["$:4]!'37T,Z6I>7HZCJ:7
M=][.S5ZE5+,04?58[RU2/IE@&/O(YE;-'38JKM"@/2Q  PZT9"5MGZ.TE?@#
M)B5\*_$\Y0JWS$MP+FTZC5 J;.5L&^ 9WH48LRG%6@BP12I)9<NT^]6FT.OS
MW56-KV&3?RYIMM":#7ZQ;'M&IM%CJJNVX^)4]08\L)]# \'T<2QTFF9%K-%9
M1"64;?(GUCGSRWTLGQ?2S)L4\<N$&85B&$>44A\9;:=3.>V(:@'%C#B=&YU,
MED*)5'8,5+$5H%4YDZ6\"'1VF8X_;ZDL(2C24ZS&JU"E"+K,I8]J'<25LM %
MC@G)W/@;B>3Y^<N:*3NS6N&5488X*(247'EM4DX&)Y8?C)X^0.GF.SQ./4%G
MJ!]LJ@Q<=5^&LG.</#60I^:XAQ"X:"A\-':$'B[,5LH:%H^;RDR7$4ME4G5Z
MDTK0;[.Y7&VO<<#:2RCWX5B65<X5N0 8[BD6&WND[PYR^T9\0PQ^UAPQ\R."
M2)!H'@SXA"J=:>?C/'GF0^GW0K73=E"PP#49DD1J$M<ZI.ZD-+1-A,5>4](<
MKD$?)B0 >I<UH9&BM3I:'M#U#6ETL.IM+UJRHQ;. XP_!X.\ !B02V!DG F8
MTFF"L@HK"L5+ #&2O*\^8VY. #@9./,RRAWCYQ,28C6 ;S2J0S<,STVPQ2;(
MY*9C!OLSD1WJA-MW:M[U+O;D&&NQ._CG*CM;5Z>SF1U-[*5-KE2M2D9X*T9[
MD?97D[?=F:"FH'(1<@V-GVYM^</VOCQ>^1WHWC=0[IPF)P6MQV><UNKMT:5S
M-^MP&5M\X/\ +;"#MO-BP4<ZZTVZQ5[%6@LC8W<F,D@/CR!;DIAJ6XZFU6JL
M34'4-\JS]X+0Q^=6Y62T,?QU=N<'!P<9$J]"-2*5\"KL-97Z!K8,A SSM*CC
M/(XF0G^,G "IK=D*<DH\^P*L=\MZB\@*RY-^*.HU.'1>B'$/+4M;<^X5$?!K
MYMU*O66.AQF5?A,H7J!J]2%V"ZP+LK3:&XV4N;*E^Q')9?<2??).GI)W&I"V
MYVR0"=UB['/VLH"M[Q,9_@E>-'Q90[U]Y+GOQ;S(15 5$-_,$;Y77AE#B*@T
M9B,GT]Q(=I<5:V:E-GLRYU;TK:@TF$O?M9;TW5[+*_2+=EI=K%W'#FPYLS[<
M6'EP,!OI QZ-1N1^Z3=6%"':,J$]3_=^B3ROLQ([$\'?$6#\1ZA>/G-(B;<'
ML=<L:(X%MELI6[:;'V6P5IUMMQ*&JV0L(N$;^8(R60\4HVY.A0HTF3*<>L=?
MK3MSJ;3L967Q>3(I56_*"L5W'DC@DX$J-)IAG%-8W*RG \U8ABOY)89V^0.2
M ,G-^A:)3JY9;E<05=%B[3T.0"EW<Y$CZ:(6>360S%= /EGO7>Y+@D'&8&0U
M;UKW41I#>O76O7.9K'9$1F)2K<*U/D@=MS8]V6Y/QFP159W"@,^"Y'FQ4;5S
M]@&!\)7EW\;>'](@7 ;>.>BK%&OMH%W.UKF2R[<XI9 U7B4D8024BD8Y,<F+
M4(FJUJ +F0AK@687'O1'(QPRW/UKU6HJ*&NUE-:%$QC"JSFPC!!!RYWY()#!
M2#E5QF]%+APZ!M[!FSG)8*$!R#D>$;< @8R/(G,JOW(.6]2H4CEW1*!5+CSN
M3&@154XZ%A30+30G;2A&X<%;7NQ[XA;##@J5!^3R1CK++L%YAQM"DTKONIM%
MU5CI:"3O4D-EL[LGV[LG<#D$$@RSU5V)W=B*Z<>%@"./+ ]A'L(Y'LD1I7C+
MX_\ .!=$#43D5'J@WF=E,W.C1@H5B'\/6ZQ!2%=/6B.\C_I$FP& 14@)(EY[
MLJ?+@R51WGUH0WI%WU>IM-ALNL<VHM=A9L[D5@RI\%5@&"C !' D+12@0)6J
MBMBZ #&&(*EOB2"02<D@R%V#P@\1[4/""K%X^<S,#:Y7S-5#P9M?9=BQ:X>/
MS[82"K9]O2)@]5I*$;-"CS=24"K!-D&A6H1)Q4G>B]0UJ%F74VAF978AN2RJ
M$#9]AV*J$C&Y0%;(XE#I-,P -%9"J5 V\!6)8CCV;B6'N8Y&#S+,;X-QQF2Q
M-:YW6D3(W5'^XQY6H/M2&NO2@+]8D=#2ZI:E;M#U?DR!3A%6U.+B/+;5K?M;
MWF/I%^,=XV#3Z/C/^IW;^Z_(W#./?-.YJ&/ O%G>CC_6;=N_\K:<9FDW"?N8
MG*^1]$ME[M1D#U*+9>?="YB]5Y7&^54,.:JW4+,%L=N7T2)10(H5?"\I->&"
M(CFPX %#'N%W6J[\XF9<[?H:CJUUU25HK4E+:KMXONM97I0HG=&QF-:C<6/B
M9B=OBPH$Y*M!76[LQ6P,CUE354@9;&#.;-B@.QP!Y*H&<+DS8)'AEQ4,URD)
M0JP'YW1N:=DC]V(4^LBFFVKYT(+6"M?J)*TF9$ATI+36)L\;8(FWW)4IZ=5:
MK"U*CB!.X$CF]/O;OFL=K;+J/1A8QYKJ+JSA% P-X!0^0 =S@ELC;T6D"M44
M(E=O?;5'#N%*J6/F=I(8>W*J/(8FV><4Z8Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(FIOF#NU_>RE:HKW6(UX0/LDFCO<S@] GQEW&,%><"0;0WS5
M]LRPV0]9<>NS[5&*<L'']Q9_0 QN+'&A2/9HMG?#O.Y[O*BSO36/ 6&XIWHV
MG'&\(5N*Y%3 Y(YM5N[L[#8'PVSNPY\6TX#=WR,_1+ UAL%P> =:"CO:G+]!
M<+L^1,>E+Z'UY7D6P$^_&XMBH;[!*WXV-<><J?M/N144CY$W?%^/ZE255O6U
M]&5\[;E*SK7T<5-CT8V=U3Z+N[GU^X U1NW\ ]YDUC4_2SW0QB8'ON\&1<$W
MV]_CO?5[P^C]UM]FSU^YYQCO.<S??A^[AOC?*]]!^<_C?[W]2^*OGOZ#OSY\
MQPOG#Y^U^+1[Y1[?SUI/X'SI\K]W^![.>=J.[[^[NL=WWC[-OJ[=QQM_%_N_
M#$[*=W=5[\[]B[MWK;L#.[X^_P",X0^H,3+=?:IH,ZARBE0@MV;N:A2"2C56
M#6=+S;&HVE1M1T&$PU(4Z]MQ;&WM*1IS3:*M7M2I\Y[Q6;&/+:[)]^=N996W
M,ZX]0@?;E5;_ )XD@^,F_J"_X0G[',Y:/C)OZ@O^$)^QQ$?&3?U!?\(3]CB(
M^,F_J"_X0G['$1\9-_4%_P (3]CB(^,F_J"_X0G['$1\9-_4%_PA/V.(CXR;
M^H+_ (0G['$1\9-_4%_PA/V.(CXR;^H+_A"?L<1'QDW]07_"$_8XB/C)OZ@O
M^$)^QQ$?&3?U!?\ "$_8XB/C)OZ@O^$)^QQ$?&3?U!?\(3]CB(^,F_J"_P"$
M)^QQ$?&3?U!?\(3]CB(^,F_J"_X0G['$1\9-_4%_PA/V.(CXR;^H+_A"?L<1
M'QDW]07_  A/V.(CXR;^H+_A"?L<1'QDW]07_"$_8XB/C)OZ@O\ A"?L<1'Q
MDW]07_"$_8XB/C)OZ@O^$)^QQ$?&3?U!?\(3]CB(^,F_J"_X0G['$1\9-_4%
M_P (3]CB(^,F_J"_X0G['$3L9MS;SS37R%:?>N(;]KY1K?I[:M)]?3W6O7T]
M?7T]=>N(DQQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B:EA?T8O(+]UE%_H
MGI6=%OS.E_P[/W]DR3U[ORU_=)+$SGFL8B,1&(C$1B(Q$8B,1&(C$1B(Q$J;
MN8*P67E%P"58?.+&Y\."B**&$H8<@399+CY)$?$)$28:!%?FC69D9"IA8?&7
MMWW3TME"]KUOIF5+ZV<A5!.68%@." 2%5B0#CR4GX3*X,U3A02Q P 0">1D
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M' WU+7[_ "?ML1'PX&^I:_?Y/VV(CX<#?4M?O\G[;$1\.!OJ6OW^3]MB(^'
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M0+"">/-*3')O1\]K1GIHZ;JDU#/Z3:5PXJ+=R5W=R%/N9@QLVXRC!3R!/-U
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MM,[HUX'KN QK1%)^<8*2RY.U4<Y.!GENZB*M+5>*]UERAUKSZJ\;G9@/4&0
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MY^+GQ>\YG34G=U5H<$HBJ<>7A ''P]WPD6YI^BMY&_NUH?\ 1%1\O;\SI?\
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MY9>&]1"/T%73--TZM-5US>K.JV:;H]3]WK=4K ,EFK?#?@[1N,$,ZG5WJ?\
M1Z0C#4)R&Y[B4TI4@'#Z@\UH?:*Q_K;!\/DU/K,2"DO;AOCIS[@T(Y(K^S5J
MOUUDQR?3.P7T@FQ]2Z<:C-[:8(6ZSK8C[W!@(6XQ7JH$B!J748*]C*E7 @[_
M *+GGZ_J>IZBU8MV5:>A2FET6G4U:/2(3DK13DX9CS;<Y>^YO'=;8W,UJI2D
M'&6=SFRQSNLL/O9O</)5&$4<*H$OG//FTA]__P!#+'^UKO\ ZD8B3#$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)1G-/T5O(W]VM#_HBH^=%OS.E_P[/W]D
MR3U[ORU_=)+SSGFL8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B>>5&;F1GHKRI"&I#
M:FEJBRY4&2E*]>F]LS(3T>7&<U^E>COM.HW]*%IW].(D/YY&]Q68KJI96:]*
MD$''GRQDL:?WMJ?*C-I;?+S9KK+2666TZ996VS[6MN;1MQ:UJD^?W#]HS*KR
M!_Z^$G&1+2)W:WCJ-79A\@U(F+;7'A"Q$)*7"9\X0>1$# !+.]Z]^2+3W68D
M9._1MO;BI$A;45A]YNR(78*./,DGR50,EC\ .?V2KN$4L?L 'F2> !\29@>;
MU @ ADC]I=CS+_<Y+):W38RMN1(CC36VA=7#N+UI>J_582_FX;K>D[F2-D#3
MZ$SB\S>[6.&(5>$080>T^]C^,QY/N&%\@)6M"H+-S8_+GV?!1^*HX'O.6\R9
M/B)$>(A229:?#&#832GYA C*8A0HC"/I6])ER5M,,-(U^4XZXA"?S[UBJFV^
MQ*:*K+KK&"UU5(UEEC'R5$0%F8^P*"3(NNIT]3WZBVJBFI2]EUUB555J/-GL
M<JB*/:6( ]\UY?\ *+GY9YZ!R@5<N\E&G%L;3R,%HW5FY"5;;]U,Z>8E@>50
M5)=UM+K3]V^6-I0XM,1SV-IW]6G8KJM"K;UR_I_9BA@&SU[4G3:UE(SFOHNG
MKU77+ 1RK+TWNSD#O!G,^-?M]T?4,U/9[3]3[7:@$I_\.:3TKIX<';MMZ]J;
M-)V?J(;(97ZIW@ 8]V<3J]UY37S_ "LGG'C^#>__ *X3<CLG2=L[^C_K<QNK
M<\K)#Z=[4CYMZ7!1[*4Z=?\ :WM-MW8GIGJIU?M3J5]MA3L_T?=_AUG7=6UE
M7D >^Z/:>3A<#-=O;_J_K6=$['Z1O94'[3=<*YX^4M7I_1M!:1R1W'7:EP &
M;)*QNX>+W-Y=7L)/I$:\^0YQ(<CM"^I6=FQ1&77(;R=S0]'<DU7E5=D1=JW)
M1+ U8209]VE45UR0VPG)';GK>E('0QH>R]2D%4[/Z--%><$$+=U.PZCK&J4X
M 9-5U"^MAD%,,P,/_1[T#6*S=H3U'M;<RL&?M+K7UVF4L""U'2*AI>AZ-QDL
MMFCZ918IP5<%5QGJ[XP^-IRHUU);QLY)%VP'&QV6"O-N?2";#4>&RVTZD@-C
M$E:]ZA*7$.)([D[UO2I&D/>TG7,.W';-+++5[6=H@]KL]FWK/4 CLY+,37WX
MKP23QLVCR  G4?Z/NPCU54MV,[+LE*)75NZ%TPV5H@"J%M]&-HP .=^X^TDS
MV_X)'C\S] NB2*UK]+\&72_TCV/]7NOA"TA/=>GZ7W?L>S^E],U_KWVI8YNZ
MFFL/M_"/3NE]2S^5Z?HM3NS[<YF/_LZ['+_9^DOH<>7X,ZGU?I6/R?P;K]+M
MQ[-N,>R5OUBA\.X)3)W0+MW?O'+ZJ/?BPF7W/(/K]G>GER#GN!%;K%<M%@NQ
M*SV8U*]F$ J@ 45-FYRT0A8R7(6EG?5H^TO5^IWKIEZ#V5ZC<X+-GLIT'2$(
MHS9;=?T_1Z 55(N6MOLL1*URSNH&12SL1TW3+OT_7NV>A48"A.V7:'6+GR54
MJZKKNHH2?)4"'/D%,U?%^,ODGY8##WWV>X>1'#/&NP1HK=:X<?(<XF]LZ# ;
ME)D[*=N/BZ-&<HU2.PM:B3.&CBYTL4&2'&.CV:&I\G0H_H7]I^A=-NTKZ;LO
MV:UO4M,SMJ=9HUZQING@LA45:5#U5^^MI<]XG4*DTH6P#T>MU"7F^G[,]573
MZNM.U_:8)J:T2@]0_ 6MOTI6P.UJ!NBU@FU0:GIU;:M>[8\5V>6Z%>XQV^B
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MC$1B(Q$8B,1&(C$1B(Q$B%#_ -%1O_[2G_N\_)/G]P_R$JGJC[_\S,\6,"
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M.F:+5 L3DEG7JVG<Y/).PGS."9]NOI5:A5ITI50%54M>L*  % 7N&4  8 '
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M=$ZINM8*A;1:A:V+' ^69!4!SRS.% Y) AM9I-K'TFGA22.\7/ Y\.=Q^X2
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M"!O?W@>>Q/@#D_2)\A0(6.ZWG'*U@Y1/B?+<WXQX'T0.2;HS&;2(4[_JY_\
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MAJ-#A0XS34>+%CM-L1V&VVFD(;0E.H)+$LQ))))).22>223R23R2?.2
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M;:]$"?/Q:%QGR G3_6+1:GCJG9GHFJ)\[] FIZ'J0?:47IE]731G\?IE@!Y
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MU0O$"H:5^+2^L]GZ(IG6_P!5I'&.8I?4G7X])<9TK?XE)UC9V83_ +UUZ_\
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MB?=24[^C25?^&(G+W^OU._\ ?K$1[_7ZG?\ OUB)V>WK_M_\/Z\1'MZ_[?\
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M-I4G'TRGGDXXY\(Y*JP&"V1D.OB8!<G!;((D?)><U%WN\QZV)=-E*]PP]V,
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M"JV+CA2[,M:@\DM9\F4&!D69. I,KZ6G>!",!@2A\RP4 N<>0"#=NY^C@9)
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M7X)PI5&\^<X! )$RU9ZI:"O3KQ0R52$+@U0.1,JGU2R/V$@*4V8U%JP"VQY
M40)&6J_5M6KJ% P#)"8$$)]S8TPVIX H;JU*"FNP.V78+AT" ^'+LAW,Q2IO
M S%0&)RN<,%E;&-C(5&%!)*MNQSA0PP &=?& "2!ZWFI-7+\ZN ;'2"<4P8E
M,(V,^1*=A#PD<L@PSR] Z5"*V8L#!,#G3/6:]6'RQ<J,%#K )N,8G-A1*F7G
M,;?@W59VE5!\6>2Q7;WV050,V[;2SA54L5:O )=1,_2Z<9W''&#@ '/=@8)(
M&,V*N20 0V2 I,C]I\^^+BZY:"5>DNF3 'F]MNS,"81KPZ(@S6>=V;H^JH7V
MT:G'6-/!*Q+7(N 4 =H#&Y$!AFUR9Q,7#FV3IEY=%?"JUM=>0&)VO:E6]?"%
M.&<>!F6PX/@ 5B(;65!6*\E4=L9 \2HS[3R6'"GQA2GXQ) -M5WRBYI9K9SB
MJBDF]N=6!.6:CEYR0(H:= ..6;0LF,BD[!$L1E!:'5Y1944"!+$*T**5V7>H
M=4^?QB'\6T=RI:YV_(MLL4;B5;"94D*54@N%RS .0XK+[3C0:BMF1!G-@W(3
MM 9?%@KELG(7/ )4%2X7<)LIG)-YBCAP56@Y(^<FMC@X>&_/)3GDN+:B0XR-
MN/ON)90XZI+:-;5O3;:U;UKZ$[WEZZWM=*ZUW.[!448R6/ '.!S\3()"@D\
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M.KUOC4\U)38QAQ$/YHDPY<J5Z;>0<C#=WWBK@CG-60Q8*,"NTN63>!M*DY!
M'65#'/AWE2V1CRLP1M)\V3:%;:WB!QC&;G"^3W-REFNM1?0:#&J(18%FHA7X
M>5.U+>=(QU;V$%6(I8Q<3;XN5L:1L@4&/M$#<<]395CKLEDNO$Z2T(CC:RV
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M@D[+T/B^ZH]]KKL=RREMQR!N9LL<N^-SX+N1N8A2S8QDRRUHIRJ@$# QY 8
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M,N95RSQT!(<VO2QA:0"-5EZ=']A:4[><!6(T-5IW3B/<$'MZ1IS3;B,0S*&
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M(WR[QHI'/*9=J7/F%KT/Z!/@2K&[9G6M+7'#UD!4PD$<D<B)L2P(%UP<\,W
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MB(XEZ5%E5411AP*(\";'2HL 34@0^ S)3)V3?).%3SDQ)$H^M)KW;N,>$:=
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M\>6G&3(6/LX-N0@U"$@2I*8%!!2T#H-U:)5\) '@YKMD)2Y(YR6ZE]#TF_
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AB(Q$8B<T?C_V?_.L1.W$1B)Z,1&(G:C\7^W_ .-8B?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g743471g13p07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g13p07.jpg
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MA;+[B<90K.%I]#2XXI+Z%)HQ+'MG9HVZFV6\K@''\90?Q5:7S.EK(T;%'S&
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M@1RP><1G82R[XE)#*2 <'D1D9[:QQ:6ZG.J_2&K)?57=!W5)L;0HOI(IUJN
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M6:7SF3S5FS!FW5+H*1]=#YS&&&=RJ)&RJ<ZCY[(%EE,<?1)TX4=*>E9H,C[
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M B7/!&(^)0Z7) F1]A#//,9SC"G!QL4.)Q<]O^;EPV'/?[G9R>.1XG$D;%'
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M-/(S"2.8,6)/2Q*$CD)ZRZ*,!CSQ4ZV\"@A8D */'@# V2-N=,>I6;F0.57
M*:GUN;#T&OEJ:#GA-6G:M9M>#),3"XM0/TF([!J98(WWL>5F (;SL<<[C*O
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M[6-_>F02FYE,@0QAMW[1CEEV_8[6/I,,>DP#')&:IBTM@G1B&,(6#X QZ0&
MV>O('('/(<NJJP1TN].[0:;76-.4**!(ZICZ-FAX8&+"&R-11B),NSK]R'%P
MRQZNX*&BQ%<1*,9=FD9DEUQ;S[B\R>=W60W3R%A-YP"6)(F("])D_MMJJ/F
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MXSNZ:0MTXN<EB3TZ]4N3DEQVTZ"'&.B0#HC#@*!]:/\ U8QC"^P53/\ D?\
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M6DC-)S8;AFTG9*I\^.!!16XT1F!W7)I;PR6L-HJ=''$[2OZ;,99F4*7.>2
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M&BQ8S*4,QXT=E"&F&&D(:::0EMM*4)QC%F2222223DD\R2>LD^LFKH    8
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M%D5BOUDY'21R*SGF%PUN\*;7W?7,KASD=UEJJDZD"$@],"P1KEBL9N[7$LQ
M'0B=TO=HF*)6FZ6-0R)!AR3I\BXN3)\K#ACH+&(PD+ &!!XX;$\N6:29@SL3
MM58T7)(CC082--Q)"J.0R23UL2Q)-]'&D0(0 ;F+L< %W;FSM@ ;F/7@ #J
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M! &#V8\*&SXBUK\*.PVCOK6KN]Y6<YLV9G8L[,S'F68EF/SDY)_'5RJJH"J
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M(E+<1'?0E]*X+:4.X4E"W$XPO.5.%?)!Q1Q?HT&N:7<Z+%9W$MQ$B7MU=Q7
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M"3"#FDJ7&)QB_P#21;XWETA@=0/:RVO92TJ\%[RV:EW0;3B;V(X.%4U#H\-
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M0_>9BY&?]W<QZ= U(WS7?U9\3B%K4VXTT0\)^8K*=/\ ,O/58\+&_P#.A/\
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ME2,D<+UKYU32F4-XA*1G6V8'E4+3E]*DPDR_%<7A<I3/<91\$>&-7\S6U_5
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M>;#5K#4_?1=_CU:,_P!O8_\ =)?>8N\M'R:<2_-I'T]I=9A\@GRK\+?-K?\
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M.?(<5]5C\]S_ $05[^A==S\T/],E;8W/CJ^AIQ2G%*<4IQ2M0'TI/X].[O\
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M8I1KTK7S8$HYB>,75F3)(NUFB,F)00S$K&%SN"XR#ER0%"VD_3$;EWJ_F]P
MB-N42;?0((49<G&,]6,*!Z6;R=,'E,P]PYK+A]W5^=M1_P $:SKEG>0JHXT_
MJ/!_(5VWJ6;6*SM/&Q<OJD*RA1_)S+6<ISV\M[OK@W!1-T)Z?;L_TG3S[=P3
MT=W0]%_^W;52W_Z[;NZ/I?K>=WV/119QNYXZ3?U^O-2%(2;"U([HL0)G1O#3
MGQIIZ4.>\3.5=]'EV0!)'<3C"<I<\SVJSG.,MI[N,JM>7KSW?\Q5?GZL=_\
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MR:.S(M/9</EG+@7(AY@236LY.SAKPHA,F$L7M3A ?*F#HH/$5I1J(U$G./\
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M>4AG() "@!550H).%5 J@9))P!EB6.22:F1%0$*,9.222Q)P!DLQ+$X ',G
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M\ZZ[_P"Z5<;571+TM:3NL*_:NU9"JUS%Q)T:&69M-W*/1HA>*_ F)\B;LY.
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M+%G8LSDLS,269B<EF+<RQ)R2<DGF:]A JJ$10BH BJH"JJJ,*%4<@H P
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M]+\(=+P/$0(L)PO$,QSV<OT_H_0^K$/Q]GZ?CKNPM=V08,K34(@!Q)J5H+7
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MX9)ZSFF /T_3MJI>*5%FZ=,<8_&#5ZN78I7Z0W98-JL8&Q,%=DFW#PRQ@+#
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MXKU6TEL-2XCUJ^LKC9TUI=ZC=3V\O12I-'TD4DK(VR6-)%W [716'->5_IO
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MU_[<>SL]?JQ3![1^(?T\^?\ R!J[8>I%*\R[' 2*.#COJB*?8#T!0QEY4 7
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M_MP,L0JC);K9B% ZR2 .9J5O(]QN@W/:6"C*KEM3M%&YV"*,EP,LS!5'66(
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MKAH8;'"2,!AJ3.@$YHR7)C0)L.,^Q)E193C3[$=YIYU"6W$*5.]O,A"NC(S
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M<0LEITUHMM_DJSQ2LN9%-X2KPMYQ(_2M<1B-([9&:1;K'L6V6B-1=9T\<=U
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MSQ$V_.*O6O>HFS06UQV9<*14L1JZ9J$I($P#OH=052AFCWF-G*A=J(%(M%5
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M#4/.(5.&)(P%3XN'8J9L7+N'VXJ0&4G) ()"G:< \\-@[3V'!P>>#U5 D$$
MKD@@9YC\8R,CM&1GJR*B; Z:B4S7KE.M-TJ3^#.[9VV;&+'F",X.\+)L/X)4
MY18Y8)-GL<*>2<65=>LLV2S'CR_5>)":K(<- CWINU$N]$;"VXA0G:&RIR'P
MH"(0/1P@]6\DNS$VXARA5G7TI3(P!)&#UKECN8$\_2)QG:,*J@1CLW2/M^HH
MH8:G6*)L*._+KR"Y%^UBX(VCF8H3IC!VG9.7CFT 9Q5DL\W5FRS<^>(%7$E.
MB[!LS<Z(N:8-1;C=I>V\G2-(!$0&VC&3(I:[9(O1B9=J":)0"8P#$I!Y*4MV
M@D78J-O!*Y.X (0+<&3)D5BS&.1B0&)#L"#N(;+'XL7\HB?K<7[7SQJ]'([1
MWBGBQ?RB)^MQ?M?%,CM'>*[WB1O<WM\^+[//?_B]U1W<[?+_ /X>_P":[G>[
M/?[G>[W9[_9V>_Q3(Z\C'SBNCXL7\HB?K<7[7Q3([1WBGBQ?RB)^MQ?M?%,C
MM'>*AOHCIF?U:,MM?MECU_=*M;Q5;J4FKRGE$0 NE:^J\:KT<&,@60N6\6&F
M+F:B=",O%WV!; ,;),V,I!)V8U?7-V)BC('C="[AP0&,DKEY&)7&/5@KM]+<
M0JJ0JVT4(C#*[(ZL%4J1Z(1%VJH#%LCKSN)Y8!+$%F\^Y]*L^UZ,U%J-O9 4
M=.U;IR?KYDY%*NPF9%N;UA"I-7NL)H<=B2HK]7L$)FUB>^^Y,'S68DF!(CDH
MK$MN:.]5+B><Q;A-.)=IVG"=,9'C)(.0ZG8W+!&000<5!H-T4<?2 &.(H#_&
MZ/8KX!_:GTAV'JY\ZM6WTW[-J6]J _6Y TWK@==&K.FP*LU?@B]:U5O9N];U
M)H->A/;(BG4Q2HB]TD 3@0J*7"2\U.M-KF,P1D#%0K&[@DMY-_*4Q[-N"3*_
M16\8E8B,KE3'(RDR*PWORR3OI"*19DVD&,-NW;@ B]),VQ1O#<U=5(V%3M7F
M,>CDL\6+^41/UN+]KYY-7^1VCO%<K#L7QV>P@*SGQ6^S&"PS.<_O\>]C&)><
MYSG^3&,9SG^3BF1VCOKLE'(V"1'&9XM.?/2^U*RHYM:<^8<[4K0N4E:%8S[R
MD+3A2<]N%8QG&<<@.H?,/Z*B2,GF.L^L=M='Q8OY1$_6XOVOD:AD=H[Q43-T
M=-T;8]CLMKKE@I=<,6*L4 42?3(9&DSA#7^UZAL6$X1M-=*#[&,>DBJHFJBK
M0'EHM%)<E1;%69+1$-!;Y>P7?1*B,&8*\C#F"%$D,D1PC J<,^]D8;),%'Y,
M:MY80[,RLJEE0'U$E)%<992&')=H8'<GV2G(%4:5Z=-ENZJU=J&'=M/SZM48
MT4-<_=5,Z.5N--3$87/HF#K!:<6AU\N19B1[1+\SFP78((C1K"77)+G7I51;
MJ 333E)@[DM'M9<1R9Y2;< %@"=H^QC8DJI 4"0Q/T<<6^(JHVMN!RR8^PW9
MS@G&X_9.!Z1R23W=X]*+FW[=8+2C8 06Z5AK'P&GB[Z\C86-.[6I$>.VF&>C
M1TML[$N-$V7V,M(RHMKH),SG)86#G#I;>]$"*FS.TY/V/,]/#(2<@G_1))%S
MSZ,K#J9@4T'2LS"0 L,#F?1'12(, '_YCI)\Z*>L CS^G756T*5NW9EANN8;
M=7>BW2$,M1*U5J04V'.LVV3UP$FI<0;L2U.*36:D\,J0R09"U$C$KT$$+CCU
M0XV!-=FNIH)+>)8V&_,99 I B"0JA4$QH/2?<Y"LX+$G.>;(4=9I&<^CZ8#%
MER^Z0LIY.Q]%<(,JN   ,<A.CQ8OY1$_6XOVOGG5=Y':.\5ZL9R-[D%,XG#<
MIQ)&=Y:28]3:,Y\]V8<<Q)RVVI?O]Q*U)RYW5=S"NXKLAZQ\Q_V5$$;3S'(C
MUCVUY7BQ?RB)^MQ?M?(U#([1WBGBQ?RB)^MQ?M?%,CM'>*Q_;1Z3;QL.VW.X
MQ=AZS %B;J(-7='.GX_N>+7$W(%45=9<N4Z&$/(J^YCX,]" 1$@;W)E6FTS8
M]<MUF!'*#Z4-[%$D:&.1@.;Y,9R08&QG8"R[X%92QW1X1 7C1EDLY(&=F<21
MJ3R7 ;D,3#/V1P<2D, ,-Z385F4I7-NZ4QMH,:\<DW45.K^OZKJ"H1AI<OAU
MPD,H%A*RK=YUN(98@OYV!59S58,-O1W6I4#,Z#/3*&37HBZ:7I190$PTCSR$
MC'(RJH3&02.B8%U.<@X(P1FIV@5BGIC"+&O,\R$)W X(!WJ=I[1D$$'%6LZ?
M-"[?UGO  _;2T>R52HZUDU\GM4K:P3D_8!E="T=6!@Y,7&R39V4,!E:;=R@K
M-BIP-8UPV64S.ES2D\M:*US<6\MNVS".\NX0A3B->DN')ST84,RR1AMLC [5
MY  *E*&.1)AN.Y%CP92PR[;(5 QTA. 5<C*#'/F226R-^+%_*(GZW%^U\\NK
M[([1WBGBQ?RB)^MQ?M?%,CM'>*]$NY&P4(85.&(5B6_VH<*#FW$Y\3/O+;<E
M)6A6/Y4J3A6,^]G&,\@.H?,/Z*BQ&X\QUGUUYWBQ?RB)^MQ?M?(U#([1WBK;
M[6I2=DU--.380<$03L=2D6UE\B/?0>I@>RBS5HJ#C:)Z$YAW(2/D58NA_#C#
MP0N2CN-Y\;&4U89.B??C+!7V<\;9"A5'^>-B'7^,H/LJ20!UV[A@E=W4<J&!
M92.QP"I]A-1MKO2]8 )3J.(-;,KK"MRUK98$!)B$YF7@LJ_7/85T&%<P95B>
M%U153=O:Q3\*@1PS%XGPY-]M:I%M(Y<BW;WB,MJ.C/UAHF;.SF(HXXR 0H9]
M_1[LREC&,1IA!SMQ"1T_UQ1TJR*I&<J79V!^RPNW?^TV[SZ;>D<U:NZ](EFJ
MS+]AU^:&6QM!Z?+)ZPBG!:8%X DKMI,^.K1_%IV)50TL!7<4G8Y1Z%)/0VW9
MU_+2V8I-PD?$6&M'?1N=L@Z/T0!,1SC81W"EUV1NP9^DB4$*<"-1E<*R4W@*
MC=&=W,DQ[N3 O$P4[G4;5V.<9 RYY'+!IG=/M;/TC1NI*C>2@I=RKNO:H)M.
M564>36D]$#Q6RC2R+IHJN<MB9AUE<O)0GA]:,NI(S4JQ*=L+ETDN)GC_ -&T
MCE.6/1+''+ QR]6!\PZJNH<K#$KD;U10W//I #//)SS]>3\YJ\'BQ?RB)^MQ
M?M?*%5<CM'>*K&DK845D8;EP7U>Y[O[R-/ARG,8\S$_?9;CONKPC'O8RO*<)
MQG*<9SVJ3C,C]7X_]AJ=""W(@XSZ_P 571Y2JM3BE:J__:(M#;RW#L[IHG:D
MTSM?:4()1+]$,S-<Z[M]WBB)4NP GHL8G(K(<FU D26FG78[,I;3CS;;BVTJ
M2A6<9M\E&J:9I]EK"W^HV-DTEU:M&MW=V]LTBK%(&*":1"P4D E<@$@&MB/(
MEK&D:78:\NI:IIVG-->631+?7UM:-*JPS!FC%Q+&7"D@,5R 2 >L5B? ].>T
MUZ:!4ZP]#G4M&OU5TAL@<(M@WI7V4])-;&N.P-BJ;KMODKJ+3Q")!IY6AGJ=
M<D+D2*C/#&ZWY62Q8D3JU]O+J]E\827$/$VCFUFU*S>2!];LPL=G;VMIF6 "
M<A6>=+J*XMSA9UDCFW Q;9LBSZYIXU26Z@XMT%K.XU>P>6V?B*P416%K9V.9
M[91<D(SW,=Y#=6IP+I)8I]RF#9/"[_(BZT/]43J?_L"VM^R?/HOJDX=_?_1?
MSI8_W]?5_59PK_";A_\ /.G?XFG^1%UH?ZHG4_\ V!;6_9/CZI.'?W_T7\Z6
M/]_3ZK.%?X3</_GG3O\ $T_R(NM#_5$ZG_[ MK?LGQ]4G#O[_P"B_G2Q_OZ?
M59PK_";A_P#/.G?XFG^1%UH?ZHG4_P#V!;6_9/CZI.'?W_T7\Z6/]_3ZK.%?
MX3</_GG3O\33_(BZT/\ 5$ZG_P"P+:W[)\?5)P[^_P#HOYTL?[^GU6<*_P )
MN'_SSIW^)I_D1=:'^J)U/_V!;6_9/CZI.'?W_P!%_.EC_?T^JSA7^$W#_P">
M=._Q-/\ (BZT/]43J?\ [ MK?LGQ]4G#O[_Z+^=+'^_I]5G"O\)N'_SSIW^)
MI_D1=:'^J)U/_P!@6UOV3X^J3AW]_P#1?SI8_P!_3ZK.%?X3</\ YYT[_$T_
MR(NM#_5$ZG_[ MK?LGQ]4G#O[_Z+^=+'^_I]5G"O\)N'_P \Z=_B:?Y$76A_
MJB=3_P#8%M;]D^/JDX=_?_1?SI8_W]/JLX5_A-P_^>=._P 33_(BZT/]43J?
M_L"VM^R?'U2<._O_ *+^=+'^_I]5G"O\)N'_ ,\Z=_B:E_Z/[I$ZL*CUO=*5
MGM?3#U#5BM -\:V*G;#8=*[)"@PHN%9H#\PD6+$JU&@#H$1E"GI,R9(9CL-)
M4XZXA&,YQX/%.OZ%/PYKD,&M:3--+I=XD446HV<DLCM X5(XTF+NS'DJJ"2>
M0%?,\9\3<.7/"?$5O;<0:)<3S:/?1PP0:K82S2R/ X2....=GD=B0%55+,>0
M!-;DKE3M.5KSBM6#.,K5G&<!B/O^_G_[;FL@=<#TEZAZQXUH_L?[EOR3X5\>
MJ=J^3-@^IB/LW([T^Z7\H>--C_<M^2?"GJG:ODS8/J8C[-QO3[I?RAXTV/\
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M4Q+OWC VN6SO4  -D#D*^BTL3-IM@UVG^5-9VQN.D0+)TQA0R&1<#;(6R9%
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M[?Q>S'M[OQU+WMS_ #Y_XYY&I:=N?Y\_\<\4KU5YS[B1O?S_ /%9O\O_ -I
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MXZ?&NJ?OE?\ \\N/[RGX&M0?T4ZV^PU7_5?'QCJ'[NO/YS-_QT^-=4_?*_\
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MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI5!6&_,5VZ4*DKK%Q+/W]=B3&L
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M26,N+"66F2<19]HO&DH3%;7"<A&(A6%)BR93<MB0I]2\16\G602AAN$?1=6
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E4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g743471g16b74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g16b74.jpg
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MQH5?J@:'KHD*.G*B^XX^_-*'*\/GPAS^4-MRIT:.S<-(CW+&]RXEDGOX(PL
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M),5+7%=EQX3=LM$8R:RA$EM/L[F26:&=(+<200#:5X8GDBWRLIN9H6X",&P
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M; T11U;@JFQ.C+JVOL:_V%L'8U$-6'I&U/9M[:+D5UG3,O94<54:MK:8X\(
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M8K. !89D6<WLN06+16T-RR#>Z1[EXO#YLB@@LYPM18[Z0/<2]:2-FC%M'@@
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MW5_&BE.(5X*1ND4S,T9 CZR[A&78MD@8K$UU+$\KY2XBCAM78AM@/$9E9XE
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M$CJY(X<:F>%.HHYEV#-N9C@# 5<DFJS-,MS:@.HA=V5E .]FX4C=8]FT;1@
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M"*+=7"E2)GRLQN <Y(F8 -+DY)8@#).>RJF"$@@QK@QB(C&!PP20F!RV@DX
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M,A")D&2A$B)(2Y'>0EQM6,<6RE&9#C*L5."",J<'!'(CER(Y$<ZGJ0P##.&
M(R,'!&>8]A]U5KEM5IQ2M;/2VZ1UYEVFP]&'2U:(3;*2K<,%L&W2/.H-(9[:
MX,_ HM0I]D%$F3E"M]S1#)HIF^"U3M&F*G?H0.E6*9FQ%2**MREG:QA%NYV
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M*0@QUW$2/CFD5GD$0:.!I6>.(L2%!R%Y9(W!>KG)..6X]IOC0JJ&0AY0@5Y
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M5QBUJ6J18,96I2LX1;;6VC&59SG.$MMFDH0GKS^BA"4H3CJ2E.,8QCEN?R>
M\JK@>_Q/G7Y]%!?K%B]\+;\;XR?=X#RI@>_Q/G3T4%^L6+WPMOQOC)]W@/*F
M![_$^=/107ZQ8O?"V_&^,GW> \J8'O\ $^=/107ZQ8O?"V_&^,GW> \J8'O\
M3YT]%!?K%B]\+;\;XR?=X#RI@>_Q/G3T4%^L6+WPMOQOC)]W@/*F![_$^=/1
M07ZQ8O?"V_&^,GW> \J8'O\ $^=/107ZQ8O?"V_&^,GW> \J8'O\3YT]%!?K
M%B]\+;\;XR?=X#RI@>_Q/G3T4%^L6+WPMOQOC)]W@/*F![_$^=/107ZQ8O?"
MV_&^,GW> \J8'O\ $^=/107ZQ8O?"V_&^,GW> \J8'O\3YT]%!?K%B]\+;\;
MXR?=X#RI@>_Q/G3T4%^L6+WPMOQOC)]W@/*F![_$^=/107ZQ8O?"V_&^,GW>
M \J8'O\ $^=/107ZQ8O?"V_&^,GW> \J8'O\3YT]%!?K%B]\+;\;XR?=X#RI
M@>_Q/G3T4%^L6+WPMOQOC)]W@/*F![_$^=/107ZQ8O?"V_&^,GW> \J8'O\
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M2)>&7D39B0F,C<IC))W-N"L02S)]LZI ',9GSSC:FU'CI=?JJ=)7]@VV_P"
MSW/K.@7X<=#OTHT']J6M?%^D?^+WIS^B/2+]D7=<0W/22O*NG%*ZQO)$_J95
MS_[ZOO\ ^61S1;T]_P 8=W^;-+_\@UZ(_)Q_BPL/SKK'ZU6PO8%(";+HUPUY
M9<2\UZ\5HU5#F($CPDW(H\/?&S\1)66W<1Y/AI+G<O9;<PVYV5]A75U9ZGTK
M4KG1]3T_5K/AB[TV\M[ZV,J<2/CVLJS1<1,KO3>@W+D9&1D5W+K&E6FN:3J6
MC7PD-EJMC=:?=B)^'*;>[A>";AR8;8_#=MK;3M.#@]E:WE>1\Z':$J6MK9B$
M)QE2E*O+24I3C'7E2E9"XQC&,?7G.<]6,?7GG;W[O_I ^OHW^K3_ ,1727[V
MOT:?]GKO^MO_ /&K\K\C_P!#AM3:7$;*0IY>6V4KO3*5.N80IS*&\*#8RM>&
MT+7E*>M780I75U)SG#]W_P!('U]&_P!6'_B*?O:_1I_V>N_ZV'_#5.[0^BZ+
MT<]=P-7ZY2715QQ J3C8.$<%"'BC$M4R9WDO$>-A3??+SW2.ZQV$=2>M7\_.
MLND_2;4^EVK2ZUJYMS>S100N;:+@1;+>,1QXCW/@[0-QW<SSKMGHET3TGH5H
ML.@Z(+D6$$UQ.@NIO6)N)<R&67,FQ,C<>J-O(<N=>3I-?JW=(/\ 8AM?^ S_
M #)T-_"_HK^DFA_M.UK'TZ_ CIC^BO2']D7E<-W/2RO*&G%*ZK/(Z_J@9_:I
M=O\ <Z[S1[Y0/X?_ /[)IO\ MW5>@_R:?XM1^?\ 5?\ 8M*V([=_HGV?^SRZ
M_P -DN=3:!]_=%_.VG?KD-=T=(_P>UW\S:I^HSUPA<].J\D*<4KJ"\BK^JQ>
MOV]6C^ -8\TK^47^'&F_HO8_M36JWV^2Y_%_JWZ77_[(T*MFVY/Z(=J_LWO/
M\,%.=-='_O\ :)^=]-_7(:[WZ2_@YT@_,FJ_J$]<(_/3FO)*G%*ZAO(L?JJW
M7]O%J_@/6?-*OE%?AQI_Z,6/[3UBM^?DO?Q>ZE^ENH_LK0ZV/=(#^@?=G[(]
MD?P:9YU%T5_"?HY^?M'_ &A;UW9TQ_!'I3^CFM_LRZKA;YZ95Y-4XI74QY&7
M]4L[^VBX?PS1N:2_*&_#NV_1W3_US4ZW_P#DQ_Q=77Z3ZG^I:56VCG1-;$U&
M&W$=LD[MT=S<>-;*.-SM.\@;G0&)-=- SP-6C=PD:^?N)P'')RHHF-:P]9P)
MA-%QD%)B?#\[Q9Y3 ),*6@A$=RI*2'@QM'(0ZLK>L0!E16(!.QGW':3M!VD+
MNS'<REX" R@R.KIU2"O!E*LQ&<#<%P,@9(SDXQ9O1"-7LO")YLY#8!2%G6FE
M"%CD[$:L39.!O\F*MB]Z !J+*RR\.%BEQZ(Z[7 "&Z=6CD\T*KT4?AJ:/BWW
MJQJ5V",'BW 3A;<&V!3U=B5^D3]LZS_;&4*7SR)MMBY!+%R#'"6WYR)B&XPP
M>0 ZAPO4!)"@"I=3WCC;J,"QPF8SEO&7')YJ8-=2[VE8RA#,<"50MOL80K#B
MGVU94I2>ZQA.%KA<O;GP_P#R*D\_9CQ__!KP^*M_V'6_>HG\F\<N\^ \Z<^X
M>)\J>*M_V'6_>HG\F\<N\^ \Z<^X>)\J>*M_V'6_>HG\F\<N\^ \Z<^X>)\J
M>*M_V'6_>HG\F\<N\^ \Z<^X>)\J>*M_V'6_>HG\F\<N\^ \Z<^X>)\J>*M_
MV'6_>HG\F\<N\^ \Z<^X>)\J>*M_V'6_>HG\F\<N\^ \Z<^X>)\J>*M_V'6_
M>HG\F\<N\^ \Z<^X>)\J>*M_V'6_>HG\F\<N\^ \Z<^X>)\JQ!6-(UVG*+^C
MU&'PHYTQ-/E!C^W-E$PDDN3-S;&5FI %8$T+'48-DB!$RU%@,,%WIDG!)J4V
M\M"L[W$C[=S@E5"@\*(-@*%4;@ QVJ %))*X&,&L2Q*F=JXR2Q'$<C))8D Y
M RQ). ,YYU<-!US$UA"FCZ/1:R&CD7(2YBG+U:2\QYH6/CB0\#SB;KA(@V(!
M"HL<6 "-2D" (UE$ /"A1,=SRR25Y2#(Y8C..JJCF2S'"X&YF)+-C<QYL2:N
M2-8P0B@ ]O6)/(8 R03@#D!V <@ *O[Q5O\ L.M^]1/Y-YCY=Y\!YU?S[AXG
MRJD'SE\#AB!,=0H5JFPHZGHU= 7&)',EW,*3C$0>_:!%;K[<A6,Y4E14Z,B]
ME*NU)2KLI550K, 7V ]K,I*CWG9N;P4GW51BP!(3<1V*K#)]PW;5\6 ]]0QH
M>Z]EIZ1%N$W,]7%A"\<LJ+KQS8PZ)C1_FQG5P82)V&&^AN'/BFKB>/2L5RP0
M]EVNM60D7E,4]5B!OCR(6?+!'ZJAC0[E*YDX;'UC/&+-$W%(*HJ#<AAC90,O
ML8$/%25^.P=AM(.$W@<(CAJ XX8YL6.T\1U8GJ[A@B[>CUMK>]^V;O"#?://
MJ\ :W02M1J-G[8./4A1ANTPU"V3,&M3U60N0:#035@DKER84$I-DCPLA\/&A
MOO67,,$<5N8W5R>('=&+%RNPY*G&Q06*J, E0"W6R!=#)*\DN]&4=0JK<MH.
MX8R <DX!/,C)('(9,N/%6_[#K?O43^3>0N7>? >=2>?</$^5:(_+=NF' _1P
M\ZP!D+&"6U.XR/+2B>7,YBZ_[S#N)(43AG"<81V,HR_V^TKM8;[&,KVA^33_
M )QTPQ_V.A^[^7JWO-:B?*OSZKT'S_..D'MS_P!7H_N%<_\ S:ZM,ZN.G]KT
MMJW9QC*O2,)V<*SE*<J\YQ>K&582K*<9S]6<X2K.,?7A.?YN0]1^]]]_8[G_
M ,EZGZ5]\]._M]G^L1UW<^*M_P!AUOWJ)_)O/+SEWGP'G7KQS[AXGRK41Y9Y
MXZYT9: DH-$PV,;UKN4.0#4PD\I[T!V3A*%,2  I"&\HRXK+N)"U)4E",,JP
MM2V^_P#Y.>/LUU3']6+SV8_^::/[S6M?RH\_8#H^<?A=8^W_ ,'UWW"N9KFZ
M%:&4XI7<WJ63;,:KUGAL+75MXU]3,-J7:"3:U(Q7!O94MM-0=2A64]65(2XY
MA.<Y3A:\8[6?,;7L?/NM<S]]M1]G_?)O?7K=T<S]CVA<A]YM+]O_ '*#W5K,
M\L\\=<Z+]"24&B8<?&^JQE#L U,)/*>^CW:.$MJ8D !2$-Y1EQ67<2%J2I*$
M895AQ2V^Z/DYX^S?5,9_!6^]G_B^A^\UT+\J3/V :/G^N%A[<_\ R77_ '"N
M9?FZ-:%TXI7<OJ"3;,:EU=AL+75MXUU2<-J7:"3:U(Q6AG94MM-0=2A64]65
M(2XYA.<Y3A:\8[6?,;7\?/NM<S]]M1]@_GDWOKUMZ-Y^QW0.0^\NE^T_S&#W
M5#7RI[]B7T*-G)("@L6+DQKOO'H9^=.D)SB_US*,(C/UL<VO"E]E*LJEM]A.
M<KQA><80KL;T&X_=)T3F?\WU?V?^$WGOKJ[Y0F?W*ND'(?YSHGM_\:L?=7)E
MS?.O..G%*[-.@_(LZ>B-T>DQ1 %Z-C6%;PR[(L9",^XWX;/94[';JTMME>?]
M+:)3Z<?Z'%?S\\Z?29C[/^EO,_?N\]GX_P"6O43T39_<UZ%<A]X++V_B'W5,
MSGPM=B4XI3BE.*4XI5N6FTC*>+P8+1;'+B9EQ87<U:G6Z\E.^F.=TRO(.E [
M :Q$0KZY4_(_P$%O_+39,=K]/ER(7.U2H.">NZ1CE^-(RKGN&<GV5:S!!DAB
M,@=5&<\_Q4#''><8'MJ)A3<&X5WNQZ[=G46K/D>D= U95[+$$DK"Q6**]T=3
M6[(A,TP3( XYFT'"%<P%?QC L2%59FQT-)U\,P6-S1!#PUEQ(^+4S,A8+OD]
M96W(7 8JBABP[6;9D[0Q58YDEWLF47,_#5L$[4X!E!.2,L2,'L #8&2NYI&:
M8NQ#96GM4[%+0HHTK?M;4:Z$Q\'O\0H)"TU@6<F1(?B5NR?"1Y$YQJ-XAQQ_
MN4([Y:G.UG,6>,13S1 DB.62,$XR0CE03CED@<\<NZLT+F2**0C!>-'('8"R
MAB!V]_?5T+L#B%J3Z/V)?94I/;1"BY0KJSG':3G,[&<I5U=:<YQC.<9QUXQS
M'CWCX^57;O<WA5%.J%6: V,/4TZ3@,E0)QJ-(A,=V@M5SHVS )V.[)(5WPL\
M(&DXWZ78\1$:[Q*V^TA5RL4.5?!VLN1GL=2C#L]JL1_?5#AAAD8C(."/:I#*
M?[B ?[JLPM0=?G30>PE]>68@5!%5FH#TB645'60S8(]KB+)CL6/ XY&#6B'$
ML5:'FXA ?5C<2*4KD47-CLO(O6:1595D ##:<*,XV[#@[<J60E7*D%U)5B1R
MJPI&Q!9&)!R,Y//=N&1G!PP#*""%/,8K)?I$Y[.V3\%%_/\ ,6!WCX^59-WX
MK>%/2)SV=LGX*+^?XP.\?'RIN_%;PIZ1.>SMD_!1?S_&!WCX^5-WXK>%/2)S
MV=LGX*+^?XP.\?'RIN_%;PIZ1.>SMD_!1?S_ !@=X^/E3=^*WA5B[0#1]HZU
MV!K4@+MHN!L&EV>E324(= =F#XEG"S0LB;%:?G99<D16IJWF4.X[M;B$I7^C
MG/.3T74GT76-*UB)(YI=*U&RU&.&0NL<LEE<QW*1N5&X([1A6*\P"2.=<3K^
ME1:_H>L:'/)-!#K.EW^ERSQ*K2PQW]K+:O+&K]4O&LI90W5) !Y5I^_D9-4_
MZRMT^ZU/_-\[^_?(Z]_5W1_](OJUL_>K]'/ZSZ[_ *)8?^VG\C)JG_65NGW6
MI_YOC]\CKW]7='_TB^I^]7Z.?UGUW_1+#_VULSZ+NF!'1=U- U-7L7FT#8!D
MT906,B1,6<XZ:E8E.LJ9@SL,8;95CLMJQCM*3]:OKYTWTUZ67/3779==N[:W
MLII;>VMS!;M*\06V38K!I07RPYD=@/97>W0+H;:= >CL/1VRN[J_@AN;JY%Q
M=1QQREKJ3B,I6+"84\E(YD=M2(](G/9VR?@HOY_GR6!WCX^5?9[OQ6\*A-TL
MZ1TC=MZ]O%/IC5<*5PK!+/#:>Z%-TJP$GXX"6BO"3-R3<; -+QVK8Y L*F8X
M:D1)#X88,+RYH*0;@D9]G+:PR1O() P*AG!610"PWLJ;%*G9E?I2$;B0-P7$
M6Y6>1'5-I!!PI5E)(4[06W$'KX/8N< $XR#ZMYB+3LNZ:OC2>C7=BH\(7AS+
M'M >K5$X]6(]=MM0M$(7KR):-G!)]<B6XV$C3;!>H,!RX"ZY7$B1==R?,"3=
M4I;R)%',1<J"RD+"1,%<LCH3*4B8/L5B%C+!"[[B^T,KTF#2/&/5W(!!:0<,
MLNUT8! T@*AB,LX!<*N NXAEF?Z1.>SMD_!1?S_(.!WCX^52]WXK>%84Z2AY
MQWHY[^:R L#6'-*;4;[UZ'&2TWVZ*>3WCJL3592VCK[2U82K.$XSG"<Y^KGT
MG0T?=?T5YC\)-#[_ .D[7W5\KTZ;[B>F/)A]RO2'M'_A%W7$=STKKRCIQ2NI
M3R09=<+HCY92(,3<?2C=%]]!C,.L?I1*_P#H=IR4RKMIZOTL=CJQUXZLYYH_
M\H$?=_VC[R:;W_7NO=7H-\FHX]&PY$_Y?U7L'XEI6P?;5@<7JK9B/1^Q([6O
MKFGMKA1<(1VJX2QVEYQ.SG"4]?6K.,9SC&,]6,_S<ZFT$?Y=T7F/OMIW?_/(
M?=7<_2)ON?UWDWWFU/V?]RGKADYZ<UY)4XI737Y&0JN#T7KRRD27G85O:SN=
M] CL.LISFA:T3W:E.2658<QV.TI.$YQA*T9[6<YSC&EGRBQ]W&F\P/N7L>_^
ME-9[@:WU^2Z<>C_5>1/W7:AV#L_R1H5;*]PV!Q>I-I(]'[$CMZYNZ>VN%%PA
M':K)/':7G$[.<)3U]:LXQG.,8SU8S_-SIKH^/\O:)S'WWTWO_GL/NKO;I*WW
M.=(.JWWDU7V?]PGKAIYZ<5Y*4XI73?Y&8JN#T6[HRD27G85O2TN=] CL.LIS
MFC:V3W:E.2658<QV.TI.$YQA*T9[6<YSC&E?RBA]W&G\P/N8L?VGK'=FM^/D
MOG'H]U+D3]UNH]@_\*T.MBF^S[CFB]T-Y 6%O#FIMC([QV'&2VWVJ>83VW%8
MFJSA">OM+SA*LX3C.<8SGZN=1=%A]T_1SF/O]I'?_2%O[J[KZ8-]R72GDWX.
M:W[/_#+JN'SGIC7DY3BE=0/D="RX/11.,I$EYV,[DM[G?08S#K..U6Z1CN\J
M<E,JPXGL]:L=CJQA2<XSGK^K2;Y0WX=VW,#[G=/[_P">:EW"M_ODR''HZNN1
M/W3ZGV#_ +EI5;>(SV9##3^6'XV7$]K+$E*4/M_7G'9=0A;B4J^KKZL+5]6<
M?7SHBMBNVOOQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2M"7ER__ (-T:_\ S/:_^ZZ]YM%\FC_..F/_ -'0O]O5JU#^5?\ YKT'_M'2
M#_R]'KGLYM=6F=7)3?\ YOJO_P!R _\ \G%Y#U'[WWW]CN?_ "7J?I7WTTW^
MWV?ZQ'7>YSR[KUYK3UY:W]5_7O[>:Y_P^V9SO_Y.?X:ZK^C%Y^U-'K6OY4GX
M Z/^EUC^Q]=KF$YNC6A=.*5W>ZB_HGUA^SRE?PV-YYBZ_P#?W6OSMJ/ZY-7K
M?T<_![0OS-I?ZC!6L'RUOZK- _;_ %?_ (=;4YW1\G+\-]4_16^_:^AUT)\J
M3\ -&_3"P_8NOUS <W2K0NG%*[N=._T1:L_9Q1_X9%\\Q=?^_NM?G;4?UR:O
M6[HW^#N@?F72_P!1@J%OE7/U(-H_^<ZY_P"(-;YV-Z#?XR=$_L^K_LF\KJ[Y
M0O\ %3T@_M.B?MJQKD8YOI7G%3BE=J707_4_Z.O[+:U_NV>>='I,_#_I;^>[
MS_;KU%]$W\6O0K\P6/\ L&I7<^&KL.G%*<4IQ2G%*<4JV#M)IEH'EA-EJ-8L
M0H_(ARSHPZ %%AYJ4.3%0/DEH4^)(C$I$%$&"B&],;><BIAQ4L*1B.SA%ZR.
MA4J[J5R%*L05SG.T@@C.3G';DU:45@0RJP."00"#CLR".>,#&>ZKD::;9;;9
M9;0TRTA#3332$MMMMMIPE#;:$XPE"$)QA*$)QA*4XQC&,8QRRKJ_?%*<4IQ2
MG%*<4IQ2G%*<4IQ2H%],2L;IO8* !#A?-E3@V@I+'6&BKL^R+-.\9J38P,5F
MUZS@0*&H8J#>S=;GU,V)NMHA5FU#:[=#C8J$&?DP^1LG@C8LS9<H 5DV1H,3
M1,VR0F3=F-6#JT:%T+QKDM@P[I9F "C"!CADW.QS$X&^/"8Q(5*E7;#!6; &
M1Z-S#>DE<1VDLTZKIBB:=>M(F-BAY>Q#@*U$+*)VEK1^PH>D#:24&7;7 &I>
MF#YN4HF.;/S7&CJ!R\5:.,.T@-JAN-[Y9XYUC81*R;6AEVX!D4QRL_#VC!VC
MJY!8E4PG80[%Y*\+2#>0^1+&6[%(= F_<<C/;CE@SLYQ]3*<4IQ2G%*<4K"'
M2:_5NZ0?[$-K_P !G^?2=#?POZ*_I)H?[3M:^5Z=?@1TQ_17I#^R+RN&[GI9
M7E#3BE=5GD=?U0,_M4NW^YUWFCWR@?P__P#V33?]NZKT'^33_%J/S_JO^Q:5
ML1V[_1/L_P#9Y=?X;)<ZFT#[^Z+^=M._7(:[HZ1_@]KOYFU3]1GKA"YZ=5Y(
M4XI74%Y%7]5B]?MZM'\ :QYI7\HO\.--_1>Q_:FM5OM\ES^+_5OTNO\ ]D:%
M6S;<G]$.U?V;WG^&"G.FNC_W^T3\[Z;^N0UWOTE_!SI!^9-5_4)ZX1^>G->2
M5.*5U#>18_55NO[>+5_ >L^:5?**_#C3_P!&+']IZQ6_/R7OXO=2_2W4?V5H
M=;'ND!_0/NS]D>R/X-,\ZBZ*_A/T<_/VC_M"WKNSIC^"/2G]'-;_ &9=5PM\
M],J\FJ<4KJ8\C+^J6=_;1</X9HW-)?E#?AW;?H[I_P"N:G6__P F/^+JZ_2?
M4_U+2JVT<Z)K8FH^[ WFY32]/R*KH:UTRR6FI4V19X%Y&>=7C]KLBP<D=3JD
M-'')MJD4(0Q-OVR,D9]3B@*#!('!,NQR!)P<)DQVX=7W.R.B.^PQG&U$W NY
M*A.*V(XL!RTA"L%#*3A>;85P RLRIN#C)9FQA4 );8/MC\UVQ@L-V"!]-'[P
M>V\V^DC4O0^>]0]9[7"0D'L6'$S76WHUD>I4TI(P(#($VI$BGV2!9:Y&08'B
M9,*.L=9CT2:W);7%OP>Q]XXDL+';MQ+ 4W@=9MR8="K':2"<JI&*13<7(*[3
MLCD SNRDN[82< !NHP*C(&/I'-9HGG@8IU#!0T)&O.-X=;9GD8<-U;65*1AQ
M#<AYM:F\K0M.%IQE/:2I/7UISC$?!/8#67(':17A],JA[55O]^#/S7&#W'P-
M,CO'B*>F50]JJW^_!GYKC![CX&F1WCQ%/3*H>U5;_?@S\UQ@]Q\#3([QXBGI
ME4/:JM_OP9^:XP>X^!ID=X\13TRJ'M56_P!^#/S7&#W'P-,CO'B*>F50]JJW
M^_!GYKC![CX&F1WCQ%/3*H>U5;_?@S\UQ@]Q\#3([QXBGIE4/:JM_OP9^:XP
M>X^!ID=X\13TRJ'M56_WX,_-<8/<? TR.\>(IZ95#VJK?[\&?FN,'N/@:9'>
M/$4],JA[55O]^#/S7&#W'P-,CO'B*>F50]JJW^_!GYKC![CX&F1WCQ%/3*H>
MU5;_ 'X,_-<8/<? TR.\>(IZ95#VJK?[\&?FN,'N/@:9'>/$4],JA[55O]^#
M/S7&#W'P-,CO'B*>F50]JJW^_!GYKC![CX&F1WCQ%:(_+=F@Y8/T<,"BPPGE
M@EM3+^!\^+-RSAR+K_#>7<1G7,MX7E"^QE?5VNPKL]?9SU;0_)I&+CIAGE]I
MT/\ V]6K43Y5Y!M>@^#G^$=(/_+T>N?_ )M=6F=7'3U)3;:LI6<)2FQA%*4K
M.,)2G!.+G.<YS]6,8Q]><Y^K&/KSR'J/WOOO['<_^2]3]*^^>G?V^S_6(Z[N
M?3*H>U5;_?@S\USR\P>X^!KUXR.\>(K4/Y9X^"*]&6@1Q9H22D(WI7GEL0",
M.8\AE-!V2A3JFX[SBTMI6XVC*\XPG"EH3G/6K&,]_P#R<P1TUU3(Q]S%Y^U-
M'K6OY49!Z Z/@C\+K']CZ[7,WS="M#*<4KN;U+;ZFUJO6;;EHKK;C>OJ8AQM
M9H:A:%HK@U*D+2J3A25)5C*5)5C&<9QG&<8SCGF-KP/S[K7(_?;4?9_WR:O6
M[HX1]CVA<Q]YM+]O_<H*UF>6>/@BO1?H4<6:$DI"-]5AY;$ E#F/(93KW:*%
M.J:CO.+2VE;C:,N93A.%.(3G/6I.,]T?)S!'3?5,@_@K??M?0ZZ$^5(0>@&C
M8(_#"P_8NOUS+\W1K0RG%*[E]06^IM:EU<VY:*ZVXWKJDH<;6:&H6A:*T,2I
M"TJDX4E258RE258QG&<9QG&,XYYC:^#\^ZUR/WVU'V'^>35ZV]&R/L=T#F/O
M+I?M'\Q@J&OE3[)72/0HV=$'GPLZ4X8UWEN-#*P94A>$7^N+7E#+#ZW%80A*
MEJRE.>RG&59ZL8SGG8WH-!_=)T3D?\WU?V?^$WE=7?*$(_<JU_F/\YT3]LV-
M<F7-\Z\XZ<4KLTZ#]IK$3HC='J+*L8&-)8UA6VWH\@N/9?9<3&SA3;K3DA+C
M:\?Z4K3A6/\ 3CGG3Z3 ?L_Z6\C]^[SV?CUZB>B8C]S7H5S'W@LO;^(:F9SX
M6NQ*<4IQ2G%*<4IQ2L2N[ZTFS&L4QW;&O41:D0B"K*]FVA.P%(SYY(5!AS\X
MF9RR_,*!30R,C.,]^1"&H#?:EB"+,;-ZO.2H$,O7&4ZC=8  DCE[ RD]P93V
M$9Q<:'K?;4ZAPW6'5.2.?/ES!'Y01V@XRC"FPR4.(1'2XT\?/C,38,Z$^U*A
MS8<II#\:7$DL+<8DQI+#B'F'V5K:>:6AQM:D*QG.(@@D$$$'!!Y$$=H(]A%9
M000"#D'F".8(/80:]/*4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MK"'2:_5NZ0?[$-K_ ,!G^?2=#?POZ*_I)H?[3M:^5Z=?@1TQ_17I#^R+RN&[
MGI97E#3BE=5GD=?U0,_M4NW^YUWFCWR@?P__ /V33?\ ;NJ]!_DT_P 6H_/^
MJ_[%I6T$V(@V ,6 E&U/##8R>((LH<6RMV"2BNPI;:'FLI<:4N.\XE+C:DK1
MG.%(SA6,9YTM;7$MI<074)"S6TT5Q$Q 8++"ZR1DJP(8!U!(((/81BN^KJVB
MO+:XM)U+074$UM,H8J6BGC:*10RD,I*,0&!!':#FM=F?)-]"7&4XS0+)C*L]
ME.,[$N.,JSU95U)_ZV^O/92I75CZ^I.<_P V,\[:_=U](_\ 2MG_ *IT_P#W
M%=+?O=_19_0U]_KK4_\ B:?R3?0F_G] +)U?]_TAW'XMQ^[KZ1_Z5L_]4Z?_
M +BG[W;T6?T-??ZZU/\ XFI;Z#Z/FK.C=39](U$)F!ZR7L,JVRH\TT2/./&"
M P0*?E-S2<F4^EER %'(0PVYAA.6E.H3A;SBE?!]*.E>M=,-0BU/7KB.XO(;
M2.Q1XK>&V46\4T\Z(8X$1"PDN926(W$$ G"BNQNB'0S0.@^FS:3T<MI;6QN+
MV34)(YKJ>[9KJ:"WMW<27#R.%,5K" @(4%2P&6)-S[D_HAVK^S>\_P ,%.0N
MC_W^T3\[Z;^N0U/Z2_@YT@_,FJ_J$]<(_/3FO)*G%*ZAO(L?JJW7]O%J_@/6
M?-*OE%?AQI_Z,6/[3UBM^?DO?Q>ZE^ENH_LK0ZV/=(#^@?=G[(]D?P:9YU%T
M5_"?HY^?M'_:%O7=G3'\$>E/Z.:W^S+JN%OGIE7DU3BE=3'D9?U2SO[:+A_#
M-&YI+\H;\.[;]'=/_7-3K?\ ^3'_ !=77Z3ZG^I:56VCG1-;$UA&?T>];2]@
M5O94.(;KEBJ@YP4)CU.Q%ZS7<#Y9MJP&(\FL!Y,4')Q99\: FU.N0>^LT(4(
M@&G)L02/:C2!<RB-HB0RN<DNJNV0NU2'8%AL!.SGU"S%<%CG"8(RZR %64$#
M:2JX)#,"HY'<0-W+K8 ;.!BNZRTY1=1QID2EPB<=N7  !$++GC-AD#ZS4HDB
M!4:D+DFYLY\?6*M#F36@@>.XB/&<($9CG?3R,Z5(MEGDF(+D<BS=554%W(+N
M0H +N0-S=IP!V "KHXDB&$!'(#F2<*O)5&2<*H)V@<AD]]91YAK)3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE:$O+E_P#P;HU_^9[7_P!UU[S:
M+Y-'^<=,?_HZ%_MZM6H?RK_\UZ#_ -HZ0?\ EZ/7/9S:ZM,ZN2F__-]5_P#N
M0'_^3B\AZC][[[^QW/\ Y+U/TK[Z:;_;[/\ 6(Z[W.>7=>O-:>O+6_JOZ]_;
MS7/^'VS.=_\ R<_PUU7]&+S]J:/6M?RI/P!T?]+K']CZ[7,)S=&M"Z<4KN]U
M%_1/K#]GE*_AL;SS%U_[^ZU^=M1_7)J];^CGX/:%^9M+_48*U@^6M_59H'[?
MZO\ \.MJ<[H^3E^&^J?HK??M?0ZZ$^5)^ &C?IA8?L77ZY@.;I5H73BE=W.G
M?Z(M6?LXH_\ #(OGF+K_ -_=:_.VH_KDU>MW1O\ !W0/S+I?ZC!4+?*N?J0;
M1_\ .=<_\0:WSL;T&_QDZ)_9]7_9-Y75WRA?XJ>D']IT3]M6-<C'-]*\XJ<4
MKM2Z"_ZG_1U_9;6O]VSSSH])GX?]+?SW>?[=>HOHF_BUZ%?F"Q_V#4KN?#5V
M'3BE.*4XI3BE6Y:09.P"\#Q-QL=&E^+BR?/E6BU&64RS'<[;T#+-UJUP"^$G
M)_R,I> ^)Z&_KA38;O\ E>7(P4Y9%D&#U7+@?E^UNC9'LZV.\&K6!88#LAR.
MLH4G\G75Q@^WEGN(J%@W1N]EW&!M(Z"TZY?:=L"*=IPX5L:V1*7)U] IVY:
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MQA&>UVMH?DT_YQTQY8^TZ%W_ %]6[R:U$^5?_FO0?GG^$=(.[_L]'[@*Y_\
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ME9!H5-]1*E.)(J;HT=L*6*.\[VXB8<NLK(6DQ] !@ SKM,;UD'=L1FP[*.8
M95B64N#SY,& 3ZQ*G*J21<M\Z5%4J5CU97Q@]DYG90 '<L2IYV-64":;8K%6
M:R))-YGPI,201G$+,RJ/$,3JT#QB ^-DV>+8RU3!6.R.T=UF9CMX3-'@*6S(
MJLS#D0< +S*AVY@["@=DJ]PJM&H&[B*'R2%PA95!Y^TEN0.T<L%@Q4-E34]#
MM>OA%B&6S:-DVJ^6NECLH@I:((R%/KH0]+Q/C4^.L8VVF:+ RG9K0B1)PE^.
M+=AB\(PP.94O%-(DK*4A2'$:(P0DAF48+\^PL,%@/;D^VLD:,@8-(TF79@6
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M_FN;%?OD]:_JSI?^F7?_ +*U?_>J:!_6S6/]"LO_ '4_D/\ 67^O6]^[%?\
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M%*<4IQ2G%*MRTV^K4@7@W<+ )K0C,N+ P2,S6($+,V<YW4.+XB0M#??R7?\
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M;5[0"?=M_P"8..7<?$>54PWUO@*>!M7M )]VW_F#CEW'Q'E3#?6^ IX&U>T
MGW;?^8..7<?$>5,-];X"G@;5[0"?=M_Y@XY=Q\1Y4PWUO@*>!M7M )]VW_F#
MCEW'Q'E3#?6^ IX&U>T GW;?^8..7<?$>5,-];X"G@;5[0"?=M_Y@XY=Q\1Y
M4PWUO@*>!M7M )]VW_F#CEW'Q'E3#?6^ IX&U>T GW;?^8..7<?$>5,-];X"
MG@;5[0"?=M_Y@XY=Q\1Y4PWUO@*>!M7M )]VW_F#CEW'Q'E3#?6^ IX&U>T
MGW;?^8..7<?$>5,-];X"G@;5[0"?=M_Y@XY=Q\1Y4PWUO@*>!M7M )]VW_F#
MCEW'Q'E3#?6^ IX&U>T GW;?^8..7<?$>5,-];X"G@;5[0"?=M_Y@XY=Q\1Y
M4PWUO@*>!M7M )]VW_F#CEW'Q'E3#?6^ IX&U>T GW;?^8..7<?$>5,-];X"
MG@;5[0"?=M_Y@XY=Q\1Y4PWUO@*>!M7M )]VW_F#CEW'Q'E3#?6^ IX&U>T
MGW;?^8..7<?$>5,-];X"G@;5[0"?=M_Y@XY=Q\1Y4PWUO@*>!M7M )]VW_F#
MCEW'Q'E3#?6^ IX&U>T GW;?^8..7<?$>5,-];X"G@;5[0"?=M_Y@XY=Q\1Y
M4PWUO@*>!M7M )]VW_F#CEW'Q'E3#?6^ IX&U>T GW;?^8..7<?$>5,-];X"
MG@;5[0"?=M_Y@XY=Q\1Y4PWUO@*>!M7M )]VW_F#CEW'Q'E3#?6^ IX&U>T
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M_5VU_P >^_XJG\L-Y2C_ &J[E[MZZ^3>/L#Z(_T);_XMU_OZ?N8]!/ZNVO\
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M*"6&S;B7:(XRJR!O^CZY0JPXCD8&"*\=DN'=5;@[2!'R!W9R@.YPQ4CZ0(W
M@[5K[Y\I@6@R9 NQ:X?KI55L)4\;))[%JT2I+(U?9.W]7W&8=MI$..BUH3!L
M6E[(W6YDZ$ZNSK*UF&Y'"32JF8U/FHL 4GWCAB0@0N7VO#;SQA4!)=BERA<
M]3:YRP7F]>QR:+:=Q09D4+E9)8F+,0 HW0MM.#NRHPI-3=U+N@IMG56L]IP,
MS1$'9>OJ9L"$)EJAR)8N)<JX-L<<=*D,L)9?D0F22(SSS24MNN-*6VG"58QS
MCIXC!--"2&,,LD18<@3&Y0D#V XS4R)Q+%'*!@21HX![0'4, ?R9K(/I0?\
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M173J$9F%24IZ.@EB-)D3I3TEEUQ]Q2JQ,T+;T;K8*]<)(,$ ?1D5U[% !QD
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MF-Q1U:D71^Q/ET:"S3F:J[3HS]L@V)5H\V$:RVL] ?D"FW):,7SJW$:,W]F
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M$$[N34+&9\DK$=<>I@]5YZY=KK+&109X3?H3L6:J1$;0+V<^-J]M'M:WF?\
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M\L#<,UYBK339.0BP0W'HXY;L82RV>#2:QF)%@&"DQR!$SYSG22$2 :E1!<S
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M@/0L%WWY$6)G3B21M(J@A21@9.2 I(]Q.X;0 =QR#MY$XF5%D"$GF <\O:6
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M$IR222Y)*D)"\(>BX1A;TMYQ6$85#4K"<*5G"<94K.,=77G.?KY03$ #:.0
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M7_>Y95U/0J1Z\S]RO^]Q2KU'1<PH4>(I>'%,-]C*\8SC"OKSGKQC.<YQ_/\
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MT'*8A&(D>0T[(%S)4"(5C1I[*%97%??&SX4]IIY*%N1)4=].,MNH5D5( )!
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73BE.*4XI3BE.*4XI3BE.*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g743471g17p84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g17p84.jpg
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M.TET)<#[D97>M;GX]3VB=<);=O\ 5>06N'%$LJ&M5>^1.VQ,9'R=C&59'<^
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M66XCCANIY2LZ!+AE!^)S$#\"DL."D[X\2222:MB62[ER.C$S201H&B?E$&(
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M%_(RM$UM0:5)S!1)+2-2IU>KC^4(*@+"61>0\<S</2BL4%1*Y45 5  _3O
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M@CAV>2312Q-(Y3T4$),W($@]_0))?B1'$J[0AEGFE>30XM'(CA%#>K:W&NB
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M,:S\1W8GBCFC!DA"MC&J]_*-()O7>02C#6NQXR84JYQL+AM$,+HHU*D5.QP
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M;MP6<K&(W:-RG,X=N5$V[9)5=0B9I%K:75]/':V=O-=7$IU'#!&TLCD#9TB
MG0&RQ]% )) &ZE65C>Y*YBL\?:W%[=S'45O;1/-,Y V=(@+:4;9FUQ5068@
MFN@OL)_+1IRS0=#V7*TU/9M#>-JEMG7;YFZE85M:8<30USJ,D0ZC5P<C9XA)
M1;]HX3,HD=)Q'OVJPMWB66UE^S[^&6YLX[@V=RK3V-VK".0PR?M+>=/# $J4
M=6!T=AE8;4Y[*7[*REO->8^.Z./O%:YQM\CK'*UO+^UM;J,Z8 LICD1E.B"K
MHPY(:W\..S[X]\*H9XIKR%=VC9UC(JK?-VWI1*=V9<GSQ8'<D*\RJG_T+$.W
MO\Y-!PI6K1PHF@[ESR\L1647V_4'5.5ZBD47<BPV<.A:XZU!BL[=5'%.,8/[
M215^'NR<F )6/MQD(-[U3UMF^K)4%],MOCX"!9XBS!AQ]JBCBG&$']K*J?#W
MIBSJ"RQ=J(B,7BSFZY&F*5C-ON56H4$\LUQG(^OP; O5P_D5@2()Q PIMVZ8
M 9=X\7[HE;,FB2[MR?\ %H(J'$"Y<B,[!44LQ] /]_ ^I/@5:[JBEG8*H]2?
M]_)^@'DUJKFJ-?\ FI,V.+I, GJ'C38IY64N$@HP%B]W%( H*:\C:4$#HN+8
MS.)5!1J"3E*H%<*/7%L?3LD=BUC=_-DKA8K2.\NYKR6QMQ;6222%TLH!Y$5N
M&\1 >!SUW JHJ<44;YVTQ-E%-?RXZQM\>F4NFO<E-#"L4F0NV&GGN"NC,S>2
M03P+-([[=V)O;1^)^AJ/5DJNCKRNV(OESH/)NTQ,=,SSTRR -UE"R*[4#QA1
M3#NHMH8(YLUZ =NDFL)U3Z9[J=VY=QE\["J2JCSOT!\_O;9K>):P(O'MJWC1
M9@&8^->I'C]RZ%:MN:O8YT+;["6G]9(N$995BLW"/1D"1MK:M.I5@CXBR+_S
M>Q1154TC)UNX@X33\,RS64,],AW-[ANHKK&7,$Z/IX)%D4G9C8J=$.H(*\E)
M5V0C:D@C59,=)=X/+8_.8F3MWN-NHKN#9(V8VVT+$$=R&=.4,T3>'ADD3?Q5
M!'%+GELOL^ZC6.-',2@VFRZ@UJD-7K&_JE%2KRST*N(NE3Q,%MW6KD%IMM$5
MQDNG&QL]6UGQ6, RB8Q**F70"X#8YV.UZAR%SE<:B6<UX5FEL7D#)).44320
M3A54F:4,Y5U7;LS$KLBI_5?5MKG.HLAEX\0V(M[]H9I;=)O>3'=F",7DSGM0
MDK<7(DFVL8)+\BI9R%V6;&U=ICFHZU]NW6/("HR%4GX]I5FLA!NXVQ,IT&3I
MY)A'PQ@EF2T?:&I9%RA)0#UL9\S5 @O(]HY;N4'&\Z1Z_N>C,=?8B;#&Z9KB
M2\A<S&V:*66**%A..S+W8?V*,KH5;[R!F5E:/P7VA^R.V]H>:QV=BSYQPBM(
ML?=0^ZB\66W@GGG5K4FY@[%Q_E$J.CK)&?@DXJRR+--=CXX[%=S+R2IW)?9M
M18K>7(P@5R&GXF*0;-46R+5JU&8BD 0(5$!Z> 5103"==198RBRD"RZTPT=M
M%#DNA\'D95YF:[0BTN+AWD9VDD?W:X?D>6OO$#0XA5 4;')>S;J2:]FNL-[3
MNI\1 _;$&/D#9"SM8XXDB6*&(WMI&(P$V/V88[)=G<L[39JNJ7BG5I:)OVPU
M]ES RCETVGW$&U@56\8H@U3;QAF[5PZ\R**Z+ET+M=<ZQA>"W_HFZ0CR^?R&
M*R5ZMQB,,N#MA D;VB74EVKSJ\C/.'D2/AR5DC[:*% CY_>=J[CI3$YW#8Q[
M3J#J)^I[PW<LL60DL(L>\=JT<*QVIBBEF[A21)9>\[ESWNW]V-28^VE^%"A9
M2NM1?R4/:F$<U*,;;BS:<T:3 ZPO#J*M%&[4S8Y10!N*;U$P !RJ) 8/%4W&
M!_H&]B8^HOZ019'O2'O8[W4VW8(3M!5D#N) >?/E$P]"&(/%>>ZJ_P :<>3$
MO1_]$I\0+:(>[9@7RWIN@7[Q9H6BB,9';[?&=#K89 1S;(=13&]I,9Q/=%2I
M=<%J##T$ZJ$HX=IR1E!=>D 7:.)"54;IH 1H*2BCE$YC*J%!!0 $Z</J*VZ4
M@%JW3.1RE[W.][W'D8$C, 7M]GA(D-NKL^Y.05& "@\E]&V/1]YU[=>_KUMB
M,)C>U[O[A+A[J29;DMW?>.Y#)<W;1K'QB*,TL;$N1VV +*V[M"WZW-!FK6H+
M=M!M)%?FD5ZJJ45(86@M0036:),G[IPH\!=4R8@D@D4&Y@!50XF(FZ=P..S0
MNA?=1X[ O!VNRM^IU<]P2<RLC2PQH(N"AOB=CS'P@ $TZPZIS'31L3C.CLQU
M3%<B<W+XIP6LNUVNVK0I!<32M-W&*_#&@$9T[-M5Q_5F_P!YL:RGJTEI[:U
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M/)8D #R36ML^K>E<A)'#8=3=/WLTK*D4-KF<=<2R.Y 1$BBN6=G8D!5"EB2
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M1M%^93VOR-U#4)!GWP<0#JZPTA:RBGU[X$J$,XDK0L)!#NF!&(4Z'Z$'X0@
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MTN$XTE;4F->R5:C(IPG(D-+C.'E+GY)V5>.!5LU30EFIFCL2N%A52**8PK7
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M!NIIGDY&S]Z]^MFAC1+3EQ8)P=9?@F,<![O+GLOKW'V9=9=&=.X'+V6?M?\
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MXU+_ .#7OLW]+S#O(_G\*H)(?J[MO-T_X^W,/O$'RM$_BY/_ -4?RK-[O/\
M.[?^" ?_ %S7G\&/=!OZ7E[LT?S^#$F0_5W;0;I_=^8/9CWF'_Q2/_6__P!:
M>[3?^-R?R_[N6J\?@M;5/_2\N-Q#^?P5'2']WL[EB'I__P (>W*^]1?^*0_E
M_P#:BGNTG_C4W\__ ,-/P4-A'_IN6>]3?G\*=DD/U 6=-TRGO4?RM8/EZJ#_
M -W^_P"-/=9/G=3_ ,&(_P"^L.GN D=;![UNWAM"T&$0,(SCAO*B)B^T#?\
M22SSX0#[0'VB'Y_9DB/*SP_U([(_\V[I_P!@K4J%[^W&K?*Y* 'U$-W-$#_J
M.M9</#B153%%SR3W^ND8@IF3&X+^&9,0[IDQ(H=4HD$OP1*("7I[! 0]F8/?
M/._=X/K]WS_.HONC;W[S<;WL'F=[^OUW_&H#1[('BHE_^[3A^?P:GKA'_P#P
M\_3_ -^;,]3YH^N0O#^^\NS_ +9JW1S'43?>ZFZB/[\Q?'_;-4T0/ :AUF(8
M5^O[5W7 P,6CY>-A(&TPT/$1S?OF4\!A&LJVFR9H]\YS^&W0(3OG,;N]3#UU
M\N2FF=I9DCEE<[>27G([GTVSLQ9CZ>2=UJ9H9;F5Y[B\O)YI#RDFFG:661M
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M.L^+G$C7T/L28X\\B-S,)2TM*PO"Z0;S-TGX8KF-DY(9Z;:*V*$0CX)(L8+
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M-H"81#H UU00#J)@*( 4W6+[$<]:(LW4?4'2G3,.N3#)9=.^H^9"H@MFT/\
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M) 321123 J:22292D33(4I"$*!2@!0 ,X@DDDDDDDDDG9)/DDD^22?4UT@
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M6[Y%FDHPBY!6UQH%,+S73\I.Z?O\3T/*T7ODL4<%JBAY,GFF%I9HG]^*W?\
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M.O,N/+7.>OKCW0-O?[*RBF+B+?\ P%S=W<.M )H 5L"J5*IU!AT*]1JI7*=
MMNGEX:KPL= Q:0]T"]XC&+;-6P*&  [RGA]\XAU,81]N>5W^1R&4N&N\E?7>
M0NG^_<7MQ-=3-\]&69W?7T&]#Y"O8\=B\;B+9++$X^RQEG']RUL+6&TMU\ ;
M$4"1IL@#9X[/S)K)LAU.IBE<.1D&,1'OI64>-X^,C&;F0D7[Q8C=HQ8LD3N7
M;QTNJ)4T&[9NFHLNLH8I$TB&.<0*41S#<7$%I;SW=U-';VUK#+<7%Q,ZQPP0
M0HTDTTLC$*D<4:L[NQ"JJEB0!5KNL:-([*B(K.[L0%55!+,Q/@*H!))\ #=<
MHIBG*4Y1 Q3% Q3 /4#%,'4! ?E 0'J _FS*"" 0001L$>00?0@_,&KJ]LK2
MN'(2,?$LG,E*OF<9',DC+O'\@Y19LFB!/REG+IR=-!!(O4.\HJH4@?*(9AN+
MBWM(9;FZGAMK>%2\UQ<2I##$@]7EED98XU'S9F 'UJUW2-6=V5$4;9W8*J@>
MI9B0 !]2=56D_+O4;Z[PM!I:EBV1-RTJTC'"]&A59:(ADW3E-NI*2$HLJS;K
M1;(% </'L4,D@@V*HJ=0/#$N>:-[7ND)\W98#"MD>I+Z[NX;:1\%9-=VEFLL
MJQ-=7%T[PQ/:P\Q)-/:FYCCC#,6^'5:0]0X]KF*UMC->R22*A-K$9(XPQ [C
MN2H,:[!9H^8"[)/@U.5^K$A<J?.5B+M,U2G\NV3;H6>O'*G,Q0D<H+J*,E#&
M(*9G"22C-4Z:B*Y4'"IFZZ"X)K$[G/XRXS.'OL7:Y6]PEQ>1+''E,<P6\M-2
MQR,T#$J5,B(T+LK)((Y',<D<G%UVMW ]S;RP)/);-(H43PG4D?Q DJ?&M@%2
M000">)!T1"NM^)6F]=2"-A&'>76XIN4WYK?>W@V"5](IG*L1\W;JD2BVCM)<
MH+-WJ3#TBB<I#>>.H0%,XKIOV2=&].7"9#W.7-YE9%G.8SLQR%W[PI#B>-'5
M;6*57'..9(/>$8 ]]F4-6LLL!CK-Q-VVN;D$,;BZ;NOS!WS53J-6!\JP3F/'
MQDC=6:STVMW3%*8I3%*8I3%*^:RR+=)5=PJF@@BF=5998Y4DDDDRB=1150XE
M(FF0H"8YSB!2E 1,( '7 !)  V3X 'DDGT %552Q"J"S,0JJH)+$G0  \DD^
M !Y)JFNV^<6H-;MI5.#?)7N3B&RSJ2<1L@TC:;!MT! JSZPW=\/H9A&MQ,47
M+]J+]JV#V.UFH=3AO++ 7MVR<U,"R$*BLK//(3Z+%;K\;,?DIXD_V0:ZZTZ/
MO?=FR&:N;;I[&1@-+=9.187"_P#-@=HRI/H!.\)/]D-Z5HOVQVJ>PN1UO>Z@
MXW5;87*&ZK"*"FM>-[%[%:UAD5CBV%SL#<3IG((N(E(PIK*OV*$[17Y4ED_6
M6O*B"I/1++HRWQD*WV7GM<-;CR+K*.KWDA&CJVL0R$.?("DQ7"DC]E+Z5I;C
MVA=(X*5K/HK"S]79E/ RMZC+80/Z"2)2BMQ5O(>.*V!!T;MAYJ2]:=DIS"Y*
MM2/.<^^F>A]62I"&?<6^*:Q&3J58*B512%V5M1\K-*3:152?SF(=O]GQ/XP5
MH*6@%"$(G&NNM<#B#QZ<QAR5XGW<SF@6"./ DM;)1'VSKT<+9OL:DCE'D\?E
M).K^L).[U9FY8[4MR7#8UA#:H/DK!"821Z$L+IV'GO!JW9\:>%_&#B#7O5WC
MSIRHZ]!9LFUE;$T9GE+O8B$[IO\ X1WB:4D+5-IBL45TVCZ65CVBAS@P9M$A
M!,. RV?S&<E[N4OY[K1VD1;A;Q>O]5;1A(8SHZ+*@9A]YF/FIECB[#&IPLK6
M.'8 9P"TKZ_ORN6D;ZZ+:!] *M!FGJ?3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*U"[(U'.,>0EDVQJ:S5&[OJY:X^_J42*F196]\X:OCO;#"1
M31HU5937E3QTFC,)Q[U631044;/(U1^J5%UV5K>1MCHK.\AFMTEA:V%PR<H%
M!3C%([$AH^7)"A90A.F5PHVOM6+S$$G35IA\S:7MA'=6<F-7(S0<[*-7C$=K
M<3.[J]OS$D+0-*BPLP#I,(U+):&U4[COV@NICQ=CCA-(Q??!%=,4&&Q=76-9
M/H*\>\%-11))15 !$JB;F!GDFI2/&JJ[0R+/)T_U)U'[/LL+S&3\4DT+BVDY
M28W*6ZG^JN(MJ&T&(5U*7%N7)CD4.2_S[[3O93C,_:G"=467<4<Y<1FK327-
ML[ :NL==\6*-X0W%K*'BDXH)XI%$3U2V4O-JX]Q[KBCVB]:CM[<7-@I&JE/W
MS+PBL_$.HX_PF,!M%DL#QZWD6*:*3MI*F65M$$]9#*1LE8F30DY"^F3=/X;K
MR)^K/9E)]A]5V0][RW2 F2!^?_"W6%?]G&T;LQ4Q*%M9E=8WCLYF]WN/!;+J
MOJ'V974727M3YYSI*\<6N#ZZ6&290F_V5GGD_:2+(B 'NNSW4)1G62_MP;FW
MT.<N-7\S>RUY!4VR\5MM[PB.S9->:'>Z!.#?K#L/0<#'WQ["'M=7O\-#J/X2
M1A#3))(L*C-0S]Y/0#J,D8^1F+4\?R"U^)N,/U997%KG,=8#JV.&ZM+^WDM(
M[/+&6T[JQO TP2>.98P@E".@BF61)$CA55'HT@&&C]ZQUY=RXB9H+K&75O<O
M=8TPW*QGXC"SV\L+N68-(K=V!D,+O*68_MS8GKUDKR#B-/$S57LT9YYLNQ,U
M>PTY$6! 7GG$%6XG:/V,PW>F=>83,HD^3="OWU 6$QOGFYMUD6>UNX@ZNLEM
M<03IL,A4Q2P2QN/*\>4;HPUK:D:\5Z3^SEC_ +,D4J?@R2(X_B&5U/X@@_C5
M3^-E;N6H+UL[1S^)FG6N8UP:[ZQM:S9RI$HQ$V[3([JYI-0O@'D&ZZY%/*$,
M58SMG.R!T@0>-S&\:]FN-S/1^=ZGZ&N+.^EZ;MI/MSIC+/%(UG'9WTH$V+:Z
M8=MKB.1PPA4AS+#?W!41RQD\]A8;G'75]BWCD:S1C=6,Y5NV(Y6^* R'P7!8
M'CX)99G(TPJY>>S5TE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4KAR,C'Q#%S)RS]G&1K)$SAY(2+I!DQ:($#J=9R[<G2001
M('M,HJH0A0^,P9DBAEGD2&"*2::1@L<42-))(Q]%1$!9F/R"@DUBFFAMHI)[
MB6*"")2\LTTB111H/5I)'*HBCYLQ 'UJAFS^TLXOT&1]6JM8IC=UW65,U85+
M3,0I<5GCP>H)))3J:C:M."F4 05+%RTF^2(4QP8*CW"']/POL=ZTRD/OE]:6
M_3>-5><M_P!13C'+&GS9K5@]XG@_"9H(8F) [H\D>1Y[VY=!8>?W"PO;GJK+
M,QCBQO3%LV3>67R%5;M2EB_D$,(+F>50">TW@&*OY2>TJY#_  -<:II7$FD/
M/Z.U[7<C9-B^7$>AE6E;7C5O(.C)"!RL9JCM2%6,5-.<Z)G6S=_8_L>Z3\Y?
M.Y'KS)1^MC@D]SQ'/Y"2\68=U ?!EMLDY*@DVQV%KG_MSVX]:>,)T]B_9SBI
M?3(]0R>_9KMGU:*Q:!NS)Q.Q%=XN,<B%%T.)8]U7^S)IEGE6MKY2[@VIR<M2
M)Q6!K9[!)UVD,SG$#F1C*_&23F59-R'^ 5LUL;6,52#NFBDR',F$>Z]LN1LH
M'L.B<!A.C+%@%+V5K#=Y*0#P&GNYH4AD<CSS>T>92=B<D U)L_83B[^XCR/7
M_4G4'7F00\NW?WD]GBHB?/&"R@F>>) ?';2]2!E\&W )%7_H&K]<:KB @=;4
M:JT:(Z$\1E5X..ADW)TP[I5WQV3=)5^Z$!$3NWJCARH83'45.8PB/EF4S67S
M<_O68R=]DY_.I+VYFN"@/JL8D=EB3Z)&%0#P% KV+#X'"=/VPL\'B<?B;8 ;
MBL+2&V5ROHTIB16FD\DF24O(Q)+,22:SO-96VIBE,4IBE,4J&MZQVMYJC'AM
MH6J)J%>D)2/3+*R<FPB53JE4,#QA&O'ZJ8(/)2'/)QBCAKWG;5B]=N40**8G
M+QG7=OTW>X)K/JC*VF'QUQ=6RB[NKJWLV+!_VUO;37#+PFNK,W5JTD6YHH)Y
MI4T4Y#6Y1+*2U,=]/';PNZ#N22)&2?[2(SD:9X^:$K\2HS,-:V/'IVBZ&TVS
MFY*94>TVL1+%52>CVA)!><4F'J14Y5-&)*=NZ=6&4DBNUG2 D9JN7RCQ59%
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M;$_VB_K6]#4^F=3Z)J#*@Z:US3=8TYAT%"O4J CH"/.OW"IG>O",$$3R,FX
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M?6>4;"UHR.VMCZ]FZJ5D\37KU6KZB3A5ZH0H,EDI)>&B'*!6ZO4ZG?4<$53
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MO%'!!#$H2.*&)!'%%&BZ"I&BJJ*  J@ >!6Y1%151%"HBA$51H*J@!5 ^0
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M0]O7'^*SIFX_\'^UCH^8G[JWKQXUC_T7OYV'\%)^5/\ '!U9;?\ A/V,]<0
M??;'QRY1!]2'CQT"D?CR ^NJ\CVJ.KXH.[== \J*0H7^F4FM71Y&B/3X^\J>
MTMW70/;UZL0'H ^SY,?XD<U/YQO571&2!^Z+;-RF1OII19.G_P!+\_XT_P#T
M@,!;^,IT?[0,41]YKKI^(1KKUVQOUD_^B%=U%=K-PL?F DC=[96S]>ZH2;UY
M;5#HF^4%"P4=-]!#XA O>R-/["O:+$-PXVQO!\C;9:P 8?5?>9K;\]5*M_\
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M)LBZQ.^O1DN(LG&3]V0@ FS.F^"G%K1IFKRG:I@Y&Q-A(H%ONA37*S>:+_\
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MIF#H8BB:@&(<A@]@E,40'Y0R'4FNC]4:K]&H#W/'_P /BE/5&J_1J ]SQ_\
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MK'=]%9U$:?$K8]0VX\J<5D;03$?\Y+V2TMP3\E2[D)^6SXJ'Y+MGN"=2,/\
M*EJ'D%J! H]%)"]\=?&B"^WH(DFJ1)W*)=E*/L$[%ZZ+U]@"(B'78)[/,Y<?
MYE<X>_.M\+;(H)/XQW$=O(O_ $E6N#R5Y<X4G[:PF>Q**=&:\Q<PMB?/W+J
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MU >YX_\ A\4IZHU7Z-0'N>/_ (?%*>J-5^C4![GC_P"'Q2GJC5?HU >YX_\
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MLDYD=%/%2D,A>X9I .X5?0!8J&  %=#C^D,M);-=Y5H<'80+RN[_ "[I9QQ
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MU?>:K_2#,?+I:^/[[CC_ /FI-/\ :;=I(N/1IV*>XO;\7G.046T_/\?BZ8*
M?%^</D#Y0RG]$>E!KE[0+#_HXN1O]E__ +:?;V=/ITM<_P ;U1^7NO\ _P!_
M*O/^T9[4QS_U3L8;NCU^+SG)2M!T]GR^+KAE^</S?$(?'\5?Z*]'#[W7UL?]
M'$R_]UVW^_FGVWU ?3I>4?OOX_\ O@6GX?7:Z.?^J=CP\1Z_%YSDQ2@Z?\?%
MAF73Y?CZ?&'Q?*_HUT./O== _P"CB+C_ +G:@S'4A].FC_&^B'^U13\-OMFW
M(?S3LCH%#K\7G.3NN0_O]H*RK(?B$/8/0>H#\OL!_1[H(>O6\I_T<1=?]R-3
M[5ZH/ITXG\;^'_O<?A^8_<'E[VX3C_JO93:V;]?B%YR@U8/3X@]O7830?CZC
M[>[[.GYNHT^P_9X/7K.[/^CA[S_9[L33[2ZK^73T'\;^W_\ NPKP'*+MWE_Z
M+LR=%LP'XO.<DM<+B >T0Z^5VX4?S /P0'K\@!\5?L?V<#UZNR+?Z.)NQ^_[
MUE_O^-/M#JX^F!M%_??6Y_V7-/PB^WO7_HNSWXP,NOQ><WG7G/=_\7E-PEZ^
MWV_!^0.GQ^W'V5[-AZ]3YAO]''2K_P!JQ-/?>L#_ /D;'C]]VA_V77ZUY_ET
M[?\ 6'\7PFX:L@'XO.;47<]W_CY3<H=>@>SV!\8@/YPQ]G>S,?\ [P9YO]&R
M _[5A5/>^LC_ /DK&#]]QO\ V7?ZU\U-P_\ E!IB&4_!9X#QR90ZF._NUN6*
M0O3VB8S?=92@ =>O4?9\$?9[0P+'V9>GVQU*W^C;P#_;8547'6C$ 8[$;/R[
MDI/_ %;O_96&R?([MUHSOA+T;LM:SW>O?],[$N#<Y.@_+XF[C@ ^SH("01'J
M'0.O7IG3%^SAON7/6$P^7"U@._Y8\?[_ #J?%8>T>X\P8.SE_P#16N0D_P"Q
M*W^VHZE.8O;-L0-YN9[+EIW?C]%RVV9\0_\ #Z%M<\!__L=_KT]G7K[9*83H
M!ONKU@W^FEC%OS_YR"+_ +O%;.+I7VL3ZX8&P3?_ !HE@_#SW[A /XU'DCSG
M[9<I_#83_ %\J)NZ1*'JF[S'.;KTZ)A+MT -\74/;[>OL$?9TDK@.@/5H^IA
M]><V/_/@?]AK9Q>S_P!K,@W):].6H]29KS?$?4]EYQX_C635GDIVY]I$INO&
MMLFH(=TM7TAM.TK% 1'V]PY&R C[0$.CLY>G3J8!ZYAFQGLYAV ,PQ'_ !V0
MLH1_/;$?ZH_E4J/H'K./SDNJNAL>/F/>+F:11\]K)%;)O\!(?WBK#UF7[:B<
M%,\G?:,P _3JU9\88J&Z=>GM!]<-E-_#Z?\ >Q_L]HFZ=.F:J8=!1[X6=RVO
MFV8>3?\ T8+,_DW\=U-3H^"'1O\ VDXDZ^]'C\";C?\ HS+DI?QU^P/R/X58
MBL5+M37?</8]KPS,P]!$OJOI*,;^T>H]])G!7)R!.GL$I7'B '^]WNO75S3]
M)#?:LF(_]-D'/\"TL \?Z/GY5-3$]%6^C<=4Y^_(]5L\=9VB,?F-76.=M?NE
M!_YU38A1>?YHTQ%=SZL*]$ [AUX=AXX>SH(*+--8"S3$?:(BFR7 !_)$/D@&
MXZ<Y?YC=\?P=]?O :\Y?S85+%YT';KJ/$YK(,/G>726RM^.[2=3_ /1#]WRJ
M([-I/M*)GQ",MVZJ:]_KT<A?;W%=.O7I_,:WI^([OR#^+D2=/: =/C&;#?=+
M1Z+V-X?^;[K;/_UI;Y_YE*C2=3XN#Q8=#X=M>DE_EKFX]/3E"V+DW^.YO/SJ
MG^W^(':?$;,K">0T=R240=G9EI1=H[$J%EC4I I1/-,;;LEA+UQ5FU4;(DE(
MLL?'/G:0HK,UE3MO*GW=GF>D23$!D<5L!C<-:6L\+E=_LV@M&256/(E'YNJZ
M(91RY"ZR]H^;QDKM'TKTXUFZ\6M,3++C;OF/ZJ1[F:%[>6./;AHS;HYY\D<:
M*/8OCKV4&D/#KVVN5;=IR.W(8PR3JKV"P.;7QZUA8$5E6[ZMZYUXLUCZ].(U
M]=$T0[L=]B9V<E)-BZDO @C+%BF6NR?65^O=LL*3BK#7 3Q1"'*7L1&UFN[H
M%Y8S*#S6&VDCCC1Q&#( 7;C<Q[]U!?MD.I9)[J9G%Q;XN::9L5C$E4/%%963
MA(F A9 ;J:-I;G?>/$.%7;RR8LHQFUCHYHUCX]BW1:,6+)NDT9LVC=,J3=JU
M:H$30;MT$B%2111(1-),I2$*4H  <2S,[,[LS,Q+,S$LS,3LEB=DDGR23LFJ
M@!0 H  &@ -  >@ '@"N5EM5IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4KA2$;'2S51C*,&4DR6#HLSD&J#QJJ'YE&[A-1(X?W&((9<
MK,A#(S(P]&4E2/W$:(J^.62%Q)#(\4B^5>-V1U_<RD,/X&J]6[B/Q_N J+.=
M?Q\$].(F*_J2SFM*(G'VBH1E&*HQ!S]?A +B-6 #!U /CZ[*',Y&#P+EI%_N
MS 2[_P"DX+C^#"NFLNL^I++07)27$8]8[Q4N@P'R,DH:<#_1E6H\_!AVA2OQ
MFGN1]ZAFZ'M:UZ\I-[?#AT^),!5[C%HG[ *(IUY<YB@ #U$H#DC[5M9_\]QE
MO(3ZR6Y,+_E\3']\H^>O6MG_ $LQ%_XS?2^/G9OOW./+64_[SQW*Y_?=*!_&
MO'KES0H'LLNM*)MZ+;_TDC1YD\',K%#XS"U?>&=50P>T$V57'NFZ@(B40$'8
MP=Q_575Q9.?19T[B#^*^G[VFJGN/0N1_S7*Y#"S-Z19" 7$"G_2CV /EN2\_
M'QYWS&/-:A1SE.-VA3-CZFE#&[JA+16'JT>!O][P7#),TFN4H^T3^A4RB42F
M+U ?91L%<,"]I/:WB?+LRJ&_B&/ ?^L-62=!Y&5#+B;[%YF(>0;2[C67_I+(
M1"O[O>"=^#JK!U';^KKX"85"_5:<75 !*P:R[0DJ'>^+Q(APHC*)=?B %6A!
M$0$/C 0#6S6=W;[[UO-&!_:9&X?P< H?X,:YN]PN6QV_?<==VZKZR/"YA_A.
MH:%O^BYJ1\C5JZX[5HU9(E;LFS=HW*90Q4&J*;=$IE5#*JF*DD4A ,HJ<ZB@
M@7J=0YCFZF,(C4L6.V)8GU)))\#0\GSX'C]U4  &@ !]!X%<C*56F*5TTE8J
M_"@)IB=AHDI0ZF-)2;)B !^<1=+I  ?\<O2.23Q'&[GZ(K-_L!K/%;7,_P#4
M6\\W_HHI)/\ L*:CN4W]I&'[P/\ ;&OR')U[R+:U0[]P7I\AF[!TZ7 ?S *8
M"/R!DE<=?O\ =L[G]YA=1_-@!6SBZ<S\^C'A\D0?1FLYXU/[FD1%/[]U'4IS
M.XWQ?>*;8B;]4O7\5%UZT/N]T_JKIPP,_P#AU<AU^/XO;DI<)DV_^3<1]6EA
M7\C)O\JV<70W5$NO_@PQ@_VI;FTCU^]3/S_ZE8B/.75;L1)6JGM:WG$>B?J_
M3DEDSF^(/:ZEFJH!U_,B8W_9$?9F;[ NUT99K2#_ -+,0?E]$8?GK\:F_P"+
M_+H-W5YA[(#U]YOF4@?]"!U^7]X#\:?A3;&D_;5^*NWY$A_Z):<;KUIN</D'
MQU8210Z?G$JI@#XNORX^R;91N7+V2Z^49$I_D)%/Y4_HCBXO\[ZOPL1'JMNR
MW;#_ **W$3?D*?RJ\PIKX4'QPKD"D;\E6T7J,<^'U^+Q$$9.$>&Z?+W6Q1_N
M#Y*>Z85/ZS)RR?A%;NN_W$I(OGY>:?8_1,'BXZHNKAOI:8^5-_N9HKA!_%Z>
M%SMG?:9UHJED-\B:<X_63#_L@=*R(G.'_:.4@C^8,KOI^/Y9"?\ >8U'Y&+Q
M_#=-^SVW_L=0W_[S;QJ?Y-:,!\O3?[_6G\D'+>;]D_R:C(5,WY2=7H44?PP'
MXP37*VK[DW3Y#*+=X/9[<>^X=/ZO%,Y_\[<./RW*/RH<UT9!_FW2DLY^1N\C
M,-_B5YW*C]P6GX*-UE/9:^4.Z)=,W](A$RB\ V/U^/HU&3E6Q>OR=4C=/[\?
M:\"_U.)L4_%T$A_GP0_G3^F%A%YL^DL%"1]UIH5N''T^/LPL?Q\C=>Y."^GG
M!RJ6";V7;5 'O&-8K@"XG-\8B(L(R/.'MZ_$?O>W\H1]N#G[T>(X[6$>FHX=
M?]IV_3\*H?:#FU!%M;XJR'R%M9<=#_YR60?EK\*S*+X<\<(KNBEK9H[4+TZJ
M2DW9I/OB'RF1>3*K;_B!4"E'Y0R.V:R;^#=,!_S8XD_-8P?SJ#+UOU1-O>5=
M ?E%!:1:_<T<"O\ S8U(T7HO2\-W1CM4Z^0.7IW5C5*#<.0Z?F=.62SCY _^
M=^/V_'D9LA?/]Z\N2#\N](!_(,!^5:R7J#.S_P!;F,DP/]D7MPJ?ZB2*OY5(
M<?#0\03PXJ*C8Q/IT[D>Q:LB=/S=ULDF7I_=TZ9&9W<[=V<_5F+'\R:UDL\\
MQW--+*?7<LCR'^;$UV66UBIBE,4IBE,4K@2L>E+1DC%KB8$9)B[8K"15V@8$
MG:"B!^ZLQ=,GJ0]U0?QC1XT<D_*0<H* 50MR,4=7'JK!AL*1L'?HP93^YE8?
M4$>*R0R&&6*5?O12)(OA&\HP8?#(DD9\CT='0_VD8;!C/46JPU7$RD::R2UI
M7E) )%62EW,LLX*HNF+N03*E(3,JV23<V![.2Q#,TF:YTY--&55EY!LK,/95
M[=^]NK]I(0J\0J!-:'PJ=JB$ZC6-/B+#:$H$0B-=MF\P<S-#+[K#9K#%VA%
MD*II3PB.XX(7)2VCMX")&D4&$M"((G6".6\AUI:8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7$?,&,FU5923)I(,UR]
MU9H^;(NVJQ?ZJJ"Y%$E"_P!QR"&7*S(0RLRL/1E)!'[B-$5?'))$XDBD>.1?
M*O&S(ZGZAE((_@:KY;N)>@+D*BKS7L7"O5.HE?511Q654CC\:A6D2JWBE%!'
MVB+F/7 3?"$.][<V,.8R,&M7+R ?V9M2[_Z3@N/X,*Z6RZRZCL=!,E+/&/6.
M\"W8(^A>8-,!_H2K]*A^P\5MG5.!F$]*\@-CL0]&O$V50LTF$@R=BHW.0&+&
M7(LP;P#A4HBDUD48KQFZHI*"Z0$GF4YL66M)I$]^QULWQ+RGB7B5T=\F33&0
M#U*E]$;^$[U6ZMNK\3>7$!SO3>+D/=C,E[:1=IT 8'N20E9&N57[SQ--Q<<@
M$;? Q;HG4_,9I79ABVVS'4-@6<<MG$=-K0NPY=L^;$(1]X!^Y86T/U4. +L?
M2;1T*Y!<JM$O%(LO+R%YA6D1C9M<,8P0Z"2V0J22N_,9?\&X,-'7+QH;?J',
M]$/<PR/AI<C)[NK)) MQC(&C8DQ\O-L\W@?#)V9$"GB'.BJSA^#AO*5^%9>6
ME['O_P!(A6(,M;[OYP3<L+ E\?Q (,T^GYA^(('VG8)_58>W_?+)W?\ JM&?
M^T:T']*.GX?%KT;CO'HUW<>];]?5)+8_]L_O]*?@55J2^%;MO;OM:@_TA7]S
M2!LKU_*[Z:\8]<" _P!SL!_.(Y3[<E3^ILK"'\5@.Q_$.H_*G].[J+Q987 6
M8^7;L6Y#Z:*RQKX_T*[F,X/<<V @=U49.:4#VBI*VJQ]3F^/O')&R,:D<1'V
MB!DQ*/RE$,L?/9-O294_T(8__KJQ_.L$O7_4\GA+R& ?2&SMO ^@,L<I'\]_
MC4B1?&;0,1W?*:FIJO<Z=/2<62;'V?UAF3OQ/_\ ;[W7Y<C/E,B_WKR<?Z#F
M/_\ M\:UDW574<^^>9OEW_Q,QM_Y=@1Z_A4BQ>OZ'"=WT+2:C$=SIW/1=;AF
M'=Z?%W?*,DN[T^3ITR,]Q<2?UD\S_P"G*[?[6-:R7)9&XWW[^]FWZ]VZGDW^
M_G(VZRT  H 4H 4H        !\0  >P #Y #,-0J\XI3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*^2Z*;E!9NL7OHKI*(JE QB"9-4@D.
M4#D,4Y>I3"'>(8IB]>I3 ( .5!(((]0=C]XJJL5964Z92&!T#H@[!T=@^?D1
MKZU$.JM0,]7+6%=&?DY]:P.$G9SR:KX_HX_>64<LX\CF4?D2BC*G3.R;J%4?
M->ZL5S)R!54_+S+N\-T(P8TC$8X_ %^+T 9M*NWUL$C2GQI%T=[O,YM\NMLI
MMHK86RL@$0C'='PA))2D,1,P4%9&!$;_  E(8N)Y3'D*M'3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*C+9&X];:C08.-@V5.!))-
MIB0;D3C)J:<IPU<1:N;-97S. C91W%U*K-WS!>TVZ319UFLHOV"L[+1Y'K4R
MN6*"68D1)RT5!\JHY-L(@+$ NY!X(-N^CQ!T:QR2QQ:+MQWL^A/A=<F/$'2K
ML<F.E78V1NOG%;IUA-WMUK:*MC1[;VGFR"R292H1CIY'1\9+RD1%V8[ E7F;
M!#Q,U$RLU7(B9>ST/&2#60DXYHS5*ME6@F6,2LA"'7G:[ )*AF3?-59E*J[*
M%9@0I)\4$L9<QAOC'RT=>@) ;7$D @E020#L@"I1S#62F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5KHWIQAW/9[#&6
MZ(O]IVE-(:ZW)0X9P\V&MH62HDYL![KB5H=G0D-004"E8:W2I2E2CF9CY9O)
MS#A:4BI-NQL+J#CVC+9V]W BE&B2$&6"0ZB]X$BQ"42(1.[E6D$BA2I"_"02
MH8DP9K>5F#!VD(CE0'GV2AD[95MQ@;52AV""3L'1X@5E&O="[:@;YKZ-LQJ]
M(5+66]MP;_#9+:6%*;O4EMBC;)K?JJXIR<60(,\7-;@M#U\X&6<1A(NHU (W
MS+F6?LJW9+<0M'(4Y!Y;>"V[6OAC$,D3<P^_B!6! !H'D[[\*"]R0R*\8;16
M.66;N<O+F577CQUXT96\[UQ1-;+$)>I=+QT54?$51\0AB>*@?PUD^H=.\DIT
M'N'#_=-T'H.:^IE='ZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4I
MZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP
M?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW
M8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'W
MF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^
MZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4
MIZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>K
MP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'S
MW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'
MWF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC
M^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL
M4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>
MKP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'
MSW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V
M'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]Y
MC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_N
ML4IZO!\]V'WF/[K%*>KP?/=A]YC^ZQ2GJ\'SW8?>8_NL4IZO!\]V'WF/[K%*
M>KP?/=A]YC^ZQ2N]23\)))+OJ*>&F1/Q%3=]53N% O?5/T#OJ&Z=XYN@=XPB
M/3VXI7TQ2F*4Q2JW\GK'<J_3J,TH]PE:'+7+=FGJ ]M$%&U.5FHZ!N5VC86<
M&*:W>N6VM%?+1[A9)!Q(U^1*V,?Q4T?$*4P2K14:1S(BR!()Y C%PI:.-F79
MC='UL?)A6&<L%7@Q0M+&G)0I(#. =<U9=Z/S4U!->WWMNI[@N/&QD:.WW<8N
MP)+52\[ G(752"5=3UM!7>QUV]S&N=;3,(\O$"^GH(\4UK.MH0K^IV^(?RC1
MLI!/I6>DM;0O!'='=LA4\XXE:8\NZT:/&LLJL(V"MRYRMIT(!^(!<"S2K*T
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M(5RKL&*EE4(-G\.1.E4'TV6((4@W?CI!G+1["5CERNH^39M9!BY*4Y"N&;U
MCEJN4JA2*%*J@H10"J$(< -T,4I@$ UY!4D'P02"/H1X-2@00"/((V/W&N9E
M*K3%*8I3%*8I3%*8I3%*8I3%*Q:\V)"GTFX6UT\9QS:KU:P6)Q(2+=Z[CV*$
M)$NY-5X^:QI3R+EFU3;&7<MV!#O5D2'3:E,N9,!OC7G(B $EW5= @$\B!H$^
M 3OP3X'S\5:[<49MZXJS;(WK0)WH>3KZ"JA\-]G[DN3FZ5?=JUA2M$11-([!
M:15R9ZX2LB+/9L':4965CW>I&K>G*:]D+=2++&T>.ES'V7'%@9M6[IHMI"M&
M5FWT4""-[?B4:2XB+1F7@3$R$ B?]IW0DBF0KJ(\E[?D/4:UDE;FLW(,%B?3
M]O>I%;9!B 7AR5@@;]H.)Y^"M7ES7U+IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4IBE,4IBE5LV5<-F5S?G'N#C9NM,-4W>2NT+:(DT.HZM<S-1.M
M+_;6JIYUTY!A!UV(/7H=<C>/8*RTQ(.7'FI2,BXTS">E11Q/;7+%6,T8C9#R
MTBJTL2?= VS-R8>3I0!H$G:X':19H0&41MS##7Q$A';[Q.@HT/ &R?4@#313
MQ.V3M>>FUZWO&;M+V\6C5M2V_#QWI/2-CUHSK=@DI!DZ2I$_J6LQ<D<K&0.U
M9)C:;)<V<U!^AYJNV6274L2;'->Q0J.5NJ"-)7A+<;A)2R@$=Q9W8>1L_ D9
M5N2L@'#>.W>0GC*6YM&LH&XFC"DD:1HT4^/'WF?8T58_%5Z<U]2Z8I3%*8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6N**V+M(6.Q)F2Y+.!U-6
MF--C[+O(^L:.DQ-M!*Y/6%[HO&>$9UQX-HC5DC1M*AU[;';H>IW21CJG7I>^
M7)C9F$;M&BBW&HM?VSEREOW9-]GM@QR73%AP;>Y&"& <%+LL<;(3 #R?&3<'
MMKQ#2]M/ZSD0\< "GE\E'(2GF0@9W# 6\T(]V3(ZJKC[;*;Y*Y.W=H7Z3+&'
MB[*>IJ6Z>-KI:YQ==2;U^,OCC7@U9>^1T"U:0S&XJ3C6+9,V*2#5&%<B(3.(
M==L<!\)9DY\%[O;+?$8^[S[98EC'QV2=DRH3(8U,OWR6]0 W'D>'(#P'*<2X
M  #;   J8<P5EIBE,4IBE8A>-?T;9L I5=B5&NW>M+/&,@K VF(8S<2=_%N4
MWL:],QD$5VXNF#M)-TS7\/Q6ZZ9%4C$.4#!?'))$W.)VC?1')&*MHC1&QHZ(
M\'ZCQZ5:Z)(O&15=?!XL 1L>1X/CP?(_&L*/QVT*>HLJ"&F=8I4J-F7-BCZL
MVI%=:P;*P/F[AG(3C:/;1Z3=&8DV3QZQE)),A7DFP>O63]9PU>.45<GO-QS,
MG?E[A4(7,C%BH((4DG?$$ @>@(! \59V(>(3M1\ 2P4*  2""=:]2"0?J#H^
M*YI-$Z53L VDFIM=DL)HL(094M/@2N1B@K84P&7L8@GX04TI:?U[G?\ 5,I:
MUW_0@ Q"GO$_'AWI>.^6NXVM\^YOU_XSX_\ 3^/[WFJ]F+ER[4?+6M\%WKCP
MUZ?W/A_T?A]/%=4GQLX^I5T*DGI;61:T$XG9?0OJ9 BP&>2B1KZ<J9$S(0,\
M)7!&M%5,(]*R8U<Z>A#&8#=[W<\N??EY<>'+FV^/+EKU].?Q_P"G\7WO-6^[
MP<>/:CX[Y:XC6]<=^G]WX?\ 1^'T\5+$'"0]9A8BN5V+80=?K\7'PD%"Q31!
MA%P\/%-$F$9%QK%L1-LR81[)!!HS:-TTT&[=%-%(A4R%*&!F9V9F)9F)9F8D
MEF)V22?)))V2?)-90 H"J %4   :  &@ /D / %=IE*K3%*8I42S>A=*62\(
M;-G]4:_F=B-EH1PA=Y*JP[NTI+UI4%J\J2;6:'D /"+!XL6/C_S%3J9OX8B(
MCF6XG6/M+-*L7Q?LP[!/C^]\(.OB^?CS\ZQ-!"SB1HHVD&M.5!8<?N^2-^/E
M]*EK,-9:8I4?7'4VL-A24',WO7U.N$K63F/ 2%DKT7,.XKO/&4B9)HN^;+G3
M;C)1D9)BUZBV])1D;(^%YV/9KHY8YIH@RQRNBO\ >",5#>"/.C]&8;^C,/0D
M&QHXW(+HK%?NEE!(\@^-_B ?W@?2I!S%5],4KJIV"A;/"RM<L<5'SL!.1[J*
MF866:(/XN5C'R)V[V/D&+DBC=VS=MU#HN&ZZ9TEDCF(H4Q3"&55F1@RDJRD,
MK*2""#L$$>00?((JA 8%6 (((((V"#Z@BNURE5IBE,4IBE,4IBE,4IBE,4IB
ME,4KYK(HN$56[A)-=!=,Z*Z"Q"JHK(JE$BB2J9P,11-0AC$.0Y1*<HB4P" B
M&*5@M"U7K75K5^RUO0ZE16DHJV6D6]5@8V#2>F8M_*1Y'!8]NAXB$:S &46V
M-_-HQD!6;!)NV*"09))I9B#+(\A&]%V+:WY.MGU)\D^I/D[-6)''&"(T5 =;
MX@#>AH;U]!X'T'@>*S[,=7TQ2F*4Q2F*55'E#MO:>MW_ !\J6H&M 4MF\MUJ
MZN]);(8V*2KL''M=2;3V8XDO(UB8A))P\44UVA&HE\[X!"2"JATCF(02S+2&
M&47+SF7A;P=[410,Q,T,0&W5AK]KOT^51KB62,PK$$Y2R]O<@8J!VW??PD'^
MQK^-85!<I+/K*Y;&UQRP9T>MR]*UQ7]OP%ZU2E<IRM7BDSEM4H#B+:4IXPEK
MJPOD/=E(2$1K,6K;#V@;;7!@%E)%=U$M\C6B2QQ2V9D99)6@:.;@K1R*@D!,
M@(0QM'R;F>'#@_+P :M%PT;.ESP4I&LJO'R*NI;@0$.W#A^(X@MRYIQ))($D
M5_EYI2>DTH%>0N53LAM@4_63BLWW6NP*1/QULV%"S<[0DI..LE<CU&,/<6=>
ME6M>LJXEKS^=;A6B21;"JE%FQ-97"CEI'3MR2AXY8Y%9(F59.)5CMD+J64?$
M%^/7'S5ZW4+'6W5N:)Q>.1&#2 E-AE&@^B%)\$_#O?BOG9>8.D:W-RE83D+M
M;+/#6"YUV0KFO-7;'V#-IN-<1]+D-@2:4?4*O+K.J_3C;"J$1-S[4%HM*SRY
M*DV<N;,U>1+<ME<,JMJ-%9$<-)-%&NI6D6,;=U 9^TY53H\!S.E(-&N8E)7;
MLP9E*I'(Y^ *7("J=JO-02-@,>/WO%6#K-DA+E6Z_;JT_)*5VTPL78H&332<
M()R$--,4)*,>D0=I(.D2NF3E!<$7*"#A(#^&NBDJ4Q"QG5D9D8:9&*L/!TRD
M@C8V#HC7@ZK.K!E5E.U8!E(^8(V#_$5WF6U6F*4Q2F*4Q2F*4Q2F*4Q2F*5U
M3Z"A9.0A961BH]])UMT[?5^0=M$'#R%>OXUW#O7<6X5(95BX=Q+]]&N%FQDU
M%F+MRU4,9%90AK@S ,H8@. & .@P!# 'Z@$ C?S /RJA4$@D E=E3]-C1U_
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M\L<&^GYC]:<Q^/Y?K3UBB_[53]BI_EC@WT_,?K3F/Q_+]:]O6"-_M%/V)_\
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MOW'H[7>Q+2SBD(-O/V6OMGLL2':N'3MK'&>AX:RK1LY>O%FZ2QE"H'<K^%W
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M%:YK-Y')VT$G?B@N[AY(DGXO&)0A^'N"-W16()57<*0';?0]/]%=)],SSW>
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MR_2GJC$?F<_M_P#1CF?P_/\ 6G ?C^7Z4]48C\SG]O\ Z,<S^'Y_K5>"_O\
M]_PIZHQ'YG/[?_1CF?P_/]:<%^GYG]:\A4XD/: .?VW^C',_A^?ZTX+^[_?\
M:]O56)_JN/VW^G',_A^?ZU3@/Q_+]*>JL3_5<?MO]..XWX?[_P :=M?Q_P!_
MX5Y]5HG^HO\ MC?Y9=WG_#^56]E/Q_G3U6B?ZB_[8W^6.\_X?RIV4_'^=>WJ
MQ%_U5_VP_9RWN-^'^_\ &KNVOX_[_P *>K$7_57_ &P_9QS/X?G^M. _'\OT
MIZL1?]5?]L/V<<S^'Y_K3@/Q_+]*>K$7_57_ &P_9QS/X?G^M. _'\OTKR%9
MBP]H%7_;#]G',_A^?ZTX#\?R_2O/JW&_F7_:_P"G',_A^?ZTX#\?R_2GJW&_
MF7_:_P"G',_A^?ZTX#\?R_2HJL6TM(U&]0&M+'?(>*NUD;S+F-A7#Q4PHI0+
M:"=O@FY%%!2*K*RK>RP:D2VLCZ)<3XR*1(%*24(L5/,L5P\;2K$3&G';:_O%
M@.(WR<;1N10,%U\6JQEH5<1E].V]#?T )V=:7PPUR(WOQNI8]7H[\RW[7_EF
M'F?P_/\ 6LG ?C^7Z4"OQH@ @"P@/M 05Z@(#\0@/3',_A^?ZTX#\?R_2OF,
M)$%[_>.8/#,0BG5P4/#.?N"0A^OY)C@H02%-T$W?)T >\'5S;Z#^1_6G!?J?
MYC]*]CP46B0ZJAE$TTRF.=0ZX$(0A0$3'.8P 4I2E 1,8P@   B(@&.9^@_/
M]:<!]3^7Z5[%@XTY2F(*ABG*!B&*L!BF*( (&*( (&*(" @(=0$! ?EQS/T'
MY_K3@/J?R_2O;T"P_,M^T_TXYG\/S_6G ?C^7Z4] L/S+?M/]..9_#\_UIP'
MX_E^E/0,?_WW[7_3CF?P_/\ 6G ?C^7Z5[!!L ]G17]I_IRG-OK^5. _'\OT
MKSZ$8_F5_:?\L<V^OY#]*<!^/Y?I7CT*P 0 ?$ 1^(/%]H] ZCT]GMZ![?\
MACFWU_(?I3@/Q_+]*]/149\?B#T\3P?Z<O\ 3"/0$O\ Z3J(!W/RNH].G7')
M_P#O]/E]?2J<%^OX>H]?IZ5]/0C'\RO[3_ECFWU_(?I5> _'_?\ A7MZ'9_]
M[^T#[..;?7\A^E5X+]/S/ZT]#L_^]_Q_Z<<V^OY#]*<%^GYG]:>AV?\ WO\
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M)]:N UX%/1K;\Q_\8Y2JUY".;!\0'_Q_\L4KSY!O_P!O_%_RQ2GD&_\ V_\
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M/72#1:M4I"):)$R.66!Y!)$.-Q,84$!$G=92'C)8$(#KFR@[2-B25SW#.K*
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M*(C"NW@7F#R<* BLVB/)4U\M@[UY1,)Q^SI,]LAYMJ8L/*>-C-7'UC$'U&6
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L,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g743471g17u63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g17u63.jpg
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M6Q05DE0 I&F&SGY1 :RCNAK5UY#@[,+&#N2;%?ULPV7'D[.XKCRUJN9KYWC
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M0.@P#,QV?22OCTS(R3VXY%SR'$9>U+56 JA7U:.].03M0+*M-'U+4W";;%O
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MK-D2(ROYIZ0%S#E^^TO!LLE;*TIJJKLI6DA>9;2WI?S+LQ9W+H%)8D!-*JJ
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M#HY$MKI-6T@.&&1%U](3=*MWG#40B*&DWA%7;-UM1%OIEPCTL[2WI$\@P%G
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MBO\ XH_40^(!^^;V)_N:NK_-L?0O1OV3TS^X8O\ E1\QD?T]W\5_\4?J(?$
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M0%S3T$Y)L&KWKC39P\'-C EP^:I*]KM$"@Y5QPFF];=*W,1\O4NQL77DC?D
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MODC9.A[D>)),E#4;'.C737=: "0H=.?C\? /@;/CS),=]9TW'IN1A+]]+%-
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M0W1!XV^G(/'[TLX9AV:CU*6'1C7OVK3>K\G)=.WVTI1>3V.6]7H579M [
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MH+.5K*_)47ZM5!1%*[);RQ.]*)#%<#D.TKBZNT*H;CQK4KQ9CZF)#,0= #P
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MC==K#@UD5R>L6L)DQA%H5WW/81%CLJABC)1F3+H)#)F-)B!+O822E698.<%
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#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g743471g31c65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g31c65.jpg
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M$'"UJ,M9ABY;LJ )4>Z^E4$T3D,Z[67B!>LW^I>1A+QEZI3[9>88^@<LO T
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MUR-K:ISCCLP0T3?(EBJLFKT]G6T67T "X-:M()L&&J&PKC ZPKN/=W-BOR3
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MC"G%<\U4U48B,1)!KO5N76^R':;4^D4*T6^KJE)LM5KMPKQJR5Y4&6U FI.
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M_9>^)OZJ#QW_ -]?-?ZS9L?E<Z0_T%QG^Z]=^XFQ^5SI#_07&?[KUW[B6_\
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M .0 \@$B&4E8Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*67"X6D!T+D]>@C
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MY3[0OZRV8W\V4U48B,1,_'HV/K<WOMA6?^ @LX_Q/YY_JT^%IR7A/SJ?MK_
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M.T?U ?EV?MQ_8+>*GZ4\;]]M]_K3CU=J_JQ_)3]F/D=H_J _+L_;E3:CX_\
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MO7M+5K7KS+T#K7K=*[L%1+ZF9F. JAP22?,!,77(UFCU*(I9WIL55',EBI
M]TS$-SWQ(\@/%WS!\23%1Y];+?XFT:H]V[I#KP(>L@7XUU?H'C49!=+Y/'C>
M_4J()NM]&A"M!$-,1X35BM1D/!;4ZS,D/;JS6:?5Z'6J]B)J[7T]!9B%%U56
MJ#56^8E*V86,>>U%)Y8FIKTFHTNKTI6MWTJ)=<%',TVV:<K94.> KNJFL# W
M,5$D?GOBMY_\I)\*\VSU(YY8+XUY!VGN77>:T@'=W_(N=4_*&37JMU.C'US"
M[U1,P>?TR$!= U8>'B.U637$2([RWXA#;]]NKX=<-1H5>U:SITHIML:OU,&T
MFYZ77 #@NY;<Y8BS=@C!$LKTNNJ-&M9*VL%[7VUHK^J"FI*I:C9.UA6@4JH'
M9V\CWR/=TY+Y&!^P]H(^.G ?*_C_ )#6_OS5EKDCG5J!7/T?_< 4ZS Y*NL]
MS"7><Z'KMH*UV-/FVH1""Q"0VQL0EQ53I$B;)8MT]VF:FCU3J='=ITT^QNL1
MDXCIR$8=30U8W,BL<(2<%<CEV<UNJU*W7'3T:JF]]0&4ULKZ"]2R^NWA\A7*
MY+@#(89Y\\;(:?7ZM>UZO:]6O:]GU^KU^KZ?J]?T_5Z_QO7]/U9QF<BG.(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1+/+A>IT#R8!"
M(=AZ= "UD'+LU[:?K%GG<W)5Q-&N2XU'J,0)5)D4]<'S?R5?CMDE$5$0[%=#
MTBO2I\JU%*]%S4K!TK$K46=@M?;06ANLKR[[G!6L+NK50,,69V "!CANY&I5
M0UH"KN<;'-978_83:A#.6VNS$Y4*$4Y<J/KC!SHCO<>GB+*2LUI!RY-_GL2Y
MH:[UD%SIL)T30:E4]$"R0F*]8)%JI\K1P38JBXEIX?7)Q*>F="LP I)7K7ZG
MJ90B,.K& U;M;NK+66$J2RA'&TJ_<6 &"K**TM9U]@8LRG><E75:]MFU$PP"
MMO0[@R\B%).0P)NC4<0FSM5KX=6W'0,@Y\7[S7L)0P0C0-Q_=>S[6U*5)T[[
MSV]:UI&T^SO>_7K$V]G=GZ+;C\&<S)W=O9CZ$MGW"!CWY'LMET8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1+
M$O-_LW1N3!ZQOG%EBU<@]5NNW6=*G/4@=#FM<ZK Z= '.3[Z*,#3"GBAJ(^[
MS\ @!=+B.CD9 *[52%7#4N1L-!15<S]:F\!J4 '6$CK'()Q6RE<*I]=8M76<
M!D<NH&#K;K*E7JVVG;:Y)-8!ZM00"; 0>9'K:[7<9*NH5C.SN7=+$#O@F%3K
M_% PAP&EE057:B568YU^WFNS@J!:^<3='19$[$(5@;+&#)(VI2P-B#G;X.E&
MGG6X48>XT^G1JR;*]Q+6!G)<"E%H:RNT;2 0Y!(+AE9:B%',D+]05<!+ H"H
MRKV3USM<M;5G()!0$ A"&#6 GN -YEG.(K5?+'G(ZI:!4-R6J,AS32GM-^K\
M0EQ2%Z1O?K_Z6T*]7YF\P57<P7.,G&9F,VU2V,X&<2.Y;+HQ$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B4_<^JI$^U^0^Z,9DG\U_6?^,B_GQ]J/Z8E0,CDL8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1/++
M@PIZ643H<6:B/)9F1TRX[,A+$N,KVX\IE+R%Z:DL+_%LOHTEUI7XI"D[^GE0
M2.XD9&#CED'O'N&, ]XSCF/=\\^%C1SCL=YR!"6]$DO3(CJXK"G8LN0AQN1*
MCN;;VIF2^V\ZV\^WM+KJ'7$K4I*U:VR>?,\^1Y]X\QE,#S#S]WE\\DWJ?U.[
M=_J:1_Q1E]7S1/LA++?F;_8F3_D<DC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(EGEPM)2'Y,@XT
M+?>8@.K Y=DNA%FC=9L')SX5-&N2(?.*7 J-,(4PO9]EW8%[L%H,3Y-KCE0M
M8YO3'C<NTD:]7,U$!TK$^IRSMM0=92MRMUB>NN7L#A=NZM4 V89K;  BLV&[
M$:E0.O"J"SD5VM4PV/BM J%-V<6,Q._*K6F2Y YXW.Z8_P!CM3-@_!$V/][W
M3YZHM4&SQZ9%=A=JCQ/''7/'S$9FJN,SN*[,/V+7/7GV'W&0TR]Z1:WTN/KQ
M5U";>JS_ .GV;"F\YHSJ>M"G?ROV[>M\["OL9E:3;US[NLQZ_OW!]G*[&FZL
MD;.=&=_5^7!L[4N"<^JI$^U^0^Z,9F-_-?UG_C)OY\?:C^F)A[]+;Z3GM7@%
M<>,5WE-)Y=;(?1ZU;#1A[H0ZV39,.2 *"(,5L:JMVZM--L.M$'52-2FI3BG$
M-[;<;3I25=G>#SH-PSI=IN)W<0U6OT[:*_3U5C1OIU5ENKL=B_7:>\D@H,;2
MHP3D&=K^#SH-PSI=IN)W<0U6OT[:*_3U5C1OIU5ENKL=B_7:>\D@H,;2HP3D
M&8AO[8_\P_TG/&K]P.H__*F=B_P+='/Z2XW^=T'^ G8O\"W1S^DN-_G=!_@)
M\_VQ]YB^U]1WQH]G\SYO=2]K\;_*_!7]7X__ /C^-]+_ +<A'@4X'UI)XOQ7
MJ/)6%T@M[O+=U!0]KG\P'+L]_:F$/ EPWU87;CNN.@Y[=,-+0NL'8P,ZXNU)
MQ9ESCAZY3UODWKI^O[8_\P_TG/&K]P.H_P#RIDW\"W1S^DN-_G=!_@)F_P "
MW1S^DN-_G=!_@)FD]$3Z1SL'I V/(!WK%.YK4M\G=Y:V!USR!:(.I^KRCH:B
M>R_SDM5FV[N+NH#_ (#X/<+V/B)GQ'Q'ML>XZS\(G0OAW1 \''#]3K=1\D!K
M^M]6/0VSU)ZBZOJ^HHHQN]4OOW;L[5QMYYZS\(G0OAW1 \''#]3K=1\D!K^M
M]6/0VSU)ZBZOJ^HHHQN]4OOW;L[5QMYYS,YUI.M(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*;]$ZO4.7LBUV91Z3*,_*;
M@X15JM8[F>D0@</1 Z52#JPPL4^2PT1;&YLSX7:%39HH-$U*.&@PV?+52]Q.
MS: N,L[K6N6.%&YR!N8]PSG 9CA58B.RU*L;MQ+9P%5G8A1ECM4$X QDXQDJ
MOC,H/ANG:>?T Z KUD)$62%@0.D-K@ #A> &'F+"*J0@M:20P?*A5@23LQH<
M&A3S;\-AYY4^7[218,]/&52BRQ690,+GD64%BJEV" D%RJJ6(7)Q@=[*#1[J
MT958G+8(PK, &8(I8@$("S  M@=Y[E8B+]3^IW;O]32/^*,MJ^:)]D)6WYF_
MV)DPVBTUJD5TS;KE8 M4JM='R"Q^R6(G## @@N(C;LHB5*D'H\$?!C-ZVM^5
M*?:9:1K:EK3KZ>74:>_575Z?34VZC47.*Z:*:VMMM=N2I76@9W9CR"J"3Y!,
MFBB_575:?34VZC47.M=-%*-;;;8QPJ5UH"[NQY!5!)/("6R_V?G@S^K$\8_]
M^7-?ZR9N_E2Z5?6WQW^Z==^XF\^5+I5];?'?[IUW[B2'?O2;^#5"@0"']DCQ
M^YIGDHHSX2@]2YG8I\)R;)8B1Y4^)\\8;D<=\1);U*(?BXHZ.E\@2<AC8LJ8
MS<O1#I.<[^ \7I&5 :[ANMK4L[!412:,%W8A$7O=V5%!9E!@OZ-=)=,BV6]'
M..JC6TTACPO6 =;J+J]/0F6J4;KK[:ZJP.;.ZJ.9DZQ?2!^#4J+&D[\O?&J+
MN0PR_N-*[?S-N5'VZVES;$EM%G<0A]GVO=O(2XXE+B5:2M6M:5NAZ(]*@2/E
M<XX<>4<*UV/P>L2<=$NE7UM\='N\)UW[B3;3?,CQ)Z)9A%+H/DYP.ZW _(7$
M!5:J];HI^P&)3;#LI<<8'%G)4^<^B,P_(4U&8<6EEEUS:=(0K>L?4]&^D.CH
MLU.KX%Q?2Z:E=UM^HX=JZ::U)"AK++*51 6(&6(&2!WF0:GHWTAT=%FIU? N
M+Z734KNMOU'#M7336I(4-9992J("Q RQ R0.\RY+-+-+&(C$2BL[L,N'W8%Q
M-',[[+BEZ21N,GJ#$<-KGXC<:2J./"39KI9$]94HN(5;;@,PE%6UQ8\MH7+!
M.$C8><4@Z=K^MK!6P(*<MUAY9+ ;<;1E>><<\9#84PFTBY:>K<@H7-O9ZL8.
M I.<Y//EC/EP1DBM602:,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$I^Y]52)]K\A]T8S)/YK^L_P#&1?SX^U'],35:
M^B5_JH>*_P!@72?NAK.>@_ E\X\?^Z]%^IOGHSP)?./'_NO1?J;YK*9WC.\8
MQ$8B;6/T,S_@?FC_ *3X\_\ *[=G07AP[^C'N<9^'A4Z"\.'?T8]SC/P\*FT
M_G0DZ$C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$M>\DO&@7Y"-5QZ00K(\K70?0*Q&>N%$:Z(':#=(%BH!J>-"N6&L;&W$
M3*  R56L^B$IL,_&FMNAR"9VEQ<O2ZHZ;=R8AFK<A+.K.ZHDJ"VU\HP9@ZX&
M<CM#'/&U&F&HV\U!5;%[=?6#%@ )"[EPX*J5;)Q@\CGEY[MXZ'[H8C3G^C0H
MH\@%KE*N\5VFS2)6T4"E7]B\50;#-R+NCY$MNFWCH2T6UX<:AGVSKI$?5Z[+
MA1$IK7JEK4@5<PSV5D. $LLJ-;DC9VD\5D3*E=N"[ F'T[.V38,$*CC8261+
M-Z@'?R;O#-@@YR$&!*U=3^IW;O\ 4TC_ (HS'J^:)]D)+;\S?[$RV#TE/U@O
MEU]HF^_Q.]G)>A'LNZ._?72_K!.6="?9;T=^^VC_ %HGYQN>SY[0G&]:W^/K
MUY#?IZ-2H2^I+55@ZJXR RG(8>V#@@^0@$<Q,'7<,T'$T2KB&DIU==5BVUI>
MF]4L0ADL4'N96565N]656&" 9SDH    P   /,!R F8JJBJB *J*%51W*JC
M ]H  "9&?1(_DC7BM]G93[BK1G#?"'[#./\ W(GQFB<.\(?L,X_]R)\9HGZ&
M^>.IXZC$1B)2$AU(C ["!Y+^!U:9+=@K9ZUQ;TR4IB:RR(K,BLP#*Y$%^S-6
MO3\8K;P8YMAJO.JD+?>DL[5#C.OZF%(-+7=:@VLJ&O%F_<P<K@[-G,(Q\?S
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MLYZ#\"7SCQ_[KT7ZF^>C/ E\X\?^Z]%^IOFLIG>,[QC$1B)M8_0S/^!^:/\
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MRJ&W9L94+LJ84@L%&>T5'-0"2P$H]Z5L%(8Y 9B ,(K,$5GR00"QQR!. Q(
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MXJ/E0T?_ !.H_%7Z(_M7WQ@_5%=T_<ZA_P!"8_A;X[_1_"OR-7_BH^5#1_\
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MY]KW_3'RA+_/-?K$?>XV#V_>]$;S[7O^F/E"7^>:_6(^]QL'M^]Z(WGVO?\
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M,._ E83<N2B*0C>[E1TR'DM.ITXOU\(5F7=M9EW*5;!(W*<94X[U.!D'D9P
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MNMPPZQ\.Q=QN;M,2"6;GS)(4DGO*J3S48IU=8*D5H"B[4.U<JH! 5>7( $@
M<@"0.1,5GE-%I4@?(I],$5;Y+A'!\*/7QJ!,)N-8WJTZ6TN#!0S$>=?U3ZW'
M:?>9<>AP1,2!$6Q";TQA[;+ 0[L^2I.XY.5W[>9Y\M['VRQ)YPM=:8*(JX!
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MJJ#R)4%BZJ 7ZNT(#N."R[20%++N!D%]CUA=@4LS$<^> $9B0F^LOW $*VX
ME@K8(E*!/F973 2H%QE+*&V;TZ7A5*6+LM-&P+'.J-,+7:ZRH,*Z'*E;AM>&
MBP)-(4S9:J#^5'%B%E(M=C'!DB1,=$RLX-@7J\%\H[% [A*P36KH78L-RH[8
MYX+%6 B&K4A2$+;\A,,@#%4+O@.4<* #@L@SRSMW#,/@^:@DRY798'FMV(C[
MI+OH^EP7?FH,*'D\\7>=FSLAXA;6&00U:.<6EJ(**Q&C;JVH#SS4;<K<5 Z%
MAN#6U@IU>\]LA>LV;5P$RQS8F2"5[^_$#6!MI6JPA^L"#L MU>[+<W&T'8V
MP#=V0.Z3G4/+6GW.!:S(JIVM(:NT&]]%@R'I%3T0L ;G=B)U(]$CB$614H03
M?/!B#(;1_8T82A:C3=$V?:FQQ]CZ-T**73<UE=1&'PK6*'4[MN& 4C=MR0<C
M!&";DU:.&8*VU:WM!RN66MBI[.[()*G&[ (\O?B7-^:U.^!B>S0.B/V&9!FD
M6ZG'%1]GTQ!-AN]/.R' LF1%L*%U^W5$37S838+YXP"71^=#'*OL]8T!6+_4
M#Y^:5;00"^[L]I:W7M>(=R.64AMA%5IW[5W2WU8GU.S=S.W':PK.C';XPVL@
M#+MW@V5C;N;$ET-YUUZ>86/E<TO3D>;8?@!+H"$U8),((,IW"C-M(VV+ 6XJ
MND:S9.YB $H7,VW[Q HGI<B.<C)!/W'A[8R+:\A<G<=H+%]0J!"V-P==.S!A
MGFR_0G<+5URDX-;\VP-O:( 2@L6 \4JUP4@_2GR\I.M%\JA'3)0$1^!5<!HV
M[1 J1<FPD:$L>08ME""]''19L:/:)KC29%',OS9K,ICV4RX>PS:9<J8TG5EF
MD-08]<A-9.0@LR"EC5'!* '%@ &#S!W<L2]-4+"%ZIU#XP6*8.ZL6C.&.,H<
MGVQCGF2MVSR?N/(;1?-,5^J$J;2@!] ^+IU<F>=M@CC)WK$,!.L 2P$9%$-R
M4"8\=BMV[F\$"1JCZ;2)Z9(+R(U)RZC2UW+7EW5[&7<?(J&Y:2P5E'6*-V2R
M6E@_8:H+FR67:EZ6?"J513M'E9Q2UH4LK'JSV?%>L+L.X6%B$@[YUTP"S;5R
M.:]/<=JYRW@64("-)9L,OG<SH(^]JKK^W]_+C0*3S&U/)="-%6'!#<<\1>$!
MH-KFU>J\/L;9BVKMJC>-DJ+>K->X?0[A:GC8[78&6*!ZMKD4,>KL[+.OB^,:
M]X?:?HMO5L>6>R-QP VV47/*+EY^0[T6Y<7*3BM!G6/<,S!D50C,CBH/2^W4
M?FTB- (GADD@5,3>/VB;[MV,[&H9$PV3:(LBWCQL7=ZDM7UJN\!;57D=XR35
M0]HY*P '7*.\&P+C&=JFSU56<V/2=U9;F-I( LN6L@$@Y;JF/=V"<YQDCV6#
MRAY/TN2 J-ZY38SH0K.$_&CS->;0BB3Y-TN/)STNZ;EDF20&"EUB4/*L64!5
MX\0 6(5JW/LG;'#IDXFDNKW/7<JLH;!5OF@ZM+E%>!ACSY%&<E@&3*J7%6U-
M5FU;*F8$KR*^(2[U-OSS7','<JC:2KG<P0SYU'R1L-(,]$%5P!7DP.70[@0F
M;-)G[^<+'->3<\ZL9K 1<&9!9'G;8-ZB"#U9QQDBV'^:UI+RA1YAV&.AQ4Z9
M;%K9F;-I0#;CL];=94K'(.50U,7[MV]%!7F3);J&1K JKBO<>UGM=74EI5<8
MPS"P!>_&QB5;( BG1/(2Q ;)68U-&!" 2Q1K&(W MPFU5&VA[; H_5K97I-A
M"V! (^%JUFG\UT$KD_53)#[''7;#;=A#LU47!N%*M,K*Y<L&7:V4*.A0O4C;
M2I96=1;N8;P5.Q=I+DHLU#!E"!2&###AT<.$L==RMM958U[5[!#=MMPV!7G'
MIO?!U%Y;5.M#QKA:OG)0.7.A+TELK' $J^0L<I+#'Q+3+9UB)#2PB)+D(CHE
M+VW(6E.MKU95IS9:]).UE# 'R%@P7S9VY/>!G'DDEEX2I;0,J<$CR[2I;NSX
MV!W'RR@%A\U3(;I#823SQP!3JN*-2.C?+T\ _96RK-!L/20HZN$(5P9K,?;M
M8##GY#Y5R0/?GGECG28;81<HKDKH%:K<+=SNP%6T-LV]8M3,P*;N3$]W,!<X
M;/+';6,+,=7M10QLW%=V=C6*%(?:,JOE\IP2N.U,4;SA"$=I8%<BZ3/GLJ+0
MRD-Y57 O"S(@AWF%)&2(MH. RK:M,^.U[GK5*%PY+#$NNQI$)LE-GPA=AT##
MONJQR(QO;*L-.0P*JR__ )-8Y,>88YP 6N]6J?%JM/,@YVKA@;P1AV4__CN>
M8!&5&,DA>W7G)4-1S)E_G-[BU$*V8E2+1+(4")#5 &V'KE3BR]QIERCOQ$EK
M#QBTQX^R&XD># DB"9F4.9?EMPGJ!\@=;67) V@6$Y*TN1XF#M6]3RR20RJ#
MRR]6KVCU=@5<G<36 0&M4'Q^66I8<\8!!..>)=:\[A3AF3J5SRT" (K_ .@)
M(GQXL>RKM$77D;'(UQ0HV1K>P#&I'"6I$0^>2TQ':-+BV(=7FT/EAMWR/.T8
ML5F;FN,E=G_IB&RH?=D:@C:O,[<J6\4V^K1N^9L%'?G ;=_ZC*X)7:/6 =QY
M=K! [Q5NG^4H6W= $\\11+<+GS+*6I!,O*EU:2&$7$.WVEV2+TY /2)I*%MO
M@]T4DK"A*;:7.K<63'8G2CL2NPOI&2HV]8A&T.J@.&9#U'/FN ?_ %"#!//#
MX. -TR:D/8*^K<$L4))3"L.NY<FR1ZPW,#Z)1W[MLGN^49Y%H):^;XU-3KMI
M&A"8V(.L!Z\'X![MG6.'1I-4@!EOR9A.M3N2S[X>#1*Z:(D:^?9 P(L H#62
M.7^I%V#M'>RLP)*K6I2BF\ARV  _7"M6+* R[B2&PMGJEMQ[*[%8*0 Q=@UU
MM(*@>5347(VL64[0 1DQ"P^29T#>G!S8ROE*;/K\.V"'41C(RRCQ(R]\BIUS
M#6 <2DM%X%Z$0>J,6&74CU3J$P&I%< -N6F>=/OT@NE5JP<L'#%#S4H6-=SH
MRD#::R:2N]7<-VF[(50]6U#+9C"E2H=<9# !ZD8,"<AP+0VUE0KR7M$DK._7
M.G7X#?.74;G,(?.W>@%^LA(NNHOWS<"#32W-1+.VQD7H_-6XX^2J_+?FF?E@
MJ[$W!B1XX.7J:[)AQTU5M7;9:2.K:M -_5Y-BVGOZJTDCJ^2[1G))88P;[;+
M%>I*P#O5V)V%\!#6.X65XSUG?D]W<91P-YK)V^99+<\-E6WNE5GF=&D5R568
MKY^PVBO<G(0AA<65MKLH I)/I#J7#DMW5?;'P(K3DQ!6=#B39FT/)2+%7UIK
M7W[B%57N!*E4&[E5XH&[.>6 <0KK,[LUL?7%K0KM&YG6E@I!<E3FWQCA<#OR
M1F/.^;-0C28#$OGU\8:GL@#?QS>J[/AC:2?,W<"W;["X,-37:O 'S^?6!9G=
ME9$P 410WYP%1!"4^-AV^H7.<65\BRX[0+.JUML7*C>2+5V[=Q8YVA@,F[U8
M@P#79SP<]D@(2XWMACM -;9W;0HQN*G($Q\P\KJW?X\],FM6D4Z(Y2.ZDLE+
M$L01]E%ZJ-.M-@358^BQ/1%T+\]P@\C#&E3;@(D^@?8I0UV< >/6VZ-JR,,A
MW7&G ))0[W5=YVC&[8Q!(7<.:@X;;=5JELSE6!%0LR1@,-J,VT9.<;P" 6P>
M3$97,HUGR"F6*]5V-T"GB9$0.Y(E"&*=6;?>KA6+LQRGDIDG9(L.OQ#A!^MS
M17D"5I^B$,!&6)&-P3!,H\/N<B%6[WTP2MC6YR>1WLE:/7UURJIW%0&!TP?!
M8[B2H4&O+V+J"SJ+$'9[MBN[J_54L6 4,2I&H*9"\@ Q.'PL4YAY7:Z-9YL3
M8!@/75]P)\H%?*#9@8?8!Z\?F>X +E88QB' 2)?(MA[0/G5EV*B<(C3@*R4B
M%/'%8DNVW2=4H.[+>IQ<V-K+N]4FAJU*DYQE"&S@D-@$%2*UZKK&(VX47&KG
MD,%ZCKE=@0,9PP*XR 1G!!$^^P>3QKD_7':+.J@YZGS1' (XFZNS)>DP[WV/
MKMQHFZS8HK:/=081*MU260J!O;[,-RU055<DI9"R5>+,4:1;J=X<APVH+)@<
MZZ:4LWJ<\R&;#KC.P[QR5\+M2U5I0H-F*0KY/S2VQEVL,<@54E#G&X;3S90:
M="_,>WW023;J-0B"[!+Z(/U2V[  +HEV;A=FK5ZL-*Z56:E<;'R9_H98Y^!\
M;U-!4RUO:@ 43;,)79%"' 4Z4Z)$8;WRHK._:PPEZO6ME3NB7"L+UHPSIS;"
MG;G<+!JV<'8F&-@";E.6I9+&2Q5=JNL+=6V51\A<L-V,&JMB\CB:*WR$E585
M;FR.JT?GUK;,O:L$FNCOP2NB\9YN$FP(1"-43Y41"?ZS)M$A@E'K1=\;6XP8
MA&KLZQ)G!X5THW7!RPZFRQ-O9#'JJK[6!(WJK'J0@QN&7)&X+@R-J#MI*A<V
MUH^X[MHZRRFL<CL8CUW=S"G"X(4MD>B/Y$'B7.*E:0U29E''ND<;H]W46AW.
MNU%L/T?J GG4^V<XL<VL/ANAM_\ UZ2P@:'..LCHI"#\Y2\.8T@<3'3*MKHS
MD+U5]E>"C/NKJ-@2U=P:KNPQ903@[5(.14:AC6C*F3UE2/D.J;;+!67K8J19
MWY4!N0(W$'D?/7?(*RO]85SXW!J)$9-M%9@BCE5EOR6'*]>0':2E>(0Y;90Q
M'.H&%N,SZP8FN,UN?(+SC;JZH""54::O!],HIZU2X(1R5<8.^MJ P(P"N1>&
M7QQ@ ;V9RM9=0W6]6P4@L@4KS!6Q;BI!R0V#25/BG)/94*"]4;[VP%2:O-L:
M %N,OQK@JBQ07S8/@2Y@ZRV]*EN5\?818XE:@L8;$G%4G*</L@^<,'D2(QV:
M/&DY4**O3M8X7<BY3K"V]655S@;BK$(Q) VN5() ."0#(]RHI;:Y[>P+L923
MWG:& +*%!;<H8$ D$X.**<N\O(5_ ]'ODFN/0Z#2Z-1^D19#/NTGD4^V67I<
M,@3.1GB#@]I5:JU'C6 G'@2WU*W\KL0E35I@MN3VZ,UM54&S:]CU'/BEU2D@
M+R![3V%1D?2YQSD->K#K985Q6B)9R\;8S6 D\\=E4#'!\^,\I"07GMSFS/U=
MH)0>J3FK$3+#);[-::D:KKE?/4&O'UF409TQ4=(N1U&CSUNKVW"DCB,Q$6:Z
M9BQ Q*YN'VIOW64C:H([?C;EL9=N0,YZJP>?*CEM)86KKJVV82P[B1R7.W::
MPV<$]W6H3[1([Q@SCR?RYKW5K'4ZY%YST:NNVT2&(QR1@7"D!ADBQ\\1U@"+
M*FP\XB$;FS>?R1Y)YN(3F+BEIR0GNWG(LV7'CNT34H[FVI]A8$*QR0MO4LRJ
MP#8%@(Y@9 W>7$OJU:VNJ"NQ=P!R0, M7UJ@D$C)KP>1/,[?(3)98\Y:*_8M
MU_5$O^D)GUYUPZF"/>KS-/M!@F$$7MXNS.<B:JKT@3*F+L[;CM(2.7!VFX+)
M$QHN7?\ (^S;NZRON;LY.[>BAC7C'C@'&SYIGZ# )%OJU,XV68[/:P-NUF*A
M\YQMY9W^(!CMY(!@7]FOS&]P8=4,<LZA(B6]R,!M :976_8!!+4]010J39W$
MSF6!T$PCI]>>7)E2X@IX-J8;#%S0<E3)UNN]0VUDNMU64!96#=[(+20O+F1U
M3<AE@>1566P)3U96X"M59VB%92OBAC6 6\P/6KW]DC)!960ORWYZ\U"@?CY_
M->E5T.!JY<N9B;KL.,[5VPM.,7(/69HQ<N&L(<.UX(WNM!C[=>4?24$S:?JR
M5OY1.C7R.M9L+;4Y9E"G<>WN<5E@<'<JLW:*[MN&ZS8V%9ZNK5<FNQ0JL6&T
M=C:A<*1D$$J.RK!2V05W+EA. #RW9MUUHU,"\[M(:48N,.K7-VY-1*^]7'"(
M_L[PU X1/FPK 5<FR^-%G4R=!FVXT"=#1*BMD&CT:N6-H]B6.UJ-MK+H$[6[
M!HSE@"HP+ARW')!P<;2UZZK>Z(*W7+[7+@+MR+B, D,<]2>>WN(Y9SM],3RV
M&&NS@^.@:0==E3NB$Z80L)&3!BAEBPX;N"B9T#+9=DQ33D&U<5)A98^)(=7$
M;FKBD7!]I&%JT.M.C*T-<UBX%8<*,ELLU&U6'(KE+PP)',CEE"'-1J@URTJC
M$]849C@* %ORRGF&P]!4@=V>UA@5$"LOG9S:M62QU%ZG=$(6"MV214I$ 6('
MSGYAR'9S-3GM0HL<HX1>AC"#W*IA.;J![,43WKE$U#;ZBQ..*O3A]KHC[Z@K
MKOR6(PI17!)QC+#K@!GF=/<.6T$V-KJU9DV6%E;9@ $E@Q0@ '/(]5D^07U?
M3'$KGO/ZL18;[@GEW6-R!MMK-.,J(4,\^W!L$TT'^<%?C01;+Y0H:8JTN;-K
M\"#'=+&C>Q@EH)MR2^EF]>'.3VKJ<%'<8L7FH5BK$MA54L &)(55R=TH=<N.
M5=N0RH<UL0&)!9<+DE@I)  R3@8R>5Q9KKY;=4XM=:H #D*_U.R4&$1>)6-A
M<H& OB(ZQ\H3\WF#86QD]JF16G/AS\4*RSN3/B%2Z&8L6?BBD;[ZW8AJEM(P
MI[35YR#NVE1R)YKN[@5&21.;3LI=5!6QD!RP[*OW$;=RL>8[FQWG)Y RGXX]
MZLG8D%HMDJS0@@+@5\I,F0(D\4+'R+'5JU9?FHVR>E+(666"V>=B_/:OMNU*
MU"F1%I%I'#K*'BO7ZK3+1M*ON5BP )#$['9-_9&$#;<]6QWH=R'+(QENGO:W
M.Y-I 4G&0!N16V]HY;;NQO7LL-KC 8"4X1YVUAL&,L4_D_3H0RP/48?7%,HJ
MQR:7-],#\^/TD4V(KEA,&$+G"NC!I!-YL?(V,<CS8S+)&0AIMV7Y'N6*BZDE
M18S^.H5:FM5VRZJIP:FP,C.5[N>(_5J[0QJM 8UA?$8EK5K9!A68]U@W<N1!
M W<L^MKSII<DJ*#1><=)<(&I (+ C/P \!>KD<+\[$IJ1"1.+,#!!2$KIM>F
M2HQ,C%)M#=[,.BF@92ME3M#P]P&8VU87<202>PHM;K  "2IZI@" 1G"[MP=4
M>K4R *[,G &0!VV-8V')Y$=:I.<$#GC:5+5 -^5%7KP/F!\G4+DW"Z(2+"YR
MH\2#/;I$@#;@E$,+LL@=-EQVHC%F/1HL4FVYH00;95%CD=V(K5Z]88UTCNUJ
MAZ\U*&&21U@9&L&T$ YV*21C([R-H=ED.J4+6Q5\6%@>0.PJZHVX@D !FQNS
MM.,9W%0TGR?-6J00ZS<^@VQF%"$T&P&-13_."LD6#ZO,KH_G4A<<5=)CC\\Q
M,M U)<0C2)M>A(6:?3+!%J>3M-XT%A;:+$R6L5<K:H9J0QMQFL<EV'![F.%'
M:#JEAUB 9*,,+6Q&ZLD"W;U><.>9+ $=ZCM>*4+>%WS? L2S QWC_7]E1" <
M94.%74&FY)PY&YD3;!PY0!XLT5F0PO6:R3E,5W1PCM$(\U&&O[17G++7U V%
M(NIPVXY+;<*IM&XAL8!-+@%MH\7)':VT]6KDCJK<C:.2YRS"H[01G) M7.W)
MY'EXNZ[ZH68==:G5[D'WM0BVUT+9A:E/0I.]CCPV,5@[W(&RIPZ1O<:4UO;T
M";,A.[_%Q94AA3;R\)T-;O6WC(S(>1'-25/(@$<QW$ ^<3+1@Z*X[G56','D
MP!',$@\CW@D>8R8LMET8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$@=BK%:MPU0:V5X'9Q"WV)*A5B$P#0U4F,OWD:0J"2CR8NWXZ_
MQ;#NVMN-+_%-J3OZ>7*[H=R,R-S&58J<'O&00>?EEK*KC:ZJP[\, PY=W(Y'
M*0R=SV@E%E72='J!%P[L4HVY.K066LPH#I.@>RJY$)Q1#8;2$Z%;E[>V.TE.
MH?N?5KU5%MBXQ8XVYVX=AMW>-C!Y;O+CO\LH:ZSG*(=V-V57M;>[/+GCR9[O
M)(ONO -NLO[!A]OQW)SS#VQL+;K#Q14U9)UESW/MMN$5DB*YSB-I5+5/FJD;
M<W*?VY;N;NW''+ED^3&/Q8&/-@>:7;5[]HSSYX'ESG\>3GSY/GF./Q(99(^4
M_FI'(--SH\ W!!06)B$RF881=NZ#!6'B-/Z6B.*7"$BX:A[*41%11H^/MG;4
M..AO9ZPXTNAQRRNXXY9;JZCN..]LDG/?DGSF:_2\]3K,\\-M&>>%WV# ]K"@
M8[L #R"5X"UBMZ\I;C2-5X'JEAO&*E0Q%0T)@:JXJ'<>F=%W;HHT!\/\DP8U
MI^;5<^<;$6(TT<^0 ORFF5\E0?<8Y=_4JV;FZPZIB7W'>2E5>PELY.S<VW)[
M.YL8R9,JKZI=-J[%TZ!4P-H#N^\!>X!]J[L#M;1G.!+B]<[Y_I8UW5&IVG S
MPB0'<U60NEBI%?CKB 7QJ]0O:@O!(KCD80[%VTL;'6MF&IEM6T[QNMLY^N/V
MLANVW:W<VSSY[CS.>_RS(ZNOEZVG9QM[*\MOBXY<MODQW>213YKUGW3#'S=!
M>YBKAN16?D@?[J,X/CLQ!ZV&_A_897!B1H\:&IO2=QH[#++.T-M(2FF]N?:;
MGG/,\\G)SSYY/,^<RNU?I5Y8QR'D[OQ8Y>:=$VFU D:39"-5K<^Q)%2 23TT
M&+E&DA)FG4RPZ2C\5<[0J5I][4@?I_X1_3SNG65:<7ZP=PNP.P7<&VAB%W#N
M;&<;AY#C,%$+;BJEL8W%1NQYLXSCGW=TA2^8<U<1*;<YY1EMS9 F7-;74@"D
M2Y8",N&"E2D['[3(D!8;CD02\[I;@Z,M;$-3+2MIW=UMO+UVSD"!VVY!CE@.
M?(,>9\Y[Y3JJ^?K:<]N>PO/;R7/+Z$<E\WDGK30*&B8T112:B@@RDDAF<FMA
MDS&D&8K<(PAJ5J%I]M)6$RS$))2O6IT5IN/*TZTA*-4ZRS&.L?!QD;FP=IR.
M6<<CS'F/,1U:9SL3(SSVC//D>>/*.1\_EG6SSGGL=@-&8HE-8C5R3$FUZ.S5
MPC; &9 =EOP989I$%+8N3"?GSGHC\%+#L9V;+<96A<A[:ZFVT[B;+#N!#9=N
MT#@$-SY@@#(/F'FCJZP -B84@J-JX4CN(Y<B,G!'=F2 -KX$OV'I<4J$$$XL
M4;R&Y1HQ ;"FL1[>S\^Q+-J89DLN-M61H6$##6CC:4DVQX@9#3*U'@16VI"S
M+140S [KTR"1V#U;%.7T.YF.WNRQ.,DRP*IML!4$8J?! /:[8W<_HL #/?@
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M7</+M  7.=H  P )'6JY<[5RMMFTX&5W %MI\FXDEL=Y))[YSUFN5Z.T$-L
M@S!D]U+C,<X79%P6R9F.(OX!\2P5GH83*(LC'V&'AS4QUY$)UEIR,EI;:-ZK
M0S'>I9BJT:@JI)PNZM@VT=PSDYQWY.92Y5[)VC+74AC@9;#C&X^7'DSW>25
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M^VJ)1V)\DJQ3:JR4F%6SLLDU7A#<^4;:7[UHQ)F(AZD/E6W/[HV0=<5+0O\
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27SMQ$8B,1&(C$1B(Q$8B?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g743471g32d67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g32d67.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6IN:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S,R9#8W/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!G,S)D-C<N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(U,#4P-S$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#$S+4%U9RTR,#$Y(#$V.C4R.C$U)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#$S+4%U9RTR,#$Y(# W.C(R.C$U)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T)B-X
M03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L
M96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P
M<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86Q-5"U";VQD
M)B-X03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @
M(" @(" @(" @(&<S,F0V-RYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!R<C$U,3$X,28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,3,M075G
M+3(P,3D@,3<Z,S<Z-34F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,3,M
M075G+3(P,3D@,#@Z,#<Z-34F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE
M('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M
M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4+4)O;&0F(WA!.T%R:6%L350F
M(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S,R
M9#8W+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R,34Q,3@Q)B-X
M03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q,RU!=6<M,C Q.2 R,#HR-CHT
M-R8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q,RU!=6<M,C Q.2 Q,#HU
M-CHT-R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU
M<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@
M(" @(" @(" @0F%R($-H87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@
M8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K
M<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R8C>$$[07)I86Q-5"8C>$$[07)I86Q-5"U";VQD)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<S,F0V-RYA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@
M(" @(" @(" @(" @,34M075G+3(P,3D@,#DZ,S(Z-3 F(WA!.T535"!4:6UE
M.B @(" @(" @(" @(" @,34M075G+3(P,3D@,# Z,#(Z-3 F(WA!.U-C<FEP
M="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO
M;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O
M<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T
M92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@
M<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@
M87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4
M)B-X03M!<FEA;$U4+4)O;&0F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z
M(" @(" @(" @(" @(" @9S,R9#8W+F%I)B-X03M5<V5R;F%M93H@(" @(" @
M(" @(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q-2U!
M=6<M,C Q.2 P.3HU,CHS,28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q
M-2U!=6<M,C Q.2 P,#HR,CHS,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @
M(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!
M.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F(WA!.T%R:6%L350M0F]L
M9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G
M,S)D-C<N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @1&5L=&$F(WA!
M.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#$U+4%U9RTR,#$Y(# Y.C4V.C0R
M)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#$U+4%U9RTR,#$Y(# P.C(V
M.C0R)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S
M=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @
M(" @(" @("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE
M8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A
M<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!
M.R8C>$$[07)I86Q-5"8C>$$[07)I86Q-5"U";VQD)B-X03LF(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C
M>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<S,F0V-RYA:28C>$$[57-E
M<FYA;64Z(" @(" @(" @(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,34M075G+3(P,3D@,3 Z,#(Z-#,F(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,34M075G+3(P,3D@,# Z,S(Z-#,F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4)B-X
M03M!<FEA;$U4+4)O;&0F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @
M(" @(" @(" @(" @9S,R9#8W+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @
M(" @($1E;'1A)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q-2U!=6<M
M,C Q.2 Q-3HT.3HT,B8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q-2U!
M=6<M,C Q.2 P-CHQ.3HT,B8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @3&EN92!#:&%R="8C>$$[)B-X03LJ*BI4
M:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E
M(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF
M(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F(WA!.T%R:6%L350M0F]L
M9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G
M,S)D-C<N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @(" @1&5L=&$F(WA!
M.TQO8V%L(%1I;64Z(" @(" @(" @(" @(#$U+4%U9RTR,#$Y(#$U.C4Q.C U
M)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(#$U+4%U9RTR,#$Y(# V.C(Q
M.C U)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S
M=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @
M(" @(" @("!,:6YE($-H87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@
M8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K
M<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF
M(WA!.R8C>$$[07)I86Q-5"8C>$$[07)I86Q-5"U";VQD)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<S,F0V-RYA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!24C$Q-S4W,B8C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,38M075G+3(P,3D@,#<Z,#4Z-#0F(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,34M075G+3(P,3D@,C$Z,S4Z-#0F(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($QI
M;F4@0VAA<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C
M;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP
M;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@
M9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[)B-X03M!
M<FEA;$U4)B-X03M!<FEA;$U4+4)O;&0F(WA!.R8C>$$[+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE
M($YA;64Z(" @(" @(" @(" @(" @9S,R9#8W+F%I)B-X03M5<V5R;F%M93H@
M(" @(" @(" @(" @(%)2,3$W-3<R)B-X03M,;V-A;"!4:6UE.B @(" @(" @
M(" @(" Q-RU397 M,C Q.2 Q-3HS,CHP,"8C>$$[15-4(%1I;64Z(" @(" @
M(" @(" @(" Q-RU397 M,C Q.2 P-CHP,CHP,"8C>$$[4V-R:7!T(%9E<G-I
M;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q
M-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @3&EN92!#:&%R="8C
M>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0
M;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@
M<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@
M<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L350F(WA!
M.T%R:6%L350M0F]L9"8C>$$[)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @
M(" @(" @(" @("!G,S)D-C<N86DF(WA!.U5S97)N86UE.B @(" @(" @(" @
M(" @1&5L=&$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @(# Y+4]C="TR
M,#$Y(#$R.C S.C4W)B-X03M%4U0@5&EM93H@(" @(" @(" @(" @(# Y+4]C
M="TR,#$Y(# R.C,S.C4W)B-X03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R
M+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A
M<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T)B-X03LF(WA!.^* HB U
M(&)L86-K(')U;&5S(&-H86YG960@=&\@;W9E<G!R:6YT+B8C>$$[)B-X03M4
M:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N
M=#HF(WA!.R8C>$$[07)I86Q-5"8C>$$[07)I86Q-5"U";VQD)B-X03LF(WA!
M.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @
M(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX;7 Z365T861A=&%$
M871E/C(P,3DM,3 M,#E4,3(Z,#0Z,#(K,#4Z,S \+WAM<#I-971A9&%T841A
M=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y+3$P+3 Y5#$R.C T
M.C R*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I#<F5A
M=&5$871E/C(P,3DM,3 M,#E4,3(Z,#0Z,#(K,#4Z,S \+WAM<#I#<F5A=&5$
M871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @
M/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW
M:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$Q-CPO
M>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O
M<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G14$S041C04%$+S=1
M07-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04$S04%!04%%
M028C>$$[05%$8T%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E1
M04)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!
M341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF
M2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF+SA!04519T%D045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!
M445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%1
M14%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G
M8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD
M55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4
M,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S
M3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+
M5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"
M0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*
M1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&
M53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L
M6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ
M;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O
M84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9
M<3=&6%EQ-T9867%W;GI(-68O34LV,75E*S!R5F]9<D9V<3A51VY03$Y#0DA$
M3$A/.&AK:E(V4U--<GA%8T0X0C-*-EI:17AR9"8C>$$[:5%52'$O;'IZ;75N
M6%5C1CE01&1A=G%12F4S=3=Q-49N8E-7:DMO:EHK0E9%=D1Y8F=Q+T(Q,D9!
M:5%7:6\R+VQZ.'EB0V%F56)V528C>$$[4F923DAE<DY94EAL,%-K8S=#4TIO
M4#-,97!,1E8Q46-6+UIO4C)01D9&1FY79R]P1#E"860K:W8K3VHY5F@K=2]W
M1$=F,#$Y5"]H-B8C>$$[-5=E8DE)-T%L,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMT3R]%5C8W9V9E85EQ,VER<U9D
M:28C>$$[<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E5,=E5,0WE4,4QY
M-6ET;R\U-6Y736)E-T594D5N:VM22C5*9"]I-WDX-')B6&8Q-B8C>$$[=B],
M1$A*964O=T1X-W),:R]#:WHX1UA55C<Y=G98-E1R-C9L<48W8DI:,V1V2&%,
M17EZ,U9U.75K=G$X=C=V,4M-,TAH=E925$)+1B8C>$$[1&U&;FHT4419,U18
M24YB<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ4F5B+THK;BMA8D,S
M<W(V-'5B6DQA-%<V:FMT2%=.*R8C>$$[84MY:7!:6#(K3W5W<EAO8VQ'5DE)
M=&(U63AO-F0U6#!Y5WAS2EIP;W!R:UA$=F--:DYZ8F=P*W=K62]9.$LT>6QA
M9U5N*U)3-T98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&5G,P,%5-5%-Z3W-C
M4T-R>4]1<6=$=5-D:&E!;T9P4"]I84LV;TY&=%ID57(P=4DV4C)N5VY,-GA*
M4B8C>$$[6%@O:D9Z4'1L;F@Q>C)B9D-R-G1V=CA!;"MT0S-E:65:.5-N<W W
M=E9&<TDW96(Q6'1.4%5(8F=Y.%=N;E9Z2CER=$=N>7)19VE54B8C>$$[>48K
M.4EN06-H9G92=BM&9$QB931E-W5V-6QN=3=M4D14>&E-;G O.$QG.%$O9TUF
M1E!L.&=R,FYL-U%,2B]5=$Y.=&)E5&%R>%%X;R8C>$$[>' P<7=!3U)--4AM
M55-Y4U!-;$U-:7=A0TE'3$)11V)Q,4YZ5$97.%9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7%Y9B8C>$$[-T$O,3 O-&U-5E@T<3=&6%EQ-T98
M67$P<F]X259G4W!O=T)R42LK2W5:;%)3>D5+;S-,2%E!67%L:S-M<GDQ1DE9
M;C%3,3E99C=P5R8C>$$[6D=K*VA&2F(X36U-8W4U<T=+6&-60S0X,E=A=U-0
M83)D+V5327!:631R2S1(3VY:6&Q32TTQ+S$X27AN<5(X,&I%97!!*TE5<DLK
M."8C>$$[,#9T85%4>%<P96I15$EJ;')O971D55E!:V5G:$5C6C,R-5--9D9C
M2D59*V%41T5E=D8W=5-*:#AR-F(V:50S-U-A<F1)47EZ6'I#428C>$$[2W<O
M85-)0EE)>C=O9W=(265M>D4U5# R.3,T=$XX<F$S67$W1EA9<3 W;VEL;EE+
M;S9S5%%$1E5*6C9R85AL,5!"8GE,2TE&47,V128C>$$[<U!J<G17;D@Y;G-4
M:'!&;WI!;#)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5DM03D]I,RMS
M85E,4W@Q1CE-;D5S8W!U62]6<28C>$$[5E$Q2T@P6F)D-E P4'@Y36Q%,&=H
M1&56=DPR<&%&<%0R;6]A=E!R37(S0WE*8S-(4&MQ;F=O5#DU2DTS5E-F=%4S
M-EEY3G%"5$E-:28C>$$[;#)+=7A6,DMP8G$R<W):4$AA,CA2=3E5=4%48E=3
M1VA)0D%-:VIB*VY%<%!X3V9K05=O1$]-3#,V3311=F,W0DQ.4#AN>D=A-G5T
M6"8C>$$[,4\Y=7)M-VM%<E)16&1X8E<P6'=H945-54QX:TM!2V9%>E8V-4DU
M96=!8DI:=6=!1F51=$AR-5,X<VAG-S9:8GI32V%I5V5.6G!!4B8C>$$[+VQY
M.#(O2$DK3$QV665,3'943T='1T=-4G=X<DA'3VE)06](,$1):S(Q:W)Y05%1
M4E5(<4U#=5965E%Q9T)12T%$64%$1EA9<3=&528C>$$[=G9D6G1,831H9SE5
M3DQ)+T9O:U9P6$$T:R]:4W!8<#-W,&DQ5#8Q9GEF,TYP=T@X.7<T5#=L5#%$
M.3E-5F0Y5G8U4#<K.#1$*U,S428C>$$[25!P6B]58C=Q67%U5%,W0E=$=$8V
M,&DW:5-9;59G9EEU5W Y1TYR4TE%4T-2<$)8:W=#;F,P;W1A8F1/*T)+-T98
M67$W1EA9<3=&6"8C>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<7-N*W=0.610
M.$%I67A69FER<U9D:7%586IR3G<Q,#)L-D]Q5#9M041023E40F%Q=TI$>D93
M2R8C>$$[<V8R67=E5&8U2R]&;&M9-U=E5%I'07$U8W9V4D=K-DYB-F-K:D)M
M=4QY-$EE-W9:84=76G=+07-104%"*WEQ9TMV65I'57)23UIL-R8C>$$[:V%K
M:4]Z<71A;V5,5D)'.4%E+UA9-49G=7A6,DMU3F%';EAT:7%%3W!7<V-C6')3
M05132W)#2D%78S%&9FA29519,'1T9E=D46TR9R8C>$$[=&A#=F%7-$Y0<$5A
M5DHK5$9C2TAF;S5P9#=U-&MN.%DQ4'!2+W=$07!U4C=->'AT859L=%EO>$=S
M0W!#:V)C=4-Q04YW4C!&4$A!;"8C>$$[5WA6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5DMF3D=J,RMR-E)*6E='<'IA4F-S455V
M64)6;'!866=-:"8C>$$[<'8R65E9;6EG:$,K5G9,*W V2'!4,FUO879.<E5Z
M,T-Y<F,S2%!K<6YG=D%C-4IJ,55N-U9.*VU'4G112UI":U5O839U25DW;3!J
M928C>$$[5&<X<E!W5W!!64Q'>DY8='0W-#!Q4C9H-6DK=3-B-EIP9#-(8E)P
M.$XU<6A:1'<V5FIT:V%V<5-B-W11;VYF:V9H>3!2049N-4YK4B8C>$$[1TES
M+TPY85EA861,,"LP5S%S24IZ1T-72D55>DTW<V%S-WEU4&ID:G5Z33%38VA)
M:VUY=VQ->4YL1F983'AV-W5X:TAG6DAJ568X028C>$$[0W,U+T1!>%5,9'1A
M864U-4IB4G(V9S1K3S=N*S=8<CA+63=,=7(K:'%J9F%U;S%(+T9C2D(K.7!(
M2#19<3<V:D]F=#,P-4AC05)+4"8C>$$[*T912#AC8E92=3E0,#9/,&UK=DI*
M5&)Q:DY/,&QX2T4T045T6#1W;T9-35%384A.16E!3%!*=E%0,&%D2G1:3E!%
M670U26M93DA1,28C>$$[*T5F84ER52M/*TTT:T=J>E=%9U)9-4IH:U=4<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D
M:28C>$$[<7EF-T$O,3 O=T-*:D96*TMS12]-;GE8<EAM3%5T075D33%$-FU.
M3V$V.6%&;$AP>BMR1W!66DI!9E5J2#=Q;DI!4TLQ;V%5>2]$;28C>$$[-$PX
M,DUS8TIB:V5O8VHS27IY>C5P4TM)-EIQ3G(K:C=M>5928W="5E5W3#EL5VM2
M4&A-5%4K1V50-$0S-$5C8VQ014IB>"M8-G8Q8R8C>$$[+V4Q.%IJ.5AZ+U@K
M=FPW;5A+>75O6E-'5FA65T<T25!C6FI.>F5+<6-33W)Y;'%59'53,$YD=4E'
M*S-T:7%P:7%%=G13=#=1;VA$4R8C>$$[,TUT9E%T66=';&5N9T-104(S6FE&
M2&,U3T=->3DS97=N35(Y-D=85$HW-&E85FER3#%J<T502T9$,DPQ2#<Q:"]L
M1&E/>3$S>5IY0R8C>$$[3S!0;C$O67A%1$QE6'DV9G161S!$4RM+*VY&-D5Q
M<45%.$)-36Q&1D)6;RM.9FMD<T%Z4TA7+V9U:S1O;GEA1G9R9'0O8S-+6'%D
M;R8C>$$[-V]#3U0O:V)%=D=G+W=#359F9D1X45!-5C=V,4@Y84MM3U)V,R]R
M2#9M:G)C54<R;U%3,E@O1G)R>F@R-VU74&UQ:B]!1BM/4&=K+R8C>$$[4U%F
M=BM8-FPX5W9Q1F9J.&,Q3%4O3D]H861*<&%83V]7,% V5W5"8E=*95)!2EA+
M32]'36QG0U1X<#AY0C%)>7-X239.9TE02DXX:28C>$$[;#)+=7A6;U-)6$M"
M9UA507-T9'=$,'%-5F)X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5D,V<&%46&UM6&1N1&-.8518328C>$$[36M59#%(6&Y%>G%61')X2T=Q:S$R
M64@S1T5&4VQ0;&)Y+W%7:&%5.7!Q1W)Z87I-.7=S:3-.>'HU2W T3'=(<5-4
M3E-Q:R]A-SE0128C>$$[>4YO07!K1U)3<V5.;65.<6="0U=)<'5A<58V,3DX
M5E,S6'9,,7)Q.&-5;G%086%J83AM<TY39V]*-$=B<E%K14UJ54A/3F=68G5/
M;28C>$$[4VI+;%-$5$PW561.,4%A6&1R1EEA<$M3,$5)3$QP=6]51E=A,5DX
M;70U93=X8C S3DA(>#5E6D-1,S,X*V\Y+V4P*T=9+U0X=6XW1R8C>$$[53)7
M<'=85'1#5F%#-VI&6G)75V=K54AA=7A)6F8X<%-2-S564$=9-SAX,W,T>D(R
M-F]L6D9:;556<6AO,GA'.4LY+VYL8DY,5S%+-"8C>$$[=FY-3VMH5VI"-'DV
M9S1R0W1$46E)9C=T664S=VIU86IJ;#-H:4\X=FPK3U16>&U7,&9N*T]A2W-D
M3G0W34UY.'!,:5=N<C--:#53>28C>$$[161/5&5!-TM.:#)!>44X:&PW;55)
M0U!V4E=16G5X5E-U<G$Q=$QE4S5U<&MT-V%)1G!:<%=#27%J<5=::4%".#A1
M3%9J=S$W5SEC*R8C>$$[1'DU04QA=V)R<G0Y1W=29U)7=')B17!*3E=U>G56
M5'5/9E1,3T5$;7%$;2]+,WEV3$Y$8UAL<RMP6'IY<S$Y9C-,5FUL5F\R5FQB
M9R8C>$$[66M63G@X16%H9F)C,7-'<&U0>&8S=%5S350K=S$Y>7!,-41U3$--
M9C19,64U,'A)>%).3VYK;'5R3&)O1E(S17-8=#9C9U5F>6Y!328C>$$[,V5!
M9F=Y-%!-<68V878X051Q<C5J93DP:$(Y<E59:D1E865D*W)4;41N0U!%>E)X
M<C=N1%E024$O4#A!5W@T1#-N-U Q2B]B,C%X4"8C>$$[0DAC5W5S>3-%17%H
M;S5E3G1):DMD=WET2$=O3F9N:T1-9%EJ-V8Q<#1$+T]0,F9Q83 V3RMJ,5,X
M5S5V:&1,-F-0<%)#25)M4&0V:R8C>$$[<T-E6$Q"3U530E%O*SE94FM#8DYJ
M,TM7;392-6=T<C,Q<GI8<$PV,C53;C9Q,71B>$1I.5!46&Y';V(Y,U$O3W4K
M4DI(8WIP3V-I;"8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M6E Y9V8V-F8X045X:7$O1EA9<3=&54IQ=6LV9G%T:DI9,SA);70U2T5Q4U9+
M<R8C>$$[<'%R;WEK36IQ=W%R2U%19'AH0DDU2WAE-FQN,&(P<E1Z3DDQ,7!+
M=4)P+VU52&A.8DTR>4IE371/0B]:131O:F1(05 R<F]34$]0>28C>$$[-S)%
M-$-83DTW3%1.5'4U-WE$5F)P8FEW:6Q666\T:'=A8V5M:E9U4TM!-T5F0VQ&
M3SE25&)*2$I!8G=&4RLW,TY58V-Z66UB:C X+R8C>$$[9BMZ6E P4E5526=#
M;V]!5E%+04%D04)M35,U1&5+=$Y4:652;TMB;71.=FYI<D=V.%@O5V=T;#5E
M9R]43BMG0UA%-G9W<V](;TLK=B8C>$$[8S!98VA89$EW-RM)2%A*:4A5-TMQ
M5W9L23-&>DAF.$%M3S4O4SDY1U$X34)8:%DR-VIC1T,R2EEC:#)K:TQ0-$5D
M3510;TYL6D9K1B8C>$$[9&ER<U9D:7%16$AK>E0Q;64W,&%A6%$W,E%L-4I,
M17%S36IN8VUA,EE.0DE4,UEP>CA'1U1%>C$S5G912E!.;S%854QB6$ER4C=A
M1R8C>$$[2S,K<&%J848P3G=736YQ8S=D*UIH2U5(*S='0CAE=T5Q-DMQ-F(U
M:VQV<C,V<3)J-FI:<GEL6#9Z8WA2<$8K-G!2<7))-6\O3#1.="8C>$$[-DAP
M:5EO=$]C:6PR2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMO9E5L=C(P-C98
M5&UJ4R]A2GAA4$Y8,#%L2VYG>C!"4$5.,7=H528C>$$[<#AR5UAM,DA46F\O
M370W0F58-U0X-%I904]#>$%+47!P2$(K,$<W9E0T1U9D14,K<6%8=#!,2WIN
M=F)Q6DDW83)J96%E5&=X-'!'<"8C>$$[6FI24U-A061S:4%L2310>D0X;GHR
M078P,7EZ1G-74E%Z,6IA<VQ1=G=/5F5N=W15,&]/3%8K>3%*8T)2>$).9$PQ
M;7HQ55A*<TQP2B8C>$$[>%IZ=F$S0D5B<GAL:G!Y035&95$S*S!T465X=T55
M;3!D>'50-3 O-$4O.$%.5T)5;CAY*UI.13!'>E=46')U2S-T8FMM16,T6DI&
M8R8C>$$[;EEO46Y0<40P4&%V64A*4FE4>5%45$1R0S,X=#999%)7=S@Y>G!P
M6D5T*VUM,FHR,#A6<D)B>%)I5T]*>$A0349154MX:#EH44MT328C>$$[;EHV
M:&)$2G)B>6Q"8W=X>G9R1W!856-Q:5)73C5C=V-G=W%P<$)*0E19.4YS:G@K
M45-Q2'E.<$PO=T(W3&54061&;78Y4FQ52'A!:R8C>$$[=5=&8V9%4#1!5FIK
M.% U3TIQ5C%O,F],<%%V3&5.:&-W-FI#84MP4$4O=DQK.$]2-C=.>4DS-F(U
M2S4P:7=N5FPU;#AM-DIP3VXR5B8C>$$[;F97.$=N4G)*83)-8T5-:DE"6FQ9
M<%9O;&5):G%#>%!B-'5M*U$T4U9S36\T,T@X-F8X04%N+VUR27!1,F\S.&5N
M5U4Q.65Z<$1A=R8C>$$[3'IM;$UB14MV9&IX2DY",U!B0T)A<$QA9FU*-4]U
M-V%#-&<Q-GE:3&PQ:FAJ63A*4WIV=U5'1FU74F9I+VU58F(Y35!!935(145F
M<"8C>$$[,VU05$Y2,4,V,#9Z=D5L=DQ,;#E::3E+4F501U)O;3-A:6UJ>'-.
M:F=-4T9T3D].>"]/;B]!;B]!2G%W2E-J6&9.5VIA1$YA439T9B8C>$$[>#)S
M;"MZ<F%+67!7-71(5&M!535!2#1H,38Y<VM):SAK13!O3C5Y.'-*3F-.*VUR
M3C-G=#0W:5E2;C%+47-F:&-C1V%T95DV94LK228C>$$[<3A*5W=M5VPV<&(V
M<EII.'-,:$IR679*1T@Y3C$K3T8R:F-567%D;E%J<&=)<$E+3UAL5#1I0V9%
M0VXX5&=6=D9867$W1EA9<3=&6"8C>$$[67$W1EA9<3=&6%EQ-T9867$W1E9S
M<U55,%1W>DES:U5I;$I),T%:5U9H47%W3WA"1TMP5R]L2'EN2EAN;W1G+TEK
M='ET6515:W-35"8C>$$[5F9'4G9V4&IH-&HS;V])*S!S3$=Z5U)B3S)I=&QM
M:V%A65%O<UEE4G%C;F)I0E9J5&-N9D%3;%AX5D0S=6XR1CE'<V0W8E)856%.
M>B8C>$$[4DIK5U%":7!4:T%W3D1X9&@X:6-)2V]'1'EH-51T=W=G,%=W:$1+
M-DU)-U=&87)+=D-25%)E:G(X3$1U365).39+0V%O:5)O<V-A:"8C>$$[15%"
M55)244%$64%!645T-'%L=#DU63AT86A),'0O<$YN9'E/=V0S;G0T<$=:9V]1
M35,V;7 T<49R-$1#2D5);TYR-6(X=7)'<U,V6"8C>$$[84-.2$UQ24E)9V]K
M2E9I-$A(-U)+2V$K=SA-94ER4UDT17)*-$E,:4-3,W5),6UG;59O-6]:1D1)
M-DU+37)+86=G9S!)3TMP52]K>B8C>$$[>64X-75(,$Q4,FY*-4=5,G-"8VYX
M-49+-4QI4&5I9VHW9E,Y371R;5<V=#=31T<U;B]V-30T,%=2+VE,9D=W04QF
M17A/+V9"85549R8C>$$[5D18=6PV6F8X4'(Q<$1D96UA>"MV1VMN13%$9D1Y
M0G X4TMF;T=%1E5(8655+TMT;5A.<&\Q:F)M4D=J:TU6=$-N2D=P>59U2VEQ
M;28C>$$[;31X-&EI9VU&=&$R=')#24Q71DE)45=94E)+155&,DQ-94MG0W)-
M>$HY.$-66$9867$W1EA9<3=&6%EQ-T9867%G=E5K+VU0,VY#:"8C>$$[43%#
M.6QT8D,U=6Q*6F]);FQ#:VUH2TM7<"M'1TES,'EI3$E$>G9Y1BMB970K6CE0
M,6DV+U))95A41&)#3S)T<$A,>6971$EP*S!$.28C>$$[;F=$.'$U;&%J5&E&
M8C@S3#%U;$='<4XR;FMF-6<V=DU%84AY>G%I23 S<'0Y66EK:5E2-V9V3TE3
M5'9863 V9&0X>"M!9#=G,GEM=R8C>$$[=C-V3$M#-SE/83,Y94Y:4%%U1DUC
M<6-H6&I);%1X661X:U-%<C=Q-FMG=%IP=U-X:5)N-#%)<GA"3DU#<U)L+TU$
M5T)9>#-.;F]K,B8C>$$[;W4Q=W-%:U9U-VMO:DM7.5)Q4G9S2U4O:FMX14U2
M2F9$-3<X=T<T:&IM.'18<7A3;%8Y5E!78FE32"LP1VAJ-&EQ9U9A;F9T>#50
M028C>$$[3SE.;VQF3V5S*W!+:W5G,V-95THS:&-L:4I*1FI2>$=+2E@T=51$
M<%@T96A.44AH2&5M,F]F3S)S33-+8GDY9G!%15HR2TLW4T5Q:R8C>$$[6C1O
M:DI'1%9P0U!I6F5N5#=156-)-S!79W(W.#%R83!,4U!O,G%F5EE$=W9P9E)!
M84-2;%)O,%IE4DAX97!1+T5+92M%63$T;6%X5"8C>$$[3DI':FIK031$04YS
M4E56,T=16DU3.#-E97)Z471C<TY/:70P;5,X0T9P1UIG5C531DYG33)';#!9
M>7=-:6%P,3)R,7AX6DEX<2M*4B8C>$$[+W=!9F5:>F-88U,K5DQY;'4P-G=U
M5VQ!;3E)2&=64&]&44@K9BMR>4Y!8TQG2&4U.6]Z+T%"<G)*=&<V*UAB-S9W
M2&M74T%H>%%*2R8C>$$[<V%S2$M58FU#>D-N:%4O0U$R1&A(971Q-F5B=%1E
M0S-K5%)B<&UL=#5*6D9(3#DS3$<T6#!7<6=.4T-7,T%0=%AO.$MB46UR+VU1
M8B8C>$$[0U%7,&5H87!.9GEY>5)7='599VYR0TMH95)'1$]3=DAC9D0X-EE2
M1'I14VXK:&$Y8C9Z85-85G1(3D9(2$Y*05)/=D)I,%1C5TE!2B8C>$$[,G)K
M4TM485(O;6@U,G902C-L5G1:=%E%=7!6;FIH155P64Q34W14.$\O8DQ-1TE4
M;%-*1V=L96<O;5IR*W V2&\K;W U9FQU:'%6="8C>$$[3E!.3&)'57A1=D9+
M.%E1,&IK4'A"2RM09T1H>5EH1U)&.&Q%:WHP=GIZ<F0P6E5U=DQ6-V%32UEH
M1CA->DDO<5-&5#AB47@X94-$;28C>$$[,61U,6%K5F=9:G951D579FY(5EIR
M6C5*9$%V24HP;'0Q3G5A;'93;D$U>6HT4E52;7125#=T-D1H2&5M,%!,*UEX
M<W)"<G969$,Q3R8C>$$[,5)&6G!'5TQN1TM41TI6-759:GE904XY;6Q$,4]0
M0C-&1G!H-5HX-&9P;5DR:RMM,V5M,SAC275*-$QH84MQ=$EY24]2-&ML=5!,
M-R8C>$$[4%1'56%30WE'<#AC9VQU<'A1>#-6=DUE=#9A-F,Y1TTX8S='0S%-
M3G='6G)H<%=72EA49T]-8E)Q2DAF9FHP;V%:25)"5S!+;FY,>B8C>$$[0C9H
M:69Y,61L,&M-8G-H8FA14U)P>41.1V]/,&I.=%556')3<$(T4C-R8DI.374U
M-W5W9W5:-V0W4U=647HR,&XR,$HO6E!426Q55"8C>$$[9U,S:7)S5E4O<3A8
M:"M/3G$W-G9&-&9J:7)V46HX36)64W5*9%!T=4@Q;6%/2#%7-%(K;S14:S-G
M=%-+;D-R5GIC86)B44<T=5HT-"8C>$$[3&-(:5IP2D923U)0141K>$%R6&)&
M5FMT-W!-37--33$Q1$A.8VM#,VIE4E9A46YO14).5W(W63!655HY83AU5R]R
M0V95<E=),GA!=28C>$$[3V,X82MM5V)I03E7*T=R0VTO9D=I:&10<DAL*S-1
M4%!Q1G1%:F9:6C4T,4(K1#%.:5<O:RM,-6(T,%9233!L;$(V6')3<$8V>FE/
M2"8C>$$[;7=8;3=!:TMT5'5X<#!'2U8Y3&9F-&AS=U4W+T%,4C9$-3<T1E5F
M<G5L+U='="]R55 Q:%%Z3D0V:3AW<54U:W)7=$8U0W9H55ED,28C>$$[87-,
M+T%%;E5)+U9S3'5'-VDO,S5"27-Q*TA60U)I45%Q<$)063-%87E7.#!C,&)S
M>4LX8FAG5U%K34%197%L4T1I<E)U3$%23$U:-"8C>$$[>$4W:4Y*3UDT;'DS
M04M$5VQE5S%02$96.&-L<DMI4$A)<G!,+V1S<D%H=2]W:TAF07%L9#,K;%=2
M079,<4<R2E(U04IP1FHK0T]N3B8C>$$[=FE)*T9E47%E,D5!;U95;7,S:U=.
M2E5A4FLY4E5$06MP5VY)04@W3F4K2U=H8U=2;6QG13!:;6=66&YI-6IK:718
M:7IR5W%G.%13=28C>$$[2W0K=&%E<5EV5E0Q44%42'E(24)G4TYQ,3-#;D97
M;V)M>&UI37--.&-K4S%$4TDT6E)4<E5G,'A6<WHR:6E9;59!3&-6;G%W+V1J
M:B8C>$$[>2M09C1F:#,S-UE&56)05DY)=EI':7,W,D,U:U%C;E-'5DI'54)I
M;%-&2G X4VMF35E30W%+8C P57-X0W%.>5-A05E&569R,FXO5R8C>$$[>%HO
M5UEV<FA"271U82MO46]"63A+.'1G=THK67<P<38T=4Q3,E)8=4IK:%)M5TY7
M:UE)0S=N:7%G:VID:6%!649A93AS63=Q2S!K=28C>$$[23!U-6Q:;V)D;E53
M3W%F84MO5'E)2&5M3DMR,$=+=6]-5F1167$V;4MU>%8R2W5X5C)+=7A6:F9N
M:B]"9C%#2"]&9D0V<#9H.41N-B8C>$$[=&95<"MZ-E!X5G!K;S,P46$V<V9S
M4#A!;%0O-DIV.$$V<%0Y2&5R0CEE+S-S+W9/2#=Q;DPT=C=V<G@W5C5:33A3
M0E-72B]Y;V)B:B8C>$$[,35252]W0T]H,3E.4%,V+S500VYV5#ER1#8P8DEQ
M4"]!2E5R*V@U=E1R*VI+5R]R52MV,"]V1#9(*U9Y-2M'+VIT9SED<#)P=40O
M;"8C>$$[5"\Q0S4Y4#%V,&(V-3EE;C91.4PQ+U)B;%=M+TPP<3EF;S-X.5,W
M2E)F9CAQ5"]X3F,X+W)(,6UJ."M(<F5H.6(Y458T,2M0,2M8*R8C>$$[=RMM
M=5-(2%-.<E9)4"M61F9O,C K=65P>2MQ43$Y9C8S-G9P*VA*=SE4-G8K-C4K
M;GIR>"]P9SEA*VQ.-U X0355,SEC,#<V=B]V5"8C>$$[>G4O<4@K.3%E9$0Y
M6BLQ=# O;2MJ065*3WE(,#,O;%(O<3)0,4MN<65P0CE2+S-V<C9N<DPV3D]8
M+T9N2')T5')T:65.1WDR."\U528C>$$[5GIU9G)01&PV<S-R,2MV9F)O=G$X
M861Q8V%C3G5N2$@Q<G-M1W(O.'%P+U(Y="MK+U@O4C-Q9C9(-FXV4SE(;E(V
M*VQ4-&8U=5A(-B8C>$$[9#990GA*3DE7,R\U56XV:BMH>#4O55HO530O6&8Y
M-5!Q=SEA=G8X058K4"M65'!V:#EA3FMT="\K5D0O04]M*W!Y-"]73'(Q4%8K
M=28C>$$[535C13EF:'@O6C9D9#8Y3S)(,7(V57@O-4%L.55H*WHY6#E2=E$O
M,W0K,SE93F509BLK<C=F4F<Y861M-W8X0355;BLT.68P*T@Q6B8C>$$[9E%P
M.6,Y4#!F55AJ.6XT95A0:C$K3' R<&HV,3)68F(O;%10<'0V4$0P=G)C2$MV
M,7IJ.5HY32MJ.7)V>"MI=EAF2#%,<V]W9CAQ4R8C>$$[*W$S+T%+4$@V='ET
M=G(S2#8Y>#5E<V91+W=#4S%A.&8Y;&HV,&)+168O2VY0<D9Z-EAR9E8O<6MN
M,3<O04AR.5 P=E-J-2MP>2]F8R8C>$$[=E0T57 K=FQH.5,W2V1X+WEO+VA,
M=S5E;#E95#8Y=RMT.&$K<3E0534O<RMR6#='+W=$<V-F5W5Z82\X<48Y83-P
M5#%E0BMR.'8P:"8C>$$[.6HP27$P<B]!354K;B]T,7@Y82ML<&8K5D(O;S5/
M3E!Q9D-8:"]X,$LX9E)J.51R.%@Y,W<O:'9J-C$Y2W9F+T%02VI/5C$Y8C1F
M8B8C>$$[;"MT,"MV8V5F<E)E<GHT9D18,694<B]404].5%-*,4@O;%1F,38S
M*W0O-S)E;V91-"]8=5A0:D9Y<C9F=#9F2W9V6#ER16-35%1+4"8C>$$[26XK
M12]W1$1K2"M&4"M/3'IK.4@K*RLQ>5!0+T%(;R]E9F$X8VA/-S-41W$R6D)K
M575X5C)+=7A6,DMV+SEK/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @
M/"]X;7 Z5&AU;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO
M(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL
M;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM
M<"YI:60Z,C1&-T9%0S(U145!13DQ,4(W-D1$-C="1$8S.34Q0D4\+WAM<$U-
M.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD
M:60Z,C1&-T9%0S(U145!13DQ,4(W-D1$-C="1$8S.34Q0D4\+WAM<$U-.D1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^
M=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,C-&-T9%
M0S(U145!13DQ,4(W-D1$-C="1$8S.34Q0D4\+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,C-&-T9%
M0S(U145!13DQ,4(W-D1$-C="1$8S.34Q0D4\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU
M1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN
M86Q$;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA
M<W,^9&5F875L=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO
M>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HU1D)#,4$Y.$)#0D1%
M.3$Q.34U-S@U039!0S X,S-%,3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C Q.2TP."TQ,U0Q-CHU,CHQ,2LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO
M<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z,C1&-T9%0S(U145!13DQ,4(W-D1$-C="1$8S
M.34Q0D4\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,3DM,3 M,#E4,3(Z,#0Z,#(K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H
M='1P.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B/@H@(" @(" @
M(" \:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A
M=&]R.E-T87)T=7!0<F]F:6QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N<R,B"B @(" @(" @(" @
M('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @(#QX;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A
M;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @
M/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM
M<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(#QS=$1I;3IW/C0Y+C8P-C8X.3PO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^-S N,34W-#<Q/"]S=$1I;3IH/@H@(" @(" @(" @
M(" \<W1$:6TZ=6YI=#Y0:6-A<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X
M;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @
M(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1.86UE/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N
M=$9A;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E
M9W5L87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B U+C(R
M/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86PN='1F/"]S=$9N
M=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350M0F]L
M9#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF
M;VYT1F%M:6QY/D%R:6%L($U4/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A
M8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\
M+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R
M<VEO;E-T<FEN9SXP,#$N,# S/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC
M;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA
M;64^87)I86)?7RY01D([(&%R:6%B7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA
M;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP
M5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA
M8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R
M;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM
M<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y
M<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,]-B!-/30@63TS($L]," Q/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXU+C@X,C0P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,N-3(Y-# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXS+C$S-S,P,CPO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA
M;64^0STP($T],"!9/3 @2STP(#$\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO
M9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO
M<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^
M061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( /P",0,!$0 "$0$#$0'_Q  >  $  00# 0$             !P4&
M" D! P0""O_$ %D0  $$ P !  4%"0H*!@@' 00" P4&  $'"!$2$Q05"18A
MD](7(C%159*7T=8R-D%35&-WE+?3&",D,T)2862!D1EBH;'!X1HE-#5$<8/7
M)C=66&9VF+7_Q  < 0$  @,! 0$              0,"! 8%!PC_Q !3$0 "
M 0,# @,& P0$"P0(!04! @, !!$%$B$&,1,B410R06&1T0=QH14C@<$S0E*Q
M%A<D-$-38G)SDO E-42R"(*3HL+2X?$F5&.4U(.5L]/D_]H # ,!  (1 Q$
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MU5QV]FM]-T^W;_>]H::< _[*Y^=/"_#FU_I+OJO57'8VUOINGV['_:]H>:<
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M#16P8&.ZU102LDI!CMVS& =LL<VV&-YQSZ'J]?I,91ZF%3ZH"+&5FL,5^*3
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MZ1KW2E@Z?:_#I?MC0G5:U]^IO?IR_P CB_UERW_LH_YN?[C6/^73?ZNU0_\
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MYE:EZ^CU&WWX<$-W>]_1K;12T?\ 6RWV*<>^(X_^)+&/_B)JG]H6Y]PR2_\
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M.RU9;?@M^&,Q*Z=%U!IDR]X+7JWJ:VFC([@1S:I+[O&2NY1ZUG3OY/RD#?\
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M6:F/))2(GENJ.A]8Z86&]=K?5=!O>=-ZBTJ3VK2;U&SM7QDS[-<^5@]K<;)
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M2LGT2\;@W^E+XEB[?VI].<[HU^)]E<LQ.3@<5H^!J5F/\FF%]"O_ (>[;;.
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MEM9V\MS._NQ0H7;YL<<*J]V=B$4<L0.:KEFB@0R32+&B]V<@#\AZD_ #))X
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M4RY35U,4IBE0>]Y(\4'(,#=O#"3(^DVGHAH6H6R+-&J=+MCU%L9K@B(91.I
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M3:\1*A"2\\&6\EG+?9+CC]V02J, Q521(6$84,P+.Y1MD8!=L$A2*J-S /\
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M,B.$2(=GGK%9).16Q.F2<@>[ ZA9&NPL?7'/5CH@J"DYB,T+\Z#(X/3N+DW
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M=)6G>];U9$@>6-#D!Y$0X[X9@#C.1G!XX-8N=JLP[A21GY FOP_?^DC^?/\
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M<?IPGKUP>#+,$5/)-(?(F%$C6&[?!41QJNTJ@&_]WN$H8J2Y))\>3WBP!VX
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MEO(Y56)+]MV?$EE&WR'L\IP0RX \V_/%'Z%X8 NPMI9Y#99"H3-UF[A*3FI
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MCB1,$@ [A@GFL?:(,X\:/. ??7&"7 P<X/\ 1OD Y&TYQ51'[/S$P26D@+G
MR$-".59N0L ,D$37&_GA/$5F&6W8&W]PY"-S8A4>9[ UQ0)([K!*4/ZTUN#!
M*"H*,&;?A2"&\BAV\N-P\I!''(.14^-&02'4A=F6!&WSMM7S9P?-D'GOQWJF
MV7R!XQ5*<QT"3Z-52*<6[9!@+!"2HM@BY VHU.SW>P1X9L(X>*\='UJG6,YP
M;VR5K<CE -^M($"BOREM.[F,1.'&S*L"I =TC4D-@X+R*/XY[ D0UQ"B>(9%
MV'=A@0P)1&=@",C(5&/\,=\550.S\EE#H^/C^DT4M^:=''@-CVZO/-6,HF0(
MB4AUYQJ27J:,:E178P@:/]N\S(^J$M&B5::S$P3 $F*0!>6\C>0 9RW'E&.0
M3QCFLA-$2 )$R<;?.OFR2/+SYN01Q\>*2G:>20TZQ6)/I-*%L+\TJO+AE6.+
M<D )A,#8;-[E,C,DN.0:UPE4L)K3DSH%E[X6^,TXLO;3#@03,I<12%0N[=M.
M"NY4RIQYO,ZCRY/.>U#-$&VF1 V[;C<,@[6?##/E\J,><=J^2^T<H"M<32'N
MA5!5JFBS0 X1BP11!Z#09/<$\*:PR6MP A=AU\VQV2TLN$V/>H)A+DKO0N!!
M,49Q&^Q0"3M.,$;LCCD;?,2.R^8\<T,T08)XB;F) 7<,Y!VX(SD>;RC_ &O+
MWXKTV/KO,*I2S^B3M]J0=+CA5E/6+YP13L6]I,5N<:&!+:+4R><9$Z2='@"+
M>+/'<:=$9>0ZWM1()7D$2QN9"<;=K9'FVY(QD -P2> >]&EB1#(SJ$ SNW#'
M;/!SR<<@#D_"J23WOB@1K$:7U2AL2#IAL>^&NT1&R(HR.A+#8Y!BP(06KYN*
M"AZG9"B53NX]MI4*>,I>BV%,9(MYR,B&3& 0=AY!95&WCS99U VY]X'L:Q-Q
M " 98\DD8W#@A68[O[.%1CYL>Z1WJXW.G\T:8K!3O0Z,T-=W=L4PARV0"&+<
M_HL0#;-8=5(:;GG='2  6VXI1:]%G!C>CVQ+*%X^#+EQX4F8_P"D&QLIP3Y^
M/+P"><< GX5GXL?E/B)A_<.]?/R!Y>?-R0.,\D>M4,;NW$# G9(3L?*RHYB.
M8F'SQNA5)\)F)*/"BAI1TIJ74PW'$2DE'1K!JG-#/'R (;;JB"QVW,C;W .#
M!,#G;@Q/G< 3C&W.< G'? )[ UCX\!&1-$1C=GQ$QC(&<Y[9(&>V2!\:[S.U
M\:CFS'9#K?,@&HXP*/D'#+Y5A6P3Y(.2D8X(Q;\JA(Q9\?#3!X8SVT/%!Q4D
M4PA; !2VH$$YQB&4Y!(Q&YR 0"1QR 64$CL6 /<5)FA&<RQC& <NHP2"0#SQ
MD*2/4 GX&N@'NG&9!E]YCJ=":T*F>=);.M,-&$L"UFQ2M2G#W0Y(L4I$6!8X
M.6BERBF=1SQ(+WNY+S>DN*DV\X(!ADYVXPC$'>JNH! (R596QWP>14">$@D2
MQ\;LY8#&UBK$@D' 92,]N.]>@'LW*CH&H6570*E'0]^'452R9N?BX3=H'0^,
M-MV#:E"A79-'MC@$:V$E[6_?P/1Z??!O:08)@SKX;EH_Z0*I;9P3YL XX![^
MA]#031%4;Q$ D&4W,%W#CW<D9[CMZCUJH0G5.86912*YT>AV!8,/\XC4PEOK
MTJH.O[9&)^.%: D7]CP_NY@9'Q-WU O8EC.^W]F^TI<-#*N-T4BY;:-R,,M_
M9&1RW!X[UD)8VSMD1L#<<.IPO'F.#VY'/;D51!^]<-,#,D!.S\H* CG!FI X
M?HE0?#!<,6<T(V82W,*9&64Y&22!TO+0IY<>:EO2MBOZ;R]GN,@>!-D]AX3Y
M.,9P-O.,CZCUK'QX""1-%@=SXB8&<XR<_'!^A]*]S_9^/"G/1A/5^:CR0\UJ
MMD1[]ZJ[1S%B42^$F!>$<E$OMS.S!21-1:V]';)&?8]A[5EQ"8\"<C/@RXV[
ML^&^-N =V<>[@@Y[8(J?&ASCQ8\[MN-ZYW9(VXS[V01COD&JK/=)YU5M&[L]
M^I=<U&N.LR.YVTP<1[@ZPW O/M&?$#A_=7&6;36'74/^HIMNQP*UZTF7C]D0
ML4KXV1R/GD;49L^\., YY1_^5O[)Q+21KG<Z+CON91CW3SD\<,O_ #+ZBJ5'
M]BY=(0Y4^F^54&(#EK%"$&R\Y&Q#+9U7D[3%2V]JD21M;%2[2;4:&9K?NI\1
M!R$P&Z]&C.DHDP2A@OAN6*JP"J6X<(5[ \_O$!'<,P4\G%0)8R"=Z@ LO) Y
M4NI[GME'(/Q"DC@56H+H5!M$AN(K-XI]BE=10\[N,@K+"R\AJ$+;">%F/<X\
MT@GX62U)1SH\A[/W1YN0!6V\I);&W,6BD0;GC=5SMRR,HW#.1D@#(P>._!]*
ME9(V.%=&. V%8$[3@@X!['(P>W(]:O#,*SIBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4K$M7A=QAK4A\+3:X-<S2J9S^<7%SS>M3%8IM
M(M_.$"E,'1YPC!MCI5TD82RRT:.!*$^X0LI&%Q,U'(DG-SVZ?C.QL.\BY7W7
M>1)<@@@X22,,BG*C+ @J<5J^QP\XW+E$1L-W5$>/!R#[R.58C!.%((89JYJK
MXO<YIES5?()Z89L6Y$Z62:2)3C3&3SR'675C3)-2<L0HR*L[NC(C1YEJ+77?
M7-("?N+Y5J?Q>[ED3PVV[<!< R $#GE0^T^?]YG;G=P#L 09+;1H^]2V[).<
M(3D_,H6'E\F,XV\XW>:O?>_'"B]$>N#5@D[9JNWUY<I;*:!*A#5R6M.J>-10
MK>YZ\4_.L3,77HZ'3'@C3;-6;EX.(LCU=(L0GQ1<1W4D6PJ$W1\(Y!+!-YD*
M>]MVEB<G;OPQ4.%.*E[=)-^XMMDY= 0%+; @?MNW!0,#=MR Q4L,U9AOAKR:
M2G#K5($V(VWR@LIJ2MI3-+?L14U):N3:+.Q(N4U2X>5CAKY80A8^ 1$U4H)T
M0::KDL@-GT9B^F50@VB,$8C!DV;1X?D(\3S*3&I);+@@E67-8&SB+%SN+D'+
MD(6).\;L[." [#"X4C@J:N&*\6^=0[XGNDC<?A8!14D'7W9D3<,S,R'/FN82
M$TIM$4V<2>741@Q/08>0$$4,LV+# ?D9A4CBUW*P.1'D@*6VG=M$AE"]\ !R
M3P 3G#$X7&0M8QC!? Y"[N ?#\,GMG)0 <D@8R,$MF@Z\-./.;BT'*MDD'!3
M\7/P<<9-L:$B5QMKL=X<C1U!QHAA$9*6JV3TM):D2S3]^^-1P4@%$Q\: )E[
M=/SC8"RE6(7ELHL>3DD A$4#  XR0223C['"<9W$*P906X4AF?C &<LS$YSW
MP,  "X+;XQTR\\S%Y59[/?92O#DO./$D2D$N0/ <IIU"9A36%UM4 J-!KIJ-
M1RQX,:4"G0 +8Q))M;3LT_BET\<IF5(PV/[+8!WB0L/-NR6'.6(*DIC9A1D]
MLCQ>$S2%?B<KEAL*;2-NW&WMA00P#YWY8]17BY1B9:)GD62^B2]8W:6Z08-+
MP^TT8&XS(LS.1U?!)KQ,80P0MHV/258PI^53%RQ0BY%S8, [#!=R!2NV,JVS
MQ 5/[PHI52QW9XX.%*C<H..6W#;(2&W2!EW;#D>0.<L%!4@YY&6#'!QGA<>Y
MSC,?:N:U_G3ERND1!4FRMMQ"XS=/*>*B:4Z?"5RNSP-BI\]7K%! M, 2'NLS
M"&/OS$7&23Y2WPV]Y'CE)6EV1LTB^;.\ ,X#,RE'5E8\C*L!M)&.:>"&B6/>
MX"-QC:3B,E54AE9648!P5/F /PJO"<*J+!-E,-D;)-%V>6I$B21*G@J=!#YU
M?I;IE1@ -@18&EQ$;;9^=,4[)ZDILP64=CC)E\(2,9 Q-PY"@!5""0# /)EC
M$3L<D\E%48&%&,A02<Y"!/,26)<H221D"-S(BC"C@,S=\G!P3@#&"'DCS2#Y
M[U#Q@H5-.G8*/Z7986M666$D4*G_ ()0KUX\OP(<:8^,Z*"O1]=@Y$HY "Y%
M9,?[(<L8$Z4#.]&UE:2*[D<*QB1G0%?+NDCNMQ(^/#L ,X&>V0"-&YC6.2VC
M0LHD958@^;;');E0#\.54DXSQWP6!Z?-OE%/XOS1V>YL,369'JM_W4K3L-]&
MQ- 3?(^L5DPZ. 6RH(>9U43B:BS)OCE/(@41+*].&5FJFPBPF>>8+*0XACWI
MGU6>%P">Y7>-Y7(&[)_K.&7L20Q$QY4ROL;!^#0RJ2!VW;"5!.3C'Q52N;5]
M\:.:](O3'0+,T<7,,AQD;L-\6L2L.Y&A%H+/#2%8:W-.!+GU!PK,G*1A(,X(
MQ @HKDI J.L"YK0CNI8H_#3 7S<Y<-DC Y5USMRV 05.X[@V%V[DEM'*^]\D
MX QY2N <GAE.-V%R1A@%&TKEMU@[\).0;"8!]\LZV C"3XT<INDR,3%E/QS,
M,RN.J\G2C:>,V'"KF@6A=5Y0I1MIL-KE6)&\$A6<"SV^8'.$' !QX@)YSRXD
M#G)VG.[("*BXC!0X>Q0XV^;&20/(0#C'"E"@P-PQMP2S.<OAA?,'XST&MPU^
MK\%)VV*A[[!L5U0(,I'"M5.(8L]XN>@JHIB';<98=LW1+5(OLSZ[ P\.:S!K
M:W7 QHANMKJ1FC9@A:-BV2"=Y*1IE\L<^2)!Y=IXW>\=U9K;HH=5+ .H7 (&
MP!G?"<?VI&/FW#G'N@"NB@>+O.N;3!DU63;.*3(5^SU\UI@N&AVB46V<7/R4
M@X]68&!/]Z"-==36P=&ZK]2;?+<K$)$FG'%DI+J250KA2 RL.&;W%V@8=F&"
M/>.-S\;V8 "B6L<9)4L,JRD @#SG<3Y54Y!SM&=J9.U0235M0_AQS6"CKC&1
MEBOPC/0X5R#O:QI&LAKM0K55.J<,_(M@5,44<N %E924$=B1HY$S.2)4A<&K
M-Z6F6LS>RL48K'F)@T?#'8=X=L9<G#$ ').% ";*Q%G&H<!I!X@Q)@J-_E*@
MG"C!7)(*XRQ)?=7KD/#KC<BAY;HDQN07J%>&D2W(2=2!*1"984B=%@;- S=1
M<E[##R8L#9'SJZ8/)1=:IWJBCR%4A#Q O9Q\5QYL@;ER&VG:61E?:K+N4!AA
MF?X.P(VD)Y.<X7!.UL%=PR%92F65MK$J<A4^* B\9[QWH\V_%.#GV:N#0U=H
M==!C*V?' QC;?*SYR6YC(*%)B#O6+HTO8I.4B0O::K\@7L+5DA)T:,CAQ:UN
M9%W9".6:1BS@D_O@JRC(8?TBJ 3[P&=C*22<VMT;&"RX5% 4@#$98QG!!]PL
M2![IXW*V!BW6?$_F# Q;;15K2=(W4CHDE,;E@E2,A<SYKF=CF)LA"XE48A<U
M.<JKDD<$+'#QC3I,PQ&A1X10HP.7MDN1PF @C"X. @6554<Y\JS.H));&,DG
M).(M8@."V2Y<G(R6+1LQ/&/,T2D@ #D@  X'NC/%_FT3,0TL,_9U(KSE9*A8
MIZ5%5&1\E6&N8C,2C:41K9[Q4F)Q^ABR;11Y$?IN,,<BP8PF9EGS#7<K!@0F
M6WAF .2'\7([[>/'DP0 >1DD 8D6T8((W>7:57=P"OA\]L\^%'G)(X. -S9D
M"6Y#S^4BK/&,U\*#=MC7HE9> '%CYG9;9S<J')ME^[O-K. EV6)4;9@Y8BS&
M$>^"E#J=8<J$T@*$L6V>ZK$E0,8(QG@$<'&..Q'%9F&,A@%"[N[+PV<Y!SSR
M#@C.>>X-17$^)O.8:61."35W5*D7C?0; 8]*PZE6R?5=*;T16IMI%?;8'!W<
MZ'7YO0U=:@5(VV;&H>3#R!4<Y<UY*R[2L>!'X:C#>1?#>+R^;).R1E\V[N#C
M(!JL6L8.[<^=^]B2OF;>DGF\O WQJV%V]L=CBJ]8O&RA6&5$L"9"U0=AC9:[
MS,7-PLD DR..Z*DX>VJ8'E8F5C'42,7*RT,TDV/+V %)/$ *&EAX^3"P6ZD4
M%<*RE8U*L#@B+&SD$'@A6X(R1SE209:VC8[LLK N0RD9!DSOP"".02.0< \8
M."/A[QHYXNKU*GC$6*.A*/>9>^5A(9<5N1AS9R;DK!(1<;,EPQ<O%@K.ECVV
M)6)- N(8!#T<):60R"67Y%U+O>0[2TD:QMD-@A5"@E0P5CA02K H2,E,@8DV
M\>U4RP5'+KR,@L22 2I(') ((< D!L$U P'B9S"J](I//*\38H2I:YY:YTJ.
M@U5JO$2#E.M_ $TL4Z8KU8B9IS=4(IU<.CYQJ09MT@9'>M8['.,F'L%;!O)G
MC>1@K/XB*"V]@-Z7.\@,Y'G$C@KC8 ?*BD C7%K$LB1+E4\-V(7:I)1[?9EE
M4-Y=BD-G><>9CS4D1WAERF,B;5%BR=QUNZDU4FRF;*K*/BWS1#G@ 1SH1BJ,
MU,P0X>R2CDL.972&RY/8D\C3$^")*,UF^F+(Q$?[L.%&&XWE22&W[P05&"'!
M RON$K5HLX@& +^?86/EYV;L979L.=QSE3DX;WAFJU3?$OE%'N%;NT2U*ER]
M4'2)#_&F:O*[%'9<N18;8\H36=V*.T'*=#N\MK<1-QRCB["Z-+;D8F+@8V)P
M>\FD1HVP%?WMN\9/D!)4/M.1'&O*G 7*X8L6E+6)'5QG<O SM/\ ;^.W<.9'
M/##);!R H'IE?%?F4H)8!/>+0!JTRMJD)]X"6$T_(!7D:SA7"OJ67&&('AIX
M&VRXCRA&QYF/3[H3"R\8>*V9@7<HVGR':$"Y!X,>S8_!'F4HIY\IY#*1Q4FU
MC.?>&XN3@CD.&#KR#PP8CCD=P0>:NVN<'H57FHN>BVI7WZ(>V\+[Q(:=8VM4
M38X56GFM,(]HE05IE?3KUD[]LIAWT^EK>EX-<2,I4[<'O@<]T;U]47]:R6"-
M6##.1GX^H8<_P8U'!OA]S23KQM3E)[H$E792KU^ER\45.17L).KTD$P+G4.Z
MZS ,DA,<_5(&GP;T0_&ER\F2\==R+:\XO:K1>RA@X6,,':0,%.0[D&5O>P?%
MP VX$ <1A*K-I&5V$R%2JH1N'*H"(P<*"/#R2N",GE]^3FX)3Q<YC,2UAECE
M61:K/#VZ%E VY9AH3;-TENH3$P4,I &CAC4E=>N* G&S=,CL.QVE,.N@)=<Q
M%W*%51M\A0J<9/D$*@<G!&($SQGOS@XK(VL1+$[O.'!&[CSF4L>V0?WK_'&,
M<<5W*\9>=D5BYU>2*L\JST&8@[!;Y4R3":EI>;@;T;T4>1]:-BP(T%9-ED"'
M2A8V,#CT@^S "##':;2F/:I0Z. @\,,J  D*K1B(CDDG" 8)).>233V:/:ZG
M<?$(9R2,E@YDSP !YB>  ,<  54+'X[<_LU:D:J8Y/BQDI-2TX8H&1&04LB=
MY9(<;EQD+*CRVD!FT24/ 4E+'O YA'Q(,D<MIA;4+<R*X<;20JKR.,+*)U/!
M'(D4'TQP1BLFMXV4J=V"Q8X/?=$82.W;8<?GSWJBN>+/,U7&+O3#UD"GXNX'
MW5H@4^.TMR2E+Y)=&D0TFOQ#\M'1,A894IB3#@Y**7+U];E9ER#X(R1!-R]K
MEV-&=I5D"8(.,+&(@<!@I8*H(+!MK>=0& (Q]FCWAQN#!R^01W+F0C)!(4L>
M0I&5\IRI(/FL?BGSFRS=HGRI6WQY=KF7I\UF'.@HX(>6(JUWJ;Y[0[==5\1D
M'0;[+$:E;$N<EV' (&,&/8K<4U!+)>2HJ* A"*%&X,20'C<#.[@9C7A=J\L2
M-QW5#6L;,S$L"YR0"H&=KIG&WDXD;ELGL,[1MJ#>]^/-/YUR*_62$G+F1)RU
MC^-%N'RX"%(Z%U:ZUFO3W5@"HF(BI")OL2P5'R-3=BC0ZO7IJNP<D+5U/,GZ
MD-BWN7EFB5E0!5VC /\ 10H[+"<L08VP0^?.RLP+XQBF>W1(9"&?+-DY(_I)
M756E!"@B09!0@A595.W@YR2GN.USH%3(H\A)3L+"UB=.#J7S;7"QS]5AG^>G
M<[)@8A!$(<"J+?I]HLD3KXH%)2 >IETR./". AB8W56=HW\0!69E!?=N(=O$
M$NYO,#G>JGRD [<$$%@=AH5D382P56(7;M&U=AC*C*D8*,PY!(SD$$#%BO>&
M_,W9*QS#=BZ$+*V:3;D39(::A$G-MCM=2:#BDEN5IT@^)!UUZTLC#SKDN[\*
M&@:R^0_4XI,"]8+Z4!1LB(5< %6Q_HLMC?PQ\%"2,>8LX =MU5^QQY9MTF6.
M2<KZ2 #W<D#Q6][)P%4DJ-M4B0X54P+]Q?F ,E8 ZC$\Y[[-%!"N08RI]!W7
M>!W Z%E=,0+8X<&5.&;=4+6AJ^0,(PQ' EB ^V8>R%P[1SS$*7,MLH)W';B"
MY0,,MRP4<%RW))()P0,"!X8P6"+'.2!M&X&6!RI\O"EN^W:<< @54W?"KBJ]
M&^P"-'<,KE2KOO3L719DX=-+B.=P$/*-R%DI<T<^;J$Y93 7 #R#:TR['.3,
M=  6$EV7WC[=/QD@X9VQF10?$,K,,+(H W3.<@!N=I8J-M/8X>>#RJ+G;&Q\
M@C4'+(QSMB08)V\;@H;FNP#PMXK'CRXK0L\ZB8U9M/ED&1;L[ZUSK'1ZQ:W3
M;9\%U;K(3-M=5MTL^9<9ZQEB2Y 2HM\"-";C=C?3DJ<KY=F!@[?W;Q.@";MB
M!?!10$505!R"3FI%G" 1AO-NSDC=YUD5R7QO8MXKDEV8YQC &*]!'AUR0BQE
M6S:IQ%@=L[UW E?8U!^3@[HBVRUPA;)#3!E2)F1GJV?+O!1D(_(E50^,88:L
M]?L):S#2WMLVT)Y=H3PR,R ,FQ8V4J'"^8+DL '#$[&48 >R1;MWFW;MX/DR
MK[RX8'9GRDX"DE"/>5CDFK6CQ7YW;X'G=:FY6XOQ/-FVM13&I.)7N4)8LM:M
MK$E+^\01"&I=F:JP*D2E?1 G?#C9F&4^J'EC 7,4NY4:5U"!I>YP> 4>,A<,
M/*5<Y5MPR%;&Y0:E[6-UC5BY$6,<CDAE8%O+[P90<KM."1[I(JIPWC-RZ!L=
MNM$< 0W*76FE4B8>V/ >]IB#ZY3:K(J&G&X)NS^T.AZ!5&W0BYPN#'*B_?@(
M@,LHQU^&NI61$)R(W\11EL;@SN,KNV<-(_(4,0<%B *D6T09W Y="C'"YP51
M#AMN[E47C=M&,@ DU;EN\/N.71L-$P'*.+CSY62!6]\ F6!RIR,DH.55N)LU
M?G8(KWF%F)6-;4=%%. (-V=&N!RXL?(B9)>SQYVD<@ ^\I(4JP\R,K<,JG@@
M'&#D$@P]I$^,@\$D9VM@D%2<.K*?*2.0<=Q@\UQ'>'_)H^7M\W[:U&&W.%EJ
MY(J+E([6QH*6.LAVX\5\2&$-*5'[M4F%&2,X5,2X\6S%Q:Y!X&*!89DWLQ5%
MP@$;!AA3RP"#)!8CG8"0H SDX&34"TBRY\Q+@J<D< DG PHSC) +9(&!G  J
MZ;YXV\[Z#.V&QRJ[ !+6@: %EE1DB*N.?;A$/C$J<@9F.F( ERS1J8&+M.SX
MLS4J)2:&\E(TC3X0\7".ZEC55&TA"Q7(((W<CS*58;#N*8(P9)!R'8'-[>.1
MF8[@6"@X(QY<_P!5@5)8;0V0<A(^Q12(\7X1\<<B(BO**N#D!"%,RX4*3)0A
M\:JSA2M]F(FTG#R-=+^)2$27T>Q)8B3U$U$\?W ><K4LV,O3U@OYP2V$W,-I
M;# ["L:E!AA@$1+YAAP<E6'&*_8H<!?/M7D+D$;@7(<@J<D&1N#E2, J<5)/
M-O':@<IM!%LJ6Y(,XRN*KIP# ];AX4_VSL(05-'QE9KL"P9,/$03#HFR-N1=
M>U(3S%5BX$6P3#!E4MS),@1\$!MP)+L1PP"@NS87S'./,V%+EBJXLCMTB;<N
M02NTCRA3VR2%503Y>,\+EMH7<V9XS7J^F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
$Q2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g743471g36i06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g36i06.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( "T A0,!$0 "$0$#$0'_Q  =   " @,! 0$
M           ("0 *! 8' @4!_\0 ,Q   @(" 0,$ @(! 0<%     P0"!0$&
M!P@1$@ )$Q05(18B05$7)#$R-G6T-U-Q=[;_Q  = 0 !!0$! 0$
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M<N9XU+!@.<*"2I48YL#\) &?@02>AVYZ?:14\"1N4@DQLQZ$,<E<GL0Q)&<
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)10JJ   !M__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g743471g40l24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g40l24.jpg
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MB<QB(D45):XBXJT/A;1;KB#6;Z*VTRU'FG!YG-D928X( F[FS2D%8T4]>Y(
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M;K1[.YU;A34)=<L[.$W%WI]Q'''J<,"=9IX6B(AO8X1@LB113[<E4?:PK9\
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M6$R-&>:3,H! !SHML5HO&390\Q>;;/VF25.<_M,[*NY'RO-'J,FT276419(
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M;<5P[V/_ (7'\57O]);5O\U\LU]2TTI32E-*4TI32E-*4TI32E-*4TI6L;Q
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M'L'TMQQ@  @]?C6L3=+-66G8Q;9)K"<\]=8FR)0<BKQ,$=TW=V>MPUH9L;7
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M(\AVX_TAJ'M^)UBN(E+ %R00" >A&.G0GJ?ABHB/B%1,B<_$C' 7=@GZO?\
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MZ8W9STJKFQ&3E<V/FXW<O>O,V_PMF=V/CC%2$<Y$R'44,4B:93'.<X@4A"%
M3&,8P\ 4I2@(F$1   !$>VK0!)  )). !U))[ #U)JLD $D@ #))Z  =R3Z
M5%^7Z!'YBQ7<<?+NB)L[E7G+%"12^_IM7*J97,3)D A@!PDTD$F;WH*;A=-+
MH 1 ^M:XOX=BXKX<UKAJZ/)35K&YLV9U.89NAAD91U^9N5C9AD'"D#K4YPQK
MTO#FOZ/K]L.:^FWD%WM5@.=#DK-&K=0.= TB!L$><'!%>7B^8UO>#[@]J&08
M%W#2+190C9RHDH:+F&A#]*<G!OA(5%^P7#I,DLD8#$Y%%R1!R11%/\E^.> N
M(N#]4FTK7+*:VNDDE6.7DRFUOHXA@75G<%=LT,R;91@9C+F.0JRL!^A^A<0Z
M3QGI<>JZ)>1W4+JI> 21"[M&DZ<BZMP_,A>$@Q]0>:J"5"5<558_([>OM =$
M3!TZ  !JW*H4H**]Q #FX-Y:1..HYNDQ@   I3&$-<FN>&GU&8K*YB5<$MCJ
MH.<X&<'(&,]"#U'>L2ZX9DOYV#N8U)!9O<#T/N!R/MZ9 JRY67G[O-GGW*;%
M@[4*0@^ZF1&9%0)^"=<2 99XN4.DAG+LZJXI@1/S/+(F0D_#!8Z-:I9(9IK=
M#EEFF:49'?86&44D^5%RH/85-0VMCHEJ;.-YI;=<-(MQ,94#8P>5N&8U]R@D
M?75.L1I])1BPF9!TX9GY<MD53F(CYA!,@)P3[$,H1,X\&$#"!%! !^(PZRK'
MY/9;FXM+:-)& CD=<%P"=RL&QT.Y<''<558KIC>)N+2WB5L!'8*-WFRP"N &
M0Y'7!]U7Y3H9JZ$A5#% !Z?7CD0$WSX'N'IZ^O/';GOKNLWMQ DCB1LC##;W
MZN =HS]>?@?JJ%UB_N( <2,3WW '(P0>@ZCKZ^X&KFRMC9G#59A:6CAJ!B/D
MD%F_6 +*$<%/W*00$1%(P ?GL''8.#"&HOA3B*>_U.?3YHY"'MW>.1B<(8R>
MO4=R.F >GVU@<*\0SWVJS:;+'*0]N\BR/G:FW/88P&)'7MT/OZ58=0M45'F2
M.[X$J?2)BJ?+CYE 1#GMSSWX#G@.VM@U72[J\WI Q(V_3SC'QR,YQ\>^?A6P
M:QIEW>;A;-O'<DY S@^H!^'<]![JN'(URB[PSB8N(AT4!8+&6<21.H%7(BF"
M94OL$A1Y.)@ 3<^@CWU&\.Z+<Z')/=7=VTIN,I'"22!M]=NX]^X]XJ'X=TJ[
MT26XN[N\:7Q!*QV[,3C;Y<A2>W]GO[1XC5%E$P^$1#CGDH&]1YX]/3\X?F_(
M.QR:IYRLA7;]2]<>A&%QW/\ O!K8CJ@W,CE"N/4*<]1^3]/PJL1\E:J<<CAB
M]55;)?$JR="HLV.4/4I2J&ZD3"'H= 4S=7'4)B\E'$FM-)UB,P7$2H64HLL.
M%?<^0I?&3)@MC&#D=.]85S::/JBLLT0C?!59(<*=Q& 7R5#@9[%D! P6 ZUF
MOB:C;F-P-;(ZQS7(:,J#]9:.6MT],1[9BBNU4\EXF"" O9I51 X"!P1BQ,8!
M(;X2'#C?. /N5^(N//":SI-O:C2/$RPKJ6H7<<-O&\,Q2?YN(S7+LJ"-@G(4
ML6QNVX-<EXGU3V><%:@T>MWUS=:I:H)HM,L+*66X^=4/'O>1H;5%D4#SFX8+
MCHI/2MGVUS9A5=ORZ]PFY4;SE*3:F;O+,Y:^SL(5LN >TQU:8J*+*-DU@ $G
M4DY.9\]2+T%(Q;JJLQ_1SV1>PO0/9=#XSG_*_$,D(@?4I(>7#9PGK);Z9"Y=
MH$E.!/,S&6=55=L2Y4\!]H/M6U7C:*/2;>!=(X<MI!)#IL+!I+J2/I%/J$RJ
MG.=!EDBQRHI&=UW,0PS8UW2N45BSNZVK5G>+CBMX?OUHLL'C1'*%!O\ D.O5
M:0DX)]DJ!Q]*&LT907=H@I:%L=5BWEP95BPNIVLR+.P-U*VW1C'K!9P+UO(:
M;J$FF3R7,,<;SFWFAA>0*X@>9=C3"-U9)&$9= K@H0YW!AT.+=VJW<:PR,PB
MYB/(JD@R+&=PC+*0R@N%8LI#>48([UAA$>$M5L;V].V8#S]D[%1H+.%RS=C^
M/L!%,XFILIF3#S;$.X&+6G\R3ULM-O-E(C%G?VTS:IN1?5._ ^D$R3<-*R$&
MO)MQ%)/'R[RS@N ]I%:S%/VIS%M;EKFS;9;)'''R-QA*QHHDAPOD=5<8@TI(
MW#P3RQ;9GF0-\_L,T(BG7=,SLW-P) S,2LF3U4E:@Z;\(:V8PKN!8W;WF247
ML5"NVP6(D[79X&L%/5J/LNC<^-FEW9PCP74=:)F?<YD3&6J2HLDUVD:*$9*,
MEUQ>M<I>(X[A[MKRV4)+#K!6.-I/G)=4:T)B+##1J@MCMDZX+>93C!LG26B6
M!;>8[HWL5+,J^5+/GX?!R&+<[!3IT'1@3D2"_P#!MKJE6F:[$[E<BPSG,&+<
MEX<W5S1:/C^0<YPI67LY9!W WGZMLWC$['#<ZO<\KY#BH23KJ,VVB*I.,V*L
M9(S<'&V%.T.)GYBNUC"PMKB"YT]>;,HM9;:TALXMY!S<H(K>%G5]A:1"0RHS
M(:SI"[6 N9 9HI(;D[$/.26:2=]H(Q"=\L@4KNPK8(9@&$K/-@4KC>&W(1M/
MO5ORQ@K+R6XBTJ;-GC/'5686NY;DX])MD2)E<W6"+D[ %;.\7FY6H,%THP]>
M?S*A9>:L4;'QT<AC#6%G:R:6*.WN[;P4?RF#-(8XK$GDLMJA5-^W8LI!8.$&
MU48LQN&P:-;D([2PS>)?PA$:AWN1\X#,P+;<EB@Z;2QR6  $"XI\()X\VQ;=
M<=9MS#.)Y5A<?[I(3<_.P+:/LJ^7)'>O3FU9S0R0M$HC'N(R4JT:QK];HMR;
M12I$(>K,4UZZHBLD1KF7'$@%_>SVMLOAVFL'T]6)C\,NER%[4\L;@RR,SR31
M$C+2$AQZV8M))MK>.>9N:([I;E@ W.-ZH$PW'&"@"JCX^BHRM9;[;?#QI^#,
M+YVP[:+X]R0CN#KI:1>+)'TZNX[D?J6VQL&+V,<W/$FF)1],IPJ\K).)V?G)
M@J4M*K(U^,KM=:1U?:1U]K,EW=6ES'"(/!OS8D:5YUYIGY[,=VU54N% 1$3R
MKEV=RSG*M]/2"&>)GYGB%V2,$6,[!'R@.FXEMN3N9FZG"A5 4829G\+;,\)@
MO*$7C3*\QG;/MXQMM#PIB>Z3[>CX/:[?R[0[S;;MAG-#21K\?+.Y>6ILI.L7
M]J8L&;B<MBZ,HWARQD/+D@H>4M=?M6NX&GMUM+2*;4;JXB0RW1O/E****ZM2
MKLH5950B,DA8_+NW,N]L.;3)A!*L<K3SO':10NVR#D>#=WAFW*"25+ O@%FP
M0NT':)]B?"5H-4S!MHR90<LV*@1FVZGX-IL;$4ZI0%8N5KA,',W#5"N6+*-7
M<P$]:*-DL5S&R=5,G1V3#2*;B5;U28IZ<P\ZL-N(II+:^@FMDF:^DNY6:21Y
M(HWNR"72"0.L<L&!R)(&@QA3(LI45?&E(LMM)',T8MD@0!%5798 0%:5<,R2
M9^=202 C(0IDFK,N7@YPL]BJ$Q75]R-VI;#_ %-N?MK%[EDJ%4)]W<L8YWRQ
M]V1V#1O*K^35IR!M)"1XR;0T@:5K:KQDBG#2BS6;8W8N)62X>X>QBE/CK/4(
M5,TB"*>TM_##)4?.(\9SM.W:^#YERIH?20T:QK<.@\-/:N>6K%XIY>:<9/E9
M6 &1G*Y'0]1,-@\+G&EL<RQ+'D.UNX6Q;F\Y[CY^+91L;'.'RF>-J<]M1LE)
M;RA%5EF3.-JT^YL<;.E06?>]D6[55K[*3KUBIKT\879#&&2QM+)&+,P7PFH)
MJ*2[>@):1 C)D#:2<YJ\VFQL3ND8AKF>X8  9Y]J;5D!] $.X-U.[X5Q5_P[
M<A,*]M_C+/N]N=TD]LV:,.Y+Q0[D,38XB82(JF(L0Y!P@6C/8&#(Q<2DI=J/
MDJ<4M5V>3BATK"P@9*O5N$8LGD1)>OK,)DO&33HXA?VMS!< 7$S,TES<PW7.
M5WR%6*:!.7$$^@75W<D,/%T^0+ &NW<VTT,D68HPH2&*2'857!)=)&W.6[A2
MJ@#!B&*\&BHP%.:8U@MP^0(S'-OQIB'$VX:M%IU-=NLRU#!N5;ME6A!#V!^D
MZE,5RYGM_L-9LDA7CRB,M756RK!E"6-JE/ADMQ-(TAF>RA::.>YN+*3FR 6T
MEW;Q6\V]!A;A<1(\8?:5<'+,AV5:&CHJ"-;B01O'#%<+M0F5897E3:QR8CF1
ME8KG*XQAO-646*?#_JF*LEXFR4PR%/2KW%&2M\.264:YA8ULWFGN]W(J&0[)
M&O7"+@ZR#>B.FY(N#72*=65:@59^5!0H$U@7&KR7$%Q 855;B#2H"0S$J-*@
MY$; $8)E'F<= I[5DQ6"12Q2B1B8Y+V3&  QO9!(P/\ V,87WCO6P/4/6?32
ME-*5'6)/ZVU._>9'_MJ:E]>^_.H_RE_ZJB="^]&G_P G7])J1=1%2U-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*
M4TI6H;%&[O'>//$4WZX0S3GAK7I6S9.VH0.WS&UVMDEY+I2U;=,?(2,7C.!?
MK+1[$D_>I8#23>#1:I2%C?J.7I57RZBIMCN--GGT;2+JUM"ZQV^H/>3Q(N1R
M[V<AIW&&.R%?*7SA  .@Q43%=QQZA?0SSA2TEJMO&[GKNMTR(E/0;G/7:!EC
MUZUI/V\4C?AN^B\=5C&&4\J-<B,O#WV>VN.S3=]Y^Y;$[7#=_M&7-QB5BR6Z
MQ;28RTUK<G9I^'JD='SU:R>K%M3M(2&9N9)9I*+BSVB\ETG33-)<6\!A.LZG
M&;6+2[&X-U"EO9%(!<2M')8QHTC,DEN&.78A<J,Q%NE[=K$D4LHD&GV;\U[R
MXBY4CRW&Z4Q(KK<,P0!EEV]%49P>DZ77*D(.ZF(KF[C<CG#'. 1WE^*?!2,Q
M#;A,Z89:@-,JVT)7$4(UF\6W2LS/NN!D9JU+T>IHNG$"W=2LRE'1*OMKQ-;%
MBMV^3W?3K*TGO/DSA]U5K.TN2>:VHBZ?9<12+N<)&)I,!SM7<W05=DE'BE2Z
MN9XX/%ZFI*W$\/5%L^2H,3J<*6?8G5<EL+U-;S_#4L>8+;L>P!8,[.[A)Y$D
M*_8O,F<ALW3&^V"DM;U:F6)[+=6[]JRD?K79,4-J5/6!>3:MY5W*R+MW)IE?
MKN-:IKB6T>JWB6@B6$.GD@(,*2F&,W$<1!(Y:7!E1-I*A5 '0"IO3FF:R@:<
MN9"K>:08D9.8XB9P0#O:+8S9&<DYZYJ2-YWXL.7O[GV7\OQ&IWV>?AGH'\K?
M]6GK6/:)^!>O_P EB_6[>M4/AM_C'?W@VC_.(?7<_:_^"/\ ZI9?S;BN'>Q_
M\+C^*KW^DMJZOTDK\06E?I.8]_5]EO6N?<U?\X%[_P!V-1_UAI-;Y[=_P+M?
MQ_8_J>I5@G]%W_JGWG_O#@C^4,LZWS[J7]S<%?Q^O_T>D5IWW/?[HXJ_B='_
M )^I5Z\M?(%?35:?=X7A82V\G*V=,J6[<CD''KZ?PY0<2[?(;&Z,*PA\?_42
MP&RVVL.1$IR$FY"VN5\_LJC>RI5*4H[XL51*U&*2ZKQHT>Q^R:;KZZ9;VEO'
M8PS!+F:XO&GWEYN<GABD)1D$8%FTD/SBRC=-(VW!(:)N]+-Y+/*]Q)&6ACBM
MQ'@"/EMS0S[E8MF<(_D*=(U&<C(L-[X6V8IO,#/($_ES"KV+=;GB[O+++)XD
MG299>9)L&V!YM[NE!CKR>X&9-L1MI);ZWU&)7@595NU480+YR4E<;/9:\-?M
MEMFA2WN@18'38U-PGAQ E^+R*9H>7DW)4<J5@^TD%E^F0M!TR5IA(TL.#=>+
M8\IN:7:VY#QB0OTB!\Z#;GLI^CDX\XG\)[/$9DD^-)V=QG$XBQS5O"IBU\R/
M<=K/\G7E_L8KD?,RRN#+ UN:3C'03]KJS6LV;ZTQ$B=C!6-RYA5)%8KQL[S+
MCB&T:#GHMPUQ-)Q PMA.%MXEU9V11=QF(B8I'(9$Y;@%T 8 8(QXM*G64HS1
M"%%TL<TQYE<V*J6Y+!_F]S+L;>#A6RN?6ZI+P3;Y.XYL&+)+.F.HB$KN&,J8
M.Q9<*/C";JN3+A!Y?W!8ZSE-6W<1:$[B^"Y6ZKEQVWB*VK MHY!Q9YV=O[E5
MD]>>Y26UXIA29)UM)V9[F"ZN(IKA9+>-[:SFM$CLH^6O*BDYY:0.6(C1(1D#
M=51T9S&T1GC55AD@B=(BLKK+<1SL]P^\[G7E@+M !9F<XSM%XW#P<+=-XD5P
M?#9KJK*C5/;UO'VU8J<25+D7-A8T#<IE[#>5*6XOKUK+-D;59L?I8[G*O9;(
M1-M)9 !]$VB543L"L\L_MQ\2Q+<"Z>UD,LE[IE]<!90$::QMKFWE$(()C28S
M)(D?58<-&OD"8K?2':$P"90BV]Y;Q$H=PCN98I$W^;SM'RRC-WDR&/FW9[^X
M7P>9S)F0<C9"QWDB@5-O9LZ6O)M<QE(UJ[0F/&59R!M)QAMEL\1+$QC<J5,A
M.-'N/%;8Q<P[II'2\)8)VG2K= )A:<:TV?$B00P0S032&.TC@DG62)IB\.HS
MW\;+SXI5V$3",AAN1D613Y=A]N-):6222.2--TS2+&5=8PKVD=LX/*=#N&S>
M"" 0Q4]\U(6&?"[NV$]VV-,X4_+E4@<:46.K*-AIL##Y/>2&15*SMJA=N[5&
M:A,EY3R;4:_8SH5Z$F7.7*B2&R#,5F'84.T&L*RDK<Y.S=:]%=Z=/:RVTCSR
MLY25W@"P[[Y[TE6@MX)'3+L@MI-T*.S31[/+$MR'3'ANHYDE58TV[E59"TFV
MV%N-PDED16PH)F0"1E C;/5SGGN?V^63/=9+$U_*=DI)VS=0AJ\D8AJ;8C"8
MQP)8FK(C266,8>A,BRC]^Q:D(54D*JOU*&D."^*K/A>\,]UHEGJ0=@1=L#\H
M6@ QFT>0O H'5F4112R9*FY5, 0'&G"MYQ/9B"TUN\TTHI!M%(^3[PYSBZ6,
M).2>BAFEEBC #"V9LDWY6L6SD378*+=9+OR3B-AHN/738O:T+--9FQ0;*IM1
M6JOFF:@HD;R#+<*BETBH'6)@"#N]6AN+NZN%TG3RDUS<2J'2Z60K),[JS[+_
M &ABI&55MH)QCITF;'2+BVL[6"35=1+Q6UO$Y62T90T4*(RH7LMQ7<"06RWQ
MZ];U=T*NS5<3K-P8MKXQ("_F*7.-AIE9R99954JBZ0QR+#S$"J%00.BS1,5%
M)(#"90#*&UK5]/TO7(Y8=2TG3;JVDP?!W-I'=VJLJA05CNS/YLC=DN2&)*LH
MP!LFF7FH:0R2V&IZA;7*;L7D%RUM='+%AF2U$ PN=H 4#:!NW').H_Q&-L%:
MJ5)IN0L4X^@J]$5R4E6=X2JL*W8F]BER,!B9:0(T3 QV;!VS69F5$/+;*2B0
MCT%5.)?C?[I'V8Z=IF@:5KW"?#UE86EA=7,>N_)ME&CB&Y,,EM>3;"9&@@EB
MD1@J,L:S#.U.@^HO81Q]?ZCK.JZ'Q)K-YJ%UJ-K%)HIU"Z:4"XM>:9K>+F;M
MTTZ/&0,Y<1'N0*U?5.19IF1 YB !..H#" >H\\CSQW^W[.W/R ?@+5K2Y8E0
MNT'.Y]R;1G/7:6ZJ?08Z=OA7T)JD$LT8,:NJOY02"0&]<@#MD>['?W5?^0)&
MBR54(@\6.A8&1S.(5=JEYYSJ' A%VCA'J ?9'92I]:QA3\A5%)0AC%*HW6U_
M0(=;LM88!/$:=.#%>K,7C1%))BEAP01*IR5(7!3*YP<U!:%!J]IJC")8Y[*?
M,%TD^](XE;S+-&5(S(I&%P,X/7H:AF'L[Z** @DH;IXX$I2_:' !R//'YN.W
MV#K=K[28)B<2HP;N2.OIV'3H?ATZGK6X7>D07!V\P8/J3@KUSC)_)TR*J;^Q
M3%Q\MLX4.9D@<HD0[=C@'83!P'/'/H(]O7D> XPX+&STI99UA1I2I =%5&\V
M 1N"ANO<]<'MG!Q6'#86FD S+%OE9CAUPIVD*I4MT)'0]LY!(QW%=&5K2C9I
M[4FF<?*X,8G C]ZY #F O]B41-P'/8!XY[<Y%E?!Y=C. '4@=SECC Z= 3[_
M $QWQ6;:Z@D\G+W]U; &<%O0>[U]:YJVJW,<A3G+^$7C\O8 '_'\OX^^K&H1
M2+\[M8J-V&7S%2,YZ*=P^)QCK6/>H5!)4;E9L$XZ'UPW;\AK(^IQ,?(&32$Z
M7!N Y,/'?@ $/L#MR("/V\CWUSC6-0N(BSH'V8^EG SC/0'!_(._YN?:E>S1
M*SA6R#\>PSV[9QCJ!G^SGRE4XNM0I7KAPW+YR8@F0%"B<0 !'D"@83>@^H@/
M(\  <@ :IX3U2[O]22$,Q6)AE_,1&V\,K.O<[<Y'3JHZ9R*L<+ZI<7U]R CL
M0ZL@)'G\PRI+84$GH%8C(]X.:VW^&]1+#2=NK=U86KEB>ZV>4N44R= 8BJ,(
M_:1L?'+&2./6F$BE&#)(=1"=;1VV4X^/7[(?<VZ#J6A>S6U.I+-&^K:C<ZM;
M039#16D\%I#"0A)*B<V[W R%+B7>1ELGYT]NVMV6L\=RK8R1SC2M.M=,NKJ-
MMZ7%["\\MQAOWW(,RVY.2,Q%02%&,_-=^KC--*5A/OAS1D#"=;VX2./)1K%.
M\B[V-I^%[4=U%Q\J5[C_ "KE>(JMTBT22+=P1DZD85VNW;RC0$I"/4,#ADX1
M7*4X2NDVL-T]\LREA!I6HW4>&9<36]NTD3':1D*P!*G*MV(-85[-) MN8R 9
M+VTA;(!S'+,J..O8E3T/<>E8(5GQB;G8*&\NH;-+&Y<6#;R.XC$-7J.5%[[8
MKM6XS</5MNEK862$K>)E[!65Z_-VQE>D4J9!Y6L$Y0F<@K'UCZWI(U!>5?AJ
M)91'\IH EYX.YDDMQ$D3M927L;([W(1]Z1&+YUK=$F(#2<OYRL%=7=HR_@V\
MUN;B%%EWLZK<+;L&58MRX9@XV+*S1Y(3?Y#=;'QA:N[QK9[XGB6/E'=-V=;L
M]U=ABJ]DV059MI7:GDJJ8ZF,3BK;<64NXQ$S:5+8RE@=W6@5"T5,"DBY_'A7
MJX>50>&I!,D7B&42:GIVGHSP+DKJ%O).MS\U<2Q,D?+*XBFDCD^DDV*N#5E,
M;2<H$K:7=RP60]&M)$C,7GB1PS[PV7C1D[-'FH6EO%!RICN]YRL%N0>6RE8P
MRIO@?05 B4ZA7TY''>V[P_L![GX.D2UF5J,G-@_6METM2;.SLSHO"J2:))EO
M,Q,>TB4\I= MYH;18B(Y;BWT@/,QD?;/?ZQ>6#RK&)%7:(XHR8SD>4["K$M5
M@ZE+').6&](I+QE0;%S'!807*H6V$YW.P##!Z^;< !6?^ ]\,_E>*W.A>L)A
MC*W;;*I1;\[KD?DEK?8^U4_)V(?NP4M0+"E4*O[CL@1:;F#M,*6(FHV$F&XG
MB+'9XY5)X:&O-*2V:QY5USX[V2:$.8#"8Y+>Y\-+Y#(^^/=AHWW(S*?,D; B
ML^"\:47.^'EO;*C[1() R21<U/-L7:V,JZX8*1E6<$&L-V_C(W) N"0F=EMW
M4>9BPEBO<[(0M!NEKRI.5C;_ )LMT73\=SS)O2<&OXN4R"NX/99NR4>U3./:
M_"P=>;IL<B3MFGF-:3DSPS'^W-NIQ8M;JXL%::*.W62\M(VDG0\V[#+"!L5)
M8UG=G<Y@2-#(</Y7?YC-F^9H(KHA'>4I;S,$C;R0$&3.XLC&-55>DC,P2NGE
M#Q;;"G7]WU7#%4Q@Z]8*KUHLE!5F)U\M?[K7:3GBM8@DK7'57(F$HO&DI S2
M$_&V&/G,9W?.M:81$VQ86.7K=F6;L">P<.IOTV3Q"W<-V\:3;$ AB>6TDN1&
M9(;IIU=2C(4GBM)&9"45T!:DFJMMNUY30R0!BF2=[A+A8"X62 1E3N5@T3SK
MM8!BK8%4C<9XOV3*56-[-9I&"(/'^5]O]'RU9,1CENT75HOD>+Q3E&N8XGKZ
MSK4AB6KTZT5I6&GU;]7 Q/EW*Z!D&\9 9 <422E3MV]5CPW!+)I3RW;S6]Y+
M;)<^&CB(@:X@>9(#(MS))')N7DN;BWM_WSP\Y5R:;G5I42]6. 1RP1S-"9FD
M',$4BQM(%,2HR%6YB\J67IA9.6QP)8R=XM;[$F8;1BFT[>V4HG5:+F=[*66D
MY9FK5',<LX(VJ2&Z2\XOEI=+"S+'T63W9#RE0C7!\B+Y.3<$CK18<+UZNR[1
M?6/!PZMQ;1W$=XR[Y;4!);9(V-M=Z@MA%<*INC,WF=9& @%O]*-+MW4BKLNJ
MF&9HGMP=J3$LDK.!+!:FZ>)CR1&/*"H^=,N1N:%5(-?4-XK5UEGC6@J[6&L;
MF^Y7_;'3<44AUG=D:CV)ANFP]DW-]-FKSDQ'%QUZ$\K=/Q!>6=L@XFCW\PV5
M"%BZQ)61M+C),C</Q*#+\H$VL4-]+<RBT/-1K"Y@M9$A@-P!,))+F(QLTL/D
M+LZH5P0U1R1'X4"=WMEB0S^1A<PRS*9).5F,JL,@=523S;0I;=D5BO\ BM/9
MW<-0\"I;8+N\,^>8%J^7K53K.ZRE&8LOFX".E'L"VCIW&%#MN*;?CZHF9,AN
M^0)?+= =,6$BO(0E/GBUZRMXFE^'PEE->&_B&!=R6T<L8MVN(K,J')2>:.XC
MFDR>5"MO,&90K2IOC+U+JF;A(/#.<F!)71C*(Y+@$J 8HWB:-,?.2-+&0#E4
M?:VW;_K6ZEJ:4II2FE*:4II2H,Q??Z''X_JK)_=JBR>M8LB#IH[LD,V=-ETU
M52J(KMUGI%454S )3IJ$*<I@$#  ZV;6]+U.75KZ2/3KZ2-YV9)$M+AT=6 *
MLK+&592.H()!'45K>BZIID6EV4<FHV,<B0A7C>[MT=&5F#*RM(&5@>A! (/0
MU?OW2\<?[_Z3_P!:H+_Q^HKY'U;_ "7J/_LKG_95)_+&D_Y4T[_WMM_M:?=+
MQQ_O_I/_ %J@O_'Z?(^K?Y+U'_V5S_LJ?+&D_P"5-._][;?[6N]&W>ES+Q*.
MB+?5Y607!04&,;/Q+YXL"29UE12:M7:JZ@)(IJ*J=!!Z$R'.;@I1$+<VFZA;
MQM+/87L$2XW2S6L\<:[B%7<[HJC+$*,GJ2 .I%7(=2T^XD6*"_LIY6SMBANH
M))&V@LVU$=F.%!8X'0 D] :\W'B"YE95;=)X@<8]W4YZQ;G6@;6]L]FV#XEQ
MIGC*U?1O>?9EAGE=W U_;Y6K I1LR&MMNA,5P5TB+)0[.V)#2)?:O8$7JSO6
MVZ-;-)8:.PT^SN+2:_ODU>YGM+=^59H;,!WO)$$MJ(XWN'B9)HSN7IN*XJ(O
MYE2ZOP;J:*>.UMWL8HYY5YEP1/Y5@4E)M[K$KJT;C:>H'>N++?B5[J=N[K+[
M%G#T2 E'^[W,E/L-YRE*25LQW3I?&FRS:OE"O8K8ERQN9Q'3J>KDR]7BV-(J
M,HEUCFHQE5LKB@8AN.1K!(/)"JWT/3[T6K%IG5=-MI4AMU6.>59]4O[=[@^'
ML+B67D11Q%FFB)W21\ZXC@0!?)M2NK<S "-2;J56DE)>-#'9VTBQ#FW,*)S'
M=\"-P,(VR)Y&)/=E_$?W)XKMN[-*^9JQC4KS-;BMK%1QIBBX8\BI]K@VL98V
M9P&;'[-U+V_<SA*DM:O)6)E.4V/N5GL\"VM&0*O>G5686>P6RLXRJ5*Z)8W$
M>G\FUN)(5L]0DGN(YV0W<EOJ;6H(6.QNY2ZH5E:*.-S'#)$)&1(WN)*FU&XB
M>ZWS1)(9[5(X7C#"%9K03'<6N8$VE@5#LZ;I$<J'+)$DBXC\17?QGS$>5LVX
M_@]O[1O@K9IM:W*S^)ON97Z<LN4K;E2FVN]94I55M'W7XI&GA%16.+-%TJ.>
MURV21K!889C,/EBPCHTU8N=%TBSN;>UG>\_;6IW]DEQSX42WBMY8XK>62/PS
M&7<TR-*RO&-B.5 W#;<BU"^GBEEC6W^8L[6Y:+ER%I6E1WE1&YH"8$;! 5<[
MF4,<*=TE[A=TV?<Z>$#NHW48\M3?$?UW=W^6VXV6M05NA+JAMK;Y)84:D61\
MX;7.&G87(62:FQE+M&6:%?Q/U:BK?7RH09Y&*76=V+/3[2TXDT_3YH_$\H0K
M>H[QO$;TP&65 #$R-#!(RQ,C!M[1/EP&P+EQ=3SZ3=74;\K?S&MV575_#B0)
M&Q\ZLLDB@N&!&U77RY&3 $IXGNX+ ^9\C;<Z&SHN?XW N(]RM0CZ5]4+5$91
MD,I;5]O<)?8)RO(V7=%FO-]HB<D6!A9/*>Y#H<(_MM?(5QCV]Y/>PDY:I'+7
M0K.[MH+V8RV9N[BQE,O,C-N(+^\>%P%2PM;5&@0IT@F98WZ310*ZHN.=3N(9
MI;>,)<""&Y0)L<2F6U@#J26NIYW65MPS)&"ZCYMY2&8UIQOZSQ8LB[,+#5=W
M>W7-%!?9TR[3KHYP?B&_TNAYHLYMIB&3J!M^).VK+5@K3W)#^WR,U1*FC4+?
M=D6][G*&XLE6)>J3-X_EJ1I%HD&IK)IM[;3+:6TD0N[F&66VC^43!->E([9)
M!"(U263F1Q?-+-LD,,JS+4;^=I+,I=V\R&>5',$,B1S-X3F1P!GE93(7)1-C
MN-[1[TYD;1F@TGQ6=W=[JU?:4FP[7<DVG(J^Q5NZNU2Q7DE*C[8,G[LL^M</
MWG;/F*O+9E?2EJR5BR(?)V8G_P!9L;6=,(N33M5(B4)&%5&N7A[3HI',R7\$
M<(U8B*2X@YM_!IUIXF*_MG\,%C@N&'+^A/'YE,<S%7JE-4NY$78UM(S^!RZ1
M2;+:2ZGY+VTR\XEY(P=WTHVZ'<@!6LK-N._7<!8_$,MNS7,TUB&Q,89+(D-$
M+8BHC8L@=WC6MTV36ME\3=[A[%DS$*=C7E)=PVCKM@X^/9E65KL!C[,%J<LS
MR5BC[W2+2/1H]3MDN4+F%F\1*=N)WE41PXLT@N=@503%=\Y-KO-;1A@J95O?
M3MJ#V<S1,%$@!BC'>-8R6?-PTL6XLQP\'+.46.5B"6W7:U>IFFE*:4II2FE*
M:4II2FE*:4II2FE*L'*^0(_$V+LDY4EF+R4BL:4&XY DXR.,@60D8^FUV1L;
MQBQ,Y.DV*\=MHU1NU,X430!=0@JG(GU&"];PFXN(+=2%:>:*%6;.%,KJ@)QU
MP"V3CKBJ)7$4<DI!(C1W('<A%+$#XG%8;8O\2?;ME:X5FK5Z>C%&4ILZ?[S+
M=9V=LJ<]#8QID/*4R.FZA>@@):1=Q%OATKB20?MU$ ;(M8B2Y4\TJ1#R<^AW
MMO')(Z,"NIKID<9CD1IY765DDBWJ T;<H@'.<LOQK#BU&WE9%4CS6AO&8,C"
M- 4!1]I)#C?G';H>M0,W\9C )-F4?O5G,;Y=KE-;YPK&$[[CZ2AHT^3,;N[6
MO%RD9:+#7VD@N5S$GQO8:UE!-G&+N)1S69YFFV;JOBJ(AE_L9O#J9TM)[9Y3
M:R74,RLW(G$896C1RH(;GH]OE@ '0D],58^6(/!^,:.94$RPR1E1S8RQ!#,H
M/4&-EE '4JPP,U?=G\3NN?79ICG#N#;WGFY3NXZQ;=*6PIESQ?!1=UDJSM9I
MV[=[=H6TW2UP-8)4W.-;<5.-6>RS9S(248N5JFHB[8'<68]"?E&>YNH;2)+%
M+V5I8KAVB634)-.$31Q1O)S!/'YL*0JL,]0V+C:DN\1PPR3NUPUN@1XE#E;9
M+HNKNZKMY;=,D$D''<9D? 'B&XPW#9%QCBZN4?(57N%^H.X>U6"%N3:OLI+%
MUKVPY<IF%<JXPNK>)G9E UJCKI<$RL'< \F*_(14<K)(2@I/&15K%YHT]E#/
M.\L,D44UG&CQ%RMQ'?VTMU;SQ%D7YMHHNH<*X9MI7(.+EO?Q7$D<2I(KO'.[
M*^W,36TRP2Q/M9AO#MTVDJ0,ANV8PO'BRX%QGFB*Q#?ZQ=*RVD=W5FV=NLA.
MO<RE/@;Q!XJQ)DN-M=@63?\ M<52; \S-4J4C*N42^Z9LZ[Z9(SAB^VADQ<.
MWD]JUS#)%(1IT>I"$;N:\3W%S"8T!7#2HMK)*5!\RX"Y;I5E]5MXIA#(KKFZ
M:T,AQL#B*&4,<'(1C.B9QT.2V%ZUS-/$XC;PWHL%@G;GE/->6+JPS[:W.-(F
MSXOI):7C;;WG:T;>K!>[?=\@6^O55DWM]_K*[2A0<>ZDYF7(HZ/(H0[:*?NT
MZ3H31&5[N]M[6WB-G&)VCN)>;/>6D=ZD,<4,3R$Q0R S.0JK@8W%@*J^4@X1
M8+>6:5_$-RPT2;([>=K=G=Y'51OD7$:@EF]0 ":V!XDR&7+&-*3D@M0NF/S7
M*OL9M:CY%AB5^]5-RZ3_ *+K]JATG3]NRF8MR59H[*S?OF*ITO:&+UVS50<*
M0]Q#X>>6#F13<IRHEA;?%(!V>-B 2K#!&0#Z$ Y%9T4G-C238\>]0=D@VNA]
M589(# ]#@D>H)&#42[SOQ8<O?W/LOY?B-;;[//PST#^5O^K3UI_M$_ O7_Y+
M%^MV]:H?#;_&._O!M'^<0^NY^U_\$?\ U2R_FW%<.]C_ .%Q_%5[_26U=7Z2
M5^(+2OTG,>_J^RWK7/N:O^<"]_[L:C_K#2:WSV[_ (%VOX_L?U/4JP3^B[_U
M3[S_ -X<$?RAEG6^?=2_N;@K^/U_^CTBM.^Y[_='%7\3H_\ /U*O7EKY KZ:
MII2FE*:4II2FE*:4II2FE*:4II2NL\9M)!HX8OVS=XR>(JM735TBDX;.6ZY!
M260706*=)9%8AA3424(8ARF$IBB \:MRQ13QO#-&DT4J-'+%(H>.2-QM='1@
M59&4D,I!!'0U7'))%(DL,CQ2Q.LD<L;%)(Y$(971QAE=2,JRD$'J.M82VOP[
M]L=HE%I9&L3547<J&57;5&?<14:<YAY'RHU=)\S9$^Q&/2:(A\D^=</UO[G+
MV6ZW>->OI%WILCY+II6HSVL#,S%F80/SXDSG&V-$0#.U1WKK.F>V_P!H6FVJ
M6GRE::@D:A4DU/3K:ZN% &T$S[8Y)&QW>4R.?5C6D#<)B1IBW/E[Q^V8OV,)
M$R#<]:))N%7CAW7G3-NM&O?:U2A[2"X'4\TZ72F1T5PET)BD8A?S\]K_  U'
MP#QCKO#]I;S66GVTZ2:9'+(TK3Z;+$CV]RTC^9VD)F5FRJ[HBJH,5]=<#\42
M\1<#:-J[W4,][/#*-3$$4<*17T<TB26Y1/H[$". 6+!95.?,*X66.!=L/-(@
M)B$( G$B?(  "4>>0#O\Q[?(-<(N>)(8Y!$92/G K]R1M<!B#VZ8/H<>ONJQ
M-Q&D=P(C)@\PJ_4]-K>8#S9&/C4?UA@#.;>1BY0(JT?G;G X"'P@H/280].#
MDX, _,H@//'&IS5;G?8Q31$%'B#(<GS#)ZG!'7OG&.F.GK4_JT_,T^*>,D*\
M0V?%=QZGODD@^X8&/KR"L-43;U92653(5 J0FZQ .D>P"' CP''(A_CXUH>F
M:P\^J);HQ.V5-@R=S,7$8!QTQEQD #R^N>HT'3]5W:K'!%(6=9!L4Y)? 9BN
M ?4*>P';\DV[9]AD9GC"I\A.[;-4FQRMJG4JRX39-92"=5^-%LQ*HZB%3,79
MU!F$)9,CAM+MR>4ETG04$H&U^A'LO^YZL/:'[/TUW4=0O-'U2[O[A-/FCCBN
M;.6QA,4;32VK&&8\R87*1,ET@"JA9'(.=<]H/MDGX,XP;1$TNPUNPMK"T?4(
M6EFM;B*_N%>8I#<*T\8"6[0,R26[DN6\Z@U*#7PRLO,7()M<TU$&0"/2X]P3
M)'A2<C\8,BN3)%,!>W3[<8.H>.L  .;EU]Q;J%Q,H;BK26MMV69].NA+CMD1
M[V0GUR90/LZUKDOM_P"&;F,FXX4U(RCJL8O+,PEO^LYBWX_\!Z>_M62>*/#N
MQ[5Y5C8LI6F6R_-1BR:[*/DFJ<33FZR8E%-16O>?)+R9TS@(@60DUF)_]L8&
M, &#L'L]^Y8X$X-ECO=39N([R-U>.-X(K73%97WH[VJM+).ZM@'FS\IE!5X6
M!(.@\1>V[6M1MIM.X<L+7A>RG!6>:V<S:I,K JZF[*0K#&ZG&(8!*A^C.3@C
M8BBBD@0J:)"IID*4A"$*!2E(0H%(0I2@!2E*4  I2@ % .   #7U B*@"H J
M@  * H 4!1@  #"@*        !7%"Q8EF)9B2222223DDD]22222>YZURZJK
MRFE*M"XT"DY";P#6\56#M;:JV^LW^MH3T<WD4H2[4R32F:G:HPCDAP:3E=ED
M$9&(D4@*X8O$B+H'(H4!U<BFEA+F*1XS)')"Y1BN^*5=LD;8[HZDJRGH1T-4
M/&DFT.JN$=9%W#.UT.Y&'N93U!]#UJ'7^SS:O*5IM3I+;YB5_5F5%>8R90#N
MDP;B,8T%]<(S(3BJLFJK0R;.(&^0L/<T4&P)"UM$3&SK4Z,FQ;.4LE=2OU<R
M+>7"R&43EQ*X8S"-H1(3GJW)=XLGO&S(?*2*M&TM64(;>(J$,878N!&7638!
MCH.8JO\ !P&'49JV)O81LJLE7J=*L.UO!\Y5*.WNC6JP4MCVO/V,0CD9P5]?
M@33=,U3.5+C)IH3-D7>G<KR\\V:3SU1:89M7R5Q-7U1)))4O[I9)3$9'69P6
M, VP]CTY2^2,# 5"4&%)%4M8V;*J-:P,J!PJF-2 ).LGI^_(!?/TF 8Y(!J]
M93:=MGFO?OO?!6,)'ZSJWM>P^V5"(7]\K9/Q]#8GR(K(];8?:CW3&E=@J+9#
M*]0RM8B6$0[\QHV33+:74;Y=FV[N%Y8A"8E8;!;S-<0!>O3E3N\L?\&1BPZF
MJC:VQW9@C.[?NR@\W,C$4F??OC54;WJ #TJ_(K#^+8->Z.8>@52,<9'AH&O7
MU9E#,D%+?!U>O'J=<B; =-(!DV$)655(*-;.1.FTBSF9I%*B(EU::YN'$0>:
M1A SO""Q/+:1^:[)_!+R>=B.[=35P11*7(C4&0*LF%'G"KL4-[PJ^49[#I4=
M6/:%M;MY\4'M& ,3SYL&1$'7L1>]:3!O Q_7JPM#N:Y7ZX59H8K2!@7E>@)"
M'A1!2,CI.$B9-HU2D(]HY2O)J-_'XCEWEPGBV9[G;*XYSON#N^#U=P[AF^DR
MLRDD,0;;6ELW*W01-R JQ913RU7:55<CHJE5('8%00,@&J2CLEVB-Y'(4LCM
MOPZE(97;R#/(CDE%@BC:F<Q96=TFVDBF#3R@:S]QCH^V6!LV3;H3UF8LYZ8(
M]E6R+LE1U34BL*F]N2+?!A'-;YLJAC4@YR2D;-&A.2D;%%PI(KSP=IEV\-#F
M3(?YM?,"P=L],>9P';'TF 8Y(S7TMLGVBN);)LZOMOPZK+9EAK57LH/E*) F
M5N<->WK>3O$?+ +04Q1NDLS93-M%L1NI9)MDRF9H[V4:-G:0:IJ(6!!>W(6V
M>-X )7^;>(;8F7KG,2DI'G/+0E$PI(H;.T)D)MX29E=93L7SK(<R ]/WY +X
M^D0"<D U2FVPS9@SF5;$VVQ872GEX5Y7%9@*+"&D30DGC9?#TQ&^UF;&7*WG
ML7.#T.Q=)P/8:R1O&31WZ#1J5&HZOJ93EF_NB@<2!>:VW>)Q<JV,XREP.<G\
M"3+)@DYI%C9AMWAH=VW;G8,[>7R2,^XQ>1OX2]&S5U6S:)M?O<)8*[<<"XML
M<+:66.X^?8RM/B'))!KB-J]8XN*=0S?ST5L?LI*1:5%TU50=0+9^\1CED$W*
MQ3VX]1OXG1X[NX1XS,499&!!N2#/Z]><0#(#D.0"<X%5O:6SA@\$3!Q&&!0'
M(ASRO]'D[,?1R<=ZZS#9OM0B;;CF]Q6W3#<7;\10<%6L93T;C^N,'U(@JLA(
MMJK&UX6C!%)@A54)B73JXII^;70EY4851B:1>BOZ=2U!HYXFO;EH[EV>X1IG
M(E>0J9&?+')D*J9/X>U=V=HP%I:AHW%O"'B"K&PC4% H(4+@=-H)"_P<G;C)
MK)36#6132E-*4TI32E-*5%V)X^/4QQ4#J,69SGAT3'.=LB8QC"HJ(F,8Q!$P
MB/<1$1$=3>NS3#6-0 ED %PX #L !@=  >E0NAPQ-I-@6BC)-NI)**2>I[DC
M)J0_=D;_ .SV/_-&_P#W>HGGS_XZ7_2/_;4KR(/\3%_HT_LI[LC?_9['_FC?
M_N].?/\ XZ7_ $C_ -M.1!_B8O\ 1I_97(DQ8HG!1%FU24+STJ)-T4SEY 2C
MP8I ,')1$!X'N B ]AUXTLK#:TDC ]PSL1^0G%>K%$IW+'&I'8JB@_E S6 >
M=]_;;$V3,E8RQ_MSS;N+D,"8[KV5MQ4MBI?&,='XEIUJ;S\G7V@(Y&O]*D+Y
M>I6O5:>L[2CTEI+2)X1JV.=P1_)Q\>XE+32#<003S7MK9+>3/;V2W G9KB6,
MHKGYB&40PJ\B1F64J-Y/3:K,,2>_$4DD:6\UP8(UEN#%R@(D8,1_A)$,CE59
M@B!C@#KD@5]8M\3':+EO*[K#T?DB!@;!)-\&2.,%+;*1,.EF!EG[$\%F3'CF
MC,73OWF#A_ 3K-BU83C.)D9*P(.HR$;2#ILH0JXT+4K>W%RT#NB^+$_+5F\,
M;.X>VG$I VX5T+$H654(9RH(I%J5I+*81(JL>08]Y4<T3Q++'RQG.2& PP!+
M9 SBI/;;Y]F4C"7JS,-R&'9.&QS-P-=NC^/M\3(C%S<_.OZ[5&*:#-1=W,*6
M"RQ<O"5A2%1DD9N:B9>.AE7;V+D$F]@Z3J:O%&UC<J\Z/)$K1,NY$0/(W4 +
MLC96DW%2BLI< ,,W?&V95W%Q"5C95<AP<,S%4'3J=S@JF,AF#!<D'&+VZS?O
MLC/C29JN7K:]LV ,GXWQ).A?<3Y:0@5;9#YCS4]Q#$PL6\QQDFHY=A8QA.5Z
M3?7NP(>YZP-6CK56G<I*R3&P5,<_3](U3GK);1K'>03W"\FXMRXC>VM1<LS"
M:"6V=BCJ(D.Z3F&-PJJ5DK%NKZR,125RT$L<3<R*4+O668Q!08Y4F4!D.]O*
MFT,NXD,M9EX=RSME)7L28NPI>,>#7G5<M]2P_2ZE)MU$C5G;R_C<=WB&K\8F
M8SA)EBN4&)J5@26(0821591KP2NETB'C+FWOB]S/=13;P\<ES+(ISOO09HG=
MNV;A=TB8^FN6'05F0RVP6&*%X]I5UA1"/H6Y$;A1[HCA&_@G /6LB0(4HF,4
MI0,<0$Y@  $X@ % 3" <F$"@!0YYX   .VL*LBOD$40*4H))@4AQ4(4"% I%
M!$PB<H '!3B)S")@X$1,8>>X\J5]%(0G5T%*7K,)S=)0+U''CDQN #DP\!R8
M>1'@.1TI7X"9 .90"$!0Q2D,H!0 YBD$PE*8W'4)2B8PE 1X 3&$ #D=*5]Z
M4II2FE*:4II2FE*:4II2FE*:4II2H[R]CUMEO$V4,4O))>%9Y-QW=<>NIALW
M3=N8EM=*U)UM>2;M55$4G*[%*2,Z2;J*I)K*)%3.H0IA,%ZVF-M<07 4,8)H
MI@I. QB=7"D]< [<9QTJW+'S8I(LXYD;QYQG&]2N<=,XSG%:P[?X/N)9NNL:
MQ3[N.+(Z0V;PFRW)2^/\>5JNRF2\?_=#Q7;[_8)B2AWD8LWLV1JUCF2H$J\6
M"36CXJ[2\DW=+OFC8JD]'Q)<*YDEB\0PU-M4@$T\CK!-R;B.%$#!O)!).LRC
MRAFB52 I-1K:3$5"H_*!LQ9R&.-5,J<R)Y&8C'FD6,QDG. Y.2156CO"*P]4
M+V_F,<9%R+!8VG\H;7<RVG%M]LETSF2;R%MBFYH8N4&]Y@O-LN",==*&]@<<
MSL&Y>2$:P@J;6QBD4F[,L<%+<1W,L06>&%YTM[^UCN(4BM-L-^J;EY5M%'&6
MBF#S(P"DO*^[).ZO1I42R%HY)!&TEK,T4C/-F2V9L'?*[/AT*QLI) 5%QT&!
M8- \'.-P5]77&W+<C:L82-!W7Y5W-XP<3^/H/)C2B1F3]O<5MM2P\UC[!/LR
M2E0HV.XT(RFOGZPOH]@G%QZB"H1*;I>]-Q*UWO%]8QW"S:=;V%P$F: S-;WK
M7WB240[999CNE &&;<V1N(%":0(-IM[AHBEU+<Q;HUD""6W%OR<,PRB1]$)Z
M@  YQDWS7O"_L^+K3BK)&#-UEEH^6*77]QS'(.0KAB6D9(>9>L^Z?+E7S7E:
MXS$&=_58"MO7-UJS(L+'P3 &<5! C%D,L9!1VYLOKT=Q'<07>GI+;RO9-##%
M<RP"V2PMGM+>-7VR.X$4AW%SEFRWP%:Z:T3QR073)*BW D=XDDYS7,JS2L5R
MBJ=ZC 4  =/?FJ.?"EQO;[K:K5F"_/LI1F0\E9TR/D:IOZA&0D1:'.?-L6+-
MM5JBT#LI5PM!IQ[7&25W@Y"/ 7T=-2X-F9VPQ#.1/Y^R&>.*..VA%NT,%G!#
M(LK,T8L[ZXOHVZJ-VXSF)P>A5<G.XBO?DN-Y'>:0RB62:21"H56Y]M%;,.AR
M,"(.".H)P.P-1K6/!WC\=8BQ90\=;C9PMUHV+\WX+OUURQB.A9MJ^?,-9SS1
M8LYSE3R[BZZ./<TU*0-SL#AW"61I,,SN%',X6?C9F.GEXIO>DXD,]S/-/8IR
MI;BTNXHK:XFM)+2YL[5+5'MIXAN17B3#QE#C";&5D#&VFD".&*..Y;>D4\#O
M+$DRSPSS-.5FB?RLRNV58$9RVX$-@;%-H>V>J;.]N.+]MM)FYBR5O&,5*L6<
M[/-85A)2;N?LDU;IET>.KD;$0<6S/-6"1"+B8Q@BUBHLK./(=P+8SE:%U&^D
MU*]GO955'G9240L54(BQJ-SLSL=J#<S$EFR>F<"0M;=;2WBMT8LL8(#,%!)9
MBQ.% 4=6. !@# KI;SOQ8<O?W/LOY?B-;-[//PST#^5O^K3UJ?M$_ O7_P"2
MQ?K=O6J'PV_QCO[P;1_G$/KN?M?_  1_]4LOYMQ7#O8_^%Q_%5[_ $EM75^D
ME?B"TK])S'OZOLMZUS[FK_G O?\ NQJ/^L-)K?/;O^!=K^/[']3U*L$_HN_]
M4^\_]X<$?RAEG6^?=2_N;@K^/U_^CTBM.^Y[_='%7\3H_P#/U*O7EKY KZ:I
MI2K!9.%S92LS45EA;)T&CN$VXJ'%!-=>Q9#366(B)O+*LLFW0354*4#J$01*
M<PE3(!9.15^1K-]J[SJ>IJ7P-Q5;722JENY52S$ G +,1U)J+B9CK5ZA9MBZ
M7IC*F3M#-=ZN&8+V#,$0,0,D*H/11B_M1E2E-*4TI32E-*4TI32E-*5AGO-/
MFUW3*M%88CU2NE;K67<W/IS$3%BS50GHEO6(HA'[ULNN$K:'D8=V9(@MTVC(
MZ3TX-7*I#[Y[/OV-#4KR;B&7=&FFWR6]MR)9A(&M)WO96Y:ML,%E'+R]W5GD
M!3S*#7/_ &A-Q*VF6D/#D0YCW]HUQ<F:*$Q,MS EE&G-9=PFO)(^81T5(_/Y
M6-97U=Y,R%<@WMBBBP<^ZBF*TU#E=-GQ(V5.W3%^S3>,U5VSI)!UYI$ET53%
M53 I^PB)0TN[2WCNKB.TG\3:I-*MO<;&C,T(<B*0HX#(S)@LK#(.16[V;W$E
MK;O=P^&NGAC:Y@#K((9RH,L8="RNJOD*RDAEP1[JA[.&VS%N?6;,MWAU23<6
MDHE"VJ'<!'V"*(J;K,DFZ!-5%XS\P3*>P23=XS!0QE$T2*G,<>9^T#V7\(^T
MFSBM>)+ O-;AUM=2M)#;:C:JX\R1SI].%F"EX)0\3$ [1USO7"/'7$/!<\DF
MCW*FVN"INM/ND$]E<E00&>)NJ2 ,56:)DD4= V, 8UQ&P-"$3<,6F79H\.X^
M]BV<56%4DR(F'@X$E3.3-RK 41Z%@B0#G@?)#L ?+-S]PEP/=ZHE]+Q?KZ6R
MR;FLX[.R4R)U\G/$N4(&!N$1ZC(&.E;K>>V"2\=)VX8LDN4(?*:IJ"P,Y.6W
MQ* S(<GRF3)& 6]:C[,/AL0KR(C97"D^K$WB-ZQE!N+]P[C[B B0Y%73IFV$
ML)(-ND4FYF$:+!9#H0711,7VL-BXR^Y&X;GX?L+'@:Y?3[[3X7BE36IYK^#5
M48LP,DI/[2G5F)#P0B!UVK)$<$G8^%_;S>PW4UOQ79+=:/-^Y5TJ-+>73"5
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MKB=^X=IJM/9N'+BTDGBN7C9H[&YND,9GA3=!)#&<M=6D8FCS*"'A/)D'F6X
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M0X'V[43 KI.4E\65X).4QQ?<33,]*V(E=8.*T\;UVV5%F[FB(HQ/L/$-G9K
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MJ7JPK!3EYJ\X^MR;Y)!&E%MH+LCHG.J_^LD2WCDO)5 Y2(^RF0%53K(?S"F
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M)NWVP9V0;J8?W 8BR*LY3(H2.J]]K<E-)@<.HI'4$E(>^6:P!^$@[8HK$$!
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M+N>'M-N OS17'T@KLN\>H;85!S_U@P/8@BLM,0;WO$2VVJMS8FW6Y EH-D)
M2J&1WI<DUP6Q #EHE'7!*43CDS@ %YB&B"Z9>037+^&.S6?%5[;?X*]9& '1
MV::(XSTY4LC8'_9(Z=ZYSK_L>X4U;>[:;:B63=\ZJ>#N@2!U$UFL:28]\T+L
MOOZFML^"OI)^7ZFJQA]U^VB/MK),2)OKOA&2<Q$LFB')3O%J18U)-G(.#!P8
MX)V"L-A'J$J28<%#;=/X[+@>+ABG(P"\!6%LGNP5V*=>^-RC&0"3@'B_$'W/
M,T3-)H=[/&NW<L%UF^B!.>AN(88)HT'8?,3OG .>];T=M7B_[!-TGL3"D9S@
M:?;'AB(EH>6SHXXM/M:G24C!H$TY]P3;X3B!?9ZY.S)^1X#D>0#<K37M,O"%
M2Y6-R =DV(SU]S,=AQVZ-CI7&-;]G7%^A%VN-(GNK=.OBM/5KN+&XC+HBBX@
M[9Q/!$0""1U&=F"*Z2Y"*)*$434*!B'(8#%.!B@8!(8.QBB40$!#D! 0'T'4
MN&##*D,#V(((/VCI6D$%25(((.&!!!!'I@^N>_V^M<VO:4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*4TI32E:P?$FW^3>Q)CBF78URGRD3=HK-\J]<W%U/-U+
M)9,:X]3F,=80QTE"$X>9<S5>)J'B:FA(*+MB05?N3A&*DGJ#;V:>T32%U8W"
MEY%:)K50(@A")/,5FNIRWT;>UB5FD(P=SQ@LH)S&ZC?&Q$1"JP<3$[BV6:./
M='#&%!S+,Y4+G]ZK]"<8NSP]MRF<L^1>?JMN!'#,SD+ 66XO&,Y<]OS6R,L8
M2%@?8PHMYM]"(VL]EN3Q.\8;MEIE\;7T&]D>-_>\(EY[&%E/>,2UMZS8VEHU
MG)9^*6&\MFN$BO#&9P@N)H8YLQI&.5<QQK/#E =K'!==K&JPN9IQ.D_):2WE
M$3/;[N46,2.Z89G(>)F,;^;N.P.0-B6H6I"FE*:4II2M<>[GQ!4]JMDR570P
MS.Y.<8\Q/@/**;:N68C&;M!LY[B)3 +>JPD*:MR8J3$*O&?6)B/MJ@6-PZ0K
MI4(@P^^!Z1PA[/#Q9;:;<_+5OI:ZCJ^OZ46N;4R06OR%PY%Q UW//XF("&=9
M?#2>0>&5&N=TP^9K1N)>-1P[/?0?)4VH-9:=HNH!8+@)+<'6-<DT5;>*(P/F
M6)H^>GG//9A!B+_"U&V1O%6IU>KEKM^/Z)"72D161L(4B"R?8\D/:/BGW'FS
M!C7-L9?LDVV/QS=Y'&-=C".D*-PO6[(=Q;7T6TDUH ';@K&2TWV4WES<VEGJ
M%_/97TNFZY?3Z7;:8E]JW/T376T273]-LY-2L8]3N)2C7WEN;8+:)*\2W&Q=
M^!?>T:TA@N;FRM(;NTCOM)M(=0GOGM--Y6K:.NKQWM_<QV%X^GP1AEM/-!,3
M<O&LAAW,$F/&N^H;](4^*=XN9P[NT;3,E[HE'$+EBH9"@D4\;Y$AL?FJT'::
M.TEJU:8>S#+%L4)=6$J@HE%>RM96IQ\NJ^CXN'U/@/Y/CO)5U5YEM>+M+X6"
MS:3>:=.3J>G3:@+J>UOGAN;6:UY)MI[*2)@9=SPW<D(CDEE+#B\WKVT;:>D3
M7'#FH<0%HM2M;V$"QOHK+P\-Q9K+;W$5QS.?%=I(I$>U9+9)"Z1W5M/WD-MT
M4HZC$<>KTD[7;EM5W!&55LZ=A*9'<]6KM8D*H4I("%'S*6%,.T6FA'IGQD"K
MDBX<&PHKX?%G!K<+1)*=16^#\1\5\/@"U-N<\+W5E;-=G-Q/TO?&!Q!_\/R]
MIEFW97(X;XH7B&1HQ9-:;="X<UO)N!-E>(;>\G6VZ0Q=;46A5I>TV_(CCVX;
M&"!\6NEN;=C^KVS$\G46V2\>YTLM9LBEP+)P1+QB#,.7L60&-YE[]4X]")>9
M00P[.R]9F5U3 2;?,*:A$RSU5"2<[3/[([U;/4;JTU>*[;3-1T&VN;;P?*G-
MAK.CZ1JL^I0IXN1I4TLZQ!#=0*O^ CDO6FB0-&NOP^TFU:ZLK>YTV2V6_LM7
MGMYS="2'QFF:GJ>G06$K>&01MJ"Z7-+;RDG$SI:".1V61MEN&<B$R]A_%.64
MXDT 3*&-:+D0D$=\$F>%)=:O%V4L2:2*T8!(&C0DP9F? Q9 [%$5P:-@4\DG
M,M:TXZ/K&K:29O$'2]2O].,X3E"<V5U+;&81;Y.7S.5OV<Q]F[;O;&3ONE7P
MU/2]-U(1<D:A86=\(2_,,0N[>.X$1DVIOY?,V[]B[L9VKG BO>=^+#E[^Y]E
M_+\1K8?9Y^&>@?RM_P!6GK6O:)^!>O\ \EB_6[>M4/AM_C'?W@VC_.(?7<_:
M_P#@C_ZI9?S;BN'>Q_\ "X_BJ]_I+:NK])*_$%I7Z3F/?U?9;UKGW-7_ #@7
MO_=C4?\ 6&DUOGMW_ NU_']C^IZE6"?T7?\ JGWG_O#@C^4,LZWS[J7]S<%?
MQ^O_ -'I%:=]SW^Z.*OXG1_Y^I5Z\M?(%?35-*5';'^NS:?X.Z%_.7)&I67[
MR67XUU3]4T>HF+[^WWXITK]<UFI$U%5+4TI32E-*4TI32E-*4TI5I76:>0$.
MS?, 1%=>VT&%/YY!4)['9;W7*Y(B4I3D$%@CY5T+<_(@DX!)4Q%"D%,V=IUM
M'=7$D4N[:MCJER-I /,L],N[N')(/EYL";QC+)N ()R,'4;F2UMXY8MNYK[2
M[8[@2.7>:G:6DV "/-RIWV'.%?:2"!@W;K!K.II2@CQI2L4=S6]_:SL_@3S>
MX+,55HBRC15W&5E5RK*76=(F!@#W)3X=)]87Z9U0!'VTC L:@H8OM;UNGRH6
M/O=5T_3@/&744+$;EC)S*X[>2-<N<GH#C&?6I[0^&->XCD,>C:=/>!?\), L
M=M$/?)<S-'"N.^W?O(^BI-><'<E])3M4^=]!;-< F9,A\U%ME+.+D4Q-QUI%
M=1E#KSP4"])NEPU7>V>6(J3I!Y"IFZTBZ;?\;QJ)$L861CG9/-ARY_A1PKD;
M0._-D3W!3WKNW#'L N+@)/K]^Q'D9K2Q4PP^8$[6OIP7DQV?P]KA>F)#N!K1
M[G#>UOBW.*N/NX[H<C2D*Z\PJE(I<@6B4D$3CV;J5^KI1$2_(!?@!=[&&=F+
MP!US" F-HUUQ-J=VQ6:\G*[F_?"*(=<@&"!-I'3H"6*X!RQ'7N>A^RGA70U#
MVVF6PF'T9!$MW,,C!;QE](TH."V0D4??&YATK$]K4JXR,"@1J;E?\(5WYE)%
M8PC\Q,],L!3<@/4).GGY?,-1#W1=MQD\V,90,@[YR< $GZP?=\:WV/2M/MT4
M+ &D \N\EXP/0,CY4'.>B#;C&*N9!L)@!)JW$P?@@DW1$W'Y/+2*(\?\7C6*
MYE/F=F8^]GW'KU]234HL('E5%4>X!0O3M[AT]*K*%>E%Q#^ARH%XYZW!@3#O
M\@(4#J=N1Y 2%X'L/<=8S,BG'0'XJ?RC'^[W@U=Y;L/,"1[B1T_+^7(S]55A
M*H&X 7#TO/H8J!#B( (>H'5,4./0.Z8CS^UXU[XDIU4[O?G(^K&?SU[X?XD?
M62?LZ'[:JR-6BR 4%/:%S<]_,6Z0'Y>B:9>/R#U"(=OLUX;U^N4R,=>HQ^0_
MU5=6!< ;\'MT7WGL22<CMW].G2JB6#BD^.A@B/?GXQ,J'';@/OHCV_CX'[-6
M'NB^,9CQWVG&[MWVX'3'YZK\.!Z!_K Z?5D_G[_&N8(UD7N#)J''</O"/;\W
MP\ZHYS-TYCG/IN;^NJC'@=5&!]1K\,P8F[&9M3!]@H)<#^?X?EZZ9/O/Y35.
MU?X(_)C\]4]U7XIP0_\ 0X-SF >%6YC)B0>. 'H 12$H?/DGH(CR'80RE="
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M^G+X=,[1+( )VR=H906Q&K9Z-WZ_2KZ<X)]A$*1QZEQ*\=W)&.=)9([K90J
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MTD$4P;/E@6CAC)$Q40?IIA9XAT8:+>I!'/XNUGMX;JTNMH FBD&,X5F7*NK
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M.GA-P=IA["\JPR324DGK(X-HXTNW."QC.DVZ(I[;)Q'/IO#?#T&FWEMXD?*
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MF2>Y,L?F801H6Y9^;8GSAATJ#UN<11PH[0*CB>0\^%9T=X(PT46U^@YCL!N
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MR/E6:8MFUJO<DW\WV1-8B!UR0U;AR+*HP%89N5F<<55R\<+R,S(2DL^FN/\
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M_#\_R!W'Y:4P<9 _XU;3VP?A)LBCSZ>T'#T'[4R=^1^PQ^WV$'UTJI Q/F7
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M0F1Y0JA<8&..#VV[>*Q;,DWRN8)P] W;,K1ZPRY;HC&U.CK)D]A)"8TFQO\
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M-\>5.RXN(_$\G (2WAF@0IN(^<>61,IEG$6Q!S#FI'L&\C>#?+3N$QS+WTN
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M #Y:]4%C@ GWX]![S[NG7)JZ-J#'H.N,]??CW]:XF4+-VSI%A_L3"G$0&3<
M8%W@%$.?8D/A4Z! >/,$2D-W#S.042+==D@Z@$Y..A)P ,^A_3CM5B616 V[
MNF01G[/ZNWYQ5?"/H-)1.Y?.$'3A/GS'+M5$$R&$!YY64,1NER//*?68W?\
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ME3@*;?[R01[G_P!L,'IQSSP4![]ND>>W?D-7 BNH)!R?R]_Z^GQ_/7O3![Y
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MH1L_,1[Q:/7=L7K5%ZFB9LHX9ND2*&4;K%)QV*TN[A2\%K<3(&*EHH9)%#
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M !$H' P_:5%,>H2@( *@@ \"7D;D'ER_?TQ^7Z_AZ?HJQ*=[<L],88'OGWC
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MI&04E%R]8F4,L8QN0^])G 3<"/\ NKC@! ?VB0_(=>7# *JQG:< L%\O?W]
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M_?J=4?\ >M7/^A(S_P +IS)/\8_^<W]M-B?P5_S1_93ZG5'_ 'K5S_H2,_\
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M )VD^O8]_3WUG%M0VH9%W>YHKNV?#*:C<7?ER^6<BJ-U5HJ@4M(Y"S$S)'3
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M&.O+7(!(!.<#).*^4>-?:%K?&MTQNI&M=.1R\.GQNQ5I#G,]T^$\1.=Q =D
M16PJCN=G6INM$II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4KA-ZI_VI_\ L:]]#]8_0:H/TOL'\X5\_M5/
M[4O^4VJ&_>_]H5778U52FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
64II2FE*:4II2FE*:4II2FE*:4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g743471g41c25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g41c25.jpg
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M04=+)-$MX;JHX42;(JN%=$==]DT$E%ML83TVVP/'C_[8O_4_+V?_  ]^@_\
M!!U!_EJIC_T7P>/'_P!L7_J?EC@+I1X;,H326C/4GH](D5\E-4%05"T*736R
M$>HCC6$MQ\4<:J9$$'+=@4QIG.6#U=%J[]I=7338>/'_ -L7>?ED?_A[]!_X
M(.H/\M5,?^B^#QX_^V+_ -3\OE,_1P__ / L_P#^,C__ (X?;4<([0^Q)P^
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MU\S7,M=R?T FE)5I=-";T<S)'\.619Q7AC#6F]\=5B;SHHI;E@UX=U9PE0+
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M@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X%.QW_, F/\
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M//[\O%9U\C1W6^L9IV0ZY[VB1FTMG";&O-(;%6NF6=>0.Z[:"V6\A-TR%JI
MG<CI^I'TH;P@X6)SB$R&7,8 876?LC15N(UR^[:QUUW]']SWMA3R1-Q#RB[(
MQ)X;+H+'Y:B\5JK9S6B%P2"KH?!)!J1WGN[<NC(6EQQUZ79PIT8)AA+"3,2*
M&Y'2.C)0*YQZ\+K37;SAG]B]L',!L"411C7!Z?(BYE&*J""XN[C@V0D+$<T7
M9'9.6KO7LQDL=C[6(B:KB0%,8[3<*$WTK)$1GPVS=LFOH*^?6D*S?Q 0"HE\
M9K6E9V6F6[>I@4 DTB%5\[&$=+_M>G:W!HLQPJSF\P53P3L>-2$C'BRD%#E,
MQK+,W,8FBFWD+(M;7UC/:^7RGCKIV(D%K&U(K+A@=F92@6\@W7#CB(C="50^
MV;,IFUHJ8"OC,E1$OXI*H*+QZ1LGDX95X:,"@4IF :.,YK)C,_?=\J/AZ#[#
M'#SS@.!KB[T2ZO:OG?7ZS7W8Q3KI<^K"WJTJ@D2HR3=@8E/ ,S2KR861#"T&
MBK1H:W,)XJV'2@,\!36'GT1T>D>R.Q@#K(V[8L:3&V4SUBZS\Y>7I<7C=CV/
M:EMD^P!&_+:=PNOH$:>LNN4UZV06*00 <G9^.#8[%YNU)'3I(B=DLE>&2A6P
M)@HS31'-QC&,MW#W!L>W]?#8QPB+KP_T5M_\+K _*9;A8UCK'NQWJ_\ NT]>
M/P,J7\@Q_A$Y\!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P
M' <!P' <!P' <!P' IV._P"8!,?^CNMO^]5K<+M'6?:'N07NI3%@VQ]E@7ZV
M-FA@G((Y6=KEP.K"F[MFD(T=J6-!ZAG/QRJ,LDT!39NU"C?=D.92-(3+G%?/
MYDVKRQ%HH*_F-XZ_<MZN&06;>54QFTXO7,TB!(Z3$NJR+;3!4)%B$:K,QV!D
MLVHBI57;@T::R;0Q9TA:S:N&;B"1V2*#&!$@C-7$<C![#QZ*^\:SGMK[,39P
M3J&_G1_JJCUPKKVAL*3L0P ?4'&F=5/A94_#D-F[!T3C;>,R<Q@G$("0*-@;
M<LB*4B</^EW3$D"!-&PSUOYY_>;T!-R]!-!XVIQ,LZW,@$+^MK@1!TFL*&1.
M)([QNR&DT(#A>[%M' #%]&6MR!C9-MHT9%68VU@"[EUN*FC!L*Q:YY]>7\>C
M![+A?3:Y&D6OC'T/*F556W V2 ^! X7LZ-70O,Z9;UO&BVQN.ZGHY--Y8$I@
M'[PZ1P%X[!M@$6GQ=S7[784V$??WZ7^LTA_:OTP?2V7V<ZLNJR15@ZA\?D+L
MH6#/18:0LQ]OQ&/FF*+Y!1-C)2X%U;U=/I,,4PL9#1J30-Z[6TBI06R%3I4^
MO+;U^PXN6=A:<:8D5/RRC)(]IL#4(JP",AV"TQ)J,S1NQ@!'!\B=@!-BES@.
M%MV+DH<$L)37X'<G%*XG[^+C"OU.=->"(TK[/WMO2RL.J: P R^-0Z.C8YLZ
MBD4@K,4%9,1$? P^%O),3 Q^/ A;5F-$,$"DPD9%Q\.W^(>.".B;A=1H/%MF
M)'R+N'H/L,<//. X&+RF%1.;HA&\MCXP^G&Y0 FL?^DFVB^X6619_H2 2 8K
MGR59$QKO3.47+??3?=NLZ9+^ZR>.FZP91P' BZ\/]%;?_"ZP/RF6X6-8ZQ[L
M=ZO_ +M/7C\#*E_(,?X1.? <!P/5?OV(MB\)DWC4<-'-7#\@0?.$FC)BQ:([
MN';QXZ7W30;-6R":BSAPMOHDBEINHIOKIKG. UG>(;XJ77OP^^M]9]CI&\0L
MT'<DOKT15P6%&&+AS/(C)UQ9Z4SJ-O4_BF[X'&:S7?RMF]TUR,+EEXI'52 [
M,I:$$36'!.*9B-HF<_;NU\]U/TA&B>M'>'IU0D1-Q2<T98X6/S3LE:H]SEXU
M@\+NB/L7-*%0CQ)3&B*8P>7%VM.M5VCAPI7Q(&D+T^D2"R:!K#^.<6'%.\:1
MQK7^.;L>(K(N44G#=5)PW<))K(+HJ:*HK(JZ8W2525TSMHHDIIMKNFIIMMIO
MIMC;7.<9QGAS5<ZM=SNOG<H?;)*@9NUF36EK>EU*SC='"6GL2J(KIIJDAGH7
M6P3B4@;J:OHI)FV<C3[31SLS4V49NTD2S$Q5Q5YPF*U;=K*CH>K8%NS>/U["
MD#D5C:\FD[[0<(0-S>3"8=%V*[I3&=$=BLC."QVBRGI;MOB<NWJS9BW<N421
M$SIG_&:1N X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@. X#@4[
M'?\ , F/_1W6W_>JUN%VCK/M#&:OZ\]58SV3FJD(EBIJPJP3;6"RZ]KS9L9@
M?6TS=^DBT-6/7U6Z)8Q79^Y4Q4BV<OUE7+9DW6F&T$8Q)K8MA8F3[]^_LN:]
M+XUMY9>E[,HNBH>O%@WS3QFR[  "K3#;""E:U\0(5*C()*^@TA<3@(8C"<HB
MI.U$-X_)F360$D*YDP /(=HV,9SD?(P8S<;L(F:FO.<_Z3Z.K46RFPBQ'AD\
M;EHJNL5JL3)[AD=# O<L/..S)-B&"B6"9Y\3')N'&XEL*#)X7<(L@K1'V$T"
M7\JN3?H14TH@\KBB!&2Y5/5VU@3?Z;))N ^6X=#L5D-N80",P1A=JH[[,3W!
MO40;"D'3%G'TA9 .\8.GQ MSZW[3^GJUOUSE16E9(I([8'6)-[-O*M>T(R<H
M+AS4>=D*\)T\=@(E,Y%8K!!)^,G M/QQ@0D(&%1O3<6??K"1"F[5JZ>"^7']
M^WGU<@]H_J%6QAG$['EL34*RN'@!8*&6E.HLP?%1%722[)^F>CX138"5(NA2
MMUV!].$&FKMDW!MA_NMVFX]Z\>BYGG_-1^D@S/K;$)9 ;HC46(99-^P<#BM6
MR$@LNF09!:A81O:$+1V#[-$=-V;=K#3TU,1;XQR4:H3>5/3+C=4<Z48ZB].2
MT/"/CS\/0?7BGMEUS58/:3V?/X36\:T6U;[R&>RH%#P>KC?7;;1#8M(7XYAJ
MMMKKMMJEEQC?;77;.-<XQGAY]7H_L#LJNK4!ZR>L)]"K'C6ZV[?20P.5 I>#
MW<)ZZ[;H:EH\_(L-EM-=]-MTL.,[ZZ[:YSKC&V/,56K-> X#@.!%UX?Z*V_^
M%U@?E,MPL:QUCW8[U?\ W:>O'X&5+^08_P (G/@. X'7[\0.][F\37H[>5*^
M$LXCUI20G<TVZQ=A9@[GD5@>L%B<,V]N<,@"Y\NUVD#*V&JXX/'CPG5V'+5^
M5D[G1RU([,]$SIAB,.*)QW$93&6OW=K=Z6_H_%K]A:;C51>+II= 73K*.WB/
M556JNP58%X>QK.7%RDEE,8=@V49EY5E( TERCLC("#[=(E$EXO$V:;$= AK=
M4UB_)4S.#_EK<;PW&TMX WA;4[!FL((=;H_=2K-^^=I3:\$ADMGFS9YLGLD(
M<'@HB+(NQ8ST;)BDW0]9VS;*?!8>;LF[-NV,S^3'.]=%^KUH&3S'JC,NM/7:
MRD.M1 O62%30.PV<4>SU2KXIA@TCBV8Z!WF$0>JEF,.3=AXN2S*FJT<)*#CB
M?QR@O1DX,1.=S%\M&G?PEO MLKPJKQE5E1SO#K;-=6-$%(K9-0.>OBT(9R5<
M<HJ_ADF9R+2\9:F)D$0*+O=6;I6.%-'((Y)0WMM5"R1)@;Q_D\<9X8B8WCV<
M9X\WAT>(;XF*51T_USE-%0_KK MEYS+6=AV!,X](YS:[C+\2*6>B(_7$J8?5
MV$QM5Q@ IL7T7>EI6?5?#M-189SDOX\>'!<S$S.D564=XU^[ML?0N,]GZBZ@
M5C!>\$AKPO=%41E6*RNPX5+2T@C<LB<31]B-S,Z:D\<B;]M(MHP@U0F2[UHL
MF\,#7\BV?^@MLU9G/%4S/ARC:/LRZR'6G](4D5B^-!,8Y*'YICT.N9P'ZXU&
MD39O68J'F8R9)(5W=CS5TBDF.^U&6&C326N'2;!4?$I5#L2)RJWK-IYG6?QQ
M&",X\49S%QO667#YXNVE:W9>BJ+*C!5QV.%K3Z7'[DV1J8HE <.PS3<J-5,O
M9V]'IPH6X352VRHQ*'V;Y-#*;K=OAJLDMN<61UQ>-*W$WR\J.X*NM-IJE[^7
M5<6!$YNWPAYZX][*\9+$TL)>>VN/<SMZ//;7'GYYQP56J);I[H]>^O\ >/6S
MKO9\V; ;1[62.1QFI@N^$MDG3V.!]B&ZYQSNNG@.T.%514.B^ZVBBL@EYL>&
M'(K;ZOE698PS,3,1EASG[]RB5J^$. X#@. X#@. X#@. X#@. X#@. X#@.
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M=M-]==]-]<Z;Z;XQMKOKMC.-M=M<XSC;7;&<XSC.,XSC.<9QY<"**FFE?W)
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MP*) (K&6HZ,.72DS^FM2#G W;X@03CR^8C]L+>=RRTGC4B-)1!.H(0VAD3L
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MN5D=Q6+A/:456#?GA-6C*(/+IGV[Z?ORU>2,9+HVDR[<5L$#8D@0E&BP8R6
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MTEOPV^ZO?.<]22_4VD7=N#JVBENC9LY;3FLHA@&]DQ> N0:&Z=@32)K/LOD
MQ)3&XQ-ZDA\-G5UNANJAJH=?Q8\.'Q>*:NJRF=+X0VN^$-2U]=+/"@Z_U#;]
M,252]*L&V^X/TS&Y15Y"4/7$COZSI>$&"),]GHVKE'Q*+R,460W(3\:-1PYP
MR($6+U-=!*1^Y]Y<\<QBQS,3E,ZY_P!K6-^]M!AUT1URN9MU@,J*IMMFW9F#
M':DC&7RN^$TAPRX"Z#BB)4_55VU13;0NTY)LHLHBGIZMG#?"M2IVSZ9^FL:[
MPL'-+BJ.MX:SL6P[3KF!5\1V&:CYW-)O&8M#7^QI#+D-JSDYPFQ".MBS;79P
M,P@^WR_0QE5K[J>,[<)5Z/4K"\:5NYH6(4Q<%76ZP N6S,Z]K"P(G/F@5V\2
M469M2SF*%BR(YR[1165;(/-T55TDE%$M=M--LX%3&L4E'@1W;-3UY>E<RVI+
M8C+695S.QGT++XJ^=$6; ^(V<(.E1C]44\8/=V+I1LEH]:Z.M$7S7*K)YHNS
M<.$%1$U-QK"H5&^%?X?/6FRP-Q4-U>@-76;&4RB 281=U*6I1DW-"W88LV\E
MI X:N6I 8^=-'+5XV<-U-%?5E/W$TM]#4X\4Q4S,PE^=4%9#N6&9[3_9VV*N
M.&ETGKV%R1K'+FI-^^1:H---EX).F/URC _*;;11814EJ5:P<.E'+Q=)1TY5
M6V)$\8OT^^=L2^TGN;6?W+'Z_0J_P2'W5)CU?FS*(S1UKC_$>NZ'OTT "AF2
M.O[;+<#V3L,VXU]U!D(<NDVR3\9<:Z_Q=]H9#%N[/7"0'1\-/SI>G["*K8:#
M:W[!1F34).#+['^*TB@6V!,3Q/M4LXSCZ2KUS*PKC77*[(FZ;9U6V%3KMQC[
MEYK78SY_/'SQGYXSC_?A#@. X#@. X#@. X#@. X#@. X#@. X#@. X&L_Q%
M3<]%.NN+0>_[?M:>+SZ9-KF3Z20F?2BXO;0@A%S 7I4M744DDDCU<LY+HJC)
M$@ZXHP8+OHQHWV?B6!UK@UAB[TN-+F(CUF/O!*?1U>*+PN:;1,CW=)-=90VP
MZ4[Q!+H!S1-Q]$M\ZZ0M&Z@$?,+1?*?IV<JAT%QF"WQ&BBV'6%-,#%K_ ,?_
M ,S$QZ3*[O#*DO=:+WQ,P581BIJLZXV_"9#/V@&XHYV'KPE98^/ BZ6C2.6$
M"BZ,MBPLLRBIS;*4T8/-W!1&-%UY("RLO&G0(^6)KCY33+^KM3VA3PD_&)B!
MZJ1.([J,GD5C?5VH9#40EJ24RZU.O#XLI+9$,>J.T=!.C)4<T'N$\MW7QBKK
M3=MJW$Y\?.;_ %"U?"(NO#_16W_PNL#\IEN%C6.L>['>K_[M/7C\#*E_(,?X
M1.? ]79BRVSG;9FUVVVSG;;;9NEG.V<Y\\YSG.GGG.<_/.<_/.>!U?\ J_\
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MX6DNU HB3<].12&2$1%](UG[Z<7H45?DDDTE+T=?,<"5QV3B(G8^_  'S]]
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MV1"8C8,4(X])",3>-AI7'GVOEMKY/ IYD_&NL>G;;7R7;;X\MML?V9SP*O\
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M37*^VRN?VF<[<,W/%Q59=5Z*IJ2_6JKX<_A9#(YT*R.#SBP-(CED\V1W5TS
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M:Q_"*D=EZ$MBY9714GKBVZ]@3:EI<?GRL2LZF)'<,2E\U7 YC\'DCYA%[PI
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MB0&(XFKC15Q"Y.Y/0<KZ/8-QHFTW5;*%B:_F+C[ZHN]ON?1O^$J![J5XU_\
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MW"+MHZ12<M7395-=NY;KZ:JHKH+I;;)+(K)[:J)*I[;:*:;:[Z;9USC/ \W
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M H@P@S\7NZ;2SXMF\>LUM1SM'"WH%1G4SERYQ'&>*ZW",)L"M*YMF-NX;:<
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M2\3!BTGKLA)'\LF)(M*39O9X9:M4QH(09GE%1UB?6/;+HV5<(<!P' BZ\/\
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MM>6&&!;YOG5W[WGLXSNC[7W?7DNU<Y_7PL'PAP' <!P' <!P' <"O=XUK);
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M7SL%4L8D+$Q%%[ /2)&-#63J51^1"6P-<][(5P94%+M1'W^6K&7=I^W;GHH
M[<@)PLR.0*"68VD< B-&-Y$9/W17<_F<9<M.SHHF@8?4Y6\(#019AV'%UMD5
M+H!.',RUCLE?CXT!!'DM5%UQK.]IB\NNTS=LMB?=>SIWV9(/D)5,(SU^%=M$
MNK8=RA4D(D-!R17>(#6X]@<LS:1L[I2M.PYZ60?5Y.HD$<T +$/8E7TJ3?3@
MT\((BLM,]=[KIZ<=]&Y;ADX#@. X#@. X#@.! MU==X9>#N'FC!V?P>8P+63
MM(K/ZNE[V%304$G YH+FT:T+-$W*:X"5-1H98DR<M%E&Q<!'9$&<"Y''PQ9B
M6_OW-)L!@L2J^#0VM8"$:QJ#5]%@$)AT=8Y6V9@HO%A30(!$-=W*J[E1 <+8
MM6B:CE==PIJEC==957;=38C+> X#@. X#@. X#@5,N#I?3EVRR22F6N)\/1L
M.+1J#7%$HG."\<A5VPJ(/S!"/1:SP#/.R98:T^L1X4_6#K@BDCC)=W$)01-1
M7#<,@6YRY:<F8:=5NO[:Y8=?@VK(8$LZ"QVQHV#/ HV"#[;-K2)0<I*R9+1@
M.0V(R!1> B$1IQRKL0&LR,D:-EL(R$GJL+FJ6#X0X#@. X#@. X#@1F>J.$2
M6S8I;9H<J^EL-K>TJG$>\XV4#;PJXCM5R*=#R(??79F14($:;A&&Z[G7;9HU
M;D6R>N4B;C&2WE6TS$]K^958'>''UR9 5HZZ4M(ZQ%Q6'0:KG)ZTI60,4-#Z
MZG,;LR @J5-_%HEHAK$Y["8-)!Y=T[,R-\K!H<*.F2\?C@L0W%S]^_ULL=3-
M&Q"D&$O3CQ"5R616++U)[8T\GA]:2S2<R[,>CT/:ECA+9%HR03%Q")1>+!0X
M,8' !P8$>S&BFWDNHN1,O <!P' <!P' <"H-P=+Z_N.Y0M]$+$O2#6/':]6K
M (2K&SR$/9BXD].JR,PV'L$63M%@]D1/Z/VDI%EEN[/MH_&&911RVCHA-J6Y
MC+;I$^[PN^D%0/IPM-7!ZV=T]IH0M1C"\V9(-H$&N,G%W,2<6\'CN^^WP<U3
M8O'9=@E\8I$A<U<JV"-B[2<YUD.HN:K+K47E]_6CW^L73F =31;..5G/;J*0
MT5'EHX%@T^LA]+HB%1<DT"[HL.$NF3?&LD>ODW*Y"0.5G),FN4+NR+AT]).G
M*@F9G7K=1]^Y+:\(<!P' <!P' <"'[CI6,74+B[0X7F,5.026MYU YM7\C<Q
M>80^5(@ST66)"GZ:;M@\0(Q:4R2.%PI\6: %1!IX@_%+J:MEFX5Q(^'5U[=1
MIM$QCVW(L)?12:0>R-HO;4Q&%+MBMDS:16180ZWS>[YR7DQ"8SN9S:3%)6Q>
MA)FV>366,PTC%"#KX<H7Q3=_=*CM^HX,T1Z248SLAG80UK+A(YG/(];&*G%R
MXFRIA>VHE%A\,C%E*UZCG ].1 P <+AFR:+MHIN?"B)J[C;F;CVTC3'BFJY5
MI%U=U>O\9:+=<(<!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <
M!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <
M!P' <!P' <!P' <!P' <!P' <!P' <!P' U@^*XWMF$=3+O[&4_V3NRD9A1M
M0RR3@H_76U4K0R4FF>R+IF[FH^>U9.#;WX7&-FR28"0QQ/+93?"NJBWI6U+%
M7$5K//Y>I95@D^CANNA4LNKLSV*P0K[N#=:^UC2"DF^I8;2-01&5J0TYF&4C
M"E-V#?X-P\A*XG84\&R$^?=29Y)A&X@0(+$7>D:1OO/5A2OB6WGG)5HVZ-E/
MI9/K$P[E@69#L)"F+5S0._TEH4;29\C$'ZD;NE!PU8HB*Y&LI5$2F'ZZC^U@
M.!KC7<5'&LZTG7WKCEY2QRXO&IH>L#LC08L8"]CU;515MPV>A878BJ:=MC<!
M:\ 86N)C=)T[+7+@U=4\#5N7"R,P#1,PP4]>FQ,4B<BDTL6<AV8C#,Q'.:BH
MG/X]^2Z_;Z[#,.HF)N*F.:L9GV(LJE*)JR9MVZ#K2,NK[F0.-+V4S:D$%VCM
MW 8(1DEAA!Y%DY8E"\>&BR+11H]7TX2-<^<]HM5"(]X)'6_;GO?3DW@W:*Y8
MG5EC4,(J_6I*'EUMB(7'Y#U5IN82 .6DL/#++8,&)B=.25PC(7KTGODKE5!1
M)ALW03+,989BLXSSC7Q8HWGA$,.Z?=];VLBA.N$6BU4D^RW8N5=?"G86TWTN
MG4=I(6"@SRUIO (8V=DMXF<2=V%,B42D(B,Q9&-AP2.D.,NI=+HNG\$L0%1G
MM%S''[[\EE*\\1RN[3 6#*X=!I5N @O2&N^ZOF;=,1)IX*GA?L$"=5>2%)Z$
M$@LNB)?KZ=&'7Z9$L)W?E-$V&SELPR[>DG#,:\9CM7IG%(O*>)W(44K=DL=Z
MK3255G0=$5U>-K3(=/X_J48H6S2&MP0B*Q&%ZA'!65D$7&=@$V*K.@0F(B-D
M)AA4PWR\#L2^':XN9J.]:[?PXJ2][)K8?3>\>U< 9P$9KU47#W8Z,4C?D![(
M4]=%5P,4E.;?A+&81P;'2[8RM6*4UCK\/*H3%G\3GN(I)0KJ1M!^-\BO\HC>
M9JIBIB9RS_MMR9/&I%FT(,EM'#-\V0>-'"?GZ%VKI+1=!;3SQC/H52WTWU\\
M8SY;8\\8X9>SP' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
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6#@. X#@. X#@. X#@. X#@. X'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g743471g41g83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g41g83.jpg
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MY5;&-RAL>&0#B6E=U\XJ1Q?O?"O'9BH6NYW7L?1*I22Y2# *"J;SB#<(%@F
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M5=K$8MP57;;G!&02QK%1R,'"V,P!!*@35+E>QZU!S6<%LIC/=@*'-@ZY&60
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M> <J2E*=:TE*=4T3K24ZUZ-:UK6O1K6OH:U]#63\0^OM7_2+?SS(M)]:Z?\
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M%@*9"Y/4'T=<2!? L3;PM0O$"V?&)$N,6JL:>1, >65M#]PAT\9#OT:LPN4
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M)S<M_1<Y3_"=SW_+2M_[RS3VGK/]4U/Q%O\ AFW,K^Z)_67Y95X@V&L$%!,
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MWV.Y0-4M*H"$J1&15#$EB-Y9V+'O9F8X 7.% $U:JH.'-A)RSLP).!@#L@*
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M G..9Y\ 9][X ?DD>=2^2UX3VP_"M'5NE>1EWL X.P A%3/4HZY,8/&FSR+
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M$5J+LD:G-L1D3"L[V7O,^4B.PF1*<==2RWI6D:J.VYF;:J[B3M085<G.%'7
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M$WNT-6HIMT]]EUE-]=E-U;6=FRJU2EB-T]ZR,5/H,M'_ $E/P[_=CNOW4/\
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M*F%(UD[ZW5V6+:^IN:Q%95<V-N57!5E4YZ!@2& QD'KF1KIZ%4HM-:H2&*A
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MNQ,0G5AA1@N^!$S)_HUIALF9C"CDH= 2K?M)<J*&*2FV$+]V@2G]MLKU0*6
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MI*)*W+<]R.>\>]/FZ'S>8]#,EZP??KW ]67SC/CX$2XS^B9S?^$&D?Y5@?\
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MLL"@,XZFM'V"P,PSC):M2 =O3(5Q\+(K7)>75V7(=F2@'.J2%DRW@<FLO2I
MJM#(+TAVMS&F9=?=?<84ZX#E,M21*U;@/M-NQU)URM0P>^]P,![K& #!\!G8
M@;QT?&??#HW>.^7:QMKK7OVHHSMV]R@>]_@_R?-W21-ZTK6TJUZ=*UO6];_8
MWK>O1O6_^760S>1@2XKRHN#A5HA10+P,8'JU?%#DQEQVA >DM%H]5@B%QG&7
MA382(>-08:Q[D9[X>5GCW7'(4IYA4HON5BPL;<6=B<YRUFW>6SW[BJDYSU4'
MO&9'RJR NQ< *H&.X)G:!X8!(&/,2.Z2(/'P!$""*%0H@P6,AQAXT:/C,PX
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M:1(RHL""Q(F26&7-55G8*@+,>X#T#)/H  ))/0 $G $R2%!+' 'G_P#?G)Z
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M]3>QM]AG"?Y7$/UGK)]K^Q%_R>\ ^'BOZZXC,3&>=3V3&(C$3]!GY#_^Q?\
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MM73VNU"3K^GD67^YR!_=,G_F5G1_<TZ/[[M3_8U7_J4Y?[JC6_>7I?[<M_\
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M^36N"V,=,F&?TD_RW_A)\<_^F>F?S>YY#^Z3_P#EC_Q__P"J>,_N6:_ON?\
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MKUMVM19H+[[;M^L7FV-9MY-)V[B3C/M@9QGOP)!4NKJJKKV:8\M%3/-M&=H
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ML/7:6E.Q1P2"C A=Q!4Y"].T1CHO4=>[J)KN7H=RX)P#D=3X#Q/H[YVY4N*
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M2^Y%5/!E(1:$F2TA"W8^Y4!^0QI]M#K2G&MN>T0EQ"E)UI:=[,K(<.K*>_#
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M89_O+,O;M7%ER2NVM*7K8E@V\[>6O5VJ"HW,W[EY5@S@##J,$8<J-G1F=7&
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MV,=J0^U[-H&*R.5R=NX[?J>SF^\]]_!VXSL_A?P9?%2.6?,_KO3+[$9'H@=
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MQ/2;\V9%'0Y9"<^W%A08S\R9)=WZK4>+%:6_(?=5_P 5MII"W%[_ +24[WF
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MB.V24(>$/K [:9MKD47M>49@5 ;D>XU#'9K7DG;Z&QMZ$L73E5N&X>Z5"K<
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I5FI-A(/:)&   ,#IT SU!.2,]<$DC)G_ "O)HQ$8B,1&(C$1B(Q$_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g743471g45e83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g45e83.jpg
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M 0$! ?_  !$( 1\"70,!$0 "$0$#$0'_Q  ?  $   8# 0$
M @,%!P@*! 8) 0O_Q !F$   !@(!  ,)!PL/!@P$!P ! @,$!08 !P@1$A,)
M%!46%R%7T]49(C%6@966&#)455B2EZ2QP=8C-38X07%R=9.4M+?4X>(D)3-V
M=]$F-SE"45)A=+6VN-)B@I&S0V-S@X2RQ/_$ !T! 0  !P$!
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M_M',?-CWU&=N<:+VV/\ ZV^E?1OCP>W1?*,]*>+T_P#:.8^;'OJ,<:+VV/\
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MD$$$A4@T!83F,8T),F,81,8QHU\)C&$>D3&$41$1$1Z1$?.(^<<J<6'VR/\
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M;WA;M(P$EDW5$+I87RS0D\=Y#1-Q8-IAD F ?W=* _8UL1DVC)[GN Y6;89
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M-Q:N3N;%ML""E]U/I-BU61HRFRIF*8K6J4H468);PBV3:15'?1Z?@=U)QL@
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MM7=B81,(F$3")A$PBQ*YWIS*O#SD.6"[7OX-:S1UNQZW7\#I"@I8>GJ^?L_
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MG:QI<X]X<SR4"X-&7$ >$KDURS5^YU^$MM3F(^PUFR1;*:@)V*<IO(R8B)%
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M.%!'R+6B3NB6\PQC=V72'(\5TIZVAT39&BGX=1?+DY\5%#)GATX#09JJ9K7
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MGA&JK6!S8);8QY)Q)Q:^5=]"Z:7:VE:QLS -[7['4O=&0LV@DS%Q&#R=@ ,
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M;'/]B[$Q(WA^7 !NT8P>Y'=8R\C/9'L?W29.S\R8=BZY-.(B8A+](ZWO9(Z
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MI[EBBZ5["Z1NYW!NXA: "YTOJ95'#<]_A"7GX,K45BI%1% 73H *_4+TB3M
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M\?H3"H+C+_"7]X?RY4C[_P 'YU59V?#^8*1E13IDOWG_  _F4#V'WC]"@/\
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MJT:-D" F@V;-D"$10013*5-)%(A$TR% I"@4 #/4M:UH#6@-:T8#6@  #L
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M/2IVT[@,%S?.I?U-=E^,,'_)O_[/D>MCQ#\8]"FX!\8?$4^IKLOQA@_O'_\
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M];CUM=?>2-]_B$WH3UT^CGRST_\ .$/I3ZM_B']T9J;Z71OK<>MKK[R1OO\
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MFSB=K.5FW7G;5(QZ$*P:/'4HDL0T=7FZ+;H^CV,FL,L]31:IH:BEKHJNJH*
MZB?0O9<;9]S9BX4QH09'-I:&&5U3*^-D):1-;P=+-J96A[X=0Q4])7Z2N%-6
M4$U%1W&X_8RRO8^V78"20&V50N#N&QU77S0MIH62R5 <#!C_ *,Y31&G]F[C
MOZE=EI-#94M!.6D8DHR+U(EIO.E;+GHB8%58I#H353KTQ6E ;"J NI-,3]#;
MM52^KU-HBHO]ET]:A5P0/LU/4LDF<)#FH?IFXV:EGI]K20ZGKJN"L;OQW$)P
M"_#3X_2FO*?3=\U'=G44]0R]U%(]D ,7*GBU5:[Y5TU3N< YE5;Z.IH7;"?N
MD[2>XRX7WL?/*BVQ>7BE*[LFC0LK3[E0XRTT*4B&5_HM96VY"WJB1]9=+/4$
MEV2-.K4-2;:P/)1??B/759O56[8J#OR]'T7W2@9!.*RSW.I@N%ONDU#=(*B2
MU7.M;8:BV7.6MC;&YS9'7"LJ+C0RB&?ANP'QM>\N9ZRMZ6+5<'U,!H[W:J6H
MMURM,%?:)Z>.[VJA=J*ENMIAH9'S,:^)MMHJ:UW&$S0<1N71RN8P,DIRO=!$
MB[ H%KB(2ZUN"@^3%DW3=:W#V))!.XUF3AM90<?'RZC51@UG+.H2E3DQ.K2;
M)&+>S-@761,F#AP=.LWHI=ZDW2@J*FVUE34Z-H].6VLGI'.-OK(:F\U4LL#7
MME?348-QIJ>F;#(Z>.GI&M=DM:#1=TOM%XM-PIJ6YT5)2ZXK=3W.BIZQK1<J
M*>EL5'##4.C,,=57%MKJJFJ=-$VGEJ:UY;@.<1RX#FUJNKT)&G,8;;\ZL6;I
MDH[?VR8:SB[]W3>24;N=2=[:3M4DE$O;-7VJ\<[@8"/BXN+LR[^47>V16:=2
M32G5=&]\KKFZX2U&GZ5O5KC!'%04\E,V..X:0ETZ*7;#0PNGCHJI[9HZFJFG
MFGHVQ0LCHFT[(7U*3I0L%!:&VR&FU%5$55LGDEN%2RJ=+);-:PZF-7NGKYVT
M\M=21NADI*2&GIX*Y\U0^6N=5231];6YFUZ5JELI+!#8%15MFKKO2F4Y#RT<
MQ*PMD[R;L>]JM(R(EDFI2U].)GU*E9'A5#/VC5]."Q:/6CHQ%KQO1U605U!<
M9'VJO;0WJVW&6FJ()I#+04VC:33-;#".#(35.GI174D9 BD?'3"62-[ 6V+N
MDNCGMUPM<3+O;W7"Q72V155-4PQ<*X56N:W5E!--]V8!2"GJS;JV0.,L<<M4
M8HY8Y"'=&YN[?K-]M]+KU-=P3V-K\2M=]@OJF]\(UB=WWM 8^P[>FH*0*@T1
MD(PCYI#0#%TDAV(DA%!;K+('*J?)]&U@K;7;[C5W&.JCFJIVVRU15\7!K*72
M]EXU)8*:IB+I'13&.2HJI6%V[-2W>UK@6C%]*.HZ&[W*V4=L?22P4=.ZZ7B6
M@EX]%5ZMOW!K=1U-+,&1LF@$T=-21/:PM(I7%CWM<'&\EOY_538]ML3VZU2\
M(5AOR"I>XJ0G19:-H-G<5V$?=$G2[[,51Q#NII>/;G--TFS%?N+)7K"#E)O,
MMF4B+ACYZW]%5=9Z&DCMM?;75C]*W&P7,W.":Z43:NIB^XW&UT]<RH93ME<!
M37*C,3*.JI=CGT[Y(=DOI;CTNT%ZN%9)<[?=&4#-7VS4EK%IJ(;17/HZ67]<
M6R[5-O?325+XFDU5KKA*^NHZP/:RJ9%-OAY$WSXH[Y-RU0@=ANFB.N]9UM%)
MVI$LFMEF]7;NM&T6C:SL"3TH8M6M<%8?%69*I(STJQ:@[14-/D=*NE)*;HLN
M<98]]5:6/==KS6.,8J)'T=/>]-T=DDDHI32P?KZAJJ7KU.6Q4L$LG#<!2&-K
M!/5=+=KE:^-E)>)&-LUCH6-D=3Q1UU38=45]^CCKH15SD4%?25OJ?4@S5<\4
M8D:35B1SSR93G]27NS6]G;Q>Q"UU2I["AGY9:+IDX]46OU^KUY/"/8QW)$E9
M6N1+BN-E&SR-V-4)DEA74GHD()B9_7922'HKN4=F?1OGM!JQ7VFHBX$]PIHF
MLM=KJ[:*B.:. P05D[:QX?'-:*^G-*P4T_6I>%5PSS]+MLEOC*]D%X%$;?>:
M:7K$%LJI2Z[W:BNII98))A/445/)0QEDD%YMM4*M[JNGZI$9:*H\Y]MVZ&OV
MT-@7>O14I!PELMT[88V*FYU_9IADUEI!=Z1*4GY19S(RS\>V%1T\>.73A58Y
MQ4<N#!VQ]NV"@J+59+5;:N>"IJ:"@IJ2:>FIHJ.GD?!$V,F"E@:R&"(;<,CC
M8Q@:!AC/8C3.HKC37>^W>Z4=//2TMPN-7604]55S5U3%'43/E#:BLJ'R3U$W
M=9DEEDD>YY)<]Y[HR]7;1O.FKS [&US/.ZY;*X[!RP?MAZR:J9O>.H^0:GZ4
M)"*D$!.UD8YT11L\;*'25((" A->[);-0VRJM%WI65=#5LV2Q/Y.:X<V30O'
M=13Q.P^*5A#XW@$'M!EL-^NNFKK27JRU<E%<**0/BE8<M<T\I(9HSW$U/,S,
M<T,@+)&$M<%M]\*^7==Y>:O/:F<6O7KG6%F<-L&N]BZ/&,9IPV.L@\@I-4HI
M/H>6216=-$#KGDXSJG92)#=1J_D.!.D7057H&]"ADG;5V^M;)46JKW,$TM,Q
MX:Z.IA:=T51 YS6/<&B&;E)">;XXOHST8](E%TBV(U\<#J.YT#HJ:\4>UY@B
MJGL+F2TD[AMEIJAK'/C:7&:#!BF!PR6:[F_/V"0W^V/CI_ZA-89K];)';\!^
M@J].%!,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+3][J+^WHWA_"UU_5
M/1<[\Z%/WM--_P#-ORW<5\Y.G?\ ?5U3[]F_J_:E@#FU%J),(F$3")A%OWP_
MZTQ?\7,OZ,EGRTG_ &>;^%D_IE?7*G_:\'\#%_0:JCE)5DPB_/\ \^J"^0Z8
M1,(F$3"+U[XW<<].7#R9P=LKC"2\+<<6MO7ESVBNUEQ,7?>FW+7IQF/3.5"T
MGDW5/9C7&U+[W5:)5JYQ#B1*T>R$[TM= ZPU=J&W^K530UDL/ U>^@93BCJZ
MQM/;=,V&AU!)^UKA1"&.X2=<?<=S7NK+?.R$OCBIN[Z+T5HO3=R]0Z6X44,Y
MJ=%QW!U0ZOHZ%]3==5ZCN&FH^=5;J_CR6V(T3+9L=&VBN=,Z<1RSU>(\>HG3
MFL=R;YY5+P419G%%U_7;7M*ET_2;NOSSJ79)[$I<*VK=<>(5P\8$(E$VQZHV
M68P;A:%;,4#*IS9H]R22]9/J&]:>TOH=M344;;G=:NBLMQN&I(ZNE93R&TW&
MI?65<;JP3=8=/0QA[9:EK:ATC@TTW%88?'4VF[%J75NOGTM/7.M5HHKC?[9;
M=+R4=7)41-O-LIF4-%(VB,'56T]QE+'14KW4K(6$MJN"\37@LW 37-:K6V)9
M6_W1XZJTEL5O G9P#V22IX4?5M4V2UA]I,:[5+ 5":?N;0-4F5U)NEL*\I$O
MI],DRDD]AX[S]%TIW>LK+% VU6Z-E=#:750DJHX77 W*]5UH?4622KKZ4OIX
MF477J=@IKC+5">*E<:=SHYY?1UW1'9J&AU#4.N]SDDH)[RRD=%22SMMHM=AM
M][CIK]%1VZL#*F9]?ZGU3S56R&B=3RU8%2ULE/#B1R U]J/2N\0U]#(W^UUZ
MF.X8E\\,S4!$2-C4=(,)IZPK#V.K[I* 0\&/B12<A(L9M87J2DH#(B)TXY/W
MVE;K?]1Z:-UJ'6JAJ[C'4&U]7IZJHAI QTM/'+6QS53'53N-&9S##+3-X9;
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MJ/69TR 8S*BR%X>&*QC4KA6(]2->K,+79A(B]C_+P=).H+M-01Q5-DH8!?\
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MU=3?Z%D_J_:UYZYMA:>3")A$PB81;[-)_894?]6(#_PIIGR[N/[H5W^N5/\
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MX>@)BJ8[Z07!/H3(":!4DN@1()S49NAWI/J)'2R:9<7NQG%UL8'<@-&!ZI^
M*>/IRZ)XF!C-5-#1G ]1M1'M))_^T^$J\WNH/!;TZH_@ZVU^@64O67Z3/)A_
MSK8_TFJGK[=%/E6WYFU#^B5FE2;I6=BU&NWNFR83-4MD2SG:_*@T?, D(I^D
M5=HZ!E)M64@V[9(P&[%XT;N"=/0HD0W2&:[N5NK+17U=LN$/5ZZAGDIJJ R1
M2\*>)VV1G$A?)$_:X8W1R/:>\XK9MKN=#>K=17:V3]9M]PIXZJCJ.'+%QJ>9
MH=')PIXXIH]S3G;+&QX['-!7:,LE?IA$PB81:M?=G?VV5<_V)U#_ ,UW[.V/
MU._^8M9_O)7_ /86I<&_JF/WP:+_ '7MWY0NZ\D\WPN>4PB81,(F$6\+Q4_:
MO<;O]@FGOZO*[GS7UO\ YZ:O_P!Z+_\ E:K7U*Z/_P#,/1/^Z.F_R-1*_>>7
M7KDPB81,(M0GNJ'[>?<O_==:_P!55*SOCH0_>TT__"7C\MW%?.CI[_?5U-_H
M63^K]K7GKFV%IY,(F$3")A%OLTG]AE1_U8@/_"FF?+NX_NA7?ZY4_P#YGKZU
M6S]S;?\ ZC2?]O&NSY9J^3")A$PBT_>ZB_MZ-X?PM=?U3T7._.A3][33?_-O
MRW<5\Y.G?]]75/OV;^K]J6 .;46HDPB81,(F$6_?#_K3%_Q<R_HR6?+2?]GF
M_A9/Z97URI_VO!_ Q?T&JHY259,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$72M@T:,V-5G-6E7LI%IGE*S/QTQ"*,4I>$L=,L\/<ZI.QOA1A+1
M*SR#L\!$2R#68BI6'>G9@TEHR0CEW+-8BD5#7-:I]"A]<HH*3T!%1X,ES69-
MC*.IUPHX._D9:<(1DUC',C+RJSF7D.]8UE'@_<JBQ8,FQ4&R)%'Y,-:^CRC?
M1* ]GX1/)AK7T>4;Z)0'L_"+C+ZCU2Z$IG.L=>N#%#JE,O2ZVJ)0$>GH**D:
M80#I\_0'FZ<J,EEC!#))& \R&/<T$^$@$*1T<;\%[&/(Y N:UV/>R"I'D:U!
MZ*=;?0:K^R\FZQ4>WS?*O_M*7@0>TQ?)L]">1K4'HIUM]!JO[+QUBH]OF^5?
M_:3@0>TQ?)L]">1K4'HIUM]!JO[+QUBH]OF^5?\ VDX$'M,7R;/0GD:U!Z*=
M;?0:K^R\=8J/;YOE7_VDX$'M,7R;/0GD:U!Z*=;?0:K^R\=8J/;YOE7_ -I.
M!![3%\FST+FIZLU@B0J:6N*&DF0.@B:=0KQ"%#X>@I"QP%*'3^X !E(N+B7.
M)<X\R222??)YE5  T - :!V   #W@.2C\F&M?1Y1OHE >S\@HIY,-:^CRC?1
M* ]GX1/)AK7T>4;Z)0'L_")Y,-:^CRC?1* ]GX1<5?46J')@.YUAKQP<"@0#
MKTJMJF H"(@4#*1IA H"8P@ #T=(B/1TB.5&2RQC#))& G)#'N:"?#@$<U(Z
M.-YR^-CCC&7-:XX\&2#RYE2?(UJ#T4ZV^@U7]EY-UBH]OF^5?_:4O @]IB^3
M9Z$\C6H/13K;Z#5?V7CK%1[?-\J_^TG @]IB^39Z$\C6H/13K;Z#5?V7CK%1
M[?-\J_\ M)P(/:8ODV>A/(UJ#T4ZV^@U7]EXZQ4>WS?*O_M)P(/:8ODV>A/(
MUJ#T4ZV^@U7]EXZQ4>WS?*O_ +2<"#VF+Y-GH7-3U9K%(A4TM<T--,@ 4A$Z
MA7R$(4/@*4I8\"E /W    ,I$EQ+G$N)YDDDDGPDGF54 #0 T  <@ , >\!R
M"C\F&M?1Y1OHE >S\@HIY,-:^CRC?1* ]GX1/)AK7T>4;Z)0'L_")Y,-:^CR
MC?1* ]GX1<5?46IW)P4<:PUXX4 H% Z]*K:IP* B(% RD88>J B(@'3T (B/
M[HY4;+*P89+(P9SAKW-&?#@$#*D=%&\Y?&QQ[,N8UQQX,D%2?(UJ#T4ZV^@U
M7]EY-UBH]OF^5?\ VE+P(/:8ODV>A/(UJ#T4ZV^@U7]EXZQ4>WS?*O\ [2<"
M#VF+Y-GH3R-:@]%.MOH-5_9>.L5'M\WRK_[2<"#VF+Y-GH3R-:@]%.MOH-5_
M9>.L5'M\WRK_ .TG @]IB^39Z$\C6H/13K;Z#5?V7CK%1[?-\J_^TG @]IB^
M39Z%SB:MUDF4I":ZHA"$*!"$)4:^4I"E  *4I0CP I2@          '1E(DD
MDDDDG))YDD]I)[Y*J       8 '( #L '> 47DPUKZ/*-]$H#V?D%%/)AK7T
M>4;Z)0'L_")Y,-:^CRC?1* ]GX1/)AK7T>4;Z)0'L_"+AJZ@U*NH*J^KM=+*
MFZ.LHK2:THH;J@!0Z3GC!,/04  .D?,   >8,J-FF8 UDLC6CL:U[F@9YG !
M [53=%$XESHXW./:7,:2<<N9(SV<E+\C6H/13K;Z#5?V7DW6*CV^;Y5_]I0X
M$'M,7R;/0GD:U!Z*=;?0:K^R\=8J/;YOE7_VDX$'M,7R;/0GD:U!Z*=;?0:K
M^R\=8J/;YOE7_P!I.!![3%\FST)Y&M0>BG6WT&J_LO'6*CV^;Y5_]I.!![3%
M\FST)Y&M0>BG6WT&J_LO'6*CV^;Y5_\ :3@0>TQ?)L]"YX:OUH   :[HH  =
M  %2@   #X  /!_F ,HJJOODPUKZ/*-]$H#V?A$\F&M?1Y1OHE >S\(GDPUK
MZ/*-]$H#V?A$\F&M?1Y1OHE >S\(N&KI_4JZAE5]7:Z65-T=916DUI10W5 "
MEZQSQ@F'H* %#I'S   'F#*C9IF -9+(UH[&M>YH&>9P 0.U4W11.)<Z*-SC
MVES&DG P,DC)Y #WAA2_(UJ#T4ZV^@U7]EY-UBH]OF^5?_:4.!![3%\FST)Y
M&M0>BG6WT&J_LO'6*CV^;Y5_]I.!![3%\FST)Y&M0>BG6WT&J_LO'6*CV^;Y
M5_\ :3@0>TQ?)L]">1K4'HIUM]!JO[+QUBH]OF^5?_:3@0>TQ?)L]">1K4'H
MIUM]!JO[+QUBH]OF^5?_ &DX$'M,7R;/0JAY,-:>CRC?1* ]GY155/)AK7T>
M4;Z)0'L_")Y,-:^CRC?1* ]GX1=YPB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*S&Q%++
M)WG7=,A+I8*0PG(N]3$N^K#.I.)5Z:N!5DH]@*UNK%J:-61C3CI9P9BR:R"B
MJ38"/TD2K(KW$6P1RR.C;(6F-K0\OVC?OR>X>PD]R,9)';R5)^XO8P.<P.:]
MQ+=N3MV8'=-=@=T<X&>SGC.;E5R&<0$6E&NK!.V=9-150TO8U(Q246!4XG!-
M4T/%P['LT0'J) FP3,!  #F./OLHO=N.0UK/_2S('G+CYU4 P,9+O=.,^8 >
M95W)5%,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MNIWY^\BJ+=)2/7,U?QM3L;]BY(!1.W>,X=XX;+D Y3$$R2R9%"@<IBB)0ZQ1
M#I#+ZUQ1SW.W0RM#XIJZDBD8<X?')41L>TX(.'-)!P0>?(K'7>:2GM-TGA>8
MYH+=6S1/&"621TTKV/&01EKF@C((Y<P5J >Z*\U?3_:_FZJ^P,[\]:3HY\E:
M'Y:N^M+YS>O-TG>5]P^1H/JB>Z*\U?3_ &OYNJOL#'K2='/DK0_+5WUI/7FZ
M3O*^X?(T'U1/=%>:OI_M?S=5?8&/6DZ.?)6A^6KOK2>O-TG>5]P^1H/JB>Z*
M\U?3_:_FZJ^P,>M)T<^2M#\M7?6D]>;I.\K[A\C0?5$]T5YJ^G^U_-U5]@8]
M:3HY\E:'Y:N^M)Z\W2=Y7W#Y&@^J)[HKS5]/]K^;JK[ QZTG1SY*T/RU=]:3
MUYND[RON'R-!]43W17FKZ?[7\W57V!CUI.CGR5H?EJ[ZTGKS=)WE?</D:#ZH
MGNBO-7T_VOYNJOL#'K2='/DK0_+5WUI/7FZ3O*^X?(T'U1/=%>:OI_M?S=5?
M8&/6DZ.?)6A^6KOK2>O-TG>5]P^1H/JB>Z*\U?3_ &OYNJOL#'K2='/DK0_+
M5WUI/7FZ3O*^X?(T'U1/=%>:OI_M?S=5?8&/6DZ.?)6A^6KOK2>O-TG>5]P^
M1H/JB>Z*\U?3_:_FZJ^P,>M)T<^2M#\M7?6D]>;I.\K[A\C0?5$]T5YJ^G^U
M_-U5]@8]:3HY\E:'Y:N^M)Z\W2=Y7W#Y&@^J)[HKS5]/]K^;JK[ QZTG1SY*
MT/RU=]:3UYND[RON'R-!]43W17FKZ?[7\W57V!CUI.CGR5H?EJ[ZTGKS=)WE
M?</D:#ZHGNBO-7T_VOYNJOL#'K2='/DK0_+5WUI/7FZ3O*^X?(T'U1/=%>:O
MI_M?S=5?8&/6DZ.?)6A^6KOK2>O-TG>5]P^1H/JB>Z*\U?3_ &OYNJOL#'K2
M='/DK0_+5WUI/7FZ3O*^X?(T'U1/=%>:OI_M?S=5?8&/6DZ.?)6A^6KOK2>O
M-TG>5]P^1H/JB>Z*\U?3_:_FZJ^P,>M)T<^2M#\M7?6D]>;I.\K[A\C0?5$]
MT5YJ^G^U_-U5]@8]:3HY\E:'Y:N^M)Z\W2=Y7W#Y&@^J)[HKS5]/]K^;JK[
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M$CC?C&]C'X\&YH./@RHY+9-L82+]BVT/MN8;LWCEJA+1LCI8D=*(MUCI)2#
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MG'J;^&_F_P#$3KWX+^7_ '$\O9_BJ7Y['V3CU-_#?S?^(G7OP7\O^XGE[/\
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#"__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g743471g46x01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g46x01.jpg
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MM+6VMY?7)"4W<GB!A)&Q,S0U.597<W2BI*7!T?_$ !T! 0  !P$!
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M,?"@L:.1E94;!-I(.5:Y 316CD$I\<!9>8[K#$20)'SZB.XC107<CL=HVJ2
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MK5DW3 J9=(W'&/$EPQ;Y5N+92<B.R*V:*/8 6XC9MOLSL[GNS$]:SV+1=+B
M'DXI",>J<&=B?CF4M@_Y( ^   K]XW7K:I=SG6%CMNK9,AB*MCU&P27R[YJ0
M@)2R&OY=Q)4&7;J@7R%RO:V9X5L=4&#Z/<F3=I5%EQOQ#:R(TUX=0B!P\-^%
MF#J2"0)\+=1GX,DXP>X9<J94^@Z;,I"0"V<_1DMCRRI]OF^L3#XAHSGV(.")
MJ\>-I.]PZKB;E)$BRS"4W=*?.JP1U#0;V=U]<YZC3$I# LLY70BY:0KR\DR9
MKNG:\>@[(P7>/%6QW2V[H91/;VUR(WB6ZM;:Z6*3Z<:W,$<X1N@R4W[=V!N
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M  ![B(Y"2 ,GH!W/PKVOG*Y:+B*)5VZPG 2BF51-3O*(#W%$H"(& 2]>H#U
M0Z]?RY )(W](=&)ST#*2?CTS_P "BN,@JWJ!!!5NH(Z@@@Y!&,@U^R22:*::
M**9$442$2222(5--)-,H$(FF0@ 4A"% "D(4 *4H      9$      !@ =
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M))(=TCO(P  +LS' [#+$G ]A141!A%5!G.%4*,GN< #J:RG(*BK^"(% 1'Z
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M ,8)WD&F:'B#][=LW0.LY<*IH-VZ1#'5456,":229"@)C**',4I2E 3&,(
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M!50ZA*SJ. JAVC)NI[DCY*U[&K%RF9]RU ?+/-0L?1$GA@%8L&S P)%U-?\
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M]2*Q7:948AC7ZK4H.*K5:@8U$&\="P,&Q0C(B*8H (@DTCV#9NU;I]1[4DB
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MJV'V*N9(\LX.NX8IXSJR"60E1;W38"Q.>@,L8&TMG&)<90^K'=EO0 0$ $!
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M , BF;I=@T%G%P\%%>H>K1M=A45'0L6SN0D'JSV0E)%T[%1_Y#?KK@K@W1N
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MD5$P03 ROF$[>X*>[T?2;RUN+2YLH&MKF"6"X0WLJ!X)D:.52PE5EW(S#<K
MC.0>E2II998I8Y9&Y4D;I+Z-H,;J5?+8](VD]01COFM#:RY:;HJ]F9V/6_(J
M[+6%LW>),UHS0<=-*>0Z:J(.^UM\L/$U %LH?N-Y9A(41. ATZAB.C^'O &B
MZC%>Z3IEG#J$:2I&5UJYG?9)&R2 127D@/H8]=A*C)&.]66RLM-M;I9K&2,7
M(5]NV8RMM9<-B,R-GTDY.WI]6#4D?OB7/+](O:GZJD3^P>9MY"P_6D/\;D_K
M*O\ YBY_';^"/]%/OB7/+](O:GZJD3^P>/(:?^M(?XW)_64\S<_CM_!G^BM(
M;@Y<<BMFNZNYVQO[8CIW7V]@0K1GW'5G!F30FE()2=!%-M4V(/ .I#0GFF.5
M86PD2 @I>I,"N(<:<$<#<6:7!IW%^GV<VF0W\5["D^LW&GQB^BMKN")A-'=V
M[,PM[FZ B,A4AF?82@*WS0-?XDT6\ENM"GFCO)+9[=S%8I=-Y9I89''+DAE
M!DBB]>T$' !ZX.?:_P"=7,2E4NN52A\A=F-ZA!QJ;*OI->,<=*-R1Y#G.F5&
M06I;I1T3O.<05.X5,;K_  N@=,R:STG2;6TM+6UM(/*VUK;VUJ%O9'06T$*1
M6X5^:Q=1"B .68N/422<U:)[V^FN)YIY7,TTTLLV8=IYTCL\I*A1M)D+94 !
M3D8&,#,?OB7/+](O:GZJD3^P>5/D-/\ UI#_ !N3^LJ5YFY_';^#/]%/OB7/
M+](O:GZJD3^P>/(:?^M(?XW)_64\S<_CM_!G^BIV>'+R_P"5&X^3T!2-L;BO
M=RISNKV]\Y@Y[0["A1R[V.BC+L5E+&WJL4J@HW6_?4FX/" Z,7RA(H ]N4&I
M6EK%;%X8(XG#H-RSM(<$]1M9F'7X@9 S51;33O, [,5VL2-F!G'3)Q_XFNB#
M,>JY4Q2F*4Q2F*4Q2N>7Q'^7O*;37)N7I.IMP7NF5!O4:E((0<#HAA?XY)](
M,557S@EB<566565<*% ZK47A@:F#RP(GUZ9D.FVMI+;!YK>.1][C<UPT9P,8
M&Q7&._?'7^4VVZFG24JC$+M7 "9Z]<]<?[_JJ!OWQ+GE^D7M3]52)_8/*_R&
MG_K2'^-R?UE4_F;G\=OX,_T4^^)<\OTB]J?JJ1/[!X\AI_ZTA_C<G]93S-S^
M.W\&?Z*TCMWFKR)O#FODVQR0O173%.1+7TI7CS%P"JJ;DS(9$6J1:HQ,] ID
M60*F*54$!%,!$@J_:QGB'@O@[B VLFO:;;3>4$RVQ?5;FV"<\Q&7K'=1;@>5
M']+.W'0C)JTZG;VM[R6U%Q\WO$1=S !NV;^S)N[*3G./JS6::YYS\NZ95VL%
MK[D1LI.M(N7CAN5GQFC)5#U#I8570E>*4MT<PBJ(]Q?.$"#[ !?IE?HG#G#>
MC6"6.CV-LEBDDKHJ:E-<*))&W2_.M/(Q]9)(+'!R!C&!4V&RUMEAL9 ;=68K
ML^>&YCE_7EB>OQ)P<CZAG7WQ+GE^D7M3]52)_8/+OY#3_P!:0_QN3^LJM\S<
M_CM_!G^BGWQ+GE^D7M3]52)_8/'D-/\ UI#_ !N3^LIYFY_';^#/]%/OB7/+
M](O:GZJD3^P>/(:?^M(?XW)_64\S<_CM_!G^BHP;<Y(;>V7:9.Q;5WS?75FD
M*E&UJ25?:$0@UCU9@XL*L>D=FWK3%-) J\U/"5Z5$BBHG5*9<X-4P2PGBC@/
M@#B+4] O^)=/LI=1T6X,^A&;6KFT:.?S-M<$QPQWD*W)Y]O;'8Z2#*A<8D(;
M(-'XCXGTNTU.VTFXF2TOXN7J*I81W"M%RY4P\CP2-".7)*-RLAQDYRN1)EOX
MAO.Q!N@BWY%;3!!%%))  XJQ1@!%,A2)@!AH@B8 (!>AA$1'ZB(_7,V\C8?K
M2'^-R?UE8_YBY_';^#_[J_;[XESR_2+VI^JI$_L'CR&G_K2'^-R?UE/,W/X[
M?P9_HI]\2YY?I%[4_54B?V#QY#3_ -:0_P ;D_K*>9N?QV_@S_15FGA;<IN2
M.\]T7JM;FVK<[U 1>M74U&1=CTNRUNT;2R=EKK(KY&7:UN&.\<$:/'* 1QG"
MA3IKJ./)$6X');-4MK:&&-H((XF,H4E)VE)!1CC:SM@9&<@?43U%55I+-)(P
MD9B N<%-HSD>Y'\@J]C+%5PIBE,4IBE,4IBE,4IBE,4IBE,4IBE<R_C <N.0
M>MN1SG0-+V$ZA=2WS1,0WM51)#U]TA*I7)Y>*]9"FD'L4XEFXR,0W19F%J_0
M% ">:V%%814'6/B9K&I:180G3[DV_.M;D2XCB??EQ'UYB/C"L0,8KI'P(X!X
M2XVM-;3B?2$U18[J&U0/<WEOM@GMG,J9M+B ^KXD[A[$5&CB!;K!JM%O9:)(
M&@IJ,0.V9/"(H/!01?-%6CD@)/TW2)_,;J'3ZG(8Q0,(E$#>^<*:UXB<8Z'K
M*7VEZP]I=H)@LRVMDY D1D<!9;9T]2L1]'ZQ@]:V'Q+]SWX0<-:Q#=:+P=;V
M5P8Y 9%U+6I3AUPPVSZC(O4,>R_#W KJAT%9)JX:7UG:;&]-)3L]4(B3E7YT
MT43.GKIN!UEA2;II()]YAZ]B21"!^0H9]%>#KVYU+A+AG4;V4SWE_H.DWEW,
M51#-<W-A!--(5C5$4O([-M1549PH P*Y UVWAM-;U>UMT$<%MJ=_!!&"S!(H
M;J6.- 6+,=J*!EB2<=2:V]F25:JJ0\3K\)N/O\R;F_Q#3N<R_=6_W.=(_=II
MOYCXCK;G@Q]]-]^T-U^<-+J9O"K\531W]!V?]Z>9O[AC[V.&OW.Z%^:K2M:Z
MS_;C5_VTU#^>35*++Y5MIBE,4IBE,4IBE,4IBE,4IBE,4K\EC"5%4Q1Z&*DH
M8H_F$""(#[^WL.#T!/PI7*)R4O%GWO$U6X[4DS6FQZ_92R-2DE46\>:)3GQC
M5I<"H123)JY]8K#QQS"\1<"F+8 1%,IU0/\ -_B?Q1XZO>,-<T6ZUZ273;+6
M]8M;6V:ST\+%;P7\T$40=;02,%BC1<LY8[<EB<FNL>&_!SPWXL@X?'$'#,.H
M">PM9I0U]JD&^2XMX'F8^6OH<;VZX& .P '2L+X/<Q.4"'*3C[Q]A-D.R:ML
M&R6S:=J(0]7!%Y"J%<2DZD:1<1/Q-,#-&CA;]X?IN![?+;B*IR$-TIX.ZWJ<
MQM=.ENBUF6N9##RX@#(\3R%BX3?DO@XW8^H"KQXK^#GAOP'P3J<O"G#4.DR6
M8B:V:.]U.XY;37D,<A N[VX#;UD8'<"!G( /6NO3.C*XVIBE,4KGQ\2_\8G8
M/_1MHG^+[JSE'[H0#]'G@L<?^?&_/O#H_P!%;K\,/O8X^_8'_P#':E5_4'_Z
M%A_YKC_[HCG5Y[G[3_IK28[#[!_HKU,\KVF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2N0?QNOQ\:S_ %'T#_,]^S3WB]_:^T_8UQ_MDKL+[E[]3Z]^V5I_
M-6K$] _@VO\ ]G_L&SYY<8?JX?\ 7_U36^?$+^V$'^0?]"UU5<7/Q=]-_P!
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M*2(RED9E.,JQ&">.]=N(;O6]7NK>02V]SJ=]<02 ,HDBFN99(W 8*PW(P.&
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MD$8QWV@9STQ/BCAZ_P!?2".PY9:&&Z,@D,@PN(I&D^;CD.R-(7>1B %4%B<
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M&WJ;K<-LJE6P#M W-A/56!!SETLOM)&MM+US+^Y7]SFWW$=L/^2',V,83TI
M<A-2\<XAM16#W8J2-PK$Q=MF.4G%G82!/AR<"F\/'+0\S'2JL/F8=V/+VVW:
M6W>1MAG$B1C;F#J"6.2#TQ\"#4L:1PX9M@L[KD\IWYQOM44,5N8;5>6#<^M&
MDE/K!&-N<88&MPR?)G0K&T*TJ/VCSEM]K96S8=5FJ_0MU<VKQ+5Y+5=LK](O
M-KFH^L[*DGC6GQ%GM,%%I2R2#A:55>*J0[%^C'R:C./G0YP+>V8@L"%L+9B-
MA 8D" G +#K[^V<&I[:'PV&V"UO'</*C+'=ZK(5Y+K'([!+DX0,ZC/OGH#@X
MTC6N<>LY%]*R-RMG+/65+KB_*YE,+6GE7S5<W22<<9MP:WU 1S3ZS#VQVRL"
M5OGMA,XPT06<;66.N!V5.B8BS/DYUU"0"XBZDVUJH'-SFRML_-NJ=!Y?KDL.
MF<@].O7%.ND</$DO9W,4:>;#;[_5#(3:S10C8BSD-O:0#&[<'P@#$,5SJ?YJ
M\:JS$'D)?9O/9O+1Y=MFM%*)MWFVM>:+]PR%HEJV<-WKB>SC.:\A7J;LFH7-
M-^Y4-&S%<EF[J$>2+E=JS<>FX@ _4]OGUY'D+;<.7M+9'(Z8# _6#TJ8VC\,
MJN3:WH8"<M'YK5.9'Y81M+O3S65VI*CCV93E23@5.B)H\5.Q49-Q.W.3+V*F
M8]E*QCQ/ESRH*F[CY!LF[9N2%4VZ10I%VRR:I2J$(<"G #E*;J 3P8SU$%I@
M_P#V.T_J:N"\*Z"P#+;3D, 0?E#4NH(R#^JOA6::>82]-Y.Z/C8[8V[)>)M+
M/:36>@[SOC<^R8"13BJ4I)1IU('85[L\.FY9/B%<-GB#))VD<! BX$,8HTUZ
MJ&TF/)MU93%M:.W@B89< ^J.-6P1T(SBL9XET>PTM;![**6)IIIDDWW5W.&5
M82P&V>:11AAG( /UXJV[,?K&:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*C#S;_$RY;_]&7?'^EMIRKL/U=9?LNV_VR5)
MN/U//_ZF7_4:HJY?:WM5;>]IW2&^]]ETQ(UCE*UV+H]RTKTWM[1[VP4>N4*&
MW;4X2=E(>VWR"L\:4:K.UYK"R,XF_B'OPMQ#-W\<HT>LP<FIY"DC[")=R="Z
M$J%#@$AF![$8)Z=,9&#5KN&M[BY$!6[$MN0K36Y>-(UG0$K)(K ;&4 ME3MV
MY&#6IMP\3^+<92JE+:&W-IO1\A5E])76#MEBV?:21+'7-=TS<],:[^5[71]R
MZVM=<B;EK<M@CB69.T2\9?8J&LWGMI&1 ]@@X7BBV@HZQE=C!MQP%",BX(=2
M RYZY]6#W[B1/9V@1&MKB"W9#!(K-,VT1+!)!'M>.>)U62+<-V]A(%?()]2Y
M=J/C)PDU3K31="GMTT>TSLA6N-LU5[.IM2"K9=N2'%2.<*46Z4J#;V=R5Y!)
M.7<G(R+6O/IAFHS631?23L&H.CEBA544NI.(B#N W\KZ+ 9[>_0G[34V&TL8
M88(VGC9BMJ5?FJO.-IDQNB[CE<DDA21CIGIFM>\;M8^&S$M*U>]1W23/1ZE5
M]2;OA-B6_9ZK6BPM?TU.[HU5K9.0=VB68N8(E:5OM]B7T=.1T:$@#R->V)R^
MLY72Q_(UMQAD8[0$<,6]("[U4=3D!=S#J![9).:E6D6F+LD@D;8L<,ZR/+B-
M4A::&('<05VF60891G(+$OFI.SM#X6/=OU_=DSN&GM[ALJ^ZHVW3FBV[X-K6
M+I>:G2K/J'7=JJ%?4FRLYY>9JLM*5E$(3U3*PKQ+44$59&/74/,(AWARXRS(
MX]8PQ *J0,X.0<=.^*JFCL3,LYG0/+)#,@\PNR21(WAB9%W8;<I9?3],K[D5
M'N9T/X=.GY>U71M;WMGL-(W%J%I9Z?5-N?.\[K^\7#ES1KWKZ.FZ<SG%9&OL
M4.0<C%24FI/IA**P[B7C))U)1S)BP9RRENA9LY*LN5#[BK&56&5ST^<(SGK@
MX[8JF>WTR!G?>69)X0R)-O:.22\C>,-&&)4"Y*DEAG;E22  -J;"XI<%D;)6
MJQL:_,H.2J%IN6^$=;V7>@0[-R^L.U+-R%L%T?TN7G4C,HYE=F]FG5+/"M(9
MT%9AWU=EYM[4H92,:S&CAR QQ@M)M+X[N9"V,]@P)R,= 03@8J;+9Z?O5)90
MI1GN.4UQM&6E:Y:0QEA@!P[;U"G8I4L47 Q+]RIX=SA*)33VW&FC=X5NUT?3
MT:3DL*L.M"6C<%0W"]B^/C$]J5:E/$[AIU?L,.-/)(K1\DF2#4%>'380[2#E
M6_3###@J@YG3!=7^;Z_C@$8]^G;I4(L],&T"9<3JZ0+YKIM>>.<BW&_\&>-6
M79G!])R,*/9BN,O!!X]G5JWNIT2S:_=;&MVUK%5^4<DUN2L!L2VP]HV6PW%/
M0UP2F24N;NE)92<B2;<1J<3)QLBVBW\4BXE&BWHC@ZX?JNXL1*=V&(WAR#G:
M67KGL00,=:]6TTX[MMP2T?->9UNR'VR.KS"9D<'EM)&"V[&T@@%>HKY9KC_X
M=#N)?6VS[;I;NH;@4WW+5R2EN14:UJSD=\[1UO>=IO=83*%H9$: CN.HTJPP
M[RM2BBM1NLAV1B[-S+HM1]*08R74J_,()DZ'>ZLVTY_'52".Q^VC6VF%2[S1
M[)O,,I-R IY\L3S&)MXQB9(V!0^ASTP6Q63->-O!E&0V-49#9,78;["4??:>
M[G=EWLA-;,2KG(*K:_JFU+;M15Y.GEH?OIVO*#!P\U)M(B,JD+#1S>)39H'_
M 'QRX<L-V6"R;\OE@) H8MDY'I50">@ &*B%KI^Z13*&E5+GGEK@-*%N4C29
MY<L2N$CC52P 10,=^LY-:2=$EJ#4G.L;) VZ@(0;"+JMAK,^PM$)(Q$*B6(;
MG8V"+=/6,H5#T(MEG*#I;JX15*H;S2G )R[2HVD%<8!!R"!T[CO5PB,9C0Q,
MKQ[0$96#J57T]&!(/;&<]ZR>E?C4<;_^9N+_ $]7R5=_J.?[8?\ :"L,XU_2
M],_9,_\ -VJUG,>K!J8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*C!S<,!>&/+@QA I2\9-\F,8P@ % -6VH1$1'V  #W$
M1]@#*NP_5UE^R[;_ &R5)N?U//\ ^IE_U&JM_P#=2\9/TC-$?[7=?_M#F1^7
MN/\ H)OX)_\ ^M;B^7-%_P ,:7_G"T_KJAG'TK@:?D=NODM;MZ\7[C?-G&I)
M:;+R%IU<2U:D:U76:6MY-O7+<YM\DZ<C8T"KR:JC:/A",_4&8*(R)0%T>2+&
M7F/(;>4LV-IY+Y3"[3@X/?\ >JA%[P^;J>ZDU;2)))>7L)O+,/"$BY9"OSR3
MNZGLN.W7O46]:<:-"59SJQ:]>(+QFO#74<?PTJ]:CH]C1:ZV>4SAC(;<7J3*
M:&1WQ:B.[';VNT$33$\W0:,8F5@CO8^ON&\BBRBY:Z=<C;NCE;9R0,6[CI#O
MQG);JV_J?;'0?"CBFT=#"9.(-)D$/DE0"XM%!2R,VP-F[?+.)?4PP RY"X.!
MD6K="\?=0VNFS%8YV\4I:":1]*AK_$W.NZEMLC(0^N-\[7WG4F^JI&;VT\B]
M3O%%]L256GI)2OW5P9*'B+150J5D:M733U-/N4*XCD(&T'-LY.%D>0;"?H?3
M()PWQ&#C$<5QHT+HR:]HY4!!(KSV3DB*XFG00EKDB'].*,=K]@Z;'P1@D)Q1
MX_0M=H+,GB!<8%Y_4E/U/6-?*JQ]%/3WCG2V^[;NNI2.R*FKOA52Y,Y9"S$K
MMHB8R:JBBTDP2MD+*1#HC2,:PC3;@!1RY?0J!?['?'H<N"PSZLYP<;>OJ!4U
M LNCA(U^7]'W0K"L?]D6NPF"X>9#*AO#O#!MK@,G4!E(QBO73XH<5%*Y;H]_
MSLX[K3]VH4M79*5:JZV:0T!:;-RNE.5=DFJ+70VXI\JU(T[*FJE=HR$JY6A(
M]DQEW=JFGZ:J*WOR;/US'-DJ1^D/@$RF4E1[#)P%ST'N:<S0]K@Z]I6Z2,J6
M%S9A5=KPW;-&GFO0FX[%C#>D $NQKY5>+^BI6^W6\67Q&=!2RMGG8209($?U
MQ-=G&5_F/K[EK'LG+9QR%=4YDZ[:2YURY/0J308E]\40OTI"R-D0F6]C?)UR
M2Q*3'=C^\2=A,)?B5]MOI51UW$$YRYNCM(\C\0Z62[*PQ=VW9+Z.]&0;PQCZ
M'*/*CC!SS""V0V^^1&K^(O(.P\B++*<P]#0<GO#3.C]4P;I&YT)U(Z_=:4V/
M?ME)32<TSV3#2\O#W63MT1$V:M1#NGO3PU>710M'J)9NYA(Y+">3F$PS R(B
MCYE\KL9FSG )#$C(&WH.^>HJ;F[T.Y:Y9M;TM3<000J?.VA,9@EDEW9%PI8.
M7 904.%.'RV5C]^Y5X\MGFKYNO<_>/-,M-6MLW;+U9:W=[&ZD;0I/[A9;=DH
MN*&X\N+8B\BG;ME\/<1FYTMVQ1)UPM?HJ.B; J[1>R_DVX])$<H(8LS"&;+$
MOO/TG;I]3[QN]0P<YI>;HP,3)K^E1NK,TC+>QDN6F$Q WZ@^02 ,3\\;OG0
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2[,;K$:8I3%*8I3%*8I3%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g743471g62l42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g62l42.jpg
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MG7YA0K+.#Q\%B$S)E2D=5_3,8DUKQK5CE=0%@-:O]#_$)CU*UKI6JEK6VSL
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M,1&(C$1B(Q$8B,1&(D4=?X7QWO\ 71]2[7S>H]/K(HTQ8QH.Y!XQH;".QH)
M8P6CQI25-MSF1Y4E#0^G7MICS9#>M^RXK-J<B_'8O1;92Y7B6K8J2I()4D?#
M8!U\P)G955<H6VM;%!Y .H8 C8![_'N9@"?#7Q2;YEOC+'CSR.+R[=B1</H5
M"I 2$&1;FF4Q6[8TW$B,O-6=N&E,!%@:>072.U\OU,U"]6,T^G9GF^?])O\
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M !;0V0-D GW(&SH?#9^<NF1)C$1B(Q$8B,1&(C$2VF PBPBB (^*&G A:(_
M*AS$&*3%$X,E&VI,(@/FM/Q)L20VI3;\:2RXRZA6T.(4G>]9*LRD,I*LIV&4
MD$$>Q!'<$?,2" 000"#V((V"/D0?>8A6.2\KI4(*-IO,^?5(=6RT\]78%8IE
M< P@!PH-DAB9D+%%#8C LL1#S)8J>1@ML3)@V5)@R'G(K[K2M'NNL+&RVURZ
MA6+V.Q95(958L22H8!@#L @$=Q*K56F@E:*%)*A45=$@@D: T2"02/<$B2#F
M4O&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B8W:
MJ;4+V)6 N]5K=R!.2&)3@6U QEA$KE15;7&DK&EXLR&J1'7O:F'ML[<95O:F
MU)WOURR.];<JW9&]N2,5;1]QM2#WE657'%U5A[Z8!AV]NQV.T\U"HM4YA2JK
MSNBAHM>IU*!#:W6PL/2_<#Q(F*W$B,^\=4M^0]MMO3DJ9)=>ES9*WI<Q]Z2^
MZZN;+'ML>VQBSV,7=C\68[)^0^X#L!V':$1:T5$&E10JCY #0^\_>3W)[GO(
MEG$B.NO7V#HA-U"C5/G3T:'J4_\ "QWI4B[ZE.L1_>>Z:<DZCQ]/N-H2I[3#
M.G-J]TCV>BQ5&'BL  S7909@!LA1CZ!/N=;.M^VSKWE03YCC?8*FA\!OGO\
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M.%!)12A[\PQ$?BJ*2Y<D,"D#.LYMK%MK5JPLUJ^6.-K,58M9\20RAE[@*=Z
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M!"'N<=X%*>W^7469<H;7[&R&O3VMV\OPW;]7)ZSA$^WF8N'U!!]S/7E=/?\
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M6XNI*NN^+J2K J2)SY-%&;6*<RFK+J%E=HJR:UOK6VEQ95:J6!E%E5BK96X
M:MU#H0P!GP3 <)Y7XF>0T'Q8\A.#<Q[;QWH#Q(UXB]6MM!JY'JNQ,5?Q!KBB
M>C2X#9\ITSG3,AKY +GG(Y/HU+V-(5\DY<816N$?TA\WJ?7.D7=<Z)U+.Q.H
M]/0'Q%TG'RKUQWK [=9Q\0.:CC/HG/K6O6*_*\J<?S;:N3$\:>)O".;C]+_#
MW5Z>AY[KC]+<9^3]&Q<ECQKZ3DU-::/+N[+TPV5FM[-8"M7=9@T7_4.M>(_!
M#0>+8>,]"[[SP=+TO4=SF?DKW"$"CO,+VV[%>H-ENM@H\"</>2N/*'S*<S+A
M/H<AS8Z%-J93\:WB#J!/',Q^E9NOCE](Z:UA'_YFK'JRB#\Q?W]P?C/ME\8=
M1O4'+QNA]44]N6;T#I#W'Y@Y=.)1G;^>\@,/N,OW^#]Y$5[ZJ+YN=-F,(^N.
M-[/RKB'2H#'_ +M4VF4OCMMEL_\ ;/M<J7Z>NOC/7?KJOX4Z5;^<^'<-3\7Z
M?F]1PW;[^.1D9]"G]BA5_FZ[2WX;Z'?^>>$>GH?TK.E=1ZO@.WW\,K+ZIBJW
MQ]&,J;_0^$X]WY^5OZDR_$7L3;7Y/>PNP^/$N6A/Y/;<:F^2T2/(<UKZUHCJ
M8]YOUTTVC\5('PQ=[KUW )^38'557]0*](9@/O(.OB2.[?@N_P!U\3]+)^3=
M+ZXJ$_(%>@,RCX;(;7N2>\AJY^5'F91NK<GKMA\#;D7Y\;;MDCHMOXMU&M]9
MB!8XX6VH6J##)T^A$I#R9RTO)@%5U">7C[<9!,'2$=P3ONHZ)T#)P\RZGQ1C
MU9-7DC&QNH8-N$UYL8A@[I?E*@"CZ]7GJAUYIK0BR>EC>&_"^;@9^3C^-L:C
M+QS0,/"ZKTR[IQR3:Q#"RQ,G-6L*!]>@Y"5MKZ0U5;"R3H'\X_&282B@+5T1
M7'+3,<U'8JGD%6+9P(])F;]?TD,C]="4^,?>5Z;VRNMRS$66C_&PY$AK>G-^
M?9X<ZPJ-;1B_A"E>YOZ7=1U2H+]IS@67M4/F+EK93V8 ]IY5OA#Q M;78V#^
M%,=1R;)Z)D8W6J53[=C=,MRFH'S%ZU,I[.JGM-JX,Z$3B1R V9%(0)C2'XDV
M#(9EQ)3#FO5#T>2PMQE]I>OK0XTM2%:^O6]ZSQ65D8HZLC*=,K JRD>X(.B"
M/D1/G'1ZV9+%9'4E61U*LI'N&5@""/B"-SU965C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B137/UX.H_P %>7?U
MU_SLM_,L3^FR_P!V-,U_*6?LU_XY*V<<TC$1B(Q$8B,1&(C$1B)KKY3^--%\
ML.-V'D5X7*%JF.Q#U+N@A*$V;FW00>W)-3Z!59*E(5'-5^>KVU-:=:CEQ4@G
M7R7O1)>?'>]CH/6\WP]U/&ZI@/QNH;3UMWJR*&[6X]RD%7JM7TL&5@#I@-J)
MY_5>EX?6>GY73<^E;L7*J:JQ#L$!AV9&&FKL0Z9+$*NC ,C*P!'SY\/^Q]2E
M7"V^/_89@FB>;'(Y#06T.R?B6^:^4-:A0%R:[=G&=-I?T<L-9C)-"K<-9W8'
M1[!-!!DU.J-]JE;^R\5]#Z=D85?BSPW66Z!F<3G=/31N\/9UK<7J5=D_@VR]
MC71R)7&N*XKE5MP,C+^*\/=6ZATWJ)\)>(KS9U1%L?H76+M+7XFZ?0H9J\AA
MI1U_ IT<Y4"G-QP.I4J5^FX^']4*5T(=;79H:7!F5BZA6VU6&EF=M)+#4N*V
MVV0A/-*5%.UZ6XE6AMB%+?'2]:VRZJ+/;DP8_P"<O64T00R-OBZ^QU\"#W5A
M\5/?X]QHG]!2P/M2"KK]9&]Q]X^#*3[,-@_<>TD#,YI&(EM,!0]A&R@Q\2-.
M")[>V9PHQ BDQLQG?Y6I4&:T_%D-[]/K;>:6G?[.LO7994ZV5.]=BG:O6Q1U
M/S5E((/W@S2JVVBQ;:;+*;4.TLJ=J[$(^*NA#*?O!!FJL[P8\<&)<DKSRIF^
M"G9+JY*S'CG=[APO3LMS?M.RB-=YN: 4NPK>5O:Y#5HK)N+)<5MV1'==_'SV
ME\2=6*A,J^OJ=0&A7U;&Q^I:4>P2W+KMR*M>P--U; =@0.T^C3QAUXJM>=DT
M]9I4!15UW$Q>L:4>RUWY]5V70![*<?(I91V5@)Y?T(?+.B_C<U\J1O11K'^1
MK7DSR2O6.:XS^Q#C=#XK+XP2@J1^I:*'JG>9GL:U\8W.>WM_+?3^B9/YWT1L
M1S[W='SKJ5!^TV+U!>H(V_BE5V,N_JE1VEOPIX:S/S_PY9@V'WR/#_4[Z$#?
M;;!ZLO5:W!^-=.3AKOZI0=IU_1P\G:-^+U7Q&)6F Q^+(M7C+U&J=.A:;U^2
M=)IG3X_#[VRE6O3WHRN"[O-87OV&7)[:=R-OP=T;)_,NNK0Q]J>L85V&W[(R
M,(]2QC]SW/C*1W(4GC'X(\/YG?IWB:O'<_5QO$'3LGI[[^PN7T]NKX9^ZR^S
M$0^Y"'M(AYW^$^X+?+]V*@QZQY'?2/E5@ @YM8'^*/?++9(SQ0(B3(C%1=&I
MMQ)A)D8O$+Q=ZMPVH(?889>%:+PO;([[<GP;U;%Q\+*>_HYQ\ZNRRFT];Z93
M65K8+L/DY-"6A@58?1VOX@ZLX/Z9Z&9_![U["Q<#-MR?#YQ.I5V78UY\1]&Q
MZC76P4L+<W,Q:K^097'T1L@(I"VFNP^6)E_POT3?\VO&'S!LWK_D_P#\#Y%'
M]Y_H_78L'/=,^O\ ^I]QZ?\ YO9]-^G#^ BOY;K'0:?G_P"\ER=?W&K*W_N[
MW\-SSOXL%/R_B#POC_/_ -[KEZ__ +;1G;_W=SC7D/Y %/KKW@EW*,TK_)2;
M]T[Q>JK:_P!CVEQJ[W"_%6$>OU^CXU#WL_7[GU_%Q^"NEI^5\2]-8_$8N'UF
M\_U&[IN*A/ZGU]\?@/HM?Y?QCT=C\5PNG^(LDC_>R.CX59_W;"/OUWG.^B^;
MY3\4/XM\,KZ5_DDW[ROL##K.O]*QU&\:[LT^OT_]&@PRCU^KW_I]>/HGAQ/R
MG6>I6_=B]$I(/^_D]8QR!]_ED_=\(^@^$:^]OB+K%Q'Z.%X;H8'_ .9F=?Q"
MH^_RB?N^$MY6/^$*-BR4<:0\0.>$9,"8S FML=AZ<L=->CN(BRT;EM<UB/JB
MO*;>3\4-?CJ4C_'PI#7M,+LA\+5NA=.O92!E+*3@8?-0>ZGC],(Y#MZ7!^3
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MZEG=)SZZ[%NK3-Z=E6X>4E=J$I:BWTNJV(2KJ RG1$PFN?KP=1_@KR[^NO\
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MI2T*]3?S'&O@"/:?68^55?4F1C9%.=AV#E5DXUB7J5^8>DLEJ_ST)/S!]S.
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M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(D4US]>#J/\ !7EW]=?\[+?S+$_ILO\
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M/MI<1<<,,$.-J?\ B'$R4NZ&-OH5IB/MK;JV]Z=]$KQ\ON_[D_\ WD?/[_\
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M!G1VI<.4PYKV7&),9]#C+[+B=[2MMU"D*U]2D[UD@D$$$@CN".Q'ZC((!!!
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M13;YE1X"HL2R%WM\SU*-(1:JCXD[[=C.3#RAD69"BJRO@XY<^/9N*IP]+';
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M\JT%5-5G)_J+P;;_ +(UMOZMRXLK(8AT(7ZQ##2_M'?;^N8Y7^Y\VM-R^@X
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MP54S(L0^XVD-  28%?+V>-UNZ]:G.P*W]*Y%7^1D2%XFB-"+T"Z+,'1A0PC
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M\1.?>?\ 9_W_ /VQ$>\_[/\ O_\ MB)K'B)CUGL<>JB'C$D982[3+K#6X-8
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M,,E+$4*=4['RQBR5;3QZ4R!#PI'+XMAEB2+-G?=B$#XU!R.Y6T$2MWQ:UK+
MOR:LVU[(XHJT8]Y1_0.;$7% P*#:H>/KXK"WL6UI=!Q6VM\B3;;5R7U=A^+#
M:/(Z+#?IV9^Z)<+)4RO-HX82%G";7>X%6LL\D1FQYPF$0AS7HC@4;%@NLDID
MB3&]AUR:2'QX$=M;NF2+KJ&&^6JM+%NY,P9*BZ  $,5(WR8G:@#VTI)/Q&IM
M8S*:P I#/Q8DG8&B1Q '<DCXD #Y^TPI_J]D1U^/3T0P>JHKHD?E3S#L:?\
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MA)H4Q*F-P2LZ#D^&U:6,UB\JU9B@6S;*MZX[$$J /QK=@VB54D@;4'1<A79
M%;3D*"2N@34;@".6SZ!WX@@$Z^!(\T[R;&QS4,%#H5J(S;%9+76*2IN=6([%
MEFT7H3/,+=)?6^:TX A";3*AN-[*-:ED@<GXZ!#>(QIH>-*X;%2QM0!$1[.S
MG@+*C<@'ITY-8/U3H,-$Z(8OI V%X-LLRKW7U<+!6Q]]KIB/<=QW'<:EC1Y=
MUU^JMW2%S^\RP$O=!%C5,?1Z48FV[H@OFI<+6FZT.-3[%)W'A]2!;(DA PLR
MTL78/AV)338%VPS] ;S/+-M0?\:3]8*$J-RL_,J$&S2W$,5)Y+O1Y!:_2APY
M^6_'T ?5)Y6"LA>*DGL+!L@'ZK?#CRR.T>3(2LT:D7+?/>GE9EW^D"HU,'5$
MB[;Q3=1A$)EEV5$I:4]&5$4.5 @;7I,<A-G#7ER80=V67@PF$SVVU^;2!5PW
M87'EL;" FF)'OO;?$ $:+:4V;("HC\+"7Y:0*>?I!)VOO\-#YDCX=Q9C?EM5
M1<OY1 I'0#UCU8OHL[7A()R85BEY*.B%@C4T?#^+*1VS],YC8;O WH>X]& 3
MJR\79&[.-[CV7I[MW-M2+QY\F;2E1Y(8@_5/"RY*SW^L' )X]ZME(#Q".6Y<
M>(&SR/,@:_G)6SC[M;UN>H5Y7UXC$&E':'>!(2RE45>ESS#06%)L]XEN5A J
ME_*-EED09PK])7%,-G6H+<=NM6EZ<N*P-8=FPV ZEE\VHLB\[ I8A*ASW9RX
MZ91P_1V3S0#9;0D9*D E'4,>*<@ 6<\=)QWL,>6O5K7%MZ V9$)7>XL=E 4<
M9JK%J_,C.3;&,@PC,FT52N_1\])AW6P6#9"/7Q#!BYP!E.KM-6'FE[#&=-VD
M<95#K9\:*R6JLX[VMYBL.R,2H1WYJ#4B:+MQK)L:SD%0@(5VREKEW\Y4'$J>
M[  \E7B=.S;XC;@(J<26[L&TK 1+9/-+G56+64(0K-V?)5CZ8,R(PX>.F.SR
M-!<O3UL$#FDDT.K(#0M3KMB0B4B*Q($]3YP\F0A1F6D?NG3K;%1E>OB_EZ))
M&A;Y0K+;&@K-8Z[!)!IM[>D;S;+K4LI5]KSWH D\.?(  DD@*IU\K*^_?MRG
MS #/3X@)'+NM1CGO!D8^S+HE@;B51VR6V?2:L1+NO0(KC8(L8'2R+A*<@2F#
M78LN;)2V186)U/X/;3-YU!4;*ZM3;\$%CA>Y')5.@HY$N0 -'E'TI=A?+MY=
MM^AM+R<HI)T/22"=]M*"3W&IQSWR[#7(%R,I(IMEBM]+?B!WS*HC L&$/+*
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M!)UK0WW(WH'<D^?V^#8>73.ET$W7Q=;^DS@03;[2),62 >APB7R21(J5.K!
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MRX!4AB5:Q671ULDJ."@<B"6UKVVCYI?(/2Z8+N0Z'(',$)!F$Z/EO1GI<">
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MAB]%B"(C,6.REMN1MKZVVV4MPUEC@!W9M,S>H[/)^/(DGN2W$;V3[20JK]4
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MFQS9TR8PX*<G^^(3;=8)QEB&1B#['.G(F66$8E0H#L79,FY*VK5B VO5MN0
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M^+#1[,NSH^XV=>\L55O=0=@J=@'L?<=_@=#8]CJ6#7+N:;4,VGG]+9<"")H
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M\,D0(M0D3)D^(_(D/1IDAYR0PZ^\XTXA;J]JS-MI4*;+"J@JJEV*A3V( WH
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M.Y   )]@ /:>>7S2H39U0G:%1X+%*L$VV!@XR+ 'AEV>6&G5]H[/A1X:-RB
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M#,R:&^W%G9EU]5F8C1)W/!-D\%VV^1XC9Y!0=G7?850=^X50>P$M3/)N5QM
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MWT2=D$]Y?+YQF@=!%2!A8",ANR)3DM94>"K+\]3LDI",D$263H,T)*1BA,;
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M1*?]TRCWLE]Y]SVG75J51F9V+.S.QUMF)9CH:&R=DZ  'W#4L%"@*H"@>P
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2&(E9'ZG7\?\ SWB)VQ$8B?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g743471g67c45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g67c45.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X8=4:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S8W8S0U/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!46#DU+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,CDS-S0X)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" Q-"U!=6<M,C Q.2 P-3HT,3HR,B8C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" Q,RU!=6<M,C Q.2 R,#HQ,3HR,B8C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03OB@*(@,2!R87-T97(@:6UA9V5S(&AA=F4@82!R97-O;'5T:6]N(&)E;&]W
M(#(V-2XF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.T%R:6%L+4)O;&1-5"8C>$$[
M07)I86Q-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&ET96US(&AA=F4@8F5E
M;B!F;&%G9V5D(&9O<B!#4SHF(WA!.R8C>$$[16UB961D960@:6UA9V4@:7,@
M;&]W(')E<R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @
M9S8W8S0U+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @($1E;'1A)B-X
M03M,;V-A;"!4:6UE.B @(" @(" @(" @(" Q-2U!=6<M,C Q.2 P-CHQ-CHQ
M-28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q-"U!=6<M,C Q.2 R,#HT
M-CHQ-28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU
M<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@
M(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H
M96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@
M87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03LF(WA!.T%R:6%L350M0F]L9"8C>$$[07)I86Q-5"8C>$$[)B-X03LM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF
M(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G-C=C-#4N86DF(WA!.U5S
M97)N86UE.B @(" @(" @(" @(" @1&5L=&$F(WA!.TQO8V%L(%1I;64Z(" @
M(" @(" @(" @(#$U+4%U9RTR,#$Y(# Y.C$R.C$W)B-X03M%4U0@5&EM93H@
M(" @(" @(" @(" @(#$T+4%U9RTR,#$Y(#(S.C0R.C$W)B-X03M38W)I<'0@
M5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ
M(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K
M)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N
M(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E
M<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86Q-5"U"
M;VQD)B-X03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @
M(" @(" @(" @(" @(&<V-V,T-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @
M(" @("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,34M075G
M+3(P,3D@,#DZ,CDZ,#0F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,30M
M075G+3(P,3D@,C,Z-3DZ,#0F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @
M(#(N-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'
M<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE
M('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M
M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X
M03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE
M(&1O8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4+4)O;&0F(WA!.T%R:6%L350F
M(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S8W
M8S0U+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @($1E;'1A)B-X03M,
M;V-A;"!4:6UE.B @(" @(" @(" @(" Q-2U!=6<M,C Q.2 P.3HS,CHP,28C
M>$$[15-4(%1I;64Z(" @(" @(" @(" @(" Q-2U!=6<M,C Q.2 P,#HP,CHP
M,28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R
M871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @
M(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K
M(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E
M(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO
M=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF
M(WA!.T%R:6%L350M0F]L9"8C>$$[07)I86Q-5"8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G-C=C-#4N86DF(WA!.U5S97)N
M86UE.B @(" @(" @(" @(" @1&5L=&$F(WA!.TQO8V%L(%1I;64Z(" @(" @
M(" @(" @(#$U+4%U9RTR,#$Y(# Y.C0S.C0T)B-X03M%4U0@5&EM93H@(" @
M(" @(" @(" @(#$U+4%U9RTR,#$Y(# P.C$S.C0T)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X
M03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L
M96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P
M<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86Q-5"U";VQD
M)B-X03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @
M(" @(" @(" @(&<V-V,T-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @
M("!$96QT828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,34M075G+3(P
M,3D@,34Z,S$Z,S4F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,34M075G
M+3(P,3D@,#8Z,#$Z,S4F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4+4)O;&0F(WA!.T%R:6%L350F(WA!
M.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S8W8S0U
M+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @($1E;'1A)B-X03M,;V-A
M;"!4:6UE.B @(" @(" @(" @(" Q-2U!=6<M,C Q.2 Q-3HT-#HR."8C>$$[
M15-4(%1I;64Z(" @(" @(" @(" @(" Q-2U!=6<M,C Q.2 P-CHQ-#HR."8C
M>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O
M<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @
M(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES
M(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O
M;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN
M9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!
M.T%R:6%L350M0F]L9"8C>$$[07)I86Q-5"8C>$$[)B-X03LM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!.T9I
M;&4@3F%M93H@(" @(" @(" @(" @("!G-C=C-#4N86DF(WA!.U5S97)N86UE
M.B @(" @(" @(" @(" @1&5L=&$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#$U+4%U9RTR,#$Y(#$V.C,U.C,P)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#$U+4%U9RTR,#$Y(# W.C U.C,P)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF
M(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@8V]M<&QE=&4N(%!L96%S
M92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M<&QE=&5D('!E<B!P<F]C
M97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S
M96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86Q-5"U";VQD)B-X
M03M!<FEA;$U4)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @
M(" @(" @(&<V-V,T-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R
M<C(Y,S<T.28C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,38M075G+3(P
M,3D@,#<Z,3(Z,C(F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,34M075G
M+3(P,3D@,C$Z-#(Z,C(F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-28C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[)B-X03M!<FEA;$U4+4)O;&0F(WA!.R8C>$$[+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X
M03M&:6QE($YA;64Z(" @(" @(" @(" @(" @9S8W8S0U+F%I)B-X03M5<V5R
M;F%M93H@(" @(" @(" @(" @(')R-3 Y,# X)B-X03M,;V-A;"!4:6UE.B @
M(" @(" @(" @(" Q-BU!=6<M,C Q.2 Q,CHR-CHP-B8C>$$[15-4(%1I;64Z
M(" @(" @(" @(" @(" Q-BU!=6<M,C Q.2 P,CHU-CHP-B8C>$$[4V-R:7!T
M(%9E<G-I;VXZ(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N
M.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R
M:R8C>$$[)B-X03OB@*(@.34@8FQA8VL@=&5X="!C:&%R86-T97)S(&-H86YG
M960@=&\@;W9E<G!R:6YT+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S
M(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[07)I86Q-
M5"U";VQD)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<V-V,T-2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!$96QT
M828C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,38M075G+3(P,3D@,C(Z
M,C@Z,S,F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,38M075G+3(P,3D@
M,3(Z-3@Z,S,F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[
M26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y
M<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H
M="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE
M8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H
M92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[)B-X03M4:6UE<TYE=U)O;6%N)B-X03LF(WA!.RTM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID
M97-C<FEP=&EO;CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/FYS865T975R;CPO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @
M>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O
M:6UG+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$Y+3 X+3$V5#(R
M.C(X.C,Y*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X
M;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y
M+3 X+3$V5#(R.C(X.C0P*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @
M(" @/'AM<#I-971A9&%T841A=&4^,C Q.2TP."TQ-E0R,CHR.#HT,"LP-3HS
M,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS
M/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.G=I9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z:&5I9VAT/C$V-#PO>&UP1TEM9SIH96EG:'0^
M"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'
M26UG.F9O<FUA=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^
M+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)
M1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!
M44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G
M:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!
M.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!
M64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%P045!
M07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!
M04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[
M05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"
M04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX
M0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H
M9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E7
M6C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ
M;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O
M4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX
M9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#
M0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[
M,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I
M6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$
M.$$Y531Q-T9867$W1EA9<3=&54IR028C>$$[<G!.-E!',VPO=T-)2$M.5"]D
M4R]Q;C=M,T(Y8V9E2&PO;VY/4S18;V5*,V]N=W@T5C1M=E)/4$-V13,V2CA-
M949E2C-O;DAH6&EA.28C>$$[130X2SA49F]N=W@T1C1N96EF1$AH6&ED-DIX
M-%8T;F5I9D1(:%AI83E%-#A+.%1V4E!H:G=R>$XK:6-E1F5*,V]N=W@T5C1N
M96EF1"8C>$$[2&A8:60V2CA-949E2C-O;G=X-%8T;F5I8V5&94HS;VYW>#16
M-&YE:6-E1F5*,V]N2&A8:60V2G@T5C1M=E)/4$-V13,V2G@T5C1L,"8C>$$[
M34HY6DYV,F@K=DI2:G5%4VQS.5IZ<VYM;EEQ-T9867$W1EA9<6AT549D375X
M-'=Y9CA13U4V:BLW;#=J.7I::2MS93A04%!11V-Z=R8C>$$[3S@T;F5G365"
M94HS;T1(9U)X3SE!63A#.%1V44=0079%-S!":G=*-&YE9TUE0F5*,V]$2&=8
M:60V07@T1C1N96=-94)E2C-O1$AG6"8C>$$[:60V07@T1C1N96=-94)E2C-O
M1$AG6&ED-D%X-$5C5'911U!!=D4W,$)J=THT;F5G365"94HS;T1(9U)X3SE!
M63A#.%1V44=006YI9"8C>$$[-D%X-$5C5'911U!!=D4W,$)J=THT;#!503E6
M4#E99G)W>&AU9WDR96Q:,6)O2%EQ-T9867$W1EA9<6]8-')9,TDX66Y(+T-N
M2S@S,"8C>$$[2#-&;FHK;V4Y:&XQ635O94(R=D4W-G1J=TQX2E9E*UED0W-9
M5VUU<FXP-&Q&=WA9;S4R<S,T5#!!5W T3G1T,3=B6DE94U5(24503"8C>$$[
M-7,P0DAU-&A,25IR3DIN:U%W5$E'*W)Y3$1)235(4EDS<$LT5#173R]W06IL
M=4A2>7E315(O15=%.#1I0V4U1C9$<D=N-C-A;65Z3"8C>$$[5E$X6F]N1D=2
M:BM"0G!557DW6&1N>3 X9T1V8EAP.55-;W-*;#E7>D,T2$DT;F96:FIW3'A/
M*W)(=W@T1C1N9E9J:G=,>$I*965A3B8C>$$[2',Y85A38FAN5UEH45I!=%56
M,T965G4K-$DS05!83FQG-TIN:W=N24]N5'9P>&-M=&I$24E(<6YF,5DU<F5"
M>75*,S%9-#A#.%1V<28C>$$[>#A-94)E2C,Q630X0SA3;&1'1S%T<&)M9'5%
M34M&-4<V,%9253=$2EDX2FY)4DA-;VQK15%395%1=6MA<'!E<GA02EE4:5E2
M,$5Q."8C>$$[5U9L2C961$%::V%V<R]*9TE%*W)6:#%58V=U2U K<DA-6&=B
M=4HS,6)(9UAI9#E73U!!=D4W-G-F1$AG6&ED.5=/4$%V13<V<V-E0B8C>$$[
M94HS,5DT.$,X5'9Q,E!!=D5U:G0O=T(T=GI'1TU.,$=7>D]--D8Q1'-69&ER
M<U9D:7)S5E5R;U9T6F@T;S,V:FM-;C!N,TUO9E5'3R8C>$$[96IM<#184#1N
M96IH-%8T;F5I365&94I4=6)#0S5T-6)A9$]C17E.2$MH<G5R:6I$8GA"=WAU
M2D)(34E*<U55=3AT86)O,7)P.&ME:R8C>$$[46U',D9X3VIQ>D]X37-%:&=K
M3EA:>CEQ3&)F<&QU9DQ03$LU;7EW>'AJ059%544Q.4A+949S-&YE:F<T5C1N
M96IH-$8T;F5J:G=R>"8C>$$[2D)Q=6XK5W!03D=L3&4R-U-A=E!(3$I9>6=U
M14,R8DLU-4%-1G%$34-+<6-Y365B2D1'67A.4E!.<6Q#0FM#4G5%+SE(36)G
M8F5*,R8C>$$[;S1E0F5*,V\T.$LX5'92=V-#.%-N9%=%1C%B5%=S-C@T2C!A
M3U9+;&%O-#1S2V=G:EDY<VY#-&M32$U);%)&1DHO2U=M849B,D5Z-B8C>$$[
M4D5Y4DYC5'=44$E36&%3,&YE,V9Q5#A)94YU4'1V,WDO5EHX;5EG>DXP,31C
M8UE$,&A04%)Z1S17,VED-D]00W9%-S!C949E2C-O-"8C>$$[.$LX5'92>#16
M-&YE:FIW3'A/.4A(:%AI9#9/4$%V17532#1H.#A22&1":WEB3G<V.3)+=7A6
M,DMU>%8R2W)*.31*0B]K;CE74FXY2B8C>$$[6E(U:$HO5'I8,#56=3E01VQT
M,W T,'1U35IP=#$W63!T<%HU8S!M*S W5$1B6# P5GAD3F-853AK<T5B4E)N
M-GAC>51I:4TP:%=G:R8C>$$[<#EO-%-,44-M9G T2U1B=E1X<&)D-F5.3&)V
M5'AP8E-,52],="]D96)D13%M2V5*3%!426)Y2S1G6D=-<FTV15E89W=92W1$
M1E4Q0B8C>$$[+T=O:T]6279D4&94>4Y*=#-P-#!T=3E01VQT,W T,'1U.5!'
M;'1*9DM/:#9N<$]K=F%A:F-1,U9Y.3-E6%)L=#0S:%-L,V-Y6$9/3"8C>$$[
M=DME<W O83(V8C U1U5T>6=':S8Y4$DP;3-E;FI3,C<P.&%7,V5N:E,R-S X
M85<S96YJ4S(W,#AA5S-E;FI3,C)S9GA$-3111DI4<B8C>$$[3FDT8G-69&ER
M<U9D:7)S5E=Y+S-4+S9P+U9K6F-I:V,P=31::# S,C=H:E,R-VAJ4S)W,BLP
M6'ID3')F;S(O;6%+1TM6<G5:-TAG=B8C>$$[<E)W>E).1F)S9RLP-&EK06(Y
M:U9R6&QT4W=14$1D8F0W2'A">&-.-SEY<G!/;"MB=$YT1%HS1W9W87!Q-UA,
M5'A,8W%)=V)-:TIX2R8C>$$[<%=1<W%Q5T1$8FMA1W1+;#1#4F1B3'AI-G9D
M;'9$255Y=#-$1VQT,T1"4S)G.5AS-VTT<U=J=')W,DUG94YZ8VA1,45J8T\V
M,$I!*R8C>$$[2E9+;C4T449T:59H-60X+WE24EA%+VUI2BM"53AO67<P8W%*
M3DI+-T5K555Y2U939W%%2#@Q3C5%95-,5&YY6F$K86].36%,>D)E,B8C>$$[
M=6]Y0FEB83AT<3AM47-X-'EN:D=J1F1G1U96<C-&4E9H26)Q0WE$:&=P3G4T
M64M7,V--85<R13,S;'IZ,4IQ=SE(>DUK1G)03F130R8C>$$[1&="2D9$27),
M0VE,42MR=RM&-B]$>$E)*TQL5F)!3G)P2$9U=G1D12]-1WHQ1DA/=5<Q-4,Y
M-6541S!U1C0O-DI+.%ET-%)X5&M7:"8C>$$[:E8R-4%J8V=D2VY"5FIK=D5Z
M4&AK2U1B=4=';'0S1$=L=$0V:F$S3GAP.3%B,G,U=&)M84HT-$QK1&M9,UI3
M1F-$=GA*<FI3,G=U2"8C>$$[>78U.'5B:6%73'I313 Q:$]B2U)E3GDW;55+
M<V-J:U)W2T9J04Q+:6LW+W1'=&-N2TY':4XP0U9I=V1M4RM7<F)723=36CE4
M,4-0528C>$$[;6UK5C=A84E)1E=0,$DP6D%55D$S-S%:1W(W.75G16]K1VE+
M55-"1FA.*T=2<$YU-%E+5S)W;31W9TQA6EIM=4]L8R]M=GEV8G9C<"8C>$$[
M8V%X67=V6DYW=D9K=5E634Q5-6-:45<K03!.9FEX5F%03C-L43-,,F\Q<7=.
M,49),$UK07599E575D]83TYL-59$3#9B,4A58U0T628C>$$[<6UC13A-.$UC
M.$5I>7=Y<4AI;%%H;%I71E9:5T=X0DA1-'$S3$Y$0V]E5C%J57-Q0FU)549N
M64EI,5!D;5E!94IX5F1I<4975U=35R8C>$$[-D))16-*.4U+0C%R1W(Q2B]W
M0FQG;'E33V%J;4DS3WA6,DMS6C@Q:7DP+U5D3#$Q;FQJ=5DU5&%U26=$-C!$
M23AR;RLT,E%2;'=F;28C>$$[3SE2;F%-4VU*67A615AV,W5$<D1(1UDU1&1G
M,70S9FID<GDX:5@S;5!6.5DK<WIT2'I&=&)7:C Y3E5H+V1.2798<DQ&3'@K
M6CAC3R8C>$$[;W5'2TU.=#DO=T)N>7!';G%E5U4Y.71V2W4O-3)Y9DU">C-9
M<3=&5VU65U5Q=T1+=V]Y;F-%2'-C5EEF3&4R='1P96]A3VQZ2W=A-"8C>$$[
M83%T-65027!(>"M.44-D>$=S8D1T6$UG4DI)3%9D5T=7,CA#5SA#46]3=U%5
M-4UA<U0S3$AU4V1Z;$).;3(P0VQ407)S5F1I<55A."8C>$$[:7AY5U8X2FYJ
M:V=L5TU2<%-K<75Y;&MB-D5Q3CAV=U=B:C-T5U=H4C=N864P3C5R1C-E2DLW
M2D-&=#%I3WEC;S)D5V(S,S5!9C(W328C>$$[-VI!1'921W!32C=K,WEH=61I
M<G-69&ER>FU,5F)3=S!$5TY$5S1U3&A*3'EB4CE0;EI2>6I:;V94-&)U2VE(
M:#$R<G1M-T]'5U-C328C>$$[;7<Y4$5F;BML,#1Y>&A#8TQ*.5A#4&PK:#9"
M6C)Y,G1R1F)Q-U-#2E%P:V5H9'E"=7I%57%Z2&,K*V%F2DUY:U-E<G1O4C19
M9TLR428C>$$[6D]X5G-D4FE&4BM::E$X*S@T*U9V271J1'%&.7)E<'HV9%!Q
M.3%.94YE>&U-5$M9.4UL=%I%:D%H97-C9&PV>"M*5TLQ3&-U;$97<B8C>$$[
M6'DO-4-&;#EF,#=Z2VM/;G@V9RMO6%9X0DYP>E%Y5%A41U=+3V52;UA"5E!7
M+V,W:'9S;7!+<5%Q9W!F2FXU6#9L939,>#AX4GDS,B8C>$$[;%=L:%HR2' S
M5FDP<VM/;G1-535F=3):=E904#%!=$9*44UO5FM"0W)'<F8X<&9Y<$TR;W1C
M*V1"22MR:4]Z:$U.,7!S8F5K5$59,28C>$$[2#=P9SAZ;7IO5T%(3F$Q571Y
M67%S;CAK95=0>7@P+UAR3%8Y0CAX2F146&]N+U)E;F5V6F5N*RMJ4U-:64EO
M-&\U=F=I5D1W<BLW5R8C>$$[9T%69'-696<R+SA!96%H+WAL2"]!0UEJ=U,U
M2FIZ53AX1S54=6)M0S)T-6)M-&M72S-H4G!*6EA)0W%I:7)-4V5G07=G16UG
M<D$W2"8C>$$[.'HY43%+5TMF5#E,9T]L6%5S<V1L9%A&,392:T5827,W9U)3
M96QS=&5,8C!O931Z6FIS-%9V3&8S3TUD4G9S15!Q,VTS42]-;#EB*R8C>$$[
M5V11<TI)<BLS=C1F5U5Y;UDP6DI"1S16-'I6>7=C<'@T:EEK-T5:6F@P:SA1
M3U%3,C13-&5R,45*;4]-:7E:1#<R<G9Z;&](:VI53B8C>$$[8U(W2U8S=611
M56A9;E)J>FUH4U@T9WA5<$=766M%5C-A;5(O2WIZ-#1'*U%R-U=73$Y$2&QN
M0W5:=C=!<#9D*V-D,V98;G!P;W%R0R8C>$$[;TUJ2TQO3DM9,#-9;T-I<5=#
M-VAE5R]3=51L,E11*W)F,TXT,61N:SE#,&I6<E!6=$YG,4=Y679B6$,X:TI&
M0TM%<7EK94MS0T1M<28C>$$[>31Z0U)I95EC<4UH25=%;CAY96,W6%,Y4G0Y
M171)>&5E66)Y3G!R87=*6D8Y1D9D,FQD=VHP1DE7055!<WI51D\T='=A8WHS
M3S!E.28C>$$[13AN1#<P:FHO3E%W5UEV3E)S659G-7)'5G1R<%AN*TY"27)#
M0U9)5'AO,S@S6'1M6DQS>F]*9DUB9E!D;T=Q-W=U;&HP4RLP82\Q=R8C>$$[
M,C5%8S$W8GIH1V-Q5BM+3D=5;&%H4S1K6713=C)V8DU/:4-"8F)D9VQ!870K
M9'1T8C,P.6Y:85),3DQB=55M831M:FA!3D%66E%G;28C>$$[-4%G,3=:;#1/
M>7I-6'A.5U160U!24'9+=FXK3%8U;TQ7.70Q<S=M.41.665M-6U365)G;5%C
M=4LX1U%,=4<V.7-Q,5=H3TU71%E(4"8C>$$[>5HT<S1L<U=5,V0S8C)D<DYD
M,TUG:71R94YP6C57-DMI07-Z2#)!1UE)0DIO3C="-V8X04UU*W8P9W8Y3C!U
M3G1'=6I3,'5B<31-1"8C>$$[=E-95S=->6E/5E5(<4XT;C1D>E-T0G-O.6YI
M=#5E<C-8-7503%!824MZ*V).3SAW5'DV0F,R:VQV9E%4>&E90U-.:T)6+S)*
M14I.5R8C>$$[-#AD,4A826Y32$@V<C)P:DQ-2F5M;3E8.# V3C51;#%I-F4P
M;6Q"=5E42TE74V=->4Q2<4]Y555Y3V1X6&,K07EV2&=L;$5D,E)Y0R8C>$$[
M16IS;$=N9FY"<4=O6%AO=V%*175X65)T941M-$A:4#-96&PW5GI-;#)447-Y
M*WAR1W)S-T(V2'!7<5=7<39F1&8R56=L=' Q-4DS9B8C>$$[=TE)-T5(66I.
M5&MX;45J13AW-6-:0U%S2E U<#@T4C909#)7;#)C079T8S%(;3%P63@O5$AP
M>'%795(S-'9X2'<P554K22]34F)P.28C>$$[3V-L:S=21$=C*T9)<F8X04Y/
M5U!3,S%054Y.:E-Z:FU.=$EB9396-5))1C4O=T(S2W-64E-V4G9O>DYL,EIV
M46QV>C5.03%7,6M*4"8C>$$[8S)8;&I69$0Q<GI"2' X,V]3,TYT9FQ%;F]6
M8FMW9'I13G=9<$EZ4TM/6%AB8U9Z2DAI635W9UID0T]8-"M$<G!$2&MH4$IW
M.5%E9B8C>$$[-"M+2C%,.#AB0TLX;G,Y4#!Q5S1M=%I$1D]:-5DT5D)(4FM+
M*W1Y53E2,#)Z2'@Y:WE03U9/=T]S:E9G36<X<F5F5S%E-'1R82MS,28C>$$[
M<S5,-4AF5#5)<%)-:W!I<5I54'=Q,&))3B]I1RLO,# V<E%N1TQ"=75B4$9N
M-&I21$QS,3=K3FIQ35%Q4'I-845R.'=E5V1&.'=7<28C>$$[5W5R44Y00D=:
M0VER3$Q#4C8P36QU+WA23D<S>%)43W98=EAQ0FER>C-Y:VXU87)9:E)T1C!0
M54Q7>6)86# K:'5M3%(V:&%R3SAR8R8C>$$[+W)J>DEI<&)S5W!S-&8W3&-N
M;W%H3D]8.&U0579.6&933&TP;3!/95!33&E795=76&ES;'A*67%(.4LT;E%X
M0FQB;#9N4E%P23)41B8C>$$[5C)P5R]W0U0Y;'%E:S9O,&0Y>E Q:E5O2D,Q
M,TE,;5A2;S)G6DIX8TU:0DI%1%=S;DAL=TA*:4%":7%/.&TS2#5/>#9T<%9N
M-5ET<B8C>$$[:5<U;&IM=')D,T8K56EI;FIA-S14+UA#4&AL5S-,>$)G93=,
M<WA*5EHT>%,P<V1734Y)56=,<VY&45%L3&1'<48R2%AE;58U-6-/3R8C>$$[
M4C=G5V5)6$E$>E-783AV;S1R5U$V;7 K=$5+;SE"9&E15SAF8DY(3%!)0THT
M+W$X;E!%66MN,#AV3E(Q3WA'<2MV;V5O,VMD>F%8128C>$$[6CE:2DQC1D=5
M14=N6'%$=G0P-C5:1%!-6DM'5#0P>$U9.$XX4#)S3'0O>60X9WEI-#12;$)B
M='A+*W!D8FUT3G8S,S-:9D1T8E5%2"8C>$$[.35Y+V]H:DQ4-'A8<#4K82LP
M,%114$M6-W!L.7 P4WAX5'=496Q/<V9Q<VIS>58U3DLW3G5R158V9U9!,GI9
M84TU.5IH24=4,5=$>28C>$$[-F(K6'5D8G)C;4Q46EEY;$1A:5!J="LQ3E!-
M4&PW44YD,6DQ=$Y894LT;79B34=9;4=J2W)/:E)$;D=Y;FM#<F)Q86=F-4IW
M>'=A<B8C>$$[2$-81% P>&QZ;V5D-V9*2C%';FQL:F-F5UDO9E9F<%-U2#AM
M+TE4>EA+2W!55WAO4C9L,5$W06HO9#-V;4)(=%1517E(:694+U)$<R8C>$$[
M1&=X-V5J;C5S;3!7,6<P5'DS06UL,UET-T-.:4DW9C!I-T%U*S5:;EIM2C5(
M97!Z17EA>DI/4&E3;EHY=V)9-&]I6$-)+V%L;FUB."8C>$$[=B],6&U$5F)3
M.#%H;'5B-F5.66QU1E=716A6<7="155I0G5V53<U9&HQ*V)(=WAJ:RMR*VE'
M0GA1:T-42&PU;TMX+TM8>5!B-G-2128C>$$[9TTQ<%-62&PK<U-)4TYX.$1Y
M<W)$-6I,1#)N;FQ)=SA4<"].1$AW35E!4$(Y<60V5$QW,&E7>5-543(Y=D,O
M<E<W5S9-<D%!*V]$."8C>$$[4C56;V5U5'E98SEC66PW=&U%8VU0:UDO87@R
M-2],8GE:<5%S-S(K:4@Q,C9#475Y*W-H0E552$EX>7%R8D0W5DLY<VQQ9&)N
M=U-%4B8C>$$[3VA)-T1H0V-/3T4T,W<X=DY(85(K5UAL2%-03454,DI#6'1S
M0DY&3R]R>7%P24E"-%-3<W!);V5O,C8U5&LW4GIY:V-:>6)F,5%Y1R8C>$$[
M2$=).%A".7))-W!:3E0P<E5B93=V;&MT0VML=F-W1T-N<4EY.%A554E)<7 R
M>D9X-FED1U%N6$0O4F):46I92$1Z.#)&2#AN+TE+5R8C>$$[358P<V9&2D-!
M27A*9&)C;4-J+V0S=FU4+TLR;T5"3'A/9CA!4D@V;78X=FI-:4](-U4U<V9+
M;FPS>71E5S%V<&]73U)V56U355).228C>$$[=V%I9S%A85)I,4YQ5E!W.75P
M>DMH4%!N<V5*6C(V9$XS2&UC8TM*:C,Y9F-I9&(P5WHQ-F(V;G$W2F-X4U%-
M<W!A3&HX3E%Y9VQ'1"8C>$$[8DUR54E0=VYC64U)>GA'44-7.$-/;FQF,T5,
M3$II36]M=6)(4"M64V510G!Y,S1J8C R24%J16PQ,$Y!4#DS*RM9,SAR-FIW
M*TQX4"8C>$$[.6E(2B],62M+=4@W5U@V5G!.=#5C:71T23!Q-E,S=#5Y6D%Q
M=VQV:4Y!4S=/>DUZ57 Q3U9:.5AK;$UC5U-Y9DQK;4=/1D=O.'9.3"8C>$$[
M=DU(:TQY.35P,68Q3F%K5S5U-U-!2DAC0EI9:C983FE&+V134C$S<60X;F<Q
M=5=%:D=/4VAZ*VM);FIG44-9+V%K=' K5E!K3T\S8B8C>$$[56QI1&966$Q#
M3U4S16=*:BM,-&ME56\S5#=,0VU(*U9S.&]'6&EC=C9)6#AT:D5Q-&9T5&YY
M<SEQ3D185#=D;S=/>E=#=#E$4&)X0R8C>$$[36IG1FM-;GA.-FYW9SAI,S U
M<V1F:#%!;4UG>5AX>7%/,TLK5')T2FUW:4A!659W:C%F<%-M4#AS=DDK=%1W
M3DY%:7II,E-S<V%Y=R8C>$$[:W%V=VIK27!6-4XT<S(O4W56-FY5-G)&;#1:
M6DMV92M%3BMN:FAL:D)J2&PU;W)Y.2M86&Q04S=T=%8P,SDQ95=$<TDS9C$U
M9FE&528C>$$[2D-34W5N:GAQ37=4,FYN>5)L951B*W%.,TLX1$A%:C O87EQ
M5R]V;S=/,W54<5%)=4-!<6E!8E9&9'I836%7;VM)0UA(>CAM=U%I4R8C>$$[
M4G<X=DY8.6$O6%5)<E4V;7!-9TQ!*V=/:3!Q3W8K5FQN:7DT>$AJ-2M40V\X
M2E!$.7)+<S-R<C-9<6MR*U-F2FHQ-39$<'IC;35M="8C>$$[<$%A=%=1.'9S
M9&%Z>4=V*U4S:6-65C1F2R]L;4=#84-(4TQ+3T,U;%=E-&E3,VE62DIK9C%5
M:V11=$=D6E!J1$AC3G8Q>%9Q6'EP-28C>$$[5VUT;V)A6%(W1U,R=#!L:6=G
M93)H6DDT-2\W-455<E)6:R]B02LQ,WA64S O=T%L951D3G4T-WI4=$(P-GEV
M26$K:F,R.7!"1DEL528C>$$[.4TX6%)&6594-&1U,C)+;VED6%-,56Q:5TAR
M0FYJ86A+:T-&539J64=Q.41L5V\O=35F,5-Z>"]54&5W;3AI:UA43%915%)%
M4VIF."8C>$$[.4%--4]94$%(8GA0<4M.:6ED.51%<D-J<DQC4FHO5E5%2"]I
M07DO9U!I9DYR2CE(>5%D;D9+1FY913AP1G1'62LW8F9Q1U5W:696."8C>$$[
M1V-I3G9I:$Y7,'%B54Y.<W)+2U9B8U%.2F-+-V=L3TM33D919V1A2S5)1S(Y
M33(S6D]V+T%#<W5):7AW>2LO6C%V865I+TUW-&)O."8C>$$[42LU,G%E4S0P
M=#=8.4<S44]R4G5S8W-Z8V\T-69G-3AI0C9J2S9J;U%E;7@W16)Q2&)X:FQ0
M14QX>5!,=3E)9%9K-T5%<UDT5%4T.28C>$$[92]D5G-9-VTS:EE&:DI)66]!
M-U5!<5I*9W R2&=$464R8W9Q37AY-5IZ031E3' X9GAB,$]$1C1E3TU#8G)Q
M:7!R6B]Q1%)!;FDX,"8C>$$[.69P4FEF,35164AG*TIB:$PQ9D%,,&AK9')%
M:V)P.59+;C-952]5,E-%0U1(+TXK,6IE>"M+>4Y*0F5Z5&MN;#9.>4-F6DI3
M1BLW128C>$$[06E:4&M5:RMK1'I#=EIA1D%B;31E-617<W!:1W!B.%-Z35A4
M,5=B;GE(17$W2&I18F5/8G9(<E S44A58F9:8G(U-&9685AR65A%5"8C>$$[
M=D5*:3ES4%)M:$\S2F=Z,"M064%%36@K>C$R*U=9;7(Q=FDT;VEV5G-4."MJ
M9F=W8T5I8E)B<DMD645M+W=!0FY8:C=,140O04UA-28C>$$[<GI%*THX+W5C
M:T@P9DIU3S-L4T<T2VMG=3EQ5RMB14PK;UEW9V%0=U5Y1FHT;U8W9# P=4]-
M8F]I6$A%9C9K;$8K-TMZ2#DR4&HY-R8C>$$[24@Q2#1*;&4R16PW3UDP2TQC
M=U1Q<TQV5V=$4DM8<E1C+T-X>F)A5$EC95E(-&9:9C-U1&YX.&-0>#-R8G94
M,&IS+W)C13-+.&I7328C>$$[>6-2=U-13DIX<7<K36AL2%)Q+U!T5$YX9'%E
M;WEL.4Y!,3-C>"MP>%1O-T%!-6]/2T]A4WAK:&9O-S-027%/24%52TYG3VXR
M<S!7828C>$$[6GE82W%S;FLW5$A(9V]89$%+='I$23$Q6FMK,5)R56HU<U=(
M-FIK6GA*;$@O3E1%-T@T<E576EAU<#$R9C9T8TY8+U9F8C=Q-'AI928C>$$[
M26YY2U-244AM1G%14$9Z44@T2'9F:DAB94QK4CDK4FI%9T@K<VMM>CA&2%10
M2F9+-G5*8C8V:FLP>350,6E+,S1S6E-S,4A91U-Q."8C>$$[3TPX=5!%13!O
M86<U,45E,4LP,$E!96]1:G8W=51O5&]$-'-I5#9423=,9% P93AS3F%N:5,V
M33%J0UIF4DE&2E@T3%1J2G1X,C=L828C>$$[8W1U;E1)82]T5T]A2&AI4')S
M,SA/;SAZ.6IB<&1$3$A,:4HY4%0T.39V6E)Z05A&0U-:2'1Q+TUQ9CA!;6Y/
M87AX3D@T3S5M4EDK3"8C>$$[5C5B=4Y*:6E&4D=S57I+0B]W059Z3'@K-T)/
M0CA-9D@W,6EF5559:U5H,3)/=35%>%5(=TAO5DDK+TQO>%!I:C,O;UE%*VHX
M9#=/<R8C>$$[-G Q3'-69&ER<U9D:7)S5E$K;WEI3%0W<59G5T5C36I&4G53
M07!.0FQ78S%J:V9)<SA9=5$Y-T1,;31S1S R>6EQ>DYS:VYW=%9D*R8C>$$[
M9%1T+VLP>FTU>6=94DA6,F-9>31I:2]R*VYJ5T5935)$*SAK3&-7-#%C055R
M5'(Q>3=X;V5,9CA/+S)T9D),9S@P3EHS1VYH<G13>B8C>$$[<7$K:W-82E-+
M*VHP-U4S>7)(3TAQ*T9F0FY+371V>'I7=F0R5&%4060O<D)Q:G)W86]75U%-
M,C%-0FY$=V=/=C=B4TEY-'HS2F(U528C>$$[=F))47A&:VUJ5U<O,4,U6G!9
M<$EY03DS349Q<G%R3'E19VEO>3=*:V=-:V9H9GEP<D5:1TI494LU,#0S5C5Y
M3D5#:$EF:%E!.%-*1B8C>$$[4%1S8W)J3TA&3#=0=EI'37%#;3$Y6E!P1'0K
M.$5X;&MD62M,8W=*054V53=C<31$:V=C9E<W4#)P-$IC9G=66'9B1EAS3TQ%
M<79P0R8C>$$[5#17,CE)1VQD=FQK:FQG1$$K-B]G:F=L4BM+,S$Y3F)5-3!,
M34QD;UI&1&-7;U1->%IQ1VYI8V502#1H+VTP9G18:&QW:G99=G$Q-R8C>$$[
M5'IL;TTV4E1/<TU/<7%:1FEL6D99>#(V<'E93%)1-&E01W S-D1F2C0X;SA+
M9F9F-T539V5-36UM=6)"8E<Q4D-Z3S-#3U)G<F)"2"8C>$$[3&EU,U1C-510
M2D1H:4(K3C)567ES;V@W<E1J<E-U0S-P561I+T4X9C-I8T-/;E@T8W-/5$@T
M,3E.+W1&35)#6$)45G9D5UAP6&YQ1B8C>$$[+VAA37AR>$Y7.45!:6YZ3U)X
M-5E62R],-T5Y:$MX6#1T1&U3,"]254\W1U5C:V1/3%8T>75#>'!3=3)61V-F
M1$AF.$%R6E9,:DM,=28C>$$[3#)Y+U-T<S9-4D=36DIN0W14:T9#8C=E07I)
M;FYG8W-33UA6<FIJ;'=%36(O3"LW=$1O="MK<5112DIE86@V2S-%57-4;$I.
M475*-"8C>$$[;C132W)#<7E+9'AK-7IG2E-(.45$-T5#37%".'EN0S-T:TY)
M:UE">$TW>4XV9D)U43E504AA;EDP>DA'4U!H*V1N-U<S9VQX<70S9"8C>$$[
M-F8X05=B16]Z1VAI3'-&8FE04G)3=3-F;&LX;5-(1D5J>2MX:D=%<5 T-7(T
M<G)4=G(Y>$<W13(W>$]O8FDR+W%U5TER5#)W=WE1128C>$$[>F8P,&9T4DM-
M=45D-DAI=3=*<D\U;&9L-GEZ=$Y(2'A913!5<E-L3S1Y=4TT.$UI960R>DU:
M8U$Y>55E84PV,U=B>6M)9E=B,'(W:B8C>$$[3UEO6E@T26)/-&E$4'=5.%)Y
M;$%*4&IL-&Y%-#9"-5(O4U R=&9#4DQC9%=1:3DP,619-7%716)+-W4O13A3
M6DM+4C V+T180C1U4"8C>$$[>&(V8B]A=D),9U$Y;&170TID,4Q!:&\K05I4
M52MJ=%5B9G1:5FIN04-8=RMX;D]-<D@T-7),:3=S6#!E,U=R;6-G;S1#=%5#
M4G<W5B8C>$$[1DLY<5E*-4E(14(Q+V)A67AL>&YU4F8Q,GA85UE*1EEL2%EY
M33-&=&TT0DMD3SEC=4=72&I!.5 R3F9"3&=)6FIN4G5T9&ER<U9D:28C>$$[
M<G-69&EQ5BMA5VQ8>7AQ-U)/63526EA*:FM'>%9H13%#4&MC<7HO,V-V8U<W
M5&HY-4@K<U!V9D]W,4AZ6"\Q9#4V*TA0*WI/6C)E;B8C>$$[.$M(8S<Y22MA
M-E9'<GHO.$@O6F<R6'=O9'IV,&HU<B]!3W)V4'0Q*U K>D1S=FA1-VYF<$AZ
M6"]!3EAE9B]G+S=-1WDK1D1U9"MK9B8C>$$[3F9F5C4O;GHO<W@R6'=O9'I8
M-E(X,6HO04M7.#E0.$%8+W-X,EAW;V1Z=C!J-7)R5#E,>B]W1$(O=T)M3WDK
M1D1U8B]!16PU<B\V=28C>$$[."\X07=F.$%::#)8=V]D>G8P:C5R2"]3,VYP
M+W(O,EE.;#A+2&-Q5SDQ-75N;FIH:C%A-$UK<DMI04U457-A1%I62BLT6DM-
M94DP3R8C>$$[<EAM.%!(07E),D-9>3)V;DM',&MU,C%M57=203AN3%-O;DI2
M>30X,FI#9S X9FYM6F@P0FQ/25!):T1Q-F=D<S9E5S!9>7,W8W1R*R8C>$$[
M845L,51Z1D1B>'HO04MA4U)(5C,T<&9X;5%"22]5;WE'34U'8F1!<$9E43A+
M2$XY+TE'03=8:RMZ.5193E=F-7-F:V8Q;S5B>E8U1R8C>$$[2TQR9TQ+5TMG
M,S9)1TM--B]A84I6,SE/;W%D=U(T-5 O43EG2%A*.6XV;E<O=T%R5% X041J
M*S,Y87HV>#5J:U):1C%7-#E-+T5T2"8C>$$[4%1T6%E6*S=/43%C4FEY>6=/
M55-1.4IP>$1*:FI)>$9K07%-.34U<E)H+W53=5=59VMU<D%G54AH.7(W:&QC
M2U!8.&9D.'DR1T5"+R8C>$$[0VAJ<5AM6FE66%=**U9!4VAA:D%(<%932VI*
M;4I'-4-I1TTY1DTS+T%*<B]!3W)V4"]W9CEM3WEF0V@S3&8P:C5R+S9U.#10
M*W8X028C>$$[,EED;#A+2&,Q*VMV3F91-G90.$$X2"]::G-V:%$W;F9P3'I8
M,2]3."]W1'=F.6U(6F9#:#-.+W!(>EAT+W58;B]W0T0O<W=B3#153R8C>$$[
M-3,V4C@Q.5 P=E O04U(+T%'661L.$M(8S<Y22MA+RMR=E O04U(+T%'64YL
M.$M(8S<Y22MA-F8X9&5F+V<O-TUD;#A+4&-Q5W5O928C>$$[87IC>%8Q96-J
M;712>CDO;&MO,6%*66]6>6943V15.&TW1EA9<3=&6%EQ-T95;3AX=$LK9V$X
M1UEE;6QP3VE+0G8O=E!Y2DIR+VQE1R8C>$$[5F%J*S=L+U9,9'!V-WE0.5EF
M92MF>4\O5#-Z;4AQ;7%D86EL8U9B;V5H,WA6;T%D3W1/;GEW2S1$=%1R:%9V
M:C@X5F%O9FUC5F149B8C>$$[1E9H;"M*:U)86C%P5F%&4G8O;$554%AT;&=X
M.&E3040X9G-'-T%Z-6=#>5!X>E9R8C9W<VE3:&Q2,5I754M+,%I46'%E;RMJ
M0GAX:28C>$$[8FIV-R]W0E@W5W9,:4]30FI,645D4#$O<U1I8E4Y5'9,935G
M=4II.$XR1U<U6%EC>$E15W%243%.3W9H=&QN.&]:0G5/8G))9&@T;R8C>$$[
M>4(T<#@W-F8X4VLQ,358,&5#>FUN:G-Z23A3.&=05FPW9%-F:C=$9DUN4V1R
M-FI*;6I#5U1H:5123E(O535M;W=1:&I-;WAS9V5A228C>$$[*W0V2$AD5'=*
M8E<K;U%W=593.&=#<$A*4FE+9T98-T%D.#-E9E)3:5)78DXW=5!K-DM'<4(U
M-#AF*VQ41S4Q0S)S:D9'8E5S:GA+-B8C>$$[<7)H06]A;W Y;'9$3D1P97HT
M6BM/57I+>$UJ;CDK,TXR96\Q<W-80TEI3F-)43%T95(S34YJ>&M74SAU1FME
M-W,P4FQA>D-S>7AR2R8C>$$[>D4W>4)A9T5!*S-43"LP97ES1T1$>'=M4V1Q
M<VHQ9#EE-S1R;SEF;'E:3T=59'5V4&)U=C-U=7)33GER36=,<%AG,S=3:SEA
M2'%-,"8C>$$[=5!,24-G9&YB1TE03D%3=T]"*S=F<T9!8C1G2V0K>D4O335E
M2F<X>#AT=C)F66IH235(.5 W9G154SAI;&I*1U%I-VAK<3%2.&=/5B8C>$$[
M9F]Y9D%#0E(S.#EV,E8K2UAI275X*VQ59U(W9TE95F%1=4%Y04M34T0W9&-H
M3TII4T0P5#1G<3<R6'DR.#!,.$IO,FIB<59C1E0Y>"8C>$$[=TIJ24AC1S%-
M3'1I;'5N:CE&8U9D42MX,GA6<FIV=4YJ+T1&5E<Q2"MK=RM"9&8Q-%DX,%,U
M1CE+-3%B>41S5F1I<G-69&ER<U938B8C>$$[6"\X06IG82\O=T%W."\X03%$
M1$MT4B]D>2]Q;'4P+SDU2"MS2&=15'1N3'95=&A0;T=&5W5.0CAU,D)7*U!B
M=#)0>G=Q,%5&4&-D."8C>$$[0W4T:V1C5E=41FM4;7%L>7!5;%8S86Q25V<K
M5UHO6F]X2%!(>&$T9E!L-5@X6$$W5$]8=TIE1F9(-6,O3W9G;CDW-6<X;GIA
M9$I:-B8C>$$[6DAC;34V:$HQ6%EH,4<U1R]W0FYL;EHU;S1Z:B]F8TAH5BM+
M+U)4>$=%-4DU4#-!;C1T+W V+W!T2F5.2$Y$=#(W-34O3W).8VXP4R8C>$$[
M1CA)=FXQ5E5J4%AR-S575U9O*S-1159P=C,W6E1-;U)D-$QM2%1P-6)60SEZ
M1VA:1D$U3C=K3'9Y24<T1DXX3VMJ:FQM:4UP<49I+R8C>$$[8S V:55X:FQW
M9E97>55A;D9E6&UQ6$)T-V4T97II4'!7,#!S5%)U-F=K,4LX5B]M.%!X>G)4
M:S!E04-/3U52935Q5FDO9EIE94U.4B8C>$$[;$YZ0BM626Y7=%!V6DIB67A1
M3S17,VI6:7%K,%E%,4)Z5V1M-GI&1TTK2U%&>DHK-7DY6F=N27AO2#91<C)6
M>F9446%F0DQB5$,U328C>$$[8W)A;SAQ96Y(139U>7A2>%9695AW<7!Q1V(W
M6%A(=%!4-D5994Q&24=D:7%.:SDO14]N,DYM:7IA:S5+;5!4-W9L6&8Y<2LV
M:D931"8C>$$[=EAV-S5O648S0U=3<'5E>#8U:T)+2&1.-G)T6'1K,51444YB
M5%-:9S<R-&YJ3&=U<$I&44\Q4G9I04Q"270P,V%73$E::5515$=U;B8C>$$[
M-FMX.'DK84Q,5V10:6IH='5$<6518TU7<EAU3F@R,GE743)E5D5C,&1N63AN
M1GA%5D@W,DTX1DIQ3FIG9# T3'-!5%1T=FIA=&-31"8C>$$[,#)X5G9H,"]8
M6$964S%50S5I.$,V+V=C365A2F-M8F%P-7$O3G)Y,V%T939H6B]78E)R:#!7
M4V1,6GEQ>79B3$-O:',U4%5*;UIG028C>$$[0WAR=CA22U(U,6)Y2W9A95E0
M>C9U3'$Q:'9F3%5.<D)70G)I.'0R<RMP;6=-<4Y(2F943C9A=VU:4U8K2FU#
M;&5.4T%Q-WEN-3 O3B8C>$$[94Q69DQU:F5D3DAT<DLU,5-7.%-E9496:TII
M=&)E1F\R2&]8139Q-WEU+TEK054O6E5$1E5&8RM:9CA!;DE0569,=V94=$)T
M<E<W=28C>$$[8DPQ67)P1FAJ:U,U83524D@V1C5D+T)31#%'4$U.6#1E:$I5
M2W!S;7(O;C%X:V,V3'!24DQE5U-.5RM'6C4P6F]O;VEQ,VIX<#9L1B8C>$$[
M;DQE;U%Q2&AU=W)I<4XX=&$U*V)..7)6:"ML3DIS-UA21V5A4%4R16-K9'A%
M>5%",31'4V-H=THU4%$U26I+,W!T27 T>4QX5EI.<B8C>$$[,R](0C$W+VU(
M;B\V:&AL5V\O=35F,5,S868X079)+S%G.$HY3E1U3W5C=3E08E-P=C%O3R]S
M8U%L=U%G:74K2W4Y355O4FET=45F=B8C>$$[=&ET=$=-539E=T]+,G-M2U)X
M8VIS2W%$6%E!:V=6<FU:,F9P4FYZ4F=445 V0F)H9&]A;S1-37!G5U)Y*TIR
M9$]T5#!85$Y.=%AD-R8C>$$[,D]E-%IW<79"2TI%66A2=4(R04(X0G9N5&9Y
M2&AY4G%*;$=H>DYF8G1U.'5E,S@K2U9Y15I795%V-TXY:W$Y359P6#5(3U!N
M1VE2,R8C>$$[4%IW;GA!2'9663%)8G W2#9C<F]K-TU:-4EW1GE)03@P93A.
M,T)B=$EL=5I8,DM*54E'-V9A3W=X.$1F,2MM4&96=5!(5UDU:C!%4R8C>$$[
M4&1A36M855 P9F-#,UI7=E-R1T%G0E%4,E9A=%-T3G%K.69B2SE03$8T,%1-
M9G4W1BLW<BM/-6QM12]$4$-F5E)P2618=G11+U-K,"8C>$$[:7A3-F1B>4MV
M,6$R37!D;&I&4CA45G%A=%AR;F%1;G U1#EX5F1A1D,O9#=Q96-N2$E$*S@U
M.4PS,E)'=EA.>$9.865L339C<E=)="8C>$$[>%EI<'$S5VAZ5SEL9E10+T%)
M6DPY1&QA,VY(*W%%6G!C*W5Y5SEH0F17:&=A2T]2=%)U,VM6+U=9:RMK23%5
M,%5"861"-#$S>D@W528C>$$[>6%%-'%X9C-L-V)(8BMD>$AR*TMC:E)2,4%N
M-B]P+T96,TYZ;5E34W!+;SE.5D1,8T-I9VMK,55R56M&44)V,$YC,'-906=C
M4#%%,28C>$$[6%AP.2]C-U5424\O3'9136EQ-C@Q,UAS-#-(,S5K>C!U5T%U
M55I22&U#1FAQ25-.4FM$.%5/,&9J.#AR8G)46'DU1#5D835:9%IF,"8C>$$[
M-#9646YN.6]%8E551W1F9DIW:D5N,4=G-FI8-G5E3UE!,D9)<GI"6BM6570P
M3VIJ,%1&.$LX5TI6;')104MF<S!'*T]42GA42D8Y9"8C>$$[>C%2;TY43U5U
M2&Y'=FMX-$QU2S5&,T1V5#A/=F-9;W1W43!P,C=9<&0V9F8R<&ET<71Q9TTX
M6&E(5W8S-4M03FI,:U@P5FY6=DIP1B8C>$$[-7IT=D]&>&]P:CAP6%9V86%U
M2EDR5U<X+W541W!Q-DY32V,O1C R05!E=4MS3E1Y<BMD575P5VPQ2C5M:'1L
M*V]P8C-Y>'9(3V=U1"8C>$$[9%9M;&EH87AH:DY,8R]U=59'1&A667-V27-Q
M:F1&,&(X-3 X,"]89%@Q<E0U3D-E-6M,861!0UA7,4Q34$5Q<S%S;%=8;45/
M-$I#:"8C>$$[=69537%L5W0V3BMF1FU,*S0P-UAB95A4-%)F6%5%0VE/5SEC
M:')I5S%H45!9=7!$0F]K6DLQ2$=I=&EQ8BM2-U0X,$,Q:'%F;7)5-"8C>$$[
M;71E13=4,F1%:&9H36M29SE33EE&06%.;&-&969E=&8Y,6A6:RMR>5)Z841R
M:E)U2%)O6G='56=G,'1W1'509DMT4B]D>2]Q;'0P+R8C>$$[.35(*W-(:5AP
M:74T;V9W3V-S.5!B87A$:T-V9D-&=&(V6C)+.69$07)F<&=I;TY#1#!W<3<P
M>%$W8FI!='4Y355R6&)W>%<Q:W%X<28C>$$[:D-50FM05E-+,7)S0E0S>DHP
M94=E5$M)=S)L,SAQ.#-',6UE1TQ%6E1&>#=U9"M32VDX;517.71C6#=7+W K
M;3%7:DM%1TU#9TY14R8C>$$[44XO65HP,G P;7!L:452;#1J5S0W+TLK6C=T
M*V)Z5VTQ=6U'47I/2&A&."LW>G)K3R]:43E)9T1A;30S>FM30TYI.6%*03=H
M97,Q+R8C>$$[87I#-G-L:&MM5E-H:6Q"25E-5D\Q0TXO:' Y3UI7:WIX9U1X
M9%A4.7)A4$IM15I9-G5.-TAR9&9Q5CE/,795-S8P14XQ8F])-'IX:28C>$$[
M;C5K=7))-41#9TQ+4CEP4TYT-D=U,4UU,5=A15EM4$UK9F4V:G,W46%I57A+
M64521UAF=G-F=T5B95%46%=N,TYR03135U)323)B628C>$$[5G P2D%.065H
M,GI6-E1,2$9M:D]1<U)L9%!4-FE";D%X0F]K254K6%IB,C9U8G4V94\S16MN
M*VHR='16;S0T-C%!<7=4*V)S=$TS928C>$$[<SEO0DEJ=S0W06,U8WHX<F16
M:#=-24AR4'E2;"]W0U@W83=A2GI->65L1W-.2T0Y;74O-#5Q=$XR<$Q%0T%"
M-G!%+TYZ375J17E,4"8C>$$[255H<DMW,4LQ:7-B95IO1FAS5FQ75V50:UIR
M<#5866@U<6=5-'%6;TMT4VY8=S)885!A*TA0:#1)=TEL='IQ;S$O3CDO=T%'
M:E-A2R8C>$$[95!*>$=7,S,K.4,K64Q/93AS;6EH86@U<357=D5-1DE*5712
M<58W8F1C=W5Y9%9(5#5H3U%S9F0U=6)Q.$IY-"M%2F)(<D]U-G!94B8C>$$[
M-EA,63(Q;DA93V=E-5%J,5-52#)35DQ64$8V;F)E9WIR9%0R<&=X>'9E9DA(
M;# S.2]2,'5(<S=*2U9C=45O,3!863!O0V0X-' V6B8C>$$[34Y,,$DV9R]!
M4V10=$%#;T$O>6ED:&=*;&5W=#%E8G1#3FU)1BLY3G)J.'9*8E-W1'@S261)
M5593-SA46&%G-4UP-FXR1UA:>%!E6B8C>$$[07)Y-4,R=D)R:$%#3F)-6F%'
M:F-30T=";W=066I+<F1U2E=,1%%J24E05&)O8TMB9#99;TMM;SEU,D)B83E,
M<V5O<G8R3TLR<3)Y1"8C>$$[,6]J469B5W1D=2M3:60P4S505G9Z3',O3D8Q
M-65I:CAU>71$9')D4E-816EZ+U9A5S9";65S=%9O=DQJ>3,V5E!&-F-'-G@U
M4FES2"8C>$$[-5HK8U)R;&UY+VU09%-Y,DU58C-U;DU*,DTP5%A%:G!*26=V
M048U.%-G64I1.%-".$95>%96;B]!0S8Q=E4Y3S!3,# W>CE/9%,P028C>$$[
M6#AD-W%#1V%A831A-FU)551E;F1O-$9V3D%6-$]Z06Q/2D9!5GA65V8X=#4Y
M5T8S2&(K8S=U.7,Q=3!&>$$P,#%W27!,4SA%-&<U3"8C>$$[8V=X4$A%:V-:
M27!)2%@Q3U976E=642MO9FQD<F1X850V4% U-W5*,G969T11,W9Q>7-8.4-9
M4VQ55S9H*T=354Y-:55O=D1J.%-+028C>$$[<7%F,FYK5%A,9GHU8RM:1#5I
M;&93-VU8,4@P3# U:$9X*W)M2&E38FMX365F0BM::'%/05551TMP.7%Y2TY&
M,71604$Y1V%G06].-R8C>$$[8UI6<5 W=5@Y571U1"LX:C=W.&%-9$LW53EJ
M+T%!>FQ8<&)B.44Q1E!O4&)#:3-E;7=03&HY1TMT1TUB,4%(=F=T6$-08VM#
M<' Y.28C>$$[36)6=C!256MD1#195G12=3=+3V4S84M1;$5.1#9G3D-T1%5%
M2#)P;51O.#@X5U539TQL,V0Y=4YR34U-;4EX;6%J,SDQ9%5.87!Q=R8C>$$[
M955487I03D1)4W)P-FIF=D9)1WIN;3%2,DY2;E0U93!.5#1F<'=%4S<V3S-W
M-%AM8V5G,'9I97)/1$AU-&AV.&)2-6A!2CA08G1N228C>$$[4TI*2E!.-C9.
M54LU25,X=6A:>C)Z,T-33EEC-C-B=T%E;T4R*WIY,BLO379246I+4D5V9S90
M=#-0;&A#2FIF0B]%4GHX:WAK.'@V1"8C>$$[9DMT='!K335K5FM#4$EQ8F]2
M*SA,.%-E3R]3;&-Y=%9I:G=',U1D;F%W;DQ'3U!I-6DO9#%T17A/>3EV=GI2
M15!A1D5P2V%6<#%!<B8C>$$[:U1&0S<Q:514.65!4591:V1J561F15I-4E9,
M<BLT:G0T,64U6F]R375O=3=I349N:FA*;S=Q04=Q5DAT;7DW3'A1;FU!;CA0
M33E"*R8C>$$[4&,P8755:&I*:GI11FXU:SAT6$9N-E9R-C=8=VI5>%)U+TUY
M4W550E5S26A252M-=#0P1D]P<#$R<C!'2&=*;$=-4C-G054V3$)Q328C>$$[
M=VU+36HU13)J4D=+54DR-F(U=WHP-DAA>G5K9FYB6$QW1G$X9TMK1W9Y2S5)
M4V16;3=-17!81UA$9C0X:U9(4'$T6&I.979)9T%52R8C>$$[95%&06%G8G-D
M<VED,%$W36\K<59J,V8R=&5N>6)F974Y5#<T=3%'=S)7:44P2%5E2&=C1$LS
M2V@R<40T1VU)2T<R:$DV8C1R82LR:B8C>$$[26YI1E R,2MF6$I23S123&M7
M439F+WIJ:#5*<V)T-VE+*S%&;&QT,G1:<F-M>E-*,&%";T-Z3$AB4B](>&-N
M;E=T4V8U;7(Q<GDV3B8C>$$[<W9Y13AM,FPO9&%G='IE>5AL,TLX,&MR;3%(
M1FY2:S1O<5<V2W%5:TY5031V='I$041&56)O;C5/95A.2'9,1S9T-WDY;$]N
M;%!1:28C>$$[;BMQ>4E22%!08TM$5T-O26MU;6]Y:TU!0E$O835+<%1D+SA!
M3U!(:S8T=7!,;C8O<454>50S1C)Y>"]546]N=7$X-4)Y=%=O>69$-B8C>$$[
M9CAN145F1E5L5D=(.&DO2W!T-U=%,W0W4S)7,U5U1G-636]T5W5'5#%G='%&
M8W-B='5D4CAD05=Q95):5D8K6&9Y8SAS-D1R3G1Q="8C>$$[<&18<W,Y;F58
M=6]14GIV0WE#8E5)5F=M<59I5C)(0D)1;'58:51I<DHY5D9D2C%K9CA64R]W
M1%5/37 Q2#DS3"MQ5S-".6-F94AK;B8C>$$[;S=%13%1.4-/;WIL6&]R8S!(
M=VEH<C-'17)B9F\Y=T%'-VI&8F-9:GA"0C)R5VYT:C!7,T=+;$=P56118U-T
M=&5G1T)P<S)03F)38B8C>$$[>D)-;'$Y<$YE:50Y13AM5S9-04132S55:$<T
M<WE!9TYV,7IP9EHR54)+6"MQ9$PW=7)Z,V(X2E-J2"]5*W1D+U(R;F5D+TIA
M5W,P328C>$$[;&I/>D]F,TQ605I147@S3E17:F-6.7=/6%@T8S9S;DE32TQY
M;WA9=T-$2#AF:CEA3S!Q4F)Q,V5:469195)Z8CAH>$IJ<G-E4$HV9B8C>$$[
M3&MF<'II+V%#8T1Q4%1Z-%)X92\K>6YS3W=)5&IP+U9Y-&IW*S<K,C$X.#AC
M3GI"8DUY4FEF;3-R4T5H15=*951%.%%Z2&)W1V%Z5"8C>$$[869X3#,R1&8R
M;#)I9%!W9T1E5C@K47!(,U9N85=%865N3TI3.'9P<WDX:6AK9C1M0VMJ9FE7
M,SA-=GHV5VAD.'8P0G<X2&$P=4U2:R8C>$$[0E5P5G1F37)61&)!:G(Q1V$Q
M,S8T3%%54'=N=&=P5WE#84)J4FAT560V-#$S;U=S:#5E4&IH<$YR1U1B=%$T
M85<Q;C%:5F,X44)Z-B8C>$$[:T%$-'9F2GEK5'I+:6Y'2VI-0W1+-T=M451B
M:D13:D1P,W=R8F)216)':$9.:FE6='(P5T%R4V\Y<U9T<WA+4B](1F)A3592
M5W4T,B8C>$$[2G=,8G943SE0=4].<F%P1$543V=P5VI,5' T-4M03D)/>C)V
M3W5E6F1I<G-69&ER<U9D:7%786U+-EIR02\T<FLO-F@Q>6Y5+W=",R8C>$$[
M3"MQ9G5B34@Q:C-H-6@V86AU;$LW6GER,$12:5=H02MD354R-'A,56LY1%-U
M2S(S-DE"<413=E59<F)L:3=B94])571'2F5696=09B8C>$$[*T=+,C%*8F]Y
M1DA!6DI!5F132V=G-U5)4%DT4DEX3FIM9V=(66]29DPR:4MW95!4-UI:1DE)
M2WA)2T5B,4<R6DHQ=6,W8V,O.4U79R8C>$$[85A%4#1)+TE),'A!9VM#;3)9
M>&(W54QR5$Q+.&DY1S9J5C%(5'-26'5#3G@Y1U1X-4I13F<P,&%J5%DX,&5'
M631G;U=U9S9B6E-E<B8C>$$[8G<P661Y>D]2-VIK5%1*-4Y2:VM.>3!A9G-Z
M5#1P8U5),&9I9G92-6IR,#9N<4\R575C,'$Q;T])*U=!2F-%5VA7;3-H:4M1
M-S!W828C>$$[2')7;WA6;U)+2T$W+W=!8U4R-'<W1F$Q2&(R>%<Q,W!G:7!!
M<#!W;U=,0T)59"LT=T).<G942$QJ,30O:4U69#939T-G<7940VDS1R8C>$$[
M2'!S3W1A2'AW56TS0TI4=7!O8TM,8T5);T1U1&=T5C!55DI9-D-O1&IR-VY*
M4C5H4V1N<T=D8S@R-T9867$W1EA9<3=&574Q2T]69"8C>$$[4#%4:T8Y3U-'
M4FM913AV-VYI45)4+THX8W Q4#DS3"MQ9G5B35 Q:C-H-7%)*U5:1DYX;DLY
M2&],,V))3DLK2%59,F@S<# S<#A*-B8C>$$[;G=X5S-"3FA1031Q-'AN8VMB
M9%!C67)B=5!W.&4S5VQ/*TMU-$-M-3ES5F)#8F=(6F@Y>'!I='1"1#A1-VUT
M4C@X5F0V4D\T3F9M2R8C>$$[.7%9,'1T<D=E:$$Y-F)9471T1D1Y4$A99S=$
M,G=,8FY1541!53ES4V],;51O=T@P:D5R8G5/.41U1S9F4$981DMB34MB+T-4
M,WA7,B8C>$$[*T(S*TAR:71T1U!S=S<Q0DAC67)B:7!.1%5B8E9P:7)I:'%+
M8FYQ4#0T<F)U1E$S2#5%67)B9W1A16Y92')I<G92655P42]2:E,R=28C>$$[
M.4]O3E)S3VQ-2TQB9U5I5TUJ9%-W<5!E=4=(34Q,:SE8>G)N;EA9<3=&6%EQ
M-T9867%H.5(Y3#E(,UAR8W93.4HO5315-6-E2G)X<B8C>$$[=%=M5EIQ-$I8
M>6]S.&0X47)N8D)Z+VA3=2\Q-G8O4$A.0B]G+W=$5"MX,B\W-RMJ.7)V*V16
M<'8Y939B+W=">EA(+T(O=T-N+W-59B8C>$$[=G8V4#)T:B]!07)Y2"LY,R]*
M3$@O0B\V9C),*RLO;R]A=$@K1DM';C$W+VMJ:B]G,SE0+T%'2V8S,SE(-U<O
M*V16<68Y-W%51F8W;28C>$$[;5 X06<O.$%4+S)+4#,S.4@W6$@O0W4S*SDS
M="]C+WAX+W=F*VXO<U8O9F8P9G1A4"M&3G8Y-S8O=T102'@W-"]W0T0O=T)0
M+UEP+R8C>$$[9F8P9G1B8B]!07)15BMV9&1V-VY%+VPO-F8R24AJ9C!F=&$O
M-3%3;2]W0F4Y<2ML:B]G,SE0-T4O=G8V4#)U4"M&3S,Q-S904W@O=R8C>$$[
M9BMN.6DO=G8V4#)T+W=$3W%D+W(Q9CA!;FIJ+T%)4"]!12]S4BLK+V\O83<O
M;E9+0W8Q-S)R-E=0*T0O04Y0-T8O9F8P9G1C4#A+-R8C>$$[52MV57!T+V,O
M=T%C9CA(+T%+9BMX6#DY+U(K,6]F-%5Q2V98*W8X07A4:B]!25 O044O<U0K
M*R]O+V$S+W=!-G!T+W9D-U4Y2"M'4"8C>$$[*T0O,"]W1%EO+V9F,&9T9"]W
M039P>% K.3%++SA662\T4#A!,"]S6#DY+U(K,7<O=W)T+W9D5#,Y2$@O04%F
M*VXO<U8O9F8P9G1C4"8C>$$[.$Q51F9R+W18,'$T+W=#1"]W0E W1B]F9C!F
M=&0O>G%V+TPY6'8X03-/4"M$+S O.6EN.3DO4BLQ,R]/<3%A;C$W=E@K-G!J
M+V<O.28C>$$[4#=%9G9V-E R=$XO:%1K9CDW=5AE;G!6>% U9BMN.6E2-#,Y
M2#=7+RMD5')V.65R,R]U<V8X1R]P+UEJ.3DO4BLQ<B]!2C%8=#EF<"8C>$$[
M5'0V5U K1"]!3E W12]V=C90,G0O=T1/<3$R*W96.793>"]W9BMN.6E0,S,Y
M2#=6,&8X06A8,55P.64U8VA4*S8V,3<P=VHX=F8X028C>$$[2#EI1#0Q9G<O
M82\O,E$]/3PO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU
M;6)N86EL<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D
M9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP
M9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,3 N,#$\+W!D9CI0<F]D
M=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @
M("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT
M(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,#1!,#$S
M,$8T-T,P13DQ,4$W,D)!-C9!13DR.3$V1D$\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,#1!,#$S,$8T
M-T,P13DQ,4$W,D)!-C9!13DR.3$V1D$\+WAM<$U-.DEN<W1A;F-E240^"B @
M(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#HP83)A968V
M-2TR86%A+30U968M83@W,"UD964Y.6-D,&0X.&,\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E
M9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ
M1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C S03 Q,S!&-#=#,$4Y
M,3%!-S)"038V044Y,CDQ-D9!/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C S03 Q,S!&-#=#,$4Y
M,3%!-S)"038V044Y,CDQ-D9!/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @
M(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z,&$R865F-C4M
M,F%A82TT-65F+6$X-S M9&5E.3EC9#!D.#AC/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D$U0S%!,3-%,C9"144Y,3%!
M,3<P1#(P,D,U0T0U.3DX/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3 X+3$T5# U.C0Q.C$W*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HP-$$P,3,P1C0W0S!%.3$Q03<R0D$V-D%%.3(Y,39&
M03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C Q.2TP."TQ-E0R,CHR.#HT,"LP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T
M1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS
M:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS
M.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @
M(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @
M(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G
M.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S
M5FES:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P
M<FEN=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C8Q,BXP,# P
M,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I;3IH/C$P,#@N,# P,# P
M/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T
M1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @
M(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y4:6UE<TYE=U)O
M;6%N/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^5&EM97,@3F5W/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F]M86X\+W-T1FYT.F9O
M;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP
M92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.G9E<G-I;VY3=')I;F<^,# Q+C P-#PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*
M(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&
M;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I
M;&5.86UE/E1P<U]?+E!&0CL@5'!S7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA
M;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP
M5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA
M8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R
M;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM
M<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y
M<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W
M871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X
M<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 78"3 ,!$0 "$0$#$0'_Q  ?   !
M P4! 0$              0,$ @4&!P@)"@O_Q !A$   !0($ P0&!@<""@<$
M!0T! @,$!081  <A,1)!40@3%&$B<8&1H? )%3*QP=$6(T)28N'Q%Z(D,S=3
M8W)VDK32&"5#=X*VPC5TLK,*&28TXB=$15165V1S=9.5EO+_Q  = 0 !! ,!
M 0               0(#!00&" <)_\0 7!$  0($ P4%!@(&!0@'!04) 0(#
M  01(042,08305%A<8&1H? '%"*QP=$RX0@5(T)2\18S8G*2)#5U@K*TPM(E
M-#9E<Z*S%T-3=*08)D1C9).CXB=49H.UQ/_:  P# 0 "$0,1 #\ ^_C!!!@@
M@P008((,$$&""#!!!@@@P008((,$$&""#!!!@@@P01@F:(7RRS%#>]"5<'OI
M^0Q1[3BNS6T(&IP/%A_]!,1;X!;'L$/_ 'OAO^^,Q\Z7AA$?L?=K;J/]+\L?
M.XMGB!RK]-([9]:POAS?N<M-0^Z_JT'W:8-T>0Y:'C3IQY=D+X> ]=X@\.;]
MWXAH&NW+W[:6P;M7+7M^W6$@\,;D6WD EM^.#=G2W*E_M!">''_-^7+U]?Y8
M3='@$WZ?E"W'+R/Y0OAC#^QY;AM;S\_C[L+NSTK3EUT[M82$\,/[G7]V_P -
M_P ?,+83='D!P_+3IQ^\'KQ]=T+W!OW-!\PY]==1WOTYAA=V>E_KW0OAQY>N
MP^$)X8P[E^)1U^=/YX-V3:U[<8/#R]>JPOAS?N^X0^ZX]?AZ\+NE>@>/=_.
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MO?[Z\H4O\2*=Y!UTI;Y0GU>/G?UZCA=RHBMJ \Z4(Z^N%(3?#7*.IJ?5_6L
MQYN@\M ^0#";H\QSU[NST;0F_'('2V@M?H.)K6%^KS^?*^_+"[H\Q3GFO;O^
MM]>,+[P.5*\B:\K^NL)]7CMK?<-?P_H/G@W) %Q0=?7/A3@-+0;X4TL-;GLX
M6\+TA?J\=[".O4=?+!NC74>/#[]*P%\5T%;<2:]M:P?5X[\([]=/=_/";HU)
MJ"+V)^E_K7A!OA6M!XVM3U\H/J\W0>MN7NP;H\TWX5%-*?+GQ@WXK< ]]A?L
MH*\8!8&WUOZ[7UVTMY!A=T>:=.8^^@]"%WXKH*ZU!.G=_.$&/&_0?6/XC?!N
ME:Z^-+>M32$#P-\HYUJ?77GW0> -SO[?5R$;V_EZL 94=".RH/&]:WTM](-]
MK8'I4D\NIZ&#ZOZ .OG?Y^.$+1XD6-Q7LX:^%!VU@WP%; 4U%3_.G9:%^KQ'
M6U]>O77K?V_'!N34U(N.8\*VI^6E:F#W@ _A&M;\#7KX6Y=IA/JX>@X-R;?A
MMI?Z\8-\GD/%5_OW:0"P'W[:^KYZ>K"[E533APK8> UMI6#?"IM6G;;3D/ :
M"]H7P)NHZ>8\^>_N^&#=*L*_7MOS%_KK9=_I;6M*%7?S^XA/J\0]NF_OM]WE
MMA-TKGUY@<N%N/<:WA _2M!VZD4-^5-/*#ZO'S]X_//XX7=*Z6UOZY0;\7^'
M3JJOWYU'C!]7#T'XX0-$<1IK7ARX>'W)A-^D4L/$_0>N4'U>/0?+7!NC2M>V
MY!X<KZVY<!K2 /IY#MJH=.%!"^ 'I]VWN]>N%#*K7%Z#4>7C#M^*Z#[Z]-;]
MNG.YX VXW]=]NOJW]7ET V:TK^9KX>=.Z$WX/"_.IKV"OKOI!]7F'][WC@+9
MYCQ[M+^NEX-^GD/%73U:$"/'EQ>PW3KI\^6F LG11Z\.=J:<N=>V$WU.G$W-
M[V\_O!]7CT'K;?U?//";DUK4#_6L::>'(=\+OD\D^)IY^M*ZB%^KQOL-];Z]
M;[::<\&Y5S%-#<4TIRZCI";X7-!2XM7L/#KV0 P$-0 ?:-[]-K>O &2.(Y?B
MKZ^0Z7A0^ =!RN>O9P\N,)X =PO?U]0^=>>%W2N8%CQ^IXB#?BM:4-]:CH;^
MKGG $>;SU^1_ ,)NCS'#CWZGGXF\&_%_.YI?A7KQO6VNL'@!'KKMKOU]>F@[
M>["[E5]+:U/'OZ:<(7?ZVTL:E7'Z==/*#ZO&VPVU'?J'M\O9Z\&Y/&E;T%:U
MX$4KTY&_6&EX6%!2M:7->'T[8/J\=OG>WKW^.#<J%/P]*=G9;GP\(7?BE,HI
MWFG&QOPUH8/J\=PT]7+I_+";DU_=KKKXGUI3A!OQ_"*Z\?M2W72E^,'U>/G[
M!]@_/OPNZ-:5'/7T//\ (+Z;?"!_BT(]?6 8\?.^VHWU^>6$W1/(\;\OI?A!
MOTDZ"_,GUXP?5XCIKY@ C\0]F%W*AQ ':+CLT\.RL&_'+MN:&W@>O&L*$?K?
M7V#S'I;RY?AA-R=*T XUH>5:6^U8-]3^?:. [NVW2$\ .^OL&VP>WEK_ "PN
MY(/[OB.S3RX7J(-\/X1XD7TN!2E^SYP?5X[6]77Y\O/!NB*Z<[7\::0;\<$C
MG49K>5H!8:\]=1N;^GW#A-R23H:ZW-/MZK!O@:_#6IYJU[=/'Y0?5YO.^^%W
M1'$=M:UIS/9 'QR'.I)^?T\H/J\0ZA?E>WSY8-RHWKYV\]*?>L('QP'^UPI?
M3AKW]D'U>:^G%?UZ];_-O=@+)IPX\>M;4-==0(7?@<!7G55^=_7*#ZO'H-_F
MW]<)NCK\.O,"I'SIP^\)ODZT'+4ZBE^WRXPOU>/0=/Z^_P ^@8 T:4%+Z7X]
M_P STA=^. %[:G6H-?EKR'*#P ]-PM?F.^H"%M_;<-[X7=*H02DZUOZ]:<H
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M+1-[U[*4 [J>'2#? ^N [K:0@(#L(;^0_?IISW^&%W1KKSX"ENRHKTIYPI>
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M6 &0:?\ +KO[K"'/4?5@W;E/PI[.',T^O=!O$C2VNE._C""R =@]8"4/AO\
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MR3I4'J/L87P9NFO3A,/WAZO?RP;@?P#Q_.%WR.OA!X,U]K?^$UO=;\,&X'\
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M)_Q?R]<X-\GU7[0>!_@^?=@W0_A/^+\H-\GU7[1=6+']4;T1#]8.W^H3$[3
M4DU3^\18CD.L8SSZ<PN/PC]VO$\33Y1[%X[0CF:#!!!@@@P008((,$$&""#!
M!!@@@P008((,$$&""#!!!@@C':P#BI*J"[\5.S86ZWC'(8K<9O@^*CGAL]_N
MKL9N&_YQD/\ YV5_]=N/+WP90V3'V6QR>&3P(IW?0]\>^[Q8T)[J0>#+_FA]
M8V'V?.@?#!N#VTTMYW@WBSJ3WT]?3K!X,HV_5C[;#A/=^@\!]X,ZCJ3WT,)X
M(M_\6/KYZ^8"&WW87<FENP:6IWG7IIRA=XNM:]_J_7E"^#*&R0^JP?-MNF$W
M&@MX"PORKQ!]:IG4-"? 1X"S%0=MY]6WTBN;664C7M7Q60>8&>=+Y4PQ,ZGP
MQ49,0.0M(3],T]'=FW^R64CLP$HZ:JLT]&NU,U(E:0F#H,24Z[&+22E_0VY7
M !+[-RDRB6:7.LR+DXOW$%:D+GW$/+5B8G$&6*FVPA:1*JRMU.\3F)3J:W\6
MWV+S#*WUIE')M,N/>U9$J3)H6A(D?=E!T!:RM)]X3565.[)2 OG6K>T]5QJ=
MS(RW[,W:0S[S?&;'L?.X/,^I<WHMV@^J*MNT#EK0&8L%#58PR_7G\F)Z70KI
M2 KBAG<94H4&W082Z-)1QW:<7(6;.#RN\E9K%,+PV3W:L72N5:E5(HTSA\T_
M+K6TJ9#4ZA*F$N,S&9HS"LR-Z0,R<)W$']W,,2,[.S.<8<I#[DPDG.Y-R[;Z
M$.!DJE5J2Z4.MY5[D"H:2?A/1V:V96:.1.9O92R3J+M2U-EGGM5+RG:DE\O*
M[SAIC,7+.+HQYGB[CZFJ*O,V*OH/+BILXW^8="QPY>97954M04-+4U5:TE-'
MDT8Z*/4HUDK)R$_+8M.MX7*S,BTEUI$PQ)N2DVMU,B%L(EI-J8F6Y1,O,+$Q
M-3;CZPZT$M!.8EJ,Y^:FY1^0EE3SS,RXIM:FG'T/RZ6S-Y7%O3+K3*Y@OLIW
M$O+H:0IM=5E>4!P][]DNK<WY*G>VBC7]8/LT*KRM[3N:E'T7(.X1E"(_4D#E
MAEG.0$!%P<<)V[..3DY=[W2":[E19P[<+*N%5ECB%/.X?A;D_LRE#:9&2GI/
M#E3ZDNE:D!Z>?:F'E.JN5AD UHD )3P K82TU/"7QA2G%34Q*S,TF6"D)2%!
MN5:<9:2@5^$N$C4DE1J:V'BB>M:GJ)T-32-0RKN9DW2DX[D1>N$W)I5ZIXER
M[ 2*%%%QWXV 2 040331(!$T4R$^QV"X1A&%X/A^&X5)RDOA<K),2\K+L-MA
MA,LAH)0D  A0(JI2B25J4I:RI:E*/ F)XAB,[B,U-SLQ,.3CLTZ\ZXXM>\+R
MEDE1)H018)%LJ E*0$@"/<+L)YMUMG#1-4#6[YY/.J0>PL(G/OSF7>R3A5H\
M76(\=GN=TZ:1Q(;OU53'74.X\0N<RJYC#\\?TL-EL P+:_!)G!Y>7E)K%\-F
M9G$I>72E"!N)AMJ5?4VF@2IVLPV%4'[.70D );%.K/8CC6*XGL_B#,^XZ\S(
M3C+,H\Z2HG.TI;S8)M1%&E$:YG2H_CCNL68"%N[$?Y:^6.5-U?4>(XVYGP&L
M>V;Q7\2O ?>#P9;?XL=K:V&WW_?TPON]^&NM!Z\OI"%Q1XGCK2H\"1Z\#P9=
MNZ^ ?UPFXKRKRM7KQYPF=6E=.RW3GUTA/!EU_5#:_E;V:_@&%W% -*]VOEP@
MSJTJ0.[R'\H/!EO_ (K3U%^=?5_(#%0=">[S_GX\3.KK?C;U?ZPH,BA_V8^P
M #W[ /NP;@\*"G2W=?ZPN=0T)OJ* #YW@\$4?^R]06#3GR'WVWYX"R-"1;G3
MRY=*PF=7,^5OIX5@\&7_ #?JT#YZX-P?5/O"A:OXCW ?EQ@\&7_-CUY6 ?+"
M;FG+LH+5[Z#O@SK_ (CSX>JP>##7]6.OJ^;^>GK'"[D]U[U'W\;P;Q?\1CRN
M^DRJRJX%IE'2T:H[CZ6J!U5<M*NVQE42.YRG0@ @XYPND<I?U*$K*R:#94!%
M9PT3>(AWD9QD['_0]P7!)G:#:C$YQ+#V+R&'2;.&MNI;6IF6FWG_ 'Z:8"@2
MAS]C+RZG4?$&G5MU"75@^!>WK$,28PC!I.76ZW(S4X\N;6VI24K=ET),NTX4
M$50 XZ\$FV=M*_Q-I(\\\H,\,P\HZD"2I:=EA0E;,I. \8X6CYY1<>!@DZ8'
M4,@X=I/S-U6:IDQ6(L4"E,)%%"'[9VVV6V=VFV?Q*0QZ3E'),RCQ<>=0VE4L
MVE)6MU#I%6BA*2L*!&520L$%((YTV:QS%L&Q:4F<-??#^_0D-(6LAY2CE2@H
M%<U2JA%#F!RD4-_I;*S 2@)DAXC 43!8N@C81 =MM>HWZX^,+DND.+2VH*0E
M2TH4!0+2"H)52IIF%[TU(L3'T&2XLI25525 %210Y54J1K?*:BM>L5>"+_F_
M@&&;CH*_ZO3KZJ(7.KB?(0G@R_YKV6+?\OGV87W?^[VT%/OZ[X,ZJ<>R@_E"
M^"+_ )KX!;VASP!BO%/9;Z5[H,ZN?RA/!%"]D[7\O://3773!N.E^[N\/5(7
M.?XCX#[]D*#(G^:^X?OPFZIQ%NRWGSU_,0F<\#Y ?>#P9?\ -CO?I]V_77"[
MD_?3[]W="AQ7\1'A?J;P>##?NA]H![KX"R:TJ"1IISZGN[80.*-\QKW$]8/!
M%#0$Q]P:AT]N#<GC0Z\NSGXPN<_Q&_0??O[8/!AL*0[[6+H'O]NWLPFYKQ!H
M.7'D.&G7\DSJYGR\?5^D ,R_YK7U!?\ '7!N.(IVV\1<09U:U->[CU]=L>"G
M:9[2F:;K/6NXR!J:3IB+R^J>0I* 8Q3@[86BD"J9H[EQ$/\ ])RCKQ"_C@*"
MZ4>=JR15! BG??3W]'OV9;)X9[.\%QES#)+$,7VAE1B$_B$RRV^\$3!!:D&G
M% J;E9=M* IA"@A;^\=<2I1 3QS[5-L\=FMJL0PYN<F920PM[W66EF75-MJ4
MU7/,K2/A4\ZM2B%J!4AK*VFB:UZX[&/:NKS-BI$<L\QG*=23"$9(/H^ICM4$
M)=VP8IIJB696;)I)OU&9_P#!R/EDA>. ?H$<+J>')Q^6_I0^RC9C!]GV=M,$
ME&<+G$XE*R4VRP AF;1-)>N46_:MJ;0M"@JB6P\DI*2@(W3V,[<XQB.)N[/X
M@^Y-L^Z/3+#BR5*94P4<= A06L$4 *U-G4*S>FG@P_S8_#;Y^&.% SP!'E]#
MI?L[[1TGO%_Q&FGTA/!AR2$-KZ!@W/&H/ &VHY<>P0@6H<3V"@]4_E!X(O\
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MQW(RDB[45>2#]TI857+E4XE3*DV0*BT;MT$O)MI=HL;VOQ>8QW:&>=Q#$9D
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M[J+]#ZZWK!X$-[CO:^FOOVV]W7? &D\:WKJ >\CZ4/? 'K$9O(_:#P6VIO<
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MGF:\-/7JD+[Q6@^NG:>?"W9Q,*+0H[@/^Y:_]/;Z@Y)NQW#D*>N,&_Z^9[>
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M#=BUAX'SJ/M!7^SQMIK?KVPG@^7!\ ^_BM@W71/KN@KPRGLM3YTA?!A^YZ]
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M3<_A/E]^I@\'U)I[!'X#;SY>S3";OH/ GY P6O\ #X =E+'Q[(!9V_9#X?\
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M\?7>N8$ZU/KQADRC<K@K3Q"(.3IBL1L98H.#(E'A,J5+B[PR13#PF4 O !A
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MC<Y1,5(UK/#'T2JYIQ2U))E'$-Y%EI:EEQLA*%A*LJJ D&G \+1B3C:GDL(
M"DB80I>8!: @(6*J02 14@ <SV1Y4]I_L*9HY=RF;M/TEV,Z+[2DNUR6R-A.
MQK/4WE3]29/Y6R]$C6T[G93%&T]1?:"RKK#LIU?6==RD;7<9F+2=;F</1=),
MV<C44Q#)PBUK+3C2]RM4XM@;]XS@4]^V=2O(EE:U+96F90AL%LM+3I<TK483
MS"TE:4RZ7:--A@I11MM2<Q<" EQ"F5*6<X*5:ZUT.1SOT:V;-9T;]*%G?4.4
M67*V<N:3/M61F2D!(9+P,IGA43G,7LT0M%TZ]HC/E[7:LK"4[+3LK4E--Z7>
MP1CJG--&=S)4Y557#1B#2%X8PEYP--&6WY#Q#"0W,J6H+9"*%02$J*B2*9;"
MD.,LM29US=H*W \&_P!F"Z2ID(&1TJ)":D@#M%;QB4=]']VVLJJ [76465.6
M.5<3!9OY3=G-O,-\BDYSLJ4!55/0M#YZ.<PZ:H>F0FL[%VF>LA6@9<4IFQ5K
MF=C668F6LXI"PR5'2C9M4#-ZIV2><DW777"IEV8H7LLRM*BY+[M2U ,_Y.$!
MQ32<O[-:<Q*]"T2TPVAY"$( <;:J&@6$D)2YF2D5<_;*.5*U$@*1;X3<?0;V
M3X&M:<[+W9WIS,B!-2]?4YDCE=3U84^I*#-K1%10E%0L7*LG$F#5H#MXDZ:*
M \4*@!2.N]2(JX*F#A77YL-JF9A32LR%/.*2K*!4*62"D5-.WL-J@"T9SAIH
M+&58;0%"M2"E(&M.E^O/6-_]WMS]?$.WL^'PQCY!6]]/E$D+W=]__5^7SIY8
M,@[/76#UKZZ0=W\/];[A#W_'!E'4\ZG7E7LA:]M];^$'= /+_P"+\MOA\,!3
M7T?*]!X0D)W8=/@;\L!3\ZTX?,:]>%K05^\ )@']#?E@"$\?'\B:7@@[L/D#
M?EA,@KPIRO\ >"'TT+E'0=^@] ]6)4HJ-?KP$-4NA%JV''\HZ9QZ]&@P8((,
M$$&""#!!!@@@P008((,$$&""#!!!@@@P008((,$$0I/_ -G2'_N3O_Y"F,:<
MO*30_P#TS_\ Z2HFE[/L'_\ .;_VTQH/N0O]@NU]QWZ?(A\,>693T/=0]W"O
M;QC=@L<CXD^>O=2 $ _< +7_ &A&X;6O^8>O#LHXT[A\]:UZ_.$SCD?\1@[D
M.9 \]0^_^6$*.H\*4\->>OV@SCD?\1@[D N/ 'EZ6P\MP^[G[,&2YN*::>%+
M^N^%S]/.$[@/W _WQMK[+A;U#Y6P9+^/Y>JCAWF?IY_E"]P%@]$/+TA'KOIM
MJ \^N#);4=M/K6#/K;MN8.X+MP  A^UQ#^ AR\A'\3)X^7R_G!G'$6[:_2 4
M2%*(B0-OWA#SZVY>OV8,@)UIY#\O76J9^G9>OS^\>>G9,[8]29^U=7T!5-#-
M(**@ZFD(B&G(DSKPT<X(^>-HZG*D!ZLKQ2[Q%@Y%!^U\,BY=HG:_5R!E$3#[
MOMY[()#9O93!]HL&Q=V>=?E&GL2D9E+2G%MEAE<QB.'EE*:2C*WVPZP[O%-M
M.)>$PH(6!SU[.?;1BFU6V&T.S..8"SA\O(SSDOAN)2JW0AM>_F&Y;#<33,+-
M9Q],L\6IAG=(=>;4S[L@N-F/0ON0WX 'RXK?F ARUQX1EOP_PV\C_+A:.A<_
M0_XCP]<-8X=KWM4S2&;DCEWEI3D7-P67<G3S+-RK955R9G'OJ@?-V3:E('PB
MR*8SIC.B)F7<G7 D@FY8A''%DX4-[OL?[(9#%=DG]H]HL3FI"9Q&5Q!W9O#I
M1+.\>3(2RYES$)TO(4?<DI0HEMM+9+10Z9A(6@1SYMG[9\2PO;1K9C9G")3$
M)+!YC#4[78M.K=+4L<1F6I9G#)!+#B <16IU 2XZIU(>SM>[G=.*/<0(%T]$
M+" #]H?7;K:_+S]_A&3K6U+]O/AV<]:QT'GXT\Z>(@[@HZ< >OB$ Y;>C?RY
M7MOT,G9>G#ERY5XGRA<XY'Q^?HP=P4/V"C;^(;CJ/D._+7E@R]G#A6G94P%=
M>![B1](.Y#_-A_O?B-]L 0::CP^NOK4:P9Q70^)^6GKC"]P70> OF%Q#_P!-
M_+U^["%%>(!Y 6[(,_2W;?UWP@(!^X&O\0Z? ?PMA<AZ#NUY]G3Z6$&<<CXG
MN_/ZPG<!IZ <].,VE]!^&H;ZX,@TK]^'KCK!GXY?/MZ=L+W!0$1 @>7I6UY<
MM_+GO>^F$RTY4I0D\^@^7JIGKP[JGOKT_E2D HE_S8?[P]/]4+=/Q#FN6_#N
M'0CF=/6D&<<CXGIZ\N,:([1^:,EDSE;)5M$1[)\_0E(.*;A(@NHQ;_6\D@R,
MY<IMUFZIRIE4$B92N$@%=1$3&$H"0]O@>&LXEB#<L^M2&E(<6=W0+.1-0E*B
M%4J;DT-@::Q7XG..RDHMYE"2X%)2,U2D5-U*2"FM *:BY'*,KRGKAQF'1T5.
MR,,>#EG#-JZ=QQCF,B*+P@JLI%B<X =2/D$0%5L90.,ABJH&,H9 55'8W@_Z
MIF]TAS>L+!4RXH?$0*!:%@&@<;) .6Q!2JU<H;A>)^_RX<4V&WDT#J 3EO7*
MM%17*L"M#=)!2:TJ<NJB?A:.IV8JFH'"4?#04>YDI)V<P_JFS4@J&X"A;O%5
M# 5)!$H]XLNHFBF G.6]6Q*NS3[+#("G7EI;0D?#\2B;F]LH^(FM  2=(SG7
MVV6ENN5"&TJ6HUK8#2^I.@'$TI<QI;)O-2J<QI-VM.TTUIZ#EX4M1T>UXES2
MQH3QQ6*#F55.<4%!D.\[YN9N@@D4$5BIBX3LKC9<<V?E\*DY9QI];KY>W4QF
M"=V59"JK:0 4A)30@J59=Z&*3"\7?GIEYMQI"&MUO60DJW@0%A'QDFBLV<4(
M2FM*BUXZ'% HC]BX=.(?=I^&WKOC52BO+PI;LK3Z7B_STX><'<A^X4/68??H
M7Y^]"CJ/#7K]OH28,XY'Q/KUTA>X+S3"W/TAT]M@^X?7RPN36X[DB#/T/B?1
MA.Y+_FP_W]QO_J_RY83)U3KR/.PZ#G2IOQ@SBUCZU[:>J0"@7]P+].+\M_Y#
MIKA<G7R^_#MKYP9^GG^4'<%_<#?<!^_G@*.SLI]J>NMX,_3S/KO@[@O(A>NI
MC#[+_';VX0HY'Q]<_+L@S]//Z<8.X#F0O^]_^'GOZM!'HN6_"G]T=/Y<83..
M1_Q'UZZ0HHA?[ <PWUM:WEY6^/F%/(@'32].)M;Y:T[#/_9X\SKZOYQS!46>
M$S"Y\$RL:TXC(124%&RCD406-,K@^*Z<+R#(05! [5@BW.0[<R BJ=!U_A)/
M0 GH.![%2V-8 Y/)FU,X@770RE2FQ+#<G(&G0I.<*>44_M X C.@;M5#FT?&
M=KIC"<;;DE2B79+(T72D+,R=Z,RG6B"4E+20K]F4$KR+^--1EZ:1[EPBDX0X
M%45DB+(JD/Q%434*!R'*-M2G*(&*("-[@-QOC07&'&G%M.I4VXTM3;C:TY5H
M6@D*0L'1255!!'6-V;>0XA#C12MMQ"7$+2JJ%H6D*0I)XI4D@C2QX1J3,S,=
M6DGU/TE34>C-UU59W!HB,,90R+6.9E_PR8?%2$J@H)&$$T4N-$%S%<'[XI&B
M^-KV3V6&/OO.33RI?#I3)OW4! 6XXNF1EM2PI*24U4M12LI!;RI4IP%.M;2[
M1*P5EIN692_B$UFW+2\Y0AM)(4ZXE)2I0!(" %(J0X2I(;*59Q1LJO4-,Q,P
M[1;INGB!A<E;"<&XK(KK-U%$./C-W*AD142 QC"!#@'$< XC5./X8UA.,XAA
M[#A=9EG0AM;@&<I4VVX HI !4C.4$@ $IK0 VLL#Q%S$\)DIY]M+;TPT5.(1
M4)S)<6V2D&I"5Y L E7PJ%S2,G[@MOL!?GZ7\@^_GOH.*<H[*]!3CV\!%MGZ
M>))@[@-/0#;]Z^OM /Q]?/"%!M^'P]5[_G!G%['Q/H=D (A^X >W?;3;UZ]-
M\.R_W?\ #^?RA,PY'_$8.Y#]P T_>$?D;<[!M;"9.P\-.P<^^U#"YQRZZGA?
M^7"#N"WMP!_O6\O=[/=A,G4<].SE2WR\X,_3IJ?7UA>Y+^YS'7C&_6][== ^
M/+!DZ^7YP9_[/G^4)W <B%]IA'_TW^.%R>B*_4>7/L@S]/,B#N"Z>@7_ 'A^
M/VL&3J/\/UK6#/T\XMTPX^JXF3DR-#NCQ\>\?%:I''O')FC95<&Z>X<:PD!,
MGH_:,&F)I:7$Q,L,*6EI+SS31<-TMAQ807"#2R <U*\[\##,S!8EWWTM*=4R
MRZZEM)^-PMH*PVFH_$LI"1U,<5=C+M3U#VD:7<3%54M'P9E7JZ4/*P?BOJ1Z
MJ5,SM>"4(]7=.$I9BR,FN"A5U$GK8%E!1:'1X5O:?:O[*)'882TS@F)3$]+%
MIHSLM.AI4Y+APAM$ZE;+;;:I1Y^K106TJ8>*$9W@LEOR#V5^T^>VXEWAB^',
M23^^=3*3$FIT2KZD N+E%)=6M:9EEK*Z%!:@\WG5NVL@#G<PHE#42![#=?.W
ML'3'B 33^7Y]:$<1XQ[+GZ>9^W3A\ZQQJS[3$G5F:SFGJ#@8Z3RSI>MF.7E4
M5DX465-+5>]<&8KQM,F;K%;"G#K@<ZZZI'1G9&CHQ$V[;N'*WMC/LHE938MW
M'<:Q!^6QR=P>8QW"\,:2A+<OAS#1>;=Q#>(4X5SB,H0AM30:WK0*EKS(3Y#_
M .TQ^?VK.$8/),/8)(XLS@>)8DZI:ES&(/.!EUF1R+2@(E5E6=Q0=+I;<RA#
M>5Q797<%_<*-_,;?//33UX\3RU&HN!6P\1>W='KN?F#4?VC]A\N[A!W(:_JR
M_P"\/OOPAZ^7+SP9?[O^'3LO_+A2#..1_P 1@[DO[A?]ZUK==!Y]!]V#+R(I
MV5X\36O2#/T/^(^O58 1+?\ Q86_UKCM^?JVU <&3J.\5/=P[:\.<+GZ><'<
M%U]$/]X?/RU^'X8,HX4TY5[]?"M?E0S]/,PO<E#]@HAIS$ $?9KSZ:ZASP9.
MH_P^5SQY#\H,_33J83N"_N  :?M7'[N7] P9.H\#X:CQ[-!!GZ><'<A_FP_W
MOQL'J'0<&2O$"]:Y?ST[H3/T/^(^N^'DT0L.@!Z6NH] Q*E H=3?A0#0<#2(
M7%&HI84TUXGB8Z#QZM&E08((,$$&""#!!!@@@P008((,$$&""#!!!@@@P008
M((P6JZU4I^3AJ>B:<E:JJ6>93$FPBHYQ%1Z",7 KP[65E).3F7[%LU9MG4_$
M-@3; _DEUGQ!;1ZR*3I9N]*,P4HJ"4I(!)J;J"B   :DY3R%KD1&M>4I2$E:
ME D 4%DE(4220!3,.9-=(O*#J4>4VJYF8M.%DU6+\7,8E()RI&HE!P1(H/TD
M&R;@5$"I+&$B)03,H*-S]WQFQ9R@EIJAJ/=WJ&E*_LU<+TC(ER2\R2,IWJ+5
MK^^*7[+QJ#'ET;I!@@@P008((,$$&""#!!""%PL(:#O?!!'@GVHLC,].SMVA
ME,P\ECRJV2^>F9=&3U11T:\*5M369BE2$?E2F67$GP0;V846F8F3,!V;%=](
M1K@[0I&GC.MO9CM[@^.[*/[,8\VP]B6$X'BLI*;YK,],80K#ELO*E%D%0>3*
M(#,PTDA2T-M.@.$++?&OM9]GN.;/;6L;5[-S$U+X5CFT&"S>(I8?+3#&,-XH
MU,2_OS84 9=<XI3\NZI.5M;KS)*4E"7/>@>/NC6  4X#6 = X[#;V7^&.2K5
MYBM^=[^)\8[)O3K3STXV[H^?'Z-S(;/+,/,NK<T\U1EF.5T;F+.U8HF]>#X;
M,O,R)G9(S%^BW36M(Q-/RCM]*#,F*=HN^208,CN4UI 6_6WM,]H,AL_LHQLG
M@X;&+3F$2\F"&0)C",#G)5@N(2M:,S3F(2J6V4LA23N'"\HA2&LW&WLL]FV(
M[1[9S>V6,NO'!)+')F>6T9I2I?&MHL/G'PPXXTA80^WA<ZX\^7E(4G?MAE%4
MET)^A/')$=E08((,$$&""#!!!@@@P008((,$$:[S9RYA\V\NJLR\G#"DQJ:)
M69D=D("BT;()F(ZB9=N01*!G,3*(,Y% HF BBC8J:ETSF <J2FER,TS--_B9
M6%$5IF3HM!/ +05)KPK741#,,)F67&%_A<24]AU21V* -.-*1P3V.&>>E(9R
M59ECFR5Z=.BLO$V3%ZHN+F*?Q9*@8)4V\A7'$/?,%VWUL*!;%49V<LWB39TB
M9N3<]I)R5G\%E)EBBLTZD A-%(46'BXASBE0HG,#95$J3:YUS")5Z5Q)YI=1
M2655)/PE*7$%*D:53\5J"HJH&AM&T_I$/TO4[-\DSHY!P[=R%948RD6+,!4>
MOHY25XR-6K<EU7*BDLG%F.@B!U#($5.8O=IJ"%'LOD&*H6Y;(P^I!.B5I3=1
M-"  WG))L.V+/&LWN1 -$J=;"S6E039/.I7EI3S$9KV1\K*VH#+YO*YH+K*5
M]4#*,0<QZSKQ84S3T2W,C!TX10IU$2+-4UEEWJ38PH)++$9IF4!D"JC]I,71
MB4PVRP:RTMFRJ%@\ZJ@6YU "4I036H!4-89@^'F3:6XY_7/Y:I-RVVFI0B]P
M3F)4!H: Z1UEC6XN8,$$&""#!!!@@@P008((,$$&"".&>UOE77RTE3F>V3IG
M/Z=T/&NH>H(MDJ*;R=HY0SIUQ1X"/"K(PJSR1/X0O J_CY%X1,RJ[5HU7W_8
M?:!C#77<-GE)3*3;B7&EN %MN8.5)2Y71#H2BBB:)6VD6SDC2=L,#>GFV\0D
M@HS,L@H<0@E+BV**(4WE()6V5*JD76A9U*0#OWL[R<S,Y,4#*SQ#)R#^&,XX
M#B!E 9G?.QC>\L(V/]7>%XB#Z2?V#@!P, 4VV(:&TF*;E)2E3R5+!24C?*:0
M7U $ T4Z5*K>I)(YFVV5WOZ@PX.$*(:6E!%_V*75I9!IQ#82FE 10 WL.#\T
M:5SOKGMN3$92 OF=/-:3I1DM5!3B6/IJEW<:!I<AURG('U@YD7LP9"**<'CT
M'1#B0K(ZBZ>\;-XS(X#LFW-NY2XX_.96:?%-3:'"$)2<IS!*$R^\<%4MI K4
MC+&GX_A4YC.TRY9LJR-LRU70KX9:66GXBJAK52R]E1JLJ-LI*H]1X>*9P<5'
M0[!,4F48S;LFI!$3&!%LD5(G&8=3*"!>)0XZG.)CFU,./*9N9=G)F8FWU9WI
MEY;SJN:W%%1H+T K0 6  $>DRTNU*2[$JPG(S+M(:;3R2@4%3Q)U)-R23%RQ
MCQ/!@@@P008((,$$&""#!!!@@A! # )3 !@'00$+@(#R$-A#E8=PWP=_7EUX
M01X.2^3&?G90[6%#4KEN62=]FS-G/* J&E$F:Q1B*7EG[M5W/TI*I*+'49GC
M(,LT$.Y< *4G -R%366>LGJ2/7^#;;;.;=>SC'F<>#*]JL&V3Q&6F5.))FIF
M78:K+3S-$!+B%31EW'DH.:7F25$);4A2N1\2V0VGV"]HF!HP!4P=D,=VJD9F
M60A0,M*3+[I,W)/545-*1*^\I:42$S$JF@S.-K"/;VLU)A&CZI6I\R1)].G)
MM2$.N=-)$DN2*=&CC*J*B5)-(KP$14.J()E+Q"<0*&G)N&I85B,@F9!,NJ<E
M0^D DEDO(WH"4_$26\U +GA72.K,14\G#I]4L4B83)32F"H@)#X97NBHFH #
MF6I-@!>/$SZ)O([.MS$L\SLUTYJ#R\BW4A+Y>4U+J*H.*CJR30-&/ZS<QBOZ
MPC-DP\2T9.W1$UI!\L1PWN@PXU^IO;KM[A34BK9+"4LN8N\AF6QF;;;%9+#&
M5)?:PI+F@<?>W;CB$?U+*"VH5>&3EWV#[$XXI_\ I-C*GVL$9<>F<$DW%_\
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M,<N90%*D1Y9LOC,UAJ\19*E+97A[\Q+H6K,A,RS5+:DI)(2%JSI<30%>5)N
M*Y-V59Z>^M*=J&9D3R!,V&<N)W#APFY=/WL$@J^%ZJ;B.N443$=M4@,)$Q(L
M<I2<"28EQMN\,E%[.)<8;;;5A2V5M(: 0E#3Y;9<0  E)#@R+M4U;%2+@S['
MXC-(V@R/+<<1B:'D.*6K.I3K 6\AQ1NL%"LZ;T%'"0#3X?0X<>&F/8A!@@@P
M008((,$$&""#!!!@@@P008((\@_I&<QYV5SD[.79RIIZ#9_5#IU7*Z13IM7*
MTHJ^4I.D3(R!N [0J1CU2104ETP.*Q16N4B>.HOT><&P]K#]KMK<1;2X):75
MA;.9)<#;"&FY_$<S-T.9T^Y %221D6$D!2HYG]O.-3[N,[';(2#JFO?'E8H\
M4D(4M\K<D<.(>-%-Y%>_$Y2*YD5%4@QJ'M*=I&MC94]GS)%M4KT:FK2NJTI.
MKIAF^%)Q-1V7CF(CHV+=2!%"G71E3U/%JO515XGZD0!G:AR.%RJ[GL;L%@4E
M[1-JL=7(,>X2N$8=BF$2;K06U*3&,,S+LT^VR4J2DRZY)\,IRT:3,4:"2A)&
MI[;;;XT_L7LALZU.O>^SV,XAA>+333I;<F6,(>E699AQX$**9@3K*G3F"G52
M_P"U4H.*S>EW9!DI0F6LE0TTN@XD<KZJDJ'.HV%(Z94&39@_11[U  (J+8S]
M9H"@W,<C<@G.<US&\&]M&'RLOM8UBDDE2&-HL,E\8*5%6;?..O,.+HKXDAU+
M#;F6@ *E  "T>[>R><F%[-.X7-+0M[9_$IC":HRE(:0TS,-IJD446U/K;S7)
M"4FO+JS'D<>G08((,$$&""#!!!@@@P008((<2V'_ %N?^J7$K?X>_CV"(G/Q
M=W#M,;\QZG&F08((X,^E%IFJ*W^CM[9U"T/2M55O6M<]G;-&CJ0I&BJ:G*MJ
M6H:EJ2E9&*AHJ+@Z>824DX6>/G**/>%;>';E,*SI9! AU"D.3922= H?.-+]
MK#('.*9R6RMK6AZGS6[0SW+/ME=F?M;5#EO6D;2E/5Q4>5^5)J595/EG1]-Q
MM*9:0P3%/C%FSBI>EIZ'C9>6S!AS1:CLTL]C2)D I4@\B*]?5JCA&7UUF=FQ
M7_:1I]:@&F=0]FUMV/\ M&3&8T5,]G:I*8(;.):H,GHS**G8]U764,5FNYGI
MRFI3-&0D*,H^65.HZIB'5G8MH*#1O*$):AYU%+UM>NEM:=;QAO84A*P[+_T>
M.1=>YHD[2U=S5$=C7LR4A*]G!QE$XE*[H"M<L:+^K)>D*!RRI'+:GJ\?3CNH
MIMK3T@^J9"HG"$=1\-./JF)$,)&9$A574JG%1.O._.D6B620S$[$?TC4[266
M>=ZV;^?F6V<LU6S.H>SYG-EO,5KFA4W9Z;Y34-1.6%"YB4/2V8]6PU'412&6
M] -*B:T:UCZCD&;FHU2LYJ2J>,A4U![Q>H@XIY"E+C2I/#J3'8V82=1.NQ%6
M*%-L\PHZL5.S+-MZ=84O'UQ3N9[*K2Y9N$85I"1L$A'9@1%7-YTK5)FUCV[2
M>:R)2$(FFL40!8:/58\LJ@H#,ZGH?)F@IY]V_P"!H'.;LQ4=-,,PLJ$,_P#-
M3-6@>V6=2'2KS],AJ)W4TADD]EHUA0SB@WV8L) =G^DY"(S/93B5-1=6U,WJ
M AW7X:UTM2GU[C7YC()FO<U4^T%E;2V:C7M$4KFNO])A,TBYG#(YNTYDA7G9
M7F<J,Y)+*&&I2K(KZKR.JN)>0$#1<C5M#Q#QW5L7FQ U%5$_3<<[33ES$* +
MZ?A/B*>'/L\(P2AI'M-K4I15+S47VUT:CI7Z/'Z0_*_,63>0?::;B_[1T'FO
MD:\R*<QM3^'+^E5?*4JSS$6RIS3IQ])GJ.%?2<92%8RPJO(Y$A !J2/Q#PO7
ML'AV1E*M"]I>HC=H*L*79=JY7-"AOH^>R14.0T-,U;V@J"I&2[1*&7W:2IG.
MZ(@XNH9BG<LIO--2GZBH)NY@JL;OH^.S =TY5,E'-JCB7\RP(!2U>9KII;C]
MM8N4_&9IRF53NN,@JI[8ATJFS34KQEE1VE\CNTY3-)/I*'R5FJ7JO*+ZHI1E
M$=I/)&%F)(T?6E,9HD)5>6S7/Z.3J&D(FIW,H51<@XWIIJ"+7UIH>SC'M%E<
MYEWF6>73RH*?F:3GG5"TBYFZ6J*70J"H*:EUZ?CU9*GYV>:E(UFYF&>F6CI.
M7;$*A)/6R[Q$I4UB@!#8L<M_EPH'_NKS;_\ -N2N)1_4.?\ BL_[#\1'^O;_
M /">_P!MB-DR7_LY_P#^Y.O_ )"F,*;_ .JS/_R[W_IJC*8_KV?_ !6_]L1H
MS'E\;G!@@@P0>JP8((,$$((@'S\A@@@ 2\A#YTP00N""/%WZ:'*&K*JRGRPS
MCI%JZ>K9,U3)IU BQ QG3: KD(5D66*F0!4528SD+#LU2I 90A987 E[E!91
M/W?V#8^QAFT$]A3SA:<QEF7,FJI&>;D%/+2P#7\;C3[JD"E2IH)352@#S[^D
M-LX]BVS,CBK3>]:P5Z:3/)^&B)/$$L(+Z@K5+<Q+L(-#5(>4HC*"1Q76_9+S
MBG?HWH;,92EJB6S)89OES@5IH63K])4LMS4TM2:BYX<Y"OQ>&4*C58I%3,Y&
M"$%O#\93%QZ?,^TO#9CVMB75B#)D&L!3@29[> RYQ83GOZJ3%<A;^+W//7+[
MPDC/37R;#O97BDI[&5O##7_UE,[1.;0JD=VHS(P<R/ZN3F8IO-Y\ GZ4*_=U
MA60 6]$?HC:"K.'R1J7,NMF;QBYS/F8X\ C( H1ZZIRF&[UFA**)*V521?2<
MA*$; L4IEF[1-VF MW"!S><?I!;3-8SM#A>$MO;Y> R;R9M5Z-S<\IIQ3%Z5
M+;#+"E4K13N4G,@@>E_HV;)NX#LWC&,NM):3M%/L*DQ09ER6'(>92^1<I#LP
M],)2%4)2T%TRK!/K+CP".D(3B .88(( $!YZ]-/SP05!T-87!!!@@@P008((
M3B#J&""%N [#?!! .""/GW[063&:D%VRZHIZCX66>L\Z)A.IX!RT274CW*$R
M=LK/KR"R('39-H.94?#(JN13!LS(@\.!45TA-Z=@>*L(P=#SCJ$IDV]V\"JZ
M5(J$"AN5.H 4@"N8U2*J$:;B<BXN=+:4%1>7G;--0H_$1Q"4&J55TXZBJ]K;
M)',V@.TZQ>47#3DS#9LQ])Q-/NHQFX4;KSD=!1U-/8!RNF!D4WHC#%F!*N9,
MH1[TJVJ;5RHF8!BS+LBM;CB&URRYAQ\*(^%I3BGM[EUR@.%-:GXA2I) @Q60
M6E]*4H4XEQ+26C>BEA(04'A4Y02*UH1PCW6R\IM6CJ#HVE'"I'#BFZ7@H1RX
M3XN[7<QD8U9N5R<0 ;@67144)< 'A,%P =,>=SLQ[U.34SH'YAYT \$K6I21
MW)($;7+-;B689_\ A--MGM0D)/=46C,?/&+$\)Q%ZA]_W8((7!!!@@@P008(
M(!$ WP00EPZA[\$$+@@C1/:9R^D\T\A\RJ%A"%5F9J [V(0.<$RNI2'?,YV/
M:=X;T2"\>1B+8IS>B4RH&,(% 1Q;X!.MX=C$A..V::>(=(_=;=;6TM=..5+A
M4>- 8J\:DUS^%3LJV*N.,@MC^);:T.I37AF* D5M< VCRS[)V4N8V;5!YL1%
M0Q\K&,&N7=4T' K3C=RQ25JV2:&:LFQ!=$(8R<0LD)Y+@*8K=15!,]CG$N/6
M=J=HY?#TX6P'4.K,]*SCJ$T6I,DW517:]70I.YU"P#0&/,]G,!>G58BXIM3:
M!*3$JVI8(2J;6,H14V_9Y3O;U36Y$9)]'Y2.99LS'K2K8:<AXW*E"59OB2[9
MPU*UG7Z"\6UAR%7 HJ+F;.GK\11!1$K=NFL<X%<M16@VUQF7&SXEV7D._K-3
M18R$+"I=IU+KCP*:@)2I*&S<?$NFJ5")]DL*>_7BGW6EM##D.!X*!04O+0IM
M#5"*E2DJ<6* @A-0:*37V>QXM'K,((@&X@'K'!!!<.H>_!\O7K\H(7!!!@@@
MP008((01 -QP007#J'OP00N""/!#Z9_**N1E\D>T/0L5)/B4N#W+ZJ'<.FLN
M^C1DI5"3HQ46[?C<BV=R+R>8"NDF)$GSF/;',"KUN4_47Z.FTLI*KQG9N9=0
MV[,N)Q:30Y0)>"&-QB"05'*2VPU+.Y-2VAY?X4*(Y<_2,V;G9@8'M/)M..(E
M4'"9Q;-2XPI<P7\-6$H^,AQYZ:9SBH#BVD&[B ><^U/V6LY(3L2=G'.)>GZ@
M"O,OZ@K2J\Q8E!LNM,TU3>8HQCR-EI5JF4SMJ6":4K"%G"G("L0M,N ?E138
MN54=XV=]I.#8C[5MIY!F;EQ(SLKA6'X/,!00U-S>$!],PRRNI0LS3T],^[FN
M5],NWN0K>)SZ/M/[.L=D?97LKBDQ*S)Q&0FL5Q'&)<@KF).4Q=4NY+3#X SM
MB4;D97WD$5EUS"]]EW:\OK=]&51%;4MV:8^H*_:O&,_F34#RN6[21 Y7Z4 ^
MC(B/A%72:EE$5)!M'&E4DE0!4&C]N90I3F,4/$/;SM#)XYMPJ7D5)6S@.'MX
M.ZIL4;,ZS,S#TXE//<N/;A1O^T:4 :"_N?L(P+$,&V'1,8HEQ,SCD\[B[273
M5Q,DZPPS*+76X4^VR9@ FN[>057-O0W'BD>T0EPZA[PP00 (#M@@A<$$&""#
M!!!@@@P00XGL;_6_])<2HT[_ *"(EZ]WU,;\QZG&F08((,$$0Y&1CXA@]E99
M\SC(N-:KOI"1D'*+)@P9-4S+.7;QVY.FW;-FZ)#JKKK*$223*8YS%* B!!&O
M:&S?H7,6KLVZ'I9]).:CR0K"(H3,5G(0$Y"$BJDG*)IG,.,;,'$S'L49YDZI
M*KZ?DT9F$._AU@?=P@^57;N$TB#EUT^7S$;.P008((,$$&""-<U]E/069[R@
MI"MX9S+N\L:U99BT,JA/U'"!!5I'1LI#LITJ<!+Q:4BNWBIJ7CR-Y8C]B+23
M?(G:F(Y5 Q!&QL$$0SR,>G(-HE1\S)*O&;V1:1IW*)7[J/C5V#:1?-V9C@X6
M9L',K%MWCE-,R+5:18)+'(=VW*H01,P008((U3+?Y<*!_P"ZO-O_ ,VY*XE'
M]0Y_XK/^P_$1_KV__">_VV(V3)?^SG__ +DZ_P#D*8PIO_JLS_\ +O?^FJ,I
MC^O9_P#%;_VQ&C,>7QN<&""#!!!@@C27:%[0>6'9ARKJ/-[-F>2A*7@$.%%$
M@I*2U03"Q%!C:;IQ@HJD:4GI51,R;-FF8I2)D7>O%6L>T>.T+C <"Q+:/$Y?
M"L+8+TR^H5-PTPT#^TF)A="&V&A=:SQHA(4M24G#GYZ7PV5<FYI>1IL=,RU?
MNMH!(S+5H!WF@!(^5_,>J^V3VSV$IVOZAS!/EOD&\"IBT;3[>LZHB*<HI&GZ
M@- 4]01&4-&))5!F)5KQ15=J^;-WSF02;24S..Z:IJ+3+']F[&[.[*[,JE]E
MV<,;Q+&"6/?)E<E*NS4X7V=_,SJUO$EG#Y1%B@K2E&9MME$S,K.?Q':'%,6Q
M!#F**FE2TF-X&6Q,.-MLY%AMMA(;"0Y,ND_BRDU"UN*;92,FXLI.SAVT$<T:
MAI"A.TDXI^JJ!CCS\L]#,[,20CQ;LB12O=#"Q,-.RDP4WULV(+!Q3;EJL4%T
MUTS)6!2]Q=6P*\&EYS$-EY>:E,0<]V9;5@^&MN9U%U&83#KK+3)265*WB9A*
MP<I3?2GDAM*F<6U+8NMIV73O%D3\RM( #:OB;2EQ3E0L I+:DD5%% 5C?U:=
MOWZ03LUU-4%!9H0>5&8:]+*12;RL'M(3[=@[0DXUC*,UVS^FY*B&A%G3.0;@
MNV?P#1^P>]\S>L&SMNNW+I$M[$?9QM/+LXEA,UC6%-327BF3:GY12FU-N.-.
M MSDOB#E$+0K*IJ96VXW13;I2H*B_=V_VJPA;DM.2TC-*:* 7W)5\(4%)2I)
M"V')='Q BH4V%(75"TA22F&*A[:^:/;<AG%,LV,/EA05'TFO4V9S-":*NTGW
MT1(HF05%^Z;MGJD;XT\,C#4VD"BRLPY%1XX?@W9K,]DV ]E6S.P6*.XI,J=V
MAQ%S$6I/!''I1.>1+J%$964+=93,)2F96_/KR);8:_8I:S.A?/7MA]J&TFVO
MO&R^%OMX#@N&X=,SVT*T36[$\99386VX[5MU; >7+RTM(MDF8FG27=\A+>[]
M.*]K[,"+^CHG\PFKQXG6[7( 9HDFEH_(T&&3$\T!N'B*]_1TQY,7  !RN+N
ML< $.<9K#<!;]MDQA;3#1P-&V3C EK;BJ9DDRP'_ ,%,X"RE-:;H! L:#HB0
MQ/:-WV!2N*OOO)V@<V%;?5-Z3!*I0!$X3J)A<EEF%+H%!U178B/+/*7MS9V=
MF/LDS>:3.FFV;E!L@5AZ-BYF?,S_ $:G62K)[,<:S9N\E5(!C#/G4JO$"+<#
M&;D".>,"'=&5Z)]H/LJV6VUG6)Z3F%8/CS,NWB&-*E94K3B.&*6[+)>*5%#
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ME+7X@TOUI77RC%IB.AUJX[)17%=]O8F2F>W:BSN).T#737M)Y,U2WA5NQAF
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MOJ<0V5+S*3O$Y0@GSS;.5Q&8?8*)=]R1::JE;25+"7E*.\4X$5*3D"4I4I(
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M!)"B">8H;$WX^_OT)K'M--:SKF;J'+*L*/R'JNE2N7$I643)4VSD*Q8NVGU
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M#V"JJ'E:<G&AB"8G \BY5!F]0. E$H@L@0>(I@M>X!T7A^TPF&$.RTS*SC!
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M[ 4N94XU,!LYZ9 G,'EAM:S%UL]@N-LXW*8A(-ON+$RA4PYNRVP6'%4F4N*
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MI>V> *Q[V/3\S)+PZ5E?:&RJ8=G<4:0VHO8+BDNVP'ELM!"E.NM@.&H)6A!
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M*$Q:,O<C<V,QGKA&&SIHOPB9E.Z=J92LP*HF4W""H)_I&!K*7 Y"B!#<-N,
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M>Z IBF[TX(XR]II':C9E2DSNVN(OI.Z0PAK$\3*W7%5!1NUS8*,F52BKXDE
M!%22D1X7C&R^*HS,;(K10*6YFF9<I0FHHK.)*]<P%* @FA%/BC;] =BW-%U
M!(TYFKE?3+1<I5E$([)&)9D5 NG$=)A4#8AN&X@43<0EN(<QQEX/[/MH-JI
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M*5+J$%25RZ'/B7E39!IF!&EK/5^5N9+2+K [C-.EIJ*IEBX7EVC3+1K&+OO
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MC)92O^D,JG>?'0,S) J *5#PX@\ >D:>_P"T;  X4IV=G_A^$_\ 2M:TX_\
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MIH.)U(CGKLFUC+-G\M2\BY4+(0CYXQ7,0YR@=2/6,B<2AQ7[M02%.4=A(("
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M/2G*#M1JOZ*6CRR+Q6"9IHD=-G3E9U-T$42BF5&07.8SB9HDQQ*E&5 )5'T
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MD%3"(B %^KV:QS:V'2Z)M1MH'KM/L[5.#/<<BP%< 2*Z=X\HQL>2'<992/\
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MR,SSOAU"Y&9-J$(;A_2*#56&PV*0$)A$#&'2P=X<A;]3!U"VXXG*[K9C 7P
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MY_2,><18?VW4 WX-2R<T4=-RF^JRAH(?PC\=!L-]9E)4#:Z1EJ:3A:L-:N@
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MI;+Z;<RS.&AVB[9U)R<@\08QK%D2*?*J.'CMTHFW:MDBIB=1990B9$RF,8P
M%\>J;>)>5A.Q8EDK<_Z0DWDH;"EJSF4FD)(2FI)L0"!J. C2L);:<F,7#P2$
MI9>'Q4&4)6V2JIH$VH:F@%+F(M85L5:K**3"23<)O) RC<S98BB+E!1JS426
M343$R2J*A52'*H01*<JA3%XBB&*C:6<KMMLVIU2=[*3DP12RDA<O)C6M:E2:
M'A4:B,V0D4_JJ?6E% 6DG,:?QN5\JZ:WOSY?S<AV<OVL(1P]8(N%X^BA-'NE
M4@.HV4%_4)5NY4$+EN4Q1$NI2&$IP IP V(-J,8Q=G:+$<$E<0FY;#\42F7G
MI)I]Q$O-I8<==;#S0.560@4- 2GX"2DTBWPC#<-=P:6Q%^3EWIR1F%KE9E;2
M5/2Y>9:2YD<I5-:G@0%?%^*\4Y0P_%G=/$]$P#2(&Z\(@D\-PB'D( /.P6UY
M8TO8R1WNT;S1^+-(S3HOIEE7E@>*12E+=\7FT+^3!I<Z99I*;BGXG4^%C2XH
M;UC%Z4@W1)#.$RXCWB5=/EBB.@@W<R+EPV+S$ !LHEP_P6M<-\.;E5NC%'02
M#+NM@&U1O75I%CT%>%::UC*#R WAB13XY5()YE*!FTJ-:\"1?E%SR\B3+=FO
M-91),3'.A5!4@*%S&%:,E.$H %A$3<10#0!VM??%KLY*9]DL7FJ79FF4@]5H
MFSYE(.E[1A8L]3:3#D:A6Z)[$N,\Z:$]NF@C!4([CR%C5;@0RM/RX6'2XE1(
M %\[WX=@U'WZW-,A>$(>)"2ZJ:2:G\0:#=A8:UH#SH(NFW*8NXD"I0XV>=*A
MR_2G>/&,RSIB%"Y$Y/*II"(!4,"HL(!H1/NI1 #FUT 3J)E_UC &F@XV_$93
M<[+X&_EIOV'S_P#LWRD4[K>7.*'"7@K'<6371+E+\2&U6/<>VA[K1F#% C/4
M$B!?1-4-/& ! -PC'@"/JN?[^F-+G9;<XG(H J%>ZN 7']9+MJ_VE=*G6D74
MJ]GDY]7_ .2^@'^Z[3MX>!J;:;.S4BCHY[Y>)< BBI S!"Z6 #IIQIU-^=CD
M&X^08WK::4+&/2<D$_ YNJUYJ994>ERI7CSC7\#>"\'G5DW#B:&YXNBEM-*=
MVIO%DRO8D=Y]*E*4![FDC$4V^T#N45UMT*<+7Y#?;7%+LE+IG=J&V -99U![
M4,S"[^6G+C41F8Z[N<#2JO\ ^*J#7GNQ]*:WL*UC%:#C56M?YVJ*)B4Q*@7<
M !@L($45042-SN4Z9RF+Y"&&N,DS>*.$69;WG&U7V4UKKHJNMA6)W%A4CA0'
M[R$H[P',WB10\;Z1UEV>YP%Z?S$43$.\95#)E((7N4PN7!"\.^NEKAO?I?'H
M_LM?W6"[3E!HH3K[@O2H=4  .TGY1I>ULM_EV'!0J%,-]39()5ZX&,J@<UX=
M"@85&4DXI"8ET9@8B/=2+1"1ERQ# CF2&-9*JE<ORL$!(X>BU25\*D<BC@2)
MF <54HYF]E[Z$M%19,^TI=#1"7)/*G.H Y1F! !U)M<Q@S.'#]>;H*R[PMJ"
M="25G\/.B:'H+Z4AW-;,%=/(4))H/=>(^JD?0$-AF(XA]=/\]UV =AUQLN*3
M_P#_ "@P?#DTRF5P]DB]S*S,H^:CM2"1J3VPS",- VH<2J^13ZKTJ06G *BA
ML>5-=>,>?M;T125,2T0O35,PT ZK*M*<J>HUXE@W8J34VZ8. <RC[N")@NZ<
M%XE5E! !5<*N')^)PY<*J^7[7;1X_CKNS>'XQBV(8G+X/)R4KA34[-.S",/D
MR@/&7EDN*4&TE:[TJ0VAIJN[::2C==F\"P7!&\>FL+PR1P]_%')F:Q-R4ET,
M+G9L%#>^?*$C.O*FO(N+<<_K'7%KV/GC#&2SUR; R9O#J0\HD![>CWIAIHXE
M 1TXA*;B]6FV+/:J32QBF'RQ2:/(D0;<7696O351\S8Z+L^_GPK$EU&9+FE]
M$F8U[P/51$:D(H#]H:G&X!]B/D $! +@4[]T ;Z<-R&Y#8=M<:[LU)9]L)*6
M*:I5-%ONWRD_15C\JQFXJ]EV>?76AS)/&EVP=>X7[#U$,L.!LY\YR*)VX&$2
MHF(AN4(2,)<NH: 8IBWTU >F,G%)5*\0Q1DB\O+O.5 '[F[ /G_.%EG0,+PL
M@V6ZI"M>+CAIIPH1W&,F[/T2)ELX# 7B,1V8Q3?Q%.@0+#:^@A8>?LQ-L1);
MV5VC)%=Q+9P>R880;F]<JC\SI6,3:=^CF$#^-('=D5:M?[.G4VY:AH^&41R3
M=*')8Q25(14#:"'=Q:Q5 &X7#4! P".][VQ0/R:_U<Z^* %^9:.H_"PEP@\:
MU)(%>?:+PO).)MIK8"74+<"[8CAR[NAK&7US"J&['\0=-,3",E3AC@ 7_5(U
M=3JRAAMN4A"G,/, #4,;6F3#6Q.&S)!_:3$R@F@OE,O2_>=/(Q2R[X.UC[?)
MM9 KQ5+S%*<*&HOQ\HL.9$:1.FZ,* >DO^BIBA;0P]_QF]Q2C>P<A]>-,Q26
M#1P\T WK<L\?]=QP\.66M8N9!W,N?.N03*.1LE)[Z5[ =*<.UGL8*2<6!2?:
MAHL^@!:YFI+[X]=FI-$N)-) JO#I!V]?_>2S9//C7OO'GJ'2X7B#^&8>38_P
MK/7[4TI'H+CL"/(H,$$&""#!!!@@@P008((,$$&""#!!!@@@P008((,$$&""
M+'4Y>*FJA+^]!RQ?>P<!BNQ@9L(Q1//#IX>,LZ(RI"T])G_]5+_^LB/*[(1H
M+C.6K790$4.Z?0R1K6 3,FH,U.$1W 5DEC!KL:_D''/L]E@G;"9;)J"C$)9/
M6C+K=*CC46&I'6/;=J7O^AI<&M067B*W 4X%<S^Z1I;6+A4E._HM(9MN7"?=
MMG:3.HD!$.$% 2CQ06 !YG.]:J  !KQ*% +"8+X^+X2N3=VGEG1D 9EYEHGB
MAM3E"/\ 632G7NA\A.)F&L'4VHJ4%N,* I8J(50WM\"Q?@!W1?.S[3/C\F*@
MA'!;^.7.*@"&IDW+5=)0PASOQC>X:ZAB[V%PTSNR..RB11S>RKR0;V2U,:U[
M>@[]*W:.<#6/2C]:@!2;FFBD4N; 4'CI&CJCB%8G)F$@W!0))(2HTXHF&MET
MWYC.B@&X@"#-Q8?,!WM?1<1E*;/2@<&5YG$YN64@&^93Q*AV@-J41;\/"M(V
M>6F K%IAQ!);7+(?2K@4E'PG_$L6O6IX6C?U;T>>>[.\$BFB*KB&CFCTA0*(
MF(>+E"/EN$ N("+9%4H?ZP^H?0L4PQ<S[/<'F&DYC(R\P%@75E$TM:S:MPE/
M&_:8U3#YQ,OM/-!9RB8=2D*TNMG=BYZFEA>PM&F:^;D>UOENU1 3'32:2RX6
M^RF0C9J@?KZ1DW@;6#NQMOIH.*L)5B.#+2/QR<DZ133*VTVDDBUPE6EK4UC9
MI1TMR&)@V&\>;2K0U4I2R!S%,HMSCH[-.ESJ5QE_5A" *;4[V/5]&P]W*QJ!
MB'-Y%5CRI_ZRQ,>G;88:I&/8+B:4DL/J:0LZIJJ5RIZ?NBU:7H+5C4L"F_\
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MRF(2Z5<]&Z"YU J.?&,O:U__ *-D:FA;<8<4*4("CF.G:*_F:P96G5Z2_MD
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M2*C(H&\2R AT ,!1!8N@7O8.?F/D C;%QL9MKAV$2DQ?>)F6 @H'!Q))3<Z
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MFW&Y/UH+8?VCLZH/Q,(#-9(D=-2A#3(I&N)DF( >-*N4HZIJ*F6-Q6U,T2*
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M)4Y-.Y9Q$UOUY@0K>I<S*32EA6J0D6 H-!&W;0X#,(EVVF6RJ7+>[200?A*
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MDI32E0=/"-.RJ$*"D3.(H(H:I?ET*KI7-N K2NA!ORM"(_274LS3!-I0]$(
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MY9-J4LG<4'(6IXQ(6^DQI=P3NG%%44Z3L<"E<4%4:A$P4  .!2&J:UC  %,
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M?1$2E#V?RP!Q7%0'G\C40*5RS==!I0<Q?G%)\HF::@)G3*8=@L2X:[6$.0Z
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MC P;"&MNMQ_+GA,ZDURBM;'B#3A3^5^R C0W(Z#A0<?$Z7OIP5+TC'XR< '
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M,>^3$@9?$LH2G%\,F'\*Q8)3<(.)8<[+33C=2<S+SCC*Q932A:,)D*<KR&1
M8>HV-3-4@ "156-",G]@"UB5/!M@'0"Z"^I^174'55U<1/B]:Q?8K%VDIQ;
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M6];<=!$<4"]^/"<#%$ L%_AKSV]VM[Z)E^(D7]:](<- "*5X5ZZ=HJ#V#J8
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MBL_-8CNTLF8<WI92HK""$I30+4!FTK6@-[5I6.Q]@MD9?8#9# =CY>==Q!C
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MF^GO.&[:3,W[.%;:+D6FYA.&8A/B10\XIC/)3$RPEO?% 6$N"7!4K)4%1 %
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M9LML.*PYX)+4L]B4S*#$);W8)W>[E$R[A*B[[XLK*$9Q#4C P2QW49&HIO5
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M76VP<Q^&*%Y3B4J4G2M->NG3N^439FED BJM1K3\^(/=6D9C%)LE2E!9,Q5
M$MC!8;#S'6^M^G/40ZU*GFBGXP0HU!-Q4UI_*]*ZF)%-O).9!JDZ<^&EJ^C<
MQH&09YF=G;M#M>T;E_1,CF5#O@.\=Q$,85YJ!J9:B'% G<#$H)^/?PJT66,D
MD%8M*1>-YA!ZD]9$8+I.4_H1^C1^D!L'A?LY=]D_M Q4;--2DU,S&$8X^V5X
M?,R<UB@Q5V4F'*TEYAN:=F$ NE+;C"T9'-XE0/&GMS]D&U6*;8)V]V1D?UR[
M,R[+.(X6TH";:F):2,BB89035UE3#;)(1F6AT'.C(H&- 5<KGA7LU YE9KH5
M8@T*X3@6+NNC"TJ&0!A#/RQL>P@#"*\/3L4W\09--TA%AXGNB,6"J"CE<G1>
M.>W3V9;4>]^S[V<3K&+*]U&,XI/X:T?U6TTF<ET% FE &:G'WEMJ649TI:2=
MXX%EM!\,9]ENVNSDNSM5MA*N8<')K]624I-K G5J5+.N%:I=/]3+MMMJ0C,4
MDN+&1!3F4#&F1D1VL1!#_HR3*O#^M&EJL,/K+*2P!RML'K]]L<(;1+0/TEF4
M\?Z5[-^)D,,-N=*UX<N$=?8(I?\ [!G1;(G9W'*CG6>Q$W[^ZD<4!L'J#'=\
M<@Q=,OXC,>@\U:4[0V7U&+9BL\OJEH*H:AI&/=%3G#OZ0J%>;AW;!F<2'D8U
M^DU5CYE".5/,- 19N8^.DN^= UN,.]M.QNPF]V&VWQ!W!9#:_#\2]RQPM;V3
MDG VF4F$3>4YF<R9I#C+BQN5%*DN.-G)FF3[.-H]K6#M#LS+-XC-[.SDGO\
M#-YNYB9;<4I]M3 51+A2J74A: =Y\22A"_BR[!C'V>V>^9L!7.9[2LXRGZ2D
M/%M35TBM$N&[1K*NJA84O2M.KE1=M6/UX[\=(O5F$>S5 [M1-1Z_<G%'2OT@
M/TEO95AOLWQS8CV<3\GM#C.UDF<.FIO"D%<E)2C[:9><G)V=4"EZ;5*H5+R[
M"'''$*6E1*&FJ'?/8][#=NYK;3"]J-L9-_!L-P":]]EY:=4!-S,PVM3TM+L2
MR<JFF$O*#SSRP$K"5!*5K62GJJ3C&SQ(SIL6P@'I%YWMJ(;#S]6_L^8B"AP;
MQNQY#EKPI2G(=*4CNX.+9<W3E>AJ3ZK;CWZ",*7;HJ =$Q!!0H& ;AKI[QM<
M-1&VEK:XMI1Q"@$$4/'RMH+#C".;Q!"Q0I4:COYV[217A>,0=MK@JGS"X!?S
MZ6Z:7TVOBVEU"JT<]*FH[;]3X]"(19/PJH*G7ASM;7RX1B'H-A42<$O<1L.E
M[ (VY^SGT#<,9K#F2J5Z\- .S2O8:WH(C=1F 4G45K>G6HY\M1Y&+0Z;(*.!
M$I1 !]( "VHZ#M8=@$-1QG)""L&G>#>_WO#4K4&ZZTX4-::"I]6BSK)I"J9%
M0 MK<#!<!#6^@[@(:#UY\\2BSE O)E-4JK=--""+U%>!B0Y5)HI.8*30VS)4
M#8@C0UTH;<(PQYEY3YUC/(KOZ=?'/WIWE-N5(DRRE[BHZ9H@:+D#C8-9%@[#
M>X6$;[O*;98YN$RN(ORFTDDA.1$GM%+(Q8,MC\+<K./J_66'I%33]7SLH1P(
MX:G,;(8*'E3$@U,X!-K5G5-X!,JPPNN$U*YF59!PZ=4:#_KTG-)&E*5$8P*.
M9D54T U1>QU0TP95P><D7K1O%2:3<Q>Y;H"=JX61?.TS'%V0S.)C4#=SW"QB
M%7XDKQM[V8SNSFT,U,2>*X!M.&99O )"3FWL7PUZ;2X79IY0F66'I&34T@2F
M2:Q+$GDJ?]X9"C+E+M*MKVB26/X%+,S>'8[LYO9ES')Z;E6<*Q%F5*$LR[(5
M+O/LSLVEQ7O(7+8=(-+2QN7<H?"F]SQL'*3SHC"%8N9%ZK<2MVJ1E5+!^T;A
M]$A2WN=10Q"%_:, :X\U<R(1O%+2A %5+6H)2@5L:K( K3*!6I.E8V_$\;PO
M Y4S>+S\KA\JE60.3+B4;QPI)R-)_&\X1<-M)4L@$T%HZ&ISLDYPU$@59%"G
MV(G*!BI2$R(J@(A< ,#!H_2 W*W>B'N&U2G&I!4Q[LRZM]VX)8:70<#F4I*!
MET^(!72I($>;O>VO8UMQ26DXM-I!LXS(H2VJ]BGWB9EW.XMBUZ4H8M5:]EG.
MBAF"LA)4I]:QJ:9U'#RFW2<P"*9 $QU%F:0)R1$BE 3G5\%W1"@(G,32]H%(
M*1\:<Q(RI75*C46%%I2%U&F4D\#PBYPCVI;'8P\AA$^N0=70(1B;1DPM2C0)
M2\5.2P74V27Q4Z5CGH4P3*'#Z.^EA ;WL-[\]=1$+W]XN(  KH>%-.H(O<@B
MG?I:/0@JHM<6OJ"*5'0V((/@>30&,03<5[:B%]N7JW#8-^O+#*T_(ZCE:M?.
ME*"'"G$#QIRU.HX\>[2'DN%4M[:#>W4! ?Y6]5L/; 76EZ@7T-:$5U/?QO#5
M*(O46/<+UMZ([KPT*+@BMBF R8\AZ>0CK[0WZ:X3(X%$:T%1K?ETY4\X6H(!
MXFMZ:F]-?'2MJ]84R9[^C8MN0W\AZ -QZ_$.9<$5J#I^$7X4[!Y\K"'$Z5I>
MAI7G>]K5\AKJ2:%%A)P7 UPM<0Z:7Z6VVZ;8%+((J:D'E>U32U3WV(AH [*W
MZ7XFPT-JZ$^;JZH'50$M]=[7WX>?MVPY:PM22+6 /=?Y^,(!0&U..O4:#O[!
M7LAQ0I0]%0MR&"]_CTY!I[.0850"5?%=*J4(^0-=*]?K "2+6(X'B;Z\^EJ<
M-;$!-(R? 4 MKI]W]==_>X!"QE36U[@]HMR]5T$--0:FG(@6T'#K7AQB,1NH
MF902&N'[OMY:Z=+XB"5BN6MB:_F.O+CRO>2O9:U>?(7IV5UY=4250-Q$<$L<
M.H!O?0;B VMS^\-<"%(OG%Q<4I8"HTIU!KV:B$^(CX:TTH3;AJ;> UK%:R);
M N4!$H>>E@ ?+D(CIL//"K30!Q-T];<;<^%A05'" *.BK$5.A.NO(4-P;:U%
M(RN )WC)0Q3&* N#::!KW2-Q'0?OQ,U4IJ"*$UXG@.L8DPH9Q4@?".0XGLC[
MA,=RQ\^8,$$&""#!!!@@@P008((,$$&""#!!!@@@P008((,$$:ZA?\J%??[*
M9=?\;7V)%?U;?]YS_@B-/]8Y_=;_ ..+5GY_D*SI_P"Z7,;_ ,GS.*7'[X%C
M0_[IQ+_<WHOMF_\ M%@/^FL+_P!^8CXLE$A#T@&PART#VVMY[Z<L<3$$7KTU
MKT\.%*UU[N]SQMXV/.M*C7L/*'S%#NRGX?(=^5@#6]^>)ETR(505L.WB33N\
MX;J32M+'CQ/CXV^H""8AZ( 43A:^@:[;[>_[KAA2EM0L,I(KQL>6OT\X/BU-
MP*T ^@KR(KQKH*0V1$Z"9TS&O?4 '7>XA[KWOI?RTPU*5(2M*E5%R/YT]4IT
MAUB:T[NIY<?MQKI%)DR*)<)R  ASL-O8([?.EL-^!39!317 C3A?EVDCD=80
MFE] +V&O(5YDWUX=!"MTSI7*!N(NMBB 6 /+^>N$:SMUJ:I'*AKVZ\.5+<:0
MNITK;Y>OYF*TB$$Q[6()AU]M@V'X[_'5[925&^6OHCYT\H0GC\OIZY"*!0,B
ML4PG"PWX@]$0^1TWV^&$ W;B3F&4_+KR[(+$:=M?*QUIS$.G*D)Q.0H#8;WZ
M"-NGW;VVZ8>HH)"A0J)[K<ZTZ5 !KUXH 0*F]:=/._JMN$,*%4 X'*',/<(\
MOFP;!?$:BH*SZ$D::<*^CKYPM*BGKH;#Y:$ZP^NQ!5(BW#J)1$1+?K[ ^0VO
MB1QH*&86-*T!I4T[?+3MAN:^6E^[M_+YF+>4.X'A,.@C8+B.HZ<M=@YAZO/&
M)F*"0:]M=1RZ]>$2W(YFG*XY7UORO:X&D23</"6Q;CH-]^>_/GKIT#$I6"E-
MA8#XM*_+SY\[PRGUYZ@>OK%9DS6*<AM-+A[0Y" C_.X=+2*!RI6DFE--.-K:
M6OW:P>N/E3U;NAU4"BF4P#Z7W^?G_3"N*"FPJU12O/2OV,'73ER/CRBPS<NA
M%((7$G?N3"1(#"-@ H7.<>O!<A;7W. [ ;'O/Z/OLKP_VH[6/M8QOAL[@$LQ
M/XNAA9:<G7'GMW)88'DD.,)F]W,N.O-T<#,JZAM:'%H6GF_])GVQ3_LBV*EG
M, W)VIVDF7\/P9V8;2\UA[<NQO9[%5,+!:F%RF]E6F67<[2GYII;K;C3;J%=
M]Y>=F"56RMIC-M>HT3LIJEX"KRQSJFYB/ASM9ZO_ .SYG!MZW<A^C*U3?6@D
M?J0JB[9<(GC=B<J1##CZ9;/8_LULP^O9'9[9V1P>4EIB9D&T84J20MM4KA9Q
M-<V]AS $\MA;*5-JG%;YQ<P0A2EK,?(G:S9;:W:QMG;G:O:J?QZ;FI>1Q-Y>
M,)GW6W$3V-(P=F28Q696</:FDS+B7TX>C<-HE<RT)2A$=.UCD7/PM)3*QJ?B
M7#:(@T)A^HM/4NI'KQ[MM.KMC-G"LIX.1,NG34Z"+=L=9912.50(F955NFM@
M#'< Q]U&'XHEJ>DL1?=DE24[ADQ,MN+"Y9IYN8E799=&Q[]+!:G6LH2\E1("
M5E%\[L_M!LQ+.XI@JG</G<*E&\01/2&+RTH\V@M3C\NY*SC$VUO%K_5TVIH,
M.%:EL94ISEI*_)J>;L?'+.(M,K9LJH8QFB8_JVYC#<.Y ;B5,;W$@")2&]%,
M"DX2EXE_2H]A>"^SIW#ML-D&_<L!QJ>.'8A@Z5+4QAF*JEW)IEV0*\RT24ZW
M+S2C+*4I,J^@I8(8<;9EN\OT,/TC]HO:FWBNP>W3AG]I,!PW];X5CJD)1,8M
M@R9MJ4?9Q((RH<GL/=FY1*)M*$JG6',\QFF&7'IG'F_>IK'XC<1>5QVO?0.F
ME[\O9CC9I:DNFI)!Y7/3MU'"L=\*RD"U_0^E.-JUBX]\"8  HB-];V$;WOT#
M"NNA*Z9+=0>?8=>&M_)0FHUIS'7Q_.)22B)R^DW"XF#6PC]]]NN,=;J3?)3A
M4CZVY:VY4A"ERIHONX^M:>C%S2X.$IRI:;@( ([ %M?S_IBNK%*@:]+GNKYT
MAJ$D*(4H_<=_/AU'&,N9I@Y23]&YBZ:[V\O*U[^KERQ7%!;?6G2O"E>^OCQ@
M_JU&IM;R!&@TM2,QBF!C@;A-80WU !UWT$>6E_.W*^*IQ)4E5%\^(J*'L^US
M;A"N.@4&6O=KQX#4:6X:QET:P4(8+*=X4PVX=!V'F(7W&XB/W:XHW\P4:$&A
M-17EZIXCE$Q<2H5RE-@*T-N_P M>W",W;,454N'NNZ5Z[:ASU'2X;VTWY[5;
M^[4" *+'<#3ZUKP\JU>AU:2#7,D\*UIKK0=@UY<#2-;NLQJEG,V(S(K*Z(BI
MRKCH'/*N)E\WC6+)T6"<50$81X^<L6+15"G40F7LB]67:HHNFC9%LZ<*KE:=
ME?H^?HO85[1MCYKVB^T#%\3PS95,V[)83)X*&OUAB2V)E,G,3;CCDO-Y)5$X
M5233+4OOW7&GG%.--(;+O,OM@]NL]L7M"SLGLI(R4YCNY1,S\QB.\,K)I>9W
M[3"&T/,9WURX3,K<6XIE#;K:,BUJ4&]9]HF7FTF-"P%2M(UE(/"Q=6QYXR:A
MJ@C92!G(6<)$S4+.T^[>Q4Q%2)FKU(%B%C'L>]8N6+Z-()VSA;H#"/T;< ]E
M^*8IMCL9B^*SN"KDWL"Q+#L:;"9Z0G$STDZ%!9E9-Q(3\"'6767"=ZT\U,+1
MO$-^)8[[9L5V]PN1P#:*0D9;$69Q&*2LWARC[O-2YE9EH@H+\PA1-5%#K3B
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MEH.7;3YCPA=+'AW]WWB@QBB6X%#3:P;>K3RL'/IAA<24DI2*#6@/#OZCS[T
MZGYT]4Y]>L.)<*R0EX=>@AKZOD<2(4'4%-LP%17G?C\_M 10UZW(IH*7-3Z(
M,5I("<W" @!K:;!R'K_4.6!"-:DI(MP.M+4YP$VKR^5O'OT&D4>'4 PB"EPZ
M:?#^OYX3(H*-% WTK?O OX_E#J6!H=.1!^U/"%.D0Y3%,6PVT'KK\[>_"D)(
MRE%%=!8^8[Z\.I$-YWX:\Z\-($4^!+@-Z1=?9TM_/6W/J]H40:T(Y5!_*_2
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M]P@(Z8<M!50CA0D'UU,%:ZDCB.0Y<_+3Y4J$#A+QB8IA#0;\M+7]NU_YX19
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MZNFEOC\+;XE/Q9C4@TKIRX:]FO6L1YZ&^A/'AP\>/\XC(J@8!24+Q&OH(WT
M/*P?'EKI;6)*ZBBA4\.SL\>Z'E-#5!H-;Z4\_6E*4ATPD*0.(HZ"%A$+>JVH
M:>WRUP[>43<&O"O#I<:??2$ 42:$*'&M];4MU]&!3N3@4BG,!$H@-K -O5Y^
M_P L!6E5$*( (!KRL*?._P!10%!G%3P% 1P/9Z\:0\DS3X3)E-Q<0Z7T 1'\
M>7E[<2(0FA2#6O,?R'KE#2M5>(IK?C6Y/SX\>.K2*7"J9+A$@B.FXAIIN(V'
MKZKW$,,0JBRG2E>SKH>RPU[8<LU0%<N%>A-*=/K%:L>=?A$%  0ZB ?._P"6
MF%6V7-%BHYVOV0B7$IL16EK<SIP]&&.%9F4R:P"8H@&UQT^ "/6WOPPYVJI5
M\0UH#RT%?'ERK:'?"Y3(:&U:\^'AWGG#A.$.!=(!*(6N ?C[>?*PV'GAX4/A
M6BU*BGWX\>/404/Q(5?B#Y5Z^M1"';@JH"R1PXQ$.( $+[A<=PO]UM]\-4,Q
MSH4 HT!%;]+\1Y<(0+RV4#86Y7H+UMPH*4UU,"K%10X" F[RUPT"UA$>?+V^
MS3 M"E*M2O$]E#;J.EX X -:"O"AMR-;&W#IUA3HK')P+6*8HVN.@F\]0#H
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M-O5^7XA;$R'4N)RN "G&UCS.NFG'OA% @FFAXC774G4?;QC#:SG"4\V:IHF
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MS6(8G-2[C[:%-222B7:=<4\XYN4(0&4N+:V7V1>S#;?$-M<'VCV@PW$<(PO
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MNESILU5S$L)U!2[Q$#GN<44427X4R %%@31;PXM.J)2A]T,E6J49&U%*:_\
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M%!1F4<!V?Z/0K'):L<V:9I6I\IZN-7-;3+&KJOS*SFSLA:P;2%8R3RN6XL:
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M,&M@"_01#;U[VOZ[XE4&W!F24A6OW'TM8<+0U*G$*RD$CG]Q7YWIQL(0I"G
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M;H$(H?4O>'  !0Y0-?A Y^(0 1]$H@ B.^..<>F!BT]B>)4R>]ON.AK4-H)
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ME/P,3:5;HE6B ^F76M1"&T*40(U"@W04XB']$HA<IK;6U_$!'?3%HV4*J%$
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MIW\,50=KB!?CSVZB([8EWZP =V#I<I"C4=_T'B(AR@U^*G2I^5#%^A9 X-5
M%F0!!P?<H?YM+I\COB9J;64FK8KF.B1R';&,^S52<JK91K4_O*MJ8^R;'=T<
M%08((,$$&""#!!&-5?54=1--RE4RS*HI"/B$DEG+.DJ5J2MZA7*LY0:$+&4M
M2$7-5'+J%4<$.LE&1;M1!L59VL5-JW763((R7!!!@@C6F;.;M!Y(4>->YDRC
MZ&I<*CHVDS2+&GZ@J,R<[7]60U#4FV<-*;BY9XS:R=4U!#Q2DL\0;P\:=ZFY
ME7[%F51P0@C9>""#!!'&66^6G96S+S2SES!R_CJM4J^C<YEZ5SD@1JO/"DLN
MGV=%/TG0U1GF9W)66GX7*2L:A0IV<H:69Y@?H',!(KI14I'U \>QB#M A;VK
MW?+T(ZHI"JHZMJ>8U+%,JBCV$@=^F@TJRE:DHF?2&.D7<6N+VF:NBX6H(XBK
MADJLR.^C6Y)"/4:R;$7$>]:.5B$BU5/5=20;PK:&RRJVLT!:D7&1@I6@&#,B
MICJE,S,G5%9T_(BX2*F14YTV"C4Q%TP2<**E632>E*5?B<2CH0L]_P *%#SB
M-2U)-$M+7U26P.SXEI/E&#Y75!,U/6F8\I/TE)T+(HL:*BB4Y-.F;V4-'LQJ
MERUG%'429U"F:2:T@\:-4F$K(J)J1+H71D>\1(:1U(2AL)6%BJSF (%3EJ*&
M]J W UMSAC2E*6X5(*#1 RD@FGQ7J+7J0*$Z7I&39TA?)S-D-KY9UX%]K7I:
M5#%#C_\ F'&_]$8EI_\ )O1?[/?Y_P #_P!,89_OK$?)$LT:'5%%0_"(A8HZ
M:B.X<@W'3EICB!:FBLI)H3ITXZ]FO93M[C"EA(4D$UOUI;Z:7O6FL0$6*K=<
MQ3 (I:AQ (B !8=0M?RW'3&.FK;A.J+BUP=>/R(X=E(E*PL"]%<; \?YU[=+
MPJJ*Y#@9/TTS#Y#;J 7"X6Y:X%*55)2*I)\.A[^AZ7@"DTH;*O3KR-_IPYD1
M*,U,9$QPL!@ - N(W +C:]^FGKOY8E!!05<1?U2GRY0RH"J=PZ6TOSIIX\(<
M.U.XC $@!WI-0$ L.P@/V;7'?V;"&'J)<EJTNDZ=G#OK0^'6&!:4O4/X2./;
MST[:]G&L0BH*'1'005)Z//4 TX=>>G36WKQCA:LM"/BO4Z]G3G;A:)A0'6U0
M*>)/'4Q):1X/$S]X-C$\[#I;G\;6WOB9I =!!N4]G32E*>/&\1..[LI(OF-!
MTMRZU%(MSAFX;KDX 'A*:_KVY\(ZWUU_/&.LJ0NJ;Y=.//RH?7&9*TE"@1<B
M]Z 'R^_?87!91V='C$.),0](!Y#Y:!^(Z[CB93SA374:$<^NORY1&$(!UH>%
MQ4UX<#ZITA#M%3MRJ)@&PB(<] UW =O7</(! <*:E&9/6H/#U]^R *2%T4>X
MGGVF_+A3J3#3! [GO+ '$2X]!T'R#ROH%K>N^&,9G">:;\Z4%C3LYZPKJDH
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M[:TT[I1Q'J [-4S:3%NUBHQUQL)?P[1)W$1#QZS1;BS$JC!^90KB3;K'.L0
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M ('73]<89_OK$?)ZNU:N$^("V7+H:X:W#;H.]KWY[:!;'#KFZ=;JF@<34T%
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M^5M;@.VFGMT]F,5S(EPI3T-ZDU(J-*=1I?QC*0XHHJ0.OT^HY>$2E&W&F!3
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MC+;*,8Q9#6Z8:EVE*<:PS#D+S.IE&G%9W7%JSS;R4.K;:#;3+62D8)BL=$Q
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MX=1919=,PF.K<QS&&YCF'F.MA'U^JV'',LJ6V0FHRI2!0) LE(%+)  2D"@
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MSN&G&FL?0B0DVL/D)3#F 2Q(R<O)L!1J=U*LH9;KS.1([=-(N+EF8"(+E#O
M  $U@N(#ON6_6P6 ?@&,1X6;<%%!*JD UJ./*P\/&,A"J9T&PI:O&O94T[>D
M"R2;@R8D)8!L WTL-@N&P]--+CTUPY10YE-$TH!R(M>U?&YJ>L""45XU-?/C
MIPY4[XJ4:F2*($'B 1"P[B'KM>VP7&^FX7##C\":#E:E_P"7?3LX0 @D*(Y]
MM]>S[<;PV5FNH(!8H=.(UMKCZ]^6O+V-&9=OAUXVIZ^_9#LR!>AIISU]4UTZ
MF*5&*I1 PE#T=[#<0U#2P;Z7Z7'>V&+2:I5;X2"?'AX"YK %4%*6(\^/9;Z=
M8J4324,/ZL>(I0N WN/7W 'GAZE(6;IJ4IIIVGS->SC#05"P-C6OY0C=J9<B
MO='X!3*(@6UA&W+7;[]\(V=XE8;)1EKIPT[?M"N*2DI*A7,1QKK6AO2GTMUB
MIFGQ'LL3B$HB'%TMY]=/NZX1A9)HX 5))%=*@<M"?*MX57(&@(&FM#SZ_2!P
M@4ST$Q*) -:PVZC:]Q'?>_LOY.<*2\*C6P)K34:'MTJ>$-22ENG?;4]U.6NG
MW4[5RP,"O>@=(][6$H@)=-!#?80\_9A%!V74%%S,A7#EV:Z"O(=MH I#H(RT
M*>E*ZD?+A%+B/%8A%T3!J'$) M</(===ATMK?#7FMZG.VJ]JT-:T^5^R_#F(
M7D(0KN)T-Q8'Z"]N$,IM#+D-PFX3%Z6 1L(7]VVH7M<<,2DK12N4BQJ.51<=
MW9X4B3-0_P 5;ZV%>%K^M(=;MW38Q3B81 !^R WV$;[!S"]QZ!IOB1D.MJJ7
M*I'"HIT)OQ\ZPQ92L4*+W%0;T/?W?>+D+<BWZT"CQ" \06Y\][Z:\^6,@J"J
MGC45H1UZ=(C (L2?*G*G'6MK><6YPS*IZ1$[6\KB/XZ;6 /NU@6A*@?PA0U(
MU[[7KR/&)4K4FM#;E?[PVG'*BF)P-<G,HVN'NY7WW$.@88EE02HA69)U'?:@
M-[<*4[Z"%+@J!2A-:'B?I7C2L-G9@*0D$  V^NEK>>FOSZVJ2C)ELE5Z$U@"
MR%5!/8>/AZ^4; IEB8L:(=Z'^/,/[/\ FD?/%M)M583\:;&@[*"*V<<27KA5
M<HTI34]L=K9<4%FO-9B9-#6KSMTDIVJ^U_\ 234/F>D^JGMCP\4GV;D*USPJ
M?LZ#)K(R+$:4IMP@RRF+EC7C%Q#3TO$+MJ0AZG?0#B3@![LCB TOI^%.E-;5
M^M?M& Y>SO:EJ>D.SA0&>4KVYJ <3W98[/R66M?4)E1GM,UXEVD\O\RLQ29K
M0&=,D1NVC:(JJIJ98Y-@\JKM10#K*ZLJ,5K9:1J)HDO6AYHA;7IEU->5+4IY
MZ&HX 6C)!@J\R\89M9=L:*[8D-+UOVY^U[+FJ6G(_M-R]"D@JHHC,JH<HYM\
M:C6KJ>JZGZE"=C#4M,4-65&T9!YD-J<FLQ:U-4-%0E&3!"'A<?A%.-*$5MXG
M2XC5SJ@NT5F3357YCMT.UO1W:IK?Z-/Z.X,@ZNBF6?F69)OM?Y</^U I6<7G
M6A'LH&CWS"GJVKNCU\TZ6SW9JTX2@ZOG9P(=2/<.))$AU0!2Q&951\)^$Y="
M>PT(O'8D8?M0RN;\<HZ'.J&SII7Z0BK4ZA 2YE_V"5/V#7K:IG%/*-FI^^R8
M>1?]D)J419*QI#UW']HJ+>)'40FY&>(^(;0:]!VU[/&^E.Z-%9;QW:II7+CL
MX1N3M)9[4I7Q*+^E@6;T_4E#YM4OETUS*J',2LZJ[,S_ #9@:BA8VAXP9F:E
M$).B):NVC0SV.DGH13M1HZ7(8@MQ_L5N*TI>FOY<1'HQV'YF%J^GYRN8-CVN
MJ?4GZ4RN85G1O:FCLVH,M*9E4_#S+6LF5&Q&=$4PJ9S-K+N69,R*II)Y,945
M/*,X)U1<H[DT*L5,0A%.7'3EUI_/NI'!=.TSF#E0;,+,2FZ>[5D'%,_I;_TI
MKILPBNT[*O*J[/LY3S>FW%1L\O11D)/,O+U]4$HR-,RM.4U4L<NUC&LO)K*1
MM+M7D80OA^'IK3GSJ./"-:QT3VA:Z9T]$50;M[1\8VRQ^FD;R(-7_; I>0&9
MC^V-34_V'F[^?A%V3]Y4!,FSSJ63*Z4LXE)BDV84K&N9.)31A%"'6Z:HX#BG
MXN8UIV=+QT-DO5V;U;YET;2W:0BNVA3U;/Z=['>8.2-1T'3&<E)Y?2T(URHH
M_P#M_H_.J1C8 F6%&SK3-\F:JV<%/9SEI:M)VAI>AX_+HSFHF%*),R&\.'&M
M::\*<>72M>$:HR'I7/[+6C>R!1V6=,=I"GZRIW-KZ0R+KZ)KB-[0RN6(5"]@
M<\'.4$EF,O4Q'5&/* EZP=Y=RE(5@Y66I&:E91]-4O,O9E_43Q0A21\78*:=
M//T=(PW,$G:SENSK-5#E@IVS(ZII'Z.*HF.?5-O4^T ?,V-[<\74^4:67:V6
M#$B2TL>LW"JF?[>NU,FDU\NI>E&=!NI))U23JAG"I""@/#\0IRI>O/IV7C=%
M9QW:#IZH.TE265]1]H")IZ)[6V5M5Y/HYQ4OVOJ_RYKVDY_L=$>YAT/,YGPC
MI;-BB,J9'-1E/R3.KZ+EIZG\ML]FM(QB](.V=0JTS)D I;32^@XG2MJZ6I<6
MZQZUY!2,_+Y%9+RM54K5E"U/)93Y=OZCHFO9Y2JJYI"==TA#KRU,5E4ZR3=>
MHZJ@GZCB+J"=7;MUY>6:NY!9N@JX.D0AIU-/7C>+K"_Y4*^_V4RZ_P"-K[$B
MOZMO^\Y_P1&G^L<_NM_\<&<!>/*7-$H7 39=5L6X;A>FI,-//7%'M#_F#'/]
M#XG_ +D_%U@!ICN"GEBV&G_ZQF/E<726;#Q"<]R_O&TOI?D !RL%KWWUQPBX
MI39K4VY$W K:YK>GA:.VTG>6!UX&O&Y\>OSO%\1;MY-KP&L"P%&PE#41* 6O
MIS\AY[;AC-1DFFZ'+FI7KZX7M;LC%4I3"S3-D-Z#A?ARXWY"+*1%R@8R)T3&
M IK%&P^C;IIZ]>6OJQA N-K*%"H&AXD<.SAU\:QE%2%)"DJX7&F6IL14:'[=
MD3#H"JB<BH&(.EO9L%P 0TZAR -L2E94DA0(''KZY:<+\(\PS#+QUM2_#S]5
MB*T9B@<I@.8Z)M#" WX1W$1N&F@Z?>-](FD[LU"JI)O74"O7LY5Y=7K77HKA
MI>O>;:C7C6G.6:'LH95-P80/<W#<0$;7W'E?I;U!B?W<9BM+FM"!6MO U.E^
M-370PP.FE"FAJ05 Z]_'7IPO"()%$QDE%1*;[( 81U'RM_7UCAJ"FJ@IRE^-
M:=E:4\:#E36%4LBA S<SKZ[>'.U129(Z:P$ MS7 2C;?GY;V\KZ],&8I6$V)
MK:GAW\.6L.*@M-3:U#]?I2U[16]6-W7"HW*50IA"X@&NG+VC\+>6'/S%$$*0
M,PXTJ#RXVX_.L1LMC-\*R0J@H2:"I-Z12L@F+1NL*7#Q"("(!;4!"P\QTWZ#
M<+;8%D%I"LH )K44Z=;\1:U?)0HYUI))IH#6UN%::\N%+PCN,(H5(>\$#&*'
M".MKZ[  :\[;^O"/-(4E)S@5 /6X/3[=1>!#QJJH-K#C;6IOPKTB0U9F%HJ@
M?TS_ +&PB-A$.@6Z>H--,/:J6EHK4VRZGLUUM0\.HUABU?M$*&FA[SZZB(B<
M<91,Z%CD7((B4.M@TTM^.X:8C2@J&2N58N*DW!YTZT$2%82>:>8/'F>G*PUO
M:T,."KH 0IBF*8#  B/,+ZWZZ>O>XXB=6MNEJ*! K;B=1X5X5B5!WE@; $UO
M4^NR)RZ1D2-U-B*EN<0'GSN(WL/PTVU'&0JH#) J7"D$#4E5@!2]22 .-3W1
M"%BKE31*:F]!1*0234< +FO\N1Z;=U!VDLZ8/+.F92*BSS\PZB*9-..W+.$:
M)M&SMTK)2JS-H^7)W[=DJLJLDR<*)%.F@4O=DXL?7;V0[ X#[&MA&L0<DR_C
MTYA\M/;28@TTVY//OOEM2<.E5+6C=RDDIQ#+;*5MH=6VN:<&\<-/CY[9MN-H
MO;;M\YAJ)SW?9Z5GIF1V7PY]UUG#V&&$N).)S0;0YO)V>2VM]U]3;KC3;J95
MO*TBIZ3I/LFYF+J9:(R+VDXQ3,B7S,B6Q9"6>-RTP7*-=V2LI.KE?JLR$5%M
MF[!S(MUT5'JBS A55$$3+)IG]F9V\P1",5=+<\\C"&<*=<W##:USBL9W0D6)
M!.^"GGUK=0VM"@T$*J LA*B.?)[V9[1..X++A[#6%XW,8TPT9B9=0C#TX%O%
M8A,XDOW=08EFVF7'4.(+Q4T <B2I*8ZGISLAN5:7D7CN2A6L[%RU:P"\,_6E
M"O5YC+Z&3FJG;)*M(MS&-/"LE!%$\D^8IKJ)G2*;BX1'%G/:0VW.L-LRTRN4
MF)?#)MN8:3+[M$OC$P9:1<4E;[;[A<<'QI8:=* 02 *TL9#V1!6&S#TS,RB9
MZ6F,8DWI685,;Y<W@4K[UB3;:VI=<LVEIH509AUE*S8*!(S<ZYV9-U)DPUC9
M6I9"!8EJ$[!U2D>W>NU9:>AW4.PF#U%'M_J]($(1@K((1"KY^JR%Y-(OFT0E
M(I1[MRCL>%;581M4S.8:B5>G64,S,KBPFI5E<BTK?ORBL/FDK=6AYZ9;;6\6
M&T/($LM"I@M*=2V='QW8C'-C)F3Q-R<EI%UY^4F\",E-S*<1>;,K+SJ,4E"V
MRVXQ+RKKS<N)EUR7<7.H6B4#R67'D8O1,R%5L5 6$/&L5.X55)P_K0$@&25$
M"VL)B\13"'" G3.8 *!K!\F/TFO95AOLSV_;1@+)E]G-II%6+X7+%2E>X/HF
M%LXAAK:E%2U2\LO<O2^914EB:;8)46LROL=^BG[7\6]JGLZ6O:5T3&U&RT^W
M@N*S80$*Q*77+(?PW%'4H^!,Q,H#[,UD2E*YB5<>2E >"$Y@I%BX+W:BI@.F
M/HWZVYZ .^G/7V8YO4V%_"I5TZ5.O*EK5_*W'I_>4ND<^0KIVUKUB(BF=F[(
MW5$3I*" "!AN&H;A<-KB/J$.M\1(66'@A1!2JNM:?SI3QORAYHZ@J%4D4/GT
MKWB]C6]S#DBW;-%A-XDB*9]2@H<" 8PA?@* _;-?D 7MJ'7%@UATU.OEJ08<
MF%90I26@2E )"05JLEM%33,M036U=::_C>U. ;,8?^L]I<8P_!I/.6Q,8A,M
MRX==H5;IE"U;Q]XBX990XX1<)(C7ALH9JJ\RJ;K)@Z9?4,1!S<=)0)X*'76D
MWDDO&.&[DDBN@*R)2FCTCKJ*"HY0!N"+$Z!)%Z8/4L*_6<IL5CFS3V#/.XQ/
MXEADW(8LG'9AI,C+R;,\V\PJ5:FMRM1$VI+:4%+#P<SS2'%2DL(YIQ#VM^Q7
M%=M<,QMK'9.8E)"4Q"5FV5;#OS!F9B:=E%H?1/OX/[T$@RZ5.+HIU(0!+K0'
MWC&W%(Y_ *D;O&:S=$QA(F51+@)Z(;)C82&*'\ B&H#Z_*Y_#\2PIX?K"7>;
M*U4#BP7&UFE3E>25(6K+<_&5"AK3AT9LUM;LKM9+%W9G&,/Q%##:2MB5<"9B
M7;)H@/R2TMS4L*U #S+?2ND2Q*EQ%[L_HG .(O[HV#6^MA"^P^H>F,!W=@@
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ME<?6-_,;AK?&.%$**%6&A([N5K</'01-GL#J ">W6OCZN8<,BHS,!RB)DS&
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M%9J#_2J7F:8I6F)=6H6R$VI'/F\BC2C>6<,B,4&@3,K.N$446KQ%DUO<)P;
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M;SY;^["+2VXV,RLI3?0'3P_(ZWO"I6M*K"QM]K<>9^QA$FX"4.[$#"0="ZW
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MO1L:1BT!V(<]%U1!T_HR*22,/>++SC]:Y0&WZM-G#N#&-?8I^Z =A,7&P/\
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M%=$2/WB15"&(('*%C7*(:E&XZ@(" "&M]0&X83<OH 5F_"0H*%04D7S UU'
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M3^Z:&HI6.;!-;<R3IPQQC:%B92S+X>J1?E<09F U*N!R6EC+K;W@W#QSLMY
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M*-AWY7N.H@(6#WZXS$.%:*DUMH>?4=_;?6,<Y4J*:7K0V^_C01;PC5# 8Q2
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M#]W2O73MZ\*S$U(Q8 .ND<BW,2B'"(WWL.OGS$-KXG#\JY12TT7QK:X[KBP
MK\HC6EY/PI/P <*W'74]U81!%LJX%, $R1M0O:XZ7O;SZ:<M]L"5-+<(U304
MK0BEZ=NG+7S0[P)!-B-::]Y\*\NIB<DP:+BHF4IB+)WX!'AL.EPT&]P,/3UV
MQ,E#"J@"BQ<'3Y6J.'TB)3KB;W*2+_%6W3U6IM6+<J3NUR(N2C^[L ^C:P"
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M"CMKKN/K]@WY8@S[I9H/A715*:\>XUK6]XF_&@9C\0XC2W"FNO?>'P3176X
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M$1$!TUUVMI[=,1EY*P@ _$*5J!K3UZI60(RJ63HJ_&WTBI=J=RF=4I;G3*
M-OW=+?"][^>O)5IWJ,XKF2?7+CRZ0@*6R$5LHV!O?ES\[<*#1IL*@)%*L4=#
M:"(7Y6#K;??RZX8A:BWE4DBAM?CJ/74\:1(4I"B0>GC0W]>%XJ<)&5,FHF8U
MR6"PWUL4 T\OOT]6'N'.0M)_#KQZBHMS[.,-0,@(-/RK7MX'SAPR9S%!02F
MX6L(AKI>VHZC?\M.JJ)6*D7&E./ VZ>/6%%$U2"*:TKIK7Y\?'6&>Z4[T#D)
M8P@'$'(=-P#U@(\]NF&#.% BQO72]M*]_HP**:?%I;N\-/7.)1S%!(4!]$QC
M<7"/,UK!:_Y8E4Y\)23=0M7M\_5.$1I;HK,#44(X\^IK^?C",$C.Q.R73'@M
M<HF"_M#<-BAM[+#AK-72IE:; "A.G'@:?.M.8AKPW8#B;&H!Z\^&M.==;GA$
M):-<LE?U9C\-_1 ;\.OPZ_?B%3;C*Q0\[5K2_"]K]W/B8G0ZET ]M>!H!_.]
M*==3%V;H.3@58-3@&OJ +;:C8>HC?SYCF(+A&:QX5%/GS\NAC'<+23EN-=2<
MMCJ!>E>WYQ;WL6H[ RI"V.GZ0VL(V#7EMRL//U &('V=Y5:+J J?RK?AV")F
M7DMY4DU"A05N*&XJ/'S[W&7$Z0,0?\<EH%^=O1_H C:_NP-.*<;*:T4FJ3S)
M%./VO2W6&N4;6%4^%1\R*UT&OC6D4%(J@(E7+<H[:;>NXV_J.^!*U-FBM+T
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MNB:D$+  -14V-#I6W/NT!B11>2F@/P<+<.0(K\^-HE*-06*=NC_VI;%VT'<
MTY_'VXE4@+JA&J@--3I<=^@XZ1&E>2CBA^'7Y>=>%H@-_%QYA8.;BG?01Y6T
M"][WY#UYWTTA;4ZS5ET$ZTX=AXGQ^L3.!IX;YL@'0@6(KR)[-!UZ14\:HG*"
MG#8UPU#F'+6P]//W[*ZE-$J%JW)/=R-NGV,#:U T!J*:=:?;K$XG>MDP(!O1
M.0-[ZWW$ ^\?SQ(%J; M4*%1Z]:\A$) 4JI J%5MS]4[.T197;)914JY ^Q?
M3GUU#<?9RZ8Q7$*4=XF]#7C3@;&^NOH1EM.H2DH4#0V/?ZY6^=S8]RX$$5R
M!S!Y;Z=;VU_"PVQD-+#ARKUY>O#^5\=X+0,R22*V)K77KTM8:PR>*15543(4
M"G)<2F#J F$.7+A]V&EA"E*2!2E2".HH=*5.E/1AR9A: %$U&I!IQUI7IZ,1
M6JHI'.T>%XR?8*(@'JT^T'*_E[\1MN95*;=!4#8>?"U3<>KQ*ZC,$NM&G$@&
MIN/'LTJ+TXPTZ142.4B:8*%$UR: )K#K8>6EK!H   7YX:YF20 G,+%)H:@:
MBE>FITORAS92I)*E932A%: T%B.IK>]HNX(%41)WGZH3%L:^EKB(#M^.G+&6
M E2 5$H% #RK2O3U>T8I5D547 -B#>U[@T_E$ 8 $;N6CH#B4;\ 7O>XC:U@
M^?,!QCF5*?VC3F8@DT%:\[W^?9I$WO@6-VZW3,",PTIY]I[M(5L[,LY%NZ0L
M8"CZ5@N%A#K?KIH/D.M\.;?*W,CJ*$BE1R/J_P K0CC(2V%MK^$FXX<:7YC0
MG6*V;9)8CL4@N<ISZ'"_$'$-P ;??K:^O56TI6'2DFJ56&O/@.?TXP/+4E30
M50?"FB@-*@:^0\(I*VCCEXC)<#@!"]K;@ ] O[!'3U:80)8H:I(7T.I-_#QM
MU@+CP_?S(-;Z^=]/GRBY)-4GJ7A50XB@!C$'32P7"]_98;!KSQ,@)=26E"W
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M$ _AN/+4/;\AB%IQ3+RT'X@3K<GGTC)=;#LNET?"4CXN9IUN=;ZQ<%&_&N
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M8Q>,US"(AK< U#KISZ81D%)IS)U).G0]GAK!,*K0\D\@.%?MYPPY2,@[%43
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4,5LZD+?*@" 4B@S$4N3P%.,?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g743471g74s65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g74s65.jpg
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M)G,G1&2&M__$ !X! 0 !!0$! 0$            & @,$!0<( 0D*_\0 :Q$
M @(! @,#! D+#0P&"0 + 0(#!  %$082$Q0A,0<B05$5%B,R89&5H=$7&%)4
M559B<932U @D,S5"@8*2L;;3U? W5W)U=G>3E[3!UN$E-%-SEN()0V-F=(.B
MLN0FH_$VL\)D98>DIO_:  P# 0 "$0,1 #\ _?QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&<3G(F0RBARIID*8YSG,!2E*4!,8QC"( !2@ B(B/(  1'/A(4$D@
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MO!'#U.+J'3EF5/?V;LDDB[@D>>79:ZG?NV5%&X\-\C9=N;K%X+0M\V$9\ B
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M3WQ7U<LL;*Q%KD@"TZ_GW\<QFX>0M#B3:/VC)\2OJN&:4(_;OU2*J,S7%+&
M\L,+]FV@E@8-&ZNLA(FKR%5=&EYU;9@I[E8-W;'$E18+RK)>OP#5N35*6HP]
M*W4DAFHQ!J.JU8I9:UF&FE>2-Y8C957>Q&T2[+()K5;0+F,C'HV]W.65M8)9
M2+</"L&EHB81B=LK'QEC;QI$.Y3M1D4E89XLLV9F=RP/W#1JU9=U9M+-B3:*
M&REAVM0V-T?=5GA5=BJOR!2CPRCE!8 \X8KW$9IM6H<DDR>Q\=>HU:!9Q%U6
MI3SR]599JC3%^I6OPLDZ*KN(X>FKN\ID>3?'JFZ!L+7M6MH]F#F4C2!)$3Y
M1.69G.QE"$*'ZA/O[9<R)!\01,GSY^N/HC0=2]E](HZ@=@\\($P'<!/$3%.
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M.\YII:PG=7)[+=57,IL&L(-FD3$SD?%2E#UPDK9FA*021LT=$6)_6YF=<TJ
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ME&J^6'BJ32*NH=AT'1TAO\0ZW HFEJQ3.Z5Z= EC&;^HB-NFK;01"&W9976
M5I8!Y9/*WP7^IS\F:\<<1<-KK?&'%<EW0.!N!]2E-:"_-3AKR7=:U^*()932
M]#EEY.=M[TT-K3:L4L=B[[)UK;TG3>\.(-U:;C4ZU*W]]%K1+2WV11Y L%4W
M4KY3<Q:;]P^=Q+<57ZC27=D2;)@F9QWUP*955E#*?ICH'"_DG\C4-.AIU'3]
M&NW89B-2L5IK^NZH(.F+,MG4EKSVG4/,C-"K0U(FE(KUXD/*/Q?XP\H7EM\O
M\URWK.J:IK.C:;9C:'AVC;33.$M :T).R0Z=HCVXJ43]&L84MS"UJ<\-:/ME
MZPZ!S5*IPK<0EX)85*GJNQS:58L$M4Y15IY.!)2SP9E"R]?A55GR2=FF6'9&
M%>.K9I9T4AD3@D8CA RDUO<<<)Z8:BW]<IUFNU(+\"R=;F%*R 8+=A5B8TZ\
MN_FRW! FX8%@58#FFG\!<8:J+;:?H-VTM&Y/I\[1]'E:]5+"Q3JLTJB]9BY2
M7AI&Q( 5;EV92?+ <,N];/33[ A==RCBGIFGB'F7#Z$C4P4K"JJ%@2!I*2;.
M0,M$KH*HNT2M!5(J7LP()S% :[7&?#%+4!I5C5H5OD52*Z169SM=57J-U(()
M(@LZLK1L9.4J=]]M\MU.!^*[VFG6*VC3OIP-L&R\M6!=Z+,EQ>G//%*6KLK+
M(HCY@PVVW(WH%IT5N"DU6N7:UZ\LT'5K8K'-X"8>L#%0>N)A@,K#-CI)F4=,
M74U%%-)PS:00:+RT<0[Z.3<M2&5#+H\3\/ZE>N:;1U:G9O4%F:U7CE\Z-*\O
M0L.&("2I7GVAL/"TBP2D1RE'(!Q+_"G$>ET*6J:AHUZK0U!H4IV982$E>S#V
MFM&5!+Q26JX,]9)DC>Q"&EA#HI89)Z>XJN*G@9NXTER[FFL9"J1CFR:6OBBS
MN#(TFXYE.HIMV:BJSFHRCZ+DVC\KN$59.2+K(A,-'I4EX\\,UW@/@3RD:8=1
M@AJ"6T;'9>(=(C2&PTT,\M>5Y'14CU"-;$4J,MI958!V@DC9EFR<\/>4+R@^
M2[5O8V>:YTJ@K=LX:UEY)JRP3P0V8HXXW=Y--E:M-%(CU6B9"46Q%*JM"?U3
M<.V^J;Q*:GK>V*0*R$?-$6:R<.\.F>1KE@CS%1EX"1%, (==DN)3H."E(F_C
MUV4DB0B#Q(H>(^+>%]1X/UVYH6I<K35BKPV(P1#<JRCFKVH>;O"2+N&0DF*5
M9(6):-L][<&<6Z;QMP]1X@TOF2&T&CGK2%3-2N0D+9J3<O<6B;8HX $L+Q3J
M LBC+WY&\E.,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S7-QRUQ
M0DK1[:0G-)S'OZZY4 /[FHR<>4F1!'_WI9"0$O\ _ ?X,X[Y4*;"?3-0 \UX
MI:;GT Q/UXP?A82R[?X!SKODRM@P:G0)\Y)8K:#UB1.C(?X)BBW_ ,(9IRW/
M4+^F[);]7S-D@9M)FJS6>UJ9.P>,V[I<IWQ&Z3J12CVC205!)U++H1,HY64:
MD<F;"NBDN3D\C60%-:65)0"HY'((4G?9=SRA2=RR\I)(! WSTKPCJ>B-"VE:
M_7J6(GG62);L FBD9$VB5F6%G+Q;-'"LDT,:I*4#A24.#-<0V(V7?56+W!L6
M(8/GCV!EHARI(1;.1.X:EE[-85FK]HSEY*JH$6%J54R[6$L,R^[5RW2C$ACW
MV"CVD#0K:F7GV5MG(W4@M(S $$QGP(;8%O0%'*>M68='E,5V70],F>!5F@EZ
M<4SQM&PAIP(Z\\4=O<<_F!Y:\2<J,9&$B6>0J<HQCGB[:#["*8J]JLZC&[P\
M9R6(R*HX%97M!26.=PR7? L9(>\R:?258157-^DWZD.YPIP9!7X6L:Q8;B;R
MC:#0XSIU[6G5Z5 04;VM:1[%4M2]DIY]1U#EJSWS7EH4NG7ZC0M8(E$7X]_J
M_P"MQMY1M0L\;5]$IC@_R3<4:IY-[MJKK$^H:N]J]IG#W$/LUJ&C>Q%6OI6D
M[WX-*CN0:GJ?5LQQ)96DK5A-ECI+>M1U;P^[IJ<E7Z7<[?<-@ZDEZ_4+_6)>
MQ5UY$5J.V$A/2QA8N(YFUD(M:;BDV@.Y-%98CY<6S9R":QD?6/$G#%_6^*^'
M;T-O4=.H4-)UVO:U#2KM>I;CL7)M*:M !*DTCQ3+6G,G) RJ8TYW3=>;P/PO
MQ7IV@\'\3Z?/3TW4]1U+6.';%/3M7HV+E*2O1AUA;=@F&2"..:!K5<1B2=68
M2OR(X5BMZ]4[=X>+35.'<NU;-#4AUH*4V*E+T>4K&V'<)9XV[7I:\L;1KJ6U
M)*Q\M W:"%V:%:)6"9B6!#Q,&]4D'C5L=GD;US0.+:5[BTZ'2L:DG%,.D-!J
M<-W0H[-.;3=,739*6KP:]!-!9TVSR=HD:K6GE;KV8UBC=Q()-H'$/!M_3^#1
MK]ZMI<G",^LK8TJQ1XADK7X-4U5M6BOZ+8X=L06*FJ53(:T:W;5>$&O4E::2
M.,QB);BXDM6R.FJOKW7=-J-D(:Z<3+SEL2LS\M<=;UC8EV0D:$XKUC=3'=@L
M*L"IWMZ\&0LZR$K%,U9%=18HB[S^'^#];BXANZMJVH:A3(T[@R/_ *)NU(-/
MUB[I.FM%JB6ZB5^<U%M#IQQ]*DKP3RK$H4^9K^).-M!GX:H:/HVFZ?=!U/CB
M7_IFE<L:EHE#6=42;27IW9+)C[8U0]264S7V2Q7B:9V<;R>O:&U-?T?3&OX;
M0?$"ZL-]1L=/ONRYI>!V;'[%G-AP5;E(.$>QEKL<-'P\-3=81;U>"J44P?*R
M[E9^::57$S=HA&T:+H>JZEQ%JMGBGA2.KI;U-0TO1ZRVM&ETFKI-FW#:L1ST
M:=B6Q8U'6IXULWYY8Q BQ"NJ[-(\US7=?TC2N&='J\(\7R7-76]IVKZY:>IK
M<.LV]9JTIZM66"_=K15JVFZ%!*]73X(I6LR/*;3/ND206 XL]BUS;&^;9?:I
M+N)V%F8/6S=.6=MI%HY=R$#J^F5V<,NC*H-GXJ)3L3)(&772 '0I=Z1.L@LD
MLI*N!-(N:%PO0TN_ E:S7LZP[01O%(B16M:U&W6Y6@9XMFK3PL%5O,YN1@K*
MRB(^4+6J7$'%FH:MI]A[56S4T1!8D2:-Y)JF@Z92M\RV%27F6W7G0NR^Z<O4
M4LC*QWQ>AP<(-S@.'!C-W;86Y]92-_LDA=(VHTRW#56K:OO8R&C(>1F(E>*>
MG)-3*$4:1%45$SC"KPJ*R"2Z"I0\P^5[C[3K7%\M?3M)X=UF'2Z<6G2W]1H]
MN=[4<UB:Q%7G2Q&#6KM/T=MB.T+896*LISUCY%?)SJ=3@N.UJFL<3:'-J]Z;
M4X-.TS43IZ1TY(*T%>:S7:"0BU96N9N8D'LK5595=6&9\?:UF]\#Q,?.BE^3
MN<N]N(^]3@WY%?\ 3,ZW[2/_ 'OXX^7_ /\ $Q]K6;WP/$Q\Z*7Y.X]N(^]3
M@WY%?],Q[2/_ 'OXX^7_ /\ $Q]K6;WP/$Q\Z*7Y.X]N(^]3@WY%?],Q[2/_
M 'OXX^7_ /\ $Q]K6;WP/$Q\Z*7Y.X]N(^]3@WY%?],Q[2/_ 'OXX^7_ /\
M$Q]K6;WP/$Q\Z*7Y.X]N(^]3@WY%?],Q[2/_ 'OXX^7_ /\ $Q]K6;WP/$Q\
MZ*7Y.X]N(^]3@WY%?],Q[2/_ 'OXX^7_ /\ $Q]K6;WP/$Q\Z*7Y.X]N(^]3
M@WY%?],Q[2/_ 'OXX^7_ /\ $Q]K6;WP/$Q\Z*7Y.X]N(^]3@WY%?],Q[2/_
M 'OXX^7_ /\ $Q]K6;WP/$Q\Z*7Y.X]N(^]3@WY%?],Q[2/_ 'OXX^7_ /\
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M79S#R<?MEY5/\Y^H?S4X/R:3GZRS'^*Y#_5%LA.A_MUH_P#C33_]KAR<Z_\
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M[K-G7=0FO6"P4GDKP\VZUX%]Y&OHWV\Z1@!SR%FV&X ]':'H]?1-/AI0!2P
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MC*\E.U8JR.F_(SUY7A9DY@K<K,A*\P!V(W /=F$O&UL-0#5_6C!8P)F*2R6
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M3OBKZ4EP ^]];_./N'\X>;OV]\4_=23\CH?HN;'ZL/E(^^5_DK0OZLQZ4EP
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M^"W]OX..Y? 7Z_SXYC_8M].-OP6_M_!QW+X"_7^?',?[%OIQM^"W]OX..Y?
M7Z_SXYC_ &+?3C;\%O[?P<=R^ OU_GQS'^Q;Z<;?@M_;^#CN7P%^O\^.8_V+
M?3C;\%O[?P<=R^ OU_GQS'^Q;Z<;?@M_;^#CN7P%^O\ /CF/]BWTXV_!;^W\
M'.1&G0<AN1?4F ?B'^7',?[$_P"\Y] [QYK>/]O1E0RG+N,8QC&,8QC&,8QC
M&,8QC&,8QC&,8RUVR]X:7TNG#+;AV[K'5"5C5>(5Y79-]JM&3G5XXK4T@C#J
M6>5BR22K KYD9X1F*QFI7;45P("Z0GO15YY^;H033<FQ;I1O)R[[[<W(IVWV
M.V^V^Q]66WEBBVZDD<?-W+SNJ;[>.W,1OMN/#)5#W:F6&35A8"VUF<F$*]7[
M<M%1$]%R4BC5+8>33JUF59,G2SDE?LJD+,$@)DR81TP>)DBQSEP+%T"5#1R*
M.9D=5YF3F96 YTVYTW(VYDYEYE\5W&X&XRH,I.P92>4-L"">5M^5MA^Y;8['
MP.QV\#DGRC*LH;BS5MI8HRHNK!"-K7-14O.PU87E6*-@EH2ON8EG.S$;#*+E
MD7T5"O)Z#:RT@V;*M(YS,Q2#M9%60:%6J".5+A6**RJSA3RJS E5+;;!F"L5
M!.Y"G;P.?.9>8+N.8@D+N.8@; D#Q(!(!/@-QOXC*YE.?<8QC&,H:5FK:UC>
MTY&P0JMNCH6-LDA5DY5B>Q,:[,/I2,B)YY"E7&2;0TI)0<U'QTHLV(R>O8B3
M:MEU5V#I-*KE;E#\K<A8J'V/*64 LH;P+ ,I(WW 8$]Q&?.9>8KN.8 $KN.8
M [@$CQ )! /@=CZLKF4Y]S&O8P-GMN?I(.$%G#-K'IO$$EDU%FAU6P+HD<I$
M,)T#JH'(LF54I142.50O,A@'-O4!6!200&9RI/<&V.QV)\=CW';P/=F+.C!E
M9D(5UW1F4@.%)4E21LP# @[;[$$'OR$>3A]H?PYD;CUCXQEC8>H?$,\3,8^0
M.]38/F;X\8]/&R1&;I%R>/D4T4'*C!Z5%0XM'J;=TU7.U7!-<J+E!4R8$63,
M:I@4Y2P*AUYTY@1S(20&7?;F4E2.8;C<$;[@Y6\+QA#)$R"1!)&70J)(R642
M)S <Z%E90R[J2K#?<'.PJ34[M>/(Z;G?MFS5XY9%73,[;M'RKQ!DZ7; <5DF
MSQ:/?HM5U"%2<*L7B:1CG;+ 3YMLH;]R2RAOW)90I90? E0ZE@.\!E)\1O\
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MQS9P\D';9BS:MW#MTZ>.$FK9LT:)&7=.G"ZYR)(MVR!#+.%E#%312*910Q2
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M7J^AU7J4'@6%YFL,)8%D;J.D<;'F)WVY8D[O7N?3D<U?A;2=;LK;O).TR0K
MIBF:->FCR.HY0#W\TK=_JV'HS<75I?S@K-=GA "C-P41+B4H"!2C),&[P2E
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M61=C!$@"6X:M>):=6MA:A([F/2*]#[TV)JU&VQ;NMVF_N(:&U/'ZBH%PEK!
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M, 9] )( \3_;O]0'I/H&9-.I8OVH*=6,RV+,BQ11KZ68^)/H51NSL>Y5!9B
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M/K;XF^C')_;F_P#+CN'UYXYSZV^)OHQR?VYO_+CN'UYXYSZV^)OHQR?VYO\
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M?;,NCL+M/T#M5?\ $!U4S0=GE+/4V,8QC&,8QC&,8QC&,8QC&6WU]^N&S?\
M.0__ -V*IG2O*%^UWDP_S:T/YU<79S#R<?MEY5/\Y^H?S4X/R:3GZRR_^*Y#
M_5%<A.A_MUH_^--/_P!KAR<Z_P#M%K7^*=1_V.;(WK']C;7O^0]3_P!@L,D_
ME2_NF^47_+OB[^<&H9%O)1_<M\FO^0'!W\W=.R<9!,G^,8QC&,8QC&,8QC&,
M8SL2 153 /$14( ![(B)@Y &5+[Y?3YP[OW\I;N5N_;S3W^KN\<_02D @FF
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MWZ\-?*]/^EQ]NEPD^^/TW\OJ]^.X^IUQY]Z'$/R5;_HL?5-\GGWZ\-?*]/\
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M$TDSJ'$I%#F A"B8P@0@&.<0 !Y%(4QC#X%*(B 9]52S!1XL0HW( W)V&Y)
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M5HDUXB,>O',2]-<>S6$,5=4C>6S7;<<E80I-<D=UD><AI8VKK(NRKR!.0<Q
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M9SX2%!8^ !)_$!N<_04DF5-)-(H>I33(F ?Q2% H!R\?8#/6RJ%4*/  */Q
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M$]*NZ5I-.WJ%_4Z/%W"\=:O1HP26;=IDU35=-M]*&")Y6VK<_*IV0GNRH/\
M;] 8*+HGF5%UVZBB*J+:-DCB"B1S$.4JIVJ;<X 8H@!R+&3,'B4P@(#C5_U3
M/D<T>Q;IR<36+ERE8GJV*]'0]:E(L5I&AECCL2T(*<H$B,%EBLO"X 9)"I#&
MCA[]1+^J.XBJ4-0AX(J:=IVIU*MZI<U3BCAB -5N0I8@EEJ5]6MZE79HI$9H
M)Z4=B,DI)$LBLH[Z+:;?N:SMZ9IFBR5DEW'2=Q)2QR1\)#,^U!)65EET#N"(
M1B!A$%%UW30RQRBU8D>29V\<XXSQ=^K3T2K!-'P;PK>NV-BL=[B*6*C4C?OY
M7[!I\UNQ:0]VT37:$A!W8H-]O0'"G_HZ=7I"'4?*QY0M)TBB"';1N"X+&K:M
M<4'9JT>I:O6TZG1F ]].NFZM A&VS@[YN/X?N&6%U"0EFLCU&Y;1=LQ;O+*=
MKV$97V[DA1=0E+8*<QCH\Y@!-]**@$S/"F11^H@T*UBF7A?R@>4OB_REZK[*
M<5:K+=,7.E*F@%?3M/B=@3%2I1[10*W*G4<\]B;D1K,\\BB3/97!7D_X)\FN
MCGA_@308=$TUW22Y.\C6]7UBQ$&5+FM:I-^N+TZ\\C0PCIT*/5ECT^I5BD9#
ME-D!R78'X/7QC/=%]/E..Z^73WYIU<^7+I[PGSY\_#ERY\^?ARR[!^S0_P#>
MQ_\ WC+4_P"P3;;[]*3P\?>'PV]/JS] 6>L\\J9HZW-'FC-L;&:"7IY7&?<$
M ?W-](+OD1_P13<$$/@$.6>8>(XNAK^L1_\ ]QMN/Q2S-*OS.,]+<.R];0=(
MDWW_ .CZJ'\<42Q-\Z'?+:9I<W66WW*L=OJ#:KA,1!1#6]Y63$O/J Z58E#E
M$.7CS Q0Y<O'GZV7(OV6/?PZB?\ W#,JBH:[34^#6JZG\1E09H\X'=BEUAQ"
MUU)VJ=*M[5"1U?*CS K9&Q'=A/4=XJ'[98\B9_7VX\P @3QA$!\.6<Z]2LP\
M6C"S)_@[!9!WGU!6/KY?Q9V+C_3>U:8+<8WDI2-(>[OZ3=T@[AX >Z'?T1Y^
MOW@ANHMIFTT%TL;L91JE8HE,P^H(]8=+.4(F'LJNV:S)40_<XTX^QG0O)EJ9
M2Q>TEV/+.@N5U/@)8MHYP/3S21F)OQ0G/(7E*TWGKT=51?.A=J<Y [S'+O)
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M&P]0^(8QC8>H?$,8QL/4/BQC/N,8QC&,8QC&<3G(F0ZBA@(1,ICG.80 I2%
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M BT 1;[&U=KQ;>M4$DY)^ &)=_A*YM)GA (.9$?  B9$1_D!FMG<[7_5K/\
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MMWG=F/K^#N^#?QN[16J$.\>V!4.LU<C',N4X%YF-(B*4?"I(E]<3#,O6)P*
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MW^$#%;6/AO6DGDM+)2E;BFLZ5:@,'-7GB'#*&W.P2SRVEEJJIGB)K-V=A/\
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MIH((I@)E%5EC@FDF0H>)CG.8I2@'B(B 94B-(ZH@+.[*BJ!N69B H '>220
M!XG*6945G=@J(I9F)V"JHW9B?0  23ZLWG:OIR=!H%6J103!:)BD"/SI<NA:
M4<=3N57*/KF*K(+N3D$1$0()2\^0!GJ'0].72=)HT!MS5ZZ"4CP:=]Y)V'P-
M,[D? <\RZUJ#:KJEZ^=^6Q.QB!\5@3W.!3\(B5 ?#OW[AD]$.8" ^L/@/\^;
M7-7GY1?1 VL>;ADW>E(I]:;<(@S0.74))5"]P(0YRB/B A)]T QN?/LQ, ^
MB ^5HQRWV7T"6=3^("0'YL]C<)M(=6T1H^YVEK_Q60<X_?4G/SF69\6)I4VJ
MJ?K=32K:H,C"(]:J"213RJA!]?Q%18YC%]?NP <1\,R:Z<T\>P[H^:PWH[P=
MT!_&>3NW_=;@=V>B[#A8W![^X0C8['=@5/CZEZC>GP'PY:!@T102*Y<])3&Y
M=D0WK%#P H@7EZHX^'2 %'I#ER#GZV:Y).R[GUGY]O$[?'W_ !YK_3W;_P F
MW?X>)R_^K.'O=.ZCD-KK7\Y+Q8K @K87""497T3 806_3F7<1L2JJW .I9F2
M0[^4.0$:*',4AL>26.+W[C?T#?Q[]O0"VWCWA2/AS47]=TG325MW$$@_]1".
MM/X>E%[EV\/=&3O[LV,ZQ]"KDUA;O=O7Z/9$ Q#JPE-;GFW9R<P$0\LSC-A$
M,5@ .@Z0U>?3 PB9-\<  QL.2]Z(PVW=^!\9!9C\&S+^+(?=\H&W,FFT%'JG
MNMU#^,0)L@_A,VWAZ]]ENJ>'+3&C6W>:54H]G*-VJQ'-NF3>5K,9L8O6Y)Y;
M?@=:-8J 0#K1T2$=%!T@8K(O+GF,#8M2QPQJ\DDTB1Q0Q*2TDCMRQHJ#=I'9
MF"KOS.20-SD$U;7;UY9+.J7F,$"/*_.XCK01QJ7=^0;1QJBAF9B.X;DG);JM
M,[JM+6AP0Y'=[F)*XG!0H@H2/DU"(5U$W4'4 MZNSA$!*;ER.F?D !X!T3RK
MR1UN)H.%:SJ]3@+1M-X,C*,&C;4-+1Y^))DY?,VL\57-<L KONDB;LVV^<>\
MD,<EOA:?BVRC)<\H6MZGQM()%*R+IVJR)!PQ P8!QV;A*EH-<JVQ#QOYJ[[9
M<K.9YU+&,8QC&,8QC(&HV8.>(OA'*ZCI=V[#<$D6->1[E%*.BUUJ%:$7#B=;
MGC':KUHY9*.&+-)N^ASI2CEFX.Z=))'8.>A<$&<Z=Q4D<]2.&2'AA;,$\3R6
M+2>W'0S''2=;,*Q21R\DTS/!;#UTEC6.)F$\=-QF30>)&#(JC2)BP8$LX$D9
M C/,H5@P#$E7!0,-@3S#])F=V&>4<M1N^D#L'6%JKJ*159$S$9*' 0]5Y6BC
M ^9IIF_:&=F1,Q,;]R=* /@(YH>)],]E]$O4U4-,8NM7]8L0'JQA?49.4Q$_
M8R-F]X:U+V)UJC<8[0B7HV/5V><&*0D>GIAA*!]D@S2,(" B AR$!Y" ^ @(
M#R$!#V!#VO;SS+GI/&,9HGX\J>O1N(12V(-P3CKFQ@[6@J0!*B9ZT;^;$ZUY
M<_[NF+!M*NCE "<Y9%0PBJ900SZ[@J%/I#)ZSN.]?1W;[[#Q[TSM/ EL6M">
ML3[IIMEQR[]Y@L'K*?XW57Q  '?G=PA68M3XL*:<BW9QNTJ=:*<Y-S_M=5ZQ
M:I6Z&$_B =X.M#/&S<P]0\W1D@_NIA"[(.>I*NQWBD20;^/*VZ-ZNX>:/#?P
M]&^6>.ZHFTE; &[59D).W>%YNB>_U-UE;N\0@[@!G[0>$"9-*:7CFAS=1H"<
MG(?Q'F($.X),)E'_  22Q2E#V"@7.V>3VSU^&X8R=S4LVJ_[Q<6!\0L; >H9
MXAX_KB#B.9P-A:K5K'[_ "&N3^^8"3\.90Y.,A6,8QC&,8QC&1:=;=LY1-R
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M<C;FTY4\/2EJP2/WNH.[T;_#F:^=*SG&,8QC&,8QC&>-RU!<Y3" #R+T^/\
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M"N6AHSCYYH"D7,BC& [<Q3AVR2=()N5NO8:5J+Z3?KZA'6JVI:K]6**ZDDD
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M ][MD>I8*"P*F(@!SOK:V((#U$,<A3F+$]0\G'%FGAG%!+T:[[R:?,DY[O5
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M[MMS&Y3F'P-MS*?2"".[*[F5F-C&,8QC&,XB8I?U1BEY^V(!_P">,9\[1/\
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MJ8_U.W"/E6AT?4M)U:CP?[")<GA&O:]9<79A;$6T\4EB_P C/%$.4,5 WYB
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M\.8.0F$ [_Y/:(J</13E=I+\TUECZ>16,$(_P>6(NO\ WA/IS@O'UXV^()8
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MCWIH[;%*=]$CEE +=&6-F,,K =_3'/(K[ D!@W@IS$.PU&A3*3\]QUG3YNS
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MB80%S")!,P;IF0!RFX[N8!MO$#))QCV@\5<0=K$(M>RUWM KF0P"43,'Z)E
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MC&,8QC&,8QC&=#ALV>(F;NVZ#I _3UH.$DUT3])@.7J25*8ANDQ0,7F4>1@
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M.HP*'"OJ1*L0UGK\$2.L?<(>Y2+.6LK(@W2R&6+*2$?!5EFY.JY%9=N9&#8
M1FJW2,190AW"U'$9E.M7S-)#+*9(^>2NC)"QZ$7[&K2S, !L.^1MR">[?837
MBXS'B+4S8EKS3&2'GEJQM% Y[+!MTT>:PR@+L#O,^[ GN!Y1E?FDR-XQC&,8
MQC&,8QC&,8QC&,9UJB!4E1$2@ )G$1.(%*  41$3"80 "A[(B(  <Q$0#&,Q
MVX/V[]KPJ\.B$I"U&N2:>EM<>4H&@NXA_2(>0-5(L[V.J3Z EY^#>5UJY,JE
M$.8><EXU=B5%1E(O&YDUS[;7BIUO5BDD\R>R-SDEM+(MF1>NX5YUECBD69AL
M9%DCC<-N&13N!O>*&1N)-=:.6U/&=6O].:ZLJ7)4%F0(]I)XH9DG90#*LL,4
MBON'C0@J,C<U.:+&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,9C'QBI*+</-T32IL1?U#3&MNFJ3KV7CXN
M1Z=I4HQEW#N"GJS*)J1!0&::%;S34BSV.;H.TGS-5Q'NMQH! U6N38DJCIV_
M=XE1W3]96.X+)%,A$A]S;>-ME<E2K ,L@X6(77*A-N6B!%?WM0I$\D?_ $=;
M[E6:&Q&1)^Q-S1,0CL5*,%=8IQV?L%5[_P"9_@@_^\_0F8NG?]9/_P +?_V"
MSD5N?L2__$5?]IBRI\1EE?T;8G#?=Q2W/)5J"NMW:V>N:BUAL':"$XE8M=S<
M!##>(^@(2"L- Q$T^:2S67FXB0C$9)JAZI@L!7R.=I,*V:FK5]]/2:2O6:&:
M_<JTS&8K4<LG9FM%1)))&K(T<<B.48^^'FF7Z% ERCKU/?28YYJE-J]C5-1H
MZ<T)@O132]C>Z4$LTL2-$T4,J2&-CW./,-4?\5],C@O@JZOXGG'V/9I"#DP8
M<+>]Y 9YPO*OH@KVA@THBPWZ%(NP4=KS=2"6C$(I=C+*NB1[YJX5H71+#]FV
MN:,.U1F5.;6M,3I (K\MGFLCLTA#!1'/R.7#(%YE8"VG#=I^Q[:CP\.VQ--'
MS\1:,G158TEY+G-='8I2'"K%:Z4C2!X@I=&4=_VT].\I.(O[&7$OVS>A(;#,
MY^UBWEY-4C'%2:7$L WD_,?N+B^IL7A(E>@)+GMS>V).ZBM$$L+1Q'I_/86?
MD#]LT?8VC5V]F--YPXG:#JE.T\PJEEZ@M$= P%9P_2(?/GM<M=,2>R'#^S7&
MH\OMAT?J"1;+5>L8^V<ZTRZF5;I JM6*V1*8&5SPC.*NG2KG7K9'6'$VU/LF
M4\E12DGPO[UBV]>6\OEKO>MA.7]&00UW%]Z,#_RI<CP[#R"!K!V_D@IG8'T6
MP@M$W-'/9$ZCA-9TUS*.D9>6J%LDVWY1R\E<2-U=HMNIYN).'+42WF.H</L*
M$?5D$?$6C2-..CU^6BJ7&-Z3E')TZ@E?K>X<O5\W+/>B#<7+GA=UE!L*5-TR
M*W3M*2DHG7"E[!5:KPL?6(X;#=KG8&3=PT</8V&B$FT%%,DW3<9.\6NG1!U2
M(2"ZB=G3:0MRL9%D:"$ R]/W[%SRQQJ=B 68\Q)!V1'/HR)W+!KQCD*"5SLG
M/[T!>]V8#T!>X>MV4>G+(W_T0^WR6N*:72>OBV"X7.J\(B3V^OY*%1JM1OW&
M"\ADM?0[.H/'J$]<P;1CQS-SWDY9LA!LGD,IUR@!-$B+\6FQB5^O+RQH]W:-
M0Q=XZ0;J,7 Y8]R.5=]RQ!'=YO-:>ZQ1.DG,S+6W<D<JO9(Y!R[[MW=[;$;
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M$U#.EI#5Q#ZO446U^8*7 ]5366G"VE5>(,+(107/:B%M9EC"=4;24MDZ_+8
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M:$NMVY!:NPZ9I=*-;.J:C,0W9ZQD6)4KP ]2U<LRNL-2M&"TDK L5C5W6S?
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MZYN='NMWF25I602MU.V93+^P:1#*%E6"\XJHE$)BG91%OSN8B9.9R@D6.-0
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M&E9%<.]CC'NO'BO%%Q,2Y*&X%=^QE9[52C+9!1L+N>[ML,C/43)=ZW!NZ+7
M+6G%65\WFC1 51DRK2BQ]5A=;2C1M'C-E=D9([P:I[D(N:KS7V"MN.M[L)QU
M6)VY-D"37()$O(.'N'XC=7E1XX-1#T/<%AYJ);4W5&YE[1[NM@==F.W3VC%
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MU1>>4%#*##T$ZCN2A4A%ID[PF1UR=-D-A;QW]L*FDBJ,RD-:V6S4AO2IR6H
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MB8C;EIT[5+=:;% UQU7Z)![&L55=JU%U;Y*)8R)5>ZLY!ZX:/ 1K:K(/>[,
MB,>]5/,T2S,B*S!I&C5QS\@8CQ( (SX)E.V^XW9@-@S#82&-69@"$#D>;S$
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M1N3WG=MSF3]3JT93*M6J?"I%1AZI7X:M1*/( [*,@HYM%L$^12@4.AJU2+R
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M)SXJ<JA57E50  !L !W #\65;R.Q$O2+1H)>S.CT]W3Z>Q44!51+ET\NS.J
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MOGQV!?<E_#C'G_A?/CL"^Y+^'&//_"^?'8%]R7\.,>?^%\^.P+[DOX<8\_\
M"^?'8%]R7\.,>?\ A?/CL"^Y+^'&//\ POGQV!?<E_#C'G_A?/CL"^Y+^'&/
M/_"^?'8%]R7\.,>?^%\^.P+[DOX<8\_\+Y\=@7W)?PXQY_X7SX[ ON2_AQCS
M_P +Y\=@7W)?PXQY_P"%\^.P+[DOX<8\_P#"^?'8%]R7\.,>?^%\^>C&7L8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
'C&,8QG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g743471g75o60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g75o60.jpg
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M P48 /9BIEMH$(*1*I#:P0,'5IT:O2Q4X)/$CMS5SKT+IMW4QFB7-<U=>GI
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MAW&W%(S2]LS\096(,4<)!/ PQ%2D1\^A2JX ([!4^YBX=0 AVD!':)'!#/\
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MT>P@89I1)CQ!A;V&V\*?,-()-,?4X480^2ZZ\O".[2,SN=3,2S'F3Q/ <!Z
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M$<DTMY:6QV'%Y[.3QQR2N$C4NQR<#D!DDGL  XDD@#SFI7=8U+.P51CB>9X
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M:GHV\M;;>7&ZF#J476T(7$\H&EMW$K%09"AU!2P8J"$#/I4VT\Q2+7%I;4=
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M0..D8!X]12RF1NHA+&K>Z3>H&;W''72J7 ?)=SU<;& G7<"JS-(KFRZ]-$V
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MU @".0$!T77K:)FTEG@9LONLKB4*X.-2M;FW7?K,IP0270Y*LVG2) ,@"50
MFO!RA*D=A&3 8(4<SD:/#%!'4086I@,=H5G)4@6^>>3EIA"$9(./))-,>RGQ
M"2R'R7E+>=<6JU)).223P&2<G & /S  #D!BK@ #@!C\GIXGOKU<A2G%*Q;Z
M@NF&,WCZQ,"MIU'F+'22]975UN%C[/!737Y))TC'QLW7I-T9MNQT:<DI"TZO
MN<6='S='LI\B4TJ3BI67A9"\MKLV^ 4$BK()4&HHT<F "589ZLB@),A!61
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MI8FAD@$0;5DP:S@9M"@59IFX!;8H0&4*"C+DJP>Q%K)')O(Y2Y&G ETC) N
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MJU7BH,XUA;Z&WELEE NOM*>;0ZI#B<N(2O.<8Q\[B6>:51A9)9'4<@[E@/S
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M61_\$;=XD?\ Q5<<OYHV1S%;A/4,S[;6']@J/NSS7O(Y#O\ &MFL'F>[PKB
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M^H?^'U>YS6Z;?#/I=\Y]O_:MW75KR?\ P#Z$_-'HW]C653>::''"$R$@6,
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MXM;E8+<<4I8K2E*6M5G[RUJSG.5+S\:LYSG/QYYS;N JW$X P!-*  0  '8
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MKY] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT]
MN'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)
M"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54
MGWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGX
MX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZ
MQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X
M\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZC
MXT] N'M)"?54GWGXX<CZQX4X\QZCXT] N'M)"?54GWGXX<CZQX4X\QZCXT]
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M=-B]%"D%S/"A:TVN6*Q2NBEB-M %B%!. !GL '"J/_AK^IO_ +NM$?0&P/\
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M.3LR7CB[:IS3J3?1Y$7#R%IE,*;[@\Q+---HREIE,G(>$VC)A&7,M]PO3/\
MW/Z5?V!M3_25A?V0N@?^^_0__P#D>R/]95V5OJ.TU)2,?6:CN_IED9:=F'&8
MN K^U:V9(S$]89-TEQF/C(^1=)/E9F8/>>RT.RZ4=(%K5A+C[V>]1N.AO2RT
M@FNKOHMTDMK:WB>:XN+C8NT88((8E+R2S2R6RQQQQH"SN[*JJ"20!5>VZ<]#
M+VX@M+/I?T5NKNZEC@MK:VV_LN>XN)Y6"10P0Q7322RR.P2.-%9W8A5!) J>
M>]=OR56_:);[KSYOJ?&[J^IZ_P 7OK4C\,SFQ9Z7:/ZV1"I&_AXJW<S'.G+?
M\;R!L_NX5@EEMO#7<\3O9PK*^]W,8QV95G'OGL=,?=OM/&?@M?=N/YUV)6MW
MLHL_L?[)SCX7;/[,_P T;=KF6YNE6A5731N]YVIW<[O?\TU_N=[M[O>];"=W
MO=GQ]WM[.WL^/L_D^/EAM7\%[2_J%Y]7DK(['_"VR_E&R^LQ5W7=Z[?DJM^T
M2WW7G,#J?&[JZZ]?XO?6M+X6;-EST=6+UFW!)$\[T3O9 >/61W_6RNYW4D,-
MM=WM_P"MVJ[>S^3&<\]E\@VG]D.RQG/N;M3MQ_)J\)]D;J_8PO\ .G'NKL?L
MS_*JY5>;TUSOIQ2N\.#5=/4L/W6JOW?5<?W>TB6[>ST1GL[>P;L[>S^7L^+M
MYRXN=/MFX]]^[R\O_,:NO]KK]K6_O?W"+G_Y:UB+\(:JU?\ ,QWSZ>W7\">6
M(SQ\B/R2B<)\UU_L\)+PZ6LJ[W=[>^K&.[V_'V]G/O\ R2:?V1NBV-6?;TW+
M^0W5>:>6K5^Q=TPSIQ[GP=F?YPLZX]N="*YETXI7;)TOJN'_ #:.G?T=JMY'
M_@,U)X&7GY3#V6?(-?\ "R[A ZD8=RCN^)A"LHPOMPG.<=F><V.FVG[L^EWO
MOA/M_E_.MW75CH!J^X/H3[WX(]&^?\S654;J_5;O^:KU&>E-5S W\"NR/2,C
MOR:G\,^4Y3Q,LX<'2WESN=O<PM6$Y5V=[.,<N?)]I^[KH?C5G[I-C=N/Y?!5
MKY3-7['G3?.G'W*[=[,_S;<5Q:<Z/5RQIQ2NR#H.5;/^9]T_^A-5W(OD 'P,
ME/R22,M^EF]GBI:'4WA?\O;A"LX__/G._P J.G]D'I9G5GW6EY?Q(ZZ?>2#5
M^QGT,QC'N-#VYS^Z2UF\CO\ <1XO=PYW4^)A&<Y1W^S'?[F58PK*>]V]W*L8
MSV=G;C&>>?UZ57UQ2G%*<4IQ2G%*UF7S5.8J[WTVWZ\OFQ]0RW5@N^VVODP=
MLVPNR0<MT<8KD<>+6%M6*3G:G#;9>CX&(B(D!^#I,V+#2 H<'&5)4C#Y5)M4
M<822.*<68B1@8X0K+?:B"_4"R-#EF8G5(I8$L7PU@\0U-K1Y(C<:W4AI-0-M
MI!T]8LHDP  ,(V"-(7(SDTE$VV TQJ*"OSSY-[A=84&)NI!)>#R2+;&U2)#L
M;Q!V''<&ONS#)BW2\.NX(<4I[#B\+[V;"X9&GF:(8C::1HQC&$+L4&/-U<<*
MNX0PBB#^_$:!^.>L%&KCY^.>-70M5R[Z_#:K'A]Y7A]\B5PON=N>[W\)&RG"
MN[V=[NYSCM[>S/9RGU?C=U3=?XO?7SWKM^2JW[1+?=>.I\;NIU_B]].]=OR5
M6_:);[KQU/C=U.O\7OIWKM^2JW[1+?=>.I\;NIU_B]].]=OR56_:);[KQU/C
M=U.O\7OIWKM^2JW[1+?=>.I\;NIU_B]].]=OR56_:);[KQU/C=U.O\7OIWKM
M^2JW[1+?=>.I\;NIU_B]].]=OR56_:);[KQU/C=U.O\ %[Z=Z[?DJM^T2WW7
MCJ?&[J=?XO?3O7;\E5OVB6^Z\=3XW=3K_%[Z=Z[?DJM^T2WW7CJ?&[J=?XO?
M3O7;\E5OVB6^Z\=3XW=3K_%[ZCJS:VG+38HRR&NPC)4<Y7%^"RO+S3V*I8TV
MJ(PR^?!F'Q2E2R<)DW(4N/<E@<-B'*=]$CW0V5^-W>/+(XYQGAZ77^+W_K^O
M&O0Q1;EB=BIT^<!EW8<IN5&&,R*.RY/^5'*:3-$.159CBEO&0Y!:G@4/MQ39
MI;KXX++3$>.$ZOQN/Y*8?XO?^O\ [FK][UV_)5;]HEONO'4^-W4Z_P 7OIWK
MM^2JW[1+?=>.I\;NIU_B]]<&\KV^M)+M[.WT\SM[/Y.WTASM[/\ \N=2+?\
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MX7=*?G'MO[3NJB?F?KYRNCWX%C,_C2FW/5"(=3/\*0_BYDG36W,.>4X;L\/
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M*[ZX+_(D-_JJ/_W1GG+:Z_?-Q_3R_P!XU=@;7][6_P#01?W:UA[\(Q^)3O\
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M^U7_ (?;2Y[[['/X;[3^:U]]J[$K6WV4?XO]D_.ZP^R-NUR^<W3K0FKKH?\
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MJ4N8,PM-_F-DP2M6Z!L\Q/S$\[9'XW<]QK5D/VW6L$.N.XKCH;(E'G2]?"X
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M;X)^R7!N#$S&;[D;K4)0ZA8MS[N<59"S[S6-)4+H.K(]./@7.H/TM+6;SK_
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M#"J!P'FSVU$G^ [^#)_\/!W^V3>/_F/RO]T6U_Y4/^7MO\JJ7N/L_P#\@_\
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M7(]Q&7B($DB1QR#$RHY,KH1O"69P_P!\(8 @!550 6RS3+"X5P=*,[H<QEE
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M/W(A_E>U?[5OO\^G\.<][#:5_P!BVMO=WCW-B_E.T?[1O/\ .I[D0_RO:O\
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M[X_PF\:BSL,<1Q4'WJ^%6YY[L?Y<+Z*C?NO)MVO(_2;QJ&\;F/HKX4\]V/\
M+A?14;]UXW:\C])O&F\;F/HKX4\]V/\ +A?14;]UXW:\C])O&F\;F/HKX5%>
MN-]W&[$SS9P8,4@-(LA&#.0L>T9F(.FK3"".F9PHQI;RWZJ7XV%)C"QS,&!.
MQ6 QH^9FZLEND87!+9R"0S8R%1CCB/,XQV@C!SDE5II.[ZLX&.(ZJYTDL!G@
M?XIY'S8P S2IY[L?Y<+Z*C?NO*6[7D?I-XU4WC<Q]%?"GGNQ_EPOHJ-^Z\;M
M>1^DWC3>-S'T5\*>>['^7"^BHW[KQNUY'Z3>--XW,?17PK+/61Y,G2(0XM2%
M$/\ K+Q%-M-L(SX<N>RCL:92AM/8AM.,]U..]GM5GM5G.<VL@ <@=G#F?,.=
M749)0$]O'D/.>57YR2IZ<4KE&_Y0_=M=U7<73HQ==,0&T2B]:6QX$Z8N-^K+
MD4PBT#(<$98I\]#C%(?<SAY3IC;SZ%8[C:TMYRGGMGDKM[N:PVL;?:$EFJWD
M 94M[:8.=R<,3/&Y7 X84@<^-;#^16UO;C9FVS:[4FV>JWUL'2.UL[@2$V[$
M,3<Q2,I X84@'SC-:IZWKK5]MU%3[M5=!4F0L%PJ8\JWK].W-J9<&JA^^YC4
M"!%!QF[92_."8N,</9'RB]71]%4HYL >UE75^(@IG[66[O8+Z>WGVG<)%!.8
M_;7M"SZTZ[,2^)U/L]+;5[7=H0JWCW/5U&%;<221^ASWU_;;2N;6XVQ=)#;7
M#1F\]S=G]:X38\>TRP:39<=F&]JN8 J[0>[ZNMK=;42314[&@DN%($&Z+M;'
M.>D9R1B/V[U"&N1L/C7S^TDSDN(-.N'Q.':.*1-CU.1$&V,0VW@=BE.%/#LN
MS>Z> 2W2&Z08X:['9:AY/;0L]U&S1A)/VR1&;A&-F#Q-R "1/[L]74W2B]0:
M>&O9NQD#R^W!8;F-VB$<N+MA$;F-VL%)U&["AF'M+T1418J&,<Z6M2B%%C'O
MSF97=.X082 =%VZ;I@(/UNSL,XN4)E;7ZA]%R)"H&9%L++IA##<;).,2KM.=
MGD7W9OB%*"/1LZP:24-8KM!FT&U54$<.\U!I"Q:(A0Q= 9%VQ<M)*HZ0;195
M*"'=[*V:\LRMLU=J.^[-DBQ+';[[5JEU%H2%4F1 ;'E]:P-=GM3UVR=&>N(.
M1W!/U:NUQLW<F\<X".N0];D8%R44U;G&W 2X:V0DLH^$7,A#MOE1A1#$_&2D
M0'<QW<LL=]+%M^ZD2PCFEFT[/V=EEMS*LN@&$=97AD33)NV) < Q.DC7D=_-
M/#M&>#I1>S)LR&>><ILO9772V:=)A&#;@AUEMY8]$PB8E5D4&"2.5ZO%:BJ]
MF:A7:ETG:?FW[0J'S5X)S?.WXVT2;5BAZ_:(%!4:1>UQL4:;4K-%V,A@F;4+
M'B>D"OGYD,""F4WOIH3()]MWT8AWF^E&S+%X4,4DL$NEQ;!W59X7A!$>6;!"
MZ=16E)M*XMS*+GI%M*$0;P3S#8^SI+9##+-;S:9%M!)(JW,#P*1"&=M+!-&I
MD]%>U1K:<7$..].FD@8>=)KC\79_X:=[$UTNLSDU6:P184D9MH\BRJ/L]_US
M JARXL8[!=O25*9AHN"G#PH2WUY'O -J[1:2(2AX?<[9HE6:..:818W)0ZH;
M6[EWBN5TP:4WCRQ*TLVTKZ+>@;;VHTL*SB2W]RMDK.L\,4]P(<"W:-M=O9WT
MV]61DTVVF/>R30H]E6N(TM6;C<Z2CIFU[)RU3U75]IL>%LG>@R)H"<I-+V#*
M1;'B7]S A->JUIDI!XAY:VC\5HID=ML@\1K%Q ^T9H+>X.V+I$GO9K(_M/9S
M;MH[BXM4<XMAD2S0HH  T&9220K&KNWEVK/:VMV=O7D<=SM"XV><V.R6,3Q7
M5U91R'%H-0GN+>- H&4WZDDJC&H%_A@T+_X1J1_M8W=[[<R?M#:?\^7'_([.
M_P!/68]S=L?[R77]G;*_TM9@_!][1TQ*=;_2E'0O3'4:Q+&[VUP-'6$396W9
M,J%+=L@*&)$>/E[<7%F.BKSAU YXI KJDX2\TM&<IS@>E%EM!.CNVWDVQ/,B
M[-NV>)K.Q02*(6)0LD*NH8<,J0P[0<U\STRV?M2/HITB>7;UQ/&FR+YGA:PV
M;&LJB!RT9>.W610PX%D8,,Y!!KMT=JU6RZYG,-G.<N+SG/K&0QVYRK/;GLP_
M_P#'FLX9N?<*TIT+R[S7QY5JOR+GZ2D/M^-;<^X>%-"\N\^-4.SQ]7KE<GI]
M%5.EG(6'D91J*CBIDJ0E'01'26HX$<-)A3Q9SC:11VQQ27ENNHPVPZKL1F92
M695U!=3 :C@ 9.,DG  ':<D#TU!E4 G23@$X&<G S@>DU$L9.:WN<G'0,CKN
M*DPI^014Y@E4G*R @]IBHZVVM%?-C+%!P<F^Q!#5224>[)QT>5#V0T6.9B7G
M4RAL=5*R("P<@J-8& #H8JFH%2PRVL8 )#)DEL:0T@T,0"@(;JDY)&H!FTD$
M \ ISD @D#!XD7)KRPT*\25JA(ZHNQJ:B2@5I7K22R.7'^O;36A2!T+;#0E#
MA=.DW651V9.&6 \!Z),D')E(Z)ED5XPC%LZQGL&0=*.0>WS.O;ALY!4#!:*%
M&+ +C3Z3Q&67/K0]F1C''.0)2\JU7Y%S])2'V_*6MN?</"I]"\N\^-/*M5^1
M<_24A]OQK;GW#PIH7EWGQJXSJ]7G*U BKB\J&8-F5L,^G&X\-;V0LO*\3#N'
M%^)W$?$M6<([OX.,=N>2!FUMQ\P\P]%3E!H'+)X?K^3OJW/*M5^1<_24A]OR
M?6W/N'A4FA>7>?&GE6J_(N?I*0^WXUMS[AX4T+R[SXU29P"CUV*,F)*(<2*&
MEO\  :/D'"2B2'FQ08\%CTA*BI&3.?'CXT-O/BFGDCBLX4Z\A.8J78@ \3Z!
MP XDGAP  ))[  2> J!50,D=Y_,!Q[2> 'G/"HLJT[JJ^6.CMMT#"IV0UTY?
M6)0LUDUVH*D!:<Z]5?6313SR)U^,N0)D@U&K\!N-]$()6IB6CLNUG66-9.OU
M1*(R!D:\&3#XQQ4&-@"?X60.*MB1=VQ3J\2A8$_P<Z<KG/ D,"0/-C/:*NJ@
MGU2["'$.U-R#*&<%>3#'2%K%G&8N194]&&RL9.PM?>#4;AHIIM<=ZZA720CA
MP9TYT(M+,D@9"!JU>D:"NH=H!5F!QP/'2V""5&1F90K9X8/(Z@<'L)! ](X9
M&00"<&K_ /*M5^1<_24A]ORGK;GW#PJ;0O+O/C3RK5?D7/TE(?;\:VY]P\*:
M%Y=Y\:KTE7:XY$5QEV*RMD8210,WZ>:GPD.2I3KB>\E["G.^ZM:^U><Y3WNZ
MGL3C&.2AFU/Q_B^8<JF*C"C'8#CMYFJ#Y5JOR+GZ2D/M^3:VY]P\*ET+R[SX
MT\JU7Y%S])2'V_&MN?</"FA>7>?&GE6J_(N?I*0^WXUMS[AX4T+R[SXUC?+7
M?7@,E/RI6K&';!4W[.PQZ6=/1UGQ4*NU=")6?8>G*W'(Q%S+=1DT55$%*S45
M/DGL(*E8D=,B6)<A'(4;W"OI[-)36V[PITL>(U@OJ"E0#@,< T24!)T=9<CC
MD-I&HD\1[TZ3IP2&.,D<<9'XJ]45C&<0V<XSC&<9]92/QXS\>/\ W_+;6W/N
M'A5;0O+O/C7]\JU7Y%S])2'V_&MN?</"FA>7>?&GE6J_(N?I*0^WXUMS[AX4
MT+R[SXU4S:U6EA0Z%Q&5(9#(;93ZP.QX:%29SJD]N'L95VNN.+[59SG'>[N,
M]W"<8@&;+<?/R'\45$HN!P\W,\SZ:IGE6J_(N?I*0^WY'6W/N'A4-"\N\^-/
M*M5^1<_24A]OQK;GW#PIH7EWGQJR-BR-#UQ4)JV2-=*D?5@)I 4,!*%8DIPT
M0$J0Q&QV""VF?&4,&442^\M T='"'2ISC,>"4^U4B#RNJ @9(!8CJJ"0,G /
MG( \Y)"CB0*E?0BEBI. 2 #Q) S@9('8">)  !)( )JQ(N;U1)W6ZK1KI&9R
MGPLYE,^+DTR>E8RLGJ!F(X,A K;AB<2.4X" @)6P(;RZ@>P(KLVZS#O5&641
MQ_?.J[+U20%!<94D9X<.TLJ\TUKEA(-V6;J<5#=;B6PIP1Z>/8%+<FTM@&0J
M1BL6V%]8D5EF+D6"G I.&1+V=94.6ED<I 4DQ.PU8E@S5A%AFX8*AV$.AF!G
M!/&1Y@AC])]2-@$D8R&PN&'9D:6=2,@C(8\00<$$"=0K#.,'SC+<#R.0I[,'
MB!P((X$&KP\JU7Y%S])2'V_)-;<^X>%3:%Y=Y\:>5:K\BY^DI#[?C6W/N'A3
M0O+O/C53/K5:<&ADN1&5I9C%MLX]8')\-K,M*.Y1VI>QE?\ &NNK[R^U7X?=
M[>ZE.,0#-EN/GY#D/142BX'#S<SS/IJF>5:K\BY^DI#[?D=;<^X>%0T+R[SX
MT\JU7Y%S])2'V_&MN?</"FA>7>?&GE6J_(N?I*0^WXUMS[AX4T+R[SXU"E6M
MU/G&JX9G6YT>7;;,S7SF$R,R'(UK+E/<M<6[<@;-'U2:8.)!;2$T'$QL^&A;
MS+S$N^#XK[5=T9=0W@(1-0X A^OH.@H74@'CEBIX$$ U34J<=0C4V".(*]35
MU@VDYP . /:...-37Y5JOR+GZ2D/M^4-;<^X>%5-"\N\^-/*M5^1<_24A]OQ
MK;GW#PIH7EWGQIY5JOR+GZ2D/M^-;<^X>%-"\N\^-5N8KM<>9@DO1.5I'A&F
M&,>GG)\-A,A(N8;[4O8ROL<<<5WU]J_PN[G/8E.,2JS=;C_"/F'HJ9D7A_PC
MG5$\JU7Y%S])2'V_)M;<^X>%2Z%Y=Y\:>5:K\BY^DI#[?C6W/N'A30O+O/C5
MD7F1H5%!C23:Z3(%RTS%1 ,8%*%)*<P?)!!&R3BB"VF6(V%'+]/D"7G$85A+
M$<)@B7DHL R= \A.#@*K,21PX D#L[6Q@?G)ZH)$K:%QD9)(  SGB0.?FS_T
M XD V2/8M3(C=HWF)HB.VK30L 7,L%*9)NRVX2NEQAXA8BR),Z(4_/MQ44XL
M8PV19"497(^6$/ADR-0K+F*,O[Y2P7_R\LP8$' !PFIN( R Y4AM,OWO#L%]
MZVDGLU'"XP>TCB /.<=4'*YD2EXIUSK<?8AZZX(@Q<@.X,Y*2:\LEQ4F9$'(
M3EW(I6&L&@/^"@\&-DVVLH;E(J*D4E1PU)]2,5SG&#G [" PYCL(["5_BLPP
M3,H5AG&.WSGS$@^GM'G /, Y NGRK5?D7/TE(?;\EUMS[AX5-H7EWGQIY5JO
MR+GZ2D/M^-;<^X>%-"\N\^-5Z9KM<>$KR'HK+B!X;P1T^GFH\)GUE(N>'VI=
MQE?\8XXOOKRI7X7=[>ZG&.2JS=;C_"/F_(*F91U>'\$<^9-4'RK5?D7/TE(?
M;\FUMS[AX5+H7EWGQIY5JOR+GZ2D/M^-;<^X>%-"\N\^-6-=)*A4M5>8+KQ!
MQMCL$'""!B2I*7!QI:P0M?*G3%/EMX:B(<J>C4F/)PM:RCH\%M'C'-9Q4C5Y
M-6" %5F)([2JLP48'OF"M@<@3V U*VA<<,DD# /-@N>WL!89_+5L5\[7$I%W
MRU5+7P3;D98!(XV1)FQJ\/8P\PU?FV+C)S?C.>#6QH:S9F<&EI-E,P8Q!(,8
M2:4/%NS,) 8T=SQ4D#!8J=3*4"X]^633C@-1&2!DB4:"&94\X!.0-7!2&)S[
MT!LYXG'8"<"I"JX-4LU<@[#BKE1N)J+"D\ &2,A@D7!C"'\-.?QR>]V87C*%
MY0VIQO*5J::4K+::;EE9EU Z21D8P<''*IU"L <8R >T^?\ /5>\JU7Y%S])
M2'V_)=;<^X>%1T+R[SXT\JU7Y%S])2'V_&MN?</"FA>7>?&JS,UNMO9B_&B<
MN>%# ,M?X^<CN,MX<\-O\%['>[O;G\-7:I7_ +6<\E5VZW'^$?,/"HE5X</,
M/.>54;RK5?D7/TE(?;\FUMS[AX5#0O+O/C3RK5?D7/TE(?;\:VY]P\*:%Y=Y
M\:L2V2E$JLI685=9,E)2RRC(+0@$J\A8 CRLCIE3G##QF4#.2#@<8*PEW)9A
M9GB,,Y! EC(^H@=PS:@ HSQ':>0P#YLDGL '$Y*@RMI4@:<Y..WL])R>> !V
MDGD"1:$:93PZI>K:!K.!AI" FC6[$RBSFMQTT<%' 2<F\-8:_!RCT_+@DR3]
M:/'8BBW<76+FZ\P44L1)A,Y#:XT,C,&4:3I&5!) RKLH52!K!+ ;ME<@9P)1
MI"LV@#!.KB<' R<$ ZCQP< ]<,N3C)EZ/K< 1'@D2%9]6GOAC/&QV)LTW !;
MK*%DA8,:=0T7@5Y2V,$MH0V_W/%0E*58QBB6() ;(!.#@#(\QQYL\O-50*,#
M(P?.,DX/Y>&:]GE6J_(N?I*0^WY#6W/N'A30O+O/C3RK5?D7/TE(?;\:VY]P
M\*:%Y=Y\:R I HH58C!0F?1Q6O3?"9\1Q[N=^0+<7_&.J4XKO.+6K\)6>SO=
MW'8G&,<MW.6)/H_Z"KA!A0!Z?^IJZ^2U-3BE:ONOKX*_47P@UMU_;]D;%V/2
M3=>5V4K<8+2/+/HIPLK)MR;SYWKZ#EG?2&W6\-M>CN,M^'G/>0I7X7/L>C/3
M2_Z+P74%I:6EPMU*DSM<[[*E$T +NI8Q@@Y.03FOONA_E!VET,MKRVL;*QNE
MO9XYY&N_;&I&CC,8";F:,8(.3J!.>S%8FQ/P!^N8"$B:S!]:/6/#UN!5WX2N
MQ=X@ (*(5ZX)L/;&0XL U' ]L\87-Y]&&;QF6+)D<]IC[KR\X_E-NY9'FDZ/
M[ DFD_=)7MI6E?[V(NO(TI=OO2K'Q)ZBA/>@"OHI/+!?3327$O1?HQ+/-PEG
MDM)GFD^]K#]\D:8N_P!Z58NLQ^]JJ>]4 >YSX"&E/*;6]UO=:#RV7&7FE/7^
M$>4VL>*]1,=W+D$K.$LP?_H9IO'\6W%9S')3@/.6>2#RE7(SCH[T>&<@@6L@
M!R^]/ 2^>3[X>;];WW&I1Y7+I00O13HL 000+*4 @R;TY FXYE^^GG)USUN-
M4HSX 36$@AYL_K)ZP3FR'5OD-EW2O$MOO.69NZ./.H>KZTN.+N+35L6M>,J5
M96FYW.<RB$E8J+Y3KU2"NP-@J0, K;2@@"'VN ,2\ ("8,=FY^]^\ZM5%\L5
M^A!3HQT94JH4%;2<$*(#:A01/D 6Q-OCLW!,/[F=-?USX /51!]1DS>KSJOE
M#*#*A3E+7,V&FS+=9EHYR.=#.B!I6K&#!OL9B(IO&6V<84/&@#+PH<1AIL/*
M=?!9T786PT6Z1H[C=PW$9F1PX99&2=68'6_:>UV(XL30>6+:(2YC3HWT=C6\
MC>*ZW4%U$9XW#AEE:.X5F!WLAXG.78CBQ-?0'P >H(N;"G8SJKZGP"(T\0Z.
M"8F*8J("2 "%$ QS,415W@U0X<%&QU<9BWFW0\5T .#6TN-';&3!O*=?O&T3
M[%V,RNK*[&.XUMK9I&8N)PV\:5WF+@AM\[2@ZR34'\L6TY8GAEZ/='W61&1V
M:*ZWCZW:1W,BW 82-,[SF12'W[M,")"6J[K-\![2;-;!+HOK$ZKH.=C8P>&B
M"JU9:U#O1,6*S#M(%$.9@5RKBG%5^$**..D3)(TZ*CCC#'R@176:$/E%N88&
MM_<'8DD;N9)!-#-('<F0ZF4RZ!C>R!55%15=U50&8&VM_*O=6]LUJ.C/1V6)
MY#+*L]O/*))&,I+,AF$8QOI55$1(T621415=@;;,^ 2UC*Q)<).]7O5=9(PB
MN(J8XUEL=2L#</7T/0J\QT F6K1:(-EP6OQD.[ZL2-E<"T[!YSZK)?%<K+Y3
M+U)%DCV%L.)Q*9RT,,\1>4B0:Y2DRF0@RNXUYQ*1)[\!A73ROW\<BRP]&NCL
M$@G]LLT$%S"99L2]>;=W"[TAII)1O-7WXB;]T56$7_\ 1J.EG_O[W_\ IUU[
MF\O/V7-M?S9LOU7?^HK(?LZ=(?YGV-__ 'O]54LZ(^ %Z<]!;GUANRN;HW7-
M3VK+M7KS$1,WY%]42,A79!F1&#DO0:J(9Z&^ZPEM_P!%)8>\/.?#=0KLSRRV
MEY3MK;3V?>;/EV?LZ.*]MI;:1X_;.\19D*%DU3LNH Y&5(SVBL=M?RQ;<VQL
MN_V5/LO944.T+2:TEDB]M[Q$G0HS)KN674 <C4I&>T&MU2J''*5E7IAOX6<Y
M_P#<?Z<]OY+GF^L^CO\ &O'M ]/=X5_/(,=^>F_U'V7&L^CO\::!Z>[PKPR6
ML(*7CS(N0(.>"/'=%);2]@=S+3J<I5EDD;#)0KZ.WOL%"O,DC/)0^.\T\VAQ
M,1(RD$8R#D<,]QX'\AX'SU QJ00<X/I\.(_**L]CIRUN,^T4.+*L%,,'--E-
M3<PV3X\EB<2=+N$)/PZ]8WTV6P)S:'EKL:,3,CAN41@M[O3FYE(()7!QPTKC
MAIPO9[T:%ZGO.J.'"I=Q'D'K9'9UCY\Y/_%UFZWON)X\:K,%I.FUDB1*A$'!
MORF&$%*R804A(PI,B8)'A-&.D,Q<4&5+RCX43&($C W#RU#"-9?7VP:>1P Q
M!QV<,<2 "3C&6(4 L<DX&3PJ(B1<XSQ].>? 9[ ,G & ,G JY?(,=^>F_P!1
M]ER36?1W^-3:!Z>[PIY!COSTW^H^RXUGT=_C30/3W>%>QVG NA"A9**PV(X2
MZA>/![ZLD^%W\*[6^SL3X2>[V8QGX\]O;\79#4<D\,FHZ1@#S#UUX_(,=^>F
M_P!1]ER.L^CO\:AH'I[O"GD&._/3?ZC[+C6?1W^-- ]/=X5XI#6%>E@WH^53
MZS ([GI ,@*":&_X3J'FO&&)&<9=\-YMMU'?0KN.MH<3V*2G.(B5E.0<$=A&
M01^<&H&-3P/$<C@_X59\=TXZLAWHDF'KH4.7!0Z*_$G1 H\7(!0K:H?*8UN0
M ;'-4+E,!$LN-N/K\483 CN5C/DM/3FXE8$,VH,VL@\06ZW'!.,]8^O/F%0W
M,8Q@8P-((P#CAPR!G'5'#T8JN0&EZA6,%8A?6 V3/1T/./FDR+R1@TN( CAG
MY)TQX.'C4O/IBX4-;$3&8()] "&])?\ $E:9W]]@XSYL<3VDXQEC@98Y8X&2
M<"HB)%[,\?3GL[!QS@#S <!DX'&KA\@QWYZ;_4?9<EUGT=_C4= ]/=X4\@QW
MYZ;_ %'V7&L^CO\ &F@>GN\*]3U,!?'#'447A(3;S:%8\'O+P\^X0K*^UO..
MW"G,IQV8Q^#C';VY^/D-9R3PXX[J:!P[>'_ORKR^08[\]-_J/LN1UGT=_C30
M/3W>%/(,=^>F_P!1]EQK/H[_ !IH'I[O"GD&._/3?ZC[+C6?1W^-- ]/=X5'
M9W35K"2]89/CSRLRA3A1JG9>5RI>'DSS9 +2L'84)"DMVBQM%0 F6(0EJ;DV
MGX]QLQ]*ZHN91C! P,#"CXO'LXMU%PQZW5''@*D,$9SD$Y.3DGT\/R=9ACLP
M2,8)J1/(,=^>F_U'V7*6L^CO\:GT#T]WA3R#'?GIO]1]EQK/H[_&F@>GN\*>
M08[\]-_J/LN-9]'?XTT#T]WA7[NT@!UH=K)9F,#-K;3G'@]JL+>=?SE7:UV=
MN%.YQCL[/BQC_3V\:SQ[./\ [<Z:!P[>'_ORK\/(,=^>F_U'V7&L^CO\::!Z
M>[PIY!COSTW^H^RXUGT=_C30/3W>%4*QZ;IEOB"X&T@LS\,<T\R3'2H81HKB
M'QWA7<X;>'5X;N1R'VDOM90\VEU?AN(RK.>3+,Z,&0Z6'81D'_KW5 Q(PPPR
M.1P?\*HC73SKIA\E]D(QK!:#V7!&Y U$8R/+/^ES08,0DG$7&@3QF$'6 "/#
M%#GSV6#IA@TL=AYN)N)#C)'#''''AP4ENTE1P4DDJ,A2 2*AN4XG!X^GAQ[0
M!V 'M8 88\3DU7X/4-9K@KHD4]*(022HPL@V0)EY(\M3+ WI4C+2[ITI(D($
M%$":>.,(<8!##!94@00=EJ5I78Y.GD !@ <@!@#B2> &22>TFHB)5X#//B<D
M_E)R3RXGL '8*K/D&._/3?ZC[+D-9]'?XU'0/3W>%/(,=^>F_P!1]EQK/H[_
M !IH'I[O"OW=I #R!D*+,Q@9G+",X\'M4G)#Y':KM;S^%WGU)^+LQW<)^+M[
M<Y:SQ[./_MSIH'#MX?\ ORK\/(,=^>F_U'V7&L^CO\::!Z>[PIY!COSTW^H^
MRXUGT=_C30/3W>%/(,=^>&_U'V7&L^CO\::!Z>[PJT8C0]$@F1V(T<UM LFS
M,#K).+D2&I$:)Q!"O)*D7RRO##AL)C A<O9$#"0@<5AIM"$IG:>1CDD<1IX
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M>1GCD+"%C@.H8R#5$V^96?>$!G)1-2NYA?3(Q,<96&XF159-)D':ATA#B0:
M0H09"#4Q!51(N44!F!GO9&H+G8-[ 7PC7U4V5#.PNG0:C*S=VD:R5HV>I-]M
M%AV%8Z\@*.<EL/6Z"F8'#3U7?&/N956$I-^]%I*V2A[:*:-;<QB5XF#3E@(P
MXN%DC1(D;)T]1E?WXQ&',D69,BJKQ.9@Y19!IBT$N5W+HS%V48SUU8>]XN5T
M/A,&K$1JGJUK% Z/:?1KI%0P^MZ'6*WN\5#HDJ_,6&&=U>QDS$E)D N25?36
MX?9\07X'I9I,A884EJ'R9@2T4VIOK)Y;YY(RV]D=K<X*Z4;?<,+G#:FA([
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ML*&U3B(H"6XA3 7R5U:6XDZE><1W8=?ON8PZDYP6TXA+Y.%X$B95 !QJ4\,
MKL4YC*OJ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
-2G%*<4IQ2G%*<4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g743471g89o26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g743471g89o26.jpg
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M  (1 0,1 ?_$ !X  0 " 04! 0             '" 8!! 4)"@,"_\0 9Q
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M*4I2E*4I2E*4I2E*4I2E*4I4E:B_?^%_R93_ '2]JTOOWL_X4_OBKFT_=U_
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M_>*O,:Z_2#!_YBGNF[M]&<_^E'6'VU3O+PWYY6GT+F_\K3O[Q5YC77Z08/\
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MK8ILT8HS<CEQFQY*RBK*4S!NY8/'C9PY*G%2BEW.;OPA9_BD[3TV;N8\(3-
M_8[^)K)A)BQ'F\QR,-,)$E6;$6<E])98]DECC=4@MA"-@CY7*+1G>8.ZUQM
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MYO<9?HME?8T\HH1\E/(3]"<W]@I[T[CY[X5_2/&^VI[]+;S>XR_1;*^QK?\
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MV>=_C(^'<-;FUQDF-M(7E>>0)=1,\T\FG,GN)I)7FN)W"J&FGDDD9552VU5
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MS(L<K)Z**\E5[3I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E0KO'^XT
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M/^2VIX?Y,VM_>GT5G?H](2?I6Z?]F-;S7_UV_AIV7@[X\[Q,/]U,6W_.:_\
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M(YL@5$DDYY0+&S.=\LT6I<@;4YH"@,PU)V5N1W*?=L]!,I01%Z] Q43*.#+
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MO*/Z1IX[3#XT'OI5Y^NIV>#R,?H#ZJ<^;RC^D:>.TP^-![Z5>?KJ=G@\C'Z
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M=W'PC.)1:'AD4BA-@,>F2KT8^D1E84,N3,NL62..*28NNP)'&F[>5C# ,VA
M8EF9N@) &H4:G0#6BIH=Q9F;3:"VG@KKJ0 H4=2!J2"3H-3T%;V0Z*A<E(;I
M)$5SN+C?&M@VK)K9L^:I)(1H$/G(QDJ!QS'JY,2N3?8)VZ[IUF00S53'Y8M$
M[-U<7,%F=1$!M^PR&1.A^V8H3NZ]1X"]!I\="BG?X]9%56_ N_33[_AG_A6!
M[5XY1R21LP\% DIC)6.@Y!HX#%)6?<!HL>CI-_&S79BY8,.R,AS:Q")"<1\H
M%J)J!'&5R"#')=)%1&>.=E8:G:#,LK,J@LK ,-0"="/#.JGQ^+6H/&""=-Q$
M;( 3H"#H="0-1U4>$.H\8ZZ5%G'S2VRAN]B6Y)VUV0+9L-.Y:J%-MM[+BNQ)
MD36(2X3)G3AMXAX>*HB.!D0#5LR>+*YRV3/BK]]),>_9L\LJL\L9A$2<LZR\
MT\J-HU&BE0/#\(L==2!X"Z +XS4D:$/O._HFP;V#'J03]KT &@Z_;,22=-!K
M/VU./D4VD<'R_&1337LZ'@7T2\=M>$Q+ P4AQ)>[MY$)(,DH*4Q*51O-[EF^
M;#9+&BN UZJZ<BLV*KU[DXH1SM&"NU'0L&V."0''B=2K*RMIT)5AJ.AUT&E1
MHPQU#,K::;E(U*^/0A@RD:]="IZ^*J^B.YZZS"0'8&K6.Q]MV@^RU(6\E""Y
M6(.9*[>PCJ$AS3*3N(8JX5B*[%B-890%RT7B YJV<,P0L4-*$F#FN;Z0R)*8
MXM\>[;T;:-W4G;O^V!)._7<2=220#5,6Z!63<^C[=W4:G;]_;KM( \'[7H=
M Q!L-#=&-XP'E<=/;.VKM$!+@&<:>!MDF8R28#A*[5XQ>(!T8_$8S=KVYD\S
M:N;+9.D[HHH8HIH]YE?.@\VXJRQQ1LK;@8PP)/0C7<[>(C4>*JH70$%F<'IH
MVGB^/Q >/7K6'/>(&HR'&YKQ:=WE2NN&EFRF)&QM+":*D$I;>;.C"TAP'XXW
M+%CJKQ4L\38)7>-R)!OWB>+G*]IA=2BX-R-O,.O33P-"NS3:3X@N@ UZ:#Y*
MD,*&+D]=GWCX7VV[77Y2VI/RZGY:L^W;H-$$&K9%-NV;(IMVZ".&*:2*".&*
M:2*2>-K8X)IIXXX888VMCCCC;&UK6M5O56OM2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4J^<,_>A%O\ -X-_N]O6N3_N\W]+)_?-9N#]QC_F+_962U2JK2E*4I2E
M*4I2E*4I2E*4I5=TN6G&UPDFNWW)"7#=9/!5!PW)9+MUTE,;9)K(+HHYI+(J
M87MFFJEGDFIA>V>&66-[7OMC<"\7HS(_#V21U)5D>':ZL#H5968,K ]"I (/
M0C6M+7NB<$.JNG$V+=& 9'2<NCJ1JK(ZJ596'564D$$$$BOIY5W'/Y7H?\\6
M]GJ7WC\6_,&0_-#_ !5-\(7!7G)C?SK_ ."GE7<<_E>A_P \6]GI[Q^+?F#(
M?FA_BI\(7!7G)C?SK_X*>5=QS^5Z'_/%O9Z>\?BWY@R'YH?XJ?"%P5YR8W\Z
M_P#@IY5W'/Y7H?\ /%O9Z>\?BWY@R'YH?XJ?"%P5YR8W\Z_^"GE7<<_E>A_S
MQ;V>GO'XM^8,A^:'^*GPA<%><F-_.O\ X*>5=QS^5Z'_ #Q;V>GO'XM^8,A^
M:'^*GPA<%><F-_.O_@IY5W'/Y7H?\\6]GI[Q^+?F#(?FA_BI\(7!7G)C?SK_
M ."GE7<<_E>A_P \6]GI[Q^+?F#(?FA_BI\(7!7G)C?SK_X*>5=QS^5Z'_/%
MO9Z>\?BWY@R'YH?XJ?"%P5YR8W\Z_P#@IY5W'/Y7H?\ /%O9Z>\?BWY@R'YH
M?XJ?"%P5YR8W\Z_^"I @6V]:;1S+IZ^F@&6J@+#\C2(=W9=<7B6[;X,S>(WQ
MP513?W&D+-%,\+8+Y,G6*>65T%+8XO)X+,846[97'75BMUS1;-<1E%F,'*YP
MC;JK&+G1<P ZKS$)'A#7,8CB+!YXW(P^3M,BUIR3=+;2;V@%QS>09%(#*LW(
MF$;$:.8I "2C:8[O/]Z#+_.!G_\ (%*H8[]W;^B;^^E7][^XC^>O]AJIM9FL
M52E*4I2E*4I2E*4I2E*4I2E*4I2E*4I5+N4VT);"I]Q]AH+<$>T@ V.3V4A*
MIQ(Q$3*,VR<4B+<X%:893%9J*:*/2.5VG?=I256NXQPPLHI9/&KNWB5TG8Q-
M,T?+VHI8$[F(;[4$G0#7Q?%5&5RK1J'"!MVK$ _:C4#PNG4U C/D[M$:^G\7
M#[7A&[@D0VQQ"CH_<L3C8-H.72W9MX=#MAZW+XA"1:)OY$$CG4D4"(#-NZ%-
MI0RQ(H($46V>=;L\9",T;PLT=R3$S$D<J(ND@U 8 MT(;77:=.AJ02-JR[U<
M*T(#J!UYD@5E.A*DA?DT(UZ@'2K8E>4<;"R1N-(:XVXVA[G98[46&V5XV"::
M^M.RTC0AP]AU3V5-I\J(=2URA'4)8W@J\2<$%<,VYQ5AGB\O;"W9E)$D181F
M7E;B7V!=Y/1=FH0;MN_=I\6O2JID .A5]N[9OT&W=KMT\>X@MX(8+MU_E:=:
M^[?D_$GTM4 C83M K%6^Q,]3.MM#8T-=ZV:[#1)W NH^JLF?\<\FK"2VRC)&
M5(0M:%#SJ:S)Y)$.H743=G8+N+QAN7S>66(D*::Z^+9J1X04OO(_DTY@UTVL
M5W%=^@V[@=-/'N\?3=MVZ]-U;2,<KH+*3,81:Q38P^$3N4.X9K_;Q4$';ZVF
M\E;9DDV[ *Z;R-W+&;8TJ(((QHW)(B!C\E6212!E7ZC\=B[&V=58[D+HN]X@
M3S$7IJ2"H4Z:C<JL67XP-#I 2J2.C!6.BN0-K'0G0==>NAT)4!NFTG4:Q5QT
MY>K3&':MMM"*ST:_V#)Y%!A>U749!"]92*;L#\G0'1AADQ.YR)@Z<L0F8T>6
M)Q$9&#1EFL.%G7Q!9)):I/:['DY;(0@#F,,QD5-%)8ZKMT&O4!BP!U(TUJ2*
M;<J[U8;B5#: (6U.@'7=XAXRH4GQ$U)\:Y:P&3E8EBWBNR!D%V')UH;KK;Y<
M (;ZVG$DMF_38,0[EO(G<M8-CZHQXC&#,FB  #)5L6Z00H]S?,+.J;6SJ&\*
M,NB[Y(@3S$7IJ3JH4Z:C<%=F7XQT.E02J2.C;6.U7.FUCU\77=UT.A90&Z::
MZBK2U;U4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E7SAG[T(M_F\&_W>WK7)
M_P!WF_I9/[YK-P?N,?\ ,7^RLEJE56E*4I2E*4I2E*4I2E*4I2J^<2OO5N-/
M\P6G_P"KZ/5M?'?\-^,?QIX@_6MW6F]SK^+[@;\3^&OU-95]XKR>T?,Y6TA0
M&9K9'R9N1QH)B7B<UC0B2R&)+%D)(#B4FDL<$1F6EA&0$XJZ'QHN5=6:ABKU
M-+-H/=KHZZ]I<1IS&0;0J.VUXW9%?;L9T1V=%;<H!=5&K*/&0*VQ;B%F"!NI
M9E&JNH9DUW*K,H5B-K:A2?$3\53Y5M5:E*5"\^Y!:LUG)VT+E16292ET!1D^
M 2+:YV3/WJ,?<$'@IN5>XP&)2; <U<$1[YHWR(9MLEU6JUDL<[87O5Q%;33(
M9$"; VS<\L,0W !B!S734@$$Z:Z:U2>:.-@C%MQ7=HL<CG;KIJ=BMIU&G6I<
M'OFY1@Q)-.O[*19MGS;M31V/<]G=HX.$>T,'Z#9\R7ZM3'KFCULW=ME.^1<H
M)+89IXT"""0?&"0=""-1\A&H/X02#\55 =0"/$1J-01X_O'J/P'K6\J%1K'@
M<KC\D>2=@#)HD'<,D-XI)T$DU\,A$@L#"22XQ>ZR26"BW@.1A"'6-LED.J()
M8=;UV"R:<S(RA"PT$B[T_P#27<R:C_:5AU^2I0RL6 .I1MK?>;:K:>BRGI\M
M;1M.8H]-N8XQ,H$#+$ZYC!)F/1=/_!$@:1D5,EQ)IRS06:!GOBP<#F$DBB[2
M[AL48V;W56<I)91,;A0Q712H<$Z#<I=H]R@]6&]67H#H0=:;U)V@@G4J0.NC
M!0VAT\1VD'0Z="/EK+*DJ:E*57N)??0;Q_F;XY?TJY'5M=]_ OAK\8>+O_D>
M$*TW'?P]XK_%G@K]8<;5ENYASHA#,\VR>2O@TDU(N,<+7RRLV31=-E5+8V\]
M\4KNL5%+^]@EAGGET8XWO; 6+A)^ITWJ4!/RZAA^7;I6TW:EH3IUVL&/X.H/
M]NM4^K.5B*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*K[M72:>SMJ:)FA-&-DXQ
MJQULAR>C\A'XD_#&4QB.$?%78M'#-T/S4'/L,7B^3RZ-\$\<<FU\UK6QM7BF
MY<4R#<&DY>UE.FFQB3J=0>H.G2J;IN>-CH0F[4$:Z[AH/R5N-P::3F\"C4*A
M:4=B;8#MC3FP>S),+#A78-<;4B<_+LVS04UZM-\38Q]RT97ZG!&[Y=')TJDC
MUBN,(I=CEWW-K'*GCU.KQL@\9\0+:G[WBJ++JH T&C(WWM%=6/B^\.GWZIT<
MX5[1D1Y$D<>:FD1T-R  ;B';AE1">2399B,@MN,)\.@#0,28J1W5N >-MDH@
MV)0XF6&D!0M 7E'!*)DB_;72W<:C1>:JF%HC$H18PS1;"Y(.LFYO#(8*03KJ
M=H!I<EB=3L)Y@?>=2Y42;@H!Z)M7P=5.A  VC4D3S#M.[YUXY=:_A<Q@(G3[
MO<$DV;XSJ-23[9[6,S.?$=E2W6"4<(A7L163+&C)J/(SU4]@3&Q8CUC..X2%
MHU+)T7EAD\-T<R\I8]O01ED01I)N#!AH #LVZ%AU;:2*G5'4[05V%V<G^5HS
MEV30@KU)(W:@JOB7<-U0KJ'@P^UB:UD%QBO'Y2*ZJEJ)YAL].-%".X96&!KO
M7<2$D Q(9C&HQ)&+C,5<Q/!<C+O']Q2C@:#"NB.:K6K)>"02'=-OD7:8]P$2
MEM-Q!!W,I&H"%0!KU9M*D2'9M4+'M0ZAMNKD==H.HZ$?&X8D_$%K*X)QDW4V
MC6G=4;#D>L76L=1[(;;/Q,Q:THM-92[!G3<GB42<BR+!L%##PYTHR<E),V+/
MWIUB'1'IQ\.H\=$:@]Q$6FE19!)+&8]K;2BA@%9M0=22H("E= 6)W'0"HK&X
M"(Q7:C!M1KJVAU"Z'Q ?&P.I'30:ZUO8AQEVX-C>D]+R.3:_7TQH.<P^6QV1
MB<)![I,R%ZQ(*E-;1DZ"=,$8U&U!CU$)G))$.D![.0IALTF@0%<HMFU@UQ$6
MFE"OS9D9&4Z<M3(-'96!W'4:[5*C;KU9M.H1OHB$KLC*D$:[F"'5%(\0TT75
M@3NT\2[NE^*LJKTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*5^TT\U<\$DL,E%%,
M\4TT\,;Y9YYYWMCAAACC:^66665[8XXVM>][WM:UNFA( U)T \9/04TUZ#J:
MOW&V2PZ/ A[FUL7#$.-:+XV\]L5F[-%)7&U_AMCGAE;I^'HZ:UJ5@TDC#Q,[
ML/P%B:SL:[$1?C50#^$#K7-5)4]*4I2E*4I2E*4I2E*4I2E5\XE?>K<:?Y@M
M/_U?1ZMKX[_AOQC^-/$'ZUNZTWN=?Q?<#?B?PU^IK*JI --[_.PV!Z6(P-GK
MT1!.0DJW"ZV\]F,9.77',MN3K:$.1A45"*DBRQ8XZ,Q\2=3DV4;9CX\O)<>N
M(NKM1CS$M/;J\DXE,C26R0"$1LO4PQQ2<QVT7:H5F79O);9XAJPV,13%4B*;
M D[2\W>IZ"5Y%"J-3JVH5MVW12WC\51'EQ,VVZAHL5?53Z,MPT'U9']H@H].
M]8R9UOG:<2-.'Y_<#J/[%9']=[19JXW6L\QW>K!YML!"2.79IW&#L#A[IY6[
M9"')YRL6DF:)FCE06T+J L(:(K+"?D[.)(XBNBAUDD I]FDV:"+;X*+(%>,F
M:13JTI#@I)\>O-V.^XEBI1*WP7BOR-RFFKC\O'JY/ 8G0+2.$()*(,+"Z:&:
MXECE]-X_F3G;&?;%"6D4<Q;YF!NJWTA";+5($-:2DJ"A L-(Z-=VNR54/VQN
M2PD20M.94 1M(S'$VU]=&F"M#H)45I"R4%M-NC+#JHBVE&0"((^KKJX>1=R^
M,1$B3JCD* U3]OG4NRBW(I'9D<B&UI+%W.E0$%R5U'NT3J(LV/BIS+S[E,[@
M_DT;5,C\AQQCD/RPS=)MG-WEN\3RSO?*VMYHEM>4SPHXN&D^S0&8%3&BC;HC
M[3JIU\6HTJO-&YFWA967E!/L<HBZAV)U!9=>A&GR=?EJ']A<<.0LIVCLF6:]
M!.(,8V1 9>*RG<RF44+/(K<WQNS@T;'1&>PK(3MT"<&[1:@<C\+/L]E:H'MT
M)%M:#R)E/7@8>RKQ75LD,22MS%BDC;EHCA7VW?,<O')NA96A+;77E3$E(73E
M!B:+V\S2R.@*%T8!W925U@V*%=-)%(D U0\R,=948.=*XW:/&K8DS )1V!\8
M(WK."$D]C72A]I9 Y(5 SLG#-<@(G-;Q0[)#6D(('=OQ<QL7F4*CFP=JC.PA
MI8#!#Y+/)\AA&&ZBC;?)=O+(.5J^V15:-7E9X]ZJMQ(0"FB2/%$=2C,5CCI)
M;R.-$@6-"9/!WHQ#[4"/L8M"@)5M619)!X+A0SR:8K-.)_(R0Q0I'R\(#RM:
M6>-I1P5='(=(#H78)+CWQHU]&9([\?2[J'"V:<I@6R;&MB#(A/MM1=1N)<Z\
M9,V,IDKA],EY:JZLLC)LV#0*ZJT0N;N1TTC42$E)(ML1DCA?J)22B:2-;3D$
M%%;=J=248JY@MT5B')0#=&^KA7E7H4&C-7+.N(_('+#8>$9!"HC)9@?(R\K-
M&DO'A5YJXD7$C7NM28<T;CBB\J:%E=GQR:MB,DR9.EAMYE>;@7)%\L0ZF O;
M;[%O9G1%"!#&6";;V24,%;P".2Z:)KU$?+;0:5-V6;1]H"LS%BP;0ONMDC(+
M+JVO,5]6^+?O4DZU)\;XGDY1L48^D^H 4*X]K322&DN/I4K&R82/)+Z>$Q'(
MN^BD5)%H&EE(YRU6.MHZ >EQPY^-'[!=9,9J8)8#:37BI$0DS/="-5[2H8,W
MV=I-H=PLG@1G:78 D$QC6-03.+7<XW1*L&YB("5*K]C5=2JDIX3ZMM&H!',^
MW8Z7;T!'9G$-#Z3B>QW2CW847U'K>.SQXL2N96=S,+#0PV4.E2]\U+E5%SC9
M\JH2NHI=]EG=UW^76]]?'W+1O<7#Q#2)YI6C&FW2-I&*#;\6BD=/B\57D*LL
M,2OU=8T5SKKJP4!NOQ]=>OQUB\2^^@WC_,WQR_I5R.K9;[^!?#7XP\7?_(\(
M5J.._A[Q7^+/!7ZPXVJP>6-LK7QRM;+'*U\<L<K6O;*U[=%[7M?S7M>WFO:_
MFO:M4K<JC$K$-5-W>?A9J 'NU;=;=!8M<7>^.5[]&>#3!^V3PPRO:_1=-+'&
M][7Z/>J^B.1D36%+B5!TW)"T@U'Q;@C=1\FNM6,SX^)ML\MM"Y&[;),D3$'X
M]I=3I]_32N-\6-+_ (V->L^?VO57;EO(7?JS^RJEVC$?=5EZU%[6GBQI?\;&
MO6?/[7IMRWD+OU9_94[1B/NJR]:B]K3Q8TO^-C7K/G]KTVY;R%WZL_LJ=HQ'
MW59>M1>UIXL:7_&QKUGS^UZ;<MY"[]6?V5.T8C[JLO6HO:T\6-+_ (V->L^?
MVO3;EO(7?JS^RIVC$?=5EZU%[6GBQI?\;&O6?/[7IMRWD+OU9_94[1B/NJR]
M:B]K3Q8TO^-C7K/G]KTVY;R%WZL_LJ=HQ'W59>M1>UIXL:7_ !L:]9\_M>FW
M+>0N_5G]E3M&(^ZK+UJ+VM/%C2_XV->L^?VO3;EO(7?JS^RIVC$?=5EZU%[6
MGBQI?\;&O6?/[7IMRWD+OU9_94[1B/NJR]:B]K3Q8TO^-C7K/G]KTVY;R%WZ
ML_LJ=HQ'W59>M1>UIXL:7_&QKUGS^UZ;<MY"[]6?V5.T8C[JLO6HO:T\6-+_
M (V->L^?VO3;EO(7?JS^RIVC$?=5EZU%[6GBQI?\;&O6?/[7IMRWD+OU9_94
M[1B/NJR]:B]K3Q8TO^-C7K/G]KTVY;R%WZL_LJ=HQ'W59>M1>UIXL:7_ !L:
M]9\_M>FW+>0N_5G]E3M&(^ZK+UJ+VM/%C2_XV->L^?VO3;EO(7?JS^RIVC$?
M=5EZU%[6GBQI?\;&O6?/[7IMRWD+OU9_94[1B/NJR]:B]K3Q8TO^-C7K/G]K
MTVY;R%WZL_LJ=HQ'W59>M1>UIXL:7_&QKUGS^UZ;<MY"[]6?V5.T8C[JLO6H
MO:T\6-+_ (V->L^?VO3;EO(7?JS^RIVC$?=5EZU%[6GBQI?\;&O6?/[7IMRW
MD+OU9_94[1B/NJR]:B]K3Q8TO^-C7K/G]KTVY;R%WZL_LJ=HQ'W59>M1>UIX
ML:7_ !L:]9\_M>FW+>0N_5G]E3M&(^ZK+UJ+VM/%C2_XV->L^?VO3;EO(7?J
MS^RIVC$?=5EZU%[6GBQI?\;&O6?/[7IMRWD+OU9_94[1B/NJR]:B]K3Q8TO^
M-C7K/G]KTVY;R%WZL_LJ=HQ'W59>M1>UIXL:7_&QKUGS^UZ;<MY"[]6?V5.T
M8C[JLO6HO:T\6-+_ (V->L^?VO3;EO(7?JS^RIVC$?=5EZU%[6GBQI?\;&O6
M?/[7IMRWD+OU9_94[1B/NJR]:B]K3Q8TO^-C7K/G]KTVY;R%WZL_LJ=HQ'W5
M9>M1>UIXL:7_ !L:]9\_M>FW+>0N_5G]E3M&(^ZK+UJ+VM9/&XO &RUR,:9A
MW*[?+O>UM'GA7)LI?'_W%5'+NS96^%[^?"Z:E\+WMT][>_3;3M>+HEP)H]PU
M"R(T6X#[Q5=PU_"-:N;<VDFKVSP2[3H6BD27:?'H65FT.GQ:@Z5G56M75*4I
M2E*4I2E*4I2E*4I2E*4JOG$K[U;C3_,%I_\ J^CU;7QW_#?C'\:>(/UK=UIO
M<Z_B^X&_$_AK]3656#K5*W*NNS>?+8KKCDQ#8@/,I-=705YK\'O%M>+$"N)(
MEO=^2CT743E: MRQA^>H%483/)CV\D/;/8/L.SI;%>[%%5GD[>R$MK(Y76:0
M2-;G>%T%N SC9KJ_/!DCCT4Z21:=->MC+<E+A5#?8TV"8!2VIF)5?" .SE>
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MRBRZJBF>7GRRO>O?<$$%K#';VT,5O;PH(XH((TAAB11HJ1Q1A41%'0*J@ =
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MXS66L9+T\R?@KAEN'+IFUZY^?*W&/RD@!UTE[-PW:2D^2R0 U5]:Q?=#M[7
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MHF73T7WR65DUERC=%[G=6RN-UD\;][:WW-6L^%Q5TN46XL895S<*6^5#!O\
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MCVL-;@S["AY.M=7S$:16'%Z<7Q=S6*R7'Y%.'(^'4X+7B%<VMU&,4+=>$_\
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M]%NC$Y;B_BG.P"VS'$&6R-L&#=FN;V=[8NIU5V@WB%W4_:NR%EZ[2-36:PO
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M!9XZ3<%,PS%G<BM@X)$'&"SNZV>*S]XMCE;-TODII3RRR:"621]O10[LVWQ
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M*4I2E*4I2E7 X] IX.6U?L)[JN4;XUBQV<^$QR!QV3G<4 >RT<X63<OEA '
MAX%+FA:0BP^Y0>@PEB8JV#K(BSCR[9/G_%ESBYES6)CSEEPOFI<+%/=Y2[LK
M4M=89AD85B2XNC%VF"WF-P9A!*TUB9B8Q#)=K(>E\%V>7A? 9F;A_(<7X&+/
M2V]EB++(782SSJMBYWF>VM!/V6XNK=;;D]HA2'(K !(TT=DZ+S#2*!L^Z("8
M:9+#-H WO+T*&.%20\6\%35D3VXS0,W+"TD5 ;QN6Q<NFY5B@WS#N>L<HH(Y
M,<\,+V[WUP.Y+/D+>";"7,? -Q<6T$,T\<^-DAP,C6_(G9A<QO!L1X)&<7":
M(S-S035S%CK4]VFWQEU<6^?M)>Z1;6UW//!;RV^4BGXBC6Y[1;JK6DB7 >1+
MB)$-L^KJBF(@5)Y/:>(_3)G8 _5NB6TGC')N^L(P[STEK1XU$:W?1@F;<Q-<
M8]C3@9(\KNP;--*52MH<F[9!P7Q;25)4P_66PD.$,O$-OBI<WQ.]E>\%]^[V
M,<29B-[C,17L%LE^DT=XLUGX%U(6L;&2VQKLEN7LV6WB5=@GSXAX9N<Q#@.$
MH[^PX^. L)#PK@I8[?!S6$]T^.>"6Q>"])DM(U&0R$=UE41[@1WRM<S,\F;+
MUTOK\U-1_'3241V$Z?<O=V0"?BG^M FQ_%>*!'T6MK37B"9H285U_%3[$G+7
M>$C"Y@RSI48HFWDC6\63LAA\-EURMOCI>+N)+_%)%P#PWE<5/%F;G$=MOKF*
M].8RK&VGMURM]:RP6*&SN!<P(LP+VC]M.[.9W"MA;K)P\%<+8W,//W2.*</F
M8)L%:9OL&.M9<?WCPJ+=6]RV'Q]Y#/D91>VIM+B1H"J7L?8%VUTE&>O-9]T9
M**&1(8!K"$<L+J/A \<T8QX%% 6RL,U$D1#-!)D@&$L6_69#F[;%O=DWR;)H
M=YE;"^WV8RV9[D< MY[BZS62X% CGEF>6[NKZYPY 9IY&:1KB>1]!,[E^8X<
MMKUK2+\X7!=VR=KFVM;/ XKNA[IK:&".*RM,?:9L%E6VC18DMK>)-QA1 G*0
MH$T.E2?J'C9R=QY>I["=A2C:VO\ =8&?3O81$FT8CGL)(2MR;.;#%/7KM#*9
MPLC'V[UV0)1ZQ=FY8%V39S:^!5/#/"9_C#@P\ G$QW,+G*\.76*QF*BADDFC
MR45BEM:XF>.-&[W9*&[>-(H;OD2)+;R.G6 D9_AO@?CP=TD9F2UN(^\W%-IF
M,MF9[B***7%39%[J[S5O++*O?/%SV:2R33V?:8I(;F*-]5N #D6OY#&9#K>4
M[R V18#.(DLY#O8>TRPQ;W9"-Z)()\>&V"%[6S0S ;5*20TBW2MA?H15M:R?
M5*YVM,K:7EIF+'AFZUEFX^L.$XLA("6YD_#+,>+'W>)A<X.&SMV=M1X2GKN
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4I2E*4I2E*4I2E*4I2E*4I2E?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
